Scientific Abstract Listing and Annual Meeting Information

Transcription

Scientific Abstract Listing and
Annual Meeting Information
April 26 – May 3, 2O14
Philadelphia, PA
Connecting All of Neurology
Early Registration Deadline: April 3, 2O14
The 66th AAN Annual Meeting
Experience breakthrough research, exceptional education programs, and boundless networking opportunities
at the AAN Annual Meeting in Philadelphia, PA, April 26–May 3, 2014.
2O14 Deadlines-At-A-Glance
Location
¡¡ March 26, 2014:
Annual Meeting Hotel Reservation Deadline
¡¡ Pennsylvania Convention Center
Philadelphia, PA
¡¡ April 3, 2014:
Annual Meeting Early Registration Deadline
Headquarter Hotel
¡¡ Marriott Philadelphia Downtown
Future Annual Meeting Dates and Locations
¡¡ Washington, DC
April 18-25, 2015
¡¡ Vancouver, BC, Canada
April 16-23, 2016
¡¡ Boston, MA
April 22-29, 2017
RED: 14AM Register Online Ad
Place in AANnews and Others?
8.25 x 5.4375 4C + Bleed
Search, Find, and Register Online
Customize Your Week with Easy Online Registration
With online registration, you can:
Register
Book your hotel
Plan your itinerary
Search for programs by topic or day
New! Choose the “Buy All” option to
purchase all education courses at one flat rate!
AAN.com/view/AM14
Table of Contents
Introduction
Thursday, May 1
Connecting All of Neurology . . . . . . . . . . . 2
Make the Meeting Your Own . . . . . . . . . . . . . . 3
About Program Listings . . . . . . . . . . . . . . . . 4
What’s Included with Your Registration? . . . . . 6
Look What’s New for 2014 . . . . . . . . . . . . 8
See What’s Back by Popular Demand . . . . . . . . . . 9
Meeting Schedule Overviews
Meeting-at-a-Glance . . . . . . . . . . . . . . 10
Scientific Sessions-at-a-Glance . . . . . . . . . 14
2014 Award Recipients . . . . . . . . . .
2014 Research Fellowships . . . . . . . .
Annual Meeting Program Schedule .
Annual Meeting Programs by Topic .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
18
. 22
. 24
. 34
Sunday, April 27
Poster Session VI . . . . . . . . . . . . . . . . . . 104
Frontiers in Neuroscience Plenary Session ��112
Scientific Sessions . . . . . . . . . . . . . . . . . 114
Integrated Neuroscience Sessions . . . . . . . . . . . 116
Poster Session VII . . . . . . . . . . . . . . . . . 118
Controversies in Neurology Plenary Session ��128
Friday, May 2
Integrated Neuroscience Session . . . . . . . . . . . 130
Clinical Trials Plenary Session��131
Section Topic Controversies/
Integrated Neuroscience . . . . . . . . . . . . . . . 132
Neurology Year in Review Plenary Session . . . 133
Other Interests
Integrated Neuroscience Sessions/
Section Topic Controversies . . . . . . . . . . . . . . 42
Poster Session Floor Plan . . . . . . . . . . . . 47
Poster Session I . . . . . . . . . . . . . . . . . . 48
Tuesday, April 29
Poster Session II . . . . . . . . . . . . . . . . . . 56
Presidential Plenary Session �� 64
Section Topic Controversies . . . . . . . . . . . . . . 65
Poster Session III . . . . . . . . . . . . . . . . . . 70
Hot Topics Plenary Session �� 80
2O14 Annual Meeting On Demand . . . . . . . 134
Connect at Social Events . . . . . . . . . . . . 136
Highlights for Students, Residents, and Fellows . 138
Registration and Meeting Information
General Information . . . . . . . . . . . . . . 140
Registration . . . . . . . . . . . . . . . . . . . 144
Hotel Reservations . . . . . . . . . . . . . . . 146
Hotel Map and Amenities . . . . . . . . . . . 148
Travel Information . . . . . . . . . . . . . . . . . 150
Exhibitor Listing . . . . . . . . . . . . . . . . . . 152
66th Annual Meeting Committee Members . . . . . . . 155
Meeting Information and Contacts . . . . . . . . . . . 158
Wednesday, April 30
Poster Session IV . . . . . . . . . . . . . . . . . . 81
Contemporary Clinical Issues Plenary Session�� 89
Poster Session V . . . . . . . . . . . . . . . . . . 94
Platform Blitzes . . . . . . . . . . . . . . . . . . 102
Fast, Easy Registration Online · AAN.com/view/AM141
Connecting All of Neurology
“Welcome to the 66th AAN Annual Meeting! As the world’s largest gathering of
neurologists, the AAN Annual Meeting has a long history of connecting all of neurology by
bringing together the latest research on the most critical topics facing neurologists. In fact,
the meeting not only attracts scientists from around the globe, but it also garners coverage
from world-leading media outlets such as the New York Times, Wall Street Journal, USA
Today, CNN, NPR, and more.
The Annual Meeting is also the go-to place for unparalleled education programming,
connecting neurology professionals to nearly 180 courses on 18 topics of interest.
With top-tier programming going on every day, all week long, the Annual Meeting is designed to offer customized convenience,
no matter what your schedule. So whether you come for a few days—or stay for all eight, you’re bound to have a great
experience and leave feeling an even deeper connection to the world of neurology.
I look forward to seeing you in historic Philadelphia.”
Stefan M. Pulst, MD, FAAN
Chair, Meeting Management Committee
Key Dates and Deadlines:
Hotel Reservation Deadline:
Location
March 26, 2014
Early Registration Deadline:
Pennsylvania Convention Center
Philadelphia, PA
April 3, 2014
Headquarter Hotel
66th AAN Annual Meeting:
Marriott Philadelphia Downtown
April 26 –May 3, 2014
Visit AAN.com/view/AM14
Make the Meeting Your Own
On Your Schedule
The AAN Annual Meeting is designed to be completely customizable so you can make the experience all your
own—and on the schedule that works best for you and/or your practice. Consider how your practice might get the most out of
this year’s meeting: send half your staff for the first few days, then the other for the remainder of the meeting. With so many
exceptional education programs and scientific sessions available in a variety of subspecialties, plus unparalleled networking
opportunities—all week long—the AAN Annual Meeting can be tailored to be a perfect fit for you no matter what your
interest, career stage, or schedule.
¡¡ For Students and Junior Members
The Annual Meeting is essential, providing exposure to a variety
of interests, career disciplines, and opportunities to network.
¡¡ For Neurologists
The Annual Meeting is the place for top CME programming,
breakthrough scientific research, and opportunities to
collaborate with neurology’s thought leaders from
around the world.
¡¡ For Other Physicians and Advanced Practice Providers
The Annual Meeting is ideal for comprehensive updates on
the latest advances in the science and treatment of patients
with common neurologic conditions such as dementia, stroke,
migraine, MS, and more.
3
About Program Listings
The program listing has
changed for the better
Please refer to the key for the following program definitions:
C Course (paid education program)
CQ Colloquium (education program included with meeting
registration)
H
I
P
S
Highlights in the Field (section-provided overview in their
subspecialty or topic of interest)
Subspecialty in Focus Track
The Subspecialty in Focus Track is a series of six special, intensive
topic-specific tracks designed for subspecialists, combining an
education course with an Integrated Neuroscience Session.
The tracks are divided into a morning and an afternoon portion in a
single day. Refer to the Meeting Events Schedule for specific times.
Look for the Subspecialty in Focus icons ( ) to identify the tracks
of your choice.
Integrated Neuroscience Session (scientific session
combining invited speakers, data blitz, and poster
discussion; included with meeting registration)
Poster Session (a hall of posters on a variety of topics.
Posters are displayed for 3½ hours, authors will be present
for 90 minutes)
Scientific Platform Session (didactic session
featuring abstracts)
New Program Feature Icons
These new icons will alert you to features of the program experience:
The program is part of a
Subspecialty in Focus track
The program is included with your registration
A registration fee is required
The program is one of the AAN Leadership
Development sessions
Cerebrovascular Disease
Sunday, April 27
C33
Prevention of Cardioembolic Stroke in
Patients with Nonvalvular Atrial Fibrillation:
Recommendations Based on Evidence-based
Guidelines and Recent Randomized Trials . . 24
I2
New Antithrombotic Agents for
Stroke Prevention . . . . . . . . . . . . . . . 43
Epilepsy
Sunday, April 27
C51
Algorithms in the Diagnosis and
Treatment of Epilepsy . . . . . . . . . . . . . 25
I1
Temporal Lobe Epilepsy and
Febrile Seizures . . . . . . . . . . . . . . . . 42
Child Neurology
Monday, April 28
C68
Stroke in Childhood and Adolescence . . . . 25
I4
Recent Advances in Translational
Research in Autism . . . . . . . . . . . . . . 45
Sleep Disorders
Monday, April 28
C84
Sleep Principles Applied to
Neurological Disease . . . . . . . . . . . . . 26
I3
Clocks, Sleep, Brain Health and Disorders:
Impact on Mechanism, Expression, and
Treatment . . . . . . . . . . . . . . . . . . . 44
Sports Neurology/Government Services
Friday, May 2
C142 Concussion in the Military and in Sports . . . 31
I12
Concussion in Sports and the Military . . . 132
Geriatric Neurology
Friday, May 2
C153 Imaging and Genomics for Detecting
Neurodegenerative Proteinopathy in
Clinical Practice . . . . . . . . . . . . . . . . 31
I11
4
2O14 Scientific Abstract Listing and Annual Meeting Information
Proteinopathy in
Neurodegenerative Disease . . . . . . . . 130
April 26–May 3, 2O14
Philadelphia, PA
One Flat Rate
and the Entire Education Program is Yours
NEW! Registration Buy All option includes access to all the exceptional 2014
Annual Meeting education courses*—in a wide variety of topics—for one
flat rate. A great value in CME programming. Select the Buy All Registration
Package when you register.
Register today at AAN.com/view/AM14.
* Skills Workshops and Skills Pavilions
excluded from Buy All pricing.
Attendee must identify courses to
be included as part of “Buy All”
purchase. Courses are subject
to closure due to reaching
maximum capacity. Buy All
registration option is only
available prior to early
registration deadline of
April 3, 2014.
What’s Included with Your Registration?
When planning your week, be sure and take advantage of these FREE education, scientific, practice, advocacy programs,
and social events—going on all week long and at no additional cost to you!
FREE Programs to help you:
Stay current with the latest research and scientific sessions
Enhance your practice with educational colloquia
Network with colleagues
Participate in Academy business
Saturday, April 26
CQ1 BRAINS Colloquium:
Understanding and Improving
Your Bottom Line
2:00 p.m.–5:00 p.m.
Sunday, April 27
I1 Temporal Lobe Epilepsy
and Febrile Seizures
8:00 a.m.–12:00 p.m.
CQ2 Research and Technology
Colloquium: From Discovery to Therapy
8:00 a.m.–12:00 p.m.
CQ3 Patient Safety Colloquium
9:00 a.m.–12:00 p.m.
S1 Section Topic Controversies:
ICU EEG Monitoring—Seizures
in Critically Ill Patients
1:00 p.m.–2:30 p.m.
CQ4 Clinical Research Colloquium
1:00 p.m.–5:00 p.m.
I2 New Antithrombotic
Agents for Stroke Prevention
1:00 p.m.–5:00 p.m.
CQ5 Practice Colloquium:
How to Navigate and Succeed in
New Payment Models
2:00 p.m.–5:00 p.m.
Opening Party
6:00 p.m.–10:00 p.m.
Monday, April 28
C61 Residents and Fellows Career
Breakfast: The Early Years
(registration required)
6:30 a.m.–8:30 a.m.
A AN/AANI Business Meeting
8:00 a.m.–8:30 a.m.
I3 Clocks, Sleep, Brain
Health and Disorders: Impact on
Mechanism, Expression, and Treatment
8:00 a.m.–12:00 p.m.
6
CQ6 Education Colloquium
8:30 a.m.–12:00 p.m.
Government Relations Committee
Meet and Greet
12:00 p.m.–1:30 p.m.
S2 Cancelled
Exhibit Hall Opening Reception
4:30 p.m.–6:30 p.m.
Student Interest Group in Neurology
(SIGN) Meeting
4:30 p.m.–6:30 p.m.
Consortium of Neurology
Residents and Fellows Meeting
5:00 p.m.–6:30 p.m.
Residents and Fellows
Career Forum and Reception
6:30 p.m.–9:00 p.m.
Tuesday, April 29
I4 Recent Advances in
Translational Research in Autism
1:00 p.m.–5:00 p.m.
AAN/ABPN MOC
Informational Session
1:30 p.m.–3:00 p.m.
CQ7 Education Research Colloquium
2:00 p.m.–4:30 p.m.
CQ8 Health Information
Technology Colloquium:
Advancements in Technology
2:00 p.m.–5:00 p.m.
P1 Poster Session I
3:00 p.m.–6:30 p.m.
P2 Poster Session II
7:30 a.m.–11:00 a.m.
Presidential Plenary Session
9:00 a.m.–12:00 p.m.
Exhibit Hall
11:30 a.m.–5:00 p.m.
PFO: Aggressive Treatment or
Just Aspirin
1:00 p.m.–2:30 p.m.
S4–S13 Scientific Platform Sessions
1:00 p.m.–2:45 p.m.
I5 Revolution of Genetic Tools and
the Impact on Neurology
1:00 p.m.–5:00 p.m.
I6 Peripheral Neuropathies
1:00 p.m.–5:00 p.m.
P3 Poster Session III
3:00 p.m.–6:30 p.m.
S14–S23 Scientific
Platform Sessions
3:15 p.m.–5:00 p.m.
Hot Topics Plenary Session
5:30 p.m.–6:30 p.m.
Included with registration
Registration fee required
Wednesday, April 30
Thursday, May 1
P4 Poster Session IV
7:30 a.m.–11:00 a.m.
Contemporary Clinical Issues
Plenary Session
9:00 a.m.–12:00 p.m.
Exhibit Hall
11:30 a.m.–5:00 p.m.
S24–S33 Scientific Platform
Sessions
2:00 p.m.–3:45 p.m.
I7 Emerging Therapeutic Advances
in Multiple Sclerosis
2:00 p.m.–6:00 p.m.
I8 Clinical Decision Making After the
Dust Settles on Clinical Trials
2:00 p.m.–6:00 p.m.
P5 Poster Session V
3:00 p.m.–6:30 p.m.
S34–S43 Platform Blitzes
4:00 p.m.–5:45 p.m.
Current Practice Issues in Neurology
5:30 p.m.–7:00 p.m.
Highlights in the Field Sessions
6:00 p.m.–7:00 p.m.
Emerging Science Session
6:00 p.m.–7:30 p.m.
P6 Poster Session VI
7:30 a.m.–11:00 a.m.
Frontiers in Neuroscience
Plenary Session
9:00 a.m.–12:00 p.m.
Exhibit Hall
11:30 a.m.–3:00 p.m.
Platform Sessions
1:00 p.m.–2:45 p.m.
I9 Emerging Concepts
in Headache Therapy
1:00 p.m.–5:00 p.m.
I10 The Global Burden of
Neurological Diseases
1:00 p.m.–5:00 p.m.
P7 Poster Session VII
3:00 p.m.–6:30 p.m.
Platform Sessions
3:15 p.m.–5:00 p.m.
5:30 p.m.–6:30 p.m.
Controversies in Neurology
Plenary Session
5:30 p.m.–7:00 p.m.
Friday, May 2
I11 Proteinopathy in
Neurodegenerative Disease
8:00 a.m.–12:00 p.m.
Clinical Trials Plenary Session
12:00 p.m.–1:30 p.m.
Pain: Methods of Treatment
1:00 p.m.–2:30 p.m.
I12 Concussion in
Sports and the Military
1:00 p.m.–5:00 p.m.
Neurology Year in Review
Plenary Session
5:30 p.m.–7:00 p.m.
Closing Party
7:30 p.m.–9:00 p.m.
Extend Your Experience with These Annual Meeting Resources
Academy Central:
Your one-stop shop for AAN products, services, and more
American Brain Foundation:
Support cures for brain disease and see the future of neurology
Neurology Career Center in Academy Central and the Exhibit Hall:
Meet employers, search for jobs, and get career tools
Resident/Medical Student Rush Line:
Free education program tickets, first-come, first-served
Annual Meeting Mobile App:
Lite version available now. Full version available March 2014.
Annual Meeting On Demand:
The digital library of content from the 2014 AAN Annual Meeting educational programs
Residents’ Experience:
A unique place to network, find information, and participate in informal
presentations specifically geared to those in the early stages of their career
International Experience:
New! Provides an opportunity for international attendees to network and
participate in discussions on a variety of topics
7
Look What’s New for 2014
Buy All Registration Option
Meet to Eat
Take advantage of this new option to purchase all your favorite
education courses for one flat rate! Hurry—the BUY ALL* option is
only available until the April 3 early registration deadline. See page
144 for more information, including Buy All exclusions and price.
You’ll notice something new in the poster sessions this year: A
selection of posters will be presented on large monitors, to allow
authors to best highlight visually compelling elements such as images
and videos.
Looking for another way to network with other neurology
professionals? Try a Meet to Eat event Monday, April 28–Thursday,
May 1. Meet to Eat events facilitate a gathering of attendees in a
casual dinner setting. Choose one of the four nights and the AAN
will make a 7:00 p.m. dinner reservation for you and other AAN
Annual Meeting attendees who signed up for the same night at one
of Philadelphia’s highly recommended restaurants. Meet new people,
make new connections, and enjoy a great meal! This service is free
of charge; attendees are responsible for the cost of the meal. Please
contact Kristine Mitchell at (612) 928-6062 or kmitchell@aan.com for
more information.
Clinical Research Track
Platform Blitzes
For attendees interested in a research career, the AAN has organized
a track of programs with that emphasis.
Utilizing a similar format to the popular Emerging Science Session,
these dynamic sessions will feature five-minute author presentations
followed by five-minutes of questions and answers. The session will
conclude with all authors participating in a panel discussion.
New Digital ePosters
More Opportunities to Network
¡¡ The hour between 12:00 p.m. and 1:00 p.m. will be free from
courses and sessions each day, making it easy for you to find
time to meet with colleagues
¡¡ Connect with colleagues before, during, and after
the meeting with the Annual Meeting LinkedIn Group
at AAN.com/view/AMLinkedIn .
¡¡ The International Experience provides a place for
international attendees to gather, network, and
participate in discussions on a variety of topics.
The International Experience is open Saturday,
April 26 through Friday, May 2.
* Skills Workshops and Skills Pavilions excluded from BUY ALL
pricing. Attendee must identify courses to be included as part
of “BUY ALL” purchase. Courses are subject to closure due to
reaching maximum capacity. BUY ALL registration option is only
available prior to early registration deadline of April 3, 2014.
8
See What’s Back by Popular Demand
These always-popular scientific programs are included free with
your registration!
Section Topic Controversies
Integrated Neuroscience Sessions (INS)
AAN Sections will debate controversies related to a specific Sectionrelated topic. This format will feature two speakers arguing a side of
the topic, followed by a rebuttal and question and answer period.
These well-attended sessions offer an in-depth look at subspecialty
areas using a variety of presentations, including data blitz sessions,
poster rounds, and invited speaker sessions.
AAN Plenary Sessions
Get essential updates covering the past year in your subspecialty
or topic of interest. Sections will provide overviews in their areas,
featuring scientific and educational abstracts, journal articles,
subspecialty society updates, tips, resources, and more.
AAN Plenary Sessions are the signature scientific sessions of the
Annual Meeting covering critical issues, hot topics, highlights,
and significant advances in neurology from the last year. This
year’s sessions showcase an outstanding lineup of premier
lecturers, chosen by their peers. Join us as they address the latest
controversies, breakthroughs, and advances in neuroscience.
Sessions run Tuesday, April 29 through Friday, May 2.
Scientific Poster and Platform Sessions
Poster Session QR Codes
Browse more than 2,500 poster and platform presentations covering
the latest research on a wide range of interest areas in neurology.
Sessions run Monday, April 28 through Thursday, May 1.
The QR code is one of the most popular types of two-dimensional
barcodes. The QR tag can be scanned by smart phones or tablets and
will link the attendee to the selected poster via AAN’s mobile access.
Once the QR tag is scanned, the attendee’s mobile device will link
to the poster title, authors, and links to the abstract, poster PDF, and
audio file. An attendee can scan a multitude of posters to see the
corresponding content.
Highlights in the Field
**Please note that each poster presenter needs to provide
permission for his or her poster information to be accessible in the
online poster viewing site.
9
Meeting Schedule Overviews
Meeting-at-a-Glance
Saturday April 26
Sunday April 27
6:00 a.m.
C20–C26
6:30 a.m.–8:00 a.m.
7:00 a.m.
8:00 a.m.
C27–C35
C1–C4
CQ2
8:00 a.m.–12:00 p.m.
8:00 a.m.–12:00 p.m. 8:00 a.m.–12:00 p.m.
Integrated
Neuroscience
8:00 a.m.–12:00 p.m.
9:00 a.m.
C5–C7
C36
9:00 a.m.–5:00 p.m.
9:00 a.m.–12:00 p.m. 9:00 a.m.–12:00 p.m. 9:00 a.m.–5:00 p.m.
CQ3
10:00 a.m.
C37–C41
C42–C44
10:00 a.m.–12:00 p.m.
11:00 a.m.
12:00 p.m.
OPEN HOUR 12:00 p.m.–1:00 p.m.
1:00 p.m.
C8–C11
1:00 p.m.–5:00 p.m.
S1
CQ4
C45–C53 Integrated
Section Topic 1:00 p.m.–5:00 p.m. 1:00 p.m.–5:00 p.m. Neuroscience
1:00 p.m.–5:00 p.m.
Controversies
1:00 p.m.–2:30 p.m.
2:00 p.m.
3:00 p.m.
CQ1
CQ5
2:00 p.m.–5:00 p.m.
2:00 p.m.–5:00 p.m.
C12–C19
3:00 p.m.–5:00 p.m.
4:00 p.m.
5:00 p.m.
6:00 p.m.
Opening Party
6:00 p.m.–10:00 p.m.
7:00 p.m.
8:00 p.m.
Current as of 2/10/2014 –Programs and dates are subject to change
Monday April 28
Tuesday April 29
C54–C60
C61
C89–C94
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:30 a.m.
(Free, Registration
Required)
6:30 a.m.–8:00 a.m.
State Society
Leadership
Roundtable
6:30 a.m.–8:30 a.m.
7:00 a.m.–8:30 a.m.
AAN/AANI Business Mtg C62–68
8:00 a.m.–8:30 a.m.
8:00 a.m.–12:00 p.m.
CQ6
Run/Walk
for Brain Research
Integrated
Neuroscience
P2
Poster
Session II
7:30 a.m.–11:00 a.m.
8:00 a.m.–12:00 p.m.
8:30 a.m.–12:00 p.m.
C69–70
C71–C76
9:00 a.m.–12:00 p.m. 9:00 a.m.–5:00 p.m.
Presidential Plenary
Session
C77
9:00 a.m.–12:00 p.m.
9:30 a.m.–12:00 p.m.
C78–C79
10:00 a.m.–12:00 p.m.
Exhibit Hall
11:30 a.m.–5:00 p.m.
S2
Cancelled
C80–C85
CQ7
CQ8
C86–C87
2:00 p.m.–4:30 p.m.
2:00 p.m.–5:00 p.m.
2:00 p.m.–5:00 p.m.
1:00 p.m.–5:00 p.m.
Integrated
Neuroscience
1:00 p.m.–5:00 p.m.
Government
Relations
Committee
Meet & Greet
12:00 p.m.–1:30 p.m.
AAN/ABPN
MOC
Informational
Session
S3
S4–S13
Section Topic 1:00 p.m.–2:45 p.m. 1:00 p.m.–5:00 p.m. Neuroscience
1:00 p.m.–5:00 p.m.
Controversies
1:00 p.m.–2:30 p.m.
C100
2:00 p.m.–5:00 p.m.
1:30 p.m.–3:00 p.m.
P1
Poster
Session I
3:00 p.m.–6:30 p.m.
P3
Poster
Session III
S14–S23
3:15 p.m.–5:00 p.m.
3:00 p.m.–6:30 p.m.
Exhibit Hall
Opening
Reception
4:30 p.m.–6:30 p.m.
5:30 p.m.–6:30 p.m.
Residents and Fellows
Career Forum and Reception
6:30 p.m.–9:00 p.m.
Corporate
Therapeutic Updates
7:00 p.m.–10:00 p.m.
Paid Programs/Events
Programs/Events Included
with Registration
Additional Events
Meeting-at-a-Glance
Wednesday April 30
Thursday May 1
C101–C107
C114–C119
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:00 a.m.
6:00 a.m.
7:00 a.m.
8:00 a.m.
P4
Poster
Session IV
P6
Poster
Session VI
7:30 a.m.–11:00 a.m.
9:00 a.m.
7:30 a.m.–11:00 a.m.
Contemporary Clinical
Issues Plenary Session
Frontiers in Neuroscience
Plenary Session
9:00 a.m.–12:00 p.m.
9:00 a.m.–12:00 p.m.
10:00 a.m.
11:00 a.m.
Exhibit Hall
12:00 p.m.
1:00 p.m.
Exhibit Hall
11:30 a.m.–5:00 p.m.
AAN/American
Brain Foundation
Awards Luncheon
11:30 a.m.–3:00 p.m.
OPEN
HOUR
OPEN HOUR
12:00 p.m.–1:00 p.m.
12:00 p.m.–1:30 p.m.
S44–S53
1:00 p.m.–5:00 p.m. Neuroscience
1:00 p.m.–2:45 p.m.
1:00 p.m.–5:00 p.m.
2:00 p.m.
S24–S33
C108–113
2:00 p.m.–3:45 p.m.
2:00 p.m.–6:00 p.m.
C124–125
Integrated
Neuroscience
2:00 p.m.–5:00 p.m.
2:00 p.m.–6:00 p.m.
3:00 p.m.
P5
Poster
Session V
3:00 p.m.–6:30 p.m.
4:00 p.m.
Current
Practice
Issues in
Neurology
Highlights in
the Field
Sessions
6:00 p.m.–7:00 p.m.
Corporate
Therapeutic Updates
7:00 p.m.–10:00 p.m.
8:00 p.m.
3:15 p.m.–5:00 p.m.
3:00 p.m.–6:30 p.m.
4:00 p.m.–5:45 p.m.
5:30 p.m.–7:00 p.m.
7:00 p.m.
S54–S63
S34–S43
Platform
Blitzes
5:00 p.m.
6:00 p.m.
P7
Poster
Session VII
Emerging
Science
Session
6:00 p.m.–7:30 p.m.
Highlights in
the Field
Sessions
5:30 p.m.–6:30 p.m.
Controversies in
Neurology
Plenary
C126–131
Session
6:00 p.m.–9:00 p.m.
5:30 p.m.–7:00 p.m.
Friday May 2
Saturday May 3
C132–C137
C154–C158 C159
6:30 a.m.–8:00 a.m.
6:30 a.m.–8:00 a.m.
8:00 a.m.–12:00 p.m. Neuroscience
C160–C165
6:30 a.m.–8:30 a.m.
8:00 a.m.–12:00 p.m.
8:00 a.m.–12:00 p.m.
C143–C148
C166
9:00 a.m.–5:00 p.m.
9:00 a.m.–12:00 p.m.
C167–169
10:00 a.m.–12:00 p.m.
Clinical Trials
Plenary Session
12:00 p.m.–1:30 p.m.
OPEN HOUR
12:00 p.m.–1:00 p.m.
S64
1:00 p.m.–5:00 p.m. Neuroscience Section Topic
1:00 p.m.–5:00 p.m. Controversies
1:00 p.m.–2:30 p.m.
Neurology Year in Review Plenary Session
5:30 p.m.–7:00 p.m.
Paid Programs/Events
Closing Party
7:30 p.m.–9:00 p.m.
Programs/Events Included
with Registration
Additional Events
Scientific Sessions-at-a-Glance
Sunday, April 27, 2014
S8
8:00 a.m.–12:00 p.m. I1 Temporal Lobe Epilepsy and
Febrile Seizures . . . . . . . . . . . . 42
1:00 p.m.–2:30 p.m. S1 Section Topic Controversies:
ICU EEG Monitoring: Seizures in
Critically Ill Patients . . . . . . . . . . 42
S9Sleep
¡¡ Presentation of the Sleep Science Award
¡¡ Presentation of the Wayne A. Hening Sleep Medicine
Investigator Award
1:00 p.m.–5:00 p.m. I2 New Antithrombotic Agents
for Stroke Prevention . . . . . . . . . 43
S10
Monday, April 28, 2014
8:00 a.m.–12:00 p.m. I3 Clocks, Sleep, Brain
Health and Disorders: Impact
on Mechanism, Expression, and
Treatment . . . . . . . . . . . . . . . . 44
1:00 p.m.–2:30 p.m. S2 Cancelled
1:00 p.m.–5:00 p.m. I4 Recent Advances in
Translational Research in Autism . 45
3:00 p.m.–6:30 p.m. P1 Poster Session I . . . . . . . . 48–55
Tuesday, April 29, 2014
7:30 a.m.–11:00 a.m. P2 Poster Session II . . . . . . . . 56-63
9:00 a.m.–12:00 p.m.
Presidential Plenary Session . . . . . . . . . . . . . 64
Features the AAN’s premier lecture awards for clinically relevant
research and a presentation by a leading lecturer. Top researchers
speak on some of the most significant findings in neurology in 2014.
PFO: Aggressive Treatment
or Just Aspirin . . . . . . . . . . . . . 65
1:00 p.m.–2:45 p.m. Scientific Platform Sessions . . . 66–67
S4
MS and CNS Inflammatory Disease: Clinical Trials
S5
Cerebrovascular Disease and Interventional Neurology:
Pre-hospital, Telemedicine, and Related Topics
S6
Neuromuscular Disease: Gene Therapy
S7
Parkinson’s Disease: Preclinical and Clinical Therapeutics
Aging, Dementia, and Cognitive and Behavioral Neurology:
PET Imaging
¡¡ Presentation of the Potamkin Prize for Research in Pick’s,
Alzheimer’s Disease, and Related Diseases
HIV, PML, and Cerebral Malaria
¡¡ Presentation of the Bruce S. Schoenberg
International Award in Neuroepidemiology
S11
Neuro Trauma, Critical Care, and Sports Neurology
Epidemiology and Risk Factors
S13 MS and CNS Inflammatory Disease: MRI Atrophy Measures
and Correlations
1:00 p.m.–5:00 p.m. I5 Revolution of Genetic Tools
and the Impact on Neurology . . . 68
1:00 p.m.–5:00 p.m. I6 Peripheral Neuropathies . . . . . 69
3:00 p.m.–6:30 p.m. P3 Poster Session III . . . . . . . . 70–77
S14 MS and CNS Inflammatory Disease: Animal and In Vitro
Studies
S15 Cerebrovascular Disease and Interventional Neurology:
Clinical and Imaging Biomarkers and Genetics
S16 Neuromuscular and Clinical Neurophysiology (EMG): Clinical
Trials and Therapy
S17 Parkinson’s Disease: Genetics and Epidemiology
S18 Aging, Dementia, and Cognitive and Behavioral Neurology:
Behavioral Neuroscience
S19 Neuro-ophthalmology/Neuro-otology I
S20 Pain and Palliative Care
¡¡ Presentation of the Mitchell B. Max Award for
Neuropathic Pain
S12
S21
Neurorehabilitation and Neural Repair
iPosters, a virtual poster hall, that transforms your poster hall into an online
and mobile experience—both during a meeting and long after.
¡¡ Online, interactive, fully searchable poster database with
the ability to magnify the poster content for detailed viewing,
contact the author directly with comments or questions,
bookmark posters for easy access on return visits, and
much more.
14
¡¡ New this year: Poster authors have the ability to record a
5- to 7-minute summary of their poster. This summary will be
linked to the author’s iPoster submission and will give viewers
the ability to hear about the poster from the author, in addition
to viewing at it.
S22Neuro-oncology
S23
MS and CNS Inflammatory Disease: Novel Therapeutics
¡¡ Presentation of the John Dystel Prize for
Multiple Sclerosis Research
5:30 p.m.–6:30 p.m.
Hot Topics Plenary Session . . . . . . . . . . . . . . 80
Features translational research related to clinical issues of
importance. Four outstanding physician-scientists provide
summaries of their recent research findings and describe the
clinical implications of the results.
Wednesday, April 30, 2014
7:30 a.m.–11:00 a.m. P4 Poster Session IV . . . . . . . . 81–88
9:00 a.m.–12:00 p.m.
Contemporary Clinical Issues
Plenary Session . . . . . . . . . . . . . . . . . . . . . . 89
Highlights issues most critical to practicing neurologists,
including abstracts related to new therapeutic developments,
clinical applications of basic and translational research, and
innovative technical developments.
Commentary and discussion follow each presentation.
S24 Diet and Hormonal Influences in MS
Hemorrhage, Aneurysms, and Vascular Malformations
S26 Biomarkers in Neuromuscular Diseases
S27 Dystonia, Tremor, and Other Movement Disorders
¡¡ Presentation of the Movement Disorders Research Award
Dementia Genetics
¡¡ Presentation of the Norman Geschwind Prize in
Behavioral Neurology
S29 Epilepsy and Clinical Neurophysiology: Inflammation, Status
Epilepticus, and Genetics
¡¡ Presentation of the Dreifuss-Penry Epilepsy Award
S30 Education, Research, and History
¡¡ Presentation of the Lawrence C. McHenry Award:
An Award for the History of Neurology
¡¡ Presentation of the S. Weir Mitchell Award
S31 General Neurology I
S32 Headache: Basic Science and Imaging
¡¡ Presentation of the Harold Wolff-John Graham Award:
An Award for Headache/Facial Pain Research
S33 Cognition Fatigue in MS
2:00 p.m.–6:00 p.m. I7 Emerging Therapeutic Advances
in Multiple Sclerosis . . . . . . . . . . 92
2:00 p.m.–6:00 p.m. I8 Clinical Decision Making After
the Dust Settles on Clinical Trials . . 93
3:00 p.m.–6:30 p.m. P5 Poster Session V . . . . . . . .94–101
4:00 p.m.–5:45 p.m. Platform Blitzes . . . . . . . . . 102–103
S34 MS and CNS Inflammatory Disease: Risk Factors for MS
Disease and Course
Issues in Acute Treatment
S36 Neuromuscular Disease: Clinical
S37 Clinical Aspects of Parkinson’s Disease
Plasma and Other Biomarkers
S39 Neuro-ophthalmology/Neuro-otology II
S40 General Neurology II
S41 Headache: Clinical
S42 Child Neurology I
S43 Epilepsy and Clinical Neurophysiology (EEG): Cognition
6:00 p.m.–7:00 p.m. Highlights in the Field
H1
Child Neurology
H2Epilepsy
H3Geriatric
H4
Headache & Facial Pain
H5
Movement Disorders
H6
Multiple Sclerosis
H7
Neural Repair & Rehabilitation
H8Neuro-oncology
H9Neuro-ophthalmology/Neuro-otology
H10Sleep
H11 Sports Neurology
6:00 p.m.–7:30 p.m. Emerging Science Session
Thursday, May 1, 2014
7:30 a.m.–11:00 a.m. P6: Poster Session VI . . . . . . 104–111
9:00 a.m.–12:00 p.m.
Frontiers in Neuroscience Plenary Session . . 112
Focuses on translational research related to clinical issues of
importance. Six physician scientists outline their recent research
findings, along with the clinical implications.
1:00 p.m.–2:45 p.m. Scientific Platform Sessions . . 114–115
S44 MS and CNS Inflammatory Disease: Neuroimaging I
Rehabilitation, Recovery, and Complications
S46 Neuromuscular Disease: Genetics, Pathogenesis, and
Measures
Scientific Sessions-at-a-Glance
S47
Movement Disorders: Huntington’s Disease, Ataxia, and
Wilson’s Disease
¡¡ Presentation of the Jon Stolk Award in
Movement Disorders for Young Investigators
S48
MRI Imaging
Practice, Policy, and Ethics
Epilepsy and Clinical Neurophysiology (EEG):
Electrophysiology, Imaging and Functional Connectivity
¡¡ Presentation of the Founders Award
S49
S50
S51
Large Vessel Atherosclerotic Disease
¡¡ Presentation of the Michael S. Pessin
Stroke Leadership Prize
S52
General Neurology III
S53 MS and CNS Inflammatory Disease: Biomarkers and
Therapeutic Mechanisms
1:00 p.m.–5:00 p.m. I9 Emerging Concepts in
Headache Therapy . . . . . . . . . 116
1:00 p.m.–5:00 p.m. I10 The Global Burden of
Neurological Diseases . . . . . . . 117
3:00 p.m.–6:30 p.m. P7 Poster Session VII . . . . . . 118–125
3:15 p.m.–5:00 p.m. Scientific Platform Sessions . . 126–127
S54 MS and CNS Inflammatory Disease: Neuroimaging II
S55 Pediatric Stroke and Stroke in the Young
S56 Anterior Horn Disease
¡¡ Presentation of the Sheila Essey Award:
An Award for ALS Research
S57
S58
S59
S60
S61
S62
S63
Movement Disorders: Imaging
Clinical Aspects
Epilepsy and Clinical Neurophysiology (EEG): Reproduction,
Health Care Delivery, and Co-morbidities
Child Neurology II
Muscle Disease: Gene Therapy and Models
Cognitive and Behavioral
Neuromyelitis Optica and Autoimmune Encephalitis
5:30 p.m.–6:30 p.m. Highlights in the Field
H12 Adult Intellectual and Developmental Disabilities
H13 Endovascular and Interventional Neurology, and Stroke and
Vascular Neurology
H14 Women’s Issues in Neurology
H15 Critical Care
5:30 p.m.–7:00 p.m.
Controversies in Neurology
Plenary Session . . . . . . . . . . . . . . . . . . . . . . 128
The program features experts discussing the most current
and controversial issues in neurology. It is set up as a series of
debates in which two speakers argue opposing sides of a
single topic, followed by a rebuttal. Each round concludes with
a 10-minute question and answer period.
Friday, May 2, 2014
8:00 a.m.–12:00 p.m. I11 Proteinopathy in
Neurodegenerative Disease . . . . 130
12:00 p.m.–1:30 p.m.
Clinical Trials Plenary Session . . . . . . . . . . . . 131
This mid-day session covers important clinical topics that affect
patient care identified from other society meetings. The latest
updates within several clinical trials conducted over the course
of the last year will be presented with an open panel discussion
at the conclusion.
Pain: Methods of Treatment . . . . 132
1:00
p.m.–5:00
p.m.
I12 Concussion in Sports
and the Military . . . . . . . . . . . . 132
5:30 p.m.–7:00 p.m.
Neurology Year in Review Plenary Session . . 133
This plenary session will feature six speakers, each focusing on
the latest research that has happened in the last year within a
specific subspecialty topic.
QR Code
¡¡ The QR code is one of the most popular types of twodimensional barcodes. The QR tag can be scanned by smart
phones or tablets and will link the attendee to the selected
poster via AAN’s Mobile access. Once the QR tag is scanned,
the attendee’s mobile device will link to the poster title,
authors, and links to the abstract, poster PDF, and audio file.
An attendee can literally scan a multitude of posters to see the
corresponding content.
Please note that each poster presenter needs to provide permission for their poster information to be accessible in the
online poster viewing site.
16
2014 Award Recipients
AAN Alliance Awards
John Dystel Prize for Multiple Sclerosis Research
Founders Award
Presented by the American Academy of Neurology and the National
Multiple Sclerosis Society and made possible through a special
contribution for the John Dystel Multiple Sclerosis Research Fund at
the National Multiple Sclerosis Society.
Sponsored by the American Brain Foundation and endowed by the
Alliance Founders and S. Weir Mitchell Permanent Endowment.
Recipient: Shennan Weiss, MD, PhD / New York, NY
S50: Epilepsy and Clinical Neurophysiology (EEG):
Electrophysiology, Imaging, and Functional Connectivity
Thursday, May 1, 1:00 p.m.
Resection of Ictal Phase Locked HFOs is Correlated With
Outcome Following Epilepsy Surgery
S. Weir Mitchell Award
Sponsored by the American Brain Foundation and endowed by the
Alliance Founders and S. Weir Mitchell Permanent Endowment.
Recipient: Michael Fox, MD, PhD / Newton, MA
S30: Education, Research, and History
Wednesday, April 30, 2:30 p.m.
Lesion-Based Network Analysis: Identifying
Distributed Effects of Peduncular
Hallucinosis Lesions
A.B. Baker Award for Lifetime Achievement in
Neurologic Education
Recipient: Barry Arnason, MD / Chicago, IL
S23: MS and CNS Inflammatory Disease:
Novel Therapeutics
Tuesday, April 29, 3:15 p.m.
Sheila Essey Award: An Award for ALS Research
Presented by the American Academy of Neurology and The ALS
Association and supported through the philanthropy of the Essey
Family Fund and The ALS Association.
Recipient: Jeremy Shefner, MD, PhD / Syracuse, NY
S56: Anterior Horn Disease
American Brain Foundation Chair’s Award
Sponsored by the American Brain Foundation.
Recipient: Linda M. Selwa, MD, FAAN / Ann Arbor, MI
Funded by and endowment created by matching funds from the A.B.
Baker Family Trust and Novartis Pharmaceuticals.
Norman Geschwind Prize in Behavioral Neurology
Recipient: Jerome Posner, MD, FAAN / New York, NY
CQ6: Education Colloquium
Monday, April 28, 8:30 a.m.
Sponsored by the American Academy of Neurology and the AAN
Behavioral Neurology Section and endowed through the Dr.
Geschwind’s family, friends, and colleagues; Pfizer Inc; and the
Society for Behavioral and Cognitive Neurology.
AAN Award for Creative Expression of Human
Values in Neurology
Recipient: Roy Hamilton, MD, MS / Philadelphia, PA
S28: Aging, Dementia, and Cognitive and Behavioral
Neurology: Dementia Genetics
Sponsored by the Neurology Ethics, Law, and Humanities
Committee.
Recipient: Jorge L. Almodovar-Suarez, MD / Manchester, NH
Mitchell B. Max Award for Neuropathic Pain
Dreifuss-Penry Epilepsy Award
Sponsored by the American Academy of Neurology and endowed by
the United States Cancer Pain Relief Committee, the Mayday Fund,
and friends of Dr. Mitchell Max.
Sponsored by the American Academy of Neurology and endowed
by members of the AAN Epilepsy Section; Abbott Laboratories,
Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals,
Inc.; GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil
Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma.
Recipient: Kathleen Foley, MD / New York, NY
S20: Pain and Palliative Care
Recipient: Catherine Schevon, MD, PhD / New York, NY
S29: Epilepsy and Clinical Neurophysiology:
Inflammation, Status Epilepticus, and Genetics
18
Jon Stolk Award in Movement
Disorders for Young Investigators
Lawrence C. McHenry Award: An Award for the
History of Neurology
Kyowa Pharmaceuticals, Inc.; Lineberry Research; Quintiles; and Dr.
Dennis Gillings.
Sponsored by the American Academy of Neurology.
Recipient: Alice Chen-Plotkin, MD / Philadelphia, PA
S47: Movement Disorders: Huntington’s Disease,
Ataxia, and Wilson’s Disease
Association of Indian Neurologists in America
(AINA) Lifetime Achievement Award
Endowed by the Association of Indian Neurologists in America
(AINA).
Recipient: Avindra Nath, MBBS, FAAN / Bethesda, MD
During the AINA Business Meeting
Tuesday, April 29, 2014, at 7:15 p.m.
International Scholarship Award
Sponsored by the American Academy of Neurology International
Subcommittee.
Recipients: Mohammadkazem Bakhshandeh Bali /
Tehran, Iran
Recipients: Farrah Mateen, MD, PhD / Boston, MA
Christopher Boes, MD / Rochester, MN
S30: Education, Research, and History
“Pinheads”: Neurological Disorders at
the Greatest Show on Earth
Medical Student Essay Awards
Extended Neuroscience Award
Recipient: Ran (Richard) Liu, MSc / Coquitlum, BC, Canada
P2: Poster Session II
Tuesday, April 29, 7:30 a.m.
Voice Discrimination and Recognition in
Patients with Prosopagnosic Complaints
G. Milton Shy Award in Clinical Neurology
Recipient: David Asuzu, PhD / New Haven, CT
HAT Score Outperforms 7 other
Hemorrhagic Transformation Scores
Prasanna Venkatesan Eswaradass / Salem, India
Meng-Shan Tan / Qingdao, China
Teng Jiang / Qingdao, China
Yael Hacohen / London, United Kingdom
Ruth Dobson / London, United Kingdom
Recipient: Trent Hodgson / Chicago, IL
Subspecialization in Neurology:
Historical Perspectives on Current Challenges
Marta Campagnolo / Padova, Italy
Saul R. Korey Award in Experimental Neurology
Dimitra Papadimitriou / Athens, Greece
Chiara Dalla Torre / Padova, Italy
Julieta Arena / Buenos Aires, Argentina
Alberto Martinez / Campinas, Sao Paulo
Francisco Varela / Buenos Aires, Argentina
Recipient: Jessica Shields / New Orleans, LA
Probing the Interaction of the Ipsilateral Posterior
Parietal Cortex with the Premotor Cortex Using a Novel
Transcranial Magnetic Stimulation Technique
Jorge jesús Llibre / Havana, Cuba
International Experience
Monday, April 28, 1:00 p.m.
Roland P. Mackay Award in Historical Aspects
Minority Scholars Program
Sponsored by a grant from the Allergan Foundation.
Recipients: Marcella Evans /
University of California School of Medicine
Gregory R. Franklin, II /
Medical University of South Carolina
Daniel A. Cristancho /
Perelman School of Medicine at the University of
Pennsylvania
19
2014 Award Recipients
Laura C. Ramirez /
Temple School of Medicine
Palatucci Advocacy Leadership Forum
Advocates of the Year
Jason Neal, PhD /
Columbia University, College of Physicians and
Surgeons
Sponsored by the AAN Government Relations Committee.
Shekinah Nefreteri Elmore /
Harvard Medical School
Patient Safety Award
Julian Flores /
Harvard Medical School
Sponsored by Professional Risk Management Services, Inc.,
management of The Neurologists’ Program.
H. Westley Phillips /
Perelman School of Medicine
University of Pennsylvania
Recipients: Shelly Ozark, MD / Charleston, SC
Physician Patient Safety Award
Sara Dawit /
University of Kansas School of Medicine
Catherine Elaine Norise /
Perelman School of Medicine
Movement Disorders Research Award
Sponsored by the American Academy of Neurology, the Parkinson’s
Disease Foundation, and the AAN Movement Disorder Section and
endowed by the Parkinson’s Disease Foundation.
Recipient: Eduardo Tolosa, MD, PhD / Barcelona, Spain
S27: Dystonia, Tremor, and Other Movement Disorders
Neuroscience Research Prize
Sponsored by the American Academy of Neurology, the American
Brain Foundation, and the Child Neurology Society.
Recipients: Charlotte Herber / Pound Ridge, NY
Stefanie Henry / Brooklyn, NY
Lisa Michaels / Plano, TX
P3: Poster Session III
Child Neurology Neuroscience Research Prize
Recipient: Donn Dexter, MD, FAAN / Eau Claire, WI
Michael S. Pessin Stroke Leadership Prize
Dr. Pessin’s family, friends, and colleagues.
Recipient: Hooman Kamel, MD / New York, NY
S51: Cerebrovascular Disease and Interventional
Neurology: Large Vessel Atherosclerotic Disease
Potamkin Prize for Research in Pick’s,
Alzheimer’s, and Related Diseases
Brain Foundation, and funded through the philanthropy of the
Potamkin Family.
Recipient: M. Marsel Mesulam, MD / Chicago, IL
S8: Aging, Dementia, and Cognitive and Behavioral
Neurology: PET Imaging
American Academy of Neurology
President’s Award
Recipient: Guy McKhann, MD / Baltimore, MD
Brain Foundation, and the Child Neurology Society.
Recipient: Laura Herman / Fort Lauderdale, FL
Note: The recipient will attend the 43rd
Child Neurology Society Annual Meeting
in Columbus, OH
20
Julio Rojas-Martinez, MD, PhD/ Dallas, TX
Resident Patient Safety Award
Quality Award
H. Richard Tyler Award
Recipients: Dheeraj Khurana, MD / India
Practicing Physician Quality Award
Archive Committee.
Recipient: Edward J. Fine, MD, FAAN / Buffalo, NY
Laura Rosow, MD / San Francisco, CA
Resident Quality Award
Kenneth M. Viste Jr., MD, Patient
Advocate of the Year Award
Neuroendocrine Research Award
Sponsored by the American Academy of Neurology and supported
by friends of Dr. Andrew Herzog.
Recipient: Stafford Lightman, MB BCHir, MRCP, PhD, FRCP /
Bristol, United Kingdom
Bruce S. Schoenberg International
Award in Neuroepidemiology
Endowed by gifts from Dr. Viste’s colleagues, friends, and patients.
Recipient: Anthony G. Alessi, MD, FAAN / Norwich, CT
Harold Wolff-John Graham: An Award for
Headache/Facial Pain Research
Endo Pharmaceuticals.
Endowed by GlaxoSmithKline, Inc.
Recipient: Devender Bhalla, PhD / Limoges, France
S10: HIV, PML, and Cerebral Malaria
Recipient: Jakob Møller Hansen, MD, PhD / Los Angeles, CA
S32: Headache: Basic Science and Imaging
Wayne A. Hening Sleep Medicine
Investigator Award
Sleep Science Award
Sleep Section and endowed by Cephalon, Inc.
Recipient: Claudia Trenkwalder, MD / Kassel, Germany
S9: Sleep
UCB, Inc.; Lilly USA; Elite Home Medical & Respiratory, Inc.; Raleigh
Neurology Associates; and friends of Dr. Wayne A. Hening.
Recipient: Aleksandar Videnovic, MD, MSc / Boston, MA
S9: Sleep
“[The Annual Meeting Science Programs] are amazing.
The poster sessions are inspiring. You get these young
researchers just starting, and they come out with
beautiful things that just blow you away. ”
Kathleen M. Fitzgerald, MD
Eugene, OR
2014 Research Fellowships
American Brain Foundation Clinical Research
Training Fellowships
Cosponsored by the American Academy of Neurology and the
American Brain Foundation.
Recipients: Brian Edlow, MD
Massachusetts General Hospital
Stefanie Geisler, MD
Washington University, Saint Louis
Eyal Kimchi, MD, PhD
Svjetlana Miocinovic, MD, PhD
UT Southwestern Medical Center
Lidia Maria Moura, MD
Peter Pressman, MD
University of California San Francisco
Lucia Rivera Lara, MD
Johns Hopkins University School of Medicine
Rainer von Coelln, MD, PhD
University of Maryland School of Medicine
Susan S. Spencer Clinical Research Training
Fellowship in Epilepsy
Cosponsored by the American Brain Foundation, the
American Epilepsy Society, and the Epilepsy Foundation.
Recipient: Colin Josephson, MD, MSc
University of Calgary
Clinical Research Training Fellowship in the
Neurologic Application of Neurotoxins
Funded by the Allergan Foundation.
Recipients: Srikant Rangaraju, MD
Emory University
Valerie Rundle Gonzales, MD
University of Florida College of Medicine
American Brain Foundation Practice Research
Training Fellowship
Cosponsored by the American Academy of Neurology and the
American Brain Foundation.
Recipient: David Hwang, MD
Yale School of Medicine
Clinical Research Training Fellowship in Ataxia
Cosponsored by the American Brain Foundation and the
National Ataxia Foundation.
Recipient: Padmaja Vittal, MD, MS
Rush University Medical Center
Clinical Research Training Fellowship in MS
Cosponsored by the American Brain Foundation and Biogen Idec.
Recipient: Bardia Nourbakhsh, MD
Robert Katzman, MD. Clinical Research Training
Fellowship in Alzheimer’s Research
Alzheimer’s Association.
Recipient: Elissios Karageorgiou, MD
Clinician-Scientist Development Three-Year Award
National Multiple Sclerosis Society.
Recipient: Matthew Schindler, MD, PhD
in Myasthenia Gravis and Related Disorders of the
Neuromuscular Junction
Myasthenia Gravis Foundation of America.
Recipient: Ricardo Roda, MD, PhD
New York University
in Parkinson’s Disease
Parkinson’s Disease Foundation.
Recipient: Amber Van Laar, MD
University of Pittsburgh Medical Center
Lawrence M. Brass Stroke Research
Postdoctoral Fellowship
American Heart Association/American Stroke Association.
Recipient: Amin Khalifeh Soltani, MD, MPH
School of Medicine
22
New! Clinical
Research Track
The outlined programs below are part of the new Clinical Research Track for the 2014 AAN Annual Meeting. For more information on the programs
below, please visit the Annual Meeting Program Search at AAN.com/view/SearchAM. To register for the programs please visit: AAN.com/view/register.
Saturday, April 26
C7 Research Career Development
Symposium: How to Be Successful
in Academic Neuroscience
9:00 a.m.–5:00 p.m.
This program is designed for academic
neurologists who are early in the development of a
clinician scientist career. The focus is on strategies
for earning a mentored career development award.
Sunday, April 27
CQ2 Research and Technology
Colloquium: From Discovery
to Therapy
8:00 a.m.–12:00 p.m.
Academic, industry, and regulatory
representatives will address challenges in the
drug development process from drug discovery
through clinical trials. Faculty will facilitate a
discussion with the attendees on how to advance
laboratory findings to novel therapies.
1:00 p.m.–5:00 p.m.
This colloquium provides a brief introduction to the
clinical trial, the cohort study, and the case-control
study with emphasis on their complementarities
and their relative strengths and weaknesses.
Monday, April 28
C79 Strategic Grant Writing
10:00 a.m.–12:00 p.m.
Faculty will emphasize strategies for devising
strong lab- or patient-based research proposals,
from establishing the importance of the research
question to developing a strong, biologically
based hypothesis, and demonstrating the
capability of carrying the study to completion.
Futures in Clinical Research Luncheon
12:00 p.m.–2:00 p.m.
Provides information on a career in clinical
research and an opportunity to interact with
senior clinical researchers for students, residents,
and fellows. Must sign up to attend.
For more details and to register, contact
Nate Kosher at nkosher@aan.com.
Tuesday, April 29
Futures in Clinical Research
Luncheon Mentoring Sessions
12:00 p.m.–1:30 p.m.
Mentoring sessions for students, residents,
and fellows in seven subspecialty areas: Child
Neurology, Epilepsy, Headache, Multiple Sclerosis,
Muscular Dystrophy, Neurocritical Care, and
Parkinson’s Disease. Must sign up to attend.
I5 Revolution of Genetic Tools
and the Impact on Neurology
1:00 p.m.–5:00 p.m.
This program will provide an integrative journey
through the revolution in molecular genetics and
associated technologies and their immediate
and long-term applications, including a broad
perspective on the promise genomic medicine
holds, an introduction to the spectrum of genomic
information that can be interrogated, perspectives
on ethical challenges, and the practical perspective
of a neurologist using genomic information.
Wednesday, April 30
I8 Clinical Decision Making After
the Dust Settles on Clinical Trials
2:00 p.m.–6:00 p.m.
Once a trial establishing the efficacy of a new
treatment is published, many questions remain
to be answered before a neurologist can apply
that new knowledge in a way to produce the full
health benefit for individual patients and across
that neurologist’s entire practice. In this session,
research in key areas that are critical to consider
is illustrated, and the current status of each of
these areas in neurology is summarized.
For more details and to register, contact
Nate Kosher at nkosher@aan.com.
April 26 – May 3, 2014
Philadelphia, PA
Annual Meeting Program Schedule
For full course information please reference the 2014 Annual Meeting Registration and Advance Program or view the
Annual Meeting Program Search at AAN.com/view/SearchAM.
Saturday, April 26
8:00 a.m.–12:00 p.m.
Clinical Approach to Muscle Disease
C1
How to Analyze Spells by Video-EEG
C2
Assessment of Rapidly Progressive Dementias
C3
and Related Neurologic Conditions
Resident Basic Science I: Neuropathology
C4
9:00 a.m.–5:00 p.m.
Clerkship and Program Directors Conference
C5
The Practice of Neurology: Issues in
C6
Coding and Reimbursement
Research Career Development Symposium:
C7
How to Be Successful in Academic Neuroscience
1:00 p.m.–5:00 p.m.
Evaluation and Management of Autonomic Disorders
C8
Differential Diagnosis of Neurologic Infections
C9
C10 Approach to Sleep Symptoms: Sleepy or Sleepless
C11 Resident Basic Science II: Neuroanatomy
2:00 p.m.–5:00 p.m.
CQ1 BRAINS Colloquium: Understanding and Improving
Your Bottom Line
3:00 p.m.–5:00 p.m.
C12 The Dystonias: Diagnosis, Treatment, and
Update on Causes
C13 Practice Survival for Neurologists: Business
Strategies for Success
C14 Preventing a First Stroke: What Every
Neurologist Needs to Know
C15 Top 10 Neuro-ophthalmic Diagnoses
You Can’t Afford to Miss
C16 Multiple Sclerosis Essentials
C17 Attention Deficit Hyperactivity Disorder
Across the Lifespan
C18 Therapy of Headache
C19 Controversies in Brain Death Determination
Sunday, April 27
6:30 a.m.–8:00 a.m.
C20 Neuro Flash: MRI and Multiple Sclerosis
C21 Neuro Flash: Acute Stroke Management
C22 You Make the Call—An Interactive, Multimedia,
Case-based Approach to Learning EMG
24
C23
Hyperkinetic Movement Disorders:
Diagnosis and Treatment
C24 Global Health Challenges:
Neurology in Developing Countries
C25Creativity
C26 Introduction to Genetics
8:00 a.m.–12:00 p.m.
CQ2 Research and Technology Colloquium:
From Discovery to Therapy
8:00 a.m.–12:00 p.m.
C27 Clinical EMG I
C28 Botulinum Toxins: Practical Issues and
Clinical Uses for Neurologists
C29 Multiple Sclerosis Overview I:
Basic and Translational Science
C30
Sleep
for the Practicing Neurologist
C31 Resident Basic Science III: Neuropharmacology
C32 Child Neurology I
C33
Prevention of Cardioembolic Stroke in Patients
with Nonvalvular Atrial Fibrillation: Recommendations
Based on Evidence-based Guidelines and Recent
Randomized Trials
C34 Neuroimaging for the General Neurologist: Brain
C35
Life Reimagined
I1
Temporal Lobe Epilepsy and Febrile Seizures . . 42
9:00 a.m.–12:00 p.m.
9:00 a.m.–12:00 p.m.
C36 EEG in Children: Developmental Maturation,
Variants, Epilepsy Syndromes, and Identification
of Surgical Candidates
9:00 a.m.–5:00 p.m.
C37 Therapy in Neurology
C38 Neurologic Intensive Care
C39Neuro-ophthalmology
C40 Spine Neurology: Assessment and
Management of Common Spine Disorders
C41 Neurophysiologic Intraoperative Monitoring
Skills Workshop
10:00 a.m.–12:00 p.m.
C42 Vascular Cognitive Impairment and Dementia:
Current Status and Future
C43 E/M: Minimize Mistakes, Maximize Reimbursement
C44 Update on Ataxias
Leadership Development
1:00 p.m.–2:30 p.m.
S1
Section Topic Controversies:
ICU EEG Monitoring—Seizures in Critically Ill Patients . 42
1:00 p.m.–5:00 p.m.
1:00 p.m.–5:00 p.m.
C45 Clinical EMG II
C46 Non-Alzheimer’s Dementia
C47 Multiple Sclerosis Overview II: Clinical Advances
C48 Autoimmune Neurology
C49 Child Neurology II
C50 Core Concepts in Pain Management
C51
Algorithms in the Diagnosis
and Treatment of Epilepsy
C52 Neuroimaging for the General Neurologist:
Spine and Peripheral Nerve
C53 Clinical Usefulness of Botulinum Toxin and Treatment
of Dystonia Skills Pavilion
I2
Stroke Prevention . . . . . . . . . . . . . . . . . . . . . . 43
2:00 p.m.–5:00 p.m.
CQ5 Practice Colloquium: How to Navigate and
Succeed in New Payment Models
7:00 a.m.–8:30 a.m.
State Society Leadership Roundtable
Leadership representatives of state neurological societies are
invited to discuss challenges, strategies, and practices related
to state society creation and maintenance. Discussion will be
facilitated by Academy staff. Participants will learn from the
experiences of established societies and be introduced to the
resources available from the Academy.
8:00 a.m.–8:30 a.m.
A AN/AANI Business Meeting
All members are invited to attend the meeting to
take part in the Academy business.
8:00 a.m.–12:00 p.m.
C62 Continuum ® Test Your Knowledge:
A Multiple-Choice Question Review
C63 Primer of Behavioral Neurology
C64 Introduction to Primary Headache Disorders
C65 Neurologic Complications of Systemic Cancer
C66 Teleneurology and Technologies
C67 Infections of the Nervous System I: Common Infections
C68
Stroke in Childhood and Adolescence
I3
Impact on Mechanism, Expression, and Treatment . . . 44
6:00 p.m.–10:00 p.m.
Opening Party . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Join your friends and colleagues for an exciting evening filled with
entertainment. Each registered meeting attendee will receive one
free ticket to these events. Guest tickets are available through
registration for $50.
8:30 a.m.–12:00 p.m.
Monday, April 28
9:00 a.m.–5:00 p.m.
C71 Movement Disorders
C72 Neurology Update I
C73 Clinical EEG
C74 Genetics in Neurology
C75
Women in Leadership (must apply)
C76 EMG Skills Workshop: Basic
6:30 a.m.–8:00 a.m.
C54 Morning Report: Lumbar Radiculopathy,
Lumbar Spinal Stenosis, Low Back Pain, and
Post-Laminectomy Syndrome
C55 Morning Report: Memory Disorders
C56 Neuro Flash: Neuro-ophthalmology
C57 Small Fiber Neuropathies: Sensory,
Autonomic and Both
C58 Hallucinations in Parkinson’s Disease
C59 Career Development for Clinician Educators
C60 Prognostication in the Era of Hypothermia
6:30 a.m.–8:30 a.m.
C61 Resident and Fellow Career Breakfast: The Early Years
(registration is required)
9:00 a.m.–12:00 p.m.
C69 Improving Accuracy of Dementia Diagnosis:
Case Studies with Both Imaging and Neuropathology
C70 Controversies in Multiple Sclerosis Therapy
9:30 a.m.–12:00 p.m.
C77 Philanthropy 101
10:00 a.m.–12:00 p.m.
C78 Tales from the Front Cover: Effective Book Writing
and Publishing for Neurologists
C79 Strategic Grant Writing
12:00 p.m.–1:30 p.m.
Government Relations Committee Meet and Greet
1:00 p.m.–2:30 p.m.
S2Cancelled
9:00 a.m.–12:00 p.m.
1:00 p.m.–5:00 p.m.
C80 Stroke in Young Adults
C81 Chronic Migraine Education Program
C82 Sports Neurology: Non-Concussion Overview
C83 Infections of the Nervous System II:
Advanced and Emerging Infections
C84
Neurological Disease
C85
Improving Your Leadership Skills:
A Practical Approach
I4
Research in Autism . . . . . . . . . . . . . . . . . . . . . 45
F eatures the AAN’s premier lecture awards for clinically relevant
research and a presentation by a leading lecturer. Top researchers
speak on some of the most significant findings in neurology in 2014.
1:30 p.m.–3:00 p.m.
AAN/ABPN MOC Informational Session
2:00 p.m.–4:30 p.m.
Presidential Lecture:
James L. Bernat, MD, FAAN
Dartmouth Hitchcock Medical Center, Lebanon, NH
Challenges to Ethics and Professionalism
Facing the Contemporary Neurologist
George C. Cotzias Lecture:
Endowed by Roche Pharmaceuticals.
University of Utah, Salt Lake City, UT
Degenerative Ataxias: From Genes to Therapies
Sidney Carter Award in Child Neurology Lecture:
Endowed by an anonymous donor.
Darryl C. De Vivo, MD, FAAN
Columbia University Medical Center, New York, NY
Rare Diseases and Neurological Phenotypes
2:00 p.m.–5:00 p.m.
CQ8 Health Information Technology Colloquium:
2:00 p.m.–5:00 p.m.
C86 ICD-10-CM: Essentials of Understanding and
Implementation
C87 Eye Movement Disorders: A Systematic
Approach to the Evaluation of Diplopia
3:00 p.m.–6:30 p.m.
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
P1
4:30 p.m.–6:30 p.m.
6:30 p.m.–9:00 p.m.
Residents and Fellows Career Forum and Reception
Tuesday, April 29
Robert Wartenberg Lecture:
David M. Holtzman, MD, FAAN
Washington University School of Medicine,
St. Louis, MO
Alzheimer’s Disease in 2014: Mapping a
Road Forward
11:30 a.m.–5:00 p.m.
Exhibit Hall
1:00 p.m.–2:30 p.m.
S3
PFO: Aggressive Treatment or Just Aspirin . . . . . . . . 65
1:00 p.m.–2:45 p.m.
Scientific Platform Sessions . . . . . . . . . . . . . . . 66–67
S4 MS and CNS Inflammatory Disease: Clinical Trials
6:30 a.m.–8:30 a.m.
2014 AAN Run/Walk for Brain Research . . . . 137
6:30 a.m.–8:00 a.m.
C89 Neuro Flash: Epilepsy
C90 Therapy of Multiple Sclerosis
C91 Advances in Autism Spectrum Disorders and Intellectual
Disability: From Genetics to Clinical Practice
C92
The Neurology of Social Behavior
C93 Therapy of Neuromuscular Disease
C94 Borderlands of Neurology and Internal Medicine
7:30 a.m.–11:00 a.m.
P2
Poster Session II . . . . . . . . . . . . . . . . . . . . 56–63
26
Pre-hospital, Telemedicine, and Related Topics
S6 Neuromuscular Disease: Gene Therapy
S7 Parkinson’s Disease: Preclinical and Clinical Therapeutics
PET Imaging
¡¡ Presentation of the Potamkin Prize for Research in
Pick’s, Alzheimer’s Disease, and Related Diseases
S9Sleep
¡¡ Presentation of the Sleep Science Award
¡¡ Presentation of the Wayne A. Hening
Sleep Medicine Investigator Award
S10 HIV, PML, and Cerebral Malaria
¡¡ Presentation of the Bruce S. Schoenberg International
Award in Neuroepidemiology
S11 Neuro Trauma, Critical Care, and Sports Neurology
Epidemiology and Risk Factors
S13 MS and CNS Inflammatory Disease:
MRI Atrophy Measures and Correlations
1:00 p.m.–5:00 p.m.
C95 Deep Brain Stimulation Management
C96 The History of Certain Disorders of
the Nervous System
C97 Emergency Neurology
C98 Practical Legal Issues for Neurologists
C99 Epilepsy Skills Pavilion
I5
Revolution of Genetic Tools and
the Impact on Neurology . . . . . . . . . . . . . . . . . . 68
I6
Peripheral Neuropathies . . . . . . . . . . . . . . . . . . 69
2:00 p.m.–5:00 p.m.
C100 The Intractable Headache Patient
3:00 p.m.–6:30 p.m.
Poster Session III . . . . . . . . . . . . . . . . . . . . 70–77
P3
3:15 p.m.–5:00 p.m.
Scientific Platform Sessions . . . . . . . . . . . . . . . . 78–79
S14 MS and CNS Inflammatory Disease: Animal and In Vitro
S15
S16
S17
S18
S19
S20
Studies
Clinical and Imaging Biomarkers and Genetics
Neuromuscular and Clinical Neurophysiology (EMG): Clinical
Trials and Therapy
Parkinson’s Disease: Genetics and Epidemiology
Behavioral Neuroscience
Neuro-ophthalmology/Neuro-otology I
Pain and Palliative Care
¡¡ Presentation of the Mitchell B. Max Award for
Neuropathic Pain
S21 Neurorehabilitation and Neural Repair
S22Neuro-oncology
S23 MS and CNS Inflammatory Disease: Novel Therapeutics
¡¡ Presentation of the John Dystel Prize for Multiple
Sclerosis Research
5:30 p.m.–6:30 p.m.
Features translational research related to clinical issues of
importance. Four outstanding physician-scientists provide
summaries of their recent research findings and describe the clinical
implications of the results.
Oleg Butovsky, PhD
Brigham and Women’s Hospital/Harvard Medical
School, Boston, MA
Identification of a Unique Molecular and Functional
Microglia Signature in Health and Disease
Jerome H. Chin, MD, PhD, MPH
Alliance for Stroke Awareness and Prevention
Project (ASAPP), San Anselmo, CA
The Global Epidemic of Stroke: Sounding the Alarm
Dennis W. Dickson, MD
Mayo Clinic, Jacksonville, FL
Emerging Concepts in Chronic Traumatic
Encephalopathy
David Eidelberg, MD, FAAN
Feinstein Institute for Medical Research,
Manhasset, NY
Functional Connectivity and Functional Imaging in
Movement Disorders
7:00 p.m.–10:00 p.m.
Corporate Therapeutic Updates . . . . . . . . . . . . . . . 147
Industry-sponsored, non-CME programs will be offered and are
open to attendees at no charge. They will provide an opportunity for
pharmaceutical companies, device companies, or other neurologicrelated organizations to share information regarding their current
therapies and projects in the pipeline in accordance with standards
set for industry by the FDA.
Wednesday, April 30
6:30 a.m.–8:00 a.m.
C101 Neuro Flash: Child Neurology
C102 Balance and Gait Disorders
C103 Therapy of Stroke
C104 Nystagmus: An Organized Approach
C105 Differential Diagnosis of Dementia: Linking
Clinical Syndromes to Biomarkers
C106 Integrative Management of Multiple Sclerosis
C107 Brain Computer Interfaces: Frontiers in Neurology
and Neuroscience
7:30 a.m.–11:00 a.m.
P4
Poster Session IV . . . . . . . . . . . . . . . . . . . . 81–88
27
9:00 a.m.–12:00 p.m.
Contemporary Clinical
Issues Plenary Session . . . . . . . . . . . . . . . . . 89
Highlights issues most critical to practicing neurologists, including
abstracts related to new therapeutic developments, clinical
applications of basic and translational research, and innovative
technical developments.
William K. Mountford, PhD
Premier Research Services, Wilmington, NC
Comparison of Thrombolytic Treatment for Acute
Ischemic Stroke Pre- and Post-Telemedicine
Implementation in the Spoke Hospital Setting
Discussant: Lee H. Schwamm, MD
Massachusetts General Hospital, Boston, MA
David R. Jacoby, MD, PhD
BioMarin Pharmaceutical Inc., Novato, CA
Epigenetic Therapy for Friedreich’s Ataxia:
A Phase I Clinical Trial
Scientific Platform Sessions . . . . . . . . . . . . . . . 90–91
S24 Diet and Hormonal Influences in MS
Hemorrhage, Aneurysms, and Vascular Malformations
S26 Biomarkers in Neuromuscular Diseases
S27 Dystonia, Tremor, and Other Movement Disorders
S28
S29
S30
William Herring, MD, PhD
Merck Research Laboratories, North Wales, PA
Clinical Profile of the Orexin Receptor Antagonist
Suvorexant for the Treatment of Insomnia in Phase-3
Clinical Trials
Discussant: Phyllis C. Zee, MD, PhD
Northwestern University Medical School, Chicago, IL
S31
Jonathan Stone, MB, ChB, FRCP, PhD
Western General Hospital,
Edinburgh, United Kingdom
Functional (Psychogenic) Disorders in Neurology
Kenneth L. Marek, MD
Institute for Neurodegenerative Disorders,
New Haven, CT
Parkinson’s Disease Progression Marker Initiative:
Developing a Translational Toolbox for PD Progression
Commentary and discussion follow each presentation.
11:30 a.m.–5:00 p.m.
Exhibit Hall
28
2:00 p.m.–3:45 p.m.
Discussant: Tetsuo Ashizawa, MD, FAAN
University of Florida, Gainesville, FL
David B. Goldstein, PhD
Duke University, Durham, NC
Direct to Consumer Genetic Testing
12:00 p.m.–1:30 p.m.
American Academy of Neurology and
American Brain Foundation Awards Luncheon . . . . . 137
S32
S33
¡¡ Presentation of the Movement Disorders
Research Award
Dementia Genetics
¡¡ Presentation of the Norman Geschwind Prize
in Behavioral Neurology
Epilepsy and Clinical Neurophysiology: Inflammation, Status
¡¡ Presentation of the Dreifuss-Penry Epilepsy Award
Education, Research, and History
¡¡ Presentation of the Lawrence C. McHenry Award:
An Award for the History of Neurology
¡¡ Presentation of the S. Weir Mitchell Award
General Neurology I
Headache: Basic Science and Imaging
¡¡ Presentation of the Harold Wolff-John Graham Award:
An Award for Headache/Facial Pain Research
Cognition Fatigue in MS
2:00 p.m.–6:00 p.m.
C108 Neurologic Issues in Pregnancy
C109 Emergency Room Neuro-ophthalmology
C110 Sports Concussion and Other Mild Concussive Injuries
C111 Bedside Evidence-based Medicine: How to
Deconstruct Articles in Order to Take Care of Patients
C112 Neuromuscular Bedside Rounds Skills Pavilion
C113 Acute Stroke Alert Skills Pavilion
I7
Emerging Therapeutic Advances in Multiple Sclerosis . . 92
I8
Clinical Decision Making After the
Dust Settles on Clinical Trials . . . . . . . . . . . . . . . 93
3:00 p.m.–6:30 p.m.
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
P5
4:00 p.m.–5:45 p.m.
Platform Blitzes . . . . . . . . . . . . . . . . . . . . . . 102–103
S34 MS and CNS Inflammatory Disease: Risk Factors for MS
Disease and Course
Issues in Acute Treatment
S36 Neuromuscular Disease: Clinical
S37 Clinical Aspects of Parkinson’s Disease
S39
S40
S41
S42
S43
Plasma and Other Biomarkers
Neuro-ophthalmology/Neuro-otology II
General Neurology II
Headache: Clinical
Child Neurology I
Epilepsy and Clinical Neurophysiology (EEG): Cognition
5:30 p.m.–7:00 p.m.
Current Practice Issues in Neurology
The interactive Current Practice Issues in Neurology session
“Do Payer Rankings Keep You at the Top of the Class or Give You
a Failing Grade” will give neurologists a chance to hear directly
from both a CMS Medical Officer and a private payer Medical
Director to gain a better understanding of how to properly interpret
their details from the Quality and Resource Use Reports (QRUR)
and physician designation programs; how to determine if the
information is accurate; the importance of ensuring your rating
is accurate; what the steps to take are if there are discrepancies
with their information; and navigate through and utilize the CMS
Physician Compare website and other available resources.
The Academy is pleased to offer this event to continue developing a
positive, constructive dialogue with payers at the physician level.
Thursday, May 1
6:30 a.m.–8:00 a.m.
C114 Morning Report: Multiple Sclerosis
C115 Neuro Flash: Palliative Care for the
Practicing Neurologist
C116 Learning Movement Disorders in Hindsight:
Lessons from My Patients
C117
Principles
of Genomic Medicine: Whole Exome
Sequencing in Neurologic Disease
C118Neurotoxicology
C119 Syndromes of Autonomic Dysfunction in
Children and Adolescents
7:30 a.m.–11:00 a.m.
P6
Poster Session VI . . . . . . . . . . . . . . . . . . . 104–111
9:00 a.m.–12:00 p.m.
Frontiers in Neuroscience Plenary Session . . 112
Focuses on translational research related to clinical issues of
importance. Six physician scientists outline their recent research
findings, along with the clinical implications.
6:00 p.m.–7:00 p.m.
S . Thomas Carmichael, MD, PhD
David Geffen School of Medicine at UCLA,
Los Angeles, CA
Tissue Environments for Brain Repair
Albert Lo, MD, PhD
H1 Child Neurology
Brown University, Providence VA Medical Center,
Providence, RI
Opportunities and Challenges of Robot Assisted and
Facilitated Neurorecovery
H2Epilepsy
H3Geriatric
H4 Headache & Facial Pain
H5 Movement Disorders
H6 Multiple Sclerosis
H7 Neural Repair & Rehabilitation
William Seeley, MD
UCSF, San Francisco, CA
Network-based Neurodegeneration
H8Neuro-oncology
Cori Bargmann, PhD
Rockefeller University, New York, NY
Using Fixed Circuits to Generate Flexible Behaviors
H10Sleep
H11 Sports Neurology
6:00 p.m.–7:30 p.m.
Emerging Science Session
7:00 p.m.–10:00 p.m.
Corporate Therapeutic Updates . . . . . . . . . . . . . . . 147
Industry-sponsored, non-CME programs will be offered and are
open to attendees at no charge. They will provide an opportunity
for pharmaceutical companies, device companies, or other
neurologic-related organizations to share information regarding
their current therapies and projects in the pipeline in accordance
with standards set for industry by the FDA.
Bruce R. Rosen, MD, PhD
Harvard Medical School, Boston, MA
Advances in Mapping Human Brain Connectivity: The
Human Connectome Project
aiken Nedergaard, MD, DMSc
M
University of Rochester Medical Center,
Rochester, NY
The Nightlife of Astrocytes
29
11:30 a.m.–3:00 p.m.
Exhibit Hall
1:00 p.m.–2:45 p.m.
Scientific Platform Sessions . . . . . . . . . . . . . . 114–115
S44 MS and CNS Inflammatory Disease: Neuroimaging I
Rehabilitation, Recovery, and Complications
S46 Neuromuscular Disease: Genetics, Pathogenesis,
and Measures
S47 Movement Disorders: Huntington’s Disease, Ataxia,
and Wilson’s Disease
¡¡ Presentation of the Jon Stolk Award in
Movement Disorders for Young Investigators
MRI Imaging
S49 Practice, Policy, and Ethics
S50 Epilepsy and Clinical Neurophysiology (EEG):
Electrophysiology, Imaging and Functional Connectivity
¡¡ Presentation of the Founders Award
Large Vessel Atherosclerotic Disease
¡¡ Presentation of the Michael S. Pessin Stroke
Leadership Prize
S52 General Neurology III
S53 MS and CNS Inflammatory Disease: Biomarkers and
1:00 p.m.–5:00 p.m.
C120 Consultations in the Medical Surgical ICU
C121 Office Orthopedics for the Neurologist
C122 Traumatic Brain Injury
C123 Neuro-ophthalmology and Neurovestibular
Exam Lab Skills Pavilion
I9
Emerging Concepts in Headache Therapy . . . . . . . . 116
I10 The Global Burden of Neurological Diseases . . . . . . . 117
S59 Epilepsy and Clinical Neurophysiology (EEG):
Reproduction, Health Care Delivery, and Co-morbidities
S60 Child Neurology II
S61 Muscle Disease: Gene Therapy and Models
S63 Neuromyelitis Optica and Autoimmune Encephalitis
5:30 p.m.–6:30 p.m.
H12 Adult Intellectual and Developmental Disabilities
H13 Endovascular and Interventional Neurology, and
Stroke and Vascular Neurology
H14 Women’s Issues in Neurology
H15 Critical Care
5:30 p.m.–7:00 p.m.
Controversies in Neurology Plenary Session . . 128
The program features experts discussing the most current and
controversial issues in neurology. It is set up as a series of debates
in which two speakers argue opposing sides of a single topic,
followed by a rebuttal. Each round concludes with a 10-minute
question and answer period.
Does Preventing Relapses Protect Against
Progressive MS?
Pro: Maria Trojano, MD
University of Bari, Bari, Italy
Con: Helen Tremlett, PhD, BPharm
University of British Columbia, Vancouver, BC,
Canada
Is Intervention for Asymptomatic AVM Useful?
Pro: Robert M. Friedlander, MD
UPMC Presbyterian, Pittsburgh, PA
2:00 p.m.–5:00 p.m.
C124 Clinical E-Pearls
C125 Status Epilepticus
Con: J. P. Mohr, MD, FAAN
Columbia University, New York, NY
3:00 p.m.–6:30 p.m.
Poster Session VII . . . . . . . . . . . . . . . . . . 118–125
P7
Should Neurologists Prescribe Marijuana for
Neurological Disorders?
Pro: Barbara S. Koppel, MD, FAAN
Metropolitan Hospital, Rye, NY
3:15 p.m.–5:00 p.m.
Scientific Platform Sessions . . . . . . . . . . . . . . 126–127
S54 MS and CNS Inflammatory Disease: Neuroimaging II
S55 Pediatric Stroke and Stroke in the Young
¡¡ Presentation of the Sheila Essey Award: An Award for
ALS Research
S57 Movement Disorders: Imaging
Clinical Aspects
30
Con: John C. M. Brust, MD, FAAN
6:00 p.m.–9:00 p.m.
C126 Case Studies: Unusual Diagnostic and
Management of Cases in Neuromuscular Disease
C127 Case Studies: Unusual Movement Disorders
C128 Case Studies in Behavioral Neurology:
Focus on Frontotemporal Degeneration
C129 Case Studies: Multiple Sclerosis
C130 Case Studies: Neurologic Consultations in
Cancer Patients
C131
Test
Your Knowledge: A Case-based
Approach to Neuroimaging
Friday, May 2
6:30 a.m.–8:00 a.m.
C132 Neuro Flash: Approach to Acute CNS Infections
C133 The Spectrum of Motor Neuron Disease
C134 Parkinson’s Disease Management:
Pearls, Pitfalls, and Future Prospects
C135
Continued
Challenges of the
Neurohospitalist Model of Care
C136 Important Drug Interactions for
Neurologists and Psychiatrists
C137 Mild Cognitive Impairment: Implications for Clinicians
8:00 a.m.–12:00 p.m.
C138 Parkinson’s Disease and Movement Disorders Update
C139 Neuromyelitis Optica: Scientific and Clinical Update
C140 Hot Topics in Headaches and Related Disorders
C141 Neurodevelopmental Disabilities Across the Lifespan
C142
Concussion in the Military and in Sports
I11
Proteinopathy in Neurodegenerative Disease . 130
9:00 a.m.–5:00 p.m.
C143 Peripheral Neuropathy
C144 Neurology Update II
C145 Cerebrovascular Disease
C146 Clinical Epilepsy
C147 Dementia Update
C148 Neuromuscular Ultrasound Skills Workshop
12:00 p.m.–1:30 p.m.
This mid-day session covers important clinical topics that affect
patient care identified from other society meetings. The latest
updates within several clinical trials conducted over the course of
the last year will be presented with an open panel discussion at the
conclusion.
Michael Wall, MD, FAAN
University of Iowa, Iowa City, IA
The Idiopathic Intracranial Hypertension Treatment
Trial: A Multicenter, Double-Blind, Randomized
Clinical Trial Comparing Acetazolamide and Placebo
on Visual Outcome
Mark R. Gilbert, MD
The University of Texas MD Anderson Cancer Center,
Houston, TX
Anti-angiogenic Therapy for Glioblastoma: A
Randomized, Double-Blinded Phase III Trial of
Bevacizumab in Newly Diagnosed Patients
Aaron E. Miller, MD, FAAN
Mt. Sinai School of Medicine, New York, NY
TOPIC: Efficacy and Safety of Once-daily Oral
Teriflunomide in Patients with First Clinical Episode
Consistent with Multiple Sclerosis
Jeffrey L. Saver, MD, FAAN
UCLA School of Medicine, Los Angeles, CA
FAST-MAG Trial in Acute Ischemic Stroke
David Dodick, MD
Mayo Clinic, Phoenix, AZ
CGRP Monoclonal Antibody LY2951742 for the
Prevention of Migraine: A Phase 2, Randomized,
Double-Blind, Placebo-Controlled Study
Peter Goadsby, MD, PhD
University of California, San Francisco, CA
Randomized, Double-blind, Placebo-controlled Trial
of ALD403: An Anti-CGRP Peptide Antibody in the
Prevention of Frequent Episodic Migraine
1:00 p.m.–2:30 p.m.
Pain: Methods of Treatment . . . . . . . . . . . . . . . . 132
1:00 p.m.–5:00 p.m.
C149Neuro-otology
C150 Neuro-oncology: Primary Brain Tumors
C151 Hot Topics in Sleep Neurology
C152 Symptomatic Management in Multiple Sclerosis
C153
Imaging and Genomics for Detecting
Neurodegenerative Proteinopathy in Clinical Practice
I12
Concussion in Sports and the Military . . . . . 132
31
5:30 p.m.–7:00 p.m.
Neurology Year in Review Plenary Session . . 133
This plenary session will feature six speakers, each focusing on the
latest research that has happened in the last year within a specific
subspecialty topic.
Anne H. Cross, MD
Washington University School of Medicine,
St. Louis, MO
Multiple Sclerosis
Headache/Pain
Robert C. Griggs, MD, FAAN
University of Rochester, Rochester, NY
Neuromuscular
Kathleen M. Shannon, MD
Rush University Medical Center, Chicago, IL
Movement Disorders
David M. Greer, MD
Yale University School of Medicine, New Haven, CT
Neurocritical Care
Todd E. Golde, MD, PhD
University of Florida Collage of Medicine,
Gainesville, FL
Alzheimer’s Disease
7:30 p.m.–9:00 p.m.
Closing Party . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Join us at the festive Closing Party, where former NFL star-turnedsinger and Public Leadership in Neurology Award-winner Ben
Utecht will enchant you with his inimitable vocal stylings.
Saturday, May 3
6:30 a.m.–8:00 a.m.
C154 Update on Endovascular Treatment of
Cerebrovascular Diseases
C155 Cumulative Sports Concussion and Risk of Dementia
C156 Evaluation and Therapy of Restless Legs Syndrome and
Periodic Limb Movements in Sleep
C157
Therapy of Epilepsy
C158 Psychogenic Movement Disorders
6:30 a.m.–8:30 a.m.
C159 Challenging Headache Cases
8:00 a.m.–12:00 p.m.
C160 Neuromuscular Junction Disorders
C161 Neurologic Complications of Medical Disease
C162 Diagnostic Dilemmas in Multiple Sclerosis
C163Myelopathies
C164 Practical Psychopharmacology for Neurologists
C165 Critical Care EEG Monitoring
9:00 a.m.–12:00 p.m.
C166 Interpretation of Polysomnography for the
10:00 a.m.–12:00 p.m.
C167 Mitochondrial Disorders in Neurology
C168 Therapy of Movement Disorders:
A Case-based Approach
C169 Common Neurologic Problems in Adults
with Intellectual and Developmental Disabilities
Current as of 2/13/2014 –Subject to change
“With every Annual Meeting that I attend I always come away from
the scientific conferences with something new and different to add
to my care and treatment of patients with neurologic diseases.”
Christopher J. Prusinski, DO
Melbourne, FL
32
Annual Meeting Programs by Topic
For full course information please reference the 2014 Annual Meeting Registration and Advance Program or view the Annual
Meeting Program Search at AAN.com/view/SearchAM.
Please refer to the key for the following program definitions:
C Course
P Poster Session
CQ Colloquium
H Highlights in the Field
S Scientific Platform Session/Section Topic Controversies
Aging, Dementia, Cognitive,
and Behavioral Neurology
C3
Assessment of Rapidly Progressive Dementias
and Related Neurologic Conditions
C17 Attention Deficit Hyperactivity Disorder
Across the Lifespan
C25
Creativity
C42 Vascular Cognitive Impairment and Dementia:
Current Status and Future
C46 Non-Alzheimer’s Dementia
C55 Morning Report: Memory Disorders
C63 Primer of Behavioral Neurology
C69 Improving Accuracy of Dementia Diagnosis: Case Studies
with Both Imaging and Neuropathology
P1
Poster
Session I . . . . . . . . . . . . . . . . . . . . 48–55
C92 The Neurology of Social Behavior
P2
Aging, Dementia, and Cognitive and
S8
Behavioral Neurology: PET Imaging . . . . . . . . . . . . 66
P3
S18
Aging, Dementia, and Cognitive and
Behavioral Neurology: Behavioral Neuroscience . . . . . 78
C105 Differential Diagnosis of Dementia:
Linking Clinical Syndromes to Biomarkers
P4
S28 Aging, Dementia, and Cognitive and
Behavioral Neurology: Dementia Genetics . . . . . . . . 90
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
P5
Behavioral Neurology: Plasma and Other Biomarkers . . 102
Geriatric Neurology Highlights in the Field . . . . . . . . 29
H3
P6
Frontiers in Neuroscience Plenary Session . . . . 112
Behavioral Neurology: MRI Imaging . . . . . . . . . . . 114
P7
Behavioral Neurology: Clinical Aspects . . . . . . . . . . 126
34
I Integrated Neuroscience Session
C128 Case Studies in Behavioral Neurology:
Focus on Frontotemporal Degeneration
C137 Mild Cognitive Impairment: Implications for Clinicians
I11
Proteinopathy in Neurodegenerative Disease . 130
C147 Dementia Update
C153
Imaging and Genomics for Detecting
Neurodegenerative Proteinopathy in Clinical Practice
Neurology Year in Review Plenary Session . . . . 133
Cerebrovascular Disease and
Interventional Neurology
C14
Preventing a First Stroke:
What Every Neurologist Needs to Know
C21
Neuro Flash: Acute Stroke Management
C33
Prevention of Cardioembolic Stroke in
Patients with Nonvalvular Atrial Fibrillation:
Recommendations Based on Evidence-based
Guidelines and Recent Randomized Trials
I2
Stroke Prevention . . . . . . . . . . . . . . . . . . . . . . 43
C60
Prognostication in the Era of Hypothermia
C68
C80 Stroke In Young Adults
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
P2
S3 Section Topic Controversies: PFO:
Aggressive Treatment or Just Aspirin . . . . . . . . . . . 65
S5
Pre-hospital, Telemedicine, and Related Topics . . . . . . 66
S12
Epidemiology and Risk Factors . . . . . . . . . . . . . . . 67
P3
S15
Clinical and Imaging Biomarkers and Genetics . . . . . . 78
C103 Therapy of Stroke
P4
Contemporary Clinical Issues Plenary Session . . 89
S25
C113
P5
S35
P6
S45
S51
P7
S55
S62
H13
C135
C145
C154
Hemorrhage, Aneurysms, and Vascular Malformations . 90
Acute Stroke Alert Skills Pavilion
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
Issues in Acute Treatment . . . . . . . . . . . . . . . . . 102
Rehabilitation, Recovery, and Complications . . . . . . . 114
Large Vessel Atherosclerotic Disease . . . . . . . . . . 115
Pediatric Stroke and Stroke in the Young . . . . . . . . . 126
Cognitive and Behavioral . . . . . . . . . . . . . . . . . 127
Endovascular and Interventional Neurology, and
Stroke and Vascular Neurology Highlights in the Field . . 32
Controversies in Neurology Plenary Session . . . 128
Continued Challenges of the
Clinical Trials Plenary Session
Update on Endovascular Treatment of
Cerebrovascular Diseases
Child Neurology and Developmental Neurology
C17
C32
C36
C49
C68
C80
I4
P1
C91
P2
P3
C101
P4
S42
Attention Deficit Hyperactivity Disorder
Across the Lifespan
Child Neurology I
EEG in Children: Developmental Maturation,
Child Neurology II
Stroke in Young Adults
Research in Autism . . . . . . . . . . . . . . . . . . . . . 45
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
Advances in Autism Spectrum Disorders
and Intellectual Disability:
From Genetics to Clinical Practice
Neuro Flash: Child Neurology
Child Neurology I . . . . . . . . . . . . . . . . . . . . . . 103
H1
Child Neurology Highlights in the Field . . . . . . . . . . 29
P6
P7
S60 Child Neurology II . . . . . . . . . . . . . . . . . . . . . . 127
C141 Neurodevelopmental Disabilities Across the Lifespan
Epilepsy/Clinical Neurophysiology (EEG)
C2
I1
C36
C41
S1
C51
C73
P1
C89
P2
C99
P3
P4
S29
P5
S43
H2
P6
S50
C125
P7
S59
C146
C157
C165
How to Analyze Spells by Video-EEG
Temporal Lobe Epilepsy and Febrile Seizures . . 42
EEG in Children: Developmental Maturation,
Neurophysiologic Intraoperative Monitoring
Skills Workshop
Section Topic Controversies: ICU EEG Monitoring:
Seizures in Critically Ill Patients . . . . . . . . . . . . . . 42
Algorithms in the Diagnosis and
Treatment of Epilepsy
Clinical EEG
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
Neuro Flash: Epilepsy
Epilepsy Skills Pavilion
Epilepsy and Clinical Neurophysiology:
Inflammation, Status Epilepticus, and Genetics . . . . . 91
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
Epilepsy and Clinical Neurophysiology (EEG): Cognition . 103
Epilepsy Highlights in the Field . . . . . . . . . . . . . . . 29
Electrophysiology, Imaging, and Functional Connectivity . 115
Status Epilepticus
Reproduction, Health Care Delivery, and Co-morbidities 127
Clinical Epilepsy
Therapy of Epilepsy
Critical Care EEG Monitoring
General Neurology
C19
Controversies in Brain Death Determination
C24
Global Health Challenges: Neurology in
Developing Countries
35
C26
Introduction to Genetics
H13
C29
Multiple Sclerosis Overview I:
Endovascular and Interventional Neurology, and
Stroke and Vascular Neurology Highlights in the Field . . 32
H14
Women’s Issues in Neurology Highlights in the Field . . . 32
C34 Neuroimaging for the General Neurologist: Brain
C37
C131 Test Your Knowledge:
Therapy in Neurology
A Case-based Approach to Neuroimaging
C48 Autoimmune Neurology
C52
Neuroimaging for the General Neurologist:
Spine and Peripheral Nerve
C136 Important Drug Interactions for
C62
Continuum Test Your Knowledge:
A Multiple-Choice Question Review
C144 Neurology Update II
C69
Improving Accuracy of Dementia Diagnosis:
Case Studies with Both Imaging and Neuropathology
C153 Imaging and Genomics for Detecting Neurodegenerative
Proteinopathy in Clinical Practice
C161 Neurologic Complications of Medical Disease
C72
Neurology Update I
C74
Genetics in Neurology
C78
Tales from the Front Cover:
Effective Book Writing and Publishing for Neurologists
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
C91
Advances in Autism Spectrum Disorders and Intellectual
Disability: From Genetics to Clinical Practice
C94
Borderlands of Neurology and Internal Medicine
C9
Differential Diagnosis of Neurologic Infections
C24
C97
Emergency Neurology
Global Health Challenges: Neurology in Developing
Countries
I5
the Impact on Neurology . . . . . . . . . . . . . . . . . . 68
C67
Infections of the Nervous System I: Common Infections
P3
Poster Session III . . . . . . . . . . . . . . . . . . . . . . 77
P2
P4
S10
HIV, PML, and Cerebral Malaria . . . . . . . . . . . . . . 67
S31
General Neurology I . . . . . . . . . . . . . . . . . . . . . 91
P4
I8
Clinical Decision Making After the
Dust Settles on Clinical Trials . . . . . . . . . . . . . . . 93
I10
The Global Burden of Neurological Diseases . . . . . . . 117
C108 Neurologic Issues in Pregnancy
P5
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
S40
General Neurology II . . . . . . . . . . . . . . . . . . . . 103
C117 Principles of Genomic Medicine:
Whole Exome Sequencing in Neurologic Disease
C118Neurotoxicology
P6
S52
General Neurology III . . . . . . . . . . . . . . . . . . . . 115
C124 Clinical E-Pearls
36
Neurologists and Psychiatrists
C167 Mitochondrial Disorders in Neurology
C169 Common Neurologic Problems in Adults with Intellectual
and Developmental Disabilities
Global Health and Infectious Disease
C83 Infections of the Nervous System II: Advanced and
Emerging Infections
C132 Neuro Flash: Approach to Acute CNS Infections
Headache
C18
Therapy of Headache
C64
Introduction to Primary Headache Disorders
C81
Chronic Migraine Education Program
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
S3 Section Topic Controversies: PFO:
Aggressive Treatment or Just Aspirin . . . . . . . . . . . 65
C100 The Intractable Headache Patient
S32
Headache: Basic Science and Imaging . . . . . . . . . . 91
P4
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
S41
Headache: Clinical . . . . . . . . . . . . . . . . . . . . . 103
P7
H5
Headache and Facial Pain Highlights in the Field . . . . . 29
H12
Adult Intellectual and Developmental
Disabilities Highlights in the Field . . . . . . . . . . . . . 32
P6
I9
Emerging Concepts in Headache Therapy . . . . . . . . 116
P7
C140 Hot Topics in Headaches and Related Disorders
C158 Psychogenic Movement Disorders
C168 Therapy of Movement Disorders:
A Case-based Approach
C159 Challenging Headache Cases
MS and CNS Inflammatory Disease
Movement Disorders
C16
C12
The Dystonias: Diagnosis, Treatment, and
Update on Causes
C23
Hyperkinetic Movement Disorders:
Diagnosis and Treatment
C28 Botulinum Toxins: Practical Issues and
Clinical Uses for Neurologists
Multiple Sclerosis Essentials
C29
Multiple Sclerosis Overview I:
C47
Multiple Sclerosis Overview II: Clinical Advances
C70
Controversies in Multiple Sclerosis Therapy
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
C44 Update on Ataxias
C90
Therapy of Multiple Sclerosis
C53 Clinical Usefulness of Botulinum Toxin and
P2
S4
MS and CNS Inflammatory Disease: Clinical Trials . . . . 66
S13
MS and CNS Inflammatory Disease:
MRI Atrophy Measures and Correlations . . . . . . . . . 67
Treatment of Dystonia Skills Pavilion
C58 Hallucinations in Parkinson’s Disease
C71
Movement Disorders
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
P3
P2
S14
S7
Parkinson’s Disease: Preclinical and
Clinical Therapeutics . . . . . . . . . . . . . . . . . . . . 66
MS and CNS Inflammatory Disease: Animal
and In Vitro Studies . . . . . . . . . . . . . . . . . . . . . 78
S23
C95
Deep Brain Stimulation Management
Novel Therapeutics . . . . . . . . . . . . . . . . . . . . . 79
P3
S17
Parkinson’s Disease: Genetics and Epidemiology . . . . . 78
C102 Balance and Gait Disorders
C106 Integrative Management of MS
P4
S24
Diet and Hormonal Influences in MS . . . . . . . . . . . 90
S33
Cognition Fatigue in MS . . . . . . . . . . . . . . . . . . 91
I7
Emerging Therapeutic Advances in Multiple Sclerosis . . 92
P5
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
S34
Risk Factors for MS Disease and Course102
Multiple Sclerosis Highlights in the Field . . . . . . . . . 29
P4
S27
Dystonia, Tremor, and Other Movement Disorders . . . . 90
H6
P5
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
C114 Morning Report: Multiple Sclerosis
S37
Clinical Aspects of Parkinson’s Disease . . . . . . . . . 102
P6
H5
Movement Disorders Highlights in the Field . . . . . . . 29
S44
MS and CNS Inflammatory Disease: Neuroimaging I . . 114
C116 Learning Movement Disorders in Hindsight:
S53
Biomarkers and Therapeutic Mechanisms . . . . . . . . 115
P6
P7
S47
Movement Disorders: Huntington’s Disease,
Ataxia, and Wilson’s Disease . . . . . . . . . . . . . . . 114
S54
MS and CNS Inflammatory Disease: Neuroimaging II . . 126
S63
Neuromyelitis Optica and Autoimmune Encephalitis . . 127
P7
S57
Movement Disorders: Imaging . . . . . . . . . . . . . . 126
C129 Case Studies: Multiple Sclerosis
Lessons from My Patients
C127 Case Studies: Unusual Movement Disorders
C139 Neuromyelitis Optica: Scientific and Clinical Update
C134 Parkinson’s Disease Management: Pearls, Pitfalls, and
Future Prospects
C138 Parkinson’s Disease and Movement Disorders Update
C152 Symptomatic Management in Multiple Sclerosis
C162 Diagnostic Dilemmas in Multiple Sclerosis
37
Neuro Trauma, Critical Care, and Sports Neurology
C38 Neurologic Intensive Care
S1
ICU EEG Monitoring: Seizures in Critically Ill Patients . . 42
P4
S26
C112
P5
C82 Sports Neurology: Non-Concussion Overview
S36
S3
PFO: Aggressive Treatment or Just Aspirin . . . . . . . . 65
P6
S11
Neuro Trauma, Critical Care, and Sports Neurology . . . 67
C97
Emergency Neurology
P7
S56
S46
S61
C126
C110 Sports Concussion and Other Mild Concussive Injuries
P5
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
H15
Critical Care Highlights in the Field . . . . . . . . . . . . 29
H11
Sports Neurology Highlights in the Field . . . . . . . . . 29
C120 Consultations in the Medical Surgical ICU
C142
S64
Concussion in the Military and in Sports
Pain: Methods of Treatment . . . . . . . . . . . . . . . . 132
I12
Concussion in Sports and the Military . . . . . 132
C165 Critical Care EEG Monitoring
Neuromuscular and Clinical Neurophysiology (EMG)
C1
Clinical Approach to Muscle Disease
C8
Evaluation and Management of Autonomic Disorders
C22 You Make the Call—An Interactive, Multimedia,
Case-based Approach to Learning EMG
C27
Clinical EMG I
C45 Clinical EMG II
C57
Small Fiber Neuropathies: Sensory, Autonomic and Both
C76
EMG Skills Workshop: Basic
S2 Cancelled
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
C93
Therapy of Neuromuscular Disease
P2
S6
Neuromuscular Disease: Gene Therapy I . . . . . . . . . 66
I6
Peripheral Neuropathies . . . . . . . . . . . . . . . . . . 69
P3
S16
Neuromuscular and Clinical Neurophysiology (EMG):
Clinical Trials and Therapy . . . . . . . . . . . . . . . . . 78
38
C133
C143
C148
C160
Biomarkers in Neuromuscular Diseases . . . . . . . . . . 90
Neuromuscular Bedside Rounds Skills Pavilion
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
Neuromuscular Disease: Clinical . . . . . . . . . . . . . 102
Neuromuscular Disease: Genetics,
Pathogenesis, and Measures . . . . . . . . . . . . . . . 114
Anterior Horn Disease . . . . . . . . . . . . . . . . . . . 126
Muscle Disease: Gene Therapy and Models . . . . . . . 127
Case Studies: Unusual Diagnostic and Management of
Cases in Neuromuscular Disease
The Spectrum of Motor Neuron Disease
Peripheral Neuropathy
Neuromuscular Ultrasound Skills Workshop
Neuromuscular Junction Disorders
Neuro-oncology
C65
Neurologic Complications of Systemic Cancer
P3
S22Neuro-oncology . . . . . . . . . . . . . . . . . . . . . . 79
Neuro-oncology Highlights in the Field . . . . . . . . . . 29
H8
P7
C130 Case Studies:
Neurologic Consultations in Cancer Patients
C150 Neuro-oncology: Primary Brain Tumors
Neuro-ophthalmology/Neuro-otology
C15
Top 10 Neuro-ophthalmic Diagnoses
You Can’t Afford to Miss
C39Neuro-ophthalmology
C56 Neuro Flash: Neuro-ophthalmology
S2 Cancelled
C87 Eye Movement Disorders:
A Systematic Approach to the Evaluation of Diplopia
P2
S19
Neuro-ophthalmology/Neuro-otology I . . . . . . . . . . 79
C104 Nystagmus: An Organized Approach
S39 Neuro-ophthalmology/Neuro-otology II . . . . . . . . . 103
Highlights in the Field . . . . . . . . . . . . . . . . . . . . 29
P6
C123 Neuro-ophthalmology and Neurovestibular Exam Lab Skills
C61
Resident and Fellow Career Breakfast:
The Early Years
C66
Teleneurology and Technologies
C75
Women in Leadership
Philanthropy 101
Pavilion
C149Neuro-otology
C77
Neuro-rehabilitation
C85
C40 Spine Neurology: Assessment and Management of
Common Spine Disorders
CQ8 Health Information Technology Colloquium:
C86
ICD 10-CM: Essentials of Understanding and
Implementation
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
S21
Neurorehabilitation and Neural Repair . . . . . . . . . . 79
C98
Practical Legal Issues for Neurologists
P4
C107 Brain Computer Interfaces: Frontiers in
Neurology and Neuroscience
C111 Bedside Evidence-based Medicine:
H7
Neural Repair and Rehabilitation Highlights in the Field . 29
How to Deconstruct Articles in Order
to Take Care of Patients
C163Myelopathies
S49
C135 Continued Challenges of the
C40 Spine Neurology: Assessment and Management of
Common Spine Disorders
Research Methodology, Education, and History
C50 Core Concepts in Pain Management
S20
Pain and Palliative Care . . . . . . . . . . . . . . . . . . . 79
P7
S64
Practice, Policy, and Ethics . . . . . . . . . . . . . . . . . 115
Section Topic Controversies: Pain:
Methods of Treatment . . . . . . . . . . . . . . . . . . . 132
C4
Resident Basic Science I: Neuropathology
C7
Research Career Development Symposium:
How to Be Successful in Academic Neuroscience
C11
Resident Basic Science II: Neuroanatomy
CQ2 Research and Technology Colloquium:
From Discovery to Therapy
C31
C35
Life Reimagined
C59
Practice, Policy, and Ethics
Resident Basic Science III: Neuropharmacology
Career Development for Clinician Educators
C5
Clerkship and Program Directors Conference
C75
Women in Leadership
C77 Philanthropy 101
C6
The Practice of Neurology:
Issues in Coding and Reimbursement
C78
Tales from the Front Cover:
Effective Book Writing and Publishing for Neurologists
and Improving Your Bottom Line
C79
Strategic Grant Writing
C13
Practice Survival for Neurologists:
Business Strategies for Success
Futures in Clinical Research Luncheon
(Registration Required) . . . . . . . . . . . . . . . . . . . 23
C19
Controversies in Brain Death Determination
C85
CQ1 BRAINS Colloquium: Understanding
C43 E/M: Minimize Mistakes, Maximize Reimbursement
CQ5 Practice Colloquium: How to Navigate and
Succeed in New Payment Models
P1
Poster Session I . . . . . . . . . . . . . . . . . . . . 48–55
C88 Hot Topics in Education (Tentative)
39
Programs by Topic
Futures in Clinical Research
Luncheon Mentoring Sessions (Registration Required) . C96 The History of Certain Disorders of the Nervous System
I5
the Impact on Neurology . . . . . . . . . . . . . . . . . . S30 Education, Research, and History . . . . . . . . . . . . . Clinical Decision Making After the
I8
Dust Settles on Clinical Trials . . . . . . . . . . . . . . . Subspecialty in Focus Track
23
68
91
93
Sleep
C10
Approach to Sleep Symptoms: Sleepy or Sleepless
C30 Sleep for the Practicing Neurologist
I3
Impact on Mechanism, Expression, and Treatment . . . 44
C84
S9Sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Poster Session V . . . . . . . . . . . . . . . . . . . .94–101
P5
H10 Sleep Highlights in the Field . . . . . . . . . . . . . . . . 29
S64 Section Topic Controversies: Pain:
Methods of Treatment . . . . . . . . . . . . . . . . . . . 132
C151 Hot Topics in Sleep Neurology
C156 Evaluation and Therapy of Restless Legs Syndrome and
Periodic Limb Movements in Sleep
C166 Interpretation of Polysomnography for the Practicing
Neurologist
“[At the Education Programs] I like to hear what other people are
doing, even if it only confirms that we are doing the up-to-the-date
thing. I learn some new ideas, things that have worked, things that
haven’t worked. The best part is that [the AAN has] put everything
on the web or app, which is new. Major improvement.”
David Kauffman, MD
Scarsdale, NY
40
Sunday, April 27
Temporal Lobe Epilepsy and Febrile Seizures
I1 8:00 a.m.–12:00 p.m.
Coordinators: Shlomo Shinnar, MD, PhD, FAAN and Tallie Z. Baram, MD, PhD
Invited Speaker Session: 8:00 a.m.–10:30 a.m.
8:00 a.m.–8:45 a.m.
Epidemiological Aspects of Febrile Seizures, Febrile Status Epilepticus and Temporal Lobe Epilepsy Dale C. Hesdorffer, PhD
8:45 a.m.–9:30 a.m.
What Are the Causal Relationships of Febrile Seizures / FSE and Temporal Lobe Epilepsy? Challenges and Emerging Answers Tallie Z. Baram, MD, PhD
9:30 a.m.–10:15 a.m. Febrile Status Epilepticus and Temporal Lobe Epilepsy: Insights from a Multi-Center Prospective Study Shlomo Shinnar, MD, PhD, FAAN
10:15 a.m.–10:30 a.m. Questions and Answers
Poster Rounds: 10:30 a.m.–11:30 a.m.
I1-1.001
Sequential Versus
Simultaneous Polytherapy in the Treatment
of Status Epilepticus Claude Wasterlain,
Roger Baldwin, Jerome Niquet, Lucie
Suchomelova
I1-1.002 Mismatch of Structural and
Functional Reorganization In Language
Network asSCX Left Temporal Lobe Epilepsy Shigetoshi
Takaya, Naoaki Tanaka, Hesheng Liu,
Douglas Greve, Claus Reinsberger, Andrew
Cole, Emad Eskandar, Steven Stufflebeam
I1-1.003 Influences of Temporal Lobe
Epilepsy and Temporal Lobe Resection on
Olfactory Function Richard Doty, Isabelle
Tourbier, Taehoon Kim, Jonathan Silas, Paul
Moberg, Ashwini Sharan, Michael Sperling,
Bruce Turetsky
I1-1.004 Physiologic and Cortical
Response to Acute Psychosocial Stress
in Left Temporal Lobe Epilepsy Jane
Allendorfer, Heidi Heyse, Lucy Mendoza,
Jerzy Szaflarski
I1-1.005 Graph Theory Based
Functional Connectivity in Lateralized
Temporal Lobe Epilepsy Sharon Chiang,
John Stern, Jerome Engel, Harvey Levin,
Zulfi Haneef
I1-1.006
Factors Independently
Associated with Anxiety and Depression
in Epilepsy Heidi Munger Clary, Marla
Hamberger
I1-1.007
Efficacy of Transcranial
Direct Current Stimulation on Working
Memory and Mood in Patients with
Temporal Lobe Epilepsy Anli Liu, Orrin
Devinsky, Andrew Bryant, Ashlie Jefferson,
Daniel Friedman, Mouhsin Shafi, William
Barr, Daniel Press, Susan Herman, Margaret
O’Connor, Steven Schachter, Alvaro PascualLeone
I1-1.008 Utility of CT Perfusion
(CTP) Imaging in Seizures: A Retrospective
Analysis and Literature Review Aunali
Khaku, Vishunmurthy Hedna, Michael
Waters
I1-1.009
Serum IL6, IL1β and IL1Ra
Levels in Patients With Epilepsy Irem
Fatma Uludag, Tarik Duksal, Yasar Zorlu,
Feriha Ozkaya, Guldal Kirkali
I1-1.010
Is Presurgical MEG Useful in
Intractable Temporal Lobe Epilepsy? Helen
Barkan, Shannon Sparrow, Ann Marie
Collier, Michael Funke
Data Blitz: 11:30 a.m.–12:00 p.m.
11:30 a.m.
I1-2.001
11:35 a.m.
I1-2.002
The Role of Toll-Like Receptor 3 in
Epileptogenesis Felix Benninger, Adi
Gross, Israel Steiner, Daniel Offen, Eitan
Okun
Human Mesial Temporal Lobe Single
Neuron Dynamics During Recruitment
Into a Generalizing Seizure Amrit Misra,
Xianda Long, Ashwini Sharan, Michael
Sperling, Karen Moxon
11:40 a.m.
I1-2.003
Association Between Human Herpes Virus
6 and Hippocampal Volume in Mesial
Temporal Lobe Epilepsy William Theodore,
Emily Leibovitch, Bridgette Billioux, Sierra
Germeyan, David Kalikhman, Sara Inati,
John Heiss, Kareem Zaghloul, Steven
Jacobson
11:45 a.m.
I1-2.004
Virtual Car Accident Rates of Epilepsy
Patients are Significantly Increased by
Interictal Generalized Spike Waves Heinz
Krestel, Andreas von Allmen, Christian
Liechti, Maja Steinlin, Johannes Mathis,
Nirkko Arto
I CU EEG Monitoring: Seizures in Critically Ill Patients
11:50 a.m.
I1-2.005
Correlation Between MRI Findings
of Mesial Temporal Sclerosis and
Histopathological Findings Judy Li, Steve
Chung
1:00 p.m.–2:30 p.m.
1:00 p.m.–1:05 p.m.Introduction: Kimford J. Meador, MD, FAAN
42
1:05 p.m.–1:45 p.m.
Debate: Most Critically Ill Patients Should Undergo
Continuous EEG Monitoring
Pro: Lawrence J. Hirsch, MD, FAAN
Con: Frank W. Drislane, MD, FAAN
1:45 p.m.–2:25 p.m.
Debate: All Seizures in Critically Ill Patients
Should Be Aggressively Treated and Stopped
As Soon As Possible
Pro: Stephan A. Mayer, MD
Con: Peter W. Kaplan, MBBS, FRCP, FAAN
2:25 p.m.–2:30 p.m.
Concluding Remarks: Kimford J. Meador, MD, FAAN
Integrated Neuroscience Sessions/Section Topic Controversies
New Antithrombotic Agents for Stroke Prevention
1:00 p.m.–5:00 p.m.
Sunday
April 27
I2 Coordinators: Seemant Chaturvedi, MD, FAAN, FAHA and Antonio Culebras, MD, FAAN, FAHA
Invited Speaker Session: 1:00 p.m.–3:30 p.m.
1:00 p.m.–1:10 p.m.Introduction Antonio Culebras, MD, FAAN, FAHA
1:10 p.m.–1:40 p.m.
The “New” Oral Anticoagulants for Stroke Prevention Cathy A. Sila, MD, FAAN
1:40 p.m.–2:10 p.m.
Periprocedural Management of Antithrombotic Therapy Jose Biller, MD, FAAN, FACP, FAHA
2:10 p.m.–2:20 p.m.Break
2:20 p.m.–2:50 p.m.
Management of Bleeding Complications Julius Latorre, MD
2:50 p.m.–3:15 p.m.
Potential Futures Uses of Novel Oral Anticoagulants Mukul Sharma, MD
3:15 p.m.–3:30 p.m.Discussion
Poster Rounds: 3:30 p.m.–4:30 p.m.
I2-1.001 Effect of Apixaban on
All-Cause Mortality in Atrial Fibrillation:
An Imputed Placebo Analysis John
McMurray, Robert Hart, Greg Flaker, Renato
Lopes, Junyuan Wang, Michael Hanna,
John Alexander, Christopher Granger, Lars
Wallentin
I2-1.002 Risk of Bleeding from
Antithrombotic Agents (AT) in Patients
with Cerebral Cavernous Malformations
(CCMs). Robert Wityk
I2-1.003 Diagnostic Yield of
I2-1.006 The Incidence of Secondary
I2-1.004 Stroke in Very Old
I2-1.007 Neuroanatomical Correlates
Prolonged Cardiac Rhythm Monitoring in
Cryptogenic Stroke Rizwan Kalani, Richard
Bernstein, Yvonne Curran, Ilana Ruff, Shyam
Prabhakaran
Patients Drini Dobi, Mira Kapisyzi, Jera
Kruja
I2-1.005 Cryptogenic Stroke with
No Cause Demonstrates the Outcome
Prediction Utility of TOAST Classifications
in a Large Stroke Patient Sample Tyler
Scullen, Dominique Monlezun, Jr,
Alexander George, James Siegler, Melissa
Schwickrath, Ramy El Khoury, Sheryl
Martin-Schild
Stroke Prevention Medication Following
Hospitalization for Ischemic Stroke Justin
Blackburn, Hong Zhao, Meredith Kilgore,
Karen Albright
of Atrial Fibrillation: A Longitudinal MRI
Study Aveen Saed, Nudrat Tasneem, Malik
Adil, Mushtaq Qureshi, Adnan Qureshi
I2-1.009 Warfarin Associated
Intracerebral Hemorrhage in Hong Kong
Chinese Kay Cheong Teo, Neeraj R
Mahboobani, Raymand Lee, David CW Siu,
Raymond Cheung, Shu Leong Ho, Gary KK
Lau, Koon Ho Chan
I2-1.010
Stroke Patients and
Diagnostic Testing—the Weekend Waiting
Game! Sally Mathias, Jessica Lee
I2-1.008 Etiologies of Intracerebral
Hemorrhages from 2009-2012 at Mayo
Clinic-Rochester James Klaas, Sherri
Braksick, Robert Brown, Alejandro
Rabinstein, Jennifer Fugate
Data Blitz: 4:30 p.m.–5:00 p.m.
4:30 p.m.
I2-2.001
Oral Anticoagulant Therapy Is Associated
with Cerebral Microbleeds Saloua
Akoudad, Sirwan Darweesh, Maarten
Leening, Peter Koudstaal, Albert Hofman,
Aad Van Der Lugt, Bruno Stricker,
Mohammad Ikram, Meike Vernooij
4:35 p.m.
I2-2.002
Mobile Cardiac Outpatient Telemetry
Identifies Occult Atrial Fibrillation After
Cryptogenic Stroke Erin Ingala, Jenny
Jara, Emily Fessler, Brett Cucchiara, Steven
Messe, Michael Mullen, Allyson Prasad,
Mathew Hutchinson, Scott Kasner
4:40 p.m.
I2-2.003
Use of Apixaban and Warfarin in Patients
Undergoing Procedures: Insights from
ARISTOTLE Renato Lopes, David Garcia,
Daniel Wojdyla, Paul Dorian, John
Alexander, Lars Wallentin, Fernando Lanas,
Michael Hanna, Claes Held, Christopher
Granger
4:45 p.m.
I2-2.004
4:50 p.m.
I2-2.005
Infarction Volume in Patients with Atrial
Fibrillation: The Impact of Left Ventricular
Stiffness Hee-Seung Ahn, Wi-Sun Ryu
Direct Thrombin Inhibitors May Have
a Decreased Risk of Intracerebral
Hemorrhage Compared with Older
Anticoagulants Sindhu Ravipati, Daniel
Woo, Padmini Sekar, Charles Moomaw,
Matthew Flaherty, Jennifer Osborne
43
Monday, April 28
I3 Clocks, Sleep, Brain Health and Disorders:
Impact on Mechanism, Expression, and Treatment
8:00 a.m.–12:00 p.m.
Coordinators: Bradley V. Vaughn, MD, FAAN and Phyllis C. Zee, MD, PhD
8:00 a.m.–8:10 a.m.Introduction Phyllis C. Zee, MD, PhD
8:10 a.m.–8:40 a.m.
Neurobiology of Sleep and Wake Regulation Clifford B. Saper, MD, PhD, FAAN
8:40 a.m.–9:10 a.m.
The Role of Circadian Rhythm Dysfunction in Huntington Disease A. Jennifer Morton
9:10 a.m.–9:45 a.m.
Bi-directional Relationship Between Sleep, Circadian Rhythms, and Neurodegeneration David M. Holtzman, MD, FAAN
9:45 a.m.–10:15 a.m. Circadian Rhythm and Sleep in Epilepsy Mark S. Quigg, MD
10:15 a.m.–10:30 a.m. Questions and Answers
I3-1.001 A Novel Capability for
I3-1.003 Diffusion Tensor Imaging
I3-1.002 Poor Sleep and White
I3-1.004 Investigating the Night to
Monitoring Cerebral and Systemic
Hemodynamics, ECG and Actigraphy During
Sleep Vladimir Ivkovic, Gary Strangman,
Quan Zhang
Matter Quality Among Middle Aged
Adults Kristine Yaffe, Jasmine
Nettiksimmons, Lenore Launer, Stephen
Sidney, Mercedes Carnethon, Kristine
Knutson, Diane Lauderdale, Cora Lewis,
Nick Bryan
as a Biomarker for REM Sleep Behavior
Disorder and Parkinson’s Disease Matthew
Brodsky, John Grinstead, David Lahna,
Jeffrey Pollock
Night Variability of REM Without Atonia
in Parkinson’s Disease Samuel Bolitho,
Sharon Naismith, Ron Grunstein, Zoe
Terpening, Moran Gilat, Simon Lewis
I3-1.005 Multiple Sclerosis Reported
Fatigue: Obstructive Sleep Apnea and
Abnormalities in Sleep Architecture in
a Community Cohort Mark Gudesblatt,
Myassar Zarif, Barbara Bumstead, Lori
Fafard, Marijean Buhse, Steven Brass,
Konstantina Bardhi, Steven Xian
I3-1.006 Diazepam Useful in ESES
Treatment Mirret El-Hagrassy, Chulaka
Gunasekara, Yaman Eksioglu
I3-1.007 Sleep Abnormalities in
Children with Dravet Syndrome Radhika
Dhamija, Maia Erickson, Erik St Louis,
Suresh Kotagal
I3-1.008 Nocturnal Melatonin
Regulation in Post-Traumatic Vegetative
State: A Possible Role for Melatonin
Supplementation? Pietro Guaraldi, Elisa
Sancisi, Giovanna Calandra-Buonaura,
Chiara La Morgia, Valerio Carelli, Cameli
Olivia, Alberto Battistini, Pietro Cortelli,
Roberto Piperno
I3-1.009 The Efficacy of Gabapentin
Enacarbil (GEn) in Adult Patients with
Severe Primary Restless Legs Syndrome
(RLS): Pooled Analyses from 3 Randomized
Trials Daniel Lee, William Ondo, Alon
Avidan, Diego García-Borreguero, Mark
Jaros, Richard Kim, Gwendoline Shang
Data Blitz: 11:30 a.m.–12:00 p.m.
11:30 a.m.
I3-2.001
Distinct Innervation Patterns of the
Melanin Concentrating Hormone
Neurons from the Basal Forebrain
Structures Minjee Kim, Lindsay
Agosstinelli, Thomas Scammell
11:35 a.m.
I3-2.002
Comparing Periodic Limb Movements
in Sleep in Subjects with and without
Waking Paretic/Plegic Limbs Mark
Dyken, Miriam Zimmerman, Kyoungbin Im,
Deborah Lin-Dyken, Christine Glenn, Mark
Blumberg, Robert Rodnitzky, Greta Sokoloff
11:40 a.m.
I3-2.003
11:45 a.m.
I3-2.004
Exploring The Neural Circuitry of REM
Sleep Behavior Disorder In Parkinson’s
Disease Using Functional MRI Samuel
Bolitho, James Shine, Sharon Naismith,
Ron Grunstein, Peter Bell, Simon Lewis
Bright Light Therapy Improves Excessive
Daytime Sleepiness Associated with
Parkinson’s Disease Aleksandar Videnovic,
Angelica Marconi, Teresa Kuhta, Scott
Miskevics, Phyllis Zee
S2 Cancelled
44
11:50 a.m.
I3-2.005
Antibodies Against the Cell Adhesion
Molecule Iglon5 Identify a Novel
Tauopathy with NREM/REM Parasomnia
and Sleep Breathing Disorder Carles Gaig,
Lidia Sabater, Ellen Gelpi, Luis Bataller, Jan
Lewerenz, Estefania Torres-Vega, Angeles
Contreras, Bruno Giometto, Yaroslau
Compta, Cristina Embid, Isabel Vilaseca,
Alex Iranzo, Joan Santamaria, Josep
Dalmau, Francesc Graus
1:00 p.m.–2:30 p.m.
Integrated Neuroscience Sessions/Section Topic Controversies
I4 Recent Advances in
Translational Research in Autism
1:00 p.m.–5:00 p.m.
Coordinators: Margaret L. Bauman, MD, FAAN and Martha R. Herbert, MD, PhD
1:00 p.m.–1:10 p.m.Introduction
Autism Spectrum and Epilepsy Spectrum Frances E. Jensen, MD
1:40 p.m.–2:10 p.m.
GI and Autism from Research and Clinical Point of View Kara Gross, MD
2:10 p.m.–2:40 p.m.
Autism, GI, MET Genes, and Connectivity Theory Pat Levitt, PhD
2:40 p.m.–3:10 p.m.
Mitochondrial Dysfunction, Purinergic Signaling, ASD, and Clinical Trials Robert Naviaux, MD, PhD
3:10 p.m.–3:30 p.m.
Questions and Answers
Monday
April 28
1:10 p.m.–1:40 p.m.
I4-1.001 SHANK3 Overexpression
Causes Manic-like Behavior with Unique
Pharmacogenetic Properties Jimmy
Holder, Huda Zoghbi
I4-1.002 Predictors of Response to
I4-1.004 Knockout of p75NTR in
Cerebellar Purkinje Cells Results in an
Autism-like Murine Phenotype Nina
Schor, Deborah Cory-Slechta, Louis Lotta,
Katherine Conrad
Propranolol for Social Functioning in Autism
Spectrum Disorder David Beversdorf,
Rachel Zamzow, Brad Ferguson, Tamera
Martin, Morgan Lewis, Janine Stichter
I4-1.005 Resting State EEG Serves
I4-1.003 Cognitive and
I4-1.006 Behavioral Profiles of
Developmental Predictors of ASD in Infants
with Tuberous Sclerosis Complex. Shafali
Jeste, Joyce Wu, Damla Senturak, Mustafa
Sahin, Charles Nelson
as a Promising Biomarker of Cognitive and
Language Function in Young Children with
ASD. Kevin McEvoy, Shafali Jeste
Children and Adolescents with Specific
Language Impairment and High Functioning
Autism Marisela Dy, Angela Ballantyne,
Doris Trauner
I4-1.007 Mean EEG Coherence
in Infants at Risk for Autism Spectrum
Disorder April Levin, Marc Shi, Helen
Tager-Flusberg, Charles Nelson
I4-1.008 Genetic Animal Models
I4-1.010
Intrinsic Excitability Defects
in Specific Subtypes of Medial Prefrontal
Cortex Pyramidal Neurons in a Mouse
Model of Autism Audrey Brumback, Vikaas
Sohal
of Autism Based on Shank/ Mutation
Molecules to Potential Therapeutics Craig
Powell
I4-1.009 Autistic Symptoms in a
Geriatric Population with Mild Cognitive
Impairment and Early Dementia Danielle
Crawford, Erin Abner, Paul Glaser, Gregory
Jicha
4:30 p.m.
I4-2.001
Abnormal White Matter Connectivity
in Children with Autism or Sensory
Processing Disorder: Overlap and
Divergence. Elysa Marco, YiShin Chang,
Julia Owen, Shivani Desai, Julia Harris,
Susanna Hill, Anne Arnette, Pratik
Mukherjee
4:35 p.m.
I4-2.002
4:40 p.m.
I4-2.003
Delayed Low Level Visual Processing in
Infants with Tuberous Sclerosis Complex
(TSC) Pilar Pichon, Jordan Ko, Charles
Nelson III, Shafali Jeste
Value of Routine EEG in Autistic
Patients with Stereotypic Behavioral
Movements Ankit Nayyar, Neha
Mirchandani, Rebecca Spiegel
4:45 p.m.
I4-2.004
High-Functioning Autistic Children Have
Abnormal Stapedial Reflexes Richard
Lukose, Randy Kulesza, Kevin Brown,
Barber Carol
4:50 p.m.
I4-2.005
Reduction in Retinal Nerve Fiber Layer
Thickness in Young Adults with Autism
Spectrum Disorders Matteo Pardini,
Leonardo Emberti Gialloreti, Francesca
Benassi, Sara Marciano, Mario Amore,
Maria Giulia Mutolo, Maria Cristina Porfirio,
Paolo Curatolo
“[The Annual Meeting is] so exciting because you see the faces
of the people whose papers you have read. People are usually
accessible and you can network with them.”
Salvatore Di Mauro, MD
New York, NY
Introducing ePosters!
The new ePoster session will take place in the poster hall,
April 28 through May 1 and will feature digital presentations
of select scientific posters. This new format will allow
authors to feature compelling visual components, such as:
¡
Images
¡
Video
¡
3D Models
For location of the ePoster session, see the poster session
floor plan on the next page.
April 26 – May 3, 2014
Philadelphia, PA
Poster Session Floor Plan
Poster Session Schedule
Monday, April 28
P1 Poster Session I
3:00 p.m.–6:30 p.m.
5:00 p.m.–6:30 p.m.*
ePosters
Tuesday, April 29
015
014
013
012
011
7:30 a.m.–11:00 a.m.
7:30 a.m.–9:00 a.m.*
016
017
018
019
020
3:00 p.m.–6:30 p.m.
5:00 p.m.–6:30 p.m.*
Wednesday, April 30
7:30 a.m.–11:00 a.m.
7:30 a.m.–9:00 a.m.*
P5 Poster Session V
3:00 p.m.–6:30 p.m.
5:00 p.m.–6:30 p.m.*
Thursday, May 1
7:30 a.m.–11:00 a.m.
7:30 a.m.–9:00 a.m.*
3:00 p.m.–6:30 p.m.
5:00 p.m.–6:30 p.m.*
021
022
023
024
025
026
027
028
029
030
060
059
058
057
056
055
054
053
052
051
061
062
063
064
065
066
067
068
069
118
117
116
115
114
113
112
111
110
119
120
121
122
123
124
125
126
127
176
175
174
173
172
171
170
169
168
177
178
179
180
181
182
183
184
185
234
233
232
231
230
229
228
227
226
235
236
237
238
239
240
241
242
243
292
291
290
289
288
287
286
285
284
293
294
295
296
297
298
299
300
301
350
349
348
347
346
345
344
343
342
031
032
033
034
035
036
037
038
039
040
050
049
048
047
046
045
044
043
042
041
070
071
072
073
074
075
076
077
078
079
109
108
107
106
105
104
103
102
101
100
128
129
130
131
132
133
134
135
136
137
167
166
165
164
163
162
161
160
159
158
186
187
188
189
190
191
192
193
194
195
225
224
223
222
221
220
219
218
217
216
244
245
246
247
248
249
250
251
252
253
283
282
281
280
279
278
277
276
275
274
302
303
304
305
306
307
308
309
310
311
341
340
339
338
337
336
335
334
333
332
080
081
082
083
084
085
086
087
088
089
099
098
097
096
095
094
093
092
091
090
138
139
140
141
142
143
144
145
146
147
157
156
155
154
153
152
151
150
149
148
196
197
198
199
200
201
202
203
204
205
215
214
213
212
211
210
209
208
207
206
254
255
256
257
258
259
260
261
262
263
273
272
271
270
269
268
267
266
265
264
312
313
314
315
316
317
318
319
320
321
331
330
329
328
327
326
325
324
323
322
Poster Board Size
All posters are 4 feet high by 6 feet wide.
010
009
008
007
006
005
004
003
002
001
Discussion Posters
*First authors stand by posters
Fast, Easy Registration Online · AAN.com/view/am14
47
Monday, April 28
P1 Poster Session I
First Authors stand by Posters from 5:00 p.m.–6:30 p.m.
3:00 p.m.–6:30 p.m.
oster Discussion Session: Aging, Dementia, and Cognitive and Behavioral
P
Neurology I
Utilizing a guided tour format, topic experts will lead attendees around the ten posters in the poster discussion session and facilitate questions with poster authors during
the 90-minute author stand-by time.
P1.001
Complementary and
Alternative Medicine Use Among
Patients with Cognitive Impairment in
Singapore Wahab Hameed, Simon Kang
Seng Ting
P1.004
Aerobic Physical Exercise
Stabilizes Cognitive Status in NonDemented Elderly: An In-Patient Pilot
Study. Manuel Seijo-Martinez, José María
Cancela Carral, Ayán Pérez Carlos
P1.007
P1.002
P1.005
P1.008
Museum-based Creative
Arts Programming Is Associated with
Less Dementia Patient Apathy and Better
Caregiver Well-being Hannah Roberts,
Carolyn Halpin-Healy, Rebecca McGinnis,
James Noble
P1.003
Evaluation of a
Multidisciplinary “Brain Fitness Program”
for Treatment of Cognitive Impairment with
Aging Majid Fotuhi, Mark Trullinger, Brooke
Lubinski, Mehdi Ghasemi
Comparative Effectiveness
of an Advanced Treatment Protocol for
Dementia Versus Standard Community
Care Emilymarie Clionsky
P1.006
Extended-release Daily
Memantine Provides Increasing Cumulative
Benefits Across Clinical Domains Over
24 Weeks in Patients with Moderate to
Severe Alzheimer’s Disease: An Analysis of
Area Under the Curve Alireza Atri, Suzanne
Hendrix, Vojislav Pejovic, Stephen Graham
Predictors of Response to 13.3
mg/24 h Rivastigmine Patch in Patients
with Severe Alzheimer’s Disease Martin
Farlow, Carl Sadowsky, Drew Velting,
Xiangyi Meng, Zahur Islam
Efficacy of 13.3 mg/24
h versus 4.6 mg/24 h Rivastigmine
Patch on Activities of Daily Living in
Severe Alzheimer’s Disease: A Factor
Analysis Joseph Micca, Drew Velting,
Xiangyi Meng
P1.009
Cognitive Efficacy of 13.3
mg/24 h versus 4.6 mg/24 h Rivastigmine
Patch in Severe Alzheimer’s Disease:
Severe Impairment Battery Factor
Analysis Steven Ferris, Richard Isaacson,
Drew Velting, Xiangyi Meng
P1.010
Bayesian Longitudinal
Modeling on Placebo Data from
Alzheimer’s Disease Clinical Studies YunFei Chen, Richard Mohs, Ying Ding, Paul
Aisen, Ronald Thomas
NEW! e
Poster Session: Movement Disorders I
The ePoster session will feature a selection of posters to be presented digitally, rather than in the traditional format. Authors will be able to take advantage of the format to
highlight compelling visual features such as images and videos. See poster map on page 47 for location.
P1.011
Validation of a Functional
Biomarker of Brain Energy Deficit in
Huntington Disease Fanny Mochel, Isaac
Mawusi Adanyeguh, Daisy Rinaldi, Romain
Valabregue, Alexandra Durr, Pierre-Gilles
Henry
P1.012
Correlating OCT Changes with
Disease Severity and Cognitive Status
in Parkinson’s Disease Shirin Vartak,
Thomas Guttuso, Jesper Hagemeier, Cheryl
Kennedy, Rebecca Melia, Ellen Carl, David
Lichter, Robert Zivadinov
General Neurology I
P1.021
AML Presenting as Autonomic
Autoimmune Ganglionopathy Joel Phillips,
Elmoatazbellah Ibrahim, Mirela Cerghet,
Naganand Sripathi, Javier Arias-Stella III
P1.022
Extensor Posturing and
a Cingulate Gyrus Lesion: An Unusual
Case Atul Ramesh, Daniel Labovitz, Shouri
Lahiri, Alexis Boro
48
P1.013
Deep Brain Stimulation in
X-linked Dystonia-Parkinsonism (DYT3/
Lubag): Partial Results from a Prospective
Trial of 12 Cases Aloysius Domingo,
Norbert Brüggemann, Roland Dominic
Jamora, Cid Diesta, Jose Aguilar, Simone
Zittel, Anne Weissbach, Dirk Rasche,
Alexander Münchau, Raymond Rosales,
Lillian Lee, Volker Tronnier, Christine Klein
P1.015
P1.014
Progressive Supranuclear
Palsy (PSP): Diagnosis Through Skin
Biopsy Ildefonso Rodriguez-Leyva, Ana
Calderon-Garcidueñas, Martha Santoyo,
Erika Chi, Verónica Medina-Mier, Maria
Jimenez-Capdeville
P1.016
P1.023
P1.025
Neurologic Imaging and
Electroencephalogram Findings After
Chasing the Dragon Kelly Andrzejewski,
Michael Devereaux
P1.024
Trends in Outcome and Cost of
Hospitalization of Mechanically Ventilated
Adult Myasthenia Gravis Patients from
1992 to 2009 Weizhen Wang, Ankit Pahwa,
Nizar Souayah
Parkinson Risk in Ashkenazi
Jewish Gaucher Patients and GBA
Heterozygotes: Is There a Gene Dose
Effect? Roy Alcalay, Tama Dinur, Timothy
Quinn, Karina Sakanaka, Oren Levy, Cheryl
Waters, Stanley Fahn, Tsvyatko Dorovski,
Wendy Chung, Michael Pauciulo, William
Nichols, Huma Rana, Manisha Balwani,
Louise Bier, Deborah Elstein, Ari Zimran
Combined Fenobam and
Amantadine Signigficantly Reduce
Levodopa-Induced Dyskinesia in
the 1-Methyl-4-Phenyl-1,2,3,6Tetrahydropyridine (MPTP)-Lesioned
Primate Model of Parkinson’s
Disease Maurizio Facheris, Wai Kin D Ko,
Elsa Pioli, Qin Li, Steve McGuire, Alison
Urkowitz, Audrey Dufour, Erwan Bezard,
Todd Sherer
Assessment of Mortality in
Sporadic Inclusion Body Myositis: A Delphi
Panel Technique Victoria Barghout, Mark
Price, Olivier Benveniste, Lisa ChristopherStine, Alastair Corbett, Marianne De Visser,
David Hilton-Jones, John Kissel, Thomas
Lloyd, Ingrid Lundberg, Frank Mastaglia,
Tahseen Mozaffar, Merrilee Needham, Jens
Schmidt, Kumaraswamy Sivakumar, Carla
Demuro, Brian Tseng
P1.017
Quantifying Musician
Performance using MIDI Analysis Before
and After EMG-Guided Botulinum
Toxin Injections for Focal Task-Specific
Dystonia Miriam Sklerov, Sarah Boschung,
Seth Pullman
P1.018
Kinematic Assessments
Effectively Guide Botulinum Neurotoxin
Type A Injections For Essential Tremor
Treatment Jack Lee, Fariborz Rahimi, Olivia
Samotus, Mandar Jog
P1.019WITHDRAWN
P1.020WITHDRAWN
P1.026
Neurologic Involvement in Val122 Ile Familial Amyloidosis Sami Khella,
Brian Drachman, Patricia Divito, Michael
Polydefkis, Thomas Brannagan, Daniel
Judge, Mathew Maurer
P1.027
Paraneoplastic Cerebellar
Degeneration with Castleman Disease: A
Case Report Sarah Lee, Scheherazade Le
Poster Session I
Search for Autoantibodies
Targeting the Nodes of Ranvier in
Chronic Inflammatory Demyelinating
Polyradiculoneuropathy (CIDP) Panos
Stathopoulos, Harry Alexopoulos, Angie
Biba, Domna Karagogeos, Marinos Dalakas
P1.029
Barriers to Discharge: A
Quality Improvement Project Anh-Thu Tran,
Thuy-Anh Vu, Sandeep Kahlon
P1.030
NAIL-ing the Diagnosis:
Real Neurologists Pay Attention to the
Nails Shin Beh, Teresa Frohman, Amy
Conger, Darrel Conger, Laura Balcer, Peter
Calabresi, David Zee, Elliot Frohman
P1.031
Cancer Risks Among the Users
of Ergot-Derived Dopamine Agonists for
Parkinson’s Disease: A Population-Based
Case-Control Survey Vinchi Wang, Chao
Tzu-Hao
P1.032
Modulation of the
Default-Mode Network and the
Attentional Network by Self-Referential
Processes in Patients with Disorder of
Consciousness Mirta Villarreal, Verónica
Mäki-Marttunen, Lisandro Olmos, Ramón
Leiguarda
P1.033
P1.042
The Underlying Mechanisms
of Autophagy in Age-related Sensitivity to
Parkinsonian Pathogenesis Ya-Ping Yang,
Hui-Fen Zheng, Cheng-Jie Mao, Fen Wang,
Li-Fang Hu, Chun-Feng Liu
P1.043
The Role of AlphaSynuclein Oligomerisation in Parkinson’s
Disease Sonia Gandhi, Mathew Horrocks,
Plamena Stroh, Marthe Ludtmann, Emma
Deas, Nicholas, W Wood, David Klenerman,
Andrey Abramov
P1.044
Generation of Alpha Synuclein
(Snca) Cell Models for High-Throughput
Drug Screening Using Zinc-Finger Nuclease
Technology Warunee Dansithong, Khanh
Thai, Sharan Paul, Stefan Pulst, Duong
Huynh
P1.045
Ataxin-2 (Atxn2)
Regulates Rgs8 Expression via Rna
Interaction Sharan Paul, Warunee
Dansithong, Stefan Pulst
P1.046Sodium-Potassium
Atpase Inhibitors as Inhibitors of Atxn2
Expression Daniel Scoles, Lance Pflieger,
Thomas Dexheimer, David Maloney, Anton
Simeonov, Ajit Jadhav, Stefan Pulst
Ehlers-Danlos Syndrome
and Postural Tachycardia Syndrome: A
Relationship Study Daniel Wallman, Anna
Hohler, Janice Weinberg
P1.047
P1.034
P1.048
Postural Tachycardia
Syndrome Associated with Ferritin
Deficiency Daniel Wallman, Anna Hohler,
Janice Weinberg, Zetta Fayos
P1.035
How Safe Is Acute High Dose
Corticosteroid Therapy in Neurological
Disorders? Itai Lotan, Liora Fireman, Avi
Weizman, Israel Steiner
P1.036
A Case of Paraneoplastic
Cerebellar Degeneration Associated with
Non-Cutaneous Metastastic Merkel Cell
Carcinoma Cen Zhang, Eric Lancaster
P1.037
Expanding the Clinical
Spectrum of Neuromyelitis Optica: Three
Cases with Brainstem Involvement Faria
Amjad, Sean Gratton, Benjamin Osborne,
Carlos Mora, Carmelo Tornatore
P1.038
Longitudinally Extensive
Spinal Cord Osmotic Myelinolysis Lina
Rodriguez, Scott Silliman
P1.039
A Diagnostic Algorithm for
Paroxyasmal Kinesigenic Dyskinesia Jasita
Sachar, Krishe Menezes, A. Rothner
P1.040
Two-Year Experience of
Neuronal Surface Antibodies Mediated
Encephalitis Diagnostic Screening in 450
Patients_A Single Center Study from
China Lei Liu, Jiawei Wang
Movement Disorders:
Basic Mechanisms
P1.041
Cellular Response to Deep
Brain Stimulation in a Rat Model Vinata
Vedam-Mai, Massoud Baradaran-Shoraka,
Alex Mafdali, Sara Ardila, Eun Mi Kim,
Jamie Schwarz, Brent Reynolds, Michael
Okun
Co-expression Networks in
Generation of Induced Pluripotent Stem
Cells (Ipscs) Lance Pflieger, Sharan Paul,
Fuying Gao, Giovanni Coppola, Stefan Pulst
Optical Coherence
Tomography in Parkinson’s Disease:
Retinal Structural Injury and Insights Into
Disease Pathology Aashka Shah, Jessica
Chorostecki-Vigrass, Ginny Bao, Fen Bao,
Carla Santiago Martinez, Veronica Gorden,
Christina Caon, Edwin George, Natalya
Shneyder, Navid Seraji-Bozorgzad, Shana
Krstevska, Elliot Frohman, Omar Khan
P1.049
Rare Variant Pathway Analysis
Highlights the Importance of Lysosomal
Pathways in Parkinson Disease Jeffery
Vance, Karen Nuytemans, Gary Beecham,
Vanessa Inchausti, LizMarie Maldonado,
Eden Martin, William Perry, Liyong Wang,
Margaret Pericak-Vance, William Scott
P1.050
The Relationship Between
Dietary Intake, Nutrition Status and
Huntington’s Disease Severity Esther
Cubo, Jessica Rivadeneyra, Natividad
Mariscal, Diana Armesto, Ana Mateos,
Rafael Camara
Neuromuscular Disease:
Basic Science
P1.051
Neuronal Activity Drives
Presynaptic pH Regulation: Insights
from Live Fluorescent pH Imaging in
Drosophila Melanogaster Motor Nerve
Terminals. Adam Rossano, Gregory
Macleod
P1.052
Familial Amyotrophic Lateral
Sclerosis with Novel p62 Immunopositive
Intra-Neuronal Nuclear and Axonal
Spheroid Inclusions Raphael Schneider,
Phedias Diamandis, Lorne Zinman, Ekaterina
Rogaeva, Janice Robertson, Julia Keith
P1.053
Long-term Electrophysiologic
Assessment of a Mild Mouse Model of
Spinal Muscular Atrophy Seward Rutkove,
Jia Li
P1.054
A Mouse Model of Adult
Polyglucosan Body Disease (Apbd), a Late
Onset Variant of Glycogen Storage Disease
Type IV (GSD IV). Hasan Akman, Valentina
Emmanuele, Sindu Krishna, Salvatore
DiMauro
P1.066
P1.055
Paraneoplastic Antibodies
in Patients with Amyotrophic Lateral
Sclerosis Michael Rosario, Richard Bedlack
P1.067
P1.056Autopsy-proven
P1.068
Amyotrophic Lateral Sclerosis Coexisted
with Parkinson Disease: A Novel
Association of TDP-43 Proteinopathy and
α-Synucleinopathy Yuishin Izumi, Hiroyuki
Sumikura, Koji Fujita, Masaki Kamada,
Yoshimitsu Shimatani, Ryosuke Miyamoto,
Hidetaka Koizumi, Yoshimichi Miyazaki,
Hiroyuki Hatsuta, Hiroyuki Nodera,
Yoshihiko Nishida, Shigeo Murayama, Ryuji
Kaji
P1.057
Genetic Background Effects
on Lifespan of Dynactin P150 Glued Mouse
Models of Motor Neuron Disease Terry
Heiman-Patterson, Juliann Jiang, Philip
Wong, Guillermo Alexander, Elizabeth
Blankenhorn
P1.058
Oligomerization of ZASP, a
Myofibrillar Myopathy Gene Product, in
Vitro and in Vivo Lisa Brubaker, Rachel
Ohman, Ian Chow, Xiaoyan Lin, Ami
Mankodi
P1.059
Pathogenic Antigen-Specific
Th17 Cells Drive Autoimmunity Myasthenia
Gravis Yonghao Cao, Margarita
Dominguez-Villar, Robert Amezquita,
Shuqiang Liu, Steven Kleinstein, Jonathan
Goldstein, Richard Nowak, Kevin O’Connor
P1.060
IgG from Guillain-BarréSyndrome (GBS) Patients Alter Autonomic
Nerve Fiber Function in Mice Christian
Ritter, Ilja Bobylev, Abhijeet Joshi, Gereon
Fink, Helmar Lehmann
Neuropathy: Animal Models
and Experiments
P1.061
Characterization of a New
Animal Model of Chronic Inflammatory
Demyelinating Polyneuropathy Laurent
Kremer, Susana Brun, Wissam Beaino,
Omar Taleb, Chanh Dao Lam, Nicolas
Collongues, Elisabeth Trifilieff, Jerome De
Seze
P1.062
CCR2 Gene Deletion and
Pharmacologic Blockade Ameliorate a
Severe Murine Experimental Autoimmune
Neuritis Model of Guillain-Barré
Syndrome. Eroboghene Ubogu
P1.063
Segmental Demyelination in
Fig4 Deficiency Bo Hu, Qing Yan, Jun Li
P1.064
Phenotype in the
Heterozygous R98C Knock-in Mouse Model
of CMT1B Is not Improved by Neuregulin
1 Type III Overexpression Yunhong Bai,
Chiara Pisciotta, Suola Wang, Xingyao Wu,
Laura Feltri, Lawrence Wrabetz, Michael
Shy
P1.065
Disruption of Myelin Junctions
and Increase of Myelin Permeability in
PMP22 Deficiency Bo Hu, Jiasong Guo,
Yang Yang, Leiming Wang, Jiawen Wu,
Sezgi Arpag, Bruce Carter, Ueli Suter
Induced Pluripotent Stem Cell
Based Models of CMT1A and HNPP Robert
Baloh, Irina Epifantseva, Kevin Kim,
Shaughn Bell, Sharon Carmona, Sharday
Grant, Megan Simpkinson, Matthew Harms,
Dhruv Sareen, AKMG Muhammad
The Effect of Hyperglycemia
on Human Schwann Cells Nizar Souayah,
Hongxin Chen
The Effect of Glucose on
the Response of Peripheral Nerve to
Anoxia Mark Stecker, Matthew Stevenson
P1.069
Noninvasive Peroneal
Sensory and Motor Nerve Conduction
Studies in the Rabbit Distal Hindlimb:
Feasibility, Variability and Response to
Vincristine John Hotson
Neuromuscular Disease:
Pathogenesis and Pathology
P1.070
NADPH Oxidases (NOX)
Enzymes Induced Oxidative Stress in
CIDP Patients Andrea Calvo, Giuseppe
Marrali, Paolina Salamone, Federico Casale,
Paolo Cugnasco, Cristina Caorsi, Antonio
Amoroso, Leonardo Lopiano, Adriano Chio,
Dario Cocito
P1.071
New Markers For
Demyelination in Diabetic Neuropathy:
A Novel Strategy Nizar Souayah, Ankit
Pahwa, Hongxin Chen
P1.072
Spinal Nerve Root
Hypertrophy as Etiology of Back Pain
in CIDP Alexis Shaefer, Mohammad
Alsharabati, Gwendolyn Claussen, Shin Oh
P1.073
Investigating the Amyloid
Properties of TDP-43 in ALS and FTLDTDP Shan Desai, Eileen Bigio
P1.074
Pulsatile TH2 Shift of
Recovering TCR-Vβ Expanded T-Helper
Effector Cells After Initiation of IVIG
Treatment in CIDP Martin Russwurm,
Michael Pütz, Tine Höft, Kerstin Schlegel,
Michael Happel, Christian Eienbröker, Maria
Seipelt, Bjorn Tackenberg
P1.075
The Investigation of Effects
of Alpha Lipoic Acid in the Sciatic Nerve
and Brain Tissue of Rats Were Created in
Experimental Diabetes Muhammed Said
Berilgen, Irem Tasci, Murat Gonen
P1.076
Post Mortem Measurement
of Intra-Epidermal Nerve Fiber Density: A
Novel Research Tool Christopher Taicher,
Eugene Dulaney, Felix Eckenstein, Michael
Hehir, Waqar Waheed, Julian Sprague, Rup
Tandan
P1.077
Clinicopathologic Analysis of
TDP-43 Expression in the Cerebral Cortex
in ALS Ryoko Takeuchi, Mari Tada, Atsushi
Shiga, Takuya Konno, Yasuko Toyoshima,
Osamu Onodera, Masatoyo Nishizawa,
Akiyoshi Kakita, Hitoshi Takahashi
P1.078
Morphological and
Mechanical Abnormalities Detected
in Tissue-Engineered Reconstructed
Skin Equivalents Derived from ALS
Patients Nicolas Dupre, Peter Gould,
Stephan Saikali, Francois Gros-Louis
49
Monday
April 28
P1.028
Monday, April 28
Iatrogenic Spinal
Cord Infarction in the Central
Artery Distribution Following
Cervical Foraminotomy Thananan
Thammongkolchai, Pichet Termsarasab,
Bashar Katirji
Autonomic Neuropathy
Anterior Horn Cell Disease:
Pathogenesis and Pathology
P1.090
P1.079
P1.080
Role of NOX2 Enzyme Activity
in Neuroinflammation: Preliminary Results
in Amyotrophic Lateral Sclerosis and
Parkinson’s Disease Andrea Calvo, Paolina
Salamone, Giuseppe Marrali, Federico
Casale, Giuseppe Fuda, Cristiana Caorsi,
Antonio Amoroso, Maurizio Zibetti, Mario
Rizzone, Leonardo Lopiano, Adriano Chio
P1.081
Fast Skeletal Muscle Troponin
Activator Tirasemtiv Increases Muscle
Function and Performance in the B6SJLSOD1G93A ALS Mouse Model Fady Malik,
Darren Hwee, Adam Kennedy, Julie Ryans,
Jeffrey Jasper
P1.082
“Reporting Biomarkers”
in ALS: Experiences from a Pilot
Compassionate Use Program Applying
G-CSF—Mobilized Hematopoietic Stem
Cells in ALS-Patients Ines Kobor, Dobri
Baldaranov, Andrei Khomenko, Siw
Johannesen, Jochen Grassinger, Katja
Kollewe, Susanne Petri, Jan Kassubek,
Albert Ludolph, Michael Deppe, Gerhard
Schuierer, Tim-Henrik Bruun, Wilhelm
Schulte-Mattler, Ulrich Bogdahn
P1.083
Mutations in ERBB4 That
Disrupt the NRG-ErbB4 Pathway Cause
Autosomal Dominant Familial ALS Type
19 Yuji Takahashi, Yoko Fukuda, Jun
Yoshimura, Atsushi Toyoda, Kari Kurppa,
Hiroyoko Moritoyo, Veronique Belzil, Klaus
Elenius, Guy Rouleau, Asao Fujiyama,
Shinichi Morishita, Jun Goto, Shoji Tsuji
P1.084
Does Altered Growth
Hormone Secretion Underlie the
Development of Hypermetabolism in
Amyotrophic Lateral Sclerosis: Studies
in HSOD1G93A Mice Pamela McCombe,
Shyuan Ngo, Frederick Steyn
P1.085
Familial Adult Spinal
Muscular Atrophy Associated with VAPB
Gene Marcos de Freitas, Victor Kosac,
Osvaldo Nascimento, Frederico Prado
P1.086
Is the Decrease in PGC1Α
Detected in ALS Patients an Up Stream
Effector or a Byproduct of Mitochondrial
Dysfunction? Rawan Albadareen, Russell
Swerdlow
P1.087
Atypical Features in a Spinal
and Bulbar Muscular Atrophy Patient with
a 68 CAG Repeat Christopher Grunseich,
Ilona Kats, Laura Bott, Ke-lian Chen, Angela
Kokkinis, Carlo Rinaldi, Kenneth Fischbeck
P1.088
Phosphorylated Tau Is a
Candidate Biomarker for Amyotrophic
Lateral Sclerosis Murray Grossman, Lauren
Elman, Leo McCluskey, Corey McMillan,
Ashley Boller, John Powers, Katya
Rascovsky, William Hu, Leslie Shaw, David
Irwin, Virginia Lee, John Trojanowski
50
P1.089
Carbidopa: A Novel Approach
to Treating Paroxysmal Hypertension in
Afferent Baroreflex Failure Lucy NorcliffeKaufmann, Jose-Alberto Palma, Jose
Martinez, Horacio Kaufmann
Cardiac Sympathetic
Denervation Without Lewy Bodies in a
Case of Multiple System Atrophy Glen
Cook, Patricia Sullivan, Courtney Holmes,
David Goldstein
P1.091
Early Predictors of Delayed
Neurocardiogenic Syncope in Tilt Table
Testing Mohammed Hussain, Derrick
Blackmore, Bilal Qarni, Zaeem Siddiqi
P1.092
Gastrointestinal Dysmotility
in Postural Tachycardia Syndrome Adam
Loavenbruck, Wolfgang Singer, David
Sletten, Phillip Low, Adil Bharucha
P1.093
Co-Morbidities of Neuropathic
Postural Orthostatic Tachycardia Syndrome
and of the Autonomic Neuropathies Kamal
Chemali, Kevin Mc Neeley
P1.094
Delayed Orthostatic
Hypotension: Implications for Autonomic
Testing and Prognosis Christopher
Gibbons, Roy Freeman
P1.095
Disproportionate Pupillary
Impairment in Diabetic Autonomic
Failure Doyle Yuan, Elaine Spaeth, Steven
Vernino, Srikanth Muppidi
P1.096
Determinants of Vagal
Baroreflex sensitivity and Normative
Data Naoki Wada, Wolfgang Singer,
Tonette Gehrking, David Sletten, Phillip Low
Interventional Neurology:
Translational Science
P1.097
Carotid Wall Tension and
White Matter Lesion Katsuhiko Kohara,
Yoko Okada, Masayuki Ochi, Tokihisa Nagai,
Michiya Igase, Tetsuro Miki
P1.098
Effects of Memantine and
Clopidogrel Alone and in Combination on
Cerebral Ischemia in Rats Hasan Özdemir,
Selçuk Ilhan, Caner Demir, Bekir Akgün,
Oktay Kapan, Ataş Eser, Muhammed Said
Berilgen, Metin Balduz
P1.099
Post-stroke Administration of
Ethanol and Normobaric Oxygen Preserves
Oxidative Metabolism by Modulating
Pyruvate Dehydrogenase Complex
in Transient and Permanent Ischemic
Stroke Omar Elmadhoun, Changya Peng,
Xiaokun Geng, Murali Guthikonda, Yuchuan
Ding
P1.100PKC-δ and Akt Signaling
in Reduced Apoptosis by Ethanol After
Transient Ischemic Stroke Adam Hafeez,
Xiaokun Geng, Murali Guthikonda, Yuchuan
Ding
P1.101
The Importance Of Measuring
Cerebrospinal Fluid Biomarkers In Cardiac
Arrest Survivors Hans Rosén, Christoffer
Rosén, Ulf Andreasson, Daniel Bremell,
Rosemary Bremler, Lars Hagberg, Lars
Rosengren, Kaj Blennow, Henrik Zetterberg
3:00 p.m.–6:30 p.m.
P1.102
The Effect of Tissue
Plasminogen Activator on the Rodent Brain
Proteome Zamir Merali, Meah Gao, Tim
Bowes, Jian Chen, Andrea Kassner
P1.114
P1.103
P1.115
Increased Frequency of
Circulating BDBF+ T Regulatory Cells
in Subjects with Acute Ischaemic
Stroke Pamela McCombe, Jun Yan, Judith
Greer
P1.104
Hemorheology of Clinically
Silent Multifocal Vascular Cerebral
Lesions Piotr Kowal, Izabela Siemieniak,
Anna Marcinkowska-Gapińska
Factor VIII as a Predictor of
Stroke Etiology Michael Halstead, Ambert
Yeh, Laurie Schluter, Dominique Monlezun,
Jr, Alexander George, Corinne Schild, Ramy
El Khoury, Sheryl Martin-Schild
Neuroprotection Against
Ischemic Brain Injury with Methylene
Blue Julio Rojas, Erik Plautz, Ann Stowe,
Mark Goldberg
Ischemic Stroke Subtype
P1.105
P1.116
Antiplatelet Agents and
Miscellaneous
P1.117
Impact of Stroke on Aβ1-40
and Aβ1-42 Plasmatic Levels Solene
Moulin, Didier Leys, Susanna SchraenMaschke, Regis Bordet
P1.106
A Concentration Response
Relationship Between the Active
Metabolite of Clopidogrel and its
Antiplatelet Activity Francis Gengo, Steve
Wolff, Erica Westphal, Michelle Rainka,
Vernice Bates
P1.107
Topical Diclofenac Does
Not Affect the Antiplatelet Properties of
Aspirin as Compared to the Intermediate
Effects of Oral Diclofenac: a Prospective,
Randomized, Complete Crossover
Study Francis Gengo, Nezami Brigette,
Erica Westphal, Michelle Rainka, Meghan
Rowcliffe, Vernice Bates
P1.108
Platelet Response to
Increased Aspirin Dose in Patients Whose
Platelets Were Non-Responsive to Lower
Aspirin Doses Erica Westphal, Francis
Gengo, Michelle Rainka, Matt Robson,
Maurice Hourihane, Vernice Bates
P1.109
Clopidogrel Enhances Platelet
Responsiveness to Aspirin Erica Westphal,
Francis Gengo, Michelle Rainka, Lisa
Kurczewski, John Hourihane, Vernice Bates
P1.110
Safety and Efficacy
of Fondaparinux for Venous
Thromboembolism Prophylaxis After Acute
Ischemic Stroke Santosh Ramanathan,
Konark Malhotra, Chris Hackett, Melissa
Tian, Matthew Quigley, David Wright,
Crystal Wong, Ashis Tayal
P1.111
Primary Prevention of Stroke
in Argentina: a Missed Opportunity? Data
from the ARENAS Registry Ana Atallah,
Osvaldo Fustinoni, Ricardo Beigelman,
Maria Zurru, Sebastian Ameriso, Juan Cirio,
Guillermo Burry
P1.112
Combination Therapy of
Intravenous Glycoprotein IIB-IIIA Inhibitors
and Tissue Plasminogen Activator for Acute
Ischemic Stroke Anshudha Sawhney,
Divyanshu Dubey, Chirantan Banerjee
P1.113
Updated Meta-analysis
of Hemodilution in Acute Ischemic
Stroke Timothy Chang, Matthew Jensen
Cryptogenic Stroke with
More than One Cause Versus No Cause
by TOAST Classification Lacks Adequate
Predictive Power for Stroke Risk Factors
and Outcomes Tyler Scullen, Dominique
Monlezun, Jr, Alexander George, James
Siegler, Melissa Schwickrath, Ramy El
Khoury, Sheryl Martin-Schild
Compare the Functional
Outcome in Ischemic Strokes Based on
the TOAST Classification. Anand Patel,
Zabeend Mahuwala, Kaustubh Limaye,
Nicolas Bianchi, Archana Hinduja, Rajan
Patel
P1.118
Cryptogenic Stroke with
No Cause Demonstrates the Outcome
Prediction Utility of TOAST Classifications
in a Large Stroke Patient Sample Tyler
Scullen, Dominique Monlezun, Jr,
Alexander George, James Siegler, Melissa
Schwickrath, Ramy El Khoury, Sheryl
Martin-Schild
P1.119
GCS Greater than NIHSS
Baseline and TOAST Predicts Better
Outcomes in Stroke Patients Adam
Friedant, Dominique Monlezun, Jr,
Alexander George, Ramy El Khoury, Sheryl
Martin-Schild
P1.120
Stroke of Cryptogenic Greater
than One Cause_Shared Major and Minor
TOAST Classifications Shoichi Shimamoto,
Dominique Monlezun, Jr, Tyler Scullen,
Alexander George, Corbin Pomeranz, James
Siegler, Melissa Schwickrath, Ramy El
P1.121
Stroke Risk Factors, Subtypes,
and 30-Day Case Fatality in Abuja,
Nigeria Sunday Bwala
P1.122
Seasonal Differences and
Circadian Variation in Stroke Occurrence
and Stroke Subtypes Rohit Bhatia, Kishan
Raj, Mamta Singh, M Padma, Kameshwar
Prasad
P1.123
Cross-Border Acute Ischemic
Stroke Subtype Comparison Between
Hispanics and Mexican Mestizos Mario
Cerdan-Trevino, Leonel Cantu-Martinez,
Ramiro Mora-Villalvazo, Hector Martinez,
Richard Hughes, Sharon Poisson
P1.124
Hypercoagulability and
Vasculitis Unlike Cardioembolic Etiology
Predict Bilateral Infarcts David Lorance,
Dominique Monlezun, Jr, Alexander George,
Sheryl Martin-Schild, Ramy El Khoury
Poster Session I
P1.125
Utility of Workup for
Thrombophilias in a Single Center—A
Qualitative Perspective Akshay Shah,
Nicolaas Anderson, Kendra Drake, Maria
Proytcheva, Bruce Coull
Interventional Neurology: Atrial
Fibrillation and Miscellaneous
P1.126
Thoracoscopic Pulmonary Vein
Isolation and Atrial Appendage Ligation
(TPVIAL) versus Medical Management
in Atrial Fibrillation Patients with Prior
Stroke Michael Waters, Vishunmurthy
Hedna, Anna Khanna, William Miles,
Catherine Price, Ilona Schmalfuss, Debra
Robertson, Ashkan Karimi, Thomas Beaver
P1.127
Neuroanatomical Correlates
of Atrial Fibrillation: A Longitudinal MRI
Study Aveen Saed, Nudrat Tasneem, Malik
Adil, Mushtaq Qureshi, Adnan Qureshi
P1.128
Prognostic significance of
Baseline EKG findings and its Association
with Future Vascular Event Anmar Razak,
Vishal Jani, Syed Hussain, Abraham Maaz,
Ali Saeed, Adnan Sadar, Adil Malik, Adnan
Qureshi
P1.129
Sinus Bradycardia Localizes
Where? Johanna Hamel, Trenton Tollefson
P1.130
Frequency of Atrial
Arrhythmias in Stroke: Prolonged
Monitoring of Cardiac Rhythm for Detection
of Atrial Fibrillation After a Cerebral
Ischemic Event (PEAACE) study Yaseen
Ibrahim, Ghazala Basir, Esseddeeg Ghrooda,
Askar Mohammad, Nazim Khan, Peter
Dobrowolski, Sajad Ghualmhusein, Ashfaq
Shuaib
P1.131
Diagnostic Yield of Prolonged
Cardiac Rhythm Monitoring in Cryptogenic
Stroke Rizwan Kalani, Richard Bernstein,
Yvonne Curran, Ilana Ruff, Shyam
Prabhakaran
P1.132
Gaze Deviation in
Acute Stroke: Neuroimaging
Evidence, Significance and Clinical
Correlation Nabeel Herial, Rema Raman,
Karin Ernstrom, Clarity Coffman, Konrad
Schlick, Karen Rapp, Royya Modir, Dawn
Meyer, Thomas Hemmen, Brett Meyer
P1.133
Development of National
Web-based Registry for Acute
Stroke Leopold J Streletz, Naveed Akhtar,
Saadat Kamran, Dirk Deleu
P1.134
Revascularization in Acute
Ischemic Stroke Based on Clinical-Diffusion
Mismatch (REVASC): A Planned Phase I
Trial Nazli Janjua
P1.135
Stroke and Cerebrovascular
Risk Factors Knowledge in Patients
Admitted to a Cardiovascular
Ward. Francisco Muñoz Giacomelli, Maria
Gonzalez Toledo, Fatima Pagani Cassara,
Agustina Tamargo, Alejandro Thomson,
Diego Nadile, Andres Ferre, Francisco Klein
Rehabilitation and Recovery
P1.136
Inter-individual Variability in
Motor and Language Recovery During the
Acute Stroke Period Ronald Lazar, Lauren
Dunn, Adam Schweber, Daniel Manson,
Andrea Lendaris, Randolph Marshall
P1.137
Factors Influencing SelfPerception of Recovery from Stroke in
Comparison to Objective Assessments T. Keta Hodgson, Randy Sanoff, Gillian
Devereux, Star Feudi, Samantha Cherin,
Fiona Chatfield, Robin Conwit, Scott
Hamilton, Nerses Sanossian, Sidney
Starkman, Jeffrey Saver
P1.138
Use of HIRREM, a NonInvasive Neurotechnology, Is Associated
with Improved Autonomic Function
and Decreased Temporal Hemispheric
Asymmetry in A 67 Year Old Male with
a Recent Stroke Charles Tegeler, Jared
Cook, Catherine Tegeler, Sung Lee, Jasmyn
Nicholas, Hossam Shaltout
P1.139
A Randomized Control
Trial of Granulocyte Colony Stimulating
Factor (G-CSF) Intervention in Acute
Ischemic Stroke to Improve Functional
Outcome Sankar Gorthi, Dheeraj Nauwhar,
Pawan Gupta, Kaukab Hassan
P1.140
Statin Therapy Reduces
Oxidized Low Density Lipoprotein and
Associate with Favorable Outcome in
Patients After Acute Ischemic Stroke NaiWen Tsai
P1.141
WITHDRAWN
P1.142
Cortical Activity Modulation
by Botulinum Toxin Type A in Patients
with Post-Stroke Arm Spasticity: Real and
Imagined Hand Movement Petr Hlustik,
Tomas Veverka, Pavel Hok, Zbynek Tudos,
Pavel Otruba, Alois Krobot, Petr Kanovsky
P1.143
Satisfaction with Botulinum
Toxin Treatment in Post-Stroke Spasticity:
Results From Two Cross-Sectional Surveys
of Patients and Physicians Djamel
Bensmail, Angelika Hanschmann
P1.144
Long Lasting Therapeutic
Effects of Yoo’s Solution for Ischemic
Stroke Seo Hong Yoo
Intracranial Disease
P1.145
CT Angiography Alone Can
Provide Sufficient Angio-Architectual
Information About Unruptured Intracranial
Aneurysms to Proceed Straight to
Treatment David Ben-Israel, David TurkelParrella, Ekaterina Kouzmina, Thomas
Marotta, Julian Spears, Airton Leonardo de
Oliveira Manoel
P1.146
Treatment Trends in
Management of Intracranial Stenosis in
The Pre- and Post-Sammpris Era Swaroop
Pawar, Tanya Turan, George Cotsonis,
Michael Lynn, Rahim Wooley, Barney
Stern, Colin Derdeyn, David Fiorella, Marc
Chimowitz
P1.147
Association Between
Lipoprotein (a) Levels and Vascular
Events in the Stenting and Aggressive
Medical Management for Preventing
Recurrent Stroke in Intracranial Stenosis
(SAMMPRIS) trial. Swaroop Pawar, Tanya
Turan, Marc Chimowitz
P1.148
Comparison of Intracranial
Stent Placement and Best Medical
Treatment Alone for Treatment of
Symptomatic Intracranial Stenosis Vikram
Jadhav, Mushtaq Qureshi, Adnan Qureshi
P1.149
Impact of SAMMPRIS trial on
Intracranial Stent Placement: A State Wide
Study Farhan Siddiq, Malik Adil, Saqib
Chaudhry, Adnan Qureshi
P1.150
Trends in Cerebral Blood Flow
Velocities of Patients with Intracranial
Atherosclerotic Disease Shawna Cutting,
Tatjana Rundek, Victor Del Brutto, Sebastian
Koch, Ralph Sacco, Jose Romano
P1.151
Association Between
Intracranial Stenosis and Cerebro-renal
Microvascular Damage in a Latin American
Cohort. Maria Zurru, Claudia Alonzo, Laura
Brescacin, Pigreti Santiago, Luis Camera,
Gabriel Waisman, Edgardo Cristiano
P1.152
Stroke Among Hospitalized
Patients Diagnosed with Vertebrobasilar
Insufficiency: A Retrospective Cohort
Study Li Yang, Harrison Bai, Xin Zhao,
Yanqiao Xiao, Yuanyuan Yang, Scott Kasner,
Liming Tan
P1.153
Long-term Stroke
Recurrence in Patients with Basilar Artery
Occlusion. Michael Ruff, Tamika Burrus,
Alejandro Rabinstein
P1.154
Postprandial Clearance
of Oxidized LDL in Stroke-related
Atherosclerosis Julia Rothlisberger, NgocAnh Le, Christy Cassarly, Renee Martin,
Tanya Turan
CNS and Disease Mechanisms
in Humans and Animal Models
P1.155
Oligodendrocyte Progenitor
Cells (OPCs) from Adult Human Brain
Expressed Distinct MicroRNAs Compared
to OPCs in Development Soo Yuen Leong,
Vijayaraghava Rao, Jenea Bin, Pavel Gris,
Mugundhine Sangaralingam, Timothy
Kennedy, Jack Antel
P1.156
Astrocyte-derived VEGF-A
Drives Blood-brain Barrier Disruption in
CNS Inflammatory Disease. Azeb Argaw,
Linnea Asp, Jingya Zhang, Trinh Pham, John
Mariani, Dipankar Dutta, Elisabeth Kramer,
Napoleone Ferrara, Michael Sofroniew,
Gareth John
P1.157
Cytokine Influence on
Oligodendrocyte Progenitor Cell
Proliferation Robert Knobler
P1.158
Latent Infection of the Central
Nervous System (CNS) and the ‘Inside-Out’
Model of Multiple Sclerosis (MS) Lorne
Kastrukoff, Allan Lau, Eva Thomas
P1.159
Protease-activated Receptor-1
(PAR-1) and Interleukin-1Beta Act
Synergistically in Granzyme b Mediated
Neurotoxicity Paul Lee, Avindra Nath
P1.160
Myelin Sulfatides Modulate
T Cell Function During Autoimmune
Demyelination Marcin Mycko, Beata
Sliwinska, Maria Cichalewska, Hanna
Cwiklinska, Krzysztof Selmaj
P1.161
Neuroendocrine Dysregulation
of the T Cell Response in Early Multiple
Sclerosis Dina Hartmann, Michael Pütz,
Kerstin Schlegel, Christian Eienbröker,
Michael Happel, Maria Seipelt, Bjorn
Tackenberg
P1.162
CD16+/Perforin+ Lymphocytes
(NK Cells) May Regulate Autoimmunity
in Multiple Sclerosis by Cytolysis of
Antigen Laden Cells in the Peripheral
Blood. Ramesh Nayak, Raymond Jacolik
P1.163
Modeling Anti-CD20
Mediated B Cell Depletion Indicates the
Role of Treg in the Response to Therapy
in MS Pablo Villoslada, Sara MartinezPasamar, Elena Abad, Beatriz Moreno,
Nieves Velez de Mendizabal, Ivan MartinezForero, Jordi Garcia-Ojalvo
P1.164
Development of Inflammatory
Demyelinating Lesions in Mouse
CNS After Injection of Cerebrospinal
Fluid Derived from Progressive MS
Patients Massimiliano Cristofanilli, Daniel
Gratch, Benjamin Pagano, Saud Sadiq
P1.165
Adult Neural Progenitor Cells
Derived from MS Patients Differentiate
into MBP Expressing Cells in the Shiverer
Mouse Massimiliano Cristofanilli,
Benjamin Pagano, Daniel Gratch, Violaine
Harris, Tamara Vyshkina, Saud Sadiq
P1.166Hyperoxygenation
Differentiates Vascular Lesions from
Parenchymal Lesions Using Susceptibility
Weighted MRI in Mice with Experimental
Autoimmune Encephalomyelitis Nabeela
Nathoo, James Rogers, V. Wee Yong, Jeff
Dunn
P1.167
Fgfr1 Ablation in
Oligodendrocytes Reduces Disease
Severity and Inflammation in the CNS in
MOG35-55 Induced EAE Ranjithkumar
Rajendran, Mario Giraldo Velasquez,
Christine Stadelmann-Nessler, Martin
Berghoff
P1.168
Brain Distribution of MS565,
an Imaging Analogue of Siponimod
(BAF312), in Non-human Primates Adriana
Tavares, Olivier Barret, David Alagille,
Thomas Morley, Caroline Papin, Ralph
Maguire, Emmanuelle Briard, Yves
Auberson, Gilles Tamagnan
P1.169
The Role of Class I
Haplotype in the Development of Immune
Mediated Brain Atrophy in a Murine
MS Model Istvan Pirko, Jeffrey Gamez,
Pascal Atanga, Stephanie LaFrance, Aaron
Johnson
P1.170WITHDRAWN
P1.171
Il-11 Induces Th17-Cell
Responses in Patients with Relapsing
Remitting Multiple Sclerosis (RRMS) Silva
Markovic Plese, Xin Zhang, Yazhong Tao,
Irena Dujmovic-Basuroski, Jelena Drulovic
Monday
April 28
Monday, April 28
P1.172
The Peripheral Network
Between Oxidative Stress and
Inflammation in Multiple Sclerosis Maira
Gironi, Marina Saresella, Vittorio Martinelli,
Cristina Cursano, Enrica Mariani, Matilde
Vaghi, Federica Piancone, Lucia Moiola,
Ivana Marventano, Mario Clerici, Giancarlo
Comi, Roberto Furlan
P1.185Genome-wide
P1.173
P1.186
Impaired Immune Regulatory
Function of Natural Killer (NK) Cells in
Multiple Sclerosis (MS) Catharina Gross,
Andreas Schulte-Mecklenbeck, Anna Rünzi,
Antia Posevitz-Fejfar, Heinz Wiendl
P1.174
Assessment of a Fluorinated
Analog of N-acetylglucosamine to Promote
Myelin Regeneration Michael Keough,
James Rogers, Ping Zhang, Jason Plemel,
Chang-Chun Ling, V. Wee Yong
P1.175
Neuroprotective, AntiInflammatory and Immune Tolerizing
Properties of Peptides Derived from
Diffusion Survival Evasion Protein (DSEP)/
Dermcidin. Jeffrey Greenstein, Timothy
Cunningham
P1.176
Ingested (Oral) Tocilizumab
Inhibits EAE Staley Brod, Victoria Bauer
P1.177WITHDRAWN
P1.178
Deletion of Virus-specific
T-cells Enhances Remyelination in a Model
of Multiple Sclerosis Aleksandar Denic,
Bharath Wootla, Laurie Zoecklein, Moses
Rodriguez
P1.179
Amelioration of Experimental
Autoimmune Encephalomyelitis by RNA
Polymerase 1 Inhibitor: Molecular and
Cellular Mechanisms Michael Gurevich,
Rina Falb, Anat Achiron
P1.180
Stress Induced Angioplasticity
Is Protective in Experimental Autoimmune
Encephalomyelitis (EAE) Vladimir Katyshev,
Nilufer Esen, Svetlana Katysheva, Zakhar
Serkin, Paula Dore-Duffy
P1.181
Inhibition of Hyaluronan
Synthesis Protects Against EAE by Inducing
CXCL12 in the CNS Andre Mueller, Bo
Hyung Yoon, Saud Sadiq
P1.182
Anti-CD20 Therapy Downregulates Lesion Formation and Microglial
Activation in Pattern I and Pattern Ii Rat
Models of Multiple Sclerosis Daniel
Anthony, Alex Dickens, Nicholas Seneca,
Sandra Campbell, Begona Checa, Veerle
Kersemans, Edward Warren, Matthew
Tredwell, Veronique Gouverneur, David
Leppert
P1.183
Bowman-Birk Protease
Inhibitor Induces Tr1 Cells and Suppress
Effector Phase of EAE Disease; A
Potential NOVEL Therapy for Multiple
Sclerosis Farinaz Safavi, Javad Rasouli,
Elisabeth Mari, Guang-Xian Zhang,
Mohamad Rostami
P1.184
Mir-155 Controls T Helper
Cell Autoimmunity During Autoimmune
Demyelination via Hsp40 Genes
Expression Marcin Mycko, Maria
Cichalewska, Hanna Cwiklinska, Krzysztof
Selmaj
52
Pharmacogenomic Study of Response
to Cannabinoids in MS Spasticity
Patients Juan Ruiz, Antonio GonzálezPérez, María Isabel Garcia-Sanchez, María
Eugenia Saez-Goñi, Macarena Rus Hidalgo,
Miguel Lucas, Antonio Alcina, Fuencisla
Matesanz, Guillermo Izquierdo Ayuso
3:00 p.m.–6:30 p.m.
P1.196Natalizumab-induced
Circulating Hematopoietic Stem Cells
have Intact Progenitor Capacity Miriam
Mattoscio, Benedetta Mazzanti, Simone
Dal Pozzo, Richard Nicholas, Omar Malik,
Riccardo Saccardi, Paolo Muraro
P1.197
Blocking LINGO-1 Does
Not Affect Inflammatory Markers in the
Cerebrospinal Fluid of Individuals with
Multiple Sclerosis Ann Ranger, Soma Ray,
Suzanne Szak, Andrea Dearth, Normand
Allaire, Diego Cadavid
Differential Impact of
Natalizumab and Fingolimod on the
Alpha-4/Beta-1 Expression-Related Subset
Diversity of T Cells Jorg Kraus, Katrin
Oppermann, Julia Wanek, Georg Pilz, Peter
Wipfler, Johann Sellner, Shahrzad Afazel,
Elisabeth Haschke-Becher, Eugen Trinka,
Andrea Harrer
P1.187
P1.198
Differentiating Plovamer
Acetate and Glatiramer Acetate: Efficacy
and Mechanism of Action in a Preclinical
Model of Multiple Sclerosis Anneli
Savinainen, Kenneth Crook, Timothy
Crandall, Michelle Seng, Ursula Boschert,
Tammy Dellovade
P1.188
Steady State
Pharmacokinetics of Formulations
of XP23829, a Novel Prodrug of
Monomethyl Fumarate (MMF), in Healthy
Subjects Dmitri Lissin, Wendy Luo, Ezra
Tai, Katie Zomorodi, Dan Chen, Son Nguyen,
Yongjin Yao, Virna Kim, Joan Zou, Kenneth
Cundy
P1.189
Preclinical Efficacy and
Phase I Clinical Testing of ATX-MS1467,
an Antigen-Specific Immunotherapy for
Multiple Sclerosis David Wraith
P1.190
The Global Neocortical Loss
of Neurons in Multiple Sclerosis Daniele
Carassiti, Maria Papachatzaki, Francesco
Scaravilli, Klaus Schmierer
P1.191
Does Axonal Degeneration
Depend on Demyelination in Chronic
Multiple Sclerosis? Daniele Carassiti,
Shaima Al Zawawi, Klaus Schmierer
P1.192
Calcitriol and Interferon-beta
Treatment Act Synergistically to Induce a
Less Inflammatory Response in Stimulated
PBMCs Niall Stewart, Ingrid van der Mei,
Bruce Taylor, Steve Simpson, Jr.
P1.193
Laquinimod Reduces Neuronal
Injury Through Inhibiting Microglial
Activation Voon Wee Yong, Manoj Mishra,
Janet Wang, Michael Keough, Claudia
Silva, Yan Fan, Scott Sloka, Liat Hayardeny
P1.194
Cognitive Resilience in
Multiple Sclerosis: Characterization of
Blood Gene Expression Profiles Associated
with Preserved Cognitive Function Anat
Achiron, Yoram Barak, Michael Polliack,
Michael Gurevich
MS and CNS Inflammatory
Disease: Treatment Mechanisms
of Action
P1.195
Laquinimod Interferes with
the Development of Follicular Helper T
Cells and Germinal Center B Cells in Cns
Autoimmunity Michel Varrin-Doyer, Ulf
Schulze-Topphoff, Kara Pekarek, Scott
Zamvil
Suppressed Pro-Inflammatory
Properties of Circulating B Cells in Patients
with Multiple Sclerosis Treated with
Fingolimod, Based on Altered Proportions
of B-cell Subpopulations Yusei Miyazaki,
Masaaki Niino, Toshiyuki Fukazawa, Eri
Takahashi, Takayuki Nonaka, Itaru Amino,
Jun Tashiro, Naoya Minami, Naoto Fujiki,
Shizuki Doi, Seiji Kikuchi
P1.199
Interferon-Beta Alters
Monocytes and B-cells in Multiple
Sclerosis and Experimental Autoimmune
Encephalomyelitis. Axtell Robert, Ryan
Schubert, Lawrence Steinman
P1.200
Therapy with Interferon-Beta
has No Impact on the T Cell Receptor
Repertoire in MS Patients Thomas
Dehmel, Clemens Warnke, Anne Mausberg,
Manuel Lopez, Xavier Montalban, Hans
Hartung, Bernd Kieseier
P1.201
Lymphocyte and Eosinophil
Responses in Healthy Subjects Dosed with
Tecfidera® and XP23829, a Novel Fumaric
Acid Ester (FAE) Lawrence Steinman,
Robert Fox, Dmitri Lissin, Katie Zomorodi,
Dan Chen, Lee Clark, Kenneth Cundy
P1.202
Laquinimod Regulates
Inflammatory Gene Induction in a Human
Model of Reactive Astrogliosis. Trinh
Pham, Jingya Zhang, Jeremy Seto, Boris
Hartmann, Liat Hayardeny Nisimov, Gareth
John
P1.203
Laquinimod Modulates
Genes Encoding Cell Migration in Multiple
Sclerosis Rina Zilkha-Falb, Michael
Gurevich, Liat Hayardeny Nisimov, Anat
Achiron
P1.204
Dimethyl Fumarate and
Monoethyl Fumarate Exhibit Differential
Effects on Glutathione, Keap1 and Nrf2
Activation In Vitro Robert Scannevin,
Melanie Brennan, Maria Matos, Xiaoping
Hronowski, Benbo Gao, Peter Juhasz,
Kenneth Rhodes
P1.205
Fumarate Esters Are
Distinguished by Differential Inhibition
of the NF-κB Mediated Proinflammatory
Response. Geoffrey Gillard, David Huss,
John Anderson, Brian Collette, Andrea
Bertolotti-Ciarlet, Robert Scannevin, Jason
Fontenot
P1.206
Dimethyl Fumarate and
Monomethyl Fumarate Are Distinguished
by Non-Overlapping Pharmacodynamic
Effects In Vivo Melanie Brennan, Normand
Allaire, David Huss, Patrick Cullen, Alice
Thai, Suzanne Szak, Ankur Thomas, Davide
Gianni, John Carulli, Jason Fontenot, Brian
Wipke, Kenneth Rhodes, Robert Scannevin
P1.207
Dimethyl Fumarate
and Monoethyl Fumarate Exhibit
Differential Pharmacodynamic Effects
and Pharmacokinetics In Vivo Robert
Scannevin, Suzanne Szak, Kristopher King,
Melanie Brennan, Normand Allaire, Patrick
Cullen, Alice Thai, Ankur Thomas, Davide
Gianni, Alexander Chou, Theresa Hillery,
Brian Wipke, Liyu Yang, John Carulli, Huang
Chaoran, Kenneth Rhodes
P1.208
Immunoregulation During
Multiple Sclerosis Relapses. Effects of
Intravenous Methylprednisolone. Vincent
van Pesch, Nathalie Muls, Christian Sindic
P1.209
Arsenicals May Prevent
Axonal Loss in Multiple Sclerosis: A
Histopathological Study Dimitrios
Papadopoulos, Nikolaos Antoniou, Katerina
Tsimaratou, Vassilis Gorgoulis, Dimos
Dimitrios Mitsikostas, Richard Nicholas
P1.210
B Cell Receptor Recognition
of Glatiramer Acetate Is Required for
Efficacy in Experimental Autoimmune
Encephalomyelitis and Results in
Differential Cytokine Production in MS
Patients Leila Jackson, Sean Selva, Tracy
Niedzielko, Timothy Vollmer
P1.211
Pharmacokinetics and
Pharmacodynamics of RPC1063 and
its Metabolites in Healthy Adult
Volunteers Gregg Timony, Jennifer Brooks,
Jeffrey Hartung, Fiona Scott, Allan Olson,
Sheila Gujrathi, Marcus Boehm, Robert
Peach
P1.212
Gene Expression Studies
Comparing Glatiramer Acetate and
Proposed Generics Benjamin Zeskind, Fadi
Towfic, Jason Funt, Kevin Fowler, Shlomo
Bakshi, Eran Blaugrund, Sarah Kolitz, Maxim
Artyomov, Michael Hayden, Iris Grossman,
Liat Hayardeny, Rivka Schwartz
P1.213
HLA Genes and InterferonBeta Preparations Influence Risk of
Developing Neutralizing Anti-Drug
Antibodies in Multiple Sclerosis Katharina
Fink, Jenny Link, Malin Lundkvist, Christina
Hermanrud, Izaura Lima, Boel Brynedal,
Ingrid Kockum, Jan Hillert, Anna FogdellHahn
P1.214
Glatiramer Acetate Treatment
Regulates CD44, Receptor for Osteopontin
in EAE Mice Sakhina Begum-Haque,
Marc Christy, Kiel Telesford, Yan Wang, Eli
Kasper, Azizul Haque, Lloyd Kasper
P1.215
Teriflunomide Does Not
Significantly Affect Primary and Memory
Antibody Responses to a Viral Antigen
in Mice Andrea Edling, Lisa Woodworth,
Adam Stockmann, Tracy Touzjian, Simon
Fricker, Bruce Roberts, Johanne Kaplan
Poster Session I
P1.216
ATX-MS-1467, An
Immunotolerizing Agent, Halts
Disease Progression and Reduces CNS
Inflammation in Rodent Models of Multiple
Sclerosis Tammy Dellovade, Stefan Rudin,
Alla Zozulya, Blake Tomkinson
P1.217
UVB Light Attenuates the
Systemic Immune Response in CNS
Autoimmunity Johanna Breuer, Nicholas
Schwab, Tilman Schneider-Hohendorf,
Martin Marziniak, Hema Mohan, Urvashi
Bhatia, Catharina Groß, Carsten Weishaupt,
Sven Meuth, Karin Loser, Heinz Wiendl
P1.218
ONO-4641 (Ceralifimod)
Prevents Evoked Potential Deficits in an
Animal Model of Multiple Sclerosis Daniel
Crawford, Dongzi Yu, Frederic Bernard,
Danielle Graham, Ursula Boschert, Tammy
Dellovade
P1.219
ONO-4641 (Ceralifimod)
Reduces MRI Lesions and Prevents Disease
Progression in an Animal Model of Multiple
Sclerosis Shuning Huang, Ji-Kyung Choi,
Audrey Gray, Dongzi Yu, Bruce Jenkins,
Joseph Mandeville, Guangping Dai, Ursula
Boschert, Tammy Dellovade, Danielle
Graham
P1.220
Treatment with Anti-mouse
CD52 Antibody Is Associated with
Preservation of Myelin and Maintenance
of Axonal Conduction in the MOG-induced
EAE Mouse Model Jianhua Huang,
Petti Pang, Nilesh Pande, Michael Turner,
Michael LaMorte, Nathalie Chretien, Carrie
Garron, Bruce Roberts, Johanne Kaplan,
William Siders
P1.221
Lipoic Acid Reduces
Inflammation in a Mouse Focal
Cortical Experimental Autoimmune
Encephalomyelitis Model. Priya Chaudhary,
Gail Marracci, Danielle Galipeau, Edvinas
Pocius, Brooke Morris, Dennis Bourdette
P1.225
Application of the 2010
Macdonald’s Criteria to a Cohort of
Patients with Clinically Isolated Spinal Cord
Syndromes Anne Vandendriessche, Helene
Zephir, Olivier Outteryck, Damien Fetter,
Nicolas Collongues, Nathalie Derache,
Gilles Defer, Patrick Vermersch, Jerome De
Seze, David Maltete, Bertrand Bourre
P1.226
MRI Phenotypes as Predictors
of Clinical Outcomes in Patients with CIS
in the Benefit Population Sven Schippling,
Dirk Pleimes, Gilles Edan, Xavier Montalban,
Mark Freedman, Hans Hartung, David
Miller, Frederik Barkhof, Ernst-Wilhelm
Radu, Julia Hermann, Christoph Pohl, Rupert
Sandbrink, Roland Martin
P1.227
Randomized Trial of
Minocycline for Clinically Isolated
Syndrome and Early Single Relapse
Multiple Sclerosis: Study Design,
Participant Characteristics, and
Recruitment Challenges Luanne Metz,
Anthony Traboulsee, David Li, Pierre
Duquette, Michael Yeung, Marcelo
Kremenchutzky, Galina Vorobeychik, Mark
Freedman, Virender Bhan, Gregg Blevins,
James Marriott, Francois Grand’Maison,
Liesly Lee, Manon Thibault, Misha
Eliasziw, V. Wee Yong, Graziela Cerchiaro,
Samuel Wiebe, Yan Cheng, Guojun Zhao,
Jamie Greenfield, Marites Topor, Andrew
Riddehough
P1.228
Predicting Response to
Interferon Beta-1B Therapy in Patients with
Clinically Isolated Syndrome MP Sormani,
Frederik Barkhof, Ludwig Kappos, Gilles
Edan, Mark Freedman, Xavier Montalban,
Hans Hartung, David Miller, Julia Hermann,
Vivian Lanius, Karola Beckmann, Rupert
Sandbrink, Christoph Pohl, Dirk Pleimes
P1.229
Anti-murine CD52 Antibody
Treatment Does Not Adversely Affect the
Migratory Ability of Immune Cells Evis
Havari, Michael Turner, James Dodge,
Christopher Treleaven, Lamya Shihabuddin,
Bruce Roberts, Johanne Kaplan, William
Siders
Longitudinal Mixed-Effect
Model Analysis of the Association
Between Global and Tissue Specific
Brain Atrophy and Lesion Accumulation
in Patients with CIS Mihael Varosanec,
Dana Horakova, Jesper Hagemeier, Niels
Bergsland, Michaela Tyblova, Zdenek
Seidl, Manuela Vaneckova, Jan Krasensky,
Michael Dwyer, Eva Havrdova, Robert
Zivadinov
P1.223
P1.230
P1.222
Glatiramer Acetate: Shorttime Versus Long-time Administration—A
mRNA-Seq Analysis Marc Kuehl, Paul
Hammer, Ronny Amberg, Peter Beyerlein,
Juergen Faiss
Disease: Clinically
Isolated Syndromes
P1.224
An Integrated Model of Risk
Factors for Predicting the Early Occurrence
of a Second Attack in Patients with
Clinically Isolated Syndromes Vittorio
Martinelli, Gloria Dalla Costa, Giovanni
Di Maggio, Bruno Colombo, Mariaemma
Rodegher, Letizia Leocani, Roberto Furlan,
Massimo Filippi, Giancarlo Comi
CSF Neurofilament Light
Chain Predicts Evolution to MS in Clinically
Isolated Syndromes Stefano Zoccolella,
Vita Direnzo, Carla Tortorella, Maddalena
Ruggieri, Mariangela Mastrapasqua, Pietro
Iaffaldano, Maria Trojano
P1.231
Possible Prognostic Value of
Cerebrospinal Fluid in Clinically Isolated
Syndrome Eva Krasulova, Eva Havrdova,
David Kemlink, Tomas Uher, Michaela
Tyblova, Jana Volna, Katerina Mrazova,
Dana Horakova
P1.232
Natural History of Clinically
Isolated Syndrome on Conversion
to Multiple Sclerosis: A Metaanalysis Masako Kinoshita, Masako Daifu,
Keiko Tanaka, Masami Tanaka
P1.233
Predictors Factora for Risk of
Conversion from Clinical Isolated Syndrom
to Multiple Sclerosis in a Mixed Brazilian
Cohort Juliana Aurencao, Ana Cristina
Wing, Regina Maria Alvarenga, Claudia
Cristina Vasconcelos
P1.234
How Much Earlier Can
Multiple Sclerosis be Diagnosed Using the
McDonald Criteria? Wallace Brownlee,
Josephine Swanton, Olga Ciccarelli, David
Miller
Aging, Dementia, and Cognitive
and Behavioral Neurology:
Basic Science
P1.235
PACAP Deficit in Alzheimer’s
Disease and Protection Against BetaAmyloid Toxicity PengCheng Han, Zhiwei
Tang, Jun-Xiang Yin, Thomas Beach, Eric
Reiman, Jiong Shi
P1.236
Peptidyl-prolyl Isomerase
Pin1 as a Potential Target to Protect
Synaptic Function in Preclinical Alzheimer’s
Disease Emily Ong, Frances Chow, Yuesong
Gong, Carol Lippa
P1.237
Inhibition of Quinone
Oxidoreductase 2 Improves Learning in a
Mouse Model of Vascular Dementia Jesse
Fitzpatrick, Talaignair Venkatraman, Hana
Dawson, Haichen Wang, Daniel Laskowitz,
Christopher Lascola
Biomarkers, Pathology, and
Basic Science
P1.245
Hereditary Diffuse
Leukoencephalopathy with Spheroids
(Hdls): Histological Features of
Microglia Mari Tada, Takuya Konno,
Masayoshi Tada, Ken-ichi Okazaki, Musashi
Arakawa, Kyoko Itoh, Toru Yamamoto,
Hideaki Yokoo, Nobuaki Yoshikura, Kenji
Ishihara, Yasuko Toyoshima, Osamu
Onodera, Masatoyo Nishizawa, Takeshi
Ikeuchi, Hitoshi Takahashi, Akiyoshi Kakita
P1.246
The Antibodies Against
Gangliosides as Probable Biomarkers in
the Serum of Demented Patients Effrosyni
Koutsouraki, Eleni Hatzifilippou, Tania
Banaki, Vassiliki Costa, Stavros Baloyannis
P1.247
Hippocampal Laminar
Distribution of Phospho-Tau Relates
to Alzheimer’s Disease and Age of
Death Alon Seifan, James Noble, Jesse
Mez, Karen Marder, Lawrence Honig
P1.248
A Beta-2 Adrenergic
Agonist Attenuates Cognitive Deficits
in Hippocampus of the Mice Following
Systemic Inflammation Hung-Ming Wu,
Wan-Yu Huang
P1.249
Abnormal Hypothalamic
Leptin Signaling Leads to Early Metabolic
Dysfunction in Mice Overexpressing the
Amyloid Precursor Protein Makoto Ishii,
Costantino Iadecola
Enhancement of Synaptic
Plasticity in Hippocampal Neurons by
RNS60, a Novel Therapeutic Containing
Charge Stabilized Oxygen-Based
Nanostructures. Avik Roy, Saurabh
Khasnavis, Khushbu Modi, Supurna Ghosh,
Richard Watson, Kalipada Pahan
P1.239Amyloid-β Induces NLRP1-
P1.250
P1.238
Dependent Neuronal Pyroptosis in
Alzheimer’s Disease Meng-Shan Tan,
Jin-Tai Yu, Teng Jiang, Xi-Chen Zhu, Hui-Fu
Wang, Chuan-Dong Jia, Lan Tan
P1.240
Increased Expression of
Kv1.3 Channels by Microglia in Alzheimer’s
Disease Srikant Rangaraju, Allan Levey
P1.241
TREM2 Knockdown
Exacerbates Aging-related
Neuroinflammation and Cognitive
Deficiency in SAMP8 Mice Jiang Teng,
Jin-Tai Yu, Lan Tan
P1.242
Direct Actions of
Granulocyte-Colony Stimulating Factor
on Human Neuronal and Monocytic Cell
Lines Amanda Pennington, Vasyl Sava,
Shijie Song, Niketa Patel, Juan SanchezRamos
P1.243WITHDRAWN
P1.244
Pathologic Aggregates of
Small Nuclear Ribonucleoproteins (Snrnp)
Are Present in Familial Alzheimer’s
Disease Chad Hales, Eric Dammer, Duc
Duong, Hong Yi, Marla Gearing, Allan Levey,
James Lah, Nicholas Seyfried
Therapeutic Efficacy of
D-penicillamine Encapsulated Alginate
Nanoparticles in Wistar Rat Model for NonWilsonian Brain Copper Toxicosis Amit Pal,
Rajendra Prasad, Rakesh Vasishta, Babu
Thapa
P1.251
Dopamine in Social
Valuation: A Genetic and Pharmacological
Study Andrew Kayser, Ignacio Saez, Ming
Hsu
P1.252
Activation of Cannabinoid
Type 2 Receptors in the Ventral Tegmental
Area Modulate Dopamine Excitability via
M-Type Potassium Channels. Brett Larsen,
Ming Gao, Jie Wu
P1.253
Insulin-Like Growth Factor-I
Receptor Stimulating Activity Is Associated
with Dementia Renée de Bruijn, Joseph
Janssen, Michael Brugts, Cornelia van
Duijn, Albert Hofman, Peter Koudstaal,
Mohammad Ikram
P1.254
De-efferented Motor Cortex
Provides a Viable Source of Neural Activity
Command Signals for Centrally-Implanted
Brain Machine Interfaces Jose Morales,
Karthikeyan Balasubramanian, Kazutaka
Takahashi, Nicholas Hatsopoulos
Headache: Basic Science
P1.255
Interictal Reduced Cranial
Parasympathetic Tone in Cluster
Headache Hilde Karen Ofte, Therese von
Hanno, Karl Alstadhaug
53
Monday
April 28
Monday, April 28
P1.256
A Survey of Cluster Headache
(CH) Sufferers Using Vitamin D3 as a CH
Preventative Peter Batcheller
P1.257
Optical Imaging of Facial
Perfusion in Migraine Jonas Peterson,
Lindsay Hunter, Melissa Cortez, Jeremy
Theriot, KC Brennan
P1.258
The CK1δ T44A Mutation
Affects Nociceptive Activation of the
Trigeminocervical Complex in an In
Vivo Model of Migraine Jan Hoffmann,
Margarida Martins-Oliveira, Weera
Supronsinchai, Simon Akerman, Michele
Lasalandra, Yonglie Zhao, Lina Matsson, Elin
Economou-Olsson, Hsien-Yang Lee, Louis
Ptacek, Peter Goadsby
P1.259
Characterization of
Photosensitivity and Pupil Oscillation
Rate in Migraine Lindsay Hunter, Jonas
Peterson, Melissa Cortez, Jeremy Theriot,
K.C. Brennan
P1.260
Does Intravenous Hydration
Before and After Lumbar Puncture
Decrease the Occurrence of Post-Lumbar
Puncture Headache? Nidhi Gupta,
Agnieszka Kowalska, Justin Smith, Patricia
Coyle
P1.261
Treatment of Withdrawal
Headache in Patients with Medication
Overuse Headache (MOH): A Randomized,
Single-blinded, Placebo Controlled
Study Sabina Cevoli, Giulia Giannini,
Valentina Favoni, Elisa Sancisi, Marianna
Nicodemo, Stefano Zanigni, Daniela
Grimaldi, Giulia Pierangeli, Pietro Cortelli
P1.262
Non-invasive Vagal
Nerve Stimulation for the Treatment
of Headache Attacks in Patients with
Chronic Migraine and Medication-overuse
Headache Innocenzo Rainero, Paola De
Martino, Elisa Rubino, Giovanna Vaula,
Salvatore Gentile, Lorenzo Pinessi
P1.263
Patient Satisfaction With
MAP0004: Results of an Optional Survey
During a Long-term Open-label Safety
Study Sheena Aurora, Dawn Buse, Biao
Lu, Donald Kellerman, Wade Cooper,
Shashidhar Kori
P1.264
Non Invasive Blood Flow
Monitoring with Functional Near Infrared
Spectroscopy Correlation with Pain
Self-Assessment in Subjects Receiving
Infusions for Chronic Migrain David Tabby,
Arash Danesh, Ahmad Pourshoghi, Kambiz
Pourrezaei
Epilepsy and Clinical
Neurophysiology (EEG): Basic
Science and ICU Monitoring
P1.265Androgen-mediated
Effects on Ictal Behavior Among Male
Rats Is Mediated Through Pregnane
Xenobiotic Receptors, which Mediated
Neurosteroidognesis Carolyn Koonce,
Jennifer Moore, Swarup Mitra, Cheryl Frye
P1.266
A Novel Mouse Model of
X-linked Epilepsy Ethan Goldberg, Jian
Zhou, Douglas Coulter, P. Wang
54
P1.267
Reduction of Tomyson
Expression Leads to a Kindling-sensitive
Phenotype in a Murine Model of
Epilepsy John Slevin, Seth Batten, Elena
Matveeva, Sidney Whiteheart, Thomas
Vanaman, Greg Gerhardt
P1.268
Spontaneous Subarachnoid
Hemorrhage: Identifying Predictors of Early
Outcome Using Continuous EEG. Caitlin
Loomis, Scott Kasner, Michael McGarvey,
Sarah Schmitt
P1.269
Synchronization Analysis of
Depth and Extracranial EEG Seizure Data in
Subarachnoid Hemorrhage Ananda-Kriiya
Fine, David Albers, J. Michael Schmidt,
Deborah Pugin, George Hripcsak, Jan
Claassen
P1.270
Evolving Patterns on
Prolonged EEG Monitoring in Patients with
Therapeutic Hypothermia Post-Cardiac
Arrest Andres Rodriguez-Ruiz, Brandon
Foreman, Hyunmi Choi, Stephan Mayer, Jan
Claassen, Sachin Agarwal
P1.271
NCSE in Neuro and
Medical ICU Patients on Continous EEG
Monitoring Mohamed Tom, Miguel FiolElias
P1.272
Pharmacologically Induced
Burst Suppression in Pediatric and Adult
Patients—Varying But Predictable
Pattern? Luda Sorin, Brice Jabo, Travis
Losey
P1.273
Does the Benefit of
Therapeutic Hypothermia in Refractory
Status Epilepticus Depend on Seizure
Etiology? Jessica Fesler, Ryan Hakimi,
Shrenik Talsania, Emmaculate Fields
P1.274
Role of VEEG Monitoring
in Neonates with HIE Undergoing
Therapeutic Hypothermia with Correlation
of Seizures and Neurodevelopmental
Outcome Misbah Salam, Anjum Hashim,
Jasmine Singh
Neural Repair and Neurorehabilitation: Basic Science
P1.275
Autologous Bone Marrow
Mononuclear Cells for Patients With Motor
Neuron Disease—Safety and Feasibility
Study Sankar Gorthi, Pawan Gupta, Satish
Kumar, Premkumar Sinha, Harinder Pal
Singh
P1.276
Development of a Modified
Central Nervous System Extracelluar
Matrix with Polylysine. Eric Marrotte,
Naoir Zaher, Yi Zhang, Michael Chopp,
Benjamin Buller
P1.277
EEG Characterization of
a Cohort of Patients with Disorders of
Consciousness: Linking Novel Research
Results and Clinical Practice. Peter
Forgacs, Mary Conte, Jonathan Victor,
Nicholas Schiff
P1.278
Gene Therapy with
Neurotrophic Factors Improves Recovery
After Sciatic Nerve Injury in Mice Mica
Glat, Felix Benninger, Tali Ben-Zur, Yael
Barhum, Israel Steiner, David Yaffe, Daniel
Offen
3:00 p.m.–6:30 p.m.
P1.279
Receptor for AGE (RAGE)
Expressed in Macrophages and Neurons
Regulates Peripheral Nerve Repair After
Injury Lingling Rong, Shifang Yan, Arthur
Hays, Clifton Gooch, Ann Marie Schmidt
P1.280
Evaluation of the Performance
of a Brain-Computer Interface Under Two
Biofeedback Paradigms Brian Appavu,
Jenessa Lancaster, Remy Wahnoun, P.
David Adelson
P1.281
Evoked and Oscillatory
Activity Dynamics in Vegetative
State Gonzalo Rivera
P1.282
Functional Organization of
the Human Auditory Fields: Activation
of Auditory Cortex in a Patient with
Auditory Agnosia from Traumatic
Injury of the Inferior Colliculus, and the
Effects of Transcranial Direct Current
Stimulation Robert Rafal, Oren Poliva,
Patricia Bestelmeyer, Nicholas Davis
P1.283
The Therapeutic Capability
of Slow-release 4-Aminopyridine for the
Treatment of Peripheral Nerve Crush
Injury Kuang-Ching Tseng, John Elfar
P1.284
Predictors of Change in
Quality of Life in Patients with Focal
Neurological Damage Following an
Outpatient Cognitive Rehabilitation
Program Galeno Rojas, Adriana Leis,
Natalia Ciufia, Gastón Saux, Carolina
Feldberg, Fernando Caceres, Ignacio Demey
History of Neurology
P1.285
General Wood: Physician,
Rough Rider, Ambassador, Presidential
Candidate, Patient. Mariza Daras, E.
Massey
P1.286
Silas Weir Mitchell on
Epilepsy Therapy in the Late 19th and
Early 20th Centuries David Burkholder,
Christopher Boes
P1.287
Historical Articles in the
Neurology® Journal as a Tool to Raise
Awareness about the Importance of
Bedside Medicine Raghav Govindarajan,
John Morren, Efrain Salgado
P1.288
Philadelphia Odd Couple—
Silas Weir Mitchell—NeurologistNovelist-Poet and Phillips Brooks—
Brahmin Prophet—Sons of 19th Century
Rittenhouse Square Benjamin Brooks
P1.289
Early Historical and
Ethnographic Descriptions of the
Properties of Curare in the Spaniards
Chronicle. Carolina Vazquez, Francisco
Carod
P1.290
Charcot-Marie-Tooth Disease
(CMT): Historical Perspectives and
Evolution Mohamed Kazamel, Christopher
Boes
P1.291
History of Anti-inflammatories
in Headache: Acetanilid, Antipyrin,
Phenacetin and Salicyclic Acid Rosen
Noah, Dennis Thornton
P1.292
Jesuit Bark and Horseback
Rides: Thomas Jefferson’s “Fits” as a
Window into 18th Century Headache
Care Matthew Luedke, E. Massey
P1.293
Neurology, Volume 1,
1951 William Campbell
P1.294
Robert E. Lee’s Last Stand:
His Dying Words and the Stroke That Killed
Him. Andrew Southerland
P1.295
Introduction of the
Pulfrich Phenomenon into Clinical
Neurology James Lanska, Douglas Lanska,
Bernd Remler
P1.296
Food for Thought: A Serving
of Food-Inspired Eponyms in Neurologic
Practice Shin Beh, Teresa Frohman, Amy
Conger, Darrel Conger, Peter Calabresi,
Laura Balcer, David Zee, Elliot Frohman
P1.297
125 Hysterical Years—the
Contribution of Charcot’s. Francisco Branco
Germiniani, Renato Munhoz, Luciano De
Paola, Helio Teive
P1.298
Social Network Analysis
of Presidents in Neurology Professional
Organizations Since 1948 Amar Dhand,
Jordan Harp, Stephen Borgatti
P1.299
Russell N. DeJong: A Seminal
Figure in American Neurology William
Campbell
P1.300
History of Neurology in
Bangladesh Nasheed Jamal, Shrikant
Mishra, Bhavesh Trikamji
P1.301
Rejected Applications: An
Early American Academy of Neurology
Struggles to Define its Membership Elan
Louis
P1.302
Description of the Pulfrich
Effect James Lanska, Douglas Lanska,
Bernd Remler
P1.303
Gerstmann, Sträussler,
Scheinker Disease: A Famous
Syndrome From an Infamous Period in
History Lawrence Zeidman, Matthias Ziller,
Michael Shevell
P1.304
Zinc-induced Myelopathy
Among Smelter Workers in Upper Silesia
During the Late 19th Century Douglas
Lanska, Bernd Remler
P1.305
The Visible Brain: Computed
Tomography’s Impact on Neurological
Practice Charlene Ong
P1.306
Meta-analyses to Investigate
Gene-environment Interactions in
Neuroepidemiology Ingrid van der Mei,
Petr Otahal, Steve Simpson, Bruce Taylor,
Tania Winzenberg
Neurology Education:
Graduate Medical Education
P1.307
Simulation Boot Camp for
Neurology Residents: A Unique Experience
From a Training Perspective Nauman Tariq,
Muna Irfan, Jeffrey Willging, Elisabeth
Hurliman, Fitzgerald Lisa, Danielle Hart,
Carly Dolan, Ezgi Tiryaki
P1.308
Educating Future Clinical
Research Investigators: An 8-Week Clinical
Research Education Course for Neurology
Residents Jeanie McGee
Poster Session I
P1.309
Can Young European
Neurologists Comfortably Manage
Patients with Traumatic Brain, Spine or
Nerve Injuries (Tbi)? Martin Rakusa, Sofya
Gak, Yuri Alekseenko, Edvard Ehler, Dafin
Muresanu, Josef Opara, Pieter Vos
P1.310
Positive Deviance for
Improvement of Efficiency and Resident
Satisfaction in Neurology Continuity
Clinic Julio Rojas -Martinez, Kartavya
Sharma, Steven Vernino, Pravin Khemani
P1.320
The Rolling Continuity Clinic: A
Flexible Scheduling Paradigm Kristin Scott,
Warren Carrigan, Heidi Woessner, David
Capobianco, Devon Rubin, Elliot Dimberg
P1.321
Implementation of Active
Learning into the Pre-Clinical Neurology
Undergraduate Medical Curriculum John
Pula, John Nixon, Meenakshy Aiyer, Jorge
Kattah
P1.322
Preparing Child Neurology
Residents for Inpatient Adult
Neurology Emily Johnson, Tracey Milligan
Heterogeneity in Neurological
Education and Care in Asian and Oceanian
Region Man Mohan Mehndiratta, Prachi
Mehndiratta, Natasha Gulati, Mohammad
Wasay
P1.312
P1.323
P1.311
Clinical Neuroscience
Podcasts for Family Medicine, Internal
Medicine, and Neurology Residents: A
Needs Assessment Study Tyson Brust,
Michael Yeung
P1.313
Trends in American Board of
Psychiatry and Neurology Specialties and
Neurologic Subspecialties Larry Faulkner,
Dorthea Juul
P1.314
Quantification of Postural
Stability Using Accelerometer and
Gyroscopic Measures from the iPad Susan
Linder, Joshua Hirsch, Mandy Koop, David
Schindler, Anil Thota, Jay Alberts
P1.315
Effectiveness of Pairing
Weekly Reading Assignments and Quiz
with Audience Response System for
Neurology Resident Learning Rashedul
Hasan, Jennifer Fry, John DeToledo,
Jongyeol Kim
P1.316
Standardized Evaluation of
Didactic Conference Content in Neurology
Residency: A New Approach Arthie
Jeyakumar, Constantine Farmakidis
P1.317
Unsuccessful Lumbar
Puncture: Blame it on the Patient, Not the
Operator Cory Edwards, Enrique Leira,
Pedro Gonzalez-Alegre
P1.318
Changing Medical Student
Perceptions of Dementia: An Arts-centered
Experience Hannah Roberts, James Noble
Neurology Education:
Graduate Medical Education/
Undergraduate Medical
Education
P1.319
Computer Generated
Checklist Significantly Improves Differential
Diagnosis in Neurologic Disease Over
Simple Recall Pasquale Finelli, Andrew
McCabe
High-Fidelity Simulation
Versus Traditional Didactic Techniques
for Teaching Neurological Emergencies
to Neurology Residents: A Feasibility
Study. Sachin Agarwal, Neha Dangayach,
Priyank Patel, Ashley Roque, Melissa
Cappaert, Dennis Fowler, Jan Claassen,
Stephan Mayer
P1.324
The One-Year Clinician
Educator Curriculum: Neurology Residents
as Teachers Veronica Santini, Anna Hohler
P1.325
Teaching Ophthalmoscopy to
Medical Students (TOTeMS) II: A One-Year
Retention Study Devin Mackay, Philip
Garza, Beau Bruce, Samuel Bidot, Linda
Kelly, Emily Graubart, Nancy Newman,
Valerie Biousse
P1.326
An Interactive Mobile
Curriculum for Teaching the HypothesisDriven Neurological Examination Dylan
Alegria, Vanja Douglas, Chandler Mayfield,
Christy Boscardin, S. Josephson, Daniel
Lowenstein, Susannah Cornes
P1.327
Neurologists Versus
Emergency Physicians: Reliability of a
Neurological Script Concordance Test
in a Multi-Centre, Cross-disciplinary
Setting Derek Soon, Nigel Tan, Derek
Heng, Liqi Chiu, Malcolm Madhevan,
Charmaine Manauis, Dong Haur Phua,
Gominda Ponnamperuma, Kevin Tan
P1.328
Methodology for Delivering
Feedback to Neurology House Staff
on Communication Skills Using AIDET
(Acknowledge, Introduce, Duration,
Explanation, Thank you) Austin Katona,
Elisabeth Kunkel, Jasmine Arfaa, Stephen
Weinstein, Christopher Skidmore
P1.329
Zygosity Detection by Next
Generation Sequencing in a Clinical
Laboratory Zhenyuan Wang, Christine
DiVincenzo, Christopher Elzinga, Martin
Bazinet, Sat Dev Batish, Malgorzata
Jaremko, Joseph Higgins
Neurology Education and
Methodology
P1.330
Chasing Veins in Vain? The
History of Vessel-Based Aetiological
Theories and Pathological Studies in
Multiple Sclerosis Aravind Ganesh, Dawn
Pearson, Frank Stahnisch
P1.331
National Survey of UK
Medical Students on the Perception of
Neurology Julia Pakpoor, Adam Handel,
Giulio Disanto, Richard Davenport, Gavin
Giovannoni, Sreeram Ramagopalan
P1.332
Comparison of American
Academy of Neurology’s online patient
Education Materials to Other Common
Internet Sources. Anjali Dagar, Vineet
Punia, Nitin Agarwal, Wenzhuan He,
Machteld Hillen
P1.333
Is Formal Faculty Assessment
of Bedside Skills Feasible for 3rd Year
Medical Students on the Neurology
Clerkship? Robert Thompson-Stone, Erika
Wexler, Jonathan Mink, Ralph Jozefowicz
P1.334
Network for Excellence in
Neuroscience Clinical Trials, NeuroNEXT:
Increasing Efficiency in Clinical Trial
Management Marianne Kearney, Dixie
Ecklund, Michael Bosch, Brenda Thornell,
Dawn McNeil, Walter Koroshetz, Petra
Kaufmann, Christopher Coffey, Merit
Cudkowicz
P1.335
Use of Mentored Peer
Review of Standardized Manuscripts
as an Educational Tool for Neurology
Residents Roy Strowd, Victoria Wong,
Rebeca Aragon-Garcia, Yeseon Moon, Blair
Ford, Sheryl Haut, Joseph Kass, Zachary
London, Mary Mays, Tracey Milligan,
Raymond Price, Patrick Reynolds, David
Spencer, Mitchell Elkind
P1.336
Scheduled Faculty
Modeling of Bedside Skills for 3rd Year
Medical Students on the Neurology
Clerkship Robert Thompson-Stone, Trenton
Tollefson, Ronald Epstein, Ralph Jozefowicz,
Jonathan Mink
P1.337
Parallel Sequencing of
26 Genes Responsible for Metabolic
Myopathy and Rhabdomyolysis Xia Tian,
Jing Wang, Margherita Milone, Yanming
Feng, Victor Zhang, Lee-jun Wong
P1.338
Comprehensive Diagnosis of
Congenital Neuromuscular Disorders by
Next Generation Sequencing of 236 Genes
with Deep Coverage Xia Tian, Wen-Chen
Liang, Yanming Feng, Jing Wang, Victor
Zhang, Lee-jun Wong, Yuh-Jyh Jong
P1.339
Feasibility of Developing
a Neurophysiologic Assessment of
Concussion Nolan Williams, Jan Enabore,
Emily Williams, Donna Roberts, Jonathan
Edwards
P1.340
ALS Clinical Research
Learning Institutes: Empowering PALS
to be Research Ambassadors Richard
Bedlack, Merit Cudkowicz
Child Neurology and
Developmental Neurology I
P1.341
Continuous Intravenous
Valproic Acid as an Abortive Therapy for
Pediatric Migraine Muhammad Zafar,
Aaron Cook, Alejandra Stewart, Robert
Baumann
P1.342
Fatal Outcome of
Status Epilepticus, Hyperthermia,
Rhabdomyolysis, Multi-Organ Failure,
and Cerebral Edema After 25I-NBOMe
Ingestion Yoshie Umemura, Thomas
Andrew, Valerie Jacobs, Andrew Giustini,
Lionel Lewis, Jennifer Hanowell, James
Filiano
P1.343
Whole Genome Sequencing
Identifies a Novel Occludin Mutation in
Microcephaly with Band-like Calcification
and Polymicrogyria that Extends the
Phenotypic Spectrum Mahmoud Osman,
Elizabeth Ross, Alice Abdel Aleem, Khalid
Ibrahim, Ben-Omran Tawfeg, Hussein Kamel
P1.344
A Prenatal Presentation of
Severe Microcephaly and Brain Anomolies
in a Patient with Novel Compound
Heterozygous Mutations in the STIL
Gene Harvey Bennett, Amy Presti, Darius
Adams, Jose Rios
P1.345
Sleep Abnormalities in
Children with Dravet Syndrome Radhika
Dhamija, Maia Erickson, Erik St Louis,
Suresh Kotagal
P1.346
Utility of Continuous EEG
Monitoring in Pediatric Man in the Barrel
Syndrome: A Case Report Jessica
Goldstein, Bilal Zonjy, Ingrid Tuxhorn,
Barbara Bangert, Nancy Bass
P1.347
Prediction of Future Seizures
in Neonates Who Received Selective Head
Cooling for HIE Tiffani McDonough, Juliann
Paolicchi, Nikkan Das, Murray Engel, Jeffrey
Perlman, Zachary Grinspan
P1.348
Value of Routine EEG
in Autistic Patients with Stereotypic
Behavioral Movements Ankit Nayyar,
Neha Mirchandani, Rebecca Spiegel
2015 Education Course Proposal Process
2015 Annual Meeting: Washington, DC
The AAN invites you to submit an Education Program suggestion for May 16, 2014. To submit your proposal, please visit
the 67th Annual Meeting. Proposals for new programs are due by
AAN.com/view/SearchAM.
Monday
April 28
Tuesday, April 29
First Authors stand by Posters from 7:30 a.m.–9:00 a.m.
7:30 a.m.–11:00 a.m.
Poster Discussion Session: Movement Disorders II
P2.001Cortico-striatal-thalamic
Network Functional Connectivity in
Hemiparkinsonism Francesca Caso,
Federica Agosta, Iva Stankovic, Alberto
Inuggi, Igor Petrovic, Marina Svetel,
Giancarlo Comi, Vladimir Kostic, Massimo
Filippi
P2.002
Neuroanatomical Changes
in Parkinson’s Disease: Neuroimaging
Evaluation of Pedunculopontine
Nucleus Fang Ba, Marguerite Wieler,
Myrlene Gee, Wayne Martin
P2.003 (18)FDG-PET Scan as a
Predictive Marker of Postoperative Apathy
After Subthalamic Nucleus Deep Brain
Stimulation in Parkinson Disease. Aude
Gesquiere-Dando, Eric Guedj, Tatiana
Witjas, Frederique Fluchere, Marie Delfini,
Laura Mundler, Jean Azulay, Alexandre
Eusebio
P2.004
Differential Patterns of
White Matter Degradation in Relation to
Cognitive and Motor Deficits in Parkinson’s
Disease Yu Zhang, Norbert Schuff
P2.005
Brain Functional Connectomics
in Early Parkinson’s Disease Sebastiano
Galantucci, Federica Agosta, Iva Stankovic,
Alessandro Meani, Igor Petrovic, Marina
Svetel, Giancarlo Comi, Vladimir Kostic,
Massimo Filippi
P2.006
Corpus Callosum Damage
and Motor Function in Parkinson’s
Disease Sebastiano Galantucci, Federica
Agosta, Iva Stankovic, Igor Petrovic, Tanya
Stojkovic, Giancarlo Comi, Vladimir Kostic,
Massimo Filippi
P2.007
Interval Changes of ForebrainCortical Versus Brainstem-thalamic
Cholinergic Integrity in Parkinson Disease
Progression Nicolaas Bohnen, Martijn
Muller, Vikas Kotagal, Kirk Frey, Roger Albin
P2.008 Dopaminergic Changes in
Corticostriatal Brain Activity and Causal
Interactions during Working Memory in
Parkinson’s Disease. Kathleen Poston,
Sophie YorkWilliams, Weidong Cai, David
Everling, Matthew Cruadhlaoich, Michelle
Fenesy, Vinod Menon
P2.009
Striatal and Extrastriatal
Dopamine Transporter Levels Relate to
Cognition in Lewy Body Diseases Stephen
Gomperts, Marta Marquie Sayagues,
Joseph Locascio, Dorene Rentz, Alex
Becker, Trey Hedden, Keith Johnson, John
Growdon
P2.010
Ascending Progression
of Grey Matter Atrophy in Parkinson’s
Disease Maria Cristina Arci Santos, Lidiane
Campos, Rachel Guimaraes, Camila Piccinin,
Paula Azevedo, Luiza Piovesana, Brunno
Campos, Augusto Amato-Filho, Fernando
Cendes, Anelyssa D’Abreu
NEW! e
Poster Session:
Cerebrovascular Disease and Interventional Neurology I
P2.011
PFO Closure for Stroke
Prevention. A Brief Meta-analysis Leila
Doldan, Manuel Latini, Jeffrey Saver
P2.012
Stroke and Etonogestrel/
Ethinyl Estradiol Ring (NuvaRing):
Clinical, Radiological, and Prognostic
Features. Pirouz Piran, Clotilde Balucani,
Brian Tark, Zachary Adler, Steven Levine
P2.013
Intracranial Arterial
Dissection Daiana Dossi, Mauricio
Farez, Julieta Arena, Virginia Pujol Lereis,
Guillermo Povedano, Sebastian Ameriso
Movement Disorders: Parkinson’s
Disease Genetics
P2.021Neuropsychological
Performance in LRRK2 G2019S Carriers
with Parkinson’s Disease Roy Alcalay,
Helen Mejia Santana, Anat Mirelman,
Rachel Saunders-Pullman, Deborah
Raymond, Laurie Ozelius, Avi Orr-Urtreger,
Lorraine Clark, Nir Giladi, Susan Bressman,
Karen Marder
P2.014
Identifying Barriers in Acute
Stroke Therapy in Argentina. ARENAS
Registry Ana Atallah, Osvaldo Fustinoni,
Maria Zurru, Ricardo Beigelman, Juan Cirio,
Sebastian Ameriso, Guillermo Burry
P2.015
Comparison of Large Vessel
Stroke Patient Outcomes Before and After
Initiation of On-site Endovascular Stroke
Treatment Services Yamin Shwe, Santiago
Ortega-Gutierrez, Amy Walker, Irene
Boniece, Alejandro Berenstein, Johanna Fifi
P2.022
Phenotypic Spectrum
of SNCA G209A Mutation Carriers
for Familial Parkinson’s Disease in
Greece Dimitra Papadimitriou, Roubina
Antonelou, Maria Stamelou, Maria Bozi,
Matina Maniati, Nikolaos Papagiannakis,
Sevasti Bostantjopoulou, Athanassios
Leonardos, Sokratis Papageorgiou, Georgios
Hadjigeorgiou, Eleni Kapaki, George
Tagaris, Alexandros Papadimitriou, Aglaia
Athanassiadou, Leonidas Stefanis
P2.023
Clinical and Neuroimaging
Features of a Patient with Early-onset
Parkinson’s Disease with Dementia
Carrying SNCA p.G51D Mutation Takayoshi
Tokutake, Atsushi Ishikawa, Nahoko
Yoshimura, Akinori Miyashita, Ryozo
Kuwano, Masatoyo Nishizawa, Takeshi
Ikeuchi
56
P2.016
The Utilization of Forced
Aerobic Exercise to Augment the Recovery
of Motor Function Following Stroke: A
Randomized Clinical Trial Susan Linder,
Anson Rosenfeldt, Amanda Penko, Jay
Alberts
P2.018
P2.017
Prediction of Ischemic Brain
Penumbra Using Acute MR Information and
Inelastic Collision Model Hassan BagherEbadian, Panayiotis Mitsias, James Ewing,
Hamid Soltanian-Zadeh
P2.019WITHDRAWN
P2.024Neuropsychiatric
P2.026
Features of GBA-Associated Parkinson
Disease Matthew Swan, Robert Ortega,
Matthew Barrett, Jeannie Soto-Valencia,
Sarah Boschung, Andres Deik Acosta
Madiedo, Harini Sarva, Jose Cabassa,
Brooke Johannes, Deborah Raymond, Joan
Miravite, William Severt, Rivka Sachdev,
Vicki Shanker, Susan Bressman, Rachel
Saunders-Pullman
P2.025
Interest in Genetic
Testing in Ashkenazi Jewish Parkinson
Disease Patients and Their Unaffected
Relatives Manisha Gupte, Roy Alcalay,
Helen Mejia Santana, Deborah Raymond,
Rachel Saunders-Pullman, Anat Mirelman,
Lorraine Clark, Laurie Ozelius, Avi OrrUrtreger, Nir Giladi, Susan Bressman, Karen
Marder
Prognostic Value of CT
Angiography in the Hyperacute Phase of
Middle Cerebral Artery Stroke. Pigreti
Santiago, Maria Zurru, Ariel Luzzi, Laura
Brescacin, Claudia Alonzo, Luis Camera,
Gabriel Waisman, Edgardo Cristiano
P2.020WITHDRAWN
Cognitive Signatures
of Parkinson’s Disease and
Glucocerebrosidase (GBA)
Mutation Masud Husain, Nahid Zokaei,
Alisdair McNeil, Christos Proukakis,
Michelle Beavan, Paul Jarman, Prasad
Korlipara, Derralyn Hughes, Atul Mehta,
Michele Hu, Anthony Schapira
P2.027
Non-motor Symptoms in
Genetic Forms of Parkinson Disease EvaJuliane Vollstedt, Christine Klein, Meike
Kasten
Poster Session II
Marrying Direct to Consumer
Genetic Data with Remote Phenotypic
Assessments in Parkinson Disease E.
Ray Dorsey, Kristin Darwin, Samara
Mohammed, Sean Donohue, Alyssa Tethal,
Meredith Achey, Susan Ward, Elaine
Caughey, Nicholas Eriksson, Emily Conley,
Bernard Ravina
P2.029
Exploring Genetic Influences
on Variation in the Phenotypic Expression of
Parkinson’s Disease. Naveed Malek, Sarah
Marrinan, Nin Bajaj, Roger Barker, Yoav
Ben-Shlomo, Catherine Bresner, David Burn,
Thomas Foltynie, Huw Morris, Nigel Williams,
Nicholas, W Wood, Donald Grosset
Movement Disorders: Friedreich’s
and Other Inherited Ataxias
P2.030 Predictive Equations to
Muscle Mass Volume in Patients with
Spinocerebellar Ataxia Christiane Leite,
Darla Macedo, Maria Schieferdecker,
Regina Vilela, Helio Teive, Adriana Moro
P2.031
Clinical and Genetic Profile
of Brazilian Patients with Late-Onset
Friedreich’s Ataxia Alberto Martinez,
Conrado Borges, Cynthia Bonilha Da Silva,
Adriana Moro, Thiago Rezende, Mariana
Moscovich, Renato Munhoz, Walter Arruda,
Simone Karuta, Anelyssa D’Abreu, Iscia
Lopes-Cendes, Marcondes Franca, Jr., Helio
Teive
P2.032
Disruption of Binaural Hearing
in Spinocerebellar Ataxia Type 13 Michael
Waters, Harry Nick, S Subramony, Joel
Advincula, Raymond Rosales, Lillian Lee,
Tetsuo Ashizawa, Middlebrooks John
P2.033
‘Pseudo-dominant’ Inheritance
in Friedreich’s Ataxia: Clinical and Genetic
Study of a Brazilian Family Adriana Moro,
Alberto Martinez, Mariana Moscovich,
Simone Karuta, Renato Munhoz, Walter
Arruda, Salmo Raskin, Francisco Germiniani,
Helio Teive
P2.034
Neurodevelopmental Defects
in Spinocerebellar Ataxia Type 13 Linked
to the EGF-R Signaling Pathway Swati
Khare, Donya Salmasinia, Daniela Arbelaez,
Jerelyn Nick, Diego Rincon-Limas, Harry
Nick, Pedro Fernandez-Funez, Michael
Waters
P2.035
When Should We Test
Patients with Familial Ataxias for
SCA31? Agessandro Abrahao Junior, Jose
Pedroso, Kinya Ishikawa, Salmo Raskin,
Paulo Sgobbi de Souza, Hidehiro Mizusawa,
Orlando Barsottini
P2.036
Substantia Nigra Echogenicity
Is Correlated with Nigrostriatal Impairment
in Machado-Joseph Disease José Luiz
Pedroso, Orlando Barsottini
P2.037
Children with Friedreich
Ataxia Undergoing Spinal Fusion Are at
Risk for Arrhythmias Kimberly Lin, David
Lynch, John Flynn, Joseph Rossano
P2.038
Assessing the Feasibility
of Quantitative Gait Analysis as an
Outcome Measure for Clinical Trials in
Spinocerebellar Ataxias Hokuto Morita,
Heather Vincent, Nawaz Hack, Bryan
Conrad, Tetsuo Ashizawa, S Subramony,
Guangbin Xia
Movement Disorders: Dystonia
P2.039
The Phenomenology and
Natural History of Idiopathic Lower Cranial
Dystonia Pichet Termsarasab, Steven
Frucht
P2.040
Clinical and Genetic Evaluation
for DYT1 and DYT6 Genes in Brazilian
Patients with Cervical Dystonia Carlos
Camargo, Sarah Camargos, Salmo Raskin,
Francisco Cardoso, Helio Teive
P2.041
Familial and Sporadic Cases
of Cervical Dystonia in 88 Patients Carlos
Camargo, Sarah Camargos, Nilson Becker,
Renato Munhoz, Salmo Raskin, Francisco
Cardoso, Helio Teive
P2.042
Tricks to Treatments: Sensory
Tricks in Dystonia Vesper Ramos, Barbara
Karp, Mark Hallett
P2.043
The Evaluation of
Environmental Factors in the Disease
Penetrance of Cervical Dystonia Anna
Molloy, Okka Kimmich, Laura Williams,
Fiona Molloy, Helena Moore, Daniel Healy,
Timothy Lynch, Cathal Walsh, Richard Reilly,
Sean O’Riordan, Michael Hutchinson
P2.044
Is Geste Antagoniste a
Predictive Factor of Effectiveness of
Botulinum Toxin A Treatment? Martin
Bares, Rastislav Sumec, Pavel Filip
P2.045
Brain Structural Changes
in Primary Focal Dystonia Lidia Sarro,
Francesca Caso, Federica Agosta,
Sebastiano Galantucci, Aleksandra Tomic,
Marina Svetel, Nikola Kresojevic, Giancarlo
Comi, Vladimir Kostic, Massimo Filippi
P2.046
Alleviating Maneuvers
(Sensory Tricks) in Cervical
Dystonia Neepa Patel, John Hanfelt, Laura
Marsh, Joseph Jankovic
P2.047
Sensory Tricks Reverse
Intracortical Facilitation Changes in
Cervical Dystonia. A Transcranial Magnetic
Stimulation Study Stefano Amadio, Elise
Houdayer, Francesca Bianchi, Habtom
Tesfaghebriel Tekle, Ivan Urban, Calogera
Butera, Roberta Guerriero, Marco Cursi,
Letizia Leocani, Giancarlo Comi, Ubaldo Del
Carro
Movement Disorders:
Co-morbidities and Novel
Care Models
P2.048 Telehealth in the Parkinson’s
Disease Subspecialty Clinic: The Key to the
Patient-Centered Medical Home Meredith
Spindler, Eileen Hummel, Stephanie
Pawlowski, Daniel Weintraub, Steven
Marcus, Margaret Stineman, James Morley,
John Duda, Jayne Wilkinson
P2.049
Proof of Concept for Operation
House Call for Underserved Parkinson’s
Disease Patients Nawaz Hack, Umer
Akbar, Amanda Eilers, Valerie RundleGonzalez, Daniel Martinez-Ramirez, Hokuto
Morita, Irene Malaty, Michael Okun
P2.050
Caregiver Tele-support
Group for Parkinson’s Disease: A Pilot
Study Shital Shah, Gretchen Glenn, Eileen
Hummel, Jane Hamilton, Rebecca Martine,
Jayne Wilkinson
P2.051
Zung Self Rating Depression
Scale in Parkinson’s Disease: A Validity
Study in Veterans Aliya Sarwar, Max
Hirshkowitz
P2.052
MDS-Sponsored Scale
Translation Program: Process, Format, and
Clinimetric Testing Plan for the MDSUPDRS and UDysRS Christopher Goetz,
Glenn Stebbins, Lu Wang, Nancy LaPelle,
Sheng Luo, Barbara Tilley
P2.053
Prevalence of Non-motor
Symptoms in Parkinson’s Disease:
A Systematic Review with MetaAnalysis Michele Tagliati, Kallol Chaudhuri,
Gennaro Pagano
P2.054
Vitamin D Concentrations and Leg Strength
in Persons with Parkinson’s Amie Peterson,
Brenna Lobb, Charles Murchison, Joseph
Quinn
P2.055
Statin Use, Apolipoprotein A1,
and Parkinson’s Disease Yosef Berlyand,
Roy Alcalay, Christine Swanson, Stanley
Fahn, Cheryl Waters, Oren Levy, Stephen
Schwartz, Alice Chen-Plotkin
P2.056
Obesity Associates with
Impaired Quality of Life in Parkinson
Disease Vikas Kotagal, Martijn Muller,
Nicolaas Bohnen
P2.057
Comorbidities and Causes
of Death in a Cohort Of 205 Patients
with Parkinsonism Mariana Moscovich,
Gabriela Boschetti, Adriana Moro, Helio
Teive, Renato Munhoz
Neuropathy: Genetics and
Outcomes
P2.058
The Allelic Spectrum
of Charcot-Marie-Tooth Disease
in Over 17,000 Individuals with
Neuropathy Joseph Higgins
P2.059
Can Glucose Disorders
Affect the Severity of CMT1A
Neuropathy? Juliana Algemiro, Rita De
Cassia Leal, Charles Lourenco, Waldemar
Algemiro, Vanessa Marques, Wilson
Marques
P2.060
Whole Exome Sequencing
Identified a Novel Mutation in PMCA4
Gene for Autosomal Dominant Familial
Spastic Paraplegia (ADFSP) in a Chinese
Family Wing Lok Ho, Shirley Pang, Miaoxin
Li, Michelle Kung, Pak-Chung Sham, Shu
Leong Ho
P2.061
Early- Versus Late-onset
Phenotypes of Transthyretin Val30Met
Familial Amyloid Polyneuropathy Valeria
Salutto, Valeria Alvarez, Diego Beratti, Fabio
Barroso, Claudio Mazia
P2.062
Wide Spectrum of Neuropathy
in Homozygous and Heterozygous Novel
Frameshift MPZ Mutation in a Tunisian
Family Youssef Sidhom, Imen Kacem,
Yousser Hizem, Mouna Ben Djebara, Amina
Gargouri, Eric Leguern, Riadh Gouider
P2.063
T118M PMP22 as a Modifier
for Hereditary Neuropathy with Liability
to Pressure Palsy (HNPP) Nivedita Jerath,
Tiffany Grider, Andrea Swenson, Michael
Shy
P2.064Adrenomyeloneuropathy
Diagnosed in a Young Female with
Spastic Paraparesis after Full Exome
Sequencing Tania Garcia, A Ordoñez
Ugalde, Beatriz Quintans, Maria Jesus
Sobrido, M. C. Amigo, Eva Costa Arpin, Julio
Pardo-Fernandez
P2.065
Detection of Copy Number
Variation (CNV) in Patients with CMT1A
by SNP-Allelotyping Brett Parker, Ryan
Alexander, Nathalie Schnetz-Boutaud,
Xingyao Wu, Michael Shy, Jun Li
P2.066
CMT2A2 Associated with
Novel MFN2 Gene Double Missense
Mutations in CIS Haatem Reda, Gyorgy
Abel, Jayashri Srinivasan
P2.067
Health-related Quality of Life
by SF-36 in Patients with HNPP compared
to Those with CMT1A Tiffany Grider, David
Cuthbertson, Shawna Feely, Michael Shy
ALS: Genetics and Outcomes
P2.068
Madras Pattern Motor Neuron
Disease Caused by a Novel Mutation in
the UBQLN2 Gene Hacer Durmus, Aslihan
Ozoguz, Ozgun Uyan, Feza Deymeer, Piraye
Serdaroglu, Nazli Basak, Yesim Parman
P2.069
Regional Variation of
Causative ALS Genes Summer Gibson,
Karla Figueroa, Linh Huynh, Mark Bromberg,
Stefan Pulst
P2.070
Meta-Analysis of ALS
Risk for Ataxin-2 (SCA2) CAG Repeat
Alleles Annalese Neuenschwander, Khanh
Thai, Karla Figueroa, Stefan Pulst
P2.071
Use of Veterans Specific
Activity Questionnaire (VSAQ) to Estimate
Exercise Tolerance in Ambulatory
Amyotrophic Lateral Sclerosis (ambALS)
Patients Mohammed Sanjak, Jasmin
Headen, Kendall Barrett, Scott Holsten,
Velma Langford, Elena Bravver, William
Bockenek, Urvi Desai, J Scott Story, Scott C
Lindblom, Thomas Paccico, Benjamin Brooks
P2.072
Amyotrophic Lateral
Sclerosis (ALS) Estimates from
National Databases in the United
States—2001-2010 Marchelle Sanchez,
Paul Mehta, Wendy Kaye, Vinicius Antao, D.
Kevin Horton
P2.073
Using Mortality Data as
a Component of Amyotrophic Lateral
Sclerosis (ALS) Surveillance in New Jersey
(NJ) Heather Jordan, Jerald Fagliano,
Daniel Lefkowitz, Lindsay Rechtman, Wendy
Kaye
P2.074
Mortality and Cause of Death
Among Confirmed ALS Cases, Los Angeles
and San Francisco Bay Area Metropolitan
ALS Surveillance Project 2009-2011 Susan
Paulukonis, Jhaqueline Valle, Natalie
Collins, Eric Roberts, Paul English, Wendy
Kaye
P2.075
Predictors of Early
Mortality in Patients with Amyotrophic
Lateral Sclerosis Undergoing Elective
Percutaneous Endoscopic Gastrostomy or
Jejunostomy Placement: The Mayo Clinic
Experience Sherri Braksick, Lyell Jones,
Jayawant Mandrekar, Sara Hocker
57
Tuesday
April 29
P2.028
Tuesday, April 29
P2.076
Predictors of Outcome in
Amyotrophic Lateral Sclerosis Elena Ratti,
James Berry, Nazem Atassi, Amy Shui,
Douglas Hayden, David Schoenfeld, Hong
Yu, Robin Conwit, Jeremy Shefner, Merit
Cudkowicz
P2.077
Investigating the Relationship
Between Length of Stay in Hospice Care
and Rates of Change on ALS Functional
Rating Scale-Revised and FVC in Patients
with Amyotrophic Lateral Sclerosis Grace
Shen, Lauren Elman, Nabila Dahodwala,
Kelly Almasy, Mary Kelley, Leo McCluskey
Neuromuscular Junction
P2.078
Incidence, Risk Factors and
Clinical Features of Myasthenic Crises Chi
Yan Lee
P2.079
Genetic Predisposition to
MuSK -Positive Myasthenia Gravis in
Patients from Argentina Claudio Mazia,
Marcelo Francisco Rugiero, Valeria Salutto,
Pablo Galarza, Flavia Canitano, Adrian
Perusco
P2.080 Is the Decremental Pattern
in Lambert-Eaton Myasthenic Syndrome
Different from That in Myasthenia
Gravis? Donald Sanders, Lucy Cao, Janice
Massey, Vern Juel, Lisa Hobson-Webb, Jeff
Guptill
P2.081
Incidence of Myasthenia
Gravis in an HMO of Buenos Aires,
Argentina Marcelo Rugiero, Mariela
Bettini, Marcelo Chaves, Diego Giunta,
Jimena Vicens, Edgardo Cristiano
P2.082
A Role for BAFF Receptor
(BAFF-R; Cd268) and its Ligand Variant(S)
in Early-onset Myasthenia Gravis
Thymus Michael Pütz, Hendrik Döbold,
Patrick Stelmach, Kerstin Schlegel, Michael
Happel, Wolfgang Oertel, Maria Seipelt,
Christian Eienbröker, Bjorn Tackenberg
P2.083 Demographics of Ocular
Myasthenia Gravis Beau Bruce, Elena
Bitrian, Mark Kupersmith, Fritz Zimprich,
Jason Peragallo, Thomas Whittaker,
Michael Lee
P2.084 Prognostic Factors and
P2.088 Increased Number of Hassall’s
Corpuscles in Myasthenia Gravis Patients
with Thymic Hyperplasia Naoko Matsui,
Ryuji Kaji
P2.089
A Biosensor Assay for the
Detection of Muscle Specific Tyrosine
Kinase (MuSK) Antibodies in Myasthenia
Gravis Patients Zahra Pakzad, Ebrima
Gibbs, Tariq Aziz, Joel Oger
P2.090
Video-assisted Thoracoscopic
Surgery for Myasthenia Gravis
Associated with Thymoma: A 13-year
Experience Minas Tzagournissakis,
Konstantinos Lasithiotakis, Alexandros
Andreou, Michalis Mavridis, Vasileios
Mastorodemos, Georgios Amoiridis,
Andreas Plaitakis, Georgios Chalkiadakis
P2.091
Association of Neuromyelitis
Optica Following Thymectomy in
Myasthenia Gravis: Case Report and
Retrospective Literature Review of 16
Patients Sajjad Nasir, V Vedanarayanan,
Robert Herndon
P2.092
De Novo Mutation in
Sodium Channel Gene SCNBA Causes
Neuromuscular Junction Disorder in Early
Onset Epileptic Encephalopathy Nina
Barisic, Sarah Weckhuysen, Peter De
Jonghe, Ingo Helbig, Arvid Suls, Vanja
Ivanovic, Ivan Lehman, Branka Bunoza, Petra
Grdan
Predictive Value of
Electrophysiology for Detecting Thymic
Pathology in Patients with Myasthenia
Gravis Tushar Gosavi, G Huang, Stephanie
Fook-Chong, Yew Long Lo
58
Succesful Treatment of
Carotid-Cavernous Fistula Through a
Percutaneous Orbital Approach Ricardo
Rangel Guerra
Behavioral, Cognitive, and
Miscellaneous
P2.101
P2.115
Postoperative Seizure
Outcomes in Patients with Intracerebral
Cavernous Malformations Neha Morparia,
Cheolsu Shin, Robert Brown, Teresa
Christianson, Kelly Flemming
P2.102
Risk of Bleeding from
Antithrombotic Agents (AT) in Patients
with Cerebral Cavernous Malformations
(CCMs). Robert Wityk
P2.103
Rare Presentation of
Churg-Strauss Syndrome: Intracerebral
Hemorrhage, Subdural Hemorrhage and an
Intracranial Aneurysm Mandeep Chahil,
Justin Morgan, Nicole Gonzales, Tzu-Ching
Wu
P2.104
Inflammatory Cerebral
Amyloid Angiopathy Mimicking an
Aggressive Glioma Adam Reynolds, Erica
Byrd, Arielle Davis, Mahmud Mossa-Basha,
Sandeep Khot
P2.105
Childhood and Young Adult
A Case of Lambert-Eaton
Myasthenic Syndrome Presenting with
Severe Autonomic Failure Ugonma
Chukwueke, Digvijaya Navalkele, Marisara
Dieppa, Jaya Trivedi, Jeffrey Elliott, Steven
Vernino
P2.095
Influence of Immunosuppressive
Medication on TCR Vβ Usage and Thymocyte
Maturation Stages in Patients with
Early-onset Myasthenia Gravis Christian
Eienbröker, Michael Pütz, Kerstin Schlegel,
Klaus Gellert, Norbert Sommer, Florian
Seitz, Wolfgang Oertel, Bjorn Tackenberg
P2.096
P2.087
P2.100
P2.094
Paraneoplastic Myasthenia
Gravis associated with Appendiceal
Mucinous Neoplasm Nicholas Lanciano,
Victoria Lawson, William Arnold
P2.085 Low Dose Medication
Myasthenia Gravis in the
Elderly: Clinical Characteristics, Treatment
Considerations, Complications and
Prognosis. Marcelo Rugiero, Mariela
Bettini, Marcelo Chaves, Hernan Gonorazky,
Vanesa Pytel, Edgardo Cristiano
P2.114
Predictors of Hemorrhagic
Complications from Endovascular
Treatment of Cerebral Arteriovenous
Malformations Juan Carlos Llibre, Jose
Jordan
P2.093
Acquired and Congenital
Vascular Malformations
P2.086
P2.099
Cerebral Amyloid Angiopathy
Related Inflammation: Case Reports and
Imaging Pitfalls Mark Mcallister, Melissa
Armstrong
Health-related Quality of Life (HRQol ) in
Ocular Myasthenia Gravis (OMG) Giuliana
Galassi, Alessandra Ariatti, Marina Stefani,
Pietro Miceli, Manuela Tondelli, Francesca
Benuzzi, Paolo Nichelli
and Long-term Outcome in Myasthenia
Gravis Salomi Salins, Barbara Teter,
Katelyn Kavak, Nicholas Silvestri, Gil Wolfe
7:30 a.m.–11:00 a.m.
Pial Arteriovenous Fistula and
Capillary Malformation-Arterial Venous
Malformation (CM-AVM) Associated
with RASA1 Mutation: 2 Illustrative
Cases Deepak Gulati, Sunil Manjila,
Nicholas Bambakidis, Asim Shahid
P2.097
Intracranial Dural
Arteriovenous Fistula Presenting with
Recurrent Transient Fluent Aphasia Bardia
Nourbakhsh, Julio Rojas -Martinez,
Chirantan Banerjee, Roberta Novakovic,
Worthy Warnack
P2.098
Cerebral Venous Congestion
Caused By Cervical Arteriovenous Fistula:
A Rare Delayed Complication Following
Heart Transplantation Hlynur Georgsson,
Annapoorna Bhat, Machteld Hillen
P2.106
Etiology and the Cost of
Pediatric Stroke William Hamilton, Haijuan
Huang, Eric Seiber, Warren Lo
P2.107
Intra-arterial Treatment in
a Child with Embolic Stroke due to Atrial
Myxoma Ido Van Der Wyngaard, Marieke
Wermer, Marianne van Walderveen, Geert
Lycklama a Nijeholt
Hypertensive Disorders in
Pregnancy and Future Risk of Stroke: A
Systematic Review Aravind Ganesh, Neha
Sarna, Rahul Mehta, Eric Smith
Undiagnosed Cognitive
Impairment Among Patients Referred for
Carotid Doppler Evaluation Is Associated
with Increased Non-adherence with
Medical Treatment of Vascular Risk
Factors Angelia Kirkpatrick, Leslie Guthery,
Calin Prodan
P2.116
Neuro-QOL for Assessment
of Cognitive Impairment After Stroke:
Comparison with Modified Rankin
Scale Rajbeer Sangha, Carlos Corado,
Deborah Bergman, Andrew Naidech, David
Cella, Richard Bernstein, Yvonne Curran,
Shyam Prabhakaran
P2.117
The Role of DiffusionPerfusion Mismatch in the Cognitive
Changes of Acute Stroke Patients Amanda
Ramadan, Melissa Motta, Rebecca
Gottesman, Argye Hillis, Richard Leigh
P2.118
The Feeling that ‘I Can
Say it in My Head’ Predicts Word-byWord Success in Subsequent Aphasia
Treatment. William Hayward, Kelli Sullivan,
Sarah Snider, Elizabeth Lacey, Rhonda
Friedman, Peter Turkeltaub
P2.119
An Unusual Cause of Altered
Mental Status: Recurrent Cerebral
Air Embolism from Atrial-Esophageal
Fistula Iftekhar Ahmed, Trenton Myers,
James Kim
P2.120
Stroke Mortality and its
Predictors in Nigeria: Results of a HospitalBased Study Kolawole Wahab, Emmanuel
Sanya, Babatunde Ademiluyi, Bello
Abiodun, Wemimo Alaofin
P2.121
Heart Rate Variability and
Vibration Perception Threshold in Healthy
Young Adults with Parental History of Type
2 Diabetes Rajesh Goit
Measurement of Hemispheric
Volume to Detect and Quantify Early
Ischemic Changes in Patients with Ischemic
Stroke Asif Khan, Mushtaq Qureshi,
Bernard Galea, Malik Adil, Muhammad Suri,
Adnan Qureshi
P2.109
P2.122
P2.108
Stroke in a Young Patient: A
Sentinel Presentation of Neurosyphilis and
HIV Elizabeth Flaherty, Shawna Cutting
P2.110
Cardiovascular Risk Factors in
Young Adults with Stroke from the AISYF
Study Julieta Mazziotti, Ricardo Reisin
P2.111
Left Ventricular Hypertrophy
as a predictor of White Matter
Hyperintensities in Young Stroke
Patients Luciana Catanese, Ashkan
Shoamanesh, Helena Lau, Jose Romero,
Viken Babikian, Carlos Kase, Aleksandra
Pikula
P2.112
Ethnic Differences in Ischemic
Stroke Subtypes: The Stroke Prevention
in Young Adults Study Megh Trivedi,
John Cole
P2.113
Pregnancy Associated
Cerebral Ischemia in Women with Sickle
Cell Disease Taqi Zafar, Malik Adil,
Muhammad Suri, Adnan Qureshi
Safety and Tolerability
of Gabapentin for Headache
After Aneurysmal Subarachnoid
Hemorrhage Laxmi Dhakal, Michael
Mayes, Alexa Richie, William Freeman
P2.123
Cerebral Autosomal Dominant
Arteriopathy with Subcortical Infarcts
and Leukoencephalopthy (CADASIL) in
Argentina Maximiliano Hawkes, Miguel
Wilken, Veronica Bruno, Virginia Pujol
Lereis, Guillermo Povedano, Maria Saccoliti,
Ana Lia Taratuto, Sebastian Ameriso
P2.124
Episodic Aphasia After
Subdural Hemorrhage Due to Cortical
Spreading Depression: A Case
Report Jillianne Grayson, Nirav Shah,
Shnehal Patel, Alejandro Forteza
Poster Session II
Evaluation, Cost, and Quality
P2.137
Stroke Patients and
Diagnostic Testing—the Weekend Waiting
Game! Sally Mathias, Jessica Lee
Sex Disparities in Access
to Stand Alone Primary Stroke Centers:
Can Telemedicine Mitigate This
Effect? Catherine Wolff, Amelia Boehme,
Tzu-Ching Wu, Michael Mullen, Charles
Branas, James Grotta, Sean Savitz, Brendan
Carr
P2.126
P2.138
P2.125
Which Diagnostic Tests for
Stroke Are the Most Costly and May Not
be Necessary? Seemant Chaturvedi,
Kumar Rajamani, Pratik Bhattacharya
P2.127
Implementing a Checklist
into Cerebrovascular Service Discharges:
A Resident-Driven Quality Improvement
Project Kate Daniello, Melissa Rayhill, Ania
Busza, Judith Clark, James Otis
P2.128
Transient Ischemic
Attack: Symptom Patterns and Imaging
Associations Elissaios Karageorgiou, David
Anderson
P2.129
Stroke Patient Length of Stay
Benchmarking and Analysis Elizabeth
Diebolt, Shannon Sims, James Conners,
Vivien Lee
P2.130
Comparability of Charges and
Payments for Hospitalized Stroke Sebina
Bulic, May Kim, Shuhan He, Suzie Kazaryan,
Steven Cen, Shannon He, William Mack,
Nerses Sanossian
Medicare Coverage Increases
Odds of In-hospital Mortality But Lack
of Insurance Increases Odds of Poor
Functional Outcome by Modified Rankin
Score (mRS) Adam Friedant, Dominique
Monlezun, Jr, Prerana Baranwal, Melisa
Valmoria, Amir Shaban, Alexander George,
Ramy El Khoury, Sheryl Martin-Schild
P2.139
Medicare and VA Patients
Have More Inpatient Complications
and Less Neuroimaging than Uninsured
Patients Prerana Baranwal, Dominique
Monlezun, Jr, Mathew Ryan, Denise Pineda,
Amir Shaban, Alexander George, Ramy El
P2.140
Uninsured Patients May Lack
Diagnoses for Chronic Diseases That Are
Known Stroke Risk Predictors Prerana
Baranwal, Dominique Monlezun, Jr, Joel
Lanceta, Amir Shaban, Alexander George,
Sheryl Martin-Schild, Ramy El Khoury
P2.148
Age-specific Incidence
Rate for Dementia and Alzheimer’s
Disease in NIA-LOAD/NCRAD and
EFIGA Families Badri Vardarajan, Kelley
Faber, Thomas Bird, David Bennett, Roger
Rosenberg, Bradley Boeve, Neill GraffRadford, Alison Goate, Martin Farlow,
Robert Sweet, Rafeal Lantigua, Martin
Medrano, Ruth Ottman, Daniel Schaid,
Tatiana Foroud, Richard Mayeux
P2.149
Distinct Genetic Variants
in Alzheimer’s Disease and Type 2
Diabetes Sun Ju Chung, Seong Yoon Kim,
Juyeon Kim, Mi-Jung Kim, Young Jin Kim,
Jae-Hong Lee
P2.150
TMEM106B Is a Genetic
Modifier of Frontotemporal Lobar
Degeneration with C9orf72 Hexanucleotide
Repeat Expansions Alice Chen-Plotkin,
Michael Gallagher, Eunran Suh, Murray
Grossman, Lauren Elman, Leo McCluskey,
John Trojanowski, Virginia Lee, Vivianna
Van Deerlin
P2.151
HDLS Family Case Showing
X-Linked Recessive Heredity Hisatomo
Kowa, Takeshi Uenaka, Takehiro Ueda,
Takashi Matsukawa, Shoji Tsuji, Fumio
Kanda, Tatsushi Toda
P2.158
Functional Neuroimaging of
Sensory Conversion Disorder: The Role of
Ancillary Activation Matthew Burke, Omar
Ghaffar, W Staines, Jonathan Downar,
Anthony Feinstein
P2.159
Impaired Processing of
Positive and Negative Facial Expressions
in Right Hemisphere Stroke Donna Tippett,
Cameron Davis, Yessina Gomez, Lydia Trupe,
Argye Hillis
P2.160
Models for PTSD
Subtypes Classification According
to Anxiety and Depressive Dominant
Symptomatology Chen Ryder, Gal RichterLevin, Radi Shahien
P2.161
Longitudinal Volume Loss
in Neuroanatomical Regions of Emotion
Versus Cognition Peter Pressman, Yuliana
Noniyeva, Nicholas Bott, Shubir Dutt, Bruce
Miller, Virginia Sturm, Joel Kramer
P2.162
Asymmetry of Perceived
Emotional Expression in Facial
Chimeras Jerry Wei, Steven Sparr
General Cognition
P2.141
P2.152
Show or No-show—That Is
the Question: Lack of Outpatient Follow-up
a After Acute Stroke. Gauhar Chaudhary,
Jessica Lee
Adherence with Post-stroke
Follow-up Clinic Visits and Factors
Influencing Compliance in a Large Urban
Hospital. Mohammad El-Ghanem, Peter
Jin, Vineet Punia, Wenzhuan He, Machteld
Hillen
P2.132
P2.142
Aging, Dementia, and
Neurology: Emotion
Primary CNS
Lymphoma Versus Intravascular
Lymphoma: Differences in Cognitive
Presentation Mariel Deutsch, Mario
Mendez
P2.153
P2.165
P2.131
Use of a Patient Navigation
System to Increase Attendance at Stroke
Follow-up Appointments Christina Sarris,
Aaron Hajart, Ennis Duffis
P2.133
Gender Differences in Primary
Stroke Center Evaluation and Utilization
of rt-PA Michael Mullen, Karen Albright,
Amelia Boehme, Scott Kasner, Michael
Kallan, Charles Branas, Brendan Carr
Risk Factors More Associated
with Ischemic Rather Than Hemorrhagic
Stroke in Black Africans: Implications for
Epidemiologic Transition Mayowa Owolabi,
Atinuke Agunloye
P2.143
Poor Outcome Among Women
Following Intracerebral Hemorrhage Preet
Varade, Seemant Chaturvedi, Pratik
Bhattacharya
Disparity
Aging, Dementia, and
Neurology: Genetics
P2.134
P2.144
Are Hispanic Subarachnoid
Hemorrhage Patients in Border States
Treated Differently Than Those Admitted
in Non-Border States? Ameer Hassan,
Taqi Zafar, Malik Adil, Muhammad Umair,
Ahmed Malik, Wondwossen Tekle, Olive
Sanchez, Adnan Qureshi
P2.135
Disparities in Access to
Primary Stroke Centers: Geography, Not
Gender, Race, or Ethnicity Michael Mullen,
Ariel Bowman, Douglas Wiebe, Catherine
Wolff, Karen Albright, Jason Roy, Laura
Balcer, Charles Branas, Brendan Carr
P2.136
Are There Disparities in
Thrombolytic Treatment and Mortality
in Acute Ischemic Stroke in the Hispanic
Population Living in Border States Versus
Non-Border States? Ameer Hassan,
Malik Adil, Taqi Zafar, Muhammad Umair,
Wondwossen Tekle, Olive Sanchez, Adnan
Qureshi
Sanger Sequencing Exons
of BDNF Gene Derived from a Latino
Sample Sara Dawit, Jazmin Acosta, Mia
Champion, Stefanie Velgos, Gabriel Shaibi,
Lawrence Mandarino, Nicole Cevette,
Richard Caselli, Yonas Geda
P2.145
Lack of AGG Interruptions
in FMR1 Is Associated with Cognitive
Impairment Deborah Hall, Victor Kaytser,
Raj Shah, David Bennett, Elizabeth BerryKravis
P2.146
Genome-wide Gene-based
Analysis of Exome Array Data for Rare
Variants in Alzheimer’s Disease Sun Ju
Chung, Seong Yoon Kim, Juyeon Kim, MiJung Kim, Young Jin Kim, Jae-Hong Lee
P2.147
Expression QTL Studies in
LOAD and PSP Brains by Next-generation
RNA Sequencing Nilufer Taner, Chen
Wang, Minerva Carrasquillo, Mariet
Allen, Curtis Younkin, Daniel Serie, Vernon
Pankratz, Thuy Nguyen, Li Ma, Kimberly
Malphrus, Sarah Lincoln, Ronald Petersen,
Neill Graff-Radford, Steven Younkin, Dennis
Dickson, Yan Asmann
Altered CpG Methylation
of APP, MAPT and GSK3B in Sporadic
Alzheimer’s Disease Atsushi Iwata,
Hiroyuki Hatsuta, Shigeo Murayama, Shoji
Tsuji
Influence of the Tau Haplotype
on Progression and Treatment Response of
Neuropsychiatric Symptoms in People with
Alzheimer’s Disease Clive Ballard, Anne
Corbett, Byron Creese
P2.154
Visual Hypoemotionality
(Secondary Visual Derealization)
in a Patient with a Right Posterior
Temporoparietal Lesion David Perez,
Sashank Prasad, Diler Acar, Mary-Ellen
Meadows, Alexandra Golby, Barbara
Dworetzky
P2.155
Major Depression as
Initial Manifestation of Limbic Lewy
Body Dementia a Clinico-pathological
Report Bernard Michel, Henri Becker,
Jean-Francois Pelissier, Bradley Boeve,
Nathalie Sambuchi, Annie Bartolin,
Catherine Gallant, Jean-Claude Saint Jean,
Hui-Mei Chen, Charles Rouyer, Jean Michel
Azorin, Ronald Petersen
P2.156
Evaluation of Emotional
Blunting in Behavioral Variant
Frontotemporal Dementia Compared to
Alzheimer’s Disease Aditi Joshi, Joseph
Barsuglia, Michelle Mather, Elvira Jimenez,
Jill Shapira, Mario Mendez
P2.157
Autistic Symptoms in a
Geriatric Population with Mild Cognitive
Impairment and Early Dementia Danielle
Crawford, Erin Abner, Paul Glaser, Gregory
Jicha
Tuesday
April 29
P2.163
Diffuse Lewy Body Disease
and Associated Balint’s Syndrome: A Case
Series Ramsey Falconer, Sean Rogers,
Fahd Amjad, Benjamin Osborne
P2.164
Using Eye-Movement
Trackings to Investigate Mechanisms
of Word-object Associations in Primary
Progressive Aphasia Mustafa Seckin, Joel
Voss, M. Mesulam, Emily Rogalski, Robert
Hurley
P2.166
Nonverbal Oral Apraxia in
Primary Progressive Aphasia and Apraxia
of Speech Hugo Botha, Joseph Duffy,
Edythe Strand, Jennifer Whitwell, Keith
Josephs
P2.167
Routine Cognitive Screening
in a General Neurology Clinic: Impact on
Physician Behavior Michael Rosenbloom,
Terry Barclay, Maria Pyle, Amanda Cagan,
Ann Hanson, Leah Hanson
P2.168
Impaired Grammar in
the Speech of Amyotrophic Lateral
Sclerosis Collin York, Lauren Elman, Leo
McCluskey, Sharon Ash, Murray Grossman
P2.169
Unawareness of Partners’
Abilities in Aged Subjects Vahid Behravan,
Paul Eslinger, A. Barrett
P2.170
Neurobehavioral Disorders in
Parkinsonian Patients Without Dopamine
Deficits (SWEDD) Amin Demerdash,
Kenneth Heilman, Joanna Myers, Chase
Mitchell, David Standaert, Frank Skidmore
P2.171
A Japanese Family with
Idiopathic Basal Ganglia Calcification
with Novel SLC20A2 Mutation Presenting
with Late-onset Hallucination and
Delusion Kensaku Kasuga, Takuya Konno,
Masatoyo Nishizawa, Takeshi Ikeuchi
59
Tuesday, April 29
P2.172
Bilingualism Is Associated
With Less Severe Cognitive
Impairment Claudia Padilla, Elvira Jimenez,
Joseph Barsuglia, Aditi Joshi, Edmond Teng,
Mario Mendez
P2.173
Differential Longitudinal
Changes in Cognition Among Amyotrophic
Lateral Sclerosis (ALS) Patients Sharon
Xie, Katya Rascovsky, Ashley Boller, Xiaoyan
Han, Leo McCluskey, Lauren Elman, David
Libon, Murray Grossman
P2.174
Subjective Cognitive
Impairment in a French Sample Bernard
Michel, Nathalie Sambuchi, Yonas Geda,
Isabelle Muraccioli, Veronique Paban,
Elisabeth Jouve, Rolland Sambuc, Hui-Mei
Chen, Annie Bartolin, Catherine Gallant,
Jean-Claude Saint Jean, Charles Rouyer,
Christian Brosset, Jean-Michel Azorin,
Beatrice Alescio-Lautier, Ronald Petersen
P2.175
Cognitive Decline Is
Associated with Progressive Grey Matter
Disease in Amyotrophic Lateral Sclerosis
(ALS) Christopher Olm, Lauren Elman,
Leo McCluskey, Corey McMillan, Murray
Grossman
P2.176
Neurological Examination
Findings in Autistic Adults Bryan Woodruff,
Joseph Hentz, Amy Duffy, Elena Pollard,
Christopher Smith, Yonas Geda
P2.177
Mild Cognitive Impairment:
Neuropsychiatric Symptom Prevalence
within Cognitive Subtypes and
Obesity Ashley Hannah, Andrea Bozoki
P2.178
Social and Executive
Contributions to Discourse Limitations
in Amyotrophic Lateral Sclerosis Anna
Menaged, Sharon Ash, Christopher Olm,
Corey McMillan, Murray Grossman, Lauren
Elman, Leo McCluskey
P2.179
Dissociating the Body
Schema: Evidence from Two Case
Studies Jared Medina, Emily Baumert,
Megan Ziegler
P2.180
Deficits in Sentence
Expression in Amyotrophic Lateral
Sclerosis Sharon Ash, Christopher Olm,
Corey McMillan, Ashley Boller, David
Irwin, Leo McClusky, Lauren Elman, Murray
Grossman
P2.181
Speaking While Gesturing
Adversely Affects Limb Praxis in pAD. A.
Barrett, Livingston Dore
P2.182
Alabama Brief Cognitive
Screener (ABCs): Design and Initial Clinical
Experience Marissa Natelson Love, David
Geldmacher
Neurophysiology: Genetics
P2.183
CLN6 Mutations Cause
Teenage-onset Progressive Myoclonus
Epilepsy Danielle Andrade, Tara Paton,
Julie Turnbull, Christine Klein, Christian
Marshall, Stephen Scherer, Berge
Minassian
60
P2.184
Mild Case of UnverrichtLundborg Disease (ULD) Mimicking
Juvenile Myoclonic Epilepsy (JME) in
Adulthood Eva Andermann, Dina Amrom,
Mahmoud Heshmati Moghaddam, Frederick
Andermann, Tarja Joensuu, Anna-Elina
Lehesjoki
P2.185
LGI1 Mutation Presenting as
Idiopathic Generalized Epilepsy: Importance
of Family History for Genetic Testing Dina
Amrom, Frederick Andermann, Hans Atli
Dahl, Eva Andermann
P2.186Lacosamide-responsive
Status Epilepticus and Epileptic Spasm in
Fumarase Deficiency France Fung, Patricia
Musolino, Ronald Thibert
P2.187
Aicardi Syndrome: Long-term
Evolution Anfal Ali, Nicky Wu, Felippe
Borlot, Timo Krings, Danielle Andrade
P2.188
Dravet Syndrome: Seizure
Control and Gait in Adults with Different
SCN1A Mutations Jennifer Rilestone,
Fernando Coelho, Berge Minassian, Danielle
Andrade
P2.189
The Prognosis of Primary
Generalized Epilepsy in Patients with
Parental Consanguinity: A One-year
Retrospective Study Hussam Assiri,
Abdulmajeed Bajunaid, Fawzi Babtain,
Muthusamy Velmurugan
P2.190
First Time Seizure in Adult
Female as Presentation of Ornithine
Transcarbamoylase Deficiency: A Case
Report and Literature Review Michael
Pizzi, Suparna Krishnaiengar
P2.191
Unusual Presentation of
Left Temporal Lobe Epilepsy Due to Large
Sphenoidal Encephalocele and Good
Epilepsy Surgery Outcome Tiffany Fisher,
Sasaki-Adams Deanna, Hae Won Shin
P2.192
Next Step for Personalized
Medicine in Epilepsy: Pharmacogenomic
Testing-based Antiepileptic Drugs in
Refractory Epilepsy Andres Cruz, Pedro
Bermejo
P2.193
A Novel Gene (Myclonin
3) for Classic Juvenile Myoclonic
Epilepsy Dongsheng Bai, Marco Medina,
Reyna Duron, Julia Bailey, Maria Alonso,
Toshimitsu Suzuki, Miyabi Tanaka, Iris
Martinez-Juarez, Adriana Ochoa, Aurelio
Jara-Prado, Jose Serratosa, Kazuhiro
Yamakawa, Antonio Delgado-Escueta
Disease: Treatment Safety
P2.194
Teriflunomide Treatment
Is Not Associated with Increased Risk
of Infections: Pooled Data from the
Teriflunomide Development Program Barry
Singer, Giancarlo Comi, Aaron Miller, Mark
Freedman, Myriam Benamor, Philippe
Truffinet
P2.195
Cardiovascular Effects of
Combined Administration of Siponimod and
Popranolol—Importance of Sequencing
During Coadministration Shibadas Biswal,
Florine Polus, Atul Pawar, Uday Kiran
Veldandi, Eric Legangneux
7:30 a.m.–11:00 a.m.
P2.196
Short-term and Long-term
Effects of Fingolimod on the Cardiovascular
Autonomic Nervous System Judith Eisele,
Jowita Zwierzanska, Manja Reimann, Silke
Prieur, Kristin Haink, Thorsten Schultheiss,
Tjalf Ziemssen
P2.206 A Case of Hemophagocytic
P2.197
P2.207
Good Cardiac Safety in
Patients with Relapsing Remitting
Multiple Sclerosis Upon First Fingolimod
Dose Volker Limmroth, Susanne Hoyer,
Stephan Schmidt, Michael Lang, Tjalf
Ziemssen
P2.198
Successful Detection
and Management of Immune
Thrombocytopenia in AlemtuzumabTreated Patients with Active RelapsingRemitting Multiple Sclerosis Adam Cuker,
Roberto Stasi, Jeffrey Palmer, Pedro Oyuela,
David Margolin, Ann Bass
P2.199
Thyroid Autoimmune
Adverse Events in Patients Treated with
Alemtuzumab for Relapsing-Remitting
Multiple Sclerosis: Four-year Follow-up of
the CARE-MS Studies Cary Twyman, Pedro
Oyuela, Jeffrey Palmer, David Margolin,
Colin Dayan
P2.200 Safety Profile of Delayed-
Release Dimethyl Fumarate in RelapsingRemitting Multiple Sclerosis (RRMS): Longterm Interim Results From the ENDORSE
Extension Study Ted Phillips, Robert Fox,
Krzysztof Selmaj, Ray Zhang, Mark Novas,
Marianne Sweetser, Vissia Viglietta, Ralf
Gold
P2.201
Safety of Using Diseasemodifying Therapy Post-alemtuzumab
Treatment in Patients with RelapsingRemitting Multiple Sclerosis in the Core
and Extension Phases of CAMMS223,
CARE-MS I, and CARE-MS II Studies Keith
Edwards, Christopher LaGanke, Pedro
Oyuela, Jeffrey Palmer, David Margolin
P2.202 Baseline Characteristics
and Interim Analysis Results of the
Fingolimod Cohort in the Worldwide Post-approval Safety Program
(PASSAGE) Paul Giacomini, Helmut
Butzkueven, Stanley Cohan, Tomas Olsson,
Dietrich Rothenbacher, Belinda Weller,
Tjalf Ziemssen, Anu Gupta, Malika Cremer,
Tricia Blankenbiller, Erika Rochotte, Davorka
Tomic, Philipp Von Rosenstiel, Maria Trojano
P2.203 Pooled Safety Data from
Four Placebo-Controlled Teriflunomide
Studies Thomas Leist, Mark Freedman,
Myriam Benamor, Philippe Truffinet,
Deborah Dukovic, Giancarlo Comi
P2.204 Prospective Evaluation
of Development of Skin Rashes in MS
Patients Treated with Daclizumab High
Yield Process Irene Cortese, Kaylan
Fenton, Joan Ohayon, Edward Cowen, John
DiGiovanna, Bibiana Bielekova
P2.205 Safety and Tolerability of
Escalating Doses of Laquinimod, an Oral
Immunomodulatory Agent in Development
for Treatment of Relapsing-Remitting
Multiple Sclerosis Hayrettin Tumani,
Tjalf Ziemssen, Friedemann Paul, Martin
Marziniak, Nils Richter, Christoph Heesen,
Maya Marglit, Yulia Sidi, Tali Gorfine, Yossi
Gilgun-Sherki
Lymphohistiocytosis Syndrome in a Patient
with Multiple Sclerosis on Fingolimod
Therapy. Pedro Abreu, Carla Peixoto,
Claúdia Carvalho, Lurdes Santos, António
Sarmento, Maria José Sá
A Comparison of the Safety/
Tolerability and Pharmacodynamics of
Acthar Gel and Methylprednisolone with
Regimens Utilized for the Treatment of
MS Exacerbations Stacie Bell, Jennifer
Vincent, Vakessa Hammock, Karen Welch,
Julia Chung, Mary Nyberg, Patrice Becker,
David Young
P2.208 Efficacy and Safety of
Fingolimod in Hispanic Patients: Pooled
Data from Three Phase 3 Clinical
Trials Angel Chinea, Regina Alvarenga,
Davorka Tomic, Allitia DiBernardo, Xiangyi
Meng, Kathleen Hawker
P2.209 Alemtuzumab Has Similar
Efficacy and Safety in Active RelapsingRemitting Multiple Sclerosis (RRMS)
Patients Who Were Treatment-Naive or
Who Relapsed on Prior Therapy David
Margolin, Bernd Kieseier, Jeffrey Palmer,
Tjalf Ziemssen
P2.210
Long-term Safety of
Fingolimod: Interim Evaluation of Data
from the LONGTERMS Trial Jeffrey Cohen,
Philipp Von Rosenstiel, Rebecca Gottschalk,
Linda Cappiello, Ying Zhang, Ludwig Kappos
P2.211
Delayed Third Degree
Atrioventricular Block with Pacemaker
Placement in a Multiple Sclerosis Patient
on Fingolimod Treatment Johann Sellner,
Barbara Holl, Peter Wipfler, Vaclav Chroust,
Georg Pilz, Maximilian Winhard, Andrea
Harrer, Katrin Oppermann, Eugen Trinka,
Jorg Kraus
P2.212
No Clinically Significant
Effect on Pulmonary Function Observed
with Siponimod (BAF312) Alone or in
Combination with Propranolol in Healthy
Adult Subjects Shibadas Biswal, Florine
Polus, Atul Pawar, Uday Kiran Veldandi, Eric
Legangneux
P2.213
Bullous Drug Eruption with
Dimethyl Fumarate Amir Khoiny, Noushin
Khoiny
P2.214
Early Tolerability of Dimethyl
Fumarate for Treatment of Multiple
Sclerosis Samuel Cohn, Robert Bermel,
Robert Fox, Jeffrey Cohen, Daniel Ontaneda
P2.215
Report an Unusual Thrombotic
Complication Two Months After Starting
Fingolimod Nancy Nealon, Nataliya
Ternopolska, Halina White
P2.216
Tolerability, Safety and
Efficacy of Fingolimod in Clinical
Pratice Jean-Claude Ongagna, Carole
Berthe, Nicolas Collongues, Fréderic Blanc,
Jerome De Seze
P2.217
GNbAC1, a Humanized
Monoclonal Antibody Against the Multiple
Sclerosis Associated Retrovirus Envelope
Protein, Is Well Tolerated in Patients
with Multiple Sclerosis. Tobias Derfuss,
Francois Curtin, Alois Lang, Herve Perron,
Ludwig Kappos, Patrice LaLive
Poster Session II
P2.218
The Autonomic Balance
Predicts Cardiac Effects After First Dose
of Fingolimod Silvia Rossi, Camilla
Rocchi, Valeria Studer, Caterina Motta,
Benedetta Lauretti, Giorgio Germani, Giulia
Macchiarulo, Gerolama Marfia, Diego
Centonze
P2.219
Electrocardiogram Monitoring
After the First Fingolimod Doses Begoña
Palazon, Ester Carreon, Rocio Hernandez
Clares, Judith Jimenez, Gema Salgado,
Encarnación Andreu, Jose Javier Martín,
Jose Meca
P2.220 Excessive Blood Pressure
Increase during Sustained Handgrip Testing
Predicts Bradycardia upon Fingolimod
Treatment Max Hilz, Ralf Linker, Tassanai
Intravooth, Sebastian Moeller, De-Hyung
Lee, Stefan Schwab, Julia Koehn
P2.221
Safety and Dosing of
Autologous Neural Progenitors Injected
Intrathecally in Multiple Sclerosis Patients:
Results of a Pilot Study Saud Sadiq,
Sydney Chirls, Daniel Koffler, Violaine Harris
P2.222 The Use of MRI to Monitor
the Safety of Anti-LINGO-1: Findings from
Phase I Studies in Healthy Volunteers and
Subjects with MS Nancy Richert, Isaac
Melamed, Hakop Gevorkyan, Lei Xu, Diego
Cadavid
P2.223 Long-term Safety of Rituximab
and Peripheral B-Cell Depletion in Multiple
Sclerosis and Other CNS Autoimmune
Disorders Anza Memon, Shitiz Sriwastava,
Fen Bao, Evanthia Bernitsas, Adil Javed,
Christina Caon, Omar Khan
P2.224 Reversible Cerebral
Vasoconstriction Syndrome and Fingolimod:
Culprit or Innocent Bystander Jason
Fleming, Matthew West
P2.225 Life Threatening Asthmatic
Crisis After 6 Months of Fingolimod
Treatment Matteo Caporro, Claudio Gobbi,
Chiara Zecca
P2.226
Tumefactive Multiple Sclerosis
in a Patient on Fingolimod YuanKai Lee,
Vijay Sawlani, Gordon Mazibrada
P2.227
Gastrointestinal Tolerability
of Delayed-Release Dimethyl Fumarate
in a Multicenter, Open-Label Study of
Patients with Relapsing Forms of Multiple
Sclerosis Edward Fox, Alberto Vasquez,
William Grainger, Tina Ma, Jie Li, Javier
Zambrano
P2.228 Transient Neurologic
Worsening After Initiation of Dimethyl
Fumarate Therapy in Progressive Multiple
Sclerosis Patients James Stark, Sydney
Chirls, Saud Sadiq
P2.229
Absence of a Relevant Effect
on Cardiac Repolarization in a QT/QTc
(TQT) Study of RPC1063, a Novel, Selective
S1P1 Receptor Agonist, in Healthy Adult
Volunteers Hartung Jeffrey, Allan Olson,
Robert Peach, Marcus Boehm, Boaz
Mendzelevski, Heather Smith, Christine Pan,
Gregg Timony, Sheila Gujrathi
P2.230 Dimethyl Fumarate Tolerability
and Treatment Adherence Amongst
Patients with Multiple Sclerosis Enrolled in
Specialty Pharmacy Services. Stephanie
Holliday, Alysha Robinson
P2.231
Severe Relapse in a Multiple
Sclerosis Patient Associated with
Ipilimumab Treatment for Metastatic
Melanoma Edward Gettings, Chris Hackett,
Thomas Scott
P2.232
Effects of Therapeutic and
Supratherapeutic Doses of Siponimod
(BAF312), a Selective S1P1,5 Receptor
Modulator, on Cardiac Repolarization:
Results of a Thorough QTc (TQT)
Study Kasra Shakeri-Nejad, Louise
Mooney, Vassilios Aslanis, Uday Kiran
Veldandi, Nicole Pezous, Eric Legangneux
P2.233
Teriflunomide: Non-Clinical
Evaluation Demonstrates no Effect
on Sperm DNA or Male Fertility Lynn
Davenport, Andreas Czich, Sandrine
Turpault
Pediatric MS and Other
Demyelinating Diseases
P2.234
The Symbol Digit Modalities
Test Is an Effective Cognitive Screen
in Pediatric Onset Multiple Sclerosis
(MS) Lauren Krupp, Leigh Charvet, Rebecca
Cleary, Kate Bartolotta, Livana Koznesoff,
Rachel Beekman, Anita Belman
P2.235
Downward Educational
Trajectory Is Seen in Children and Young
Adults After Diagnosis of Pediatric
MS Stephanie Grover, Austin Sye,
Berengere Aubert-Broche, Brenda Banwell,
Louis Collins, E. Ann Yeh
P2.236
Phenotypic and Functional
Analysis of Immune Cell Subsets in
Pediatric-onset Multiple Sclerosis (MS):
Towards Definition of Earliest Disease
Mechanisms Mukanthu Nyirenda, Rui Li,
Craig Moore, Ayal Rozenberg, Ayman Rezk,
Trina Johnson, Dessa Sadovnick, Douglas
Arnold, Ruth-Ann Marrie, Brenda Banwell,
Amit Bar-Or
P2.237
Results of a Population of
YOUTH MS; With More Than Ten Years of
Follow Up: Some Entity to Think About. C.
Curbelo, Maria Curbelo, A. Martínez, G.
Rojas, J. Steinberg, A. Carrá
P2.238 Fingolimod in Pediatric MS:
Design of a Double-blind Study Versus
Interferon β-1a IM Tanuja Chitnis, Brenda
Banwell, Jutta Gaertner, Goeril Karlsson,
Bingbing Li, Martin Bernhard Merschhemke,
Norman Putzki
P2.239
Evaluation of Thalamic
Fraction in Adults with Pediatric-Onset
MS Samira Farough, Antonia Ceccarelli,
Svetlana Egorova, Tanuja Chitnis
P2.240 Clinical and MRI Phenotype
of Children with MOG antibodies Cristina
Fernandez Carbonell, David Vargas
Lowy, Mussalam Alexander, Brian Healy,
Katherine McLaughlin, Kai Wucherpfenning,
Tanuja Chitnis
P2.241
Myelin Oligodendrocyte
Glycoprotein (MOG) Auto-antibodies
in Children Predicts a Non-MS Course
of Acquired Demyelination Syndrome
(ADS). Yael Hacohen, Michael Absoud,
Kumaran Deiva, Marc Tardieu, Evangeline
Wassmer, Ming Lim, Angela Vincent, Patrick
Waters
P2.249
P2.242
P2.250 Fingolimod to Treat Severe
Rate of Agreement for
Manual and Automated Techniques for
Determination of New T2 Lesions in
Children with Multiple Sclerosis and Acute
Demyelination Leonard Verhey, Colm
Elliott, Helen Branson, Cristina Philpott,
Manohar Shroff, Tal Arbel, Brenda Banwell,
Douglas Arnold
P2.243 Radiologically Isolated
Syndrome in Children: Report of 5 Children
with Long-Term Follow-Up Mefkure
Eraksoy, Zuhal Yapici, Pinar Tekturk, Murat
Kurtuncu, Hifzi Ozcan
Disease: Progressive Multifocal
Leukoencephalopathy Risk
P2.244 Low Body Weight
as a Potential Surrogate Risk
Factor for Progressive Multifocal
Leukoencephalopathy John Foley, Mark
Gudesblatt, Myassar Zarif, Ellen Lathi
P2.245 Lipid-Specific IgM Bands
Contribute to Stratify PML Risk in MS
Patients Treated with Natalizumab Luisa
Villar, Lucienne Costa-Frossard, Thomas
Masterman, Oscar Fernandez, Xavier
Montalban, Bonaventura Casanova,
Guillermo Izquierdo, Francisco Coret Ferrer,
Hayrettin Tumani, Albert Saiz, Rafael
Arroyo, Katharina Fink, Laura Leyva, Carmen
Espejo, Roberto Alvarez-Lafuente, Javier
Olascoaga, Javier Olaskoaga Urtaza,
Agustin Oterino, Sara Llufriu Duran, Florian
Lauda, Clara De Andres, Juan Antonio
Garcia-Merino, Ricardo Fernandez-Bolaños,
Lamberto Landete Pascual, Eduardo Aguera
Morales, Santiago Diaz Nicolas, Manuel
Menendez, Laura Navarro, Domingo Perez,
Lluis Ramio, Fernando Sanchez Lopez,
Pedro Serrano Castro, Alberto Tuñon, Jose
Alvarez-Cermeño
P2.246
Transient Punctuate
Gadolinium-enhancing Lesions Preceding
Natalizumab-associated Progressive
Multifocal Leukoencephalopathy
(PML) Giovanni Castelnovo, Eric Thouvenot,
Dimitri Renard, Guillaume Taieb
P2.247
Modeling PML Risk in JCV
Sero-Negative Natalizumab-Treated MS
Patients Robert Carruthers, Tanuja Chitnis,
Brian Healy
P2.248 Association Between
Infratentorial Onset of Progressive
Multifocal Leukoencephalopathy (PML)
and Long-Term Exposure to Natalizumab
(NAT) Robert Hoepner, Jonas Ahlbrecht,
Ruth Schneider, Stefanie Dahlhaus, Ortwin
Adams, Andrew Chan, Martin Stangel, Ralf
Gold
Excellent Outcome in
Natalizumab-Associated PML Due to Early
Diagnosis and Optimal Treatment Georg
Pilz, Andrea Harrer, Peter Wipfler, Katrin
Oppermann, Johann Sellner, Shahrzad
Afazel, Elisabeth Haschke-Becher, Theo
Rispens, Desiree van der Kleij, Eugen Trinka,
Jorg Kraus
Multiple Sclerosis After Natalizumabassociated Progressive Multifocal
Leukoencephalopathy: A Valid
Option? Elisabeth Maillart, Céline Louapre,
Catherine Lubetzki, Caroline Papeix
P2.251
Multicenter Retrospective
Study of extended Dosing of Natalizumab
in Multiple Sclerosis: A Strategy for
Mitigating Risk of Progressive Multifocal
Leukoencephalopathy While Maintaining
Efficacy? Joseph Herbert, Lana Zhovtis
Ryerson, Carmelo Tornatore, John
Foley, Bianca Weinstock-Guttman, Ilya
Kister, Krupa Pandey, Gina Remington,
Teresa Frohman, Eugene Major, Sara
Qureshi, Shin Beh, Darin Okuda, Puspa
Utomo, Channa Kolb, David Hojnacki, Elliot
Frohman
Tuesday
April 29
P2.252
Immune Modulation During
Natalizumab Treatment of Multiple
Sclerosis. Jeffrey Greenstein
P2.253
Dynamics of the Anti-JCvirus Antibody Index in an Austrian MS
Cohort Peter Wipfler, Andrea Harrer, Georg
Pilz, Johann Sellner, Michael Guger, Gerhard
Ransmayr, Eugen Trinka, Jörg Kraus
Disease: Neuro-Ophthalmology
and Optical Coherence
Tomography
P2.254 Optical Coherence
Tomography Correlates of Clinical and
Imaging Outcomes in Early Multiple
Sclerosis Amir Hadi Maghzi, Nisha
Revirajan, Laura Julian, Rebecca Spain,
Ellen Mowry, Shuang Liu, Jacqueline
Marcus, Chengshi Jin, Ari Green, Charles
McCulloch, Daniel Pelletier, Emmanuelle
Waubant
P2.255 OCT, Visual Function and
MRI Measures in Acute Optic Neuritis:
Baseline Data from a Clinical Trial Rhian
Raftopoulos, Simon Hickman, Ahmed Toosy,
Claudia Wheeler-Kingshott, Daniel Altmann,
Shahrukh Mallik, David Paling, Marios
Yiannakas, Klaus Schmierer, Basil Sharrack,
Rose Sheridan, Gavin Giovannoni, David
Miller, Raju Kapoor
P2.256
Cross-platform Comparison
of Retinal Neuronal Layers in Multiple
Sclerosis Utilizing a Novel Open-Source
Optical Coherence Tomography Automated
Segmentation Algorithm Pavan Bhargava,
Andrew Lang, Omar Al-Louzi, Aaron Carass,
Shiv Saidha, Jerry Prince, Peter Calabresi
P2.257
Diffusion Tensor Imaging
Correlates of Retinal Nerve Fiber
Layer Thinning in Early Multiple
Sclerosis Nataliya Ternopolska, Michael
Dayan, George Parlitsis, Nancy Nealon, Jai
Perumal, Timothy Vartanian, Szilard Kiss,
Susan Gauthier
61
Tuesday, April 29
P2.258 Optic Nerve Head Blood
Flow Assessment by Optical Coherence
Tomography Angiography May Be More
Sensitive Than Retinal Nerve Fiber Layer
Thickness in Detecting Multiple SclerosisRelated Optic Nerve Dysfunction Rebecca
Spain, Xiaogang Wang, Yali Jia, Ou Tan,
Dennis Bourdette, David Huang
P2.259
In Vivo Assessment Of Retinal
Neuronal Layers in Multiple Sclerosis
Patients Muhammad Taimur Malik, Brian
Healy, Bonnie Glanz, Howard Weiner,
Tanuja Chitnis
P2.260
Factor Affecting Recovery
from Acute Optic Neuritis in Multiple
Sclerosis Patients Muhammad Taimur
Malik, Brian Healy, Leslie Benson, Pia
Kivisakk, Alexander Musallam, Howard
Weiner, Tanuja Chitnis
P2.261
Retinal Structural Injury
Is Worse in African-Americans
than Caucasians with Multiple
Sclerosis Jessica Chorostecki-Vigrass,
Ginny Bao, Fen Bao, Shah Aashka, Carla
Santiago Martinez, Alexandros Tselis,
Christina Caon, Evanthia Bernitsas, Navid
Seraji-Bozorgzad, Elliot Frohman, Omar Khan
P2.262
Axonal Protective Role of
LINGO-1 Blockade in the Visual System:
Results from a Study in Rats and Design
of a Phase 2 Clinical Trial for BIIB033, an
Anti-LINGO-1 Monoclonal Antibody, in
Subjects with a First Episode of Acute
Optic Neuritis Diego Cadavid, Laura Balcer,
Steven Galetta, Bing Hu, Kwok-Fai So, Blake
Pepinsky, Sha Mi
P2.263
Color Vision Impairment
Is Associated with Disease Severity
in Multiple Sclerosis Elena MartínezLapiscina, Santiago Ortiz-Pérez, Elena Fraga,
Eloy Martínez-Heras, Iñigo Gabilondo, Sara
Llufriu, Santiago Bullich, Marc FiguerasRoca, Albert Saiz, Bernardo SanchezDalmau, Pablo Villoslada
P2.264
Quantification of Macular
Blood Flow Volume and Microvascular
Network in Multiple Sclerosis (MS) Hong
Jiang, Delia Cabrera DeBuc, Silvia Delgado,
Aizhu Tao, Byron Lam, Jianhua Wang
Disease: Neuromyelitis Optica
and Neuromyelitis Optica
Spectrum Disorders
P2.265
Estimated Incidence and
Prevalence of Neuromyelitis Optica in
the England from 1998 to 2011 Cris
Constantinescu, I-Jun Chou, Chang-Fu Kuo,
Radu Tanasescu, William Whitehouse
P2.266
Aquaporin-4 Antibodypositive Cases Beyond Current
Diagnostic Criteria for NMO spectrum
Disorders Douglas Sato, Ichiro Nakashima,
Toshiyuki Takahashi, Tatsuro Misu, Patrick
Waters, Hiroshi Kuroda, Shuhei Nishiyama,
Chihiro Suzuki, Yoshiki Takai, Kazuo Fujihara,
Yasuto Itoyama, Masashi Aoki
P2.268
Anti-Aquaporin-4 Antibodies
Without Optic Neuritis or Transverse
Myelitis Robert Joshua, Bonnie Keung,
Meena Gujrati, Michael Zagardo, Jorge
Kattah
P2.269
Neuromyelitis Optica with
Severe Behavioral Dysregulation: A Case
Report Teri Schreiner, Cassie Karlsson,
Harrison Levine, Julia Barnes, John Binder,
Robin Gabriels, Carol Beresford
P2.270
Hydrocephalus in
Neuromyelitis Optica Stacey Clardy,
Claudia Lucchinetti, Karl Krecke, Vanda
Lennon, Orna O’Toole, Brian Weinshenker,
Clara Boyd, Stephen Krieger, Corey
McGraw, Yong Guo, Sean Pittock
P2.271
Presence of HLA DR10 in
Mexican Patients with Neuromyelitis
Optica (Devic’s Disease) Veronica Rivas,
Jose de Jesus Flores, Teresa Corona
Vazquez, Julio Granados
P2.272
Distinct Acute Spinal
Cord Syndrome Between Aquaporin4IGG Seropositive and Seronegative
Longitudinally Extensive Transverse
Myelitis Samira Apostolos-Pereira,
Douglas Sato, Frederico Jorge, Paula Melo,
Paulo Marchiori, Dagoberto Callegaro
7:30 a.m.–11:00 a.m.
P2.280 The Course Of Ocular
Myasthenia Gravis: A Retrospective Study
Of 162 Patients Joao Lemos, Lina Nagia,
Khawla Abusamra, Brooke Johnson, Wayne
Cornblath, Jonathan Trobe, Christopher
Glisson, Sunita Yedavally, David Kaufman,
Eric Eggenberger
P2.281
Role of Mitochondrial
Reactive Oxygen Species in Cell Death
Caused by Connexin 26 Mutations
Associated with Keratitis-ichthyosisDeafness Syndrome Xueshui Guo, Sabrina
Yum
P2.282 Modified Brainstem Auditory
Evoked Responses Are Associated
with Elevated Intracranial Pressure in
Subjects with Idiopathic Intracranial
Hypertension Heather Moss, John Fino,
Heeren Patel, James Stone
P2.283 Transcranial Direct Current
Stimulation for the Treatment of Chronic
Tinnitus: A Randomized, Double-Blind,
Sham Controlled Study David Benninger,
Natassja Pal, Marianne Stephan, Francois
Herrmann, Raphael Maire
P2.284 Evolution of Macular Findings
Is Optic Neuritis Incidence
Rising? Evidence from an Epidemiological
Study in Barcelona, Spain 20082012 Elena Martínez-Lapiscina, Elena
Fraga, Xavier Pastor, Mónica Gómez, Artur
Conesa, Raimundo Lozano-Rubí, Bernardo
Sanchez-Dalmau, Alvaro Alonso, Pablo
Villoslada
P2.293
Optical Coherence
Tomography Visualization of Optic Nerve
Head Structure Detects Acute Changes in
the Intracranial Pressure Aashish Anand,
Anastas Pass, Eusebia Calvillo, Rosa Tang,
Christian Cajavilca, Mian Urfy, Jose Suarez,
Chethan Rao, Eric Bershad
P2.294
Comparison Rate Between
Headshaking Maneuver And Vibration
Maneuver in Ageotrophic Horizontal
BPPV Hyoung Suk Han, Dae Soo Shin
P2.295
Endovascular Treatment of
Cerebral Venous Sinus Thrombosis with
Combination of Rheolytic Thrombectomy,
Angioplasty and tPA Thrombolysis
Reversed Severely Elevated ICP Syndrome:
A Case Study. Takamasa Higashimori,
Joshua Seinfeld, Victoria Pelak
on Optical Coherence Tomography (OCT)
in Papilledema Farah Villanueva, Fawzi
Abukhalil, Mark Morrow
P2.296
P2.285 Measuring Transmission Delay
P2.297
P2.274
P2.286 Retinal Ganglion Cell Layer
P2.298
Neuro-ophthalmology/
Neuro-otology I
P2.287
P2.299
P2.273
Myelin Oligodendrocyte
Glycoprotein (MOG) Associated
Neuromylitis Optica Sprectum Disorder
(NMOSD) Presenting with Isolated Absent
F Wave Shahpar Nahrir, Naim Kajtazi,
Jameelah Saeedi
Differential Diagnosis of
Transverse Myelitis Maureen Mealy,
Daniel Becker, Scott Newsome, John
Ratchford, Michael Levy, Carlos PardoVillamizar
P2.275
The Characteristics of Square
Wave Jerks in Normal Subjects Michael
Rosenberg, Anitha Nimma, Gita Pisupati,
Neha Rane
P2.276
Temporal Aspects
of Visual Perception Following
Demyelination Gabriel Shear-yashuv, Noa
Raz, Shlomo Dotan, Panayiota Petrou, Adi
Vaknin-Dembinsky, Netta Levin
P2.277
Lamotrigine as an Effective
Pharmacotherapy for Ménière’s Disease: A
Case Series Lixin Zhang, Merika Wilson
P2.278
Diagnostic Algorithm for
Approaching Patients with Suspected Giant
Cell Arteritis M. Tariq Bhatti, Mays El-Dairi,
Alan Proia, Thomas Cummings
P2.279
High Resolution Optical
Coherence Tomography of the Retina
Demonstrates Selective Changes in
Individual Retinal Layers in Parkinson’s
Disease Irene Gottlob, Anastasia Pilat,
Rebecca McLean, Gail Maconachie, Viral
Sheth, Yusuf Rajabally, Frank Proudlock
Due to Demyelination in INO Alessandro
Serra, Margaret Skelly, Manuela Matta,
Jonatan Jacobs, Mark Walker, Jeffrey
Cohen, R. John Leigh
Thinning Within One Month of Presentation
for Non-arteritic Anterior Ischemic Optic
Neuropathy and Optic Neuritis Mark
Kupersmith, Mona Garvin, Jui-Wang Wang,
Mary Durbin, Randly Kardon
Incidence of Visual
Defects in Epileptic Children Treated
with Vigabatrin Mohammadkazem
Bakhshandeh Bali
P2.288 Clinical Characteristics of
Recurrent Benign Paroxysmal Positional
Vertigo Seung-Han Lee, Jong-Kyung Lee,
Yun-Ju Choi, Jae-Myung Kim, Byung-Kun
Kim
P2.289
Spectral Domain Optical
Coherence Tomography Findings in
Myotonic Dystrophy. Maria Laura Ester
Bianchi, Edoardo Abed, Guglielmo D’Amico,
Marcella Masciullo, Gabriella Silvestri
P2.290
Evaluations of Visual Pathways in Multiple
Sclerosis Patients with Acute and Chronic
Optic Neuritis Ahmet Onur Keskin, Fethi
Idiman, Alatas Ozkan, Emel Ada, Ali Osman
Saatci, Egemen Idiman
P2.291
Optical Coherence Tomographic (OCT)
and Perimetric Findings in Patients with
Papilledema Mark Morrow
P2.267
Pain at Onset of Neuromyelitis
Optica Elizabeth Shuster, Reema Kola, Tori
Hysko, Melanie Box
62
P2.292
Abnormal Electroretinogram
in Neuromyelitis Optica Spectrum
Disorder Aimee Szewka, Anjali Tannan
Unusual Presentation of an
Isolated III Cranial Nerve Palsy from Brain
Metastasis Saiqa Choudhry, Reuben
Valenzuela, Hrachya Nersesyan, Jorge
Kattah
Analysis of Anatomical and
Functional Outcome in Three Months
Follow up After a Single Intravitreal
Dexamathazone (Ozurdex) Injection
in Retinal Vein Occlusion Avathvadi
Srinivasan
Utility of Optical Coherence
Tomography Measurements as a Biomarker
for Systemic Lupus Erythematosus
with or Without Neuropsychiatric
Symptoms Gabrielle Liu, Jacqueline
Bernard
P2.300 Videoculography (VOG)
Findings with 4 Aminopyridine in Downbeat
Ny (DBN): Description of 3 Cases Ana
Bisonni, Guillermo Videla, Edgardo Cristiano
P2.301
Dynamic Formation of Macular
Microcysts Independent of Vitreous
Traction Changes Timm Oberwahrenbrock,
Ella Kadas, Wolf Lagrèze, Friedemann Paul,
Alexander Brandt
P2.302
Oculomotor Dysfunction Due
to Idiopathic Intracranial Hypertension and
Thiamine Deficiency Channaiah SrikanthMysore, Blanca Marky
CNS Infectious Disease:
Miscellaneous
P2.303 Predictive Factors of
Central Nervous Infection: Prospective
Evaluation of 124 Cases with Suspicion of
Meningitis. Irene Trevino, Maria Alejandra
Gonzalez Duarte, Alberto Avila-Funes
P2.304 A Retrospective Study
of Presenting Clinical and Laboratory
Variables in HIV Negative Tuberculous
Meningitis Patients Brian Chisulo
Poster Session II
P2.305 NELL-2 as a Biomarker in
Diagnosing Tuberculous Meningitis: An
iTRAQ Based Quantitative Proteomic
Analysis of Cerebrospinal Fluid Zesong
Yang
P2.306Next-Generation
Sequencing for Pathogen Discovery in
Meningoencephalitis Michael Wilson,
Erik Samayoa, Samia Naccache, Sneha
Somasekar, Guixia Yu, Joseph DeRisi,
Charles Chiu
P2.307
Varicella Zoster Virus Lumbar
Radiculitis: A Case Report Jazba Soomro,
Hesham Allam, Aninda Acharya
P2.308 First Case of Familial
Creutzfeldt-Jakob Disease Associated
with E200K Mutation in Peru: A Case
Report Jonathan Eskenazi
P2.309
Evoked Potentials in
Sarcoidosis Patient Renata Hebel, Zyta
Banecka Majkutewicz
P2.310
Causes of Encephalitis in
Buenos Aires: A Retrospective Cohort
Study Wilken Miguel, Mauricio Farez,
Ameghino Lucía, Julieta Arena, Angel
Cammarota, Martin Alejandro Nogues
Bacterial Illnesses of CNS
and West Nile Virus
P2.311
MRI Ventral Nerve Root
Enhancement In 3 Patients Presenting with
Lower Extremity Weakness Secondary
to West Nile Virus Chirag Patel, Shrikant
Mishra, Bhavesh Trikamji, Brian Zipser
P2.312
The N-methyl-D-aspartate
Receptor Encephalitis Mimicking Bacterial
Meningitis Jeremy Ragland, Hannah
Goldstein, Barry Czeisler, Jan Claassen,
Stephan Mayer, Sachin Agarwal
P2.313
Diagnostic Dilemma
of Encephalomyelitis Due to Lyme
Neuroborreliosis Tiffani Stroup, Sheeraz
Daudi, Heeren Patel
P2.314
Disseminated Cerebritis with
Myelitis by Propionibacterium Acnes in
Healthy Elderly Female Jinsan Lee, Sung
Hyuk Heo, Dae-Il Chang, Ji Hoon Lee, Seon
Hee Bu
P2.315Rhombencephalitis
Due to Listeria Monocytogens in
Immunocompetent Patient Ruchir Shah,
Umang Shah, Thomas Bosley
P2.316Syphilitic
Polyradiculoneuropathy in an
Immunocompetent patient Safaa Zahlane,
Nissrine Louhab, Najib Kissani
P2.317
Widespread Leptomeningeal
Involvement in Borreliosis Carolina Maciel,
Erwin Wang, Prasad Shirvalkar, Alexander
Merkler, Joseph Safdieh
P2.318
Arachnoiditis Associated
with an Unusual Pathogen: Aerococcus
Urinae Kara Steijlen, Shawn Vasoo, Berbari
Elie, Carrie Robertson
P2.319
PATTERN of Nerve Conduction
Study IN leprosy neuropathy Marcia
Jardim, Robson Vital, Salim Balassiano,
Mariana Hacker, Ximena Illarramendi,
Euzenir Sarno
P2.320
A Case Report of CNS
Whipple’s Disease Daniel Smith
Fungi, Parasites, and
Other Pathogens
P2.321
A Young Woman
with Seizures: A Case of
Neuroschistosomiasis Eli Zimmerman,
Matthew Rose, Liangge Hsu, Alexandra
Golby, Rebecca Folkerth, Sandro Santagata,
Danny Milner, Shakti Ramkissoon
P2.322
A Rare Case of
Isolated Intramedullary Cervical
Spine Neurocysticercosis That Was
Initially Misdiagnosed and Treated
as Demyelinating Disease—a Case
Report. Crystal Dixon, Yazan Suradi,
Rossitza Chichkova
P2.323
Meningitis Due to
Cryptococcus gattii: First Reported Case
of an Emerging Infectious Disease in an
Immunocompetent Patient Residing in the
Northeast United States Katie Warren,
Colum Amory, Ellis Tobin
P2.324
The Rhino Without Its
Sugar Jasmine Kahlon, Harneet Gahley,
Niket Sonpal, Robert Graham
P2.325
Necrotizing Cryptococcal
Fasciitis of the Lower Extremity:
Report of a Case Following Orthotopic
Cardiac Transplantation for Systemic
Amyloidosis Matthew Cykowski
P2.326
CSF and CSF:Serum Ratios
of (1,3)-beta-D-glucan Are Lower in
Non-Fungal CNS Pathology than Proven
or Probable Fungal CNS Disease Jennifer
Lyons, Kiran Thakur, Sean Zhang
P2.327
Chronic Meningitis
by Histoplasma Capsulatum in
Immunocompetent Patients: a Diagnostic
Challenge Bruna Silva, Alberto Martinez,
Marcondes França Jr., Anamarli Nucci,
Augusto Penalva-de-Oliveira
P2.328
A Case of Ciguatera Poisoning
in a New York City Hospital: Learning
Points for Hospitals Serving Diverse
Immigrant Populations. Neville Jadeja,
Ali Haider, Reena Gottesman, Mark
Kozicky, Abhinav Nafday, Kyle Kelson, Nana
Jinjolava
P2.336
P2.329
P2.337
Acute Necrotizing
Encephalopathy Caused by Influenza A
Leading to a Rapidly Progressive Amnestic
Syndrome and Coma Brett McCray,
Deborah Forst, Galen Henderson
Child Neurology and
Developmental Neurology II
P2.330 Trends in Outcome and
Hospitalization Charges of Pediatric
Patients Admitted with Guillain Barre
Syndrome Treated with Plasmapheresis
in the United States. Data from
Kids’ Inpatient Database (KID) 19972009 Weizhen Wang, Wenzhuan He, Nizar
Souayah
P2.331
Trends in Outcome and
Hospitalization Charges for Pediatric
Patients Admitted with Guillain Barre
Syndrome Treated with Intravenous
Immunoglobulin in the United States. Data
from Kids’ Inpatient Database (KID), 19972009 Kathleen Sullivan, Ankit Pahwa, Nizar
Souayah
P2.332
Hospitalization Charges of Pediatric
Patients Admitted with Botulism in the
United States: A Comparative Analysis
Between Kids’ Inpatient Database
(KID) and National Inpatient Sample
(NIS) Mohammad El-Ghanem, Ankit
Pahwa, Nizar Souayah
P2.333
The Six-Minute Walk Test
Captures Weakness and Gait Abnormalities
in Glut 1 Deficiency Syndrome Michelle
Blumenschine, Jacqueline Montes, Ashwini
Rao, Aliza Alter, Kristin Engelstad, Darryl De
Vivo
Regional Hippocampal
Involvement in Paediatric Multiple
Sclerosis: A Radial Mapping MR
Study Maria Elisa Morelli, Maria Rocca,
Elisabetta Pagani, Lucia Moiola, Angelo
Ghezzi, Andrea Falini, Giancarlo Comi,
Massimo Filippi
MHCI Immune Molecules
Are Required for Developmental Synapse
Elimination of the Neuromuscular
Junction Mazell Tetruashvily, Lisa
Boulanger
P2.338 NextGen Sequencing as a
Tool to Assist in Diagnosis and Expedite
Treatment: RAPSN Congenital Myasthenic
Syndrome Alvin Das, Dimitri Agamanolis,
Bruce Cohen
P2.339
A Neonatal Case of
Congenital Myasthenic Syndrome with
COLQ Mutation Matthew Imperioli,
Cristian Ionita, Gyula Acsadi, Andrew Engel
Medical Student Essay
Award Recipients
Tuesday
April 29
P2.340 Voice Discrimination
and Recognition in Patients with
Prosopagnosic Complaints Ran (Richard) Liu
P2.341
HAT Score Outperforms
7 other Hemorrhagic Transformation
Scores David Asuzu
P2.342
Subspecialization in
Neurology: Historical Perspectives on
Current Challenges Trent Hodgson
P2.343 Probing the Interaction
of the Ipsilateral Posterior Parietal
Cortex with the Premotor Cortex
Using a Novel Transcranial Magnetic
Stimulation Technique Jessica Shields
P2.334
Longest Living Reported Case
of Congenital Myopathy with Excess of
Muscle Spindles Julia Henry, Yael ShilohMalawsky, Stevie Rowe, Zheng Fan
P2.335
Muscular Distrophy, Mental
Retardation and Deletion 2q37: A Case
Report Cristiane Rocha, Carlos Andrade,
Isabel Pinheiro, Alzira Carvalho
Membership Pays!
Did you know? AAN members save 50% or more on Annual Meeting Registration and program fees. Make sure your membership is
up-to-date. Join or renew your AAN membership at AAN.com/membership.
63
Tuesday, April 29
Current as of 2/13/2014
Presidential Plenary Session
9:00 a.m.–12:00 p.m.
F eatures the AAN’s premier lecture awards for clinically relevant research and a presentation
by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2014.
Moderator: Lisa M. DeAngelis, MD, FAAN
Chair, Science Committee
Presidential Lecture:
James L. Bernat, MD, FAAN
Dartmouth Hitchcock Medical Center, Lebanon, NH
Challenges to Ethics and Professionalism Facing the Contemporary Neurologist
George C. Cotzias Lecture:
Endowed by Roche Pharmaceuticals.
University of Utah, Salt Lake City, UT
Degenerative Ataxias: From Genes to Therapies
Sidney Carter Award in Child Neurology Lecture:
Endowed by an anonymous donor.
Darryl C. De Vivo, MD, FAAN
Columbia University Medical Center, New York, NY
Rare Diseases and Neurological Phenotypes
Robert Wartenberg Lecture:
David M. Holtzman, MD, FAAN
Washington University School of Medicine, St. Louis, MO
Alzheimer’s Disease in 2014: Mapping a Road Forward
For Full Abstracts and Bios for Plenary Speakers
Visit AAN.com/view/SearchAM
64
Section Topic Controversies
PFO: Aggressive Treatment or Just Aspirin
1:00 p.m.–2:30 p.m.
1:00 p.m.–1:05 p.m.Introduction Antonio Culebras, MD, FAAN, FAHA
1:05 p.m.–1:30 pm.
PFO: Aggressive Treatment John D. Carroll, MD
1:30 p.m.–1:55 p.m.
PFO: Just Aspirin Steven R. Messé, MD, FAAN, FAHA
1:55 p.m.–2:05 p.m.Rebuttal John D. Carroll, MD
2:05 p.m.–2:15 p.m.Rebuttal Steven R. Messé, MD, FAAN, FAHA
Open Discussion/Conclusion Antonio Culebras, MD,
FAAN, FAHA
Tuesday
April 29
2:15 p.m.–2:30 p.m.
Obtaining Your CME and Evaluations
To receive CME for education programs or scientific sessions, evaluations must be completed online or via the Annual Meeting mobile app.
Wireless internet hotspots will be available at the convention center. Details will be provided prior to the meeting.
Education Program Syllabi
Full text syllabi and program slides will be available electronically only—online or via the Annual Meeting mobile app. All registered
attendees will receive an email notification once syllabi are available.
65
Tuesday, April 29
S4 MS and CNS
Inflammatory Disease:
Clinical Trials
1:00 p.m.
S4.001
Rationale for Advancing Laquinimod
for Progressive MS: Evidence
from Large Clinical Trials in
RRMS Giancarlo Comi, Maria Pia
Sormani, Gavin Giovannoni, David
Ladkani, Nissim Sasson, Talia
Gorfine, Volker Knappertz
1:15 p.m.
S4.002
Safety and Tolerability of DelayedRelease Dimethyl Fumarate
Administered as Add-On Therapy
to Beta Interferons or Glatiramer
Acetate in Relapsing-Remitting
Multiple Sclerosis (RRMS)
Patients Vissia Viglietta, Timothy
Vollmer, Ray Zhang, Mark Novas,
Sarah Sheikh, Robert Fox
1:30 p.m.
S4.003
Peginterferon Beta-1a May Improve
Recovery Following Relapses: Data
from the Pivotal Phase 3 ADVANCE
Study in Patients with RelapsingRemitting Multiple Sclerosis Bernd
Kieseier, Thomas Scott, Scott
Newsome, Sarah Sheikh, Serena
Hung, Xiaojun You, Bjorn Sperling
1:45 p.m.
S4.004
Effect of Fingolimod on Macular
Volume and Retinal Nerve Fiber Layer
Thickness: A One-year Longitudinal
Study Pavle Repovic, Dong Won
Lee, Steven Hamilton, Eugene May,
James Bowen
2:00 p.m.
S4.005
Interim Analysis of 2-year Clinical
Efficacy and Safety of Peginterferon
Beta-1a in Patients with RelapsingRemitting Multiple Sclerosis: Data
from the Pivotal Phase 3 ADVANCE
Study Aaron Deykin, Douglas
Arnold, Serena Hung, Sarah Sheikh,
Ali Seddighzadeh, Ying Zhu, Shifang
Liu, Bernd Kieseier
2:15 p.m.
S4.006
Natalizumab Treatment
Improves Walking Speed in MS
Patients: A Post Hoc Analysis of
AFFIRM Richard Rudick, Michael
Hutchinson, Eva Havrdova, Xiaojun
You, Diego Cadavid, Shibeshih
Belachew
2:30 p.m.
S4.007
Peginterferon Beta-1a Significantly
Increases the Proportion of Patients
with Freedom from Measured
Disease Activity in RelapsingRemitting Multiple Sclerosis:
Findings from the ADVANCE
Study Douglas Arnold, Bernd
Kieseier, Sarah Sheikh, Aaron
Deykin, Ying Zhu, Xiaojun You, Bjorn
Sperling, Serena Hung
66
S5 Cerebrovascular Disease
and Interventional Neurology:
Pre-hospital, Telemedicine,
and Related Topics
1:00 p.m.
S5.001
The REliability of MObile
TEchnologies for Acute Stroke
Neuroimaging Data Interpretation:
The REMOTE Study Clotilde
Balucani, Sundeep Mangla, Adrian
Marchidann, Michael Szarek,
Wissa Usama, Yitzchok Lederman,
Charles Ramkishun, Lin Wang, Ethan
Brandler, Pia Chatterjee, Susan Law,
Craig Linden, Gautam Mirchandani,
Diana Rojas-Soto, Daniel
Rosenbaum, Hyman Shwarzberg,
Richard Sinert, Mark Silverberg,
Helen Valsamis, Volodymyr
Vulkanov, Shahriar Zehtabchi, David
Aharonoff, James Gugger, Mohit
Sharma, Andrew Truong, Steven
Levine
1:15 p.m.
S5.002
Mobile Telestroke During Ambulance
Transport Is Feasible in a Rural
EMS Setting—Pilot Data from
the Improving Treatment with
Rapid Evaluation of Acute Stroke
via Mobile Telemedicine (iTREAT)
Study Sherita Chapman, Jason
Lippman, Brian Gunnell, Timothy
McMurry, Prachi Mehndiratta,
Donna Burns, Debra Perina, David
Cattell-Gordon, Nina Solenski,
Bradford Worrall, Andrew
Southerland
1:30 p.m.
S5.003
Tablet Computers Address
Limitations of Telestroke
Systems Steven Rudolph, Susan
Law, Holly Morhaim, Jill Slater
1:45 p.m.
S5.004
Enrolling Patients in Ambulance
Stroke Trials Using Mobile
Televideo Consent: Preliminary
Experience. Amrit Ahluwalia,
Sidney Starkman, Nerses Sanossian,
David Liebeskind, Latisha Ali, Lucas
Restrepo, May Kim-Tenser, Miguel
Valdes-Sueiras, Marc Eckstein,
Franklin Pratt, Samuel Stratton,
Robin Conwit, Jeffrey Saver
2:00 p.m.
S5.005
Strategy to a 5-Minute Door to
Needle Time Sarah Parker, Teresa
Swanson-Devlin, Jan Jahnel,
Clayton McNeil, Arun Talkad, Judith
Beck, Deepak Nair, David Wang
2:15 p.m.
S5.006
Reducing Time to Treatment—The
Role of Stroke Neurologist as First
Responder Shelly Ozark, Perette
Sabatino, Christine Holmstedt,
Tanya Turan
2:30 p.m.
S5.007
Novel Graphical Comparative
Analyses of 7 Prehospital Stroke
Scales Mohit Sharma, Richard
Sinert, Steven Levine, Ethan
Brandler
1:00 p.m.–2:45 p.m.
S6 Neuromuscular
Disease: Gene Therapy
S7 Parkinson's Disease:
Preclinical and Clinical
Therapeutics
1:00 p.m.
S6.001
Safety Profile and Pharmacokinetic
Properties of Eteplirsen in the
Treatment of Boys with Duchenne
Muscular Dystrophy Jihad Saoud,
Jerry Mendell, Louise RodinoKlapac, Zarife Sahenk, Kandice
Roush, Loren Bird, Linda Lowes,
Lindsay Alfano, Ana Maria Gomez
Ramirez, Sarah Lewis, Vinod Malik,
Kim Shontz, Christopher Shilling,
Peter Sazani, Edward Kaye
1:00 p.m.
S7.001
A Large-Scale Non-Human Primate
Study of the Safety and Efficacy
of Neural Stem Cells Derived
from Human Pluripotent Stem
Cells Ruslan Semechkin, Rodolfo
Gonzalez, Ibon Garitaonandia, Alina
Ostrowska, Tatiana Abramihina,
Gerald Wambua, Alexander Noskov,
Andrew Crain, Maxim Poustovoitov,
Francesca Boscolo, Louise Laurent,
Evan Snyder, Eugene Redmond
1:15 p.m.
S6.002
Results at 96 Weeks of a Phase IIb
Extension Study of the Exon-Skipping
Drug Eteplirsen in Patients with
Duchenne Muscular Dystrophy
(DMD) Edward Kaye, Jerry
Mendell, Louise Rodino-Klapac,
Zarife Sahenk, Kandice Roush, Loren
Bird, Linda Lowes, Lindsay Alfano,
Ana Maria Gomez Ramirez, Sarah
Lewis, Vinod Malik, Kim Shontz,
Christopher Shilling, Peter Sazani,
Jihad Saoud
1:15 p.m.
S7.002
TIGAR Inhibition Rescues
Dopaminergic Neurons in Common
Forms of Early Onset Parkinson’s’
Disease Oliver Bandmann, Marcus
Keatinge, Marc DaCosta, Heather
Mortiboys, Laura Flinn
1:30 p.m.
S6.003
Results of a Phase 2 Open-Label
Study of ISIS-SMNRx in Patients
with Infantile (Type 1) Spinal
Muscular Atrophy Richard Finkel,
John Day, Claudia Chiriboga,
Jiri Vajsar, Dawn Cook, Karolina
Watson, Shirley Paulose, Rosangel
Cruz, Jacqueline Montes, Darryl
De Vivo, Mason Yamashita, Dawn
McGuire, Katie Alexander, Daniel
Norris, Frank Bennett, Kathie Bishop
1:45 p.m.
S6.004
Future Clinical and Biomarker
Development for SMT C1100, the
First Utrophin Modulator to Enter
Clinical Trials for Duchenne Muscular
Dystrophy (DMD) Jon Tinsley, Neil
Robinson, Francis Wilson, Graeme
Horne, Kay Davies
2:00 p.m.
S6.005
Gene Therapy in a Model of CMT1X
Neuropathy Using a Lentiviral
Vector Kleopas Kleopa, Alexia
Kagiava, Stavros Bashardes, Jan
Richter, Christina Christodoulou,
Irene Sargiannidou
2:15 p.m.
S6.006
Treatment of Experimental CIDP
Using Lentivirus Transduced Dendritic
Cells Expressing VIP Mehmet
Yalvac, William Arnold, Syed-Rehan
Hussain, Cilwyn Braganza, K. Reed
Clark, Eroboghene Ubogu, Jerry
Mendell, Zarife Sahenk
2:30 p.m.
S6.007
Schwann Cell-Derived
Desert Hedgehog Provides a
Neuroprotective Effect Against
the Mechanical Stimuli from
Compressive Neuropathies Tahseen
Mozaffar, James Jung, Derek Frump,
Jared Su, Ranjan Gupta
1:30 p.m.
S7.003
Isradipine Rescues Alpha-synuclein
Toxicity in a Zebrafish Model of
Parkinson’s Disease by Upregulating
Autophagy Mark Stahl, Shubhangi
Prabhudesai, Aaron Lulla, Jeff
Bronstein
1:45 p.m.
S7.004
Phase-3 Clinical Trial of the
Adenosine 2a Antagonist
Preladenant, Given as Monotherapy,
in Patients with Parkinson’s
Disease Fabrizio Stocchi, Olivier
Rascol, Robert Hauser, Susan
Huyck, Anjela Tzontcheva, Rachel
Capece, Kenneth Wolski, Tony Ho,
Peter Sklar, Christopher Lines, David
Michelson, David Hewitt
2:00 p.m.
S7.005
Global Long-term Registry on Efficacy
and Safety of DUODOPA in Patients
with Advanced Parkinson’s Disease
in Routine Care (GLORIA): 12-month
interim findings Angelo Antonini,
Ashley Yegin, Cornelia Preda,
Werner Poewe
2:15 p.m.
S7.006
Real Life Aerobic Walking Exercise
in Parkinson’s Disease Ergun Uc,
Kevin Doerschug, Jeffrey Dawson,
Joel Kline, Sara Newman, Warren
Darling
2:30 p.m.
S7.007
Rapid Levodopa Augmentation
Following Inhaled CVT-301 Results
in Rapid Improvement in Motor
Response When Administered to PD
Patients in the OFF State Martin
Freed, Donald Grosset, Paul Worth,
Tanya Gurevich, Tia Defeo-Fraulini,
Jerome Moore, Richard Batycky
S8 Aging, Dementia, and
Neurology: PET Imaging
1:00 p.m. Presentation of
Potamkin Prize for Research in
Pick’s, Alzheimer’s, and Related
Diseases
Recipient:
M. Marsel Mesulam, MD
Chicago, IL
1:30 p.m.
S8.003
Cerebral Amyloid Related Alterations
in Neuronal Metabolism and
the Contribution of Multimodal
Measures of Vascular Function. Eric
McDade, Albert Kim, Timothy
Hughes, Beth Snitz, Ann Cohen,
Julie Price, Chester Mathis, James
Becker, William Klunk, Oscar Lopez
1:45 p.m.
S8.004
Integrated Analysis of (123I)FP-CIT
(DaTscan; Ioflupane I123 Injection)
SPECT Brain Imaging—Diagnostic
Effectiveness in Patients with
Movement Disorders and/or
Dementia Donald Grosset, Igor
Grachev, John O’Brien, Ian McKeith,
Walker Zuzana, Klaus Tatsch,
Eduardo Tolosa, Paul Sherwin,
Wolfgang Oertel
2:00 p.m.
S8.005
Diagnostic Accuracy of Amyloid and
FDG PET in Pathologically-Confirmed
Dementia Gil Rabinovici, Manja
Lehmann, Howard Rosen, Pia
Ghosh, Brendan Cohn-Sheehy, John
Trojanowski, Mario Mendez, Harry
Vinters, Dennis Dickson, Marilu
Gorno-Tempini, Adam Boxer, Joel
Kramer, Bruce Miller, Lea Grinberg,
William Seeley, William Jagust
2:15 p.m.
S8.006
FDG PET, Aging and APOE Genotype
in Cognitively Normal Persons David
Knopman, Clifford Jack, Heather
Wiste, Emily Lundt, Stephen
Weigand, Prashanthi Vemuri, Jeffrey
Gunter, Val Lowe, Kejal Kantarci,
Matthew Senjem, Michelle Mielke,
Rosebud Roberts, Bradley Boeve,
Ronald Petersen
2:30 p.m.
S8.007
Imaging Tau Pathology in vivo in
FTLD: Initial Experience with (18F)
T807 PET Bradford Dickerson,
Kimiko Domoto-Reilly, Daisy
Hochberg, Michael Brickhouse,
Michael Stepanovic, Keith Johnson
Scientific Sessions
1:00 p.m. Presentation of Sleep
Science Award
Recipient:
Claudia Trenkwalder, MD
Kassel, Germany
Wayne A. Hening Sleep Medicine
Investigator Award
Recipient:
Aleksandar Videnovic, MD, MSc
Boston, MA
1:30 p.m.
S9.003
Bright Light Therapy Improves
Excessive Daytime Sleepiness
Associated with Parkinson’s
Disease Aleksandar Videnovic,
Angelica Marconi, Teresa Kuhta,
Scott Miskevics, Phyllis Zee
1:45 p.m.
S9.004
Distinct Innervation Patterns of the
Melanin Concentrating Hormone
Neurons from the Basal Forebrain
Structures Minjee Kim, Lindsay
Agosstinelli, Thomas Scammell
2:00 p.m.
S9.005
Antibodies Against the Cell Adhesion
Molecule IgLON5 Identify a Novel
Tauopathy with NREM/REM
Parasomnia and Sleep Breathing
Disorder Carles Gaig, Lidia Sabater,
Ellen Gelpi, Luis Bataller, Jan
Lewerenz, Estefania Torres-Vega,
Angeles Contreras, Bruno Giometto,
Yaroslau Compta, Cristina Embid,
Isabel Vilaseca, Alex Iranzo,
Joan Santamaria, Josep Dalmau,
Francesc Graus
2:15 p.m.
S9.006
The Effects of Obstructive Sleep
Apnea on Olfactory Functions Tekeli
Hakan, Murat Salihoğlu, Mustafa
Kendirli, Aytuğ Altundağ, Melih
Cayonu, Mehmet Şenol, Ozdag Fatih
S10 HIV, PML, and Cerebral
Malaria
1:00 p.m. Presentation of Bruce
S. Schoenberg International Award
in Neuroepidemiology
Recipient:
Devender Bhalla, PhD
Limoges, France
1:30 p.m.
S10.003
Delivery of Tenofovir to the Brain
by Novel Nano-Vesicles for the
Treatment of Neuro-HIV Eliahu
Heldman, Charles Linder, Sarina
Grinberg, Mary Popov, Irwin
Hollander
1:45 p.m.
S10.004
Voxel Based Morphometry Findings
in an Irish Cohort of HIV Positive
Patients Patricia McNamara,
Janice Redmond, Peter Bede,
Andrew Fagan, Colm Bergin, Arun
Bokde, Colin Doherty
2:00 p.m.
S10.005
Development of a Functional
Scale for Progressive Multifocal
Leukoencephalopathy: The NIH PML
Scale Gloria Von Geldern, Irene
Cortese, Joan Ohayon, Daniel Reich,
Avindra Nath
2:15 p.m.
S10.006
Survival of Non-AIDS Progressive
Multifocal Leukoencephalopathy Yuri Hanada, Allen Aksamit
2:30 p.m.
S10.007
Performance of Cerebrospinal
Fluid (CSF) Plasmodium falciparum
Histidine-Rich Protein-2 (pfHRP-2)
in Prediction of Death in Cerebral
Malaria Kiran Thakur, Jimmy
Vareta, Kathryn Carson, Terrie Taylor,
David Sullivan, Karl Seydel
S11 Neuro Trauma,
Critical Care, and Sports
Neurology
1:00 p.m.
S11.001
Axonal Injury, Neuroinflammation and
Amyloid Pathology after Traumatic
Brain Injury: Making Connections to
Neurodegeneration David Sharp,
Gregory Scott, Ramlackasingh Anil,
Hellyer Peter, Leech Robert, Federico
Turkheimer, Paul Matthews, David
Brooks
1:15 p.m.
S11.002
Evolution of Traumatic Parenchymal
Intracranial Hematomas (ICHs):
Comparison of High Density and Low
Density Components. Sean Wilkes,
Erin McCormack, Leah Harburg,
Tanya Bogoslovsky, Kimbra Kenney,
Dzung Pham, Ramon Diaz-Arrastia
1:30 p.m.
S11.003
King-Devick Test Identifies
Symptomatic Concussion in Realtime and Asymptomatic Concussion
Over Time. Priya Dhawan, Amaal
Starling, Lisa Tapsell, Jennifer Adler,
Steven Galetta, Laura Balcer, David
Dodick
1:45 p.m.
S11.004
Prognostic Value of Post-anoxic
Myoclonus and Malignant EEG
Patterns in Comatose Cardiac
Arrest Survivors Treated with
Hypothermia Edilberto Amorim,
Alexandra Popescu, Maria Baldwin,
Yin Zhao, Jon Rittenberger
2:00 p.m.
S11.005
Blood Biomarkers for Brain Injury
in Concussed Professional Ice
Hockey Players Pashtun Shahim,
Yelverton Tegner, David Wilson,
Jeffrey Randall, Birgitta Kallberg, Kaj
Blennow, Henrik Zetterberg
2:15 p.m.
S11.006
Increased Connectivity Between
the Sensorimotor Cortex and Dorsal
Attention Network in Children After
Mild to Moderate Traumatic Brain
Injury Sarah Risen, Anita Barber,
Stewart Mostofsky, Stacy Suskauer
2:30 p.m.
S9.007
Nocturnal Melatonin Regulation in
Post-Traumatic Vegetative State:
A Possible Role for Melatonin
Supplementation? Pietro Guaraldi,
Elisa Sancisi, Giovanna CalandraBuonaura, Chiara La Morgia, Valerio
Carelli, Cameli Olivia, Alberto
Battistini, Pietro Cortelli, Roberto
Piperno
2:30 p.m.
S11.007
Development of a Medical Device
for the Rapid Assessment of
Concussion Donald Weaver, Ying
Tam, Christopher Barden, Ryan
D’Arcy, Love Kalra, Lauren Petley,
Chen Wei
S12 Cerebrovascular
Disease and Interventional
Neurology: Epidemiology
and Risk Factors
1:00 p.m.
S12.001
Ascertainment of Stroke Incidence
Among Alaskan Native Populations,
2005-2009: The Alaska Native
Stroke Registry Bernadette BodenAlbala, Eric Roberts, James Allen,
Lisa Bulkow, Brian Trimble
1:15 p.m.
S12.002
Racial and Ethnic Disparities
in Stroke. Declining Age at
Time of Stroke. Analysis of the
Nationwide Inpatient Sample
1988-2010 Cynthia Costa, Richard
Dubinsky
1:30 p.m.
S12.003
Indonesia Stroke Registry Fenny
Yudiarto, Mochammad Machfoed,
Amir Darwin, Anam Ong,
Muhammad Karyana, - Siswanto
1:45 p.m.
S12.004
Mobile Cardiac Outpatient Telemetry
Identifies Occult Atrial Fibrillation
After Cryptogenic Stroke Erin
Ingala, Jenny Jara, Emily Fessler,
Brett Cucchiara, Steven Messe,
Michael Mullen, Allyson Prasad,
Mathew Hutchinson, Scott Kasner
2:00 p.m.
S12.005
Stroke Severity in Men and Women:
What Proportion of the Disparity
Can be Explained by Differences in
Cardiovascular Risk Factors? Karen
Albright, Amelia Boehme, Bisakha
Sen, Michael Mullen, Nicole
Gonzales, Sean Savitz, Sheryl
Martin-Schild
2:15 p.m.
S12.006
Less than Ideal: Trends in
Cardiovascular Health Metrics
Among US Stroke Survivors,
NHANES 1988-2010 Michelle Lin,
Daniela Markovic, Bruce Ovbiagele,
Amy Towfighi
2:30 p.m.
S12.007
Incidence and Predictors of
Unprovoked Seizures After
Stroke Ettore Beghi
S13 MS and CNS
MRI Atrophy Measures
and Correlations
1:00 p.m.
S13.001
A Gender-based 3T MRI Comparison
of Brain and Spinal Cord Involvement
in Relapsing-Remitting Multiple
Sclerosis Antonia Ceccarelli, Gloria
Kim, Jennifer Miller, Shahamat
Tauhid, Tanuja Chitnis, Mohit
Neema, Rohit Bakshi
1:15 p.m.
S13.002
Thalamic Atrophy in RIS:
MRI Evidence of Early CNS
Neurodegeneration Christina
Azevedo, Eve Overton, Sankalpa
Khadka, Jessica Buckley, Shuang
Liu, Mehul Sampat, Orhun Kantarci,
Christine Lebrun Frenay, Aksel Siva,
Darin Okuda, Daniel Pelletier
1:30 p.m.
S13.003
Thalamic Dysfunction Is Associated
with Fatigue in Patients with
Multiple Sclerosis: A Graph
Theory Study Massimo Filippi,
Paola Valsasina, Alvino Bisecco,
Alessandro Meani, Laura Parisi,
Maria Josè Messina, Bruno
Colombo, Andrea Falini, Giancarlo
Comi, Maria Rocca
1:45 p.m.
S13.004
Clinical and Paraclinical
Parameters Associated with Brain
Atrophy in Newly Diagnosed
MS Patients. Bertrand Bourre,
Christine Clerc, Frederic Blanc,
Vincent Noblet, Stephane Kremer,
Julien Lamy, Jean-Paul Armspach,
Baradi Brice, Helene Zephir, Olivier
Outteryck, Marc Debouverie, Sophie
Pittion, Patrick Vermersch, Jerome
De Seze
2:00 p.m.
S13.005
Magnetic Resonance Imaging
Correlates of Clinical Outcomes
in Early Multiple Sclerosis Amir
Hadi Maghzi, Nisha Revirajan,
Laura Julian, Rebecca Spain,
Ellen Mowry, Jacqueline Marcus,
Shuang Liu, Chengshi Jin, Ari Green,
Charles McCulloch, Daniel Pelletier,
Emmanuelle Waubant
2:15 p.m.
S13.006
Proportion of Patients with Brain
Volume Loss Comparable to Healthy
Adults in Fingolimod Phase 3
Multiple Sclerosis Studies Nicola
De Stefano, Davorka Tomic, Dieter
Haering, Allitia Dibernardo, Gordon
Francis, Ernst-Wilhelm Radue,
Ludwig Kappos
2:30 p.m.
S13.007
Spinal Cord Lesion Load Is
Associated With Disability
Independently From Atrophy In
Multiple Sclerosis Hugh Kearney,
Rebecca Samson, Marios
Yiannakas, Claudia WheelerKingshott, Olga Ciccarelli, David
Miller
67
Tuesday
April 29
S9 Sleep
Tuesday, April 29
I5 Revolution of Genetic Tools and
the Impact on Neurology
1:00 p.m.–5:00 p.m.
Coordinators: Petra Kaufmann, MD and Mark F. Mehler, MD, FAAN
1:00 p.m.–1:25 p.m.
Advances in Epigenetics and their Implications for Understanding and Treating Neurological Disorders Mark Mehler, MD, FAAN
1:25 p.m.–1:50 p.m.
How Gene Networks and Systems Biology Informs Our Understanding of Nervous System Disease Daniel Geschwind, MD, PhD
1:50 p.m.–2:15 p.m.
New Genetic Tools and Their Impact on the Diagnosis of Neuromuscular Disorders Kenneth Fischbeck, MD
2:15 p.m.–2:40 p.m.
Clinical Whole-Exome Sequencing in the Diagnosis of Mendelian Disorders of the CNS Arthur Beaudet, MD
2:40 p.m.–3:05 p.m.
Using Genomics in Routine Clinical Care Teri Manolio MD, PhD
3:05 p.m.–3:30 p.m.
Advances in Genetics and Impact on the Treatment of Neurological Disease Beverly Davidson, PhD
I5-1.001 Exome Sequencing
Identifies PINCH2 Mutations in Early
Onset Autosomal Recessive LGMD with
Severe Cardiomyopathy and Triangular
Tongues Jodi Warman Chardon, Amanda
Smith, John Woulfe, Kawan Rakhra, Elena
Pena Fernandez, Chandree Beaulieu,
Jeremy Schwartzentruber, Cynthia Hawkins,
Matthew Harms, Mei Zhang, Jacek
Majewski, Dennis Bulman, Kym Boycott,
David Dyment
I5-1.002 Genetic and Neuroanatomic
Associations in Sporadic Frontotemporal
Lobar Degeneration Corey McMillan, Jon
Toledo, Brian Avants, Philip Cook, Elisabeth
Wood, Eunran Suh, David Irwin, John
Powers, Christopher Olm, Lauren Elman, Leo
McCluskey, Gerard Schellenberg, Virginia
Lee, John Trojanowski, Vivianna Van
Deerlin, Murray Grossman
I5-1.003 Transcript Profiling Analysis
of Alzheimer’s Disease Brains. Mariet
Allen, Daniel Serie, Michael Walsh, Sun
Zhifu, Saurabh Baheti, Fanggeng Zou, High
Seng Chai, Curtis Younkin, Julia Crook,
Vernon Pankratz, Minerva Carrasquillo,
Asha Nair, Sumit Middha, Sooraj Maharjan,
Thuy Nguyen, Li Ma, Kimberly Malphrus,
Sarah Lincoln, Gina Bisceglio, Christopher
Kolbert, Jin Jen, Ronald Petersen, Neill
Graff-Radford, Dennis Dickson, Steven
Younkin, Yan Asmann, Nilufer Taner
I5-1.004 Novel Mutation in VCP
Causes Charcot-Marie-Tooth Type 2
(CMT2) Phenotype Shawna Feely, Michael
Gonzalez, Chris Weihl, Michael Shy,
Stephan Zuchner
I5-1.005 GCH1 Heterozygous
I5-1.008 TMEM106B Is a Genetic
I5-1.006 Structural and Functional
I5-1.009 Expression QTL Studies in
Mutation Identified by Whole-ExomeSequencing as a Treatable Condition in
a Patient Presenting with Progressive
Spastic Paraplegia Zheng Fan, Robert
Greenwood, Ana Felix, Yael ShilohMalawsky, Myra Roche, Kristy Crooks,
Jonathan Berg, James Evans
Implications of Modeling Non Synonymous
Mutations in Patients with SCN1A-related
Seizure Disorders Mu Gao, Hongyi Zhou,
Izabela Karbassi, Khalida Liaquat, Daniel
Fischer, Jeffrey Skolnick, Joseph Higgins
I5-1.007 The Dissection of
High-Penetrance Variants in Extended
Late-onset Alzheimer Disease Families by
Whole-Exome Sequencing Martin Kohli,
Brian Kunkle, Adam Naj, Li-San Wang, Kara
Hamilton, William Perry, Regina Carney,
Patrice Whitehead, John Gilbert, Eden
Martin, Gary Beecham, Jonathan Haines,
Gerard Schellenberg, Stephan Zuchner,
Margaret Pericak-Vance
Modifier of Frontotemporal Lobar
Degeneration with C9orf72 Hexanucleotide
Repeat Expansions Alice Chen-Plotkin,
Michael Gallagher, Eunran Suh, Murray
Grossman, Lauren Elman, Leo McCluskey,
John Trojanowski, Virginia Lee, Vivianna
Van Deerlin
LOAD and PSP Brains by Next-generation
RNA Sequencing Nilufer Taner, Chen
Wang, Minerva Carrasquillo, Mariet
Allen, Curtis Younkin, Daniel Serie, Vernon
Pankratz, Thuy Nguyen, Li Ma, Kimberly
Malphrus, Sarah Lincoln, Ronald Petersen,
Neill Graff-Radford, Steven Younkin, Dennis
Dickson, Yan Asmann
4:30 p.m.
I5-2.001
Late-onset Alzheimer Disease
Neuropathology Genomic Screen Identifies
Novel Loci for Neuritic Plaque and Other
AD Neuropathology Features Gary
Beecham, Kara Hamilton, Gerard
Schellenberg, Margaret Pericak-Vance,
Thomas Montine
4:35 p.m.
I5-2.002
4:40 p.m.
I5-2.003
The TREM2 Variant p.R47H Is a Risk
Factor for Sporadic Amyotrophic Lateral
Sclerosis Matthew Harms, Janet Cady,
Erica Koval, Bruno Benitez, Craig Zaidman,
Jennifer Jockel-Balsarotti, Peggy Allred,
Robert Baloh, John Ravits, Ericka Simpson,
Stanley Appel, Alan Pestronk, Alison Goate,
Timothy Miller, Carlos Cruchaga
TIGAR Inhibition Rescues Dopaminergic
Neurons in Common Forms of Early Onset
Parkinson’s Disease Oliver Bandmann,
Marcus Keatinge, Marc DaCosta, Heather
Mortiboys, Laura Flinn
68
4:45 p.m.
I5-2.004
Investigation of Transcriptional
Regulation at the Alzheimer’s Disease
Risk Loci. Michaela Kachadoorian, Mariet
Allen, Aditya Karhade, Lester Manly,
Fanggeng Zou, High Seng Chai, Curtis
Younkin, Julia Crook, Vernon Pankratz,
Minerva Carrasquillo, Asha Nair, Sumit
Middha, Sooraj Maharjan, Thuy Nguyen,
Li Ma, Kimberly Malphrus, Sarah Lincoln,
Gina Bisceglio, Christopher Kolbert, Jin
Jen, Ronald Petersen, Neill Graff-Radford,
Steven Younkin, Dennis Dickson, Nilufer
Taner
4:50 p.m.
I5-2.005
Spinal Muscular Atrophy Phenotype Is
Ameliorated Either by SMN Increase
or Modulation of Secondary Cell Death
Events with RNA Therapy Giulietta
Riboldi, Monica Nizzardo, Chiara Simone,
Federica Rizzo, Margherita Ruggieri,
Serena Pagliarani, Gianna Ulzi, Sabrina
Salani, Andrea DalMas, Monica Bucchia,
Emanuele Frattini, Giulia Stuppia,
Francesca Magri, Nereo Bresolin, Franco
Pagani, Giacomo Comi, Stefania Corti
Integrated Neuroscience Sessions
I6 Peripheral Neuropathies
1:00 p.m.–5:00 p.m.
Coordinators: P. James B. Dyck, MD, FAAN and Tahseen Mozaffar, MD, FAAN
1:00 p.m.–1:10 p.m.Introduction Tahseen Mozaffar, MD, FAAN
1:10 p.m.–1:35 p.m.
Role of Anti-Ganglioside Antibodies in Neuropathies, Including Latest Advances Kazim Sheikh, MD
1:35 p.m.–2:00 p.m.
Post-Surgical Inflammatory Neuropathies P. James B. Dyck, MD, FAAN
2:00 p.m.–2:25 p.m.
Role of Exome and Next Generation Sequencing in Peripheral Neuropathies Christopher J. Klein, MD
2:25 p.m.–2:50 p.m.
Neuropathy in Diabetes and the Metabolic Syndrome James W. Russell, MD, MS, FRPC, FAAN
2:50 p.m.–3:15 p.m.
Update on Acquired Inflammatory Demyelinating Polyradiculopathies Kenneth C. Gorson, MD
3:15 p.m.–3:30 p.m.
Panel Discussion
Transporter 1 (MCT1) Is Critical for
Regeneration in Peripheral Nerves Brett
Morrison, Akivaga Tsingalia, Sylvain
Lengacher, Luc Pellerin, Pierre Magistretti,
Jeffrey Rothstein
I6-1.002 Characteristics of
Muscle Cramps in Patients with
Polyneuropathy Katzberg Hans, Sarah
Maxwell, Seint Kokokyi, Hamid Ebadi, Ari
Breiner, Vera Bril
I6-1.003 Gene Therapy in a Model
I6-1.004 Peripheral Edema and
Weight Gain in Adult Patients with Painful
Diabetic Peripheral Neuropathy (DPN)
Receiving Gabapentin Enacarbil (GEn) or
Pregabalin Enrolled in a Randomized Phase
2 Trial Anne Calkins, Joseph Shurman,
Mark Jaros, Richard Kim, Gwendoline
Shang
I6-1.005 Deletion of Sarm1 Gene
Protects Against Paclitaxel-induced
Peripheral Neuropathy Ahmet Hoke, Elliot
Turkiew, Nicole Reed
of CMT1X Neuropathy Using a Lentiviral
Vector Kleopas Kleopa, Alexia Kagiava,
Stavros Bashardes, Jan Richter, Christina
Christodoulou, Irene Sargiannidou
I6-1.006 Peripheral Nerve
Amyloidosis: Phenotype, Natural History,
and Autonomic Dysfunction in Inherited
Versus Acquired Subtypes Adam
Loavenbruck, Wolfgang Singer, Paola
Sandroni, Michelle Mauermann, P. James
B. Dyck, Christopher Klein, Phillip Low
I6-1.007 DS-5565 for the Treatment
of Diabetic Peripheral Neuropathic Pain:
Randomized, Double-blind, Placebo- and
Active Comparator-controlled Phase II
Study Aaron Vinik, Uma Sharma, Karen
Feins, Ching Hsu, Domenico Merante
I6-1.009 Is IVIg Therapy Warranted
Tuesday
April 29
I6-1.001Monocarboxylate
in Progressive Lower Motor Neuron
Syndromes without Conduction
Block? Neil Simon, Gretchen Ayer,
Catherine Lomen-Hoerth
I6-1.010
Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)
Sera Alter Regulators of Schwann Cell
Differentiation Abhijeet Joshi, Ilja Bobylev,
Christian Ritter, Andre Heinen, Helmar
Lehmann
I6-1.008 Neuropathy Associated
with Nondiabetic Obesity J. Singleton, Eric
Volckmann, Timothy Graham, Albert Smith
4:30 p.m.
I6-2.001
Schwann Cell-Derived Desert Hedgehog
Provides a Neuroprotective Effect Against
the Mechanical Stimuli from Compressive
Neuropathies Tahseen Mozaffar, James
Jung, Derek Frump, Jared Su, Ranjan Gupta
4:35 p.m.
I6-2.002
4:40 p.m.
I6-2.003
Neuropathy Improvement Following
Peripheral Blood Stem Cell Transplantation
for POEMS Syndrome. Chafic Karam,
Christopher Klein, Angela Dispenzieri,
Jayawant Mandrekar, P. James B. Dyck,
Anita D’Souza, Michelle Mauermann
4:45 p.m.
I6-2.004
Induced Pluripotent Stem Cell Based
Models of CMT1A and HNPP Robert
Baloh, Irina Epifantseva, Kevin Kim,
Shaughn Bell, Sharon Carmona, Sharday
Grant, Megan Simpkinson, Matthew
Harms, Dhruv Sareen, AKMG Muhammad
4:50 p.m.
I6-2.005
Treatment of Experimental CIDP Using
Lentivirus Transduced Dendritic Cells
Expressing VIP Mehmet Yalvac, William
Arnold, Syed-Rehan Hussain, Cilwyn
Braganza, K. Reed Clark, Eroboghene
Ubogu, Jerry Mendell, Zarife Sahenk
Quantification of Sciatic Nerve
Pathology in Inherited Neuropathies via
Magnetization Transfer MRI Richard
Dortch, Lindsey Dethrage, Audra Hamilton,
John Gore, Seth Smith, Jun Li
69
Tuesday, April 29
3:00 p.m.–6:30 p.m.
Poster Discussion Session: Epilepsy/Clinical Neurophysiology (EEG)
P3.001
Antibodies to GABAa
Receptor Associate with Seizures, Status
Epilepticus, and Remove the Receptors
from Synapses Mar Petit, Thais Armangue,
Xiaoyu Peng, Rebecca Davis, Lindsey
McCracken, Rita Balice-Gordon, Francesc
Graus, Josep Dalmau
P3.002
Is Generic Drug Quality as
Good as Brand? Surveillance Testing
of Marketed Lamotrigine Batches
and Comparison to Brand Soundarya
Vaithianathan, Siddarth Raman, Wenlei
Jiang, Tricia Ting, Maureen Kane, James
Polli
P3.003
Characteristics of
Traumatic Fractures in Patients with
Epilepsy Franziska Herpich, Kenneth Walsh,
Neha Vijayvargiya, Wayne Satz, Mercedes
Jacobson
P3.004
Utility of Selective Posterior
Cerebral Artery Amobarbital Testing
in Surgical Evaluation for Patients with
Temporal Lobe Epilepsy Courtney Schusse,
Wil Schultz, Caleb Pearson, Steve Chung
P3.005
Utility of CT Perfusion (CTP)
Imaging in Seizures: A Retrospective
Analysis and Literature Review Aunali
Khaku, Vishunmurthy Hedna, Michael
Waters
P3.006
Where and How Are the
Initial Antiepileptic Drugs Administered
to Children Who Develop Refractory
Status Epilepticus? Results from the
Pediatric Status Epilepticus Research
Group (pSERG) Ivan Sanchez Fernandez,
Nicholas Abend, Satish Agadi, Ravindra
Arya, Rajit Basu, Jessica Carpenter, Kevin
Chapman, Nathan Dean, William Gaillard,
Tracy Glauser, Howard Goodkin, Michele
Jackson, Mohamad Mikati, Katrina Peariso,
Geetanjali Rathore, Robert Tasker, Alexis
Topjian, David Turner, Angus Wilfong,
Korwyn Williams, Tobias Loddenkemper
P3.007
The Experience of the
GENESS International Consortium to
Accelerate Discovery of New Epilepsy
Genes Antonio Escueta, Maria Alonso,
Marco Medina, Reyna Duron, Julia Bailey,
Iris Martinez-Juarez, Miyabi Tanaka,
Donsheng Bai, Aurelio Jara-Prado, Adriana
Ochoa, Jesus Machado-Salas, Thiery Grisar,
Kazuhiro Yamakawa, Elza Targas Yacubian,
Laura Guilhoto, Jose Serratosa, Christopher
Patterson, Joan Spellman, Jenny Wight,
Yu-Chen Lin, Sumia Aftab
P3.010
Reversible Intraoperative
Neurophysiologic Monitoring Changes
Associated with Surgical Retraction Leslie
Lee, Sungho Cho, Viet Nguyen, Gary
Steinberg, Steven Chang, Robert Dodd,
Stephen Ryu, Jaime Lopez
P3.008
Serum IL6, IL1β And IL1Ra
Levels in Patients with Epilepsy Irem
Fatma Uludag, Tarik Duksal, Yasar Zorlu,
Feriha Ozkaya, Guldal Kirkali
P3.009
Review of Aggression in
Adults and Adolescents in Perampanel
Phase III Epilepsy Clinical Trials Antonia
LoPresti, Alan Ettinger, Haichen Yang, Betsy
Williams, Sharon Zhou, Randi Fain, Antonio
Laurenza
NEW! e
Poster Session:
Neuromuscular and Clinical Neurophysiology (EMG) I
P3.011
Discriminant Value of
18FDG-PET in Amyotrophic Lateral
Sclerosis Adriano Chio, Marco Pagani,
Andrea Calvo, Cristina Moglia, Flavio Nobili,
Piercarlo Fania, Silvia Morbelli, Consuelo
Valentini, Antonio Canosa, Angelina Cistaro
P3.012
Cytoplasmic Redistribution
of Mutant TDP-43 in a BAC Based
Mouse Model of Amyotrophic Lateral
Sclerosis Kevin Talbot, David Gordon,
Ruxandra Mutihac, Javier AlegreAbarrategui, Lucy Farrimond, Ben Davies,
Richard Wade-Martins
P3.013
Real-time Video Microscopy to
Assess Pathologic Leukocyte-Endothelial
Cell Interactions at the Human BloodNerve Barrier In Vitro: A Tool to Guide
Specific Drug Therapy for Peripheral
Neuropathies Eroboghene Ubogu
P3.014
Medical Marijuana Utilization
and Perceived Therapeutic Value in
Patients with ALS Jacob Kaufman, Kelly
Almasy, Ashley Boller, Nabila Dahodwala,
Lauren Elman, Mary Kelley, Leo McCluskey
70
P3.015
Looking for an Early Diagnosis
in a Late Onset Pompe Disease High
Risk Population: a LOPED Study Olimpia
Musumeci, Giancarlo la Marca, Severo
Pagliardini, M Spada, Cesare Danesino,
Giacomo Comi, Elena Pegoraro, Giovanni
Antonini, Gianni Marrosu, Rocco Liguori,
Lucia Morandi, Maurizio Moggio, Roberto
Massa, Sabrina Ravaglia, Antonio Di Muzio,
Corrado Angelini, Massimiliano Filosto,
Paola Tonin, Giuseppe Di Iorio, Serenella
Servidei, Gabriele Siciliano, Tiziana
Mongini, Antonio Toscano
P3.016
Plasmapheresis Enables
Robust Micro-Dystrophin Expression
Following Gene Transfer in Subjects with
Pre-Existing Immunity Louis Chicoine,
Chrystal Montgomery, Thomas Preston,
Danielle Griffin, William Bremer, K. Reed
Clark, Zarife Sahenk, Christopher Walker,
Jerry Mendell, Louise Rodino-Klapac
P3.018
Quantitative Ultrasound
Provides Insight into How Electrical
Impedance Myography Measurements
Are Impacted by Disease. Irina Shklyar,
Tom Geisbush, Aleksandar Mijailovic, Amy
Pasternak, Nicole Visyak, Heather Szelag,
Jim Wu, Craig Zaidman, Basil Darras,
Seward Rutkove
P3.019
Anti-Growth Factor Receptor
3 Antibodies Identify a Sub-Group of
Sensory Neuropathy Patients JeanChristophe Antoine, Boutahar Nadia,
Véronique Rogemond, Jerome Honnorat,
Jean-Phillippe Camdessanche
P3.017
Characterization of B-cell
Subsets in MuSK Myasthenia Gravis Jeff
Guptill, John Yi, Donald Sanders, Amanda
Guidon, Sara Sparks, Robyn Osborne,
Janice Massey, Vern Juel, Lisa HobsonWebb, Kent Weinhold
P3.020
Bone Mineral Content as
Measure of Bone Health in Ambulatory
Boys with Duchenne Muscular
Dystrophy Cuixia Tian, Meilan Rutter,
Lindsey Hornung, Jane Khoury, Lauren
Miller, Jean Bange, Brenda Wong
Poster Session III
P3.021
A randomized Controlled
Trial Comparing Botulinum Toxin Type A
Xeomin® and Dysport® for Treatment of
Primary Axillary Hyperhidrosis Francesca
Pastorelli, Roberto Michelucci, Rosaria
Plasmati
P3.022
Multiplex Testing of AntiNeural Autoantibodies Lars Komorowski,
Kristin Rentzsch, Sandra Saschenbrecker,
Bianca Teegen, Christian Probst, Winfried
Stoecker
P3.023
Brain Lactate in Patients
with Autosomal Dominant Adult-Onset
Leukodystrophy (ADLD): a 1H-MR
Spectroscopy Study. Stefano Zanigni,
Caterina Tonon, Claudia Testa, Rossana
Terlizzi, Laura Gramegna, Claudio Bianchini,
Pietro Guaraldi, Giovanna Calandra
Buonaura, Pietro Cortelli, Raffaele Lodi
P3.035
Neurological Complications
After Kidney Transplantation Kateryna
Kurako, Nancy Rosales, Ramon Lugo
P3.050
P3.036
P3.051
Relationship Between Bone
Mass and Muscle Weakness in Chronic
Neurological Diseases Maria Gutierrez,
Gabriel Eduardo Rodriguez, Domingo
Garcea, Raul Rey, Sandra Lepera, Ercolano
Monica, Drnovsek Monica, Kerzberg
Eduardo, SIlva Berenice
P3.037
Functional Brain Dimorphism
in Psychopath Offenders Evidenced by
QEEG Analysis Ana Calzada-Reyes, Alfredo
Alvarez Amador, Lídice Galán-García
P3.038
The Vulpian-Bernhardt
Syndrome in the Clinical Spectrum of
Amyotrophical Lateral Sclerosis: A Case
Report and Literature Review. Armando
Jordan, Marie-Catherine Boll
P3.039
P3.024
Trigeminal Neuralgia to a Tibial
tumour; Four Degrees of Separation Laura
Williams, Ronan Killeen, Thomas Crotty,
Michael Hutchinson, Christopher McGuigan
P3.025
P3.040
Prognosis of Treated
Neurosarcoidosis Allen Aksamit, Blake
Fechtel, Tyler VanDyck, Andrew Tseng
Spinal Cord Compression
Associated with a Systemic IgG4
Disease Mohamad Ezzeldin, Ahmad
Shawagfeh, Vicki Schnadig, Robert Smith,
Xiang Fang
P3.026
Conversion of New Active
MRI Lesions at 6 Months to T1 Hypointense
‘Black Holes’ at 12 Months in RRMS
Subjects from the GALA Study Robert
Zivadinov, Joshua Steinerman, Volker
Knappertz, Hadas Barkay, Omar Khan
P3.027
Olfactory Dysfunction in
Chagas’ Disease Fidias Leon-Sarmiento,
Edgardo A Bayona, Carlos V Rizzo-Sierra,
Alicia Garavito, Maria Fernanda Campos,
Richard Doty
P3.028
Multiple Sclerosis Comorbidity
Study Robert Simpson
P3.029
Paclitaxel Affects Axonal
Mitochondria in a Murine Model of
Chemotherapy-Induced Peripheral
Neuropathy Ilja Bobylev, Abhijeet Joshi,
Christian Ritter, Ahmet Hoke, Helmar
Lehmann
P3.030
Using Rapid Reaching Tasks
to Reveal the Underlying Mechanisms of
Decision Making in Humans Maria Khami
P3.031
Acute Focal Dystonia
Heralding the Diagnosis of Type 2 Diabetes
Mellitus Alok Sachdeva, Deepak Gulati,
Michael Devereaux
P3.032
Primary Angiitis of the Central
Nervous System presented with Tumor-like
lesion: A Case Report Yasaman Kianirad,
Shyam Prabhakaran
P3.033
Utility of Computed Tomogram
of Head for Patients with Altered Mental
Status Sanjeev Sivakumar, Zakhar Serkin,
Camelia Arsene, Ramesh Madhavan, Navid
Seraji-Bozorgzad
P3.034
A Case of Adult Langerhans
Cell Histiocytosis Presenting as Isolated
Central Diabetes Insipidus: A Powerful
Tool to Detect the Hypophyseal and
Extrahypophyseal Involvement Junko
Maeda, Junwa Kunimatsu, Sohtaro Mine,
Kaoru Aishima, Atsuto Yoshizawa
The European Union Is worth
saving Anne Hoeritzauer, Gavin McDonnell,
Marjo Van Der Knaap
Neural Repair and Neurorehabilitation: Clinical
P3.041
Hyperbaric Oxygen Therapy
Versus Antiepileptic Drugs in the Control
of Late Post Traumatic Non Convulsive
Epilepsy Refractory to Phenytoin Sherif
Abd Elmonem, Soliman Tahon, Ann Abd
Elkader, Akram Fayed
P3.042
A Compilation of Spasticity
Studies Evaluating Onabotulinumtoxin A Payal Patel, Aubrey Manack
P3.043
Treating Neglect by Body
Movements: A Case Report and Follow-up
Study Amit Chaudhari, Kara Pigott, Peii
Chen, A. Barrett
P3.044
A Preliminary Examination
of Psychological and Neuropsychological
Outcomes in Patients with Mild Traumatic
Brain Injury Shannon McNally, Katherine
Lopez, Sarah Levy, John Dsurney, Leighton
Chan
P3.045
Functional Motor Recovery
In Stroke Survivors—Determinants in a
Stroke Unit in Sub-Saharan Africa. Frank
Imarhiagbe
P3.046
Cognitive Training Program for
Memory/Executive Reasoning Deficits in
Adults with Traumatic Brain Injury Barbara
Fisher, Danielle Garges
P3.047
Alterations in Muscle
Coordination Following Robot-Assisted
Gait Training in Hemiparetic Stroke: A Case
Series Adam Thrasher, Stanley Fisher
P3.048
Comparison of Headache in
OEF/OIF Veterans with Traumatic Brain
Injury (TBI) against Controls Matched
for Age, Sex, Race and Deployment
Time James Couch, Kenneth Stewart
P3.049
Higher Coated-Platelets in
Patients with Mild Traumatic Brain Injury
Correlate with Lower Cognitive Screening
Performance Calin Prodan, Andrea Vincent,
George Dale
Patient Registry of Outcomes
in Spasticity (PROS) Care World Alberto
Esquenazi, Nathaniel Mayer, Stella Lee
Fatigue and Functional MRI
in Multiple Sclerosis: A Quantitative
Coordinate-based Activation Likelihood
Estimation Meta-analysis Radu Tanasescu,
Cris Constantinescu, Ali Manouchehrinia,
Dorothee Auer, Christopher Tench
P3.052
White Matter Disease Ratings
in Right Hemisphere Stroke Annapoorna
Bhat, Marianne Kim, Anne Foundas, Peii
Chen
P3.053
The Effects of Salsa
Dance on Gait and Balance in Multiple
Sclerosis Rosalind Mandelbaum, Elizabeth
Triche, Susan Fasoli, Albert Lo
P3.054
Prospective Assessment of
Falls Among People with Multiple Sclerosis
and Healthy Matched Controls Rajarshi
Mazumder, Charles Murchison, Michelle
Cameron
P3.055
Brain-Computer Interface
Driven Functional Electrical Stimulation
System for Overground Walking: A Case
Report Christine King, Colin McCrimmon,
Po Wang, Cathy Chou, Zoran Nenadic, An
Hong Do
P3.056
Improvement of Gait Following
Walking Based Long-term aerobic
Endurance Exercise In Mildly Disabled
MS Patients Stephan Schmidt, Marc
Wonneberger
P3.057
The Potential Diagnostic
Approach to Characterize Peripheral Nerve
Injury Using 4-AP Kuang-Ching Tseng,
John Elfar
P3.058
Action Observation Therapy
Modifies Structural Brain Plasticity in
Healthy Adult Individuals Paolo Preziosa,
Maria Rocca, Roberto Gatti, Melissa
Petrolini, Roberta Messina, Gabriele Salini,
Silvia Fumagalli, Andrea Falini, Giancarlo
Comi, Massimo Filippi
P3.059
VR-based Training Using Wii
Fit Improve Obstacle Crossing Performance
and Dynamic Balance in Patients with
Parkinson Disease Yingyi Liao, Yea-Ru
Yang, Ray-Yau Wang
Movement Disorders: Clinical
Features of Parkinson’s Disease
P3.060
Parkinson’s Disease Among
Mexican Americans Aged 74 Years
and Older in the Southwestern United
States Nicte Mejia, Sunshine Rote, NaiWei Chen, Kyriakos Markides, Soham Al
Snih
P3.061
Recurrent Falls in Parkinson
Disease (PD) Abraham Lieberman,
Rohit Dhall, Aman Deep, Narayanan
Krishnamurthi, Naomi Salins, Di Pan
P3.062
Auditory Processing Abilities
of Parkinson Disease Patients Robert
Folmer, Jay Vachhani
P3.063
Levodopa and Posture—
Quantification of Trunk Performance in
Parkinson’s Disease Felix Benninger,
Alexander Khlebtovsky, Yaniv Roditi, Eldad
Melamed, Ruth Djaldetti
P3.064
Tactile Cueing Improves
Motor Performance and Motor-Cognitive
Integration in Parkinson’s Disease Vladimir
Ivkovic, Stanley Fisher, William Paloski
P3.065
Carotid Artery Thickening
and Neurocirculatory Abnormalities in De
Novo Parkinson Disease Joong-Seok Kim,
Yoon-Sang Oh, Kwang-Soo Lee, In-Uk Song,
Yeong-In Kim, Dong-Won Yang, Ja-Seong
Koo, David Goldstein
P3.066
Effect of Parkinson Disease
Age of Onset on Family History Nicholas
Hac, Madaline Harrison, G. Wooten,
Matthew Barrett
P3.067
Discordance Between
Medication Apps and Needs of Patients
with Parkinson’s Disease Anupama
Divakaruni, Melissa Armstrong, Ann GruberBaldini, Lisa Shulman
P3.068
Neuroprotection by
Sex Steroid Hormones in Parkinson’s
Disease Kara Smith, Nabila Dahodwala
Tuesday
April 29
General Neurology II
P3.069
Gender and Dopaminergic
Medication Treatment in Early Parkinson
Disease Chizoba Umeh, Adriana Pérez,
Erika Augustine, Rohit Dhall, Richard
Dewey, Zoltan Mari, David Simon, Anne
Marie Wills, Chadwick Christine, Jay
Schneider, Oksana Suchowersky
Movement Disorders: Assessing
Parkinson’s Disease
P3.070
Motion Sensor Dyskinesia
Assessment During Activities of Daily
Living Christopher Pulliam, Michelle
Burack, Joseph Giuffrida, Thomas Mera
P3.071
Walking Capacity (WalkCap)
Measured by Six-Minute Walk (6MW)
Does Not Demonstrate Fatigue in Patients
with Amyotrophic Lateral Sclerosis (ALS),
Multiple Sclerosis (MS),and Parkinson
Disease (PD) Mohammed Sanjak, Laura
Morgan, Ashely Simpson, Scott Holsten,
Mark Hirsch, Danielle Englert, Sanjay Iyer, Jill
Conway, Michael Kaufman, Elena Bravver,
Urvi Desai, Priscilla Russo, Benjamin Brooks
P3.072
Quantitative Motor
Assessment in Parkinson’s Disease (PD)
with the MovAlyzeR® Digital Writing
Tablet Alexander Pantelyat, Rebecca
Freedman, Stephanie Pawlowski, Adhithi
Kesari, Jayne Wilkinson, John Duda, James
Morley
P3.073
Dynamic Fall-risk Predictors
in Parkinson’s Disease Ashutosh Mani,
Kari Dunning, Travis Larsh, Cyndy Cox, Amit
Shukla, Amit Bhattacharya, Fredy Revilla
P3.074
Objective Assessment
of Electro-acupuncture Benefit for
Improving Balance and Gait in Patients
with Parkinson’s Disease Hong Lei, Nima
Toosizadeh, Michael Schwenk, Scott
Sherman, Stephen Karp, Saman Parvaneh,
Esther Esternberg, Bijan Najafi
P3.075
Low Health Literacy: An
Under-Recognized Obstacle in Parkinson’s
Disease Jori Fleisher, James Minger,
Whitney Fitts, Nabila Dahodwala
71
Tuesday, April 29
P3.076
Avoiding Ventricular
Transgression During DBS Surgery: A Quality
Improvement Intervention Meagan Bailey, Roy
Strowd, Jessica Tate, Ihtsham Haq, Stephen
Tatter, Adrian Laxton, Mustafa Siddiqui
P3.077
Sex Differences in Clinical
Features of Early, Treated Parkinson
Disease Erika Augustine, Rohit Dhall,
Adriana Perez, Chizoba Umeh, Oksana
Suchowersky
P3.089
Can Neuronal Voltage-gated
Potassium Channels be Associated with
Parkinsonism? Hardik Doshi, Edwin George,
Natalya Shneyder
Interventional Neurology: Clinical
Management
P3.090
Is There a Relationship
Between Social Phobia and Parkinson’s
Disease? Christina Saldivar, Guillermo
Moguel-Cobos
Factors Associated with
30-day Readmission Rate Among Stroke
Patients from 2009-2012 at Two Tertiary
Level Hospitals in Metro Portland
Area Amit Kansara, Tamela Stuchiner,
Elizabeth Baraban, Archit Bhatt
P3.079
Pronounced Task
Specific Writing Tremor in Parkinson’s
Disease Katelyn Smith, Aws Alawi, Joanna
Ramiro, Pratap Chand
P3.091
Movement Disorders: Other
Parkinsonian Disorders
P3.092
P3.078
P3.080
Olfactory Impairment and
Other Features of Parkinson Disease
That Predict Persistent Drug-Induced
Parkinsonism James Morley, Stephanie
Pawlowski, Alexander Pantelyat, Adhithi
Kesari, Ivy Maina, John Duda
P3.081
Long-term Levodopa Use in
Normal Substantia Nigra Cases Michele
Rajput, Ali Rajput, Christopher Robinson,
Alexander Rajput
P3.082
The Entity of Parkinsonism
and Associated Lipomatosis Maria
Stamelou, Una-Marie Sheerin, Nicholas, W
Wood, Kailash Bhatia
P3.083
REM Sleep and Motor
Symptoms in Parkinson’s Disease: A Cross
Sectional Analysis Abhimanyu Mahajan,
Charlene Gamaldo, Rachel Marie Salas,
Gregory Pontone, Chizoba Umeh, Liana
Rosenthal, Arita McCoy, Zoltan Mari
P3.084
Mild Parkinsonian Signs Are
a Risk Factor for Falls Nabila Dahodwala,
Chinwe Nwadiogbu, Whitney Fitts, Helen
Partridge, Jason Karlawish
P3.085
A Family with Corticobasal
Degeneration, Parkinson’s Disease,
Amyotrophic Lateral Sclerosis, and
Dementia Shinsuke Fujioka, Monica
Sanchez Contreras, Audrey Strongosky,
Pawel Tacik, Bradley Boeve, A Stoessl,
Matthew Baker, Rosa Rademakers, Dennis
Dickson, Zbigniew Wszolek
P3.086
Three New Families with
Perry Syndrome from Distinct Parts of the
World—Novel Mutation and Successful
Treatment Attempt of Respiratory
Insufficiency Pawel Tacik, Shinsuke Fujioka,
Owen Ross, Wolfdieter Springer, Fabienne
Fiesel, Felipe Pretelt, Camilo Castañeda
Cardona, Alexa Kidd, Michael Hlavac,
Anthony Raizis, Michael Okun, Zbigniew
Wszolek
P3.087
Vascular Parkinsonism in a
Tertiary Care Stroke Prevention Clinic:
Prevalence and Development of a New
Screening Strategy Herbert Manosalva
Alzate, Thomas Jeerakathil, Maher Saqqur,
Richard Camicioli, Oksana Suchowersky
P3.088WITHDRAWN
72
Etiologies of Neurologic
Deterioration in the First 30 Days Following
Ischemic Stroke Iftekhar Ahmed, Kirstin
Hirni, Sakher Albadarin, Neeta Duggal
Vertigo and Dizziness in
Anterior Circulation Cerebrovascular
Disease: A Systematic Review Yun Zhou,
Seung-Han Lee, Georgios Mantokoudis, Ali
Saber Tehrani, Sarah Ying, Kevin Kerber,
Yu-Hsiang Hsieh, Karen Robinson, Daniel
Hanley, David Zee, David Newman-Toker
P3.093
Risk Factors for Ischemic
Stroke Mortality Claudia Alonzo, Maria
Zurru, Laura Brescacin, Ariel Luzzi, Luis
Camera, Gabriel Waisman, Edgardo
Cristiano
P3.094
Relation of Serial
Hemodynamic and Autonomic changes
in Acute Ischemic Stroke to Stroke Type,
Location and Outcome. Arunodaya Gujjar,
Deepali Jaju, Jacob Poovathur, Mohan
Dikshit, Abdullah Al-Asmi
P3.095
Cerebral Infarction Occurrence
in Settings of Acute Traumatic Injury.
Analysis of a Prospective Multicenter
Trial Tanya Mohindroo, Malik Adil,
Sheharyar Minhas, Adnan Qureshi
P3.096
Nonmydriatic Ocular Fundus
Photography Among Patients with Focal
Neurologic Deficits in an Emergency
Department (ED) Beau Bruce, Laurel
Vuong, Praneetha Thulasi, Valerie Biousse,
David Wright, Nancy Newman
P3.097
Peripheral Artery Disease
in Patients with Ischemic Stroke: A Cross
Sectional Observational Study Attiya
Rahman, Syed Akhtar, Qaiser Jamal
P3.098
Factors Affecting the
Acceptance of Decompressive Craniectomy
in Patients with a Malignant Middle
Cerebral Artery Infarction Seungnam Son,
Jiho Hong, Dae Seob Choi, Min Kyun Oh,
Soo-Kyoung Kim, Heeyoung Kang, Ki-Jong
Park, Nack-Cheon Choi, Oh-Young Kwon,
Byeong Hoon Lim
P3.099
NIH Stroke Scale Change
Correlates with Length of Stay in Intensive
Care Unit Stroke Patients Prashanth
Krishnamohan, Qian Fan, Michael Dobbs
3:00 p.m.–6:30 p.m.
Interventional Neurology: tPA
P3.100
Stroke Outcomes and Usage
of IV Alteplase during Pregnancy in the
Nationwide Inpatient Sample 20052010 Sarah Song, Bichun Ouyang, Taylor
Knopf, James Conners, Shawna Cutting,
Vivien Lee, Laurel Smit, Elena Kuklina
P3.101
Baseline Body Temperature:
Paradoxical Association with Severity and
Non-Modification of Treatment Benefit in
the NINDS TPA Stroke Trials Seo Hyun
Kim, Jeffrey Saver
P3.102
Collateral Circulation
Recruitment and Failure in Acute Ischemic
Stroke Patients Treated with IV rTPA. Leonard
Yeo, Prakash Paliwal, Hock Luen Teoh, Chee
Seong Seet, Eric Ting, Bernard Chan, Rahul
Rathakrishnan, Jonathan Ong, Vijay Sharma
P3.103
Direct and Indirect Cost
Burden of Stroke Mimics Post Intravenous
Tissue Plasminogen Activator (IV-tPA): A
Single Center Study Nitin Goyal, Shailesh
Male, Ameer Al Wafai, Ramin Zand
P3.104
Is the Use of r-tPA in Mild
Stroke Patients Cost-Effective? Gregory
Guzauskas, Er Chen, Pooja Khatri, Peter
Sandercock, Darren Tayama, David Veenstra
P3.112
Vessel Wall Characteristics
of Bilateral and Unilateral Moyamoya
Syndrome using High Resolution Magnetic
Resonance Imaging Russell Cerejo,
Ferdinand Hui, Stephen Jones, Emmanuel
Obusez, Ken Uchino
P3.113
Thyrotoxic Graves’ Disease
and Moyamoya-like Vasculopathy in Latino
Patients: A Case Series Nirav Shah, Gillian
Gordon-Perue, Gustavo Ortiz, Alejandro
Forteza
P3.114
Cephalometric Features
of Moyamoya Disease: A Case Control
Study Waqas Gilani, Sarwat Gilani, Malik
Adil, Adnan Qureshi
P3.115
The Association and
Treatment of Distal PICA Aneurysms
with Posterior Fossa Arteriovenous
Malformation: A Case Series David Case,
Takamasa Higashimori, Joshua Seinfeld
P3.116
Obesity in a Young Adult
Stroke Population Jina Youn, Joni Clark
P3.117
Erythropoetin associated
Posterior Reversible Encephalopathy
Syndrome Rajanandini Muralidharan,
Madhurima Anne, Elissa Fory, Wirkowski
Elizabeth
P3.118
P3.105
Reversible Cerebral
Vasoconstriction Syndrome in Association
with Fingolimod Use Scott Belliston, Nancy
Hammond, Jayashree Sundararajan
P3.106
Primary and Comprehensive
Stroke Centers
Effect Of Education to
Hospital Staff on Efficiency of Acute
Stroke Thrombolysis Dheeraj Khurana,
Anish Hirachan, Ashish Bhalla, Sudesh
Prabhakaran
Etiologies of Neurologic
Deterioration Following Intravenous
Thrombolysis for Acute Ischemic
Stroke. Alex Perchuk
P3.107
HAT Score External Validity:
A Predictor of Hemorrhagic Transformation
After Intravenous Thrombolysis Elizeu
Neto
P3.108
Determine the Gender
Differences in Outcome Following
Thrombolysis in Ischemic Stroke. Zabeend
Mahuwala, Kaustubh Limaye, Anand Patel,
Archana Hinduja, Rajan Patel
P3.109
HAT Score Outperforms 7
Other Hemorrhagic Transformation Scores
in Ischemic Stroke Patients Treated with
Thrombolysis David Asuzu, Karin Nystrom,
Janet Halliday, Charles Wira, David Greer,
Joseph Schindler, Kevin Sheth
Interventional Neurology: Large
Vessel Nonatherosclerotic
Arteriopathies
P3.119
Automated Datamining to
Create Stroke Database and Concurrent
‘Managed Alerts’ for Comprehensive
Stroke Center Metrics Ramesh Madhavan,
Fnu Abhishek, Connie Parliament, Megan
Dietrich, Navid Seraji-Bozorgzad, Pratik
Bhattacharya
P3.120
90 Day Outcomes in Stroke/
Transient Ischemic Attack Patients
Receiving Initial or Follow-up Care in
a Comprehensive Outpatient Stroke
Center Vernice Bates, Erica Westphal,
Michelle Rainka, Francis Gengo
P3.121
The Impact of a Stroke
Prevention Clinic After Discharge for TIA/
Stroke: University Hospitals Case Medical
Center Comprehensive Stroke Center
Experience Tanzila Shams, Kathleen
Vickers, Richard Jung, Cathy Sila
P3.122
Quantifying Cerebral
Collaterals in Carotid Artery Dissection
May Help Stratify Stroke Risk. Andrew
Southerland, John Gaughen, Jr., Timothy
McMurry, Max Wintermark, Jennifer
Majersik, Bradford Worrall
Rates of In-hospital Adverse
Events and Discharge Outcomes Among
Ischemic Stroke Patients Admitted to Joint
Commission Primary Stroke Centers in
United States Saqib Chaudry, Taqi Zafar,
Mohammad Afzal, Mohammad Umair,
Mohammad Owais, Gautam Sachdeva,
Malik Adil, Vishal Jani, Syed Hussain,
Adnan Qureshi
P3.111
P3.123
P3.110
Ischemic Stroke and Cervical
Artery Dissection. Risk Factors and
Functional Outcome in a Single Tertiary
Care Hospital: The Clinica Alemana Stroke
Registry (RECCA), 1997-2003 Violeta Diaz,
Maria Vicuña, Jose Fernandez, Marcela
Valenzuela, Pablo Lavados
Characteristics of Certified
Stroke Center Programs Led by Vascular
Neurologists Lucas Ramirez, Aaron Krug,
Joshua Perese, Gregory Gasparian, Suzie
Kazaryan, Nerses Sanossian
Poster Session III
P3.124
Failed Bedside Dysphagia
Screen Predicts Pneumonia Treatment in
Acute Stroke: A Resident Quality Initiative
Project in a JC-Certified Primary Stroke
Center Mohamed-Ali Babi, Mark Gorman,
Christopher Commichau, Sharon Kenney,
Lakshmi Boyle, Mary Comeau, Steve Hulsey
P3.125
Hydration Practices for the
Acute Stroke Patient in an Academic,
Certified Stroke Center Mona Bahouth,
Argye Hillis, Rebecca Gottesman
P3.126
Leadership of Certified Stroke
Center Programs Lucas Ramirez, Aaron
Krug, Joshua Perese, Gregory Gasparian,
Suzie Kazaryan, Nerses Sanossian
P3.127
Compare the Weekend
Effect in Telestroke and Primary Stroke
Center. Zabeend Mahuwala, Anand Patel,
Kaustubh Limaye, Archana Hinduja, Nicolas
Bianchi, Rajan Patel
P3.128
Differences in Payment for
Inpatient Transient Ischemic Attack Care
Between Stroke Center and Non-StrokeCenter Hospitals Shuhan He, Sebina Bulic,
Suzie Kazaryan, Steven Cen, May Kim, May
Kim, William Mack, Nerses Sanossian
Disease: Tools for Clinical
Assessment and Therapeutic
Response
P3.129
Multiple Sclerosis
Performance Test: A Reliable, Sensitive,
and Meaningful Tool to Quantify MS
Related Disability Richard Rudick, Deborah
Miller, Francois Bethoux, Stephen Rao, JarChi Lee, Darlene Stough, Christine Reece,
David Schindler, Jay Alberts
P3.130
Multiple Sclerosis
Documentation System MSDS3D—
Innovative Management of Patients with
Multiple Sclerosis Judith Eisele, Raimar
Kern, Suhrbier Alexander, Lars Großmann,
Thorsten Schultheiss, Tjalf Ziemssen
P3.131
Psychometric Properties of
the MSIS-29 and Factors Predicting Score
Changes in Clinical Trials: An Analysis
of Data from the SELECT Study Glenn
Phillips, Jane Castelli-Haley, Shien Guo,
Irina Proskorovsky, Jacob Elkins
P3.132
The Multiple Sclerosis
Performance Test: An Innovative Approach
to Measuring MS-Related Manual
Dexterity Impairment Francois Bethoux,
Richard Rudick, Deborah Miller, Stephen
Rao, Jar-Chi Lee, Darlene Stough, Christine
Reece, David Schindler, Jay Alberts
P3.133
Multiple Sclerosis Decision
Model (MSDM): A Multifactorial Model to
Monitor Treatment Response and Disease
Course in Relapsing Remitting Multiple
Sclerosis Martin Stangel, Iris Katharina
Penner, Boris Kallmann, Carsten Lukas,
Bernd Kieseier, Ralf Gold
P3.134
Plasticity-Based Cognitive
Remediation in Multiple Sclerosis
(MS) Leigh Charvet, Maria Amella, William
Scherl, Dana Serafin, Emily Taub, Patricia
Melville, Lauren Krupp
P3.135
Kinect-based Gait Analysis in
Patients with Multiple Sclerosis Janina
Behrens, Karen Otte, Sebastian MansowModel, Alexander Brandt, Friedemann Paul
P3.136
The Turkish Multiple
Sclerosis Walking Scale (MSWS-12v2T):
Is it the Same Measure as the Original
Version? Hussein Dib, Yusuf Tamam, Murat
Terzi, Jeremy Hobart
P3.137
Patient Preferences in the
Choice of Disease Modifying Drugs for
Multiple Sclerosis Arnfin Bergmann,
Michael Lang, Christian Ludger Bischoff,
Petra Schicklmaier, Hans-Dieter Nolting,
Guido Schiffhorst, Julian Rellecke, Erika
Kunz
P3.138
Identifying Individuals with
Multiple Sclerosis in an Electronic Medical
Record Kristen Krysko, Noah Ivers,
Jacqueline Young, Paul O’Connor, Karen Tu
P3.139
Assessment of Disability in
Multiple Sclerosis Using the Kinect-Camera
System: A Proof-of-Concept Study Marcus
D Souza, Christian Kamm, Jessica
Burggraaff, Prejaas Tewarie, Ben Glocker,
Jonas Dorn, Thomas Vogel, Cecily Morrison,
Abigail Sellen, Matthias Machacek, Peter
Chin, Bernard Uitdehaag, Antonio Criminisi,
Frank Dahlke, Chris Polman, Ludwig Kappos
P3.140
Multiple Sclerosis
Performance Test: Patients Express High
Satisfaction with the Application Deborah
Miller, Jar-Chi Lee, Francois Bethoux,
Stephen Rao, Jay Alberts, David Schindler,
Darlene Stough, Christine Reece, Richard
Rudick
P3.141
Cultural Adaptation and
Evaluation of the Psychometric Properties
of the MSTCQ© “MS Treatment Concerns
Questionnaire” Spanish Language
Version Elvira Munteis, Navarro Guillermo,
Jose Meca La Llana, Asuncion Maestre
Martinez, Ángel Sempere, Julia Gracia,
Antonio Pato
P3.142
Validating an Electronic
Method for Prospective Fall Counting in
People with MS Ashley Downs, Charles
Murchison, Rajarshi Mazumder, Michelle
Cameron
P3.143
The Role of G-tubes In
Decreasing UTIs in a Cohort of Patients
with Advanced MS Kathleen Healey, Neil
Jouvenat, Mac McLaughlin, Lyndsay HartWann, Kristine Rutledge, Rana Zabad
P3.144
Graded Response Analysis of
the MSIS-29 in Clinical Trial Participants
with Relapse-Remitting Multiple
Sclerosis Glenn Phillips, Elizabeth Danzie,
Kathy Wyrwich
P3.145
Comparing Disability of
Multiple Sclerosis Cohort in a Tertiary Clinic
and Volunteer North American Research
Committee on Multiple Sclerosis Registry
Using Patient-Derived Multiple Sclerosis
Severity Score Ariel Antezana, Joseph
Herbert, Eric Chamot, Gary Cutter, Amber
Salter, Ilya Kister
P3.146
Relationship Between
Immunological Markers and Short-term
Brain Volume Changes in Patients with
Relapsing-Remitting Multiple Sclerosis
Receiving Interferon Beta-1a Michael
Dwyer, Robert Zivadinov, Yazhong Tao, Xin
Zhang, Cheryl Kennedy, Niels Bergsland,
Deepa Ramasamy, Jackie Durfee, David
Hojnacki, Bianca Weinstock-Guttman,
Brooke Hayward, Fernando Dangond, Silva
Markovic-Plese
P3.153
P3.147
P3.154
Correlations Between
Immunological Biomarkers and
Conventional and Advanced MRI
Measures Following Interferon Beta-1a
Treatment for Relapsing-Remitting
Multiple Sclerosis Silva Markovic Plese,
Yazhong Tao, Xin Zhang, Michael Dwyer,
Cheryl Kennedy, Niels Bergsland, Deepa
Ramasamy, Jacqueline Durfee, David
Hojnacki, Bianca Weinstock-Guttman,
Brooke Hayward, Fernando Dangond,
Robert Zivadinov
P3.148
Burden of Multiple Sclerosis
on Caregivers and Patients and Degree of
Satisfaction with Current Treatment: The
MS-Feeling Study José Meca, Maria Del
Mar Mendibe Bilbao
Disease: Clinical Trials Outcomes
P3.149
Clinical Trial of Helminthinduced Immunomodulatory Therapy
(HINT 2) in Relapsing-Remitting Multiple
Sclerosis John Fleming, Leslie Hartman,
Jane Maksimovic, Sara Nace, Christopher
Luzzio, Monica Koehn, Anna Ritter, Todd
Risa, Benjamin Lawler, Andrea Maser,
Pamela Mundt, Loren Rolak, Thomas Cook,
Aaron Field, Zsuzsanna Fabry
P3.150
Safety and Efficacy of
Teriflunomide for up to 9 Years in Relapsing
Forms of Multiple Sclerosis: Update of the
TEMSO Extension Trial Mark Freedman,
Jerry Wolinsky, Giancarlo Comi, Ludwig
Kappos, Tomas Olsson, Aaron Miller,
Myriam Benamor, Deborah Dukovic, Jinjun
Liang, Philippe Truffinet, Paul O’Connor
P3.151
Safety and Efficacy of
Siponimod (BAF312) in Patients with
Relapsing-Remitting Multiple Sclerosis:
Results from Dose-blinded Extension Phase
of BOLD Study Ludwig Kappos, Olaf Stuve,
Hans Hartung, Mark Freedman, David Li,
Bernhard Hemmer, Peter Rieckmann, Xavier
Montalban, Tjalf Ziemssen, Brian Hunter,
Sophie Arnould, Erik Wallstrom, Krzysztof
Selmaj
P3.152
24-month Interim Results
of PANGAEA: A 5-year Registry Study
Evaluating Long-term Safety, Efficacy
and Pharmacoeconomic Data of German
Multiple Sclerosis Patients on Fingolimod
Therapy Tjalf Ziemssen, Maria DiazLorente, Alexandra Fuchs, Christian
Cornelissen
A Multinational, Multicenter,
Randomized, Double-Blind, ParallelGroup, Active-Control Study to Evaluate
the Efficacy, Safety, and Tolerability of
Oral Laquinimod 0.6mg or 1.2mg QD
versus IFNβ-1a in Patients with Relapsing
Remitting Multiple Sclerosis Hans-Peter
Hartung, Frederik Barkhof, Oscar Fernandez,
Jeremy Hobart, Gavin Giovannoni, Maria
Pia Sormani, Yuval Dadon, Nissim Sasson,
Volker Knappertz
Efficacy and Safety of Anti
LINGO-1 for the Treatment of Relapsing
Forms of Multiple Sclerosis: Design of the
Phase 2 SYNERGY Trial Diego Cadavid,
Glenn Phillips, Tuan Dong-Si, Jonathan Tran,
Lei Xu
P3.155
Pilot Trial of Recombinant
Human Growth Hormone for Remyelination
in Multiple Sclerosis: Current Status
and Preliminary Safety Analysis Muriel
Stoppe, Barbara Ettrich, Eva Thomae,
Juergen Kratzsch, Karl-Titus Hoffmann, Dirk
Hasenclever, Florian Then Bergh
P3.156
Fingolimod Efficacy and Safety
in an African-American Patient Subgroup
from FREEDOMS II Patricia Coyle, Bruce
Cree, Philippe Cabre, Matilde Inglese, Jai
Perumal, Xiangyi Meng, Peter Chin, Ron
Hashmonay, Omar Khan
P3.157
Predicting Confirmed Disability
Progression in MS: Importance of Early
on-Treatment MRI Changes on Modeling
the CombiRx Trial Database Florent Lalys,
Leorah Freeman, John Lincoln, Flavia
Nelson, Ponnada Narayana, Stacey Cofield,
Tarah Gustafson, Gary Cutter, Fred Lublin,
Jerry Wolinsky
P3.158
Alemtuzumab Improves Visual
Outcomes Versus Subcutaneous Interferon
Beta-1a in Patients with Active RelapsingRemitting Multiple Sclerosis (RRMS)
Who Relapsed on Prior Therapy: Analysis
from the CARE-MS II Study Jennifer
Graves, Laura Balcer, Jeffrey Palmer, David
Margolin, Steven Galetta
P3.159
Effect of Delayed-Release
Dimethyl Fumarate on Freedom from
Measured Clinical and Neuroradiological
Disease Activity in Relapsing-Remitting
Multiple Sclerosis (RRMS) Patients:
An Integrated Analysis of DEFINE and
CONFIRM Eva Havrdova, Ralf Gold, Robert
Fox, Ludwig Kappos, J. Theodore Phillips,
Annie Zhang, Nuwan Kurukulasuriya, Sarah
Sheikh, Vissia Viglietta, Gavin Giovannoni
P3.160
4-Year Follow-up of DelayedRelease Dimethyl Fumarate Treatment in
(RRMS): Integrated Magnetic Resonance
Imaging (MRI) Outcomes from DEFINE,
CONFIRM, and the ENDORSE Extension
Study Douglas Arnold, Robert Fox, Ralf
Gold, Eva Havrdova, Ludwig Kappos, Tarek
Yousry, Ray Zhang, Minhua Yang, Vissia
Viglietta, Sarah Sheikh, David Miller
73
Tuesday
April 29
Tuesday, April 29
P3.161
Effect of Ceralifimod
(ONO-4641), a Sphingosine-1-Phosphate
Receptor-1 and -5 Agonist, on Magnetic
Resonance Imaging Outcomes in Patients
with Multiple Sclerosis: Interim Results from
the Extension of the DreaMS Study Amit
Bar-Or, Frauke Zipp, Matthew Scaramozza,
Timothy Vollmer, Bryan Due, Karthinathan
Thangavelu, Tanya Fischer, Krzysztof Selmaj
P3.162
Effect of Delayed-Release
Dimethyl Fumarate on Health-Related Quality
of Life in Relapsing-Remitting Multiple
Sclerosis (RRMS) Patients According to Prior
Therapy: An Integrated Analysis of the Phase
3 DEFINE and CONFIRM Studies Ludwig
Kappos, Robert Fox, Ralf Gold, Mariko Kita, J.
Theodore Phillips, Sujata Sarda, Lixian Zhong,
Timothy Niecko, Nuwan Kurukulasuriya, Gavin
Giovannoni
P3.163
Disability Progression in
Multiple Sclerosis Patients Treated with
Natalizumab in the Long-term STRATA
Study Andrew Goodman, Ludwig Kappos,
Fred Lublin, Shibeshih Belachew, Madalina
Chirieac, Fiona Forrestal, Petra Duda
P3.164
Patients Free of Clinical MS
Activity in TEMSO and TOWER: Pooled
Analyses of Two Phase 3 Placebo-Controlled
Trials Tomas Olsson, Giancarlo Comi, Mark
Freedman, Aaron Miller, Jerry Wolinsky,
Philippe Truffinet, Steven Cavalier, Deborah
Dukovic, Paul O’Connor, Ludwig Kappos
P3.165
Sustained Improvement in
Disability Outcomes with Alemtuzumab
in Active Relapsing-Remitting Multiple
Sclerosis Patients Who Participated in
CARE-MS II: Three-year Follow-up Gavin
Giovannoni, David Margolin, Jeffrey Palmer,
Joseph Herbert
P3.166
Categorical Change in T2
Lesion Volume and Clinical Outcomes in
the Phase III FREEDOMS and its Extension
Study, Evaluating Fingolimod in Patients
with Relapsing-Remitting Multiple
Sclerosis Douglas Jeffery, Elisabetta
Verdun Di Cantogno, Daniela Meier,
Michael Meinel, Peter Chin, William Camu
P3.167
A Stabilized Release
Neuropeptide exhibits efficacy in a Phase
II Double Blind Placebo Controlled Clinical
Trial of Secondary Progressive Multiple
Sclerosis Christopher Moore, Jeffery
Vernes, Deirdre McIntosh, Syed Haq
P3.168
Oral versus Intravenous
High Doses of Methylprednisolone in
Multiple Sclerosis Relapses, a Double
Blinded Randomised Controlled Trial
(COPOUSEP): Results at 1 Month (Primary
End Point) Emmanuelle Le Page, David
Veillard, David Laplaud, Rasha Wardi,
Christine Lebrun Frenay, Fabien Zagnoli,
Sandrine Wiertlewski, Veronique
Deburghgraeve, Marc Coustans, Gilles Edan
P3.169
Subgroup and Sensitivity
Analyses of the Primary Endpoint from
the Peginterferon Beta-1a ADVANCE
Study: A Pivotal Phase 3 Study in Patients
Sclerosis Bernd Kieseier, Douglas Arnold,
Ying Zhu, Shifang Liu, Serena Hung, Aaron
Deykin, Sarah Sheikh
74
P3.170
A Phase I/II Study of Pixantrone
in Patients with an Aggressive RelapsingRemitting or SecondaryProgressive Multiple
Sclerosis (PIXAMS) Richard Gonsette, Gilles
Edan, Marc Debouverie, Christian Sindic,
Jean Christophe Ferre
P3.171
Clinical Efficacy of DelayedRelease Dimethyl Fumarate in Minority
Patients with Relapsing-Remitting Multiple
Sclerosis (RRMS): An Integrated Analysis
of the Phase 3 DEFINE and CONFIRM
Studies Michael Hutchinson, J. Theodore
Phillips, Macaulay Okwuokenye, Nuwan
Kurukulasuriya, Ralf Gold, Robert Fox
P3.172
FDA-Approved Phase I Clinical
Trial of Autologous Neural Progenitors
Injected Intrathecally in Multiple
Sclerosis Violaine Harris, Daniel Koffler,
Sydney Chirls, Saud Sadiq
P3.173
4-Year Follow-up of DelayedRelease Dimethyl Fumarate Treatment in
(RRMS): Integrated Clinical Efficacy Data
From DEFINE, CONFIRM, and the ENDORSE
Extension Study Ralf Gold, Ted Phillips,
Amit Bar-Or, Michael Hutchinson, Ludwig
Kappos, Ray Zhang, Minhua Yang, Vissia
Viglietta, Sarah Sheikh, Robert Fox
P3.174
Efficacy of Fingolimod in
Pre-treated Patients with Disease Activity:
Pooled Analyses of FREEDOMS and
FREEDOMS II Niklas Bergvall, Nicolaos
Sfikas, Peter Chin, Davorka Tomic, Philipp
Von Rosenstiel, Ludwig Kappos
P3.175
Comparative Efficacy of
Switching to Natalizumab Versus Switching
to Interferon-Beta or Glatiramer Acetate
After On-treatment MS Relapse Using
Propensity-Matched Registry Data Maria
Trojano, Timothy Spelman, Tomas Kalincik,
Annie Zhang, Heinz Wiendl, Ludwig Kappos,
Shibeshih Belachew, Robert Hyde, Freek
Verheul, Francois Grand-Maison, Helmut
Butzkueven
P3.176
The PREFERMS Study:
Evaluating Real-world Patient Retention on
Oral Fingolimod Compared with Injectable
Disease Modifying Therapies in RelapsingRemitting Multiple Sclerosis Nadia
Tenenbaum, Lesley Schofield, Xiangyi
Meng, Ralph Kern
P3.177
Evaluation of Immunogenicity
in Multiple Sclerosis Patients Treated
with Daclizumab-HYP During the SELECT
and SELECTION Clinical Trials Lakshmi
Amaravadi, Alvydas Mikulskis, Manjit
McNeill, Katherine Riester, Marianne
Sweetser, Jacob Elkins, Gavin Giovannoni
P3.178
Assessing a Scoring System
to Predict Disease Activity in Patients with
Multiple Sclerosis: Post Hoc Analyses of
Data from Clinical Trials of Subcutaneous
Interferon Beta-1a Mark Freedman,
Ali-Frédéric Ben-Amor, Ernesto Aycardi,
Delphine Issard, Florence Casset-Semanaz
3:00 p.m.–6:30 p.m.
P3.179
Lymphocyte Count Reductions
in Relapsing-Remitting Multiple Sclerosis
(RRMS) Patients Treated with DelayedRelease Dimethyl Fumarate: An Integrated
Analysis of the Placebo-Controlled
Studies Robert Fox, Ralf Gold, J. Theodore
Phillips, Krzysztof Selmaj, Kartik Raghupathi,
Huixing Yuan, John O’Gorman, Mark Novas,
Vissia Viglietta, Nuwan Kurukulasuriya
P3.189
P3.180
P3.190
Consistent Reduction in
the Annualized Rate of Brain Volume
Loss Across Phase 3 Core and Extension
Trials of Fingolimod in Relapsing Multiple
Sclerosis Ernst-Wilhelm Radue, Till
Sprenger, Peter Chin, Daniela Piani Meier,
Nicolaos Sfikas, Frederik Barkhof
P3.181
Lymphocyte Counts Do Not
Predict Risk of Subsequent Relapse or
Disability Accumulation in AlemtuzumabTreated Relapsing-Remitting Multiple
Sclerosis Patients: An Analysis of the
CARE-MS Studies Alasdair Coles, Jeffrey
Palmer, David Margolin
P3.182
Early and Consistent
Reduction in Relapses among Patients with
Receiving Subcutaneous Interferon
Beta-1a: A Post-Hoc Analysis of PRISMS
Data Mark Cascione, Carol Gaines, Juanzhi
Fang, Fernando Dangond, Aaron Miller
P3.183
Patient-Reported Outcomes
After Therapy Switch to Fingolimod:
Post-hoc Subgroup Analysis of the EPOC
Study Barry Singer, Mark Gudesblatt,
Neetu Agashivala, Stan Li, Simrat
Randhawa, Kevin McCague, Luigi Barbato
P3.184
Diagnosing Multiple Sclerosis:
Analysis of the Output from an Adjudication
Panel in the Setting of a MS Diagnostic
Assay Clinical Trial Benjamin Greenberg,
Nancy Monson, Douglas Bigwood, Eric
Eastman
P3.185
Four-year Expanded Disability
Status Scale (EDSS) Outcomes in Patients
Treated with Fingolimod in the Phase 3 and
Extension Trial Program Bruce Cree, Jeffrey
Cohen, Peter Chin, Shannon Ritter, Daniela
Piani Meier, Philipp von Rosenstiel, Ludwig
Kappos
P3.186
Natalizumab in Patients with
Early MS: The STRIVE Study Roumen
Balabanov, Jai Perumal, Robert Fox, Denise
Campagnolo, Emese Dian, Stefan Lanker,
Jiankang Liu, Mary-Jean Fanelli
P3.187
Reduction in Brain Atrophy
with Extended Daclizumab HYP Treatment:
Results of SELECT and the SELECT
Extension Study Ernst-Wilhelm Radue,
Dusan Stefoski, Ralf Gold, Manjit McNeill,
Katherine Riester, Jacob Elkins
P3.188
Decrease in T1 Black Hole
Volume Over 2 Years of Daclizumab HighYield Process Treatment Jacob Elkins,
Eva Havrdova, Manjit McNeill, Katherine
Riester, Ernst-Wilhelm Radue
Clinical Efficacy of DelayedRelease Dimethyl Fumarate in RelapsingRemitting Multiple Sclerosis (RRMS)
Patients with Highly Active Disease:
An Integrated Analysis of the Phase 3
DEFINE and CONFIRM Studies Michael
Hutchinson, Annie Zhang, Minhua Yang, Ray
Zhang, Nuwan Kurukulasuriya, Robert Fox,
Ralf Gold
Do MRI Lesions Predict MS
Relapses? Nancy Richert, Fiona Forrestal,
Sophia Lee, Petra Duda
P3.191
The Vitamin D to Ameliorate
Multiple Sclerosis (VIDAMS) Trial Pavan
Bhargava, Sonya Steele, Sandi Cassard,
Elizabeth Sugar, Daniel Pelletier,
Emmanuelle Waubant, Ellen Mowry
P3.192
Pharmacokinetics of Vitamin D
in Multiple Sclerosis Patients and Healthy
Controls. Sonya Steele, Pavan Bhargava,
Jacqueline Marcus, Nisha Revirajan,
Emmanuelle Waubant, Ellen Mowry
P3.193
Efficacy Benefits of Fingolimod
0.5 mg Once Daily in Patients Previously
Treated with Glatiramer Acetate: Pooled
Analysis of the Phase 3, Placebo-controlled
FREEDOMS and FREEDOMS II Studies
in Relapsing Multiple Sclerosis Douglas
Jeffrey, Ernst-Wilhelm Radue, Goeril
Karlsson, Hanzhe Zheng, Philipp Von
Rosenstiel, Ludwig Kappos
P3.194
Pharmacokinetics and
Pharmacodynamics of Peginterferon Beta1a in Patients with Relapsing-Remitting
Multiple Sclerosis: Data from the Pivotal
Phase 3 ADVANCE Study Xiao Hu, Yue Cui,
Joleen White, Ying Zhu, Aaron Deykin, Ivan
Nestorov, Serena Hung
P3.195
Mediation of the Effect of
Laquinimod on Disability Progression in
(RRMS) Giancarlo Comi, David Ladkani,
Timothy Vollmer, Maria Pia Sormani, Yulia
Sidi, Volker Knappertz
P3.196
MRI Correlates of Disability:
Neuroimaging Substudy at 20 Years in the
Ongoing US Glatiramer Acetate Open-label
Extension Study Omar Khan, Fen Bao,
Megha Shah, Gautam Ramesh, Christina
Caon, Carla Santiago, Zahid Latif, Rimma
Aronov, Imad Zak, Yulia Sidi, Scott Kolodny
Clinical Aspects
P3.197
Validation of a Simple
Model for Prediction of Disease Duration
in Persons Presenting with Alzheimer
Disease: “ Tell Me Doc, How Long do I
Have?” Ashleigh Long, Richard Kryscio,
Gregory Jicha
P3.198
Frontal Release Signs
in Adults with Down Syndrome Are
Associated with Dementia Gregory Jicha,
Mellani Lefta, William Robertson, Elizabeth
Head, Frederick Schmitt
P3.199
Computerized Cognitive
Testing of Individuals with Down Syndrome
and Alzheimer Disease Michael Gutman,
Ethan Moskovic, Joseph Jeret
Poster Session III
P3.200
Clinical Features of
Mild Cognitive Impairment of the
Cerebrovascular Type (MCI-CVD) Gregory
Jicha, Laura Hench, Debra Moser, Erin Abner
P3.201
Clinical Characteristics of
bvFTD Across CDR Stages Kamalini
Ranasinghe, Peter Pressman, David Perry,
Katherine Rankin, Bruce Miller
P3.202
Visual Perception Test Predicts
a Pathological Diagnosis of Alzheimer’s
Disease in Patients Presenting with
Corticobasal Syndrome Clara Boyd, Michael
Tierney, Eric Wassermann, Karen Marder,
Salvatore Spina, Adrian Oblak, Bernardino
Ghetti, Jordan Grafman, Edward Huey
P3.203
Mental Status Examination
Practices Among Resident and Attending
Physicians in Patients Hospitalized for
Evaluation of Confusion Serggio Lanata,
Brian Ott
P3.204
Assessment of Memory in the
Clinic: How Useful Is Cued Recall? Christian
Bocti, Catherine Liu, Helene Imbeault, Nancy
Leblanc, Francis Langlois
P3.205
Plasma Levels of HDL and
Carotenoids Are Lower in Alzheimer’s
Disease Patients with Vascular
Comorbidities But Plasma Protein Nitration
and Oxidation Is Unaffected Gereon
Nelles, Irundika Dias, Daniela Weber, Li Li,
Wilhelm Stahl, Tilman Grune, Maria Polidori,
Helen Griffiths
P3.206
Atypical Antipsychotic
Utilization in Dementia Patients at a
Long-Term Care Facility: A Retrospective
Study Douglas Scharre, Shu-Ing Chang,
Haikady Nagaraja, Michael Merjanian, Gail
Greenley, Rebecca Davis
P3.207
P3.212
The Role of Gender
Differences in Dementia Caregiver
Risk Carol Lippa, Kate Bowen, Candace
Robertson-James, Ana Nunez, Elizabeth
Gonzalez
P3.213
Normal Cognition in a 99-yearold Man with High Levels of Alzheimer
Disease Pathology Kristoffer Nissinen,
Barbara Agee Shah, Maria Corrada, Ronald
Kim, Szofia Bullain, Claudia Kawas
P3.214
Intermittent Temporal Slowing
in Cognitively Normal Oldest-old: The 90+
EEG Study Szofia Bullain, Maria Corrada,
Dana Greenia, Claudia Kawas
P3.215
Neuropsychiatric Symptoms,
ApoE4 and the Risk of Incident Dementia:
The Mayo Clinic Study of Aging Anna Pink,
Jazmin Acosta, Rosebud Roberts, Michelle
Mielke, Teresa Christianson, Vernon
Pankratz, G Stokin, Bradley Boeve, Yonas
Geda
P3.216
Cognitive Reserve markers
independently predict Cognitive outcomes
in patients with SAH Neha Dangayach,
Laura Zhaodne, Yaakov Stern, Christina
Falo, Sachin Agarwal, Meyers Emma, Jan
Claassen, Stephan Mayer
Executive Function
P3.217
Functional Near-Infrared
Spectroscopy (fNIR) based Detection of
Increased Prefrontal Cortex Activity in
Frontotemporal Dementia Jillian Edwards,
Tooba Fayyaz, Lauren Scull, Hasan Ayaz,
Patricia Shewokis, David Libon, Carol Lippa,
Anahita Deboo, Terry Heiman-Patterson
Amyloid PET Screening
for Enrollment into Alzheimer’s Disease
Clinical Trials: Initial Experience in a Phase
1b Clinical Trial Jeff Sevigny, Joyce Suhy,
Ping Chiao, Gregory Klein, Joonmi Oh, Derk
Purcell, Mehul Sampat, Jerome Barakos
P3.218
P3.208
Cognitive and Functional
Decline and their Relationship in Patients
with Mild Alzheimer’s Disease Hong LiuSiefert, Eric Siemers, Karen Sundell, Karen
Price, Baoguang Han, Katherine Selzler, Joel
Raskin, Richard Mohs
P3.219
P3.209
P3.220
Florbetapir F18 PET Amyloid
Neuroimaging and Baseline Characteristics in
Patients with Alzheimer’s Dementia Elisabeth
Degenhardt, Michael Witte, Michael Case,
Peng Yu, David Henley, Helen Hochstetler,
Deborah DSouza, Paula Trzepacz
P3.210
Impact of Amyloid Beta
Imaging on Diagnosis and Clinical
Management of Hypothetical Patients
with Mild Cognitive Impairment or
Dementia. Joshua Cohen, Yue Zhong,
Jason Karlawish
P3.211
MRI Volumetric Analysis,
Cognitive Profiles and Biomarkers
in a Sample of Argentina -ADNI
patients Marcos Fernandez Suarez,
Griselda Russo, Patricio Chrem Mendez,
Fernando Ventrice, Ezequiel Surace, Maria
Russo, Jorge Campos, Federico Nahas,
Gustavo Sevlever, Silvia Vazquez, Ricardo
Allegri
Strategic Choice In
Frontotemporal Dementia: Evidence From
The Ultimatum Game Stefano Cappa,
Alessandra Dodich, Chiara Cerami, Nicola
Canessa, Chiara Crespi, Alessandra
Marcone
Digit Span: A Comparison
of Chinese Versus Alphabetic Language
Speakers in Dysexecutive Dementia
Patients Simon Kang Seng Ting, Shahul
Hameed, Eng-King Tan, Christopher Gabriel,
Kinjal Doshi
P3.224
Neuroanatomy of GoalDirected Behavior in behavioral variant
Frontotemporal Degeneration Lauren
Massimo, John Powers, Lois Evans, Brianna
Morgan, Corey McMillan, Katya Rascovsky,
Paul Eslinger, Mary Ersek, Murray Grossman
P3.225
Temporal Discounting of
Future Rewards in Behavioral Variant
Frontotemporal Dementia (bvFTD) and
Alzheimer’s Disease (AD) Katya Rascovsky,
Joe Kable, Rebecca Kazinka, Eileen Moran,
Christopher Olm, Jenna Glasenberg, Ashley
Boller, Joe McGuire, Corey McMillan, Robin
Clark, Murray Grossman
P3.226
Video Tracking of Cancellation
Is Sensitive to Acute Brain Impairment
and Disability Lynita Mullins, Victor Mark,
Adam Woods, Mary Banasiewicz
Neurophysiology: Clinical
Manifestations
P3.227
Epileptic Vertigo and
Dizziness—a Systematic Review of the
Literature Alexander Tarnutzer, Seung-Han
Lee, Karen Robinson, Peter Kaplan, David
Newman-Toker
P3.228
Whistling Seizure: A Unique
Case Report of a Rare Automatism Kaitlyn
Lillemoe, Daniel Torres, Anuradha Singh
P3.229
Post-ictal Lateralized
Hyperkinetic Motor Behavior Brian Beck,
Gregory Chang
P3.230
Epilepsy Classification in
Adults with a First Epileptic Seizure;
Experience from a Tertiary Epilepsy
Clinic Michael Koutroumanidis, Vasiliki
Tsirka, Ioannis Zoukos, Mark Richardson
P3.231
Seizures Without Awareness:
A Pure Cohort William Tatum, Langston
Michael, Kirsten Yelvington, Jerry Shih
P3.232
A Stimulating Inner
Conversation Daniel Goldenholz, Xiangping
Zhou, William Theodore, Kareem Zaghloul,
Sara Inati
P3.233
Pancytopenia Associated
with Shapiro Syndrome in a Patient with
Posterior Porencephaly Jordan Schaefer,
Amy Crepeau, Vilmarie Rodriguez
Transfer of Working Memory
Performance Enhancement Induced by
Transcranial Direct Current Stimulation
(tDCS) Jay Gill, Roy Hamilton
P3.234
P3.221
P3.235
Correlation of Executive
Dysfunction and Delusions or
Hallucinations with Autoimmune
and Paraneoplastic Antibodies in
Elderly Presenting with Memory
Complaints Rhonna Shatz, Wendy Lemere,
Lynn Etters, Marina Novikova
P3.222
Hyperostosis Frontalis
Interna, Causing Frontal Lobe Dysfunction
and Refractory Headaches Mitra Assadi
Khansare, Marc Duome, Arlan Mintz
P3.223
Beyond Words: Pragmatic
Inference in the Behavioral Variant of
Frontotemporal Dementia Nicola Spotorno,
Corey McMillan, Katya Raskovsky, Robin
Clark, Murray Grossman
Hemimegalencephaly: Adult
Evolution Nicky Wu, Felippe Borlot, Anfal
Ali, Timo Krings, Andres Lozano, Danielle
Andrade
New Onset Seizures in
Elderly: Clinical Presentation and Etiology
of First Ever Seizure Erum Shariff, Majed
Alhameed
P3.236
Subclinical EEG Seizures as
a Predictor of Tumor Progression in Brain
Tumor Patients Presenting with Altered
Mental Status Meghan Ward, Simran
Singh, Irena Garic, Jeffrey Kennedy, Priya
Kumthekar, Michael Macken, Elizabeth
Gerard, Jeffrey Raizer, Stephan Schuele
Neurophysiology: AED
P3.237
Safety of Eslicarbazepine
Acetate in Patients with Refractory PartialOnset Seizures Treated With or Without
Concomitant Carbamazepine: A Pooled
Analysis of Three Phase III Controlled
Studies Selim Benbadis, Victor Biton,
Mercedes Jacobson, Eugen Trinka, Mar
Carreño, David Blum, Patrício Soaresda-Silva, Helena Gama, Rui Sousa, Todd
Grinnell, Raymond Claus
P3.238
Effects of Eslicarbazepine
Acetate on Cardiac Function in Patients
with Refractory Partial-Onset Seizures:
A Pooled Analysis of Three Phase III
Controlled Studies Inna Vaisleib, Patricia
Penovich, Bassel Shneker, Elza Yacubian,
David Blum, Helena Gama, Patrício Soaresda-Silva, Todd Grinnell
P3.239
Efficacy of Eslicarbazepine
Acetate in Patients with Refractory
Partial-Onset Seizures Treated With or
Without Concomitant Carbamazepine:
A Pooled Analysis of Three Phase III
Controlled Studies Steve Chung, Gregory
Krauss, Michael Sperling, Eugen Trinka, Mar
Carreño, David Blum, Patrício Soares-daSilva, Rui Sousa, Todd Grinnell, Hailong
Cheng
P3.240
Safety of Eslicarbazepine
Acetate in Elderly Subjects: A Pooled
Analysis of Five Phase II Placebo-controlled
Non-Epilepsy Studies Eva Andermann, R.
Eugene Ramsay, Elinor Ben-Menachem,
David Blum, Helena Gama, Patrício Soaresda-Silva, Todd Grinnell
P3.241
Incidence of Allergic Reaction
Adverse Events during Adjunctive
Treatment with Eslicarbazepine Acetate
in Patients with Refractory Partial-Onset
Seizures: A Pooled Analysis of Three Phase
III Placebo-Controlled Studies Joanne
Rogin, Trevor Resnick, Laura Strom, Elinor
Ben-Menachem, Silvia Kochen, David Blum,
Helena Gama, Patrício Soares-da-Silva,
Todd Grinnell
P3.242
Conversion to Monotherapy
with Eslicarbazepine Acetate in Adults
with Partial-Onset Seizures—Results of a
North-American Study Michael Sperling,
J. Harvey, David Blum, Todd Grinnell
P3.243
Co-administration of
Carbamazepine with Eslicarbazepine
Acetate Decreases Eslicarbazepine
Exposure: A Population Pharmacokinetic
Analysis Blanca Vazquez, Robert Wechsler,
William Rosenfeld, Christian Elger, Pedro
Kowacs, Patrício Soares-da-Silva, Joana
Moreira, Jahnavi Kharidia, Gary Maier,
David Blum, Todd Grinnell
P3.244
Pharmacokinetic Rationale
for mg-to-mg Overnight Switch from b.i.d.
Immediate Release Topiramate (TPM-IR)
to Extended-release Once-daily SPN-538
(Trokendi XR™) Jennifer Dugan Stocks,
Janet Johnson, Scott Brittain, Paolo Baroldi
75
Tuesday
April 29
Tuesday, April 29
P3.245
Steady-State Bioequivalence
of Extended-release Once-daily SPN-538
(Trokendi XR™) to Immediate-Release
Topiramate (TPM-IR, Topamax®) Janet
Johnson, Scott Brittain, Jennifer Dugan
Stocks, Paolo Baroldi
P3.246
Topiramate Pharmacokinetics
of Extended-release Once-daily SPN-538
(Trokendi XR™) in the Elderly Welton
O’Neal, Scott Brittain, Jennifer Dugan
Stocks, Janet Johnson, Paolo Baroldi
P3.247Pharmacokinetic-
Pharmacodynamic Analysis of Extendedrelease Once-daily Oxcarbazepine
Formulation SPN-804 (Oxtellar XR™) in
Adults with Epilepsy Scott Brittain, Janet
Johnson, Paolo Baroldi
P3.248Oxcarbazepine
Pharmacokinetics of Extended-release
Once-daily SPN-804 (Oxtellar XR™) in the
Elderly Welton O’Neal, Scott Brittain, Janet
Johnson
P3.249
Long-Term Efficacy of
Clobazam for Drop Attacks in LennoxGastaut Syndrome Is Consistent Across
Patient Age Ranges Jouko Isojarvi,
Deborah Lee, Vivienne Shen, Jeffrey
Buchhalter
P3.250
Patients Treated with
Clobazam Experienced Fewer Seizurerelated Injuries Than Placebo Patients
During the Phase III CONTAIN Trial in
Lennox-Gastaut Syndrome Jouko Isojarvi,
Michael Sperling, Deborah Lee
P3.251
IV Carbamazepine (CBZ)
as Short-Term Replacement Therapy for
Oral CBZ in Adults with Epilepsy: Primary
Results of a Phase III Safety Trial Suresh
Dheerendra, Pavel Klein, Victor Biton,
Xiaolin Zhang, Uwa Kalu, Deborah Lee,
Jonathan Halford
P3.252
Clobazam Response in
Patients with Previous Benzodiazepine
Use: Subanalysis of the Phase III CONTAIN
Trial in Lennox-Gastaut Syndrome
(LGS) Deborah Lee, William Rosenfeld,
Jouko Isojarvi
P3.253
Long-Term Response to
Clobazam By Baseline Seizure Frequency
in Patients with Lennox-Gastaut Syndrome
(LGS) Deborah Lee, James Wheless, Jouko
Isojarvi
P3.254
Efficacy and Safety of
Clobazam in Lennox-Gastaut Syndrome:
Completers Analysis of the 15-week, Phase
III CONTAIN Trial Joan Conry, Yu-Tze Ng,
Guangbin Peng, Deborah Lee, Jouko Isojarvi
P3.255
A Comparison Between
Pharmacological Treatment of Epileptic
Patients with and Without Intellectual
Disability. Jonathan Fridhandler, Fernando
Coelho, Peter Tai, Nathalie Jette, Danielle
Andrade
P3.256
How Well Do We Know Our
AEDs? Neurology Resident Screening
Practices of AED Side Effects Gunjan
Narwani, Reena Nanjireddy, Aashit Shah,
Maysaa Basha
76
P3.257
Impact of Delayed-Dose
Administration of USL255, an Extendedrelease Topiramate Formulation Bob
Anders, Qiang Lu, Elizabeth Ludwig, Annie
Clark
P3.258
Comparison of the
Pharmacokinetics of USL255, an Extendedrelease Topiramate, When Sprinkled onto
Soft Food or Swallowed Intact Annie Clark,
Bob Anders, Mark Halvorsen
P3.259
Extended-release Oncedaily SPN-538 (Trokendi XR™) Versus
Twice-Daily TPM-IR (Topamax®): Impact
of Dosing Irregularities on Topiramate
Concentrations Scott Brittain
P3.260
Dose Linearity and Dose
Strength Equivalence of Extendedrelease Once-daily SPN-538 (Trokendi
XR™) Jennifer Dugan Stocks, Erika Roers,
Scott Brittain, Paolo Baroldi
P3.261
Efficacy, Safety, and Impact
on Quality of Life of USL255 in Patients
with Refractory Partial-Onset Seizures:
The PREVAIL Study Steve Chung, Toufic
Fakhoury, Stephan Arnold, Balduin Lawson,
Ilan Blatt, Annie Clark, Mark Halvorsen,
Venkatesh Nagaraddi, Bob Anders
P3.262
Adverse Event Profile of
USL255 in Patients with Refractory PartialOnset Seizures: The PREVAIL Study Robert
Hogan, Stephan Arnold, Toufic Fakhoury,
Bob Anders
P3.263
Efficacy of USL255 Across
Partial-Onset Seizure Types and Refractory
Patient Status: Subgroup Analyses From
the PREVAIL Study Ilan Blatt, Venkatesh
Nagaraddi, Robert Hogan, Stephan Arnold,
Balduin Lawson, Bob Anders, Annie Clark,
Mark Halvorsen, Steve Chung
P3.264
Early Onset of Efficacy and
Safety Outcomes with USL255 Treatment:
The PREVAIL Study Venkatesh Nagaraddi,
Steve Chung, Stephan Arnold, Annie Clark,
Bob Anders, Toufic Fakhoury
P3.265
USL255, Extended-release
Topiramate, Displays an Improved
Pharmacokinetic Profile with Reduced
Adverse Events Compared with ImmediateRelease Topiramate Annie Clark, Robert
Hogan, Bob Anders
P3.266
Comparison of Adverse
Effects of USL255 and Commonly
Prescribed AEDs: Assessment of Relative
Risk Kimford Meador, Frank Gilliam, Robert
Hogan, Mary Holmay, Annie Clark, Bob
Anders
P3.267
Therapeutic Time Window
of Perampanel for the Termination of
Diazepam-Resistant Status Epilepticus
(SE) in a Lithium-Pilocarpine Rat
Model Katsutoshi Ido, Takahisa Hanada
P3.268
Perampanel Clinical Studies:
Analysis of Psychiatric and Behavioral
Events Alan Ettinger, Antonia LoPresti,
Haichen Yang, Betsy Williams, Sharon Zhou,
Randi Fain, Antonio Laurenza
3:00 p.m.–6:30 p.m.
P3.269
Effect of Adjunctive
Lacosamide on Complex Partial Seizures
and Partial Seizures with Secondary
Generalization in Adults: Pooled Analysis of
Three Open-label Extension Trials Svetlana
Dimova, Cindy McShea, Pamela Doty,
Konrad Werhahn, Marc De Backer
P3.270
Anti-Seizure Effects of
Perampanel in Combination with Other
Antiepileptic Drugs (AEDs) in a Rat
Amygdala Kindling Model Ting Wu,
Takahisa Hanada
P3.271
Interim Efficacy and Safety
Analysis of Adjunctive Perampanel in
the Adolescent Population from the
Extension Phase of 3 Double-Blind,
Placebo-Controlled, Phase 3 (Core) Studies
in Patients with Refractory Partial-Onset
Seizures Ben Renfroe, Haichen Yang, Betsy
Williams, Steven Huang, Antonio Laurenza
P3.272
Analysis of Falls in Epilepsy
Patients with Partial Onset Seizures in
Perampanel Phase 3 Trials Ilo Leppik,
Haichen Yang, Betsy Williams, Sharon Zhou,
Randi Fain, Antonio Laurenza
P3.273
Adjunctive Perampanel Based on Number
of Antiepileptic Drugs at Baseline Tracy
Glauser, Antonio Laurenza, Haichen Yang,
Betsy Williams, Dongyuan Xing, Randi Fain
P3.274
Lacosamide Conversion to
Monotherapy for the Treatment of Partialonset Seizures in Adults: Results from a
Multicenter, Randomized, Double-blind,
Historical-controlled Trial Robert Wechsler,
George Li, Jacqueline French, Terence
O’Brien, O Neil D’Cruz, Paulette Williams,
Melissa Brock
P3.275
Lacosamide Added to Existing
Monotherapy in Epilepsy Patients with
Partial Onset Seizures: Second Interim
Analysis of the VITOBA Study Matthias
Noack-Rink, Thomas Mayer, Stephan
Arnold, Uwe Runge
P3.281
Differences in Usage
of Clobazam Versus Clonazepam for
Epilepsy Daniel Jones, Jouko Isojarvi, Alice
Guiraud-Diawara, Vivienne Shen, Patrice
Verpillat
P3.282
What a “Drop-Out” Reveals
About the Nocebo Effect in Patients Tricia
Ting, James Polli, Wenlei Jiang
P3.283
Hematologic Profile
Associated with Newer-generation
Anti-epileptic Medications in the Pediatric
Population Puja Joshi, Sonam Verma, Anita
Sui, Yen-Hong Kuo, Victor Johnson, Richard
Sultan
P3.284
Long-term Open-label
Extension (OLE) Study Evaluating USL255,
Once-daily Extended-release Topiramate,
in Patients with Partial Onset Seizures:
Interim Analysis from PREVAIL OLE Toufic
Fakhoury, Robert Hogan, Ilan Blatt, Steve
Chung, Bob Anders
P3.285
Pharmacokinetics of USL261,
a Novel Intranasal Formulation of
Midazolam, in Subjects with Epilepsy Lindy
Bancke, Heather Dworak, Mark Halvorsen
P3.286
Lacosamide Experience in
Patients with Lennox-Gastaut Syndrome
and Epilepsy Pedro Bermejo, Andres Cruz
P3.287
Cortical Mapping of Language
in the Basal Temporal Area in Pediatric
Patients Undergoing Epilepsy Surgery
Evaluation. Christelle Moufawad El Achkar,
Joseph Madsen, Jeffrey Bolton, Tobias
Loddenkemper
Myopathies/Muscle Disease
P3.288
Abnormalities of Mitophagy in
Sporadic Inclusion-Body Myositis (s-IBM)
Muscle Fibers Anna Nogalska, Carla
D’Agostino, Mafalda Cacciottolo, King W.
Engel, Valerie Askanas
P3.289
P3.276
Lacosamide for Uncontrolled
Primary Generalized Tonic-clonic Seizures:
An Open-label Extension Study Stephen
Yates, Robert Wechsler, Cynthia Beller
Progressive Ophthalmoplegia
with Ocular and Generalized Myopathy
with Ragged-Red Fibers, Linear
Scleroderma and Contralateral Cerebral
Hemiatrophy Walter Haupt, Monika
Rabenstein, Anna Brunn, Lothar Burghaus
P3.277
Safety and
Pharmacodynamics of USL261, a Novel
Intranasal Formulation of Midazolam, in
Subjects with Epilepsy Robert Hayes, Lindy
Bancke, Heather Dworak
P3.290
P3.278
P3.291
Can We Trust Standard
Healthy Volunteer Data to Assess Generic
Drug Quality: Lamotrigine Experience in
Patients? James Polli, Tricia Ting, Wenlei
Jiang
P3.279
Levetiracetam in the
Treatment of Epilepsy as Add On or Mono
Therapy Sarwer Al-Bajalan, Murad Kamel
P3.280
Use of Investigator Training to
Improve Seizure Classification in PREVAIL:
A Phase 3, Global Study Evaluating
USL255, Once-daily Extended-release
Topiramate, in Adults with Partial-Onset
Seizures Bree DiVentura, Jacqueline
French, Bob Anders, Dawn Laine
Carnitine Deficiency, A
Spectrum Disorder: Case Series and
Histopathological and Ultrastructural
Characterization Amanda Michael,
Bassam Malo, Stanley Iyadurai
Early Onset and Fulminant
Course of Sporadic Inclusion Body Myositis
(sIBM): A Case Report Alison Walsh, Goran
Rakocevic
P3.292
Lipid Storage Myopathy
Unmasked by the Antianginal Drug
Ranolazine Charles Kassardjian, Duygu
Selcen, Georgirene Vladutiu, Lee-jun Wong,
Margherita Milone
P3.293
Late-onset Pompe Disease:
A Case Series. Omar Jawdat, Mamatha
Pasnoor, April McVey, Ahmad Abuzinadah,
Laura Herbelin, Richard Barohn, Mazen
Dimachkie, Majed Dasouki
P3.294
Not PFK Deficiency Lydia
Sharp, Nadine Romain, Ronald Haller
Poster Session III
P3.295
Clinical Anatomical and
Epidemiologic Study of 11 Patients with
McArdle’s Disease Alzira Carvalho, Pâmela
Delgado, Miriam Koch, David Feder
P3.296
Asymptomatic Pompe
Disease: A Study of 6 Patients. Andoni
Echaniz-Laguna, Robert-Yves Carlier, Kenza
Laloui, Pierre Carlier, Emmanuelle SalortCampana, Jean Pouget, Pascal Laforet
Neurologic
Complications of Cancer
P3.307
Myelitis Following Intrathecal
Chemotherapy in Acute Lymphoblastic
Leukemia: A Case Report Alicia Parker,
Ahmed Yassin, Karin Woodman
P3.308
Muscle Disease
Atypical Neurological
Complications of Ipilimumab Therapy in
Patients with Metastatic Melanoma Alicia
Parker, Ahmed Yassin, Karin Woodman
P3.297
P3.309
Pompe Disease: Distal
Myopathy in a Previously Unreported
Heterozygous Variant João Dib, Osvaldo
Nascimento, Eduardo Davidovich, Ricardo
Dornas, Camila Pupe, Bruno Coutinho
P3.298
Frequencies of Seven
Muscle Enzyme Deficiencies in Samples
Tested for Myoglobinuria in a Clinical
Laboratory Malgorzata Jaremko, Kaylan
Burnham, Maximo Tatis, Jamie Willis, Sat
Dev Batish, Joseph Higgins
P3.299
A Diagnostic Flowchart
for POLG Related Diseases Based on
Signs Sensitivity and Specificity Maya
Tchikviladzé, Mylène Gilleron, Thierry
Maisonobe, Damien Galanaud, Pascal
Laforet, Alexandra Durr, Bruno Eymard,
Fanny Mochel, Hélène Ogier, Anthony
Béhin, Tanya Stojkovic, Bertrand Degos,
Isabelle Gourfinkel-An, Frederic Sedel,
Mathieu Anheim, Alexis Elbaz, Karine Viala,
Marie Vidailhet, Alexis Brice, Claude Jardel,
Anne Lombes
P3.300 Myopathy as a Cause of
Camptocormia: A Prospective Study JeanBaptiste Chanson, Béatrice Lannes, Andoni
Echaniz-Laguna
P3.301
Serum Cytokine Analysis
in Idiopathic Inflammatory Myopathies
Diagnosed on the Basis of Pathological
Findings Meiko Maeda
P3.302
Expanding the Clinical and
Genetic Spectrum of MYH7 Related
Skeletal Myopathies in the United
Kingdom Kathryn Brennan, Anna Sarkozy,
Cheryl Longman, Michela Guglieri, Tuomo
Polvikoski, Maria Farrugia, Richard Petty,
Victoria Murday, Dean John, Steven Hardy,
Hanns Lochmuller, Katie Bushby, Volker
Straub
P3.303
Paroxysmal Vocal Cord
Motion Dysfunction Masquerading as
Neuromuscular Disorders Darine Kassar,
William Arnold, Chad Hoyle, John Kissel
A Unique Presentation of
Pediatric Stroke Attributed to Intrathecal
Methotrexate Mohammed Ilyas, Mitchel
Williams
P3.310
Nafcillin® and Rifampin®
Therapy for MSSA Ventriculitis Associated
with CSF Shunt: A Case Report Christopher
Goshgarian, Abdulrahman Alwaki, Anibal
Lugo, Tamer Abdelhak
P3.311
Corneal Confocal Microscopy
in Patients with Chemotherapy-Induced
Neuropathy Marta Campagnolo, Daniela
Lazzarini, Iva Fregona, Mario Cacciavillani,
Francesca Bergamo, Raffaele Parrozzani,
Edoardo Midena, Chiara Briani
P3.312
Characterization of Seizures
and Their Response to Treatment in a
Cohort of Patients with Glial Tumors in a
University Institute José Tafur Canabal,
Alejandra Gonzalez Roffo, Valeria Beatriz
Kuchkaryan, Victoria Campanucci, Jorge
Igirio Gamero, Alejandra Báez, Cecilia
Sánchez Retamar, Ignacio Casas Parera
P3.313
Epilepsy and Cancer: Ancient
Problem in a Top Mortality Illness Bernardo
Cacho Diaz
P3.314
Palinopsia and
Palinacousis Emily Johnson, Mohammad
Salajegheh
P3.315
Focal Injection of
Incobotulinum Toxin A Improves Refractory
Local Cancer Pain at the Site of Radiation/
Surgery Rezvan Rostami, Duarte Machado,
Diana Richardson, Bahman Jabbari
P3.316
Neuropathic Itch as a
Presenting Feature of Post-Mastectomy
Pain Syndrome Robert Knobler
Neuro-oncology: Paraneoplastic
Syndromes and Other Antibodymediated Disorders
P3.317
P3.304
Myalgia and Hyper-CKemia
Due to Novel Homozygous ANO5
Deletion Rajat Lahoria, Thomas Winder, Jie
Liu, Margherita Milone
Humoral Immune Response
Against Neural Antigens in Endometrial
Cancer Patients Slawomir Michalak,
Karolina Poplawska-Domaszewicz, Agata
Paluch, Dariusz Szpurek, Stefan Sajdak,
Wojciech Kozubski
P3.305
P3.318
Slow Channel Syndrome
Leading to Distal Myopathy in a Large
Family: Therapeutic Perspectives Corrado
Angelini, Giovanni Vazza, Maria
Mostacciuolo
P3.306
Familial Distal Myopathy Due
to PNLPA2 Mutation Corrado Angelini,
Daniela Tavian, Elisabetta Tasca, Sara
Missaglia
The Expression of
Neurotrophic Factors in Peripheral Blood
Mononuclear Cells and Neurological
Complications of Cancer Slawomir
Michalak, Joanna Rybacka-Mossakowska,
Daria Swiniuch, Joanna Gazdulska, Maria
Litwiniuk, Rodryg Ramlau, Wojciech
Kozubski
P3.320Anti-NMDA-receptor
Encephalitis: Case Report of Persistent
Anti-NMDAR Antibodies 10 Years from
Initial Undiagnosed Presentation Maria
Fang-Chun Chen, Michelle Dougherty,
Josep Dalmau
P3.321
Atypical Encephalitis with
Voltage-gated Potassium Channel (VGKC)
and N-Methyl-D-Aspartate-Receptor
(NMDAR) Antibodies with HIV and
Pathologic Confirmation Debra Ehrlich, Atul
Ramesh, Steven Herskovitz, Howard Geyer,
Patrick Lasala, Karen Weidenheim, Jerome
Graber
P3.322
Suspected Paraneoplastic
Autonomic Neuropathy in a Patient
with Newly Diagnosed Glioblastoma
Multiforme Alyx Porter, Brent Goodman
P3.323
The Population-based
Survey of Paraneoplastic Neurological
Syndromes in the Czech Republic During
the Eight Years´ Period Pavel Stourac, Jana
Bednarova, Petra Praksova, Magdalena
Hladikova, Krystyna Kantorova
Child Neurology and
Developmental Neurology III
P3.332
Behavioral Profiles of
Children and Adolescents with Specific
Language Impairment and High Functioning
Autism Marisela Dy, Angela Ballantyne,
Doris Trauner
P3.333
Acute Disseminated
Encephalomyelitis in a Pediatric RenalTransplant Recipient. Daniel Vela-Duarte,
Eugene Schnitzler, Vikram Prabhu
P3.334
An Unusual Prolonged
Presentation of Synthetic Cathinone
Encephalopathy Responsive to Steroids: A
Case Report Rawan Albadareen, Jennifer
Lowry, Stephen Thornton, Arezou Heshmati
P3.335
A Polio-Like Syndrome
in California: Clinical, Radiologic, and
Serologic Evaluation of Five Children
Identified by a Statewide Laboratory Over
a Twelve-Month Period Alexandra Roux,
Sabeen Lulu, Emmanuelle Waubant, Carol
Glaser, Keith Van Haren
P3.324
P3.336
Neuro-oncology:
Meningioma, Neurofibromatosis,
and Other Non-glial Tumors
P3.337
Glioblastoma Multiforme in
a Patient with Multiple Sclerosis: A Case
Report Carlos Romo, Aline Herlopian,
Nabeel Chauhan, Robert Archer, Shirley
Ong
P3.325
Hormone Replacement
Therapy Increases the Risk of Cranial
Meningioma Lene Andersen, Soren Friis,
Jesper Hallas, Pernille Ravn, Henrik Daa
Schrøder, David Gaist
P3.326
Clinical and Radiological
Response of NF2 Associated Tumours to
Bevacizumab in an English Cohort Katrina
Morris, Shazia Afridi, Patrick Axon, Gareth
Evans, Allyson Parry, Dorothy Halliday, Pieter
Pretorius
P3.327
Neurofibromatosis 2 with
Limited Phenotype in a Kindred with
Deletion of Exon 9 in the NF2 Gene. Leif
Wiklund, Anna Flodin, Karin Zyk-Zackrisson,
Ole Kvorning, Margareta Nordling
P3.328
Novel Constitutional
Chromosomal Deletion, 4q32.1, in a
Patient with Neurofibromatosis Type 1
and Glioblastoma Multiforme Amanda
Michael, Colin Hirst, Ryan Miller, Miguel
Guzman, Ghazala Hayat
P3.329
Diagnostic Dilemma of Bell’s
Palsy: Case of Facial Nerve Schwannoma
Presenting as Acute Bell’s Palsy Nidhi
Mehta, Satinder Kaur, Kelsey West
Abnormalities of the Brain
Functional Connectome in Pediatric
Patients with Multiple Sclerosis Massimo
Filippi, Paola Valsasina, Sara Sala, Vittorio
Martinelli, Angelo Ghezzi, Pierangelo
Veggiotti, Andrea Falini, Giancarlo Comi,
Maria Rocca
Ten Years in the
Making—A Longitudinal Study of
Language Development in Children and
Adolescents Jerzy Szaflarski, Yingying
Wang, Mekibib Altaye, Akila Rajagopal,
Anna Byars, Elena Plante, Scott Holland
P3.338Magnetoencephalographic
Parameters of Fetal Brain
Maturation Naim Haddad, Hari Eswaran,
Eric Siegel, Curtis Lowery, Rathinasami
Govindan, Srinivasan Vairavan
Neuroscience Research Prize
Recipients
P3.339
Evidence of Toll-like
Receptor Nine-mediated Amelioration
of Amyloid Pathology in a TgSwDI
Mouse Model of Alzheimer’s
Disease Charlotte Herber
P3.340
Promoting Repair
of Damaged Corticospinal
Tract Stefanie Henry
P3.341Pan-neuronal
Over-expression of the GCLc
Gene to Mitigate Redox Stress
and Mitochondrial ETC Complex
Dysfunction in Alzheimer’s
Disease Lisa Michaels
P3.330
Treatment of Pituitary Tumors
with Temozolomide: A Case Series Justin
Jordan, Tucker Cushing, Jorg Dietrich
P3.331
Thoracolumbar Spinal
Angiolipoma Demonstrating High Signal on
STIR Imaging: A Case Report. Alex Linn,
Denny Reyes
P3.319
Atypical Neuroimaging
Findings in Hodgkin’s Lymphoma
Associated with Anti-GAD
Antibodies Caelan Ford, Ratna BhavarajuSanka, Rebecca Romero
77
Tuesday
April 29
Tuesday, April 29
S14 MS and CNS
Animal and In Vitro Studies
3:15 p.m.
S14.001
Endothelial TREK1 Potassium
Channels Are Critical Regulators
of Immune Cell Migration into the
CNS Stefan Bittner, Tobias Ruck,
Kerstin Goebel, Nico Melzer, Heinz
Wiendl, Sven Meuth
3:30 p.m.
S14.002
Amyloid Fibril-forming Hexapeptides
Modulate the Immune Response
and Reduce Symptoms in an
Animal Model of Multiple
Sclerosis Michael Kurnellas,
Jonathan Rothbard, Jill Schartner,
Lawrence Steinman
3:45 p.m.
S14.003
Contribution of a Dysfunctional
RNA Binding Protein, hnRNP A1, to
Neurodegeneration in MS Michael
Levin, Sangmin Lee, Lidia Gardner,
Joshua Douglas, Yoojin Shin,
Paul Sawchenko, Stephen Lalor,
Benjamin Segal
4:00 p.m.
S14.004
A Nasal Anti-CD3 Vaccine Treats
a Model of Secondary Progressive
MS by Inducing IL-10 Dependent T
Regulatory Cells and Regulating CNS
Innate Immunity Lior Mayo, Andre
Pires Da Cunha, Raymond Sobel,
Hans Lassmann, Francisco Quintana,
Howard Weiner
4:15 p.m.
S14.005
IRX4204: A Highly Selective RXR
Agonist Modulates Adaptive
Treg Differentiation Independent
of RAR, and Effectively Inhibits
Central Nervous System
Inflammation Elizabeth Nowak,
Rosh Chandraratna, Randolph
Noelle
4:30 p.m.
S14.006
IRX4204: A Clinical Stage, Potent,
and Highly Selective RXR Agonist
Compound Is Brain Penetrant,
and Promotes Differentiation
of Oligodendrocyte Precursor
Cells (OPCs) In Vitro Martin
Sanders, Satish Medicetty, Rosh
Chandraratna
4:45 p.m.
S14.007
Effects of Polarized Human
Lymphocytes and Myeloid
Cells on Astrocyte Responses
and Oligodendrocyte
Differentiation Craig Moore,
Nebras Warsi, Qiao Ling Cui, Bryce
Durafourt, Jack Antel, Amit Bar-Or
78
S15 Cerebrovascular Disease
Clinical and Imaging
Biomarkers and Genetics
3:15 p.m.
S15.001
Abnormal Left Ventricular Geometry
in Lacunar Stroke: Spectrum,
Prevalence and Prognostic
Implications in the SPS3 Trial Thalia
Field, Lesly Pearce, Nathan ChanSmyth, Sabe De, Gordon Gubitz,
Stephen Phillips, Robert Hart, Oscar
Benavente
3:30 p.m.
S15.002
Infarction Volume in Patients with
Atrial Fibrillation: The Impact of Left
Ventricular Stiffness Hee-Seung
Ahn, Wi-Sun Ryu
3:45 p.m.
S15.003
The Collateral Circulation on
Day-2 CT Angiography Is a Reliable
Predictor of Functional Outcomes
in Acute Ischemic Stroke. Leonard
Yeo, Prakash Paliwal, Hock Luen
Teoh, Bernard Chan, Chee Seong
Seet, Eric Ting, Gavin Lim, Venetia
Ong, Ganesh Shamugam, Amit
Varma, Vijay Sharma
4:00 p.m.
S15.004
Identifying Novel Biomarkers of
Cerebral Ischemia through the Use of
Mass Spectroscopy Paul George,
Christopher Adams, Michael
Mlynash, Christian Kjaergaard,
Calvin Kuo, Stephanie Kemp,
Madelleine Garcia, Gregory Albers,
Jean-Marc Olivot
4:15 p.m.
S15.005
Proteomic Profiling of Acute Stroke
Patients Post IV Thrombolysis:
Mapping tPA Efficacy in Real
Time MingMing Ning, Mary Lopez,
David Sarracino, David McMullin,
Xiaoying Wang, Ferdinando
Buonanno, Eng Lo
4:30 p.m.
S15.006
COL4A1 Mutations: Clinical and
Radiological Phenotypes in a French
Adult Cohort Aurélie Siri, Elisabeth
Tournier-Lasserve, Manuelle Mine,
Eloi Magnin, Eric Berger, Caroline
Arquizan, Xavier Ayrignac, Clarisse
Carra-Dalliere, Giovanni Castelnovo,
Nicolas De Champfleur, Pierre
Labauge, Jean Philippe Neau,
Tiphaine Rouaud, Sonia Alamowitch
4:45 p.m.
S15.007
An Autosomal Dominant
Arteriopathy of the Brain Due to a
Novel Mutation in Collagen 4A1 Gene
in a Family with Early-onset Stroke
and Leukoencephalopathy Matthew
Schrag, William Graf, Anna Szekely
3:15 p.m.–5:00 p.m.
S16 Neuromuscular and
Clinical Neurophysiology
(EMG): Clinical Trials and
Therapy
3:15 p.m.
S16.001
Lack of Correlation Between
Biomarker and Clinical Outcome
Measures in the Arimoclomol
Inclusion Body Myositis Pilot
Study Mazen Dimachkie, Pedro
Machado, Jianghua He, Yunxia
Wang, April McVey, Mamatha
Pasnoor, Philip Gallagher, Laura
Herbelin, Jeffrey Statland, Adrian
Miller, Linda Greensmith, Janice
Holton, Michael Hanna, Richard
Barohn
3:30 p.m.
S16.002
Phase II Trial of Methotrexate
in Myathenia Gravis Mamatha
Pasnoor, Laura Herbelin, Jianghua
He, Mazen Dimachkie, Sharon
Nations, Vera Bril, Annabel Wang,
John Kissel, Ted Burns, David
Saperstein, Jeffrey Rosenfeld,
Aziz Shaibani, Carlayne Jackson,
Andrea Swenson, James Howard,
Namita Goyal, Matthew Wicklund,
Joann Miller, Richard Barohn, MSG
Methotrexate Study MG Group
3:45 p.m.
S16.003
A Single-Blind, Randomized,
Controlled Clinical Trial of Exercise in
Ambulatory Spinal Muscular Atrophy
(SMA) Patients Jacqueline Montes,
Samantha Kramer, Sally Dunaway,
Megan Montgomery, Brendan Carr,
Shirit Rosenberg, Douglas Sproule,
Nancy Strauss, Carol Garber, Darryl
De Vivo
4:00 p.m.
S16.004
Is IVIg Therapy Warranted in
Progressive Lower Motor Neuron
Syndromes Without Conduction
Block? Neil Simon, Gretchen Ayer,
Catherine Lomen-Hoerth
4:15 p.m.
S16.005
The Effect of Tirasemtiv on Functional
Status in Patients with ALS Jeremy
Shefner, Jacqueline Lee, Donna
Barragan, Lisa Meng, Andrew Wolff,
Jinsy Andrews
4:30 p.m.
S16.006
Randomized Trial of Rifampicin
in MSA: Effect on Autonomic
Function Wolfgang Singer, William
Cheshire, Robert Fealey, Paola
Sandroni, J. Ahlskog, Joseph
Matsumoto, James Bower, Melinda
Burnett, Andrew McKeon, Tonette
Gehrking, Jade Gehrking, Eduardo
Benarroch, Phillip Low
4:45 p.m.
S16.007
Neuropathy Improvement
Following Peripheral Blood
Stem Cell Transplantation for
POEMS Syndrome. Chafic
Karam, Christopher Klein, Angela
Dispenzieri, Jayawant Mandrekar,
P. James B. Dyck, Anita D’Souza,
Michelle Mauermann
S17 Parkinson's Disease:
Genetics and Epidemiology
3:15 p.m.
S17.001
Mutations in the GCH1 Gene
Are Associated with Parkinson
Disease Niccolò Mencacci, Ioannis
Isaias, Martin Reich, Christos Ganos,
James Polke, Jose Bras, Joshua
Hersheson, Maria Stamelou, Alan
Pittman, Alastair Noyce, Kin-Ying Mok,
Thomas Opladen, Erdmute Kunstmann,
Katie Sidle, Mary Sweeney, Henry
Houlden, Hodecker Sybille, Amit Batla,
Alexander Munchau, Jens Volkmann,
Samuel Samnick, Giorgio Marotta,
Anna Zecchinelli, Gianni Pezzoli,
Andrew Lees, Paulo Alegria, Paul Krack,
Florence Cormier, Suzanne Lesage,
Alexis Brice, Peter Heutink, Thomas
Gasser, Huw Morris, Steven Lubbe,
Elisa Majounie, Raphael Gibbs, Andrew
Singleton, John Hardy, Stephan Klebe,
Kailash Bhatia, Nicholas, W Wood,
None International Parkinson’s Disease
Genomics Consort
3:30 p.m.
S17.002
Age Specific Penetrance of the
LRRK2 G2019S Mutation in the
Michael J Fox Ashkenazi Jewish (AJ)
LRRK2 Consortium Karen Marder,
Mingxin Tang, Roy Alcalay, Helen
Mejia-Santana, Deborah Raymond,
Anat Mirelman, Rachel SaundersPullman, Lorraine Clark, Laurie
Ozelius, Avi Orr-Urtreger, Nir Giladi,
Susan Bressman
3:45 p.m.
S17.003
RER1: A Novel Regulator of AlphaSynuclein Nikolaus McFarland,
Hyo-Jin Park, Lauren Ricchiuti
4:00 p.m.
S17.004
Apolipoprotein A1 Levels Are
Associated with APOA1 Promoter
Variation and Influence Parkinson’s
Disease Risk Christine Swanson,
Katherine Li, Travis Unger, Michael
Gallagher, Vivianna Van Deerlin,
Pinky Agarwal, James Leverenz,
John Roberts, Ali Samii, Rachel
Goldmann Gross, Howard Hurtig,
Jacqueline Rick, Daniel Weintraub,
John Trojanowski, Cyrus Zabetian,
Alice Chen-Plotkin
4:15 p.m.
S17.005
Prevalence and Predictors of AntiParkinson Drug Use in a Nationally
Representative Sample of Medicare
Beneficiaries, 2006-2010 Nabila
Dahodwala, Allison Willis,
Pengxiang Li, Jalpa Doshi
4:30 p.m.
S17.006
Serum Cholesterol, Statin, and
Parkinson’s Risk in the Atherosclerosis
Risk in Communities (ARIC) Study Xuemei Huang, Alvaro Alonso, Xuguang
Guo, David Umbach, Richard Mailman,
Thomas Mosley, Honglei Chen
4:45 p.m.
S17.007
Time Trends in the Incidence of
Parkinsonism and Parkinson Disease
in Olmsted County, Minnesota
Over Thirty Years Rodolfo Savica,
Brandon Grossardt, James Bower, J.
Ahlskog, Walter Rocca
Neurology: Behavioral
Neuroscience
3:15 p.m.
S18.001
Neuroeconomic Measures of
Impaired Decision-Making in
Frontotemporal Dementia Winston
Chiong, Kristie Wood, Andrew
Kayser, Mark D’Esposito, Howard
Rosen, Bruce Miller, Joel Kramer
3:30 p.m.
S18.002
Strategic Problem Solving in
Behavioral Variant Frontotemporal
Dementia Laura Baehr, Corey
McMillan, Katya Rascovsky, John
Powers, Lisa Burkholder, Murray
Grossman
3:45 p.m.
S18.003
A CSF Signature of Frontotemporal
Lobar Degeneration with C9orf72
Repeat Expansions William
Hu, Jonathan Glass, Vivianna
Van Deerlin, Murray Grossman,
Kelly Watts, James Lah, John
Trojanowski, Allan Levey
4:00 p.m.
S18.004
Cholinergic Integrity and Visual
Hallucinations in Parkinson
Disease Nicolaas Bohnen, Martijn
Muller, Vikas Kotagal, Roger Albin,
Kirk Frey
4:15 p.m.
S18.005
Neuropsychological Profiles of
Voltage-gated Potassium Channel
Complex and Other Autoimmune
Encephalopathies; More Than
Memory Impairment Michael
Geschwind, Jeffrey Gelfand, Sarosh
Irani, John Neuhaus, Sven Forner,
Brianne Bettcher
4:30 p.m.
S18.006
Predictors of Response to
Propranolol for Social Functioning in
Autism Spectrum Disorder David
Beversdorf, Rachel Zamzow, Brad
Ferguson, Tamera Martin, Morgan
Lewis, Janine Stichter
4:45 p.m.
S18.007
SHANK3 Overexpression Causes
Manic-like Behavior with Unique
Pharmacogenetic Properties Jimmy
Holder, Huda Zoghbi
Scientific Sessions
3:15 p.m.
S19.001
Good Vibrations: A Novel Method
of Damping Acquired Pendular
Nystagmus with Vibration Shin
Beh, Amir Kheradmand, Teresa
Frohman, Darrel Conger, Amy
Conger, Peter Calabresi, Laura
Balcer, Elliot Frohman, David Zee
3:30 p.m.
S19.002
A Novel Quantitative Bedside Test of
Balance Function: the Video Visually
Enhanced Vestibulo-ocular Reflex
(VVOR) David Szmulewicz, Hamish
MacDougall, Elsdon Storey, Ian
Curthoys, Michael Halmagyi
3:45 p.m.
S19.003
Alice in Wonderland Syndrome:
Presenting and Follow-up
Characteristics Grant Liu,
Alessandra Liu, Jonathan Liu,
Geraldine Liu
4:00 p.m.
S19.004
Eye Movement Perimetry for
Evaluation of Visual Field Loss
in Patients with Glaucoma and
Recovered Optic Neuritis Matthew
Thurtell, David Warren, Alice Xu,
Andrew Papendieck, Michael Wall
4:15 p.m.
S19.005
Evaluation of Face and Voice
Perception and Recognition
Impairments in Prosopagnosia Ran
(Richard) Liu, Raika Pancaroglu,
Charlotte Hills, Bradley Duchaine,
Jason Barton
4:30 p.m.
S19.006
Vision Testing Is Additive to the
Sideline Assessment of SportsRelated Concussion Rachel
Ventura, Zoe Marinides, Steven
Galetta, James Clugston, Laura
Balcer
4:45 p.m.
S19.007
Capturing Episodic Vertigo Miriam
Welgampola, Corinna Lechner,
Hamish Macdougall, Michael
Halmagyi
S20 Pain and Palliative
Care
Mitchell B. Max Award for
Neuropathic Pain
Recipient:
Kathleen Foley, MD
New York, NY
3:30 p.m.
S20.002
ALS: Pain in Addition to Anything
Else Nathalie Guy, Catherine
Cornut Chauvinc, Xavier Moisset,
Pierre Clavelou
3:45 p.m.
S20.003
Identifying Palliative Care Needs
in the Neurological Intensive Care
Unit Claire Creutzfeldt, J Curtis
4:00 p.m.
S20.004
DS-5565 for the Treatment of
Diabetic Peripheral Neuropathic Pain:
Randomized, Double-Blind, Placeboand Active Comparator-controlled
Phase II Study Aaron Vinik, Uma
Sharma, Karen Feins, Ching Hsu,
Domenico Merante
4:15 p.m.
S20.005
Peripheral Edema and Weight Gain in
Adult Patients with Painful Diabetic
Peripheral Neuropathy (DPN)
Receiving Gabapentin Enacarbil
(GEn) or Pregabalin Enrolled in a
Randomized Phase 2 Trial Anne
Calkins, Joseph Shurman, Mark
Jaros, Richard Kim, Gwendoline
Shang
4:30 p.m.
S20.006
Botulinum Toxin for Muscle
Cramps Associated with
Diabetic Neuropathy: A DoubleBlind, Placebo-Controlled
Study Domenico Restivo, Antonino
Pavone, Damiano Gullo, Stefano
Jann, Riccardo Vigneri
4:45 p.m.
S20.007
Virtual Family Meetings in the ICU
Setting: Results from an Audiovisual
Conferencing Intervention Adam
de Havenon, Casey Petersen, Ali
Sultan-Qurraie, Robert Hoesch
S21 Neuro-rehabilitation
and Neural Repair
S22 Neuro-oncology
3:15 p.m.
S21.001
Randomized Controlled Trial
of Constraint-induced Aphasia
Therapy in Patients with Chronic
Stroke Jerzy Szaflarski, Jane
Allendorfer, Angel Ball, Christi
Banks, Aimee Dietz, Kimberly Hart,
Christopher Lindsell, Amber Martin,
Jennifer Vannest
3:15 p.m.
S22.001
A Vaccine Targeting Mutant IDH1
Induces Antitumor Immunity Michael
Platten, Theresa Schumacher, Lukas
Bunse, Felix Sahm, Stefan Pusch,
Jasmin Quandt, Oliver Menn, Matthias
Osswald, Angelika Riemer, Philipp
Beckhove, Manuel Alexander Friese,
Andreas von Deimling, Wolfgang Wick
3:30 p.m.
S21.002
Measuring Health-related Quality
of Life (HRQOL) During Inpatient
Stroke Rehabilitation Pasquale
Frisina, Ann Kutlik, Kimberly Hreha,
A. Barrett
3:30 p.m.
S22.002
Neurocognitive Function (NCF)
Substudy and Mini-Mental State
Examination (MMSE) Results from
the Randomized, Placebo-Controlled
Phase III AVAglio Trial of Bevacizumab
(BEV) Added to Radiotherapy (RT)
and Temozolomide (TMZ) for Newly
Diagnosed Glioblastoma Jeffrey S
Wefel, Olivier Chinot, Wolfgang Wick,
Warren Mason, Roger Henriksson, Frank
Saran, Ryo Nishikawa, Cedric Revil,
Josep Garcia, Timothy Cloughesy
3:45 p.m.
S21.003
Brain Structural and Functional
Changes After Action Observation
Therapy in Parkinson’s Disease
Patients with Freezing of
Gait Federica Agosta, Elisa Canu,
Elisabetta Sarasso, Mariano
Gemma, Alessandro Meani,
Antonietta Volonté, Lidia Sarro,
Sebastiano Galantucci, Andrea
Falini, Giancarlo Comi, Roberto Gatti,
Massimo Filippi
4:00 p.m.
S21.004
Neuroprotective and
Neurorestorative Effects of Thymosin
Beta4 Treatment After Traumatic
Brain Injury Asim Mahmood, Ye
Xiong, Michael Chopp
4:15 p.m.
S21.005
Recovery from Brain Injury
After Prolonged Disorders of
Consciousness: Outcome of Patients
Admitted to Rehabilitation with 1-8
Year Follow-up Douglas Katz, Meg
Polyak, Daniel Coughlan, Emily Goff,
Meline Nichols, Alexis Roche
4:30 p.m.
S21.006
Comparison of the Checkerboard
P300 Speller Versus the Row-Column
Speller in Normal Elderly and an
Aphasic Stroke Population Jerry
Shih, George Townsend, Dean
Krusienski, Kevin Shih, Ryan Shih,
Kristin Heggeli, Trevor Paris, James
Meschia
4:45 p.m.
S21.007
Individualized Treatment with
Transcranial Direct Current
Stimulation in Patients with
Chronic Nonfluent Aphasia Due to
Stroke Priyanka Shah, Catherine
Norise, Gabriella Garcia, Jose
Torres, Olu Faseyitan, Roy Hamilton
3:45 p.m.
S22.003
Overview of Arterial Thromboembolic
Events (ATEs) in AVAglio, a
Randomized, Placebo-controlled
Phase III Trial of Bevacizumab,
Radiotherapy and Temozolomide
(BEV+RT/TMZ) for Newly Diagnosed
Glioblastoma Warren Mason,
Timothy Cloughesy, Wolfgang Wick,
Roger Henriksson, Frank Saran, Ryo
Nishikawa, Sunita Dhar, Cedric Revil,
Josep Garcia, Olivier Chinot
4:00 p.m.
S22.004
Predicting Progressive Gangliogliomas:
Early Identification of Those at Risk in
a Sample of 156 Consecutive Patients
Treated at the Barrow Neurological
Institute Glynnis Zieman, Christopher
Dardis, Andrea Gomes, Adrienne
Scheck, Jennifer Eschbacher, Lynn
Ashby
4:15 p.m.
S22.005
The Neurologic Assessment in
Neuro-Oncology (NANO) Scale: A
Tool to Assess Neurologic Function
for Integration in the Radiologic
Assessment in Neuro-Oncology
(RANO) Criteria Lakshmi Nayak, Lisa
DeAngelis, Patrick Wen, Alba Brandes,
Riccardo Soffietti, Nancy Lin, David
Peereboom, Marc Chamberlain, David
Macdonald, Evanthia Galanis, James
Perry, Kurt Jaeckle, Minesh Mehta,
Roger Stupp, Martin Van Den Bent,
David Reardon
4:30 p.m.
S22.006
Improved Progression Free Survival
in 1p/19q Co-deleted Anaplastic
Oligodendroglioma Treated with Both
Chemotherapy and Radiation Therapy
at Diagnosis Jacob Mandel, Courtney
Webre, Nicole Shonka, W K Yung, John
De Groot
S23 MS and CNS
Novel Therapeutics
John Dystel Prize for Multiple
Sclerosis Research
Recipient:
Barry Arnason, MD
Chicago, IL
3:45 p.m.
S23.003
A Combination Trial of Estriol
Plus Glatimer Acetate in
Relapsing-Remitting Multiple
Sclerosis Rhonda Voskuhl, HeJing
Wang, T.C. Jackson Wu, Nancy
Sicotte, Angela Bates, Gary Beaver,
John Corboy, Anne Cross, Suhayl
Dhib-Jalbut, Corey Ford, Barbara
Giesser, Dina Jacobs, Sharon Lynch,
Andrew Pachner, Michael Racke,
John Ratchford, Anthony Reder,
John Rose, Dean Wingerchuk,
Margaret Burnett, Chi Hong Tseng,
Robert Elashoff
4:00 p.m.
S23.004
Effect of Alfacalcidol on Fatigue in
MS Patients: A Randomized, Doubleblind Study Yoram Barak, David
Magalashvili, Mark Dolev Dolgopiat,
David Ladkani, Dalia Nitzani, Zeev
Mazor, Anat Achiron
4:15 p.m.
S23.005
STREAMS: A Phase 2 Clinical Trial of
Autologous Mesenchymal Stem Cells
in Active Multiple Sclerosis Rehiana
Ali, Stephen Marley, Renuka
Palanicawandar, Francesco Dazzi,
Richard Nicholas, Paolo Muraro
4:30 p.m.
S23.006
The MIRROR Study: A Randomized,
Double-blind, Placebo-controlled,
Parallel-group, Dose-ranging
Study to Investigate the Safety
and MRI Efficacy of Subcutaneous
Ofatumumab in Subjects with
Sclerosis (RRMS) Amit Bar-Or,
Richard Grove, Daren Austin, Jerry
Tolson, Susan Vanmeter, Eric Lewis,
Per Solberg Sorensen
4:45 p.m.
S23.007
Randomized Controlled Trial of
CI Therapy for Progressive MS:
Increased Real-world Function and
Neuroplasticity on MRI Victor Mark,
Edward Taub, Gitendra Uswatte,
Gary Cutter, David Morris, Staci
McKay, Mary Bowman, Michelle
Haddad, Tyler Rickards, Chelsey
Sterling
4:45 p.m.
S22.007
Ionizing Radiation Arrests
Subventricular Zone Neural Precursors
in G2/M without Affecting Long-Term
Self-Renewal Hongxin Chen, Sonia
De Toledo, Matthew Goodus, Azzam
Edward, Steve Levison, Nizar Souayah
79
Tuesday
April 29
S19 Neuro-ophthalmology/
Neuro-otology I
Tuesday, April 29
5:30 p.m.–6:30 p.m.
F eatures translational research related to clinical issues of importance. Four outstanding physician-scientists provide summaries of their recent
research findings and describe the clinical implications of the results.
Moderator: Aleksandar Videnovic, MD, MSc
Member, Science Committee
Identification of a Unique Molecular and
Functional Microglia Signature in Health and Disease
Oleg Butovsky, PhD
Brigham and Women’s Hospital/Harvard Medical, Boston, MA
The Global Epidemic of Stroke: Sounding the Alarm
Jerome H. Chin, MD, PhD, MPH
Alliance for Stroke Awareness and Prevention Project (ASAPP), San Anselmo, CA
Emerging Concepts in Chronic Traumatic Encephalopathy
Dennis W. Dickson, MD
Mayo Clinic, Jacksonville, FL
Functional Connectivity and Functional Imaging
in Movement Disorders
David Eidelberg, MD, FAAN
Feinstein Institute for Medical Research, Manhasset, NY
80
Wednesday, April 30
Poster Session IV
7:30 a.m.–11:00 a.m.
Poster Discussion Session: MS and CNS Inflammatory Disease I
Autologous Hematopoietic
Stem Cell Transplantation in Neuromyelitis
Optica Jodie Burton, Jan Storek, Fiona
Costello, Peter Duggan, Luanne Metz
P4.002
Rate Evaluation of
25-Hydroxy-Vitamin D in Neuromyelitis
Optica Laurent Kremer, Ilhame Slassi
Sennou, Nada Benkirane, Adil Araqi
Houssaini, Nicolas Collongues, Jean
Baptiste Chanson, Frederic Blanc, MarieCéline Fleury, Arnaud Theulin, Rose-Marie
Javier, Jerome De Seze
P4.003
Laquinimod Prevents NMOIginduced Disease Exacerbation in a Model
of Neuromyelitis Optica. Azeb Argaw,
Linnea Asp, Jingya Zhang, Patrick Waters,
Liat Hayardeny Nisimov, Michael Levy,
Gareth John
P4.004
Trial of C1-Esterase Inhibitor
in Acute Relapses of Neuromyelitis
Optica Michael Levy, Maureen Mealy
P4.005
Analysis of the Treatment
of Neuromyelitis Optica at the Hospital
of the University of Pennsylvania Jose
Torres, Amy Pruitt, Clyde Markowitz, Nabila
Dahodwala
P4.006
Adoptive Transfer of
T-cells Reactive to Aquaporin-4
Creates Neuromyelitis Optica Mouse
Model Michael Levy, Melina Jones, Hwa
Huang, Maureen Mealy
P4.007
The Largest Genomics
Study of NMO in History: Whole Genome
Sequencing of 150 Patients with
Neuromyelitis Optica Benjamin Greenberg,
Douglas Kerr, Tim Harris, Aaron DayWilliams, John Carulli
P4.008
Typical and Atypical Initial
Presentations of Neuromyelitis Optica:
A Retrospective Study Juebin Huang,
Burhan Chaudhry, Kimberly McDonald,
V Vedanarayanan, Colette Parker, James
Corbett, Robert Herndon
P4.009
The Spectrum of Brain MRI
Abnormalities in Neuromyelitis Optica
Spectrum Disorders Juebin Huang,
Burhan Chaudhry, Kimberly McDonald,
V Vedanarayanan, Colette Parker, James
Corbett, Robert Herndon
P4.010
Neuromyelitis Optica and
Neuromyelitis Optica Spectrum Disorders:
The Evaluation of 70 Patients Followed
by Istanbul Bilim University, Department
of Neurology Burcu Altunrende, Ayca
Altınkaya, Baris Topcular, Kocaslan Meryem,
Sadik Server, Sinem Firtina, Sedef Yenice,
Gulsen Akman-Demir
NEW! e
Poster Session:
Aging, Dementia, and Cognitive and Behavioral Neurology II
P4.011
PET Amyloid Imaging with
Florbetapir Predicts Cognitive Decline in
the Oldest-Old Dana Greenia, Claudia
Kawas, Michelle Caunca, Szofia Bullain,
Maria Corrada
P4.012
Assessing Brain System
Dysfunction in Amnesic Mild Cognitve
Impairment Through MRI-based
Connectomics Federica Agosta, Elisa Canu,
Sebastiano Galantucci, Alessandro Meani,
Giuseppe Magnani, Alessandra Marcone,
Andrea Falini, Giancarlo Comi, Massimo
Filippi
P4.013
Cerebral Blood Flow
and White Matter Hyperintensities
in Nondemented Elderly Lisa Silbert,
Hiroko Dodge, David Lahna, Nutta-on
Promjunyakul, William Rooney, Deniz ErtenLyons, Jeffrey Kaye
P4.014
Genetic Influences of Survival
in the Behavioral Variant of Frontotemporal
Degeneration David Irwin, Corey McMillan,
Eunran Suh, Katya Rascovsky, Jon Toledo,
Virginia Lee, John Trojanowski, Vivianna
Van Deerlin, Murray Grossman
P4.015
Utility of Amyloid
Neuroimaging in Clinical Practice Patricio
Chrem Mendez, Gabriela Cohen, Julieta
Russo, Marcos Fernandez Suarez, Jorge
Campos, Griselda Russo, Janus Kremer,
Alejandra Amengual, Silvia Vazquez, Ramon
Leiguarda, Gustavo Sevlever, Ricardo Allegri
P4.016
Improved Accuracy of the
Diagnosis of Early Alzheimer’s Disease
Using Combined Measures of Hippocampal
Volume and Sulcal Morphology Lorraine
Hamelin, Cruz de Souza Leonardo, Fabian
Corlier, Helene Corne, Marie Chupin, Bruno
Dubois, Michel Bottlaender, Olivier Colliot,
Marie Sarazin
P4.017
Presence of Microinfarcts at
Autopsy Is Associated with Increased Rate
of Gray Matter Atrophy on Antemortem
MRI Mekala Raman, Matthew Senjem,
Jeffrey Gunter, Scott Przybelski, Prashanthi
Vemuri, Melissa Murray, Bradley Boeve,
David Knopman, Ronald Petersen, Joseph
Parisi, Dennis Dickson, Clifford Jack, Kejal
Kantarci
P4.018
Longitudinal Patterns of
Brain Atrophy in Frontotemporal Lobar
Degeneration Clinical Syndromes
Compared with Alzheimer’s Disease Pilar
Ferraro, Federica Agosta, Elisa Canu,
Filippi
P4.019
White-Matter Evidences
of Corticospinal Pathway Involvement
in Frontotemporal Dementia Chiara
Crespi, Chiara Cerami, Alessandra Dodich,
Alessandra Marcone, Nicola Canessa,
Sandro Iannaccone, Massimo Corbo,
Christian Lunetta, Elisa Scola, Andrea Falini,
Stefano Cappa
P4.020
Whole Brain, Voxel Level
Analysis of Grey Matter Volume and Time
to Incident Mild Cognitive Impairment
or Alzheimer’s Disease Lubov Zeifman,
William Eddy, Oscar Lopez, Lewis Kuller,
Cyrus Raji, James Becker
Wednesday
April 30
P4.001
Wednesday, April 30
General Neurology III
P4.021
Lumbar Spine Manifestation
of Intracranial Hypotension Brion Reichler,
Darius Melisaratos
P4.022
Case Report—Multi-focal
Intracranial Tuberculoma in the Setting
of Miliary TB in an Immunocompetent
Patient Ali Saeed, Gautam Sachdeva, Syed
Hussain
P4.023
Anti-NMDA Receptor
Encephalitis Presenting with Atrial
Fibrillation Olha Taraschenko, Josep
Dalmau, Earl Zimmerman, Mary Ann McKee
P4.024
The Gender Divide in Multiple
Sclerosis: A Review of the Environmental
Factors Influencing the Increasing
Prevalence of Multiple Sclerosis in
Women Rebecca Klein, Jodie Burton
P4.025
Population Based Study of
Co-Morbidity of Neurological Autoimmune
Diseases and Thyroid Disease in Buenos
Aires, Argentina Andres Villa, Florencia
Aguirre, Luciana Melamud, Marianna Di
Egidio, Ricardo Alonso, Raul Rey
P4.026
Lupus-Associated Transverse
Myelitis Masquerading as Septic
Shock Rahul Dave, Ciro Ramos Estebanez
P4.027
Third Ventricular Tumors
and Sudden Deterioration: Is Coronary
Vasospasm a Missing Link? Marissa
Kellogg, Holly Hinson
P4.028
Hypoxic Ischemic Brain Injury
Following in Hospital Cardiac Arrest—
Lessons from Autopsy Harsh Gupta,
Archana Hinduja, Sanjeeva Onteddu, Ju
Dong Yang
P4.029
Multiple Cranial Neuropathy
in Paraneoplastic Anti-Hu Antibody
Syndrome Thomas Schmidt, Andrew
Solomon
P4.030
Dysganglionosis as a Cause of
Idiopathic Gastroparesis. A New Way to its
Diagnosis and Treatment Ulrich Liebetrau,
Volker Limmroth, Carl Eisenberger, Anke
Brunn, A.J. Dormann
P4.031
Quality of Life in Liver
Transplant Patients with Neurologic
Complications. Maria Gonzalez Toledo,
Analia Calle, Fatima Pagani Cassara,
Agustina Tamargo, Alejandro Thomson,
Diego Nadile, Fernando Gruz, Vladimiro
Sinay
P4.032
Brain and Liver Iron
Accumulation Demonstrated
by 1.5-tesla and 3-tesla MRI in
Aceruloplasminemia Koji Fujita, Yusuke
Osaki, Masafumi Harada, Satoshi Kono,
Hiroaki Miyajima, Yuishin Izumi, Ryuji Kaji
P4.033
Akinetic Mutism and
Parkinsonian Features Progressing to Coma
Following a Hypoxic Event with Extended
Lucid Interval: Manifestations of Delayed
Post-hypoxic Leukoencephalopathy Alden
P. Doerner Rinaldi, Eliza Miller, Barry
Czeisler, Joshua Willey, Crary John, Jan
Claassen, Stephan Mayer, Sachin Agarwal
82
P4.034
A Winged Scapula
and Dropped Wrist: Cervical
Radiculomyelopathy as an Unusual
Presenting Manifestation of Copper
Deficiency Sajish Jacob, Harsh Gupta,
Robert Archer, Betul Gundogdu
P4.035Metachromatic
Leukodystrophy Mistaken for Manganese
Toxicity in a Patient with Common
Variable Immunodeficiency: A New Triad
of Devastating Disease? Zubair Ahmed,
Hesham Abboud, Edward Manno
P4.036
Treatment of Post-Influenza
Vaccination-induced Acute Disseminated
Encephalomyelitis (ADEM) with Plasma
Exchange—a Case Report Mandeep
Chahil, Clement Pillainayagam, Paul Schulz
P4.037
A Rare Case of Churg Strauss
Syndrome associated with Cervical Spine
and Brain Involvement Shilpi Mittal, Agnes
Acsadi, Lorinda Cruz, Taylor Aglio, Kirsten
Ek, Santhanam Lakshminarayanan, Kristen
Logee
P4.038
Neurology Telemedicine
Interest in Arkansas L Greenfield, Maryam
Bashiri, Sukanthi Kovvuru
P4.039
Subacute Sclerosing
Panencephalitis: Case study and Literature
Review Danny Estupinan, Nikolaus
McFarland
P4.040
Thoracic Myelopathy Due to
Hypertrophic Pachymeningitis Secondary
to Adalimumab Yefim Yushvayev-Cavalier,
Warren Zeigler, Mary Ann McKee, Marjorie
Bunch, Adolfo Ramirez Zamora
Movement Disorders:
Parkinson’s Disease Biomarkers
P4.041
Longitudinal Quantitative
EEG Changes Correlate With
Neuropsychological Assessment
Decline John Caviness, Joe Hentz, Erika
Driver-Dunckley, Christine Belden, Jessica
Powell, Michael Ahmadi, Charles Adler
P4.042
Glucocerebrosidase Enzyme
Activity in GBA1 Mutation Parkinson
Disease Robert Ortega, Paola Torres,
Sarah Boschung, Matthew Swan, Jeannie
Soto-Valencia, Matthew Barrett, Brooke
Johannes, Deborah Raymond, Lawrence
Severt, Vicki Shanker, Susan Bressman,
Gregory Pastores, Rachel Saunders-Pullman
P4.043
The BioFIND Study (Fox
Investigation For New Discovery Of
Biomarkers In Parkinson’s Disease): Design
And Methodology Un Kang, Roy Alcalay,
Jennifer Goldman, Claire Henchcliffe,
Penelope Hogarth, Paul Tuite, Tao Xie,
Mark Frasier, Catherine Kopil, Lona Vincent,
Nicole Willis, Cindy Casaceli, Alice Rudolph
P4.044
Evaluation of the Cutaneous
Silent Period in Patients with Parkinson’s
Disease Serdar Tasdemir, Hakan Akgun,
Mehmet Yucel, Semih Alay, Oguzhan Oz,
Umit Ulas, Seref Demirkaya
P4.045
Association of Serum Cystatin
C Levels on the Progression and Cognition
in Parkinson’s Disease Jing Chen,
Chunfeng Liu
7:30 a.m.–11:00 a.m.
P4.046
Defining Impaired Olfaction
in Parkinson’s Disease: a Comparison of
Methods. Katherine Grosset, Naveed
Malek, Sarah Marrinan, Nin Bajaj, Waiken
Chan, Christina Banks, Huw Morris, Roger
Barker, Thomas Foltynie, Nicholas, W
Wood, Nigel Williams, Yoav Ben-Shlomo,
David Burn, Donald Grosset
P4.047
An Aptamer-Based
Screen of 1000+ Plasma Proteins for
Diagnostic Biomarkers in Parkinson’s
Disease Benjamine Liu, Christine Swanson,
Jacqueline Rick, Daniel Weintraub, Howard
Hurtig, John Trojanowski, Alice Chen-Plotkin
P4.048
Plasma Long Chain Fatty
Acids and Cognition in Parkinson’s
Disease Charles Murchison, Joseph Quinn,
Brenna Cholerton, James Leverenz, Thomas
Montine, Cyrus Zabetian, Kathryn Chung,
Amie Peterson, Gene Bowman
Movement Disorders:
Biomarkers and Treatment
P4.049
In Vivo Gastric Detection
of α-Synuclein Inclusions in Parkinson’s
Disease Alvaro Sanchez, Alberto
Rabano, Maria-Jose Catalan, Fernando
Canga, Servando Fernandez-Diez, Jaime
Herreros-Rodriguez, Elvira Garcia-Cobos,
Marina Mata Alvarez-Santull, Lydia LopezManzanares, Mosqueira Antonio J, Lydia
Vela, Juan Lopez-Lozano, Eva Lopez-Valdes,
Jose Antonio Molina
P4.050
Reduction in Post-Botulinum
Toxin Flu-like Symptoms After Injection
with Incobotulinum Toxin Edwin George,
Natalya Shneyder
P4.051
Antibody Mediated
Movement Disorders and Their Differential
Response to Immunomodulatory
Therapy Laura Bishop, Mustafa Siddiqui,
Jessica Tate, Ihtsham Haq
P4.056
Physical Activity and Risk
of Comorbid Depression with Parkinson
Disease Rui Liu, David Umbach, Yikyung
Park, Xuemei Huang, Albert Hollenbeck,
Aaron Blair, Honglei Chen
P4.057
Hereditary Spastic Paraplegia
Due to a Novel Mutation in SPG11 Gene
Presenting as Dopa Responsive Dystonia,
Parkinsonism and Spasticity Subhashie
Wijemanne, Joseph Jankovic
P4.058
Motor Symptom Lateralization and NonMotor Symptoms (NMS) in Parkinson’s
Disease Patients Tarannum Khan, Raja
Boddepalli, Denny Reyes
Movement Disorders:
Hyperkinetic Disorders:
Chorea and Tic Disorders
P4.059
Acute Recurrent, Persistent
Hypoglycemia-induced Chorea/Ballism in a
Diabetic Patient on Hemodialysis Padmaja
Vittal, Cynthia Comella, Kathleen Shannon
P4.060
Clinical Pyramidal Signs in
a Series of Patients with Huntington’s
Disease Emilia Gatto, Virginia Laura Parisi,
Ana Sanguinetti, Jose Luis Etcheverry,
Gabriel Persi
P4.061
Estimating Huntington’s
Disease (HD) Onset Using a Low-Cost
Balance Assessment Andrew Herndon,
Jody Corey-Bloom, Marcella Scholl,
Danielle Burt, Sean Huynh, Daniel Goble
P4.062
Estimate Huntington Disease
Prevalence in Latin America Emilia Gatto,
Virginia Laura Parisi, Ana Sanguinetti,
Gabriel Persi, Jose Luis Etcheverry
P4.063
P4.052
Primary CNS Lymphoma
Presenting with a Rapidly Progressive
Huntington’s Disease-Like Picture Hesham
Abboud, Mohamed Hegazy, Rebecca
Kuenzler, David Peereboom
P4.053
P4.065
A Comprehensive Approach
to Parkinson’s Disease Camille Vaughan,
Anna Vandenberg, Felicia Goldstein,
Lynn-Marie Trotti, Adriana Hermida, Mary
Weeks, Stewart Factor
Safety and Efficacy Study
of ADS-5102 (amantadine HCl) Extended
Release Capsules in Levodopa-Induced
Dyskinesia (EASED Study) Rajesh Pahwa,
Caroline Tanner, Robert Hauser, Kapil Sethi,
Stuart Isaacson, Daniel Truong, Lynn Struck,
Mary Jean Stempien, Natalie McClure,
Greg Went
P4.054
Economic Burden of
Parkinson´s Disease in a Population of
Monterrey, Mexico Leonel Cantu-Martinez,
Jesus Santos-Guzman, Ingrid EstradaBellman, Ramiro Mora-Villalvazo, Erika
Salinas-Lezama, Hector Martinez
P4.055
Dietary Source of Vitamin
D Is Associated with Parkinson Disease
and Total Vitamin D Modifies the Genetic
Association Between Vitamin D Receptor
(VDR) Gene and Parkinson Disease Liyong
Wang, Jeffery Vance, Marian Evatt, Lizmarie
Maldonado, William Perry, James Ritchie,
Gary Beecham, Eden Martin, Jonathan
Haines, Margaret Pericak-Vance, William
Scott
P4.064
Psychogenic Movement
Disorders in Nonagenarians: Report of Two
Cases Stephen Reich, Melissa Armstrong,
Ana Sanchez, Roy Fried
A Case of Psychogenic
Belching Rainer Paine, Mark Hallett
P4.066
Social Functioning in Youth
with Tourette Syndrome Sarah Pearl
Aronow-Werner, Heather Adams, Amy
Vierhile, Alyssa Thatcher, Jonathan Mink,
Erika Augustine
P4.067
Increased Dopamine Receptor
Occupancy in People with Tourette
Syndrome, Obsessive-Compulsive Disorder,
and Neuroleptic Exposure James Brasic,
Harvey Singer, Eram Zaidi, Emily Gean, Anil
Kumar, Anil Mathur, Rebecca MellingerPilgrim, Vanessa Raymont, Ahmet Dogan,
Mohab Alexander, Marika Maris, Gerald
Nestadt, Albert Gjedde, Dean Wong
Movement Disorders:
Essential and Other Tremors
P4.068
Clinical and Surface
Electromyography (SEMG) Correlation in
Tremors Man Mohan Mehndiratta, Munish
Kumar, Sanjay Pandey, Dinesh Sharma
Poster Session IV
P4.069
Decreased EAAT2 Protein
Expression in the Essential Tremor
Cerebellar Cortex Sheng-Han Kuo,
Michelle Lee, Etty Cortes, Jean Paul
Vonsattel, Elan Louis, Phyllis Faust
P4.070
Genome-Wide Linkage
Scan for Essential Tremor: The FASET
Study Lorraine Clark, Nora Hernandez, Ruth
Ottman, Iuliana Ionita-Laza, Elan Louis
P4.071
Case Control Analysis of
Spinocerebellar Ataxia (SCA) Loci Repeat
Expansion Size in Essential Tremor
(ET) Lorraine Clark, Xinmin Liu, Xin Ye, Nora
Hernandez, Ruth Ottman, Iuliana IonitaLaza, Elan Louis
P4.072
Tacrolimus-Induced Tremor:
Switching from Immediate-release (IR-TAC)
to LCP-Tacro Extended-release Tacrolimus
(LCPT) Reduces Tremor and Improves
Quality of Life John Morgan, Anthony
Langone, Vincenza Nigro, Shyamal Mehta,
Kapil Sethi
P4.073
Shaky Handwriting: What
Is the Rate of Decline During Prospective
Follow-up of Essential Tremor? Elan Louis,
Monika Michalec, Art Gillman
P4.074
Case Study: First Reported
Case of Interferon-alpha Induced Postural
and Action Tremor David Rydz, Madeleine
Sharp, Stanley Fahn
P4.081
Eighteen Month
Experience with Diaphragmatic
Pacing in ALS: Outcomes, Efficacy and
Adversities Margaret Allred, Robert
Baloh, Ashraf Elsayegh, Evgeny Tsimerinov,
Abirami Muthukumaran, Anishee Shah,
Richard Lewis
P4.090
P4.082
P4.091
Effects of Cough
Augmentation on Pulmonary Morbidity,
Survival, and Quality of Life in Patients
with Amyotrophic Lateral Sclerosis
in Respiratory Failure: A Randomised
Trial Muhammad Rafiq, Michael Bradburn,
Alison Proctor, Christopher McDermott,
Pamela Shaw
P4.083
Phrenic Nerve Conduction
Studies as a Biomarker of Respiratory
Insufficiency in ALS Liberty Jenkins,
Sarada Sakamuri, Jonathan Katz, Dallas
Forshew, Lee Guion, Dan Moore, Robert
Miller
P4.084
Vitamin D Is a Prognostic
Factor of Amyotrophic Lateral Sclerosis
and Confers Protection to Motoneurons
in Vitro Camu William, Boris Tremblier,
Carine Plassot, Sebastien Alphandery,
Celine Salsac, Nicolas Pageot, Raul JuntasMorales, Frederique Scamps, Jean Pierre
Daures, Cedric Raoul
P4.085
ALS: Trials and Biomarkers
Serum Creatinine, a
Biomarker for Muscle Mass in Amyotrophic
Lateral Sclerosis (ALS), Predicts Loss of
Ambulation Measured by ALS Functional
Rating Scale-Revised Walking Item Score
(ALSFRS-Rw) Benjamin Brooks, Michael
Fischer, Mohammed Sanjak, Scott Holsten,
Boris Kandinov, William Bockenek, Elena
Bravver, Urvi Desai, John Scott Story,
Thomas Pacicco, Scott Lindblom, Velma
Langford, Kathryn Wright, Amber Ward,
Nicole Lucas, Nicole Smith, Mindy Nichols,
Cynthia Lary, Joanne Nemeth, Priscilla
Russo
P4.077
P4.086
P4.075
Tremor Assessment:
Correlation Between Clinical and
Functional Performance Tests Munish
Kumar, Man Mohan Mehndiratta, Sanjay
Pandey
P4.076
Functional Balance
Difficulty in Essential Tremor: The Role of
Cognition Ashwini Rao, Arthur Gilman, Elan
Louis
Tirasemtiv Amplifies Skeletal
Muscle Response to Nerve Activation in
Humans Fady Malik, Richard Hansen, Vipin
Vijayakumar, Stoltz Randall, Roger Enoka,
David Morgans, Andrew Wolff
P4.078
A Pilot Trial of High Frequency
High Dose Granulocyte Colony Stimulating
Factor (GCSF) in Patients with Amyotrophic
Lateral Sclerosis (ALS) Tuan Vu, Terry
McClain, Chuanhai Cao, Natalie Tucker,
Brittany Golden, Lara Katzin, Clifton Gooch
P4.079
Safety and Tolerability of
Systemic Beta-2-Adrenergic Agonist
(Albuterol) as Pharmacological Therapy in
Non-Invasive Ventilation (NIV) -supported
Amyotrophic Lateral Sclerosis (ALS)Patients
with Chronic Respiratory Failure Benjamin
Brooks, Boris Kandinov, Velma Langford,
Scott Lindblom, Mohammed Sanjak, Kathryn
Wright, Amber Ward, Scott Holsten, Michael
Fischer, Nicole Lucas, Nicole Smith, Mindy
Nichols, Cynthia Lary, Joanne Nemeth,
Priscilla Russo, William Bockenek, Elena
Bravver, Urvi Desai, John Scott Story,
Thomas Pacicco
P4.080
Bilateral Phrenic Nerve Pacing
(PNP) in Amyotrophic Lateral Sclerosis
(ALS) Patients: The Mayo Clinic Current
Experience Mohamed Kazamel, Ronald
Reeves, Eric Sorenson
A Clinical Demonstration
of an EEG Brain-Computer Interface
(BCI) for ALS Patients (VA Cooperative
Study #567): Enrollment, Retention, and
Adherence Richard Bedlack, Robert Ruff,
Domenic Reda, Theresa Vaughan, Helen
Shi, Katya Hill, Robert Ringer, Patricia
Banks, Tamara Paine, Jonathan Wolpaw
Anterior Horn Cell Disease:
Biomarkers
P4.087
Sensory-motor Circuit
Dysfunction in Adult Ambulatory SMA
Type 3 Patients Claudia Chiriboga, Louis
Weimer, Jonathan Marra, Nicole Holuba
LaMarca, Jacqueline Montes, Sally
Dunaway, George Mentis, Brian McCabe,
Darryl De Vivo
P4.088
A Significant Increase
of Apparent Diffusion Coefficients in
Corticospinal Tracts Differentiates
Amyotrophic Lateral Sclerosis from
Cervical Spondylotic Myelopaty Yuka
Koike, Masato Kanazawa, Kensi Terajima,
Kei Watanabe, Naoto Endo, Takayoshi
Shimohata, Masatoyo Nishizawa
P4.089
Excessive Daytime Sleepiness
Does Not Predict the Degree of Sleep
Disordered Breathing in ALS: An Autonomic
Dysfunction Matrix Urvi Desai
Chronological Changes in
Cardiac Sympathetic Function in Patients
with Ayotrophic Lateral Sclerosis: An
Analysis Using Cardiac I-123-MIBG
Scintigraphy Yuji Tanaka, Megumi Yamada,
Akihiro Koumura, Yuichi Hayashi, Akio
Kimura, Takashi Inuzuka
Familial Amyloid
Polyneuropathy Presenting as Atypical
Lower Motor Neuron Disease: A Case
Report Fabrizio Salvi, Plasmati Rosaria,
Francesca Pastorelli, Claudio Rapezzi
P4.092
Uric Acid in Amyotrophic
Lateral Sclerosis: No Effect on Outcome
in a Population-based Series Antonio
Canosa, Andrea Calvo, Davide Bertuzzo,
Galmozzi Francesco, Cugnasco Paolo, Pisano
Fabrizio, Giancarlo Logroscino, Cristina
Moglia, Enrica Bersano, Letizia Mazzini,
Adriano Chio
P4.093
Sexual Dimorphism in
ALS Peter Bede, Marwa Elamin, Susan
Byrne, Orla Hardiman
P4.094
Subscales of the ALS
Functional Rating Scale (ALSFRS-R) as
Determinants of Survival in Amyotrophic
Lateral Sclerosis (ALS) Katya Rascovsky,
Sharon Xie, Ashley Boller, Xiaoyan Han,
Leo McCluskey, Lauren Elman, Murray
Grossman
P4.095
Time to Generalization as a
Predictor of Prognosis in ALS. Rosanna
Tortelli, Massimiliano Copetti, Federica
Siena, Rosa Cortese, Rosa Capozzo, Fabio
Pellegrini, Isabella Simone, Giancarlo
Logroscino
P4.101
Magnetic Resonance
Imaging Brachial Plexus Alterations in
ALS Patients Edoardo Spinelli, Gerevini
Simonetta, Federica Agosta, Nilo Riva,
Elisabetta Pagani, Andrea Falini, Giancarlo
P4.102
Predominantly C8 Myotomal
Electrodiagnostic Findings in Hirayama
Disease Timothy Rust, William Arnold,
Miriam Freimer
P4.103
Electrical Impedance
Myography for the Evaluation of the Tongue
Musculature in Amyotrophic Lateral
Sclerosis. Seward Rutkove, Sanjana
Shellikeri, Yana Yunusova, Jordan Green,
Lorne Zinman
P4.104
Functional Connectivity
Measured by Spectral EEG as Potential
Biomarker for Amyotrophic Lateral
Sclerosis Parameswaran Iyer, Bart
Michaels, Edmund Lalor, Richard Reilly, Orla
Hardiman, Orla Hardiman
P4.105
Multiple System Atrophy and
Amyotrophic Lateral Sclerosis in a Family
with Hexanucleotide Repeat Expansions
in C9orf72 Jill Goldman, Cheryl Waters,
Hiroshi Mitsumoto, Thomas Brannagan,
Stephanie Cosentino, Edward Huey, ShengHan Kuo
Neuromuscular:
Electrodiagnostic
P4.106
Differences in Denervation
Patterns Between Patients with Limb
Onset and Bulbar Onset ALS Rocio Garcia
Santibanez, Stephen Scelsa
Can Follow-up
Electrodiagnostic Studies in Patients with
CIDP That Improved Following IGIV-C
Treatment Predict Relapse After Treatment
Discontinuation? Russell Chin, Chunqin
Deng, Vera Bril, Norman Latov, Hans
Hartung, Ingemar Merkies, Peter Donofrio,
Pieter Van Doorn, Marinos Dalakas
P4.097
Voxel-based Morphometry
(VBM) Study in ALS (Amyotrophic Lateral
Sclerosis): Temporal Cortical Damage as a
Prognostic Marker Milena Albuquerque,
Helen Andrade, Cynthia Silva, Anamarli
Nucci, Marcondes Franca, Jr.
P4.107
P4.098
P4.108
P4.096
Cognitive Changes and
White Matter Tract Damage in the Motor
Neuron Disease Spectrum Elisa Canu,
Federica Agosta, Edoardo Spinelli, Nilo Riva,
Massimiliano Copetti, Adriano Chiò, Stefano
Messina, Sandro Iannaccone, Andrea Calvo,
Vincenzo Silani, Andrea Falini, Giancarlo
P4.099
Non-invasive Imaging of
Transplanted Neural Stem Cell Survival
in Amyotrophic Lateral Sclerosis Amit
Srivastava, Sarah Gross, Piotr Walczak,
Camille Bulte, Nicholas Maragakis, Jeff
Bulte
P4.100
Cortical Hemodynamics
Assessment in ALS During Cognitive
Testing Using Functional Near Infrared
Spectroscopy (fNIR) Tooba Fayyaz, Jillian
Edwards, Lauren Scull, Hasan Ayaz, Patricia
Shewokis, David Libon, Anahita Deboo,
Terry Heiman-Patterson
Clinical and
Neurophysiological Spectrum of Peripheral
Neurotoxicity in Patients with CD30Positive Malignancies, Treated with
Brentuximab Vedotin. Rosaria Plasmati,
Francesca Pastorelli, Fabrizio Salvi
Characteristics and
Differential Diagnosis of Neuropathy in a
Tertiary Neuromuscular Clinic Hui Gong,
Amaiak Chilingaryan, Grigor Harutunian,
Nazely Ashikian, Said Beydoun
P4.109
The Neurohysiological
Phenotype Of AH-TTR Amiloidoses Francesca Pastorelli, Rosaria Plasmati,
Claudio Rapezzi, Fabrizio Salvi
P4.110
Evaluation of Conduction
Slowing in Amyotrophic Lateral Sclerosis:
A Novel Approach Zubeda Sheikh, Ankit
Pahwa, Hongxin Chen, Nizar Souayah
P4.111
IVIG Responsive Motor
Neuropathy in the legs: A Diagnostic
Challenge Eliz Agopian, Dale Lange
P4.112
Absence of Spontaneous
Activity in Cervical Paraspinal Musculature
in Patients with Multifocal Motor
Neuropathy/Motor Neuropathy Nuri
Jacoby, Russell Chin, Bridget Carey,
Jennifer Langsdorf, Naomi Feuer, Norman
Latov
83
Wednesday
April 30
Wednesday, April 30
P4.113
Diagnostic Utility of
Repetitive Nerve Stimulation Test of the
Trapezius Muscle in Amyotrophic Lateral
Sclerosis Yuki Hatanaka, Takashi Chiba,
Hidehiko Okuma, Takamichi Kanbayashi,
Midori Kuwabara, Mana Higashihara,
Masahiro Sonoo
P4.114
A Standardized Grading
System for Ulnar Neuropathy at the
Elbow. Ebinehita Arhebamen, Faten Abu
Ghazal, Dilip Pandey, Lawrence Zeidman
P4.115
Association of Autonomic
Symptoms in Carpal Tunnel Syndrome
with Abnormalities in Sympathetic Skin
Responses Anibal Lugo, Faisal Ahmad,
Lonni Schultz, Jose Garcia, Abdulrahman
Alwaki, Naganand Sripathi
Neuropathy: Pathogenesis
and Diagnostic Testing
P4.116
Reduced Neurofilament
Expression in Cutaneous Nerve Fibers of
CMT2E Patients Chiara Pisciotta, Yunhong
Bai, Kathryn Brennan, Tiffany Grider,
Shawna Feely, Suola Wang, Steven Moore,
Michael Shy
P4.117
Characteristics of Patients
Evaluated for Small Fiber Neuropathy with
Skin Biopsy David Saperstein, Todd Levine,
Glenn Lopate, Mamatha Pasnoor, Kayla
Newby
P4.118
Comparison of Epidermal
Nerve Fiber Density and Quantitative
Sudomotor Axon Reflex in Neuropathy
Diagnosis Ahmad Abuzinadah, Patricia
Kluding, Douglas Wright, Linda D’Silva,
Janelle Ryals, Bill Hendry, Omar Jawdat,
Laura Herbelin, April McVey, Richard
Barohn, Mazen Dimachkie, Mamatha
Pasnoor
P4.119
Characterisation and
Diagnostic Evaluation of Chronic
Polyneuropathies Induced by Oxaliplatin
and Docetaxel Comparing Skin Biopsy to
Quantitative Sensory Testing and Nerve
Conduction Studies Thomas Krøigård,
Henrik Schrøder, Camilla Qvortrup, Lise
Eckhoff, Per Pfeiffer, David Gaist, Soren
Sindrup
P4.120
Comparison of CIDP
and MGUS Associated Neuropathy
Patients Nuha Alkhawajah, Samantha
Dunnigan, Vera Bril
P4.121
Demyelinating Polyneuropathy (CIDP) Skin
Biopsies Gene Expression Analysis Thierry
Kuntzer, Adrian Panaite, Puttini Stefania,
Susanne Renaud, Andreas Steck
P4.122
Chronic Immune-Mediated
Demyelinating Polyneuropathy After
Cetuximab Sarah Kranick, Tanya Lehky,
Christine Chung, Hyunseok Kang
P4.123
Peripheral Neuropathy in
Primary Sjögren’s Syndrome Camila
Leijoto, Osvaldo Nascimento, Frederico
Prado, Victor Kosac, Caroline Bittar, Giseli
Quintanilha, Carlos Bruno Nogueira, Felipe
Vianna
84
P4.124
Peripheral Neuromuscular
Manifestations of Sarcoidosis Lipika
Nayak, Brennen Bittel, Yunxia Wang, Mazen
Dimachkie, Laura Herbelin, April McVey,
Richard Barohn, Mamatha Pasnoor
P4.125
Monofocal Motor Neuropathy:
A Case Series Dipika Aggarwal, Mamatha
Pasnoor, Laura Herbelin, Mazen Dimachkie,
Richard Barohn, April McVey
Disease: Biomarkers
P4.126
Cerebrospinal Fluid Protein
Expression Profiles in Benign and
Aggressive Multiple Sclerosis Ying Liu,
Marwan Alahiri, Shivani Agarwal, Saud
Sadiq
P4.127
Extracellular Vesicles Isolated
by Cerebrospinal Fluid as Biomarkers of
Inflammation in Multiple Sclerosis and
Inflammatory Neurological Diseases Paolo
Ragonese, Maria Antonietta Mazzola,
Fabiana Geraci, Giuseppina Turturici, Giulia
Musso, Rosaria Tinnirello, Vincenzina Lo Re,
Sabrina Realmuto, Marianna Lo Re, Paolo
Aridon, Giuseppe Salemi, Gabriella Sconzo,
Giovanni Savettieri
P4.128
Recirculating Phagocytes Are
a Novel Source of Biomarkers for Brain
Injury Ramesh Nayak, Timothy Vollmer,
Roberto Bomprezzi, Raymond Jacolik
P4.129
CSF Biomarkers in
Tumefactive Multiple Sclerosis and Other
Disease Subtypes Ayse Altintas, Hayrettin
Tumani, Sinem Yazici, Vera Lehmensiek
P4.130
Is KIR4.1 Antibody a Marker
of Multiple Sclerosis ? Elodie Nerrant,
Mahmoud Charif, Xavier Ayrignac, Clarisse
Carra-Dalliere, Giovanni Castelnovo, Celine
Salsac, Cedric Raoul, Jean Francois Eliaou,
Pierre Labauge, Thierry Vincent
P4.131
JCV Antibody Positivity
and Status Switching Depends on Assay
Cutpoint Florian Deisenhammer, Micheal
Auer
P4.132
Changes in Immunological
Biomarkers in Patients with RelapsingRemitting Multiple Sclerosis Treated with
Interferon Beta-1a Xin Zhang, Yazhong
Tao, Bianca Weinstock-Guttman, Robert
Zivadinov, Brooke Hayward, Fernando
Dangond, Silva Markovic Plese
P4.133
A Multicentric Crosssectional Study of the Usefulness of
Cerebrospinal Fluid-Glial Fibrillary Acidic
Protein (CSF-GFAP) in the Diagnosis and
Prognosis of Inflammatory Demyelinating
Diseases Shuhei Nishiyama, Tatsuro Misu,
Yuko Shimizu, Kazumasa Yokoyama, Takashi
Kageyama, Yoshiki Takai, Rina Takano,
Toshiyuki Takahashi, Juichi Fujimori, Shigeru
Satoh, Ichiro Nakashima, Yasuto Itoyama,
Kazuo Fujihara, Masashi Aoki
P4.134
B Cell Subsets in the
Cerebrospinal Fluid of Multiple Sclerosis
Patients Christopher Sears, Jerry Lin,
Alexandra Berman, Saud Sadiq
P4.135
Reduced Level of Sialylated
IgG Antibody in the CSF of Patients with
Multiple Sclerosis Xiaoli Yu, Kathryn
Dennison, Tiffany Pointon, Timothy Vollmer
7:30 a.m.–11:00 a.m.
P4.136
CSF Isoelectric Focusing
Differentiates Multiple Sclerosis from Other
CNS Autoimmune Disorders Abdulradha
Alqallaf, Shitiz Sriwastava, Fen Bao,
Evanthia Bernitsas, Erica Errigo, Alexandros
Tselis, Scott Millis, Christina Caon, Omar
Khan
P4.137
Can inflammatory Markers
from CSF be Helpful in Diagnosis of
Multiple Sclerosis? Zuzana Matejcikova,
Hana Prikrylova-Vranova, Jana Klosova,
Vladimira Sladkova, Jana Zapletalova, Jan
Mares, Petr Kanovsky
P4.138
Update on MSPrecise:
A Novel Diagnostic Test for Multiple
Sclerosis Nancy Monson, Eric Eastman,
Douglas Bigwood, Mikhail Levin, William
Rounds, Lindsay Cowell, Benjamin
Greenberg
P4.139
Detection of Anti-natalizumab
Antibodies in Treated Multiple Sclerosis
Patients Using a Biacore™ Platform Fronda
Anna, Ebrima Gibbs, Tariq Aziz, Joel Oger
P4.140
A One Year Follow-up of JCV
Serology with Index Values in a French
Natalizumab Treated Multiple Sclerosis
Cohort Olivier Outteryck, Hélène Zephir,
Arnaud Kwiatkowski, Albert Verier, Didier
Ferriby, Marine Viallet, Philippe Devos,
Jean-Bertin N’Kuendjo, Olivier Derepeer,
Patrick Hautecoeur, Patrick Vermersch
P4.148
Pharmacoeconomic and
Clinical Characteristics in Patients with
Multiple Sclerosis Treated with Disease
Modifying Therapies: PEARL—24 Months
Results Sylia Moser, Sonja Ortler, Tom van
Lokven, Tjalf Ziemssen
P4.149
Estimated Productivity Loss
amongst U.S. Employees with Multiple
Sclerosis Slaven Sikirica, Huanxue Zhou,
Vivian Herrera, Jinhee Park, Rahul Sasane
P4.150
The Impact of Spasticity
Severity on Healthcare Utilization Among
MS Patients: A Large-Scale Six-year
Follow-up Study Tuula Tyry, Amber Salter,
Joan Largent, Ruth-Ann Marrie
P4.151
Substantial Declines in Rates
of Hospitalization in Multiple Sclerosis:
A Population-based Study Ruth-Ann
Marrie, Nancy Yu, Aruni Tennakoon, James
Marriott, Michael Cossoy, Lawrence Elliott,
James Blanchard
P4.152
MS Related Employment in
Germany After the Introduction of Disease
Modifying Drugs Alexei Korchounov
P4.153
Nursing Home MS Residents
Experience Less Stress and Pessimism
Compared to Home-Based NonAmbulatory MS Patients. Zilfah Younus,
Irfan Ahsan, Sahil Gupta, Katelyn Kavak,
Barbara Teter, Bianca Weinstock-Guttman
P4.141
P4.154
P4.142
Disease: Pregnancy and
Hormonal Influences
Anti-JC Virus Antibody
Prevalence in Canadian MS
Patients Virender Bhan, Yves Lapierre,
Mark Freedman, Pierre Duquette, Daniel
Selchen, Vladimir Migounov, Len Walt,
Annie Zhang
Cerebrospinal Fluid
Mononuclear Phagocytes Are Decreased in
Number and Express Less IL-10 in Multiple
Sclerosis Compared to Values Seen with
Normal Controls Shivani Agarwal, Irene
Jarchum, Ying Liu, Saud Sadiq
P4.143
Fetuin-A, a Cerebrospinal Fluid
(CSF) Biomarker of Multiple Sclerosis (MS)
Disease Activity, Promotes Immune Cell
Infiltration into the CNS Lena Bell, Violaine
Harris, Mark Landy, Kristi Clark, Saud Sadiq
P4.144
Association Between Immune
Cell Neurotrophins Levels and Subcortical
Grey Matter Volume in Multiple Sclerosis
Patients Alicja Kalinowska-Lyszczarz,
Mikolaj Pawlak, Slawomir Michalak,
Wlodzimierz Paprzycki, Wojciech Kozubski
Cost and Impact Care of MS
P4.145
The Economic Impact of
Functional Impairment Among Respondents
with Multiple Sclerosis: Findings from the
US Medical Expenditure Panel Survey Ravi
Iyer, Matthew Sussman, Monica Fay, Terrie
Livingston, Glenn Phillips, Joseph Menzin
P4.146
Peginterferon Beta-1a
Reduces Relapse-Associated Costs in
Patients with Relapsing-Remitting Multiple
Sclerosis Ken O’Day, Kellie Meyer, Matt
Mitchell, Sonalee Agarwal, Elizabeth Kinter
P4.147
Cost Sharing Among Persons
with MS Eric Cheng, Vinita Dora, Miriam
Ayad, Alex Chen, Annette Langer-Gould,
Susan Ettner
Satisfaction with Multiple
Sclerosis Care in Daily Practice of
Patients Without an Immunmodulating
Therapy—Results of a Patient Survey
(FOLLOW) Volker Heeschen
P4.155
Birth Outcomes In Newborns
Fathered By Men With Multiple Sclerosis
Exposed To Disease-Modifying Drugs Ellen
Lu, Feng Zhu, Yinshan Zhao, Mia van der
Kop, Anne Synnes, Leanne Dahlgren, Dessa
Sadovnick, Anthony Traboulsee, Helen
Tremlett
P4.156
Gestational Exposure to
Natalizumab and Pregnancy Outcomes—
Results from a Prospective Cohort
with Relapsing Remitting Multiple
Sclerosis Neda Ebrahimi, Sandra Herbstritt,
Ralph Gold, Lilyana Amezcua, Gideon Koren,
Kerstin Hellwig
P4.157
Pregnancy and Fetal
Outcomes After Paternal Exposure to
Disease Modifying Drugs for Multiple
Sclerosis Maria Pia Amato, Marta Giannini,
Emilio Portaccio, Angelo Ghezzi, Bahia
Hakiki, Luisa Pasto’, Lorenzo Razzolini,
Chiara Pecori, Andrea Sturchio, Laura De
Giglio, Carlo Pozzilli, Damiano Paolicelli,
Maria Trojano, Maria Marrosu, Francesco
Patti, Gian Luigi Mancardi, Claudio Solaro,
Rocco Totaro, Maria Tola, Giovanna De
Luca, Alessandra Lugaresi, Lucia Moiola,
Vittorio Martinelli, Giancarlo Comi
P4.158
Serum Anti-Müllerian
Hormone Levels in Reproductive-age
Women with Relapsing Remitting Multiple
Sclerosis Kerstin Hellwig, Susanne Kollar,
Gisa Ellrichmann, Darryl Nousome, Ingo
Kleiter, Ralf Gold, Jan Thoene
Poster Session IV
P4.159
Pregnancy Decisionmaking for Women with Multiple
Sclerosis Barbara Teter, Katelyn Kavak,
Karen Zakalik, Channa Kolb, Patricia Coyle,
Bianca Weinstock-Guttman
P4.160
Reproductive Attitudes
and Pregnancy in Females with Multiple
Sclerosis: Outcomes and Exposure to
Disease-Modifying Drugs Ayse Altintas,
Bjar Najar, Gokcen Gozubatik-Celik, Sukriye
Menku
P4.161
Updated Pregnancy Outcomes
in Patients and Partners of Patients in the
Teriflunomide Clinical Trial Program Lily
Jung Henson, Myriam Benamor, Philippe
Truffinet, Bernd Kieseier
P4.162
Influence of Sex Hormone
Ratios on the Clinical Course of Multiple
Sclerosis: A Case Study After the First
Year of Follow Up. Dimitrios Kitsos, Charis
Liapi, Sotirios Tsiodras, Antonios Poulios,
Konstantine Voumvourakis
P4.163
Menopause in a Longitudinal
Clinical Cohort of Women with Multiple
Sclerosis. Riley Bove, Brian Healy,
Alexander Musallam, Nafiseh Alsharif,
Bonnie Glanz, Tanuja Chitnis
P4.164
Differencies in the Severity
of Multiple Sclerosis Within Gender
Determinated by Age at Onset Jimena
Míguez, Juan Ignacio Rojas, Liliana
Patrucco, Edgardo Cristiano
Cognition in MS
P4.165
Mismatch Negativity Links
to Information Processing in Multiple
Sclerosis (MS) Felicia Jackson, Leigh
Charvet, Maria Amella, Greg Proudfit,
Lauren Krupp
P4.166
Cognitive Dysfunction
in Patients with Multiple Sclerosis Is
Related with Apathy and Depression, But
Not Subjective Fatigue Masaaki Niino,
Nobuhiro Mifune, Susumu Kusunoki, Yusei
Miyazaki, Seiji Kikuchi
P4.167
Presence and Significant
Determinants of Cognitive Impairment in
a Large Sample of Patients with Multiple
Sclerosis Martina Borghi
P4.168
Predictivity of Executive
Functions in Episodic Memory in Multiple
Sclerosis Rekha Barthelemy, Bruno Lenne,
Dephine Leuse, Arnaud Kwiatkowski, Patrick
Hautecoeur
P4.169
The Symbol Digit Modalities
Test (SDMT) Has Been the Standard
Cognitive Measure Used in Multiple
Sclerosis (MS) Clinical Trials: How Does
It Correlate with Computerized Cognitive
Screening Tools? Myassar Zarif, Mark
Gudesblatt, Barbara Bumstead, Marijean
Buhse, Lori Fafard, Cynthia Sullivan, Jeffrey
Wilken, Glen Doniger, Juskaran Chahda
P4.170
Cognitive Changes During and
After MS Relapses—6 Months FollowUp Katrin Gross-Paju
P4.171
Cognitive Evolution in Tysabri
(natalizumab)-Treated Multiple Sclerosis
Patients Francois Jacques, Brian Harel,
Adrian Schembri, Joanne Gale
P4.172
Effects of Natalizumab
on Cognition and Neurodegeneration
in Relapsing-Remitting Multiple
Sclerosis Garrick Talmage, Oscar Coppes,
Ashley Finch, Christina Sprayberry, Adil
Javed, Jacqueline Bernard
P4.181
P4.173
P4.182
Multiple Sclerosis and Driving:
Cognitive Profile Correlation to Patient
Self-Reported Driving Mark Gudesblatt,
Myassar Zarif, Barbara Bumstead, Marijean
Buhse, Smitha Thotam, Lori Fafard, Jennifer
Kalina, Cynthia Sullivan, Jeffrey Wilken,
Glen Doniger
Disease: Quality of Life
P4.174
Quality of Life and Fatigue in
Radiologically Isolated Syndrome Christine
Lebrun Frenay, Mikael Cohen, Pierre
Clavelou
P4.175
Cognition and Grey Matter
Atrophy Are Predictive of Health Related
Quality of Life in Early Treated Patients
with Clinically Isolated Syndrome Mikael
Cohen, Bruno Brochet, Pierre Clavelou,
Emmanuelle Lepage, Patrick Vermersch,
Ayman Tourbah, Thibault Moreau, Christine
Lebrun Frenay
P4.176
Health-Related Quality of Life
in US Patients with Relapsing-Remitting
Multiple Sclerosis (RRMS) Treated with
Delayed-Release Dimethyl Fumarate: An
Integrated Analysis of the Phase 3 DEFINE
and CONFIRM Studies Mariko Kita, Robert
Fox, Ralf Gold, Sujata Sarda, Ravi Iyer,
Timothy Niecko, Leslie Meltzer, J. Theodore
Phillips
P4.177
Peginterferon Beta-1a
Treatment Reduces the Impact of
Multiple Sclerosis Relapse and Disability
Progression on Health-Related Quality
of Life: Results from the ADVANCE
Trial Elizabeth Kinter, Shien Guo, Arman
Altincatal, Irina Proskorovsky, Glenn Phillips,
Bjorn Sperling
P4.178
Two-Year Interim Analysis of
Quality of Life in Patients with RelapsingRemitting Multiple Sclerosis (RRMS)
treated with Delayed-Release Dimethyl
Fumarate in the ENDORSE Study Mariko
Kita, Robert Fox, Ralf Gold, Gavin
Giovannoni, J. Theodore Phillips, Sujata
Sarda, Macaulay Okwuokenye, Jessica
Kong, Ray Zhang, Vissia Viglietta, Sarah
Sheikh, Ludwig Kappos
P4.179
Interim Results of the Swiss
Post Marketing Surveillance Monitoring
Quality of Life and Treatment Satisfaction
in Patients with Relapsing-Remitting
Multiple Sclerosis (SWISSASCENT) Adam
Czaplinski, Emilie Jaquiery, Petra Stellmes,
Simon Ramseier, Andreas Baumann, Oleg
Kurlandchikov, Christian Berger, Michel
Chofflon, Franziska Lieder, Sandra Gass,
Thomas Maier
P4.180
Patient-reported Quality
of Life in the BENEFIT Trial Gilles Edan,
Ludwig Kappos, Xavier Montalban, Mark
Freedman, Hans Hartung, David Miller,
Frederik Barkhof, Julia Hermann, Vivian
Lanius, Christoph Pohl, Rupert Sandbrink,
Dirk Pleimes
Multiple Sclerosis: the Need
to Understand Patients’ Quality of Life in
a Latin American Country Sandra Vanotti,
Natalia Ciufia, Cecilia Yastremiz, Maria
Saladino, Nora Fernandez Liguori, Alberto
Yorio, Fernando Caceres
Health-Related Quality of Life
in Relapsing-Remitting Multiple Sclerosis
(RRMS): Comparison with Other Medical
Conditions and Effect of Delayed-Release
Dimethyl Fumarate Treatment Sujata
Sarda, Glenn Phillips, Julia Gaebler, Nuwan
Kurukulasuriya
P4.183Patient-Reported
Psychological Functioning in Natalizumabtreated Patients with Multiple Sclerosis
in US Clinical Practice John Foley, Kavita
Nair, Judith Stephenson, Timothy Vollmer,
Timothy Niecko, Sonalee Agarwal, Crystal
Watson
Disease: Disability Progression
P4.184
Predicting Disability in the
Modern MS Cohort Roland Henry, Esha
Datta, Alyssa Zhu, Bagrat Amirbekian,
Regina Schlaeger, Refujia Gomez, Rachel
Kanner, Caroline Ciocca, Jeffrey Gelfand,
Douglas Goodin, Ari Green, Stephen Hauser,
Bruce Cree
P4.185
The Risk of Progression in
MS Depends on the Features of Preceding
Relapses: Application to First Generation
Immunomodulating Theraphy Helen
Tedeholm, Bengt Skoog, Bjorn Runmarker,
Anders Odén, Oluf Andersen
P4.186
Incomplete Relapse Recovery
and Sustained Disability Progression in
Multiple Sclerosis in Pittsburgh Edward
Gettings, Chris Hackett, Carol Schramke,
Thomas Scott
P4.187
Clinical Predictors of
Expanded Disability Status Scale Rank
Change Over 5-Year Intervals in the
MSBase Registry Stella Hughes, Timothy
Spelman, Maria Trojano, Alessandra
Lugaresi, Guillermo Izquierdo, Francois
Grand-Maison, Pierre Duquette, Marc
Girard, Pierre Grammond, Celia OrejaGuevara, Raymond Hupperts, Cavit Boz,
Roberto Bergamaschi, Giorgio Giuliani,
Edite Rio, Jeannette Lechner-Scott, Vincent
Van Pesch, Gerardo Iuliano, Marcela Fiol,
Freek Verheul, Michael Barnett, Mark Slee,
Joseph Herbert, Ilya Kister, Norbert Vella,
Fraser Moore, Tatjana Petkovska-Boskova,
Vahid Shaygannejad, Vilija Jokubaitis, Gavin
McDonnell, Stanley Hawkins, Frank Kee,
Helmut Butzkueven, Orla Gray
P4.188
Predictors of Disability
Extremes in Patients with Multiple
Sclerosis Treated with Interferon-beta
Using the Swedish MS Registry Katharina
Fink, Anna Fogdell-Hahn, Jan Hillert
P4.189
Previous Disability Has
an Influence in Recovery of Multiple
Sclerosis Relapses Treated with
Methylprednisolone? Cristina Ramo, Laia
Grau-López, Maria Tintore-Subirana, Alex
Rovira, Lluis Ramio, Luis Brieva, Albert Saiz,
Carlos Nos, Antonio Cano, Olga Carmona,
Ferran Torres, Jose Vicente Hervas, Xavier
Montalban, Joan Costa
P4.190
Sustained Expanded Disability Status Scale
Progression and Simultaneous Changes in
Individual Functional Systems in RelapsingRemitting Multiple Sclerosis Thomas
Scott, Bjorn Sperling, Ping Wang, Xiaojun
You, Monica Mann
P4.191
Evaluating TMS Motor
Evoked Potentials in Early Stages of
Multiple Sclerosis Aid in Predicting
Disability Nilufer Kale, Gulten Ozdemir, Eda
Coban, Jale Agaoglu
P4.192
Sustained Disability
Improvement Associated with Reduced
MRI Lesion Burden in Natalizumab-Treated
Patients with Multiple Sclerosis Luca
Prosperini, Floriana De Angelis, Rosanna De
Angelis, Fulvia Fanelli, Carlo Pozzilli
P4.193
A Multi-Modal
Neurophysiological Evaluation of Primary
Progressive Multiple Sclerosis—a
Cross Sectional and Longitudinal Cohort
Analysis Luke Canham, David Cottrell, Nick
Kane, Jonathan Witherick, Kelly Blake, Peter
Walsh
Early Diagnostic Markers
P4.194
Normal HDL But Not the HDL
from Patients with Coronary Heart Disease
Prevent LDL Induced Toxicity in Cultured
iCell Neurons. Samra Vazirian
P4.195
A Predictive Model for
Cognitive Impairment in Individual Patient
with Diabetes Mellitus Martin Rakusa,
Matej Rakusa, Miro Cokolic
P4.196
Mild Cognitive Impairment
(MCI)in Parkinson Disease (PD) and Lewy
Body Disease(LBD): Who Became to
Dementia? Maria Garcia Basalo, Maria
Fernandez, Carla Stefani, Waleska Berrios,
Diego Bauso, Juan Ignacio Rojas, Edgardo
Cristiano, Angel Golimstok
P4.197
A portable Non-Invasive
Biosensor Based Approach to Actively
Assess Cognitive Function in Alzheimer’s
Disease (AD) and Beyond Allan Bernstein,
Terry Hess, Parham Ghorbanian, Hashem
Ashrafiuon, David Devilbiss, Adam Simon
P4.198
Cognitive Impairment in
Healthy Filipino Adults with MRI Nonspecific White Matter Change Ty Alekzander Talamera, Jacqueline
Dominguez, Merceditas Dizon
P4.199
Microstuctural Alteration of
the Default Mode Network as a Predictor
of Cognitive Impairment in Alzheimer’s
Disease Marina Weiler, Brunno de
Campos, Mateus Nogueira, Tátila Lopes,
Benito Damasceno, Fernando Cendes,
Marcio Balthazar
P4.200
Theory of Mind: a Cognitive
Marker of Conversion from Mild Cognitive
Impairment to Alzheimer Disease? Noémie
Moreau, Stéphane Rauzy, François Viallet,
Maud Champagne-Lavau
Wednesday
April 30
Wednesday, April 30
P4.201
The Pituitary Adenylate
Cyclase Activating Polypeptide Levels Are
Associated with Pathological Features of
Alzheimer’s Disease Jiong Shi, P Han, L
Baxter, W Liang, Z Tang, J Yin, T Beach, R
Caselli, E Reiman
Frontotemporal Lobar
Degeneration
P4.202
Motor Neuron Dysfunction
In Frontotemporal Lobar Degeneration:
A Clinical and Neurophysiological
Study Chiara Cerami, Alessandra Marcone,
Claudio Marangoni, Chiara Crespi,
Alessandra Dodich, Nicola Canessa, Sandro
Iannaccone, Zamboni Michele, Valeria Golzi,
Maria Cristina Giusti, Stefano Cappa
P4.203
Do We Need a Change?
Utility of Standard Cognitive Screening
Instruments in Patients with Amyotrophic
Lateral Sclerosis Eileen Moran, Katya
Rascovsky, Ashley Boller, Leo McCluskey,
Lauren Elman, David Libon, Murray
Grossman
P4.204
Cognitive Impairment (CI)
in Amyotrophic Lateral Sclerosis (ALS):
A Clinical Based Study Marcelo Chaves,
Maria Garcia Basalo, Mariela Bettini, Maria
Fernandez, Edgardo Cristiano, Marcelo
Francisco Rugiero, Angel Golimstok
P4.205
Cytokine Gene Expression
in Peripheral Cells from Patients with
Frontotemporal Lobar Degeneration Due
to GRN and C9ORF72 Mutation Daniela
Galimberti, Chiara Fenoglio, Rossana Bonsi,
Maria Serpente, Chiara Villa, Sara Cioffi,
Cinzia Barone, Andrea Arighi, Laura Ghezzi,
Giorgio Fumagalli, Elio Scarpini
P4.206
TDP-43 in Alzheimer’s Disease
Is Not Associated with Parkinsonian
Features or Clinical FTD Youngsin Jung,
Dennis Dickson, Melissa Murray, David
Knopman, Bradley Boeve, Ronald Petersen,
Keith Josephs
P4.207
The Clock Drawing Test
in Behavioral Variant Frontotemporal
Dementia Versus Alzheimer’s
Disease Robin Barrows, Joseph Barsuglia,
Donald Eknoyan, Valeriy Sabodash, Mario
Mendez
P4.208
Clinician Versus Family
Caregiver Ratings of Behavioral Variant
Frontotemporal Dementia Joseph
Barsuglia, Hemali Panchal, Aditi Joshi,
Robin Barrows, Michelle Mather, Elvira
Jimenez, Mario Mendez
7:30 a.m.–11:00 a.m.
Acute Stroke Endovascular
Acute Stroke Thrombolysis
P4.209
P4.219
“Heparin-Less” Protocol for
Endovascular Treatment of Acute Ischemic
Stroke Asif Khan, Ameer Hassan, Taqi
Zafar, Ahmed Malik, Malik Adil, Muhammad
Suri, Adnan Qureshi
P4.210
Interim Recanalization in
Acute Ischemic Stroke Patients Selected
for Endovascular Treatment by CT
Angiography Mushtaq Qureshi, Farhan
Siddiq, Daraspreet Kainth, Adnan Qureshi
P4.211
Troponin Elevation in Intraarterial Stroke Intervention Abhay Kumar,
Sonal Mehta, Aws Alawi, Amanda Michael
P4.212
Downstream Clot Fragment
Migration During Endovascular Clot
Extraction Adversely Affects Clinical
Outcome James Frey, Carol Darbonne, Joni
Clark, Allison Tucker, Christina Chapple
P4.213
Intervention Stroke
Assessment Scale for Eligibility
in Endovascular Therapy (ISASET) Dababneh Haitham, Asif Bashir,
Mohammed Hussain, Sara Misthal,
Mohammad Moussavi, Jawad Kirmani
P4.214
“No Turn Back Approach”
to Reduce Treatment Time for
Endovascular Treatment of Acute Ischemic
Stroke Hossam Egila, Malik Adil, Harris
Siddiqi, Nidaullah Mian, Ameer Hassan,
Jefferson Miley, Gustavo Rodriguez,
P4.215
Thrombus Density Predicts
Successful Recanalization with StentRetriever Thrombectomy in Acute Ischemic
Stroke Maxim Mokin, Simon Morr,
Sabareesh Natarajan, Adnan Siddiqui, Elad
Levy
P4.216
Optical Bedside Monitoring
of Cerebral Blood Flow in Acute Ischemic
Stroke Patients During Head of Bed
Manipulation Christopher Favilla, Rickson
Mesquita, Michael Mullen, Turgut
Durduran, Meeri Kim, David Minkoff, Scott
Kasner, Greenberg Joel, Arjun Yodh, John
Detre
P4.217
Endovascular Treatment of
Acute Basilar Artery Occlusion Roman
Herzig, Tomas Dornak, David Skoloudik,
Daniel Sanak, Martin Kuliha, Martin
Roubec, Roman Havlicek, Lenka Hajdukova,
Martin Kocher, Vaclav Prochazka, Jiri
Lacman, Frantisek Charvat, Michal Kral,
Tomas Veverka, Jana Zapletalova
P4.218
Intra-procedural Heparin
Increases Mortality and Reduces Rates
of Favorable Outcome in Acute Ischemic
Stroke Patients Undergoing Endovascular
Treatment Vishal Jani, Avean Saed,
Tanya Mohindroo, Mushtaq Qureshi, Syed
Hussain, Fareed Suri, Adnan Qureshi
Safety of tPA + Transcranial
Emission of Low-energy Lasers for Acute
Stroke Recovery—Results Thomas
Hemmen, Rema Raman, Souvik Sen,
Madeleine Geraghty, Karen Rapp,
Steven Richeri, Brett Meyer, Justin Zivin,
Christopher Fanale
P4.220
Thrombolytic Outcomes
for Acute Ischemic Stroke in Patients
with Primary Brain Tumors in the United
States Santosh Murthy, Yogesh Moradiya,
Shreyansh Shah, Aditi Shastri, Eric Bershad,
Jose Suarez
P4.221
Balancing Rapid Treatment
Goals with Thorough Laboratory Evaluation
in Alteplase Candidates: A Review of a
Stroke Center’s Current Practices and
Outcomes Stacy Smith, John Volpi
P4.222
Serum Albumin Is Associated
with Cerebral Hemorrhage in PostIntravenous Thrombolytic Therapy for
Acute Stroke: A Retrospective Chart
Review Haris Kamal, Ping Li, Kelly Smith,
Ghulam Mustafa, Robert Sawyer, Marilou
Ching, Bijal Mehta
P4.223
Thrombolytic Treatment
for Acute Ischemic Stroke Patients with
History of Migraine Headaches Ahmed
Malik, Malik Adil, Saqib Chaudhry, Adnan
Qureshi
P4.224
Intravenous Thrombolysis
for Acute Ischemic Stroke in the 3- to
4·5-hour Window—the Malabar
Experience Karadan Ummer, K. Salam,
Mohan Noone, Pradeep Kumar
P4.225
The effect of statin
pretreatment and Serum Lipid Values on
Hemorragic Conversion After rt-PA for
Acute Ischemic Stroke Ayaz Khawaja,
Michael Lyerly, Gyanendra Kumar, Kara
Sands, Reza Bavarsad Shahripour, Andrei
Alexandrov
P4.226
Can CT Perfusion
Identify Patients Unlikely to Show
Improvement Following Intravenous
Thrombolysis? Dushyant Damania, Nancy
Kung, George Koch, Minal Jain, Anunaya
Jain, Babak Jahromi
Life Threatening Intracranial
Hemorrhage as a Consequence of
Dobutamine Stress Echocardiography: A
Case Report Adithya Sivaraju, Vineet Punia,
Machteld Hillen
P4.231
Can Transthoracic
Echocardiography be Useful Detecting
Patent Foramen Ovale in Stroke? The
of Valsalva Maneuver Ana Iglesias
Mohedano, Fernando Diaz Otero, Andres
García Pastor, Raquel Yotti, PIlar Vazquez
Alen, Raul Dominguez Rubio, Fernando
Romero Delgado, Adriana Muñoz González,
Pilar Sobrino García, Yolanda Fernández
Bullido, Antonio Villanueva Osorio, Antonio
Gil-Nunez
P4.232
Cardiac Autonomic
Neuropathy, Screening, Staging and
Follow-Up, a Five Year Study from a
General Hospital Lalitha Rajanala,
Sundarachary Nagarjunakonda, Veeramma
Doctor
P4.233
Cardiac Valve Strands
in Ischemic Stroke: Strand Effects
and Outcomes of Medical or Surgical
Intervention Jennifer Chu, Roderic Fabian
P4.234
Review of Cardiac
Abnormalities with Hypercoagulable
Testing in Ischemic Stroke
Patients Nicolaas Anderson, Akshay Shah,
Kendra Drake, Maria Proytcheva, Bruce
Coull
P4.235
Systemic Inflammation
Exacerbates Stroke in Patients with Left
Ventricular Assist Device Ryo Ohtomo,
Atsushi Iwata, Osamu Kinoshita, Jun
Shimizu, Minoru Ono, Shoji Tsuji
P4.236
Transcranial Doppler
to Assess Cerebral Blood Flow in
Patients on Extra Corporeal Membrane
Oxygenation Sanam Baghshomali, Patrick
Reynolds, Aarti Sarwal
Endovascular Neurology
P4.237
Venous Flow Stagnation in
Acute Ischemic Stroke Patients Undergoing
Endovascular Treatment Mushtaq Qureshi,
Daraspreet Kainth, Adeel Memon, Adnan
Qureshi
P4.227
P4.238
and Interventional
Neurology: Cardiac
P4.239
Vitreous Hemorrhage as a
Complication of IV-tPA Therapy in a Patient
with Acute Stroke Laxmi Shah, Thierry
Verstraeten, David Wright, Sandeep Rana
P4.228
Utility of Pelvic MRV in
Evaluation of Patients with Cryptogenic
Stroke and PFO Marcey Osgood, Elizabeth
Budman, Nils Henninger
P4.229
Effect of Patent Foramen
Ovale (PFO) Endovascular Closure on Stroke
Quality of Life Feeney-Heinzelmann K,
MingMing Ning, W Deng, T Wickham, I
Inglessis, Eng Lo, I Palacios, Ferdinando
Buonanno
86
P4.230
Functional Status
and 5-year Survival Among Elderly
Americans: Implications for Patient
Selection for Surgical and Endovascular
Procedures Ahmed Malik, Malik Adil,
Adnan Qureshi
Is Hemoglobin A1c (HbA1C)
Level an Independent Predictor of
Adverse Outcomes in Patients with Acute
Ischemic Stroke Undergoing Endovascular
Treatment? Mohammad Afzal, Saqib
Chaudry, Taqi Zafar, Ali Saeed, Mohammad
Owais, Malik Adil, Vikram Jadhav, Ameer
Hassan, Syed Hussain, Adnan Qureshi
Poster Session IV
P4.240
Motor Component of
National Institute of Health Stroke
Scale Effect on Functional Outcome
and Mortality at Discharge in Patient
Receiving Endovascular Therapy Sara
Misthal, Dababneh Haitham, Asif Bashir,
Mohammed Hussain, Mohammad
Moussavi, Jawad Kirmani
P4.241
Versus Endovascular Treatment for Acute
Ischemic Stroke: A Meta-Analysis of
Randomized Controlled Trials Nidaullah
Mian, Farhan Siddiq, Mushtaq Qureshi,
Malik Adil, Asif Khan, Muhammad Suri,
Adnan Qureshi
P4.253
Case of Occipital Epilepsia
Partialis Continua Presenting as Status
Migrainosus: Clinical, EEG and Brain MRI
Findings Weiwei Dai, Madeleine GriggDamberger
P4.254
Efficacy of Lacosamide in
Epilepsia Partialis Continua Devanshi
Jadhav, Daniel Birnbaum, Kathleen Burger,
Mohamad Koubeissi
P4.255
Epilepsia Partialis Continua
Secondary to Ischemic Stroke, Responsive
to the Combination of Levetiracetam and
Lacosamide Rebecca Thompson, Najib
Murr, Pierre Fayad
P4.242
Neurophysiology (EEG):
Non-Epileptic Seizures and SUDEP
P4.243
P4.256
The Future Role of
Interventional Neurology—A Survery of
Neurology Department Program Directors
and Clerkship Directors. John Leschke
An Updated CostEffectiveness Analysis (CEA) of r-tPA
for Acute Ischemic Stroke (AIS) Treated
Within 3 Hours of Symptom Onset Denise
Boudreau, Gregory Guzauskas, Darren
Tayama, Susan Fagan, David Veenstra
P4.244
The Future Role of
Interventional Neurology—a Survey of
Neurology Department Chairmen. John
Leschke
P4.245
Performance Metrics for The
Interventional Treatment of Acute Ischemic
Stroke; Results from a Comprehensive
Stroke Center Ali Sultan-Qurraie, Adam
de Havenon, Kyra Becker, Deepak Sharma,
Danial Hallam, Basavaraj Ghodke, Louis
Kim, David Tirschwell
Status Epilepticus
P4.246WITHDRAWN
P4.247Non-convulsive
Status Epilepticus in Comatose
Patients. Alejandro Thomson, Analia Calle,
Agustina Tamargo, Maria Gonzalez Toledo,
Fatima Pagani Cassara, Diego Nadile,
Vladimiro Sinay, Alfredo Thomson
P4.248
Early Identification of Status
Epilepticus Etiology with a Simple Clinical
Tool Vincent Alvarez, Jong Lee, M.
Westover, Andrea Rossetti
P4.249
Intravenous Versus
Non-intravenous Benzodiazepines for
the Treatment of Status Epilepticus:
A Systematic Review and MetaAnalysis Ahmad Abulaban, Abdussalam
Alshehri, Suleiman Kojan, Rakan Bokhari
P4.250Benzodiazepine
Administration for Seizure Emergencies: A
Review Sheryl Haut, Syndi Seinfeld, John
Pellock
P4.251
Diazepam Useful in ESES
Treatment Mirret El-Hagrassy, Chulaka
Gunasekara, Yaman Eksioglu
P4.252
Temperature Modulation
for Refractory Status Epilepticus Barry
Czeisler, Sohil Manvar, Gian Marco De
Marchis, Deborah Pugin, Andres Fernandez,
Brandon Foreman, J. Michael Schmidt,
Neeraj Badjatia, Sachin Agarwal, Stephan
Mayer, Jan Claassen
A Case Series Exploration
of a Possible Relationship Between
Non-Epileptic Behavioral Spells and
Migraine Andrew Tseng, Jeffrey Staab,
Ivan Garza, Gregory Cascino
P4.257
Relevance of Psychogenic and
Epileptic Seizures Coexisting in an Epilepsy
Monitoring Unit Population Alan Krumholz,
Diane Thomas
P4.258
Role of Placebo Induction in
Epilepsy Monitoring Unit Ahmed Yassin,
Todd Masel
P4.259
Diagnostic Yield of Prolonged
Electroencephalogram In Pediatric Syncope
Patients Cimy Jacob, Alice Daniel, Josiane
LaJoie
P4.260
The Spectrum of Ictal
Asystole: A Case Series David Harris,
Maromi Nei
P4.261
Age-specific Periictal
Electroclinical Features of Generalized
Tonic-clonic Seizures and Potential
Risk of Sudden Unexpected Death in
Epilepsy (SUDEP). Gurmeen Kaur, Joel
Freitas, Samden Lhatoo, Guadalupe
FernandezBacaVaca, Curtis Tatsouko
P4.267
Lamotrigine, a Narrow
Therapeutic Index Drug or Not? Wendy
Cai, Tricia Ting, James Polli, Michel Berg,
Michael Privetera, Wenlei Jiang
P4.268
Psychogenic Non-Epileptic
Spells: Analysis of Clinical Perspectives
and Practice Amy Hessler, Barbara Slevin,
Malachy Bishop, Amelia Anderson
P4.269
Pharmaceutical Quality
Assessment of Generic Lamotrigine
Immediate Release (IR) Tablets Kunyi Wu,
Daniel Peng, Wenlei Jiang
P4.270
The Effect of an Educational
Intervention on Compliance with AAN
Guidelines for Return Epilepsy Visits: A
Quality Improvement Project Gary Nelson,
Lynne Kerr, Francis Filloux
P4.271
David Versus Goliath: Two
Competing US Trials of 3,4-Diaminopyridine
(3,4-DAP) in Lambert-Eaton Myasthenic
Syndrome (LEMS) Donald Sanders
P4.272
Development and
Implementation of a Quality Improvement
Strategy for Obtaining Muscle Biopsies
Utilizing DMAIC Methodology Charles
Kassardjian, Michelle Williamson, Dorothy
Van Buskirk, Floranne Ernste, Andrea Leep
Hunderfund
P4.273
Routine Versus Electronic
Data Collection in Multiple Sclerosis
Patients Wael Richeh, Jesus Lovera,
Amparo Gutierrez, Nicole VillemarettePittman, Raisa Martinez
P4.274
Cross Validation of Local
Labs to Eliminate Reference Lab Testing
for Varicella Zoster ELISA: A Model for
Reducing Send Out Labs to Improve Care
and Lower Cost. Alexander Hartmann
P4.275
Does Effective Communication
Between Patients and Ordering
Physicians Improve Patient Satisfaction
and the Quality of Electrodiagnostic
Studies? Divpreet Kaur, Yadira VelazquezRodriguez, Aiesha Ahmed
P4.262
Practice, Policy, and Ethics:
Training and Common
Practices in Neurology
P4.263
P4.276
Epilepsy, Syncope, and SUDEP,
a Small Case Series Camilo Garcia-Gracia,
Nancy Rosales, Rachana Gandhi
Vigabatrin in 90 Pediatric and Adult
Patients with Epilepsy Dimitrios Arkilo,
Caitlin Narusiewicz, Janet Branson, Jennifer
Brunn, Carol Hoskin, Patricia Penovich,
Michael Frost
P4.264
Lacosamide Retention Rates
in Pediatric Epilepsy Emily Robbins, Sudha
Kessler, Julia Cohen
P4.265
Prescribing Trends of
Antiepileptic Drugs for Epilepsy Within the
Veterans Health Administration Tung Tran,
Rizwana Rehman, Aatif Husain
Epilepsy, Neuromuscular,
and Neuroimmunology
P4.266
Improving Patient Satisfaction
The Neurology Service Sonia Krish, Nicole
Harrison, Enedra Allen-Mcbride, Paul Schulz
Unplanned Transfers to a
Neurological Intensive Care Unit Carl Gold,
Stephan Mayer, Laura Lennihan, Joshua
Willey
P4.277
Who Is Your Neurologist?:
Measuring the Efficacy of a Resident
Run Continuity Clinic Reshma Gokaldas,
Maheep Singh, Robert Fekete
P4.278
Improving Patient Hand-Offs
in a University Neurology Residency
Program Catherine Porter, Lynn Chouhfeh,
Alyssa Fiddler, Salomi Salins, Novreen
Shahdad, Nicholas Silvestri
P4.279
Standardized Patient Handoff
Improves Resident Confidence and Patient
Safety Justin Jordan, Steven Vernino
P4.280
Timeliness of
Neurology Consultations in the
Emergency Department: A Quality
Evaluation Samantha Holden, Steven Lewis
P4.281
Lumbar Puncture: a Dying
Procedure Among Neurologists? Elizabeth Flaherty, Aimee Szewka
P4.282
Physician Compensation
and Patient Satisfaction:
Unintended Consequences of Policy
Misalignment Jack Riggs, Kevin Riggs
P4.283
Analysis of Inter-Provider
Conflicts in Healthcare Mark Stecker,
Mona Stecker
Stroke, Critical Care, and Other
P4.284
Timely Initiation of
Therapeutic Hypothermia Following
Cardiac Arrest: A Resident-Driven Quality
Improvement Project Laura Rosow, S.
Josephson
P4.285
Re-evaluating Brain Death:
The Potential for Treatment and Recovery
After Brain Injury Philip Defina, Christine
Zakrzewski, Charles Prestigiacomo, Calixto
Machado, Peter Bernad, James Halper,
Jonathan Fellus
P4.286
Are AHA/ASA Stroke
Guidelines Evident Enough? Swaroop
Pawar, Andrea Boan, M. Kamran Athar,
Tanya Turan
P4.287
Improving Secondary
Stroke Prevention Following Acute
Ischemic Stroke: A Practice Improvement
Project. Andrea Harriott
P4.288
Natural Language Processing
Method Accurately Classifies and Extracts
Unstructed Data from Stroke Admission
and Progress Notes Daniel Franc
P4.289
What’s the True Definition of
an Adverse Event? Raghav Govindarajan
P4.290
Improving Assessment and
Documentation of Pain Management at
University of Florida—Jacksonville. Denys
Shapovalov, Nader Antonios
P4.291
Quality Improvement Project
on Hand Washing at Memorial Hermann
Hospital Jitesh Kar, Kristin Brown, Terry
Walker, Janete Sheiner, Janelle Headley,
Allison Murphy, Stephanie Cooper, Enedra
Allen-McBride, Miriam Morales, Paul Schulz
Global Health and Infection
P4.292
Helping Haiti: Addressing the
Burden of Neurologic Disease Veronica
Santini, Anthony Alessi, Elaine Jones, Mill
Etienne, Anna Hohler
P4.293
Cognitive and
Neurodegenerative Disorders in Adults
in Africa: A Systematic Review Hannah
McLane, Tarun Singhal, Joel Negin, Neelum
Aggarwal, Anhar Hassan, Farrah Mateen
P4.294
Epidemiology and Etiology of
Acute Infectious Neurologic Disease (AIND)
in Singapore Kevin Tan, Monica Chan,
Nadika Wijesoma, Peng Soon Ng, Ambihai
Sivalingam, Tianrong Yeo, Yee-Sin Leo,
October Sessions, Eng-Eong Ooi, Duane
Gubler, Umapathi Thirunagnam, James
Sejvar
87
Wednesday
April 30
Wednesday, April 30
P4.295NeurologicManifestations
of Neglected Tropical Diseases Pooja
Raibagkar, Aaron Berkowitz, Bobbi Pritt, E.
Tessa Headley-Whyte, Farrah Mateen
P4.296
Aspirin for Acute Stroke of
Undetermined Etiology in Resource-limited
Settings: A Decision Analysis Aaron
Berkowitz, M. Westover, Matt Bianchi,
Sherry Chou
P4.297
Risk Factors for Cerebral Palsy
in Botswana David Bearden, Baphaleng
Monokwane, Dennis Kolson, Greg Bisson
P4.298
Variations in Brain Death
Declaration: A Worldwide Survey Sarah
Wahlster, Eelco Wijdicks, Pratik Patel, David
Greer, Claude Hemphill, Farrah Mateen
P4.299
Neurology International
Residents Videoconference and Exchange
(NIRVE) Mary Jane Lim Fat, Manav Vyas,
Jenny Tsai, Mark Kinach, Tim Patterson,
Morris Freedman
P4.300
International Affiliation as a
Tool to Improve the Quality and Safety of
Inpatient Care. Experience Neurological
Center, the American British Cowdray
Medical Center. Mexico City Aurelio
Mendez, Roberto Alfonso De Leo-Vargas,
Alejandro Alfonso-Díaz, Guillermo ReyesCaballero, Marco Alegria, Patricia ConchaHein, Claudia Cabrera
P4.301
International Electives in
Neurology Training: A Survey of U.S. and
Canadian Program Directors Jennifer
Lyons, Mary Coleman, John Engstrom,
Farrah Mateen
P4.307
Central and Peripheral
Markers of Neurodegeneration and
Monocyte Activation in HIV-Associated
Neurocognitive Disorders Jennifer
McGuire, Alexander Gill, Steven Douglas,
Dennis Kolson
P4.308
The Effects of a Novel
Interferon Inhibitor in a Model of HIV
Encephalitis William Tyor, Cari Lessing,
Ramzi Shawahna, Jennifer Ward, Leonard
Maroun
P4.309
Biochemical Evidence of
Neuronal Injury in HIV Patients with
Normal Neurocognitive Function Defines
Pre-symptomatic Stage Gloria Von
Geldern, Caroline Anderson, Ned Sacktor,
Justin McArthur, Avindra Nath
P4.310
Establishment of a
Multi-disciplinary Platform for HIVinfected Patients with Neurological
Complications Renaud Du Pasquier,
Samanta Simioni, Deolinda Alves, Reto
Meuli, Giorgio Maccaferri, Alexandre
Berney, Matthias Cavassini
P4.311
Clinical and Bacteriological
Features of Central Nervous System
Tuberculosis in Patients with HIV-Infection
in Siberian Region of Russia Yury Bykov,
Tatiana Filippova, Olga Novitskaya
Viral Encephalitis and
Progressive Multifocal
Leukoencephalopathy
P4.312
NeuroAIDS
Analysis of YouTube as a
Source of Information for West Nile Virus
Infection Anshudha Sawhney, Divyanshu
Dubey, Amod Amritphale, Nupur Amritphale
P4.302
P4.313
Risk Factors for Epilepsy in
Children with HIV/AIDS in Botswana David
Bearden, Greg Bisson, Dennis Kolson,
Andrew Steenhoff, Sudha Kessler, Dennis
Dlugos
P4.303
Stroke in Children with Human
Immunodeficiency Virus in Botswana: A
Report of Six Cases Esha Khurana, David
Bearden
P4.304
The Risk of Large-Artery
Atherosclerotic Stroke Is Proportionally
Greater than Cardioembolic Stroke in
HIV-Infected Individuals Compared to HIVUninfected Controls Felicia Chow, Richard
Price, Priscilla Hsue, Anthony Kim
P4.305
Presentations in an Out-patient Setting
in the Effective Antiretroviral Therapy
Era Samitha Fernando, Matthew Poynton,
Alex Everitt, Alan Winston
P4.306
Deficiency of Brain
Heme Oxygenase-1 in HIV-Infected
Individuals: Potential Target for
Adjunctive Therapy Alexander Gill, Suren
Ambegaokar, Colleen Kovacsics, Stephanie
Cross, Benjamin Gelman, Dennis Kolson
88
HSV 2 Encephalitis Presenting
as Episodic Receptive Aphasia Mohamad
Ezzeldin, Ahmed Yassin, Merry Chen
P4.314
Diagnostic Delay in a Case of
HSV Encephalitis Janhavi Modak, Kevin
McMahon, Avinash Prasad
P4.315
HHV6 Encephalitis
Complicating Post Stem Cell
Transplantation Course: A Case Series of
Five Leukemic Patients Ahmed Yassin,
Tummala Sudhakar
P4.316
Eastern Equine Encephalitis in
a Patient Treated with Rituximab: Clinical
Presentation and Histopathology Shibani
Mukerji, Pedro Ciarlini, Sandro Santagata,
Umberto De Girolami, Sashank Prasad
P4.317
Magnetic Resonance Imaging
and Electroencephalograhic Characteristics
in Two Cases of Fatal Eastern Equine
Encephalitis (EEE) Mohamed-Ali Babi,
Angela Applebee, Robert Shapiro, Todd
Raleigh, Joseph McSherry
P4.318
Thrombocytopenia as a
Prognostic Factor in Encephalitis Anthony
Asemota, Kiran Thakur, Romergryko
Geocadin, Arun Venkatesan
7:30 a.m.–11:00 a.m.
P4.319
Progressive Multifocal
Leukoencephalopathy Associated with
Ofatumumab Presenting as Alexia Without
Agraphia: A Case Report Jose Avila,
Jennifer Han, Islam Zaydan
P4.320
Non-HIV PML: A Case of PML
in an Immunocompetent Patient with a
Retrospective Review on Non-HIV PML
Risk Factors Barbara Graves, William
Bambach, Rebecca Hosey, Jonathan Hosey
P4.321
A Unique Case of Progressive
Multifocal Leukoencephalopathy in
a Patient with Chronic Lymphocytic
Leukemia Who Has Never Received
Chemotherapy Jared Noroozi, Sonia Lal,
Brij Ahluwalia-Singh, Ramandeep Sahni
Child Neurology and
Developmental Neurology IV
P4.322
Diagnostic Yield of Pediatric
EMG in Myopathic Disorders Partha
Ghosh, Eric Sorenson
P4.323
Can You Fine Tune the
Ketogenic Diet Jessica Selter, Zahava
Turner, Sarah Doerrer, Eric Kossoff
P4.324
Occipital Headaches and
Neuroimaging in Children Joshua Bear,
Amy Gelfand, Peter Goadsby, Nancy Bass
P4.325
Infantile Cerebral Arterial
Calcification Jennifer Chu, Shannon
DiCarlo, Robert Zeller
P4.326
Efficacy and Tolerability of
Intravenous Lacosamide in Children Less
Than 12 Years of Age Dimitrios Arkilo,
Mary Gustafson, Jason Doescher, Frank
Ritter
P4.327
Methylphenidate Exerts DoseDependent Effects on Glutamate Receptors
and Cognitive Behaviors Jia Cheng, Zhe
Xiong, Lara Duffney, Sihang Liu, Zhen Yan
P4.328
Neurologic Injury in Isolated
Sulfite Oxidase Deficiency Thomas Bosley,
Ibrahim Alorainy, Darren Oystreck, Khaled
Abu-Amero, Mustafa Salih
P4.329
The Epidemiology of
Pediatric Open Brain Surgery in the United
States. Shalini Selvarajah, Nicholas
Carchedi, Edward Hammond, Marcelo
Cerullo, Anthony Asemota, Joseph Canner,
Eric Schneider
P4.330
Hemodynamic Changes
Associated with Interictal Epileptiform
Activities Using Simultaneous Video
Electro-encephalography (EEG)/Near
Infrared Spectroscopy (NIRS) in Patient Self
Control Study Kumar Sannagowdara
P4.331
Management of
Choreoathetosis Secondary to Sequential
Herpes Simplex Virus Type-1 Infection
and Anti-NMDA Receptor Encephalitis
in a 6-Month-Old Girl Yefim YushvayevCavalier, Charles Nichter, Adolfo Ramirez
Zamora
P4.332
Eight-year Latency to
Diagnosis in an Adolescent with Bilateral
Basal Ganglia Germinomas Mimicking
a Neurodegenerative Condition Anna
Nordvig, Alexis Dallara, Arthur Mandel, Toni
Pearson
P4.333
3D Kinematic Gait Analysis
in Mucopolysaccharidoses Igor Nestrasil,
Christopher Fuller, Alia Ahmed, Elsa
Shapiro, John Anderson
P4.334
Correlation Between MRI
Findings of Mesial Temporal Sclerosis and
Histopathological Findings Judy Li, Steve
Chung
P4.335
Familial Episodic
Encephalopathy, Dysarthria, and Paralysis
Is Associated with a Dominantly Inherited
Mutation in ATP1A3 Gyula Acsadi, Richard
Young, Tara Newcomb, Benjamin Nelson,
Louis Viollet, Kathryn Swoboda
P4.336
Genetic Animal Models
of Autism Based on Shank/ Mutation
Molecules to Potential Therapeutics Craig
Powell
P4.337
Knockout of p75NTR in
Cerebellar Purkinje Cells Results in an
Autism-like Murine Phenotype Nina
Schor, Deborah Cory-Slechta, Louis Lotta,
Katherine Conrad
P4.338
Exonic Deletion of SLC9A9
in Autism with Epilepsy Meeta Wagle,
Jimmy Holder
P4.339
High-Functioning Autistic
Children Have Abnormal Stapedial
Reflexes Richard Lukose, Randy Kulesza,
Kevin Brown, Barber Carol
P4.340
Delayed Low Level Visual
Processing in Infants with Tuberous
Sclerosis Complex (TSC) Pilar Pichon,
Jordan Ko, Charles Nelson III, Shafali Jeste
P4.341
Mean EEG Coherence in
Infants at Risk for Autism Spectrum
Disorder April Levin, Marc Shi, Helen
Tager-Flusberg, Charles Nelson
CNS and Disease Mechanisms
in Humans and Animal Models
P4.342
B Cells from Blood of Patients
Sclerosis Induce Apoptosis in Neurons
In Vitro Robert Lisak, Liljana Nedelkoska,
Hanane Touil, Joyce Benjamins, Beverly
Bealmear, Riu Li, Hetoum Misirliyan, Amit
Bar-Or
Plenary Session
Current as of 2/13/2014 Contemporary Clinical Issues Plenary Session
ighlights issues most critical to practicing neurologists, including
H
abstracts related to new therapeutic developments, clinical
applications of basic and translational research, and innovative
technical developments.
9:00 a.m.–12:00 p.m.
Moderator: Lisa M. DeAngelis,
MD, FAAN
Comparison of Thrombolytic Treatment for Acute Ischemic Stroke Pre- and PostTelemedicine Implementation in the Spoke Hospital Setting
William K. Mountford, PhD
Premier Research Services,
Wilmington, NC
Discussant:
Lee H. Schwamm, MD
Massachusetts General Hospital,
Boston, MA
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial
David R. Jacoby, MD, PhD
BioMarin Pharmaceutical Inc.,
Novato, CA
Discussant:
Tetsuo Ashizawa, MD, FAAN
University of Florida,
Gainesville, FL
Clinical Profile of the Orexin Receptor Antagonist Suvorexant for the Treatment of
Insomnia in Phase-3 Clinical Trials
William Herring, MD, PhD
Merck Research Laboratories,
North Wales, PA
David B. Goldstein,
PhD
Duke University,
Durham, NC
Direct to Consumer Genetic Testing
Discussant:
Phyllis C. Zee, MD, PhD
Northwestern University Medical
School, Chicago, IL
Jonathan Stone,
MB, ChB, FRCP, PhD
Western General
Hospital,
Edinburgh,
United Kingdom
Functional (Psychogenic) Disorders
in Neurology
Kenneth L. Marek,
MD
Institute for Neurodegenerative
Disorders,
New Haven, CT
Parkinson’s Disease Progression Marker
Initiative: Developing a Translational
Toolbox for PD Progression
For Full Abstracts and Bios for Plenary Speakers Visit AAN.com/view/SearchAM
89
Wednesday, April 30
S24 Diet and
Hormonal Influences
2:00 p.m.
S24.001
Increased Archaea Species and
Changes with Therapy in Gut
Microbiome of Multiple Sclerosis
Subjects Sushrut Jhangi, Roopali
Gandhi, Bonnie Glanz, Sandra Cook,
Parham Nejad, Doyle Ward, Ning
Li, Georg Gerber, Lynn Bry, Howard
Weiner
2:15 p.m.
S24.002
Role of Melatonin in MS
Pathogenesis Mauricio Farez,
Santiago Mendez Huergo, Iván
Mascanfroni, Gabriel Rabinovich,
Francisco Quintana, Jorge Correale
2:30 p.m.
S24.003
Investigation of Sex Differences in
the Association Between Multiple
Sclerosis Disease Severity and
Hormonal Markers of Vitamin D,
Obesity, and Testosterone. Riley
Bove, Alexander Musallam, Brian
Healy, Pejvak Soltany, Pia Kivisakk,
Bonnie Glanz, Philip De Jager, Karen
Miller, Tanuja Chitnis
2:45 p.m.
S24.004
Body Mass Index and Multiple
Sclerosis Risk. The Role of
Leptin Jorge Correale, María
Eugenia Balbuena Aguirre, Mauricio
Farez
3:00 p.m.
S24.005
Differential Effects of Vitamin D
in GA- Versus IFN-Treated MS
Patients Dalia Rotstein, Brian
Healy, Muhammad Taimur Malik,
Robert Carruthers, Alexander
Musallam, Pia Kivisakk, Bonnie
Glanz, Tanuja Chitnis
3:15 p.m.
S24.006
Delayed−Release Dimethyl Fumarate
and Pregnancy: Preclinical Studies
and Pregnancy Outcomes Reported
During the Clinical Development
Program Ralf Gold, J. Theodore
Phillips, Eva Havrdova, Amit Bar-Or,
Ludwig Kappos, Janet Clarke,
Huixing Yuan, Mark Novas, Jie
Li, Marianne Sweetser, Nuwan
Kurukulasuriya, Vissia Viglietta,
Robert Fox
3:30 p.m.
S24.007
Aromatic-Turmerone Induces Neural
Stem Cell Proliferation In Vitro and
In Vivo Michael Schroeter, Joerg
Hucklenbroich, Klein Rebecca, Bernd
Neumaier, Rudolf Graf, Gereon Fink,
Maria Rueger
S25 Cerebrovascular
Neurology: Hemorrhage,
Aneurysms, and Vascular
Malformations
2:00 p.m.
S25.001
Clinical Outcomes of Aneurysmal
Subarachnoid Hemorrhage
with Cocaine Use in the United
States Santosh Murthy, Shreyansh
Shah, Yogesh Moradiya, Aditi
Shastri, Stelios Smirnakis
2:15 p.m.
S25.002
CSF Diversion in Aneurysmal
Subarachnoid Hemorrhage: How
Low Should We Go? Jennifer
Fugate, Alejandro Rabinstein,
Eelco Wijdicks, William Freeman,
Giuseppe Lanzino
2:30 p.m.
S25.003
The SEDAN Score and the Risk
of Intracerebral Hemorrhage in
Monocenter-Study Toralf Brüning,
Mohamed Al-Khaled
2:45 p.m.
S25.004
Validation of the ICH Score
in Hyperacute Intracerebral
Hemorrhage Sebina Bulic, Nerses
Sanossian, Sidney Starkman, David
Liebeskind, Pablo Villablanca, Scott
Hamilton, Robin Conwit, Jeffrey
Saver
S26 Biomarkers in
Neuromuscular Diseases
2:00 p.m.
S26.001
Quantitative Muscle Ultrasound:
Comparison of Backscatter Versus
Grayscale Methods in Duchenne
Muscular Dystrophy Patients and
Healthy Controls Irina Shklyar, Tom
Geisbush, Aleksandar Mijailovic,
Amy Pasternak, Nicole Visyak,
Heather Szelag, Jim Wu, Basil
Darras, Seward Rutkove, Craig
Zaidman
2:15 p.m.
S26.002
Basal Ganglia Involvement in
Amyotrophic Lateral Sclerosis Peter
Bede, Marwa Elamin, Susan Byrne,
Russel McLaughlin, Kevin Kenna,
Alice Vajda, Niall Pender, Daniel
Bradley, Orla Hardiman
2:30 p.m.
S26.003
Impaired Cortico-Ponto-Cerebellar
Networks Underlie Pseudobulbar
Affect In Motor Neuron
Disorders Mary Kay Floeter, Rohan
Katipally, Meredith Kim, Olivia
Schanz, Stephen Matthew, Laura
Danielian, Tianxia Wu, Edward Huey,
Avner Meoded
3:00 p.m.
S25.005
Vitamin C Depletion Is Spontaneous
Intracerebral Hemorrhage Risk
Factor. Stéphane Vannier, Ronzière
Thomas, Ferré Jean-christophe,
Jean Francois Pinel, Marc Verin
2:45 p.m.
S26.004
Pre-symptomatic Loss of Cerebral
White Matter Integrity in Those
at Genetic Risk of Amyotrophic
Lateral Sclerosis Martin Turner,
Nicola Filippini, Varan Govind, Peter
Andersen, Christine Stanislaw,
Eliana Reyes, Sumaira Hussain,
Joanne Wuu, Michael Benatar
3:15 p.m.
S25.006
Spinal Cord Cavernous
Malformations; 62-patient
Retrospective Review to Define
Disease Natural History Lindsy
Williams, Kelly Flemming, Robert
Brown
3:00 p.m.
S26.005
Profiling of miRNAs in Cerebrospinal
Fluid from Patients with Amyotrophic
Lateral Sclerosis Akira Machida,
Takuya Ohkubo, Atsunobu Tsunoda,
Hidenori Matsuo, Yokota Takanori,
Hidehiro Mizusawa
3:30 p.m.
S25.007
Effect of Hyperosmolar Therapy on
Outcome Following Spontaneous
Intracerebral Hemorrhage: The
ERICH Study Manan Shah, Jennifer
Rasmussen, Lee Birnbaum, Charles
Moomaw, Padmini Sekar, Jennifer
Osborne, Esther Nanez, Anastasia
Vashkevich, Daniel Woo
3:15 p.m.
S26.006
Diagnostic Utility of p62
Immunohistochemistry for
Differentiating s-IBM from
PM Chiseko Ikenaga, Jun Shimizu,
Hida Ayumi, Shoji Tsuji
3:30 p.m.
S26.007
Clinical Patterns in NT5C1A Antibody
Positive Sporadic Inclusion Body
Myositis Patients Compared to
Seronegative Patients Namita
Goyal, Farzin Pedouim, Usman Alam,
Sameen Enam, Farah Mozaffar,
Tahseen Mozaffar
2:00 p.m.–3:45 p.m.
S27 Dystonia, Tremor, and
Other Movement Disorders
2:00 p.m. Presentation
of Movement Disorders
Research Award
Recipient:
Eduardo Tolosa, MD, PhD
Barcelona, Spain
2:30 p.m.
S27.003
Conversion from AbobotulinumtoxinA
to IncobotulinumtoxinA Formulation
of Botulinum Toxin: Clinic Experience
in 257 Cases Donald Grosset,
Elaine Tyrrell, Katherine Grosset
2:45 p.m.
S27.004
Clinimetric Testing of the Modules for
the Comprehensive Cervical Dystonia
Rating Scale (CCDRS) Cynthia
Comella, Joel Perlmutter, H.
Jinnah, Charles Adler, Richard
Barbano, Stewart Factor, Susan
Fox, Christopher Goetz, Wendy
Galpern, Joseph Jankovic, Laura
Marsh, William Mcdonald, Stephen
Reich, Ramon Rodriguez, Ami Rosen,
William Severt, Tracy Waliczek,
Glenn Stebbins
3:00 p.m.
S27.005
Focused Ultrasound MR Guided
Thalamotomy: 2 Year Follow-Up
Safety and Efficacy Data Binit
Shah, Diane Huss, Tiffini Voss,
Johanna Loomba, Mohamed Khaled,
Madaline Harrison, W. Jeffrey Elias
3:15 p.m.
S27.006
Predictors of Subjective Disability
in Functional Movement
Disorders Tracy Fulton, Kathrin
LaFaver, Sarah Kranick, Mark Hallett
3:30 p.m.
S27.007
Clusterin CSF Levels in Differential
Diagnosis of Neurodegenerative
Disorders Hana Prikrylova Vranova,
Eva Henykova, Michaela Kaiserova,
Katerina Mensikova, Miroslav
Vastik, Jan Mares, Petr Hlustik, Jana
Zapletalova, Miroslav Strnad, David
Stejskal, Petr Kanovsky
S28 Aging, Dementia,
and Cognitive and
Behavioral Neurology:
Dementia Genetics
Norman Geschwind Prize in
Behavioral Neurology
Recipient:
Roy Hamilton, MD, MS
Philadelphia, PA
2:15 p.m.
S28.002
Late-onset Alzheimer Disease
Neuropathology Genomic Screen
Identifies Novel Loci for Neuritic
Plaque and Other AD Neuropathology
Features Gary Beecham, Kara
Hamilton, Gerard Schellenberg,
Margaret Pericak-Vance, Thomas
Montine
2:30 p.m.
S28.003
Whole-exome Sequencing of Hispanic
Early-onset Alzheimer Disease Families
Identifies Rare Variants in Multiple
Alzheimer-related Genes Christiane
Reitz, Brian Kunkle, Badri Vardarajan,
Martin Kohli, Adam Naj, Patrice
Whitehead, William Perry, Eden Martin,
Gary Beecham, John Gilbert, Lindsay
Farrer, Jonathan Haines, Gerard
Schellenberg, Margaret Pericak-Vance,
Richard Mayeux
2:45 p.m.
S28.004
The Dissection of High-Penetrance
Variants in Extended Late-onset
Alzheimer Disease Families by Wholeexome Sequencing Martin Kohli,
Brian Kunkle, Adam Naj, Li-San Wang,
Kara Hamilton, William Perry, Regina
Carney, Patrice Whitehead, John Gilbert,
Eden Martin, Gary Beecham, Jonathan
Haines, Gerard Schellenberg, Stephan
Zuchner, Margaret Pericak-Vance
3:00 p.m.
S28.005
Transcript Profiling Analysis of
Alzheimer’s Disease Brains. Mariet
Allen, Daniel Serie, Michael Walsh,
Sun Zhifu, Saurabh Baheti, Fanggeng
Zou, High Seng Chai, Curtis Younkin,
Julia Crook, Vernon Pankratz, Minerva
Carrasquillo, Asha Nair, Sumit Middha,
Sooraj Maharjan, Thuy Nguyen, Li Ma,
Kimberly Malphrus, Sarah Lincoln, Gina
Bisceglio, Christopher Kolbert, Jin Jen,
Ronald Petersen, Neill Graff-Radford,
Dennis Dickson, Steven Younkin, Yan
Asmann, Nilufer Taner
3:15 p.m.
S28.006
Investigation of Transcriptional
Regulation at the Alzheimer’s Disease
Risk Loci. Michaela Kachadoorian,
Mariet Allen, Aditya Karhade, Lester
Manly, Fanggeng Zou, High Seng Chai,
Curtis Younkin, Julia Crook, Vernon
Pankratz, Minerva Carrasquillo, Asha
Nair, Sumit Middha, Sooraj Maharjan,
Thuy Nguyen, Li Ma, Kimberly
Malphrus, Sarah Lincoln, Gina Bisceglio,
Christopher Kolbert, Jin Jen, Ronald
Petersen, Neill Graff-Radford, Steven
Younkin, Dennis Dickson, Nilufer Taner
3:30 p.m.
S28.007
Screening for NOTCH3 Mutation in
Patients with Subcortical Vascular
Cognitive Impairment Cindy Yoon,
Young-Eun Kim, Jong-Won Kim, Duk L.
Na, Chang-Seok Ki, Sang Won Seo
90
Scientific Sessions
S30 Education,
Research, and History
Dreifuss-Penry Epilepsy Award
Lawrence C. McHenry Award: An
Award for the History of Neurology
Recipient:
Catherine Schevon, MD, PhD
New York, NY
Recipient:
Farrah Mateen, MD, PhD
Boston, MA
2:15 p.m.
S29.002
The Role of Toll-like Receptor 3 in
Epileptogenesis Felix Benninger,
Adi Gross, Israel Steiner, Daniel
Offen, Eitan Okun
2:30 p.m.
S29.003
Association Between Human
Herpes Virus 6 and Hippocampal
Volume in Mesial Temporal Lobe
Epilepsy William Theodore, Emily
Leibovitch, Bridgette Billioux, Sierra
Germeyan, David Kalikhman, Sara
Inati, John Heiss, Kareem Zaghloul,
Steven Jacobson
2:45 p.m.
S29.004
Sequential Versus Simultaneous
Polytherapy in the Treatment
of Status Epilepticus Claude
Wasterlain, Roger Baldwin, Jerome
Niquet, Lucie Suchomelova
3:00 p.m.
S29.005
Etiology of Pediatric Refractory
Convulsive Status Epilepticus.
Results from the Pediatric Status
Epilepticus Research Group
(pSERG) William Gaillard, Howard
Goodkin, Nicholas Abend, Satish
Agadi, Ravindra Arya, Rajit Basu,
Jessica Carpenter, Kevin Chapman,
Nathan Dean, Tracy Glauser,
Michele Jackson, Mohamad Mikati,
Katrina Peariso, Geetanjali Rathore,
Ivan Sanchez Fernandez, Robert
Tasker, Alexis Topjian, David Turner,
Angus Wilfong, Korwyn Williams,
Tobias Loddenkemper
Recipient:
Christopher Boes, MD
Rochester, MN
2:30 p.m. Presentation of S. Weir
Mitchell Award
Recipient:
Michael Fox, MD, PhD
Newton, MA
2:45 p.m.
S30.004
The Effects of Repeated Quizzing on
Long-Term Retention in AAN Annual
Meeting Courses Douglas Larsen,
Wint Yan Aung, John Corboy,
Deborah Friedman, Ann Tilton,
Andrew Butler
3:00 p.m.
S30.005
Osler, MacNalty, and the Recognition
of Encephalitis Lethargica in
England Christopher Boes
3:15 p.m.
S30.006
Closing the Loop: Mount Sinai
Neurology Resident Clinical Acumen
Assessment Project Sarah Zubkov,
Rachel Brandstadter, Christine
Hannigan, Stephen Krieger
3:30 p.m.
S30.007
Development of a Simulated Patient
Exercise to Improve Acute Stroke
Care by Neurology Residents Adam
Kelly, Ralph Jozefowicz
S31 General Neurology I
2:00 p.m.
S31.001
Gadolinium Enhancement in
Spondylotic Myelopathy Mimicking
Tumors and Inflammation: A Case
Series of 56 Patients Eoin Flanagan,
Karl Krecke, Richard Marsh, Caterina
Giannini, Mark Keegan, Brian
Weinshenker
2:15 p.m.
S31.002
GLACIER: an Open-label,
Randomized, Multicenter Study
to Assess Safety and Tolerability
of Glatiramer Acetate 40 mg/1mL
3-times Weekly Versus 20
mg/1mL Daily in Patients with
Sclerosis Wolinsky Jerry, Thor
Borresen, Dennis Dietrich, Beverly
Gilder, Yulia Sidi, Volker Knappertz,
Scott Kolodny
2:30 p.m.
S31.003
24-Month Efficacy and Safety of
Glatiramer Acetate 40mg/1mL
3-Times Weekly: Open-label
Extension Study of the GALA Trial in
Subjects with Relapsing-Remitting
Multiple Sclerosis Omar Khan,
Peter Rieckmann, Alexey Boyko,
Krzysztof Selmaj, Hadas Barkay,
Scott Kolodny, Robert Zivadinov
2:45 p.m.
S31.004
B Cell-specific Signal in Whole
Blood and Serum of NatalizumabTreated PML Patients Is Revealed
Using Transcript and Protein
Profiling Tatiana Plavina, John
Carulli, Huo Li, Daniel Park,
Raghavendra Hosur, Normand
Allaire, Peter Juhasz, Teresa
Compton
3:00 p.m.
S31.005
Neuroimaging and Clinical
Features in Late Onset Alexander
Disease Jonathan Graff-Radford,
Kara Schwartz, Ralitza Gavrilova,
Daniel Lachance, Neeraj Kumar
3:15 p.m.
S29.006
Hippocampal Malrotation Is
Associated with Chromosome
22Q11.2 Microdeletion Anne
Bassett, Timo Krings, Eva Chow,
Tim-Rasmus Kiehl, Danielle Andrade
3:15 p.m.
S31.006
Dosing Feasibility and
Pharmacokinetics by Seizure Type
and Status, and Tolerability of
Intranasal Diazepam in Adults with
Epilepsy Michael Sperling, Hussam
Seif Eddeine, Kevin Haas, Gregory
Krauss, Herbert Henney III, Adrian
Rabinowicz, Gary Bream, David
Squillacote, Enrique Carrazana
3:30 p.m.
S29.007
Structural and Functional
Implications of Modeling Non
Synonymous Mutations in Patients
with SCN1A-related Seizure
Disorders Mu Gao, Hongyi Zhou,
Izabela Karbassi, Khalida Liaquat,
Daniel Fischer, Jeffrey Skolnick,
Joseph Higgins
3:30 p.m.
S31.007
Dextromethorphan and Quinidine for
Treatment of Pseudobulbar Affect
(PBA): Time Course of PBA Episode
Remission Andrea Formella,
Benjamin Brooks
S32 Headache: Basic
Science and Imaging
2:00 p.m. Presentation of Harold
Wolff-John Graham: An Award for
Headache/Facial Pain Research
Recipient:
Jakob Møller Hansen, MD, PhD
Los Angeles, CA
2:15 p.m.
S32.002
Ictal Lack of Binding of (11C)Dihydroergotamine to Brain
Parenchyma Suggests That the
Blood-Brain Barrier Remains Intact
During Migraine Attacks Christoph
Schankin, Farooq Maniyar, Youngho
Seo, Shashidar Kori, Michael Eller,
Joseph Blecha, Stephanie Murphy,
Till Sprenger, Henry VanBrocklin,
Peter Goadsby
2:30 p.m.
S32.003
Multi-Center 3T MRI Study of
Thalamic Morphology in Migraine
Using Label-Fusion-Based
Segmentation and Deformation
Based Morphometric Surface
Analysis Stefano Magon, Arne
May, Anne Stankewitz, Peter
Goadsby, Amy Tso, Messoud Ashina,
Faisal Amin, Christian Seifert, Mallar
Chakravarty, Jannis Müller, Till
Sprenger
2:45 p.m.
S32.004
Enhanced Pain-Induced Activation of
Pain Processing Regions in Interictal
Episodic Migraine Todd Schwedt,
Catherine Chong, Chia-Chun Chiang,
Leslie Baxter, Bradley Schlaggar,
David Dodick
3:00 p.m.
S32.005
Therapeutic Efficacy of Transcranial
Direct Current Stimulation in
Trigeminal Neuralgia Mark
Obermann, Vera Bude, Dagny Holle,
Tim Hagenacker, H. Diener, Zaza
Katsarava
3:15 p.m.
S32.006
Interictal Resting-State Connectivity
of the Insula Is Altered in Migraine
Without Aura Amy Tso, Andrew
Trujillo, Christine Guo, Peter
Goadsby, William Seeley
3:30 p.m.
S32.007
Autonomic Dysfunction in Migraine:
Comparison Between Populations
With and Without Orthostatic
Intolerance Mark Stillman, Lan
Zhou, Fetnad Fouad-Terazi
S33 Cognition Fatigue
in MS
2:00 p.m.
S33.001
Processing Speed Test (PST): A
Self-Administered iPad®-Based Tool
for Assessing MS-Related Cognitive
Dysfunction Stephen Rao, Jay
Alberts, Deborah Miller, Francois
Bethoux, Jar-Chi Lee, Darlene
Stough, Christine Reece, Lyla
Mourany, David Schindler, Joshua
Hirsch, Richard Rudick
2:15 p.m.
S33.002
Structural MRI Corrrelates of
Cognitive Impairment in Patients
with Multiple Sclerosis: A Multi
Center Study Paolo Preziosa,
Maria Rocca, Matteo Atzori,
Frederik Barkhof, Nicola De Stefano,
Christian Enzinger, Franz Fazekas,
Antonio Gallo, Hanneke Hulst,
Laura Mancini, Xavier Montalban,
Elisabetta Pagani, Alex Rovira,
Maria Laura Stromillo, Gioacchino
Tedeschi, Giancarlo Comi, Massimo
Filippi
2:30 p.m.
S33.003
A Longitudinal Evaluation of
MRI Predictors of Cognitive and
Clinical Impairment in Multiple
Sclerosis Alfredo Damasceno,
Benito Damasceno, Fernando
Cendes
2:45 p.m.
S33.004
Longitudinal Evaluation of Cognitive
Functioning in Pediatric Multiple
Sclerosis (MS): Report from the
U.S. Pediatric Multiple Sclerosis
Network Lauren Krupp, Leigh
Charvet, Ellen O’Donnell, Rebecca
Cleary, Dana Serafin, Joy Parrish,
Laura Julian, Natalie Baruch,
Anita Belman, Ralph Benedict,
Tanuja Chitnis, Jayne Ness, Moses
Rodriguez, Emmanuelle Waubant,
3:00 p.m.
S33.005
Longitudinal Evidence for Brain
Reserve and Cognitive Reserve
in Multiple Sclerosis: Larger
Maximal Lifetime Brain Growth
and Greater Intellectual Enrichment
Attenuate Cognitive Decline Over
4.5 Years James Sumowski, Maria
Rocca, Victoria Leavitt, Jelena
Dackovic, Sarlota Mesaros, Jelena
Drulovic, John DeLuca, Massimo
Filippi
3:15 p.m.
S33.006
Social Cognition in Pediatric Multiple
Sclerosis (MS) Leigh Charvet,
Rebecca Cleary, Katherine Vazquez,
Livana Koznesoff, Kate Bartolotta,
Jeremy Benhamroun, Lauren Krupp
3:30 p.m.
S33.007
Deep Transcranial Magnet
Stimulation Can Improve Depression
and Fatigue in Multiple Sclerosis—a
Clinical Phase I/IIa Study Sven
Schippling, Marina Tiede, Ina Lorenz,
Caspar Pfueller, Jan Doerr, Judith
Bellmann-Strobl, Abraham Zangen,
Friedemann Paul, Gunnar Gaede
91
Wednesday
April 30
S29 Epilepsy and
Clinical Neurophysiology:
Inflammation, Status
Wednesday, April 30
I7 Emerging Therapeutic Advances in Multiple Sclerosis
2:00 p.m.–6:00 p.m.
Coordinators: Robert J. Fox, MD, FAAN and Eric Klawiter, MD
2:10 p.m.–2:35 p.m.
Treating Relapsing MS: Choosing Among the Options Myla Goldman, MD
2:35 p.m.–3:00 p.m.
Treating Relapsing MS: Risk Stratification and Mitigation Bruce A. C. Cree, MD, PhD, MCR
3:00 p.m.–3:25 p.m.
Is No Evidence of MS Disease Activity an Achievable Goal? Robert A. Bermel, MD
3:25 p.m.–3:50 p.m.
Treating MS in 2020: Remyelination, Progressive MS, and Beyond Catherine Lubetzki, MD
3:50 p.m.–4:15 p.m.
Treating Pediatric MS: Is It Different from Adults? Tanuja Chitnis, MD
4:15 p.m.–4:30 p.m.
I7-1.001
S1P Receptor Modulation
by Fingolimod Promotes Human
Oligodendrocyte Progenitor Cell
Differentiation Through Cell-Autonomous
and Non-Cell Autonomous Mechanisms via
ERK1/2 and p38MAPK Activation Qiaoling
Cui, Timothy Kennedy, Guillermina Almazan,
Jack Antel
I7-1.002 Peginterferon Beta-1a May
Improve Recovery Following Relapses:
Data from the Pivotal Phase 3 ADVANCE
Study in Patients with Relapsing-Remitting
Multiple Sclerosis Bernd Kieseier, Thomas
Scott, Scott Newsome, Sarah Sheikh,
Serena Hung, Xiaojun You, Bjorn Sperling
I7-1.003 A Nasal Anti-CD3 Vaccine
Treats a Model of Secondary Progressive
MS by Inducing IL-10 Dependent T
Regulatory Cells and Regulating CNS
Innate Immunity Lior Mayo, Andre Pires Da
Cunha, Raymond Sobel, Hans Lassmann,
Francisco Quintana, Howard Weiner
I7-1.004 Differential Effects of
Vitamin D in GA- versus IFN-Treated
MS Patients Dalia Rotstein, Brian
Healy, Muhammad Taimur Malik, Robert
Carruthers, Alexander Musallam, Pia
Kivisakk, Bonnie Glanz, Tanuja Chitnis
I7-1.005 Therapeutic Plasma
Exchange in 90 GlucocorticosteroidUnresponsive Patients with
Multiple Sclerosis—Prediction of
Response Johannes Ehler, Martin Sauer,
Sebastian Koball, Steffen Mitzner, Heiko
Hickstein, Reiner Benecke, Uwe Zettl
I7-1.006 A Phase II Trial of
Neuroprotection with Riluzole in Early
Relapsing-Remitting MS: Lessons for
Future Neuroprotection Trials Emmanuelle
Waubant, Amir-Hadi Maghzi, Nisha
Revirajan, Rebecca Spain, Laura Julian,
Ellen Mowry, Jacqueline Marcus, Shuang
Liu, Ari Green, Charles McCulloch, Daniel
Pelletier
I7-1.007
The MIRROR Study: A
Randomized, Double-blind, Placebocontrolled, Parallel-group, Dose-ranging
Study to Investigate the Safety and MRI
Efficacy of Subcutaneous Ofatumumab
in Subjects with Relapsing-Remitting
Multiple Sclerosis (RRMS) Amit Bar-Or,
Richard Grove, Daren Austin, Jerry Tolson,
Susan Vanmeter, Eric Lewis, Per Solberg
Sorensen
I7-1.009 Laquinimod Reduces
Neuronal Injury Through Inhibiting
Microglial Activation Voon Wee Yong,
Manoj Mishra, Janet Wang, Michael
Keough, Claudia Silva, Yan Fan, Scott Sloka,
Liat Hayardeny
I7-1.010
I7-1.008 Randomized Controlled
Alemtuzumab Improves
Visual Outcomes Versus Subcutaneous
Interferon Beta-1a in Patients with
Active Relapsing-Remitting Multiple
Sclerosis (RRMS) Who Relapsed on Prior
Therapy: Analysis from the CARE-MS
II Study Jennifer Graves, Laura Balcer,
Jeffrey Palmer, David Margolin, Steven
Galetta
5:40 p.m.
5:45 p.m.
I7-2.004
5:50 p.m.
I7-2.005
Trial of CI Therapy for Progressive MS:
Increased Real-World Function and
Neuroplasticity on MRI Victor Mark,
Edward Taub, Gitendra Uswatte, Gary
Cutter, David Morris, Staci McKay, Mary
Bowman, Michelle Haddad, Tyler Rickards,
Chelsey Sterling
5:30 p.m.
I7-2.001
IRX4204: A Clinical Stage, Potent, and
Highly Selective RXR Agonist Compound
Is Brain Penetrant, and Promotes
Differentiation of Oligodendrocyte
Precursor Cells (OPCs) In Vitro Martin
Sanders, Satish Medicetty, Rosh
Chandraratna
92
5:35 p.m.
I7-2.002
A Combination Trial of Estriol Plus Glatimer
Acetate in Relapsing-Remitting Multiple
Sclerosis Rhonda Voskuhl, HeJing Wang,
T.C. Jackson Wu, Nancy Sicotte, Angela
Bates, Gary Beaver, John Corboy, Anne
Cross, Suhayl Dhib-Jalbut, Corey Ford,
Barbara Giesser, Dina Jacobs, Sharon
Lynch, Andrew Pachner, Michael Racke,
John Ratchford, Anthony Reder, John Rose,
Dean Wingerchuk, Margaret Burnett, Chi
Hong Tseng, Robert Elashoff
I7-2.003
Safety and Tolerability of Delayed-Release
Dimethyl Fumarate Administered as
Add-on Therapy to Beta Interferons or
Glatiramer Acetate in Relapsing-Remitting
Multiple Sclerosis (RRMS) Patients Vissia
Viglietta, Timothy Vollmer, Ray Zhang, Mark
Novas, Sarah Sheikh, Robert Fox
Deep Transcranial Magnet Stimulation
Can Improve Depression and Fatigue in
Multiple Sclerosis—a Clinical Phase I/
IIa Study Sven Schippling, Marina Tiede,
Ina Lorenz, Caspar Pfueller, Jan Doerr,
Judith Bellmann-Strobl, Abraham Zangen,
Friedemann Paul, Gunnar Gaede
Stopping Disease Modifying Therapy
in Progressive Multiple Sclerosis—a
Prospective Study Gary Birnbaum
I8 Clinical Decision Making After
the Dust Settles on Clinical Trials
2:00 p.m.–6:00 p.m.
Coordinators: Barbara G. Vickrey, MD, MPH, FAAN and Linda S. Williams, MD, FAAN
2:10 p.m.–2:40 p.m.
Intervention Research on Improving Access to and Quality of Neurologic Care Ray Dorsey, MD, MBA
2:40 p.m.–3:10 p.m.
Effectiveness Research in Neurology Seemant Chaturvedi MD, FAAN, FAHA
3:10 p.m.–3:40 p.m.
Translating Neurologic Advancements into Practice through Decision Support Eric M. Cheng MD, MS, FAAN
3:40 p.m.–4:10 p.m.
Research on Incorporating Patient Preferences in Neurologic Care Adam Kelly, MD
4:10 p.m.–4:30 p.m.
Patients’ Preferences for Communication
About Advanced Care Planning Keiran
Tuck, Lissa Brod, John Nutt, Erik Fromme
I8-1.002 Vascular Parkinsonism in
a Tertiary Care Stroke Prevention Clinic:
Prevalence and Development of a New
Screening Strategy Herbert Manosalva
Alzate, Thomas Jeerakathil, Maher Saqqur,
Richard Camicioli, Oksana Suchowersky
I8-1.003 Multiple Sclerosis
Documentation System MSDS3D—
Innovative Management of Patients with
Multiple Sclerosis Judith Eisele, Raimar
Kern, Suhrbier Alexander, Lars Großmann,
Thorsten Schultheiss, Tjalf Ziemssen
I8-1.004Neuro-oncology
Telemedicine Follow-up Visits Richard
Green, Emily Woyshner, Amanda Hauser
Dehaven
I8-1.005 Long Term Efficacy of
Outpatient Interdisciplinary Treatment
for Patients Suffering from Chronic
Headaches Mark Stillman, Steven Krause
I8-1.006 Adherence to Oral
I8-1.008 Treatment Trends in
I8-1.007 Influence of CREST on
I8-1.009 Antiepileptic Drug
5:40 p.m.
I8-2.003
5:50 p.m.
5:45 p.m.
I8-2.004
Migraine Preventive Medications Among
Patients with Chronic Migraine: Analysis
of a Large US Health Insurance Claims
Database Zsolt Hepp, David Dodick,
Sepideh Varon, Patrick Gillard, Ryan
Hansen, Emily Devine
CEA and CAS Trends in Women—Do
the Results Matter? Shahram Khalid,
Sanath Reddy, Seemant Chaturvedi, Kumar
Rajamani, Pratik Bhattacharya, Navid SerajiBozorgzad
Management of Intracranial Stenosis in
the Pre- and Post-sammpris Era Swaroop
Pawar, Tanya Turan, George Cotsonis,
Michael Lynn, Rahim Wooley, Barney
Stern, Colin Derdeyn, David Fiorella, Marc
Chimowitz
Prescribing for OEF/OIFVeterans with NewOnset Epilepsy: 2008-2010 Mary Jo Pugh,
Anne Van Cott, Christine Baca, Megan
Amuan
5:30 p.m.
I8-2.001
Identifying Palliative Care Needs in the
Neurological Intensive Care Unit Claire
Creutzfeldt, J Curtis
5:35 p.m.
I8-2.002
Appropriateness of Dopamine Antagonist
Prescribing in Hospitalized Patients
with Dopamine Requiring Diseases
After Implementation of an Automated
Prescribing Alert System Marie Morris,
Allison Willis, Franklin McCann, Angela
Birke, Brad Racette
Development and Implementation of
a Quality Improvement Strategy for
Obtaining Muscle Biopsies Utilizing
DMAIC Methodology Charles Kassardjian,
Michelle Williamson, Dorothy Van Buskirk,
Floranne Ernste, Andrea Leep Hunderfund
A Comparison of Co-located and
Traditional Outpatient Consultation for the
Treatment of ADHD in Two Urban Medical
Homes: Costs and Outcomes David Urion
I8-2.005
Malformation Risks of Antiepileptic Drug
Monotherapies in Pregnancy: An Update
From the UK and Ireland Epilepsy and
Pregnancy Registers Ellen Campbell,
Fiona Kennedy, Aline Russell, W Smithson,
Linda Parsons, Beth Irwin, Brenda Liggan,
Norman Delanty, Patrick Morrison, Stephen
Hunt, John Craig, Jim Morrow
93
Wednesday
April 30
I8-1.001 Parkinson’s Disease
Wednesday, April 30
P5 Poster Session V
3:00 p.m.–6:30 p.m.
oster Discussion Session:
P
Cerebrovascular Disease and Interventional Neurology II
P5.001
MRI Detection of Blood
After Perimesencephalic Subarachnoid
Hemorrhage Jordan Samuels, James
Conners, Sarah Song, Shawna Cutting,
Vivien Lee
P5.002
Use of Apixaban and Warfarin
in Patients Undergoing Procedures: Insights
from ARISTOTLE Renato Lopes, David
Garcia, Daniel Wojdyla, Paul Dorian, John
Alexander, Lars Wallentin, Fernando Lanas,
Michael Hanna, Claes Held, Christopher
Granger
P5.004
Oral Anticoagulant
Therapy Is Associated with Cerebral
Microbleeds Saloua Akoudad, Sirwan
Darweesh, Maarten Leening, Peter
Koudstaal, Albert Hofman, Aad Van Der
Lugt, Bruno Stricker, Mohammad Ikram,
Meike Vernooij
P5.005
The Incidence of Secondary
Stroke Prevention Medication Following
Hospitalization for Ischemic Stroke Justin
Blackburn, Hong Zhao, Meredith Kilgore,
Karen Albright
P5.006
Effects of Angiopoietin-1 on
Hemorrhagic Transformation and Cerebral
Edema After Tissue Plasminogen Activator
Treatment for Ischemic Stroke Masato
Kanazawa, Kunio Kawamura, Tetsuya
Takahashi, Hironaka Igarashi, Tsutomu
Nakada, Masatoyo Nishizawa, Takayoshi
Shimohata
P5.008
P5.007
P5.009
The Influence of Obesity on
Outcomes After Intravenous Thrombolysis
for Acute Ischemic Stroke AV Nickles,
Saqib Chaudry, Syed Hussain, M J Reeves
P5.003
Effect of Apixaban on AllCause Mortality in Atrial Fibrillation: An
Imputed Placebo Analysis John McMurray,
Robert Hart, Greg Flaker, Renato Lopes,
Junyuan Wang, Michael Hanna, John
Alexander, Christopher Granger, Lars
Wallentin
A Utility-Weighted Modified
Rankin Scale: Derivation and Application
to Completed Stroke Trials Napasri
Chaisinanunkul, Jeffrey Saver, Tudor Jovin,
Scott Berry, Roger Lewis, Kennedy Lees,
Anthony Furlan, Blaise Baxter, Helmi Lutsep,
Marc Ribo, Olav Jansen, Rishi Gupta, Vitor
Pereira-Mendes, Raul Nogueira
Geography of Stroke
Mortality: Hotspotting Areas for Targeted
Interventions Catherine Wolff, Michael
Mullen, Douglas Wiebe, Charles Branas,
Brendan Carr
P5.010
Predictors of Neurological
Deficit After Endovascular Treatment of
Cerebral Arteriovenous Malformations and
Functional Repercussion in Prospective
Follow-Up Juan Carlos Llibre, Jose Antonio
Jordan
NEW! e
Poster Session: MS and CNS Inflammatory Disease II
P5.011
Therapeutic Plasma Exchange
in 90 Glucocorticosteroid-unresponsive
Patients with Multiple Sclerosis—
Prediction of Response Johannes Ehler,
Martin Sauer, Sebastian Koball, Steffen
Mitzner, Heiko Hickstein, Reiner Benecke,
Uwe Zettl
P5.012
MRI Detection of Pial and
Subpial Abnormalities in the MS Spinal
Cord Hugh Kearney, Marios Yiannakas,
Rebecca Samson, Claudia WheelerKingshott, Olga Ciccarelli, David Miller
P5.013
Phenotypic Differences in
the Distribution of Gray Matter Lesions in
Multiple Sclerosis and Their Relevance to
Cognition Varun Sethi, Tarek Yousry, Nils
Muhlert, Daniel Tozer, Daniel Altmann,
Maria Ron, Claudia Wheeler-Kingshott,
David Miller, Declan Chard
P5.014
EDSS and MSFC Incompletely
Capture Patient Reported Disability in
a Longitudinal Cohort of Patients with
Multiple Sclerosis Carolyn Bevan,
Pierre-Antoine Gourraud, Monica Bucci,
Regina Schlaeger, Refujia Gomez, Caroline
Ciocca, Rachel Kanner, William Stern, Alan
Evangelista, Samuel Arnow, Aya Abounasr,
Adam Santaniello, Jeffrey Gelfand, H. Von
Budingen, Ari Green, Douglas Goodin,
Sergio Baranzini, Stephen Hauser, Roland
Henry, Bruce Cree
94
P5.015
The Brief International
Cognitive Assessment for Multiple
Sclerosis (BICAMS): Normative Values with
Gender, Age and Education Corrections in
the Italian Population Maria Pia Amato,
Emilio Portaccio, Claudia Niccolai, Bahia
Hakiki, Benedetta Goretti, Andrea Sturchio,
Vittorio Martinelli, Monica Falautano,
Eleonora Minacapelli, Ugo Nocentini, Chiara
Incerti, Maria Marrosu, Eleonora Cocco,
Monica Murgia, Giuseppe Fenu, Ferdinando
Ivano Ambra, Elisabetta Garofalo, Maurizio
Maddestra, Marilena Consalvo, Giovanni
Zimatore, Nunzia Alessandra Losignore,
Alessandra Lugaresi, Erika Pietrolongo, Rosa
Viterbo, Maria Trojano
P5.016
Vitamin D as Predictor
of Multiple Sclerosis Activity and
Progression in Patients with CIS Treated
Early with Interferon Beta-1b Alberto
Ascherio, Kassandra Munger, Rick White,
Karl Kochert, Kelly Claire Simon, Mark
Freedman, Hans Hartung, David Miller,
Xavier Montalban, Gilles Edan, Frederik
Barkhof, Dirk Pleimes, Rupert Sandbrink,
Ludwig Kappos, Christoph Pohl
P5.017
A Phase II Trial of
Neuroprotection with Riluzole in Early
Relapsing-Remitting MS: Lessons for
Future Neuroprotection Trials Emmanuelle
Waubant, Amir-Hadi Maghzi, Nisha
Revirajan, Rebecca Spain, Laura Julian,
Ellen Mowry, Jacqueline Marcus, Shuang
Liu, Ari Green, Charles McCulloch, Daniel
Pelletier
P5.018
Implicating MicroRNAs as
Regulators of Microglia and Astrocyte
Responses in Human CNS Inflammatory
Disease Craig Moore, Vijayaraghava
Rao, Shih-Chieh Fuh, Barry Bedell, Samuel
Ludwin, Amit Bar-Or, Jack Antel
P5.019
Grey Matter Expression
of Fetuin-A Correlates with Cortical
Demyelination in Multiple Sclerosis Mark
Landy, Ying Liu, Violaine Harris, Saud Sadiq
P5.020WITHDRAWN
Poster Session V
P5.035
P5.048
P5.021
The Utility of Paraneoplastic
Serology in the Saskatoon Health
Region Ilia Poliakov, Gary Hunter
Is Intracranial Arterial
Involvement a Subgroup of Neuro-Behcet
Syndrome? Burcu Zeydan, Ugur Uygunoglu,
Melih Tutuncu, Cengiz Yalcinkaya, Ayse
Altintas, Sabahattin Saipoglu, Aksel Siva
America’s First Epilepsy
Journal: Transactions of the National
Association of the Study of Epilepsy and
Care and Treatment of Epileptics Edward
Fine, Alyssa Fiddler
Epidemiology and Health
Care Utilization
P5.022
P5.036
P5.049
P5.062
Isolated Cerebral
Mucormycosis: A Case Report Monica
Dhakar, Mahmoud Rayes, Kupsky Williams,
Alexandros Tselis, Gregory Norris
P5.023
Role of Neurological
Consultation in Evaluating
Syncope Adithya Sivaraju, Appaji Rayi,
David Marks
P5.024
Anomalous Origins of Bilateral
Anterior Cerebral Arteries (ACA) from
the Cavernous Internal Carotid Arteries
(ICA). Swetha Pedavally, Matthew Omojola
P5.025
A Case Report of a Transient
Lesion of the Splenium Resulting from
Vasospasm Secondary to Pituitary
Apoplexy Tooba Fayyaz, Jocelyn Cheng
P5.026
Rare Neurological
Complications After Epidural Anesthesia in
Obstetric Patients: 2 Case Reports Gayane
Melikyan, Naveed Akhtar, Saadat Kamran,
Hassan Al-hail, Dirk Deleu
P5.027
Tongue Abnormalities on MRI
Associated with Severity and Progression
in ALS César Escamilla, Hector Martinez,
Jorge Moreno-Cuevas, Maria Teresa
Gonzale-Garza, Sergio Salazar Marioni,
Alfonso Gil Valadez
P5.028
Management Standardization
of Limbic Encephalitis and Rapidly
Progressive Dementia Elmoatazbellah
Ibrahim, Joel Phillips, Andrew Biondo
P5.029
Anti-Aquaporin 4
Autoantibodies in Patients with
Systemic Lupus Erythematosus
Without CNS Involvement: A long-term
assessment Ioanna Tatouli, Harry
Alexopoulos, Sofia Akrivou, Athanasios
Tzioufas, Marinos Dalakas
P5.037
Clinical Prodromes of
Neurodegeneration in Anderson-Fabry
Disease Matthias Löhle, Alan Milligan,
Linda Richfield, Heinz Reichmann, Derralynn
Hughes, Atul Mehta, Anthony Schapira
P5.038
This Is a Novel Case a
Variant of Miller-Fisher Syndrome with a
Positve Anti-GQ1b Antibody Presenting as
Parinaud’s Syndrome. Rick Magun, Jamie
Silva
P5.039
Evaluating the True Clinical
Relevance of Genomic Intervals Associated
with Amyotrophic Lateral Sclerosis Kevin
Kenna, Russell Mc Laughlin, Susan Byrne,
Marwa Elamin, Mark Heverin, Elaine Kenny,
Paul Cormican, Derek Morris, Colette
Donaghy, Daniel Bradley, Orla Hardiman
P5.040
Alcoholic Wernicke’s
Encephalopathy with Cranial Nerve XII
Involvement on MRI Maya Lichtenstein,
Dan Nguyen
P5.041
Delayed Recognition of
POEMS Hai Chen, Benjamin Greenberg,
Steven Vernino
First-time Seizure or Seizurelike Presentations in U.S. Adult Emergency
Departments 2007-2010 Wenyu Sun,
Anbesaw Selassie, Paul Pritchard
P5.050
Necessity of Emergency
Medical Care for Patients with Epilepsy
Presenting with Typical Seizures Timothy
Rust, Bassel Shneker
P5.051
Economic Outcomes in
Patients Receiving Anti-epileptic Drug
(AED) Adjunctive Therapy Zhixiao Wang,
Xuan Li, Annette Powers, Jose Cavazos
Neurophysiology: EEG
P5.052
Utility of After Hours
Emergency Electroencephalograms Ram
Narayan, Puneet Gupta, Barbara Voth,
Lakshmi Beeravolu, Ryan Hays, Pradeep
Modur, Paul Van Ness, Mark Agostini
P5.053
Usefulness of Emergent
Electro-Encephalogram In Known Epileptic
Patients Louise Tyvaert, Marie Girot, Xavier
Lenne, Pierre Williate, William Szurhaj,
Stephanie Leblanc, Maxime Chochoi, Herve
Hubert, Philippe Derambure
P5.054
Use of Prolonged VEEG
Monitoring in Children with First
Unprovoked Seizure Misbah Salam, Anjum
Hashim, Jasmine Singh
P5.055
Frequent Additional
Epileptogenic Abnormalities Detected
with Inpatient Long-Term EEG
Monitoring Ehtesham Khalid, Shobhit
Sinha, Khurram Siddiqui
A Presentation of Progressive
Multifocal Leukoenceophalopathy Leading
to Diagnosis of Underlying Marginal
Zone Lymphoma: An Unusual Antecedent
Cause of Immunosuppression. Alexander
Hartmann, Sara Mayer
Quality Improvement,
Health Care Utilization,
and History of Epilepsy
P5.030
Multiple Autoimmune
Antibody Limbic Encephalitis: A Case in
a Pregnant Woman Meha Goyal, Kasey
Gildersleeve, Stuart Tomko, Joseph Kass
P5.042
Variation in Quality of
Epilepsy Care and Association with Seizure
Control. Lidia Moura, Jonathan de Jesus,
Rogger Andrade, Daniel Hoch
Should Idiopathic Generalized
Epilepsy be Labeled “generalized” or
“System” Epilepsy Syndromes? Istabrak
Abdelkefi, Yousser Hizem, Imen Kacem,
Mouna Ben Djebara, Amina Gargouri,
Olivier Dulac, Riadh Gouider
P5.031Hemophagocytic
P5.043
P5.057
Lymphohystiocytosis Associated with
Encephalitis: Two Case Reports Sheetal
Sheth, Carl Gold, Emma Meyers, Amy
Jongeling, Stephan Mayer, Sachin Agarwal,
Jan Claassen, Brandon Foreman
P5.032
Extending the Olive Branch:
A Cost-Benefit Analysis of Thymectomy
in Myasthenia Gravis Shrikant Mishra,
Nasheed Jamal, Poonum Chaturvedi,
Bhavesh Trikamji
P5.033
Determination of Antibodies
to GAD67 and Other Antigens in Patients
with GAD65 Antibody-associated
Syndromes Núria Gresa-Arribas, Helena
Ariño, Lidia Sabater, Eva Caballero, Mercè
Alba, Eugenia Martínez-Hernandez, Mar
Petit, Albert Saiz, Josep Dalmau, Francesc
Graus
P5.034
Basal Ganglia Encephalitis
and Autoimmune Retinitis Associated with
Influenza B Barbara Graves, Jonathan
Hosey
Implementation of an Easyto-use Database for the Assessment
of Physician Performance in Epilepsy
Care Rodolfo Callejas, Yamil Matuk-Perez,
Daniel Vargas-Mendez, Nephtali CruzReyes, Nelson Garcia, Ildefonso RodriguezLeyva
P5.044
Complications in the
Epilepsy Monitoring Unit: A Nationwide
Study Monica Dhakar, Maysaa Basha
P5.045
How Long Is Long Enough?
The Utility of Prolonged Inpatient Video
EEG Monitoring Brian Moseley, Sandra
Dewar, Zulfi Haneef, John Stern
P5.046
Epidemiological Pilot Analysis
of Epilepsy Patients in a Community Clinic
Aims to Inform Effective Care Laura Karas,
Corey Goldsmith, Sara Ruppelt, Alica
Goldman
P5.047
Epilepsy Surgery: Historical
Perspective Pawan Rawal
P5.056
“Re-build Up” Phenomenon
Revisited Hesham Allam, Daniel Weber,
Stanley Iyadurai
P5.058
Infraslow Delta Co-exists with
High Frequency Oscillation in Cases of Ictal
Internal Vibration Aura Hisanori Hasegawa
P5.059
Quantitative EEG (qEEG) as
Marker for Mild Cognitive Impairment
(MCI) in Patients with Parkinson’s Disease
(PD) Habib Bousleiman, Shaheen Ahmed,
Martin Hardmeier, Florian Hatz, Christian
Schindler, Volker Roth, Ronan Zimmermann,
Ute Gschwandtner, Peter Fuhr
P5.060
Triphasic Waves
and Epileptiform Correlates on
Electroencephalogram Alyssa Fiddler,
Osman Farooq, Barbara Teter, Katelyn
Kavak, Arie Weinstock
P5.061
When Should We Treat
Periodic Lateralized Epileptiform
Discharges (PLEDS) Ahmad Solaiman,
Anza Memon, Maysaa Basha, Lusine
Avedian
Hospitalization Rates and
Early Versus Late Addition of Adjunctive
Anti-epileptic Drugs: A Retrospective
Study in a Commercially-Insured U.S.
Population Fulton Velez, Thirupathi
Pattipaka, Maria Malmenäs
P5.063
Knowledge About Sudden
Unexpected Death in Epilepsy Among
Health Personnel, Epilepsy Patients
and Their Relatives. A Pilot Survey in
Honduras. Reyna Duron, Juan Argenal,
Sylvia Gonzalez-Canelo, Dario ZunigaMartinez, Lupe Martinez, Susan PietschEscueta
P5.064
A Unique Partnership for
Research in Epilepsy Outcomes: The
Emory University and UCB Pharma
Collaboration Sandra Helmers, Fred Cox,
David Thurman, R Faught, Archna Patel,
Tracy Durgin, Patty Fritz, Kelly Simontacchi,
Akshatha Kalsanka Pai
P5.065
Risk of Bone Fractures Among
Epilepsy Patients in the United States: An
Analysis of a Large Administrative Claims
Database Fulton Velez, Joseph Menzin,
Michael Munsell, Molly Frean
P5.066
Known Epileptic Patients Use
of Emergency Departments Marie Girot,
Philippe Derambure, Maxime Chochoi,
Stephanie Leblanc, Patrick Goldstein,
William Szurhaj, Pierre Williate, Xavier
Lenne, Eric Wiel, Herve Hubert, Florence
Richard, Louise Tyvaert
P5.067
Known Epileptic Patients
Use of Resources of Emergency
Departments Marie Girot, Xavier Lenne,
Stephanie Leblanc, William Szurhaj,
Maxime Chochoi, Patrick Goldstein, Pierre
Williate, Eric Wiel, Herve Hubert, Philippe
Derambure, Louise Tyvaert
P5.068
Severe Overutilization of the
Emergency Department in Patients with
Uncontrolled Epilepsy Neha Vijayvargiya,
Steven Tobochnik, Kenneth Walsh, Camilo
Gutierrez, Wayne Satz, Mercedes Jacobson
P5.069
Comparison of Health
Care Resource Utilization and Costs in
Treatment-Adherent Patients with Epilepsy
With and Without Breakthrough Seizures in
A U.S. Managed Care Population Charles
Makin, Allison Petrilla, Victoria Divino,
Vamsi Bollu, Fulton Velez, Shawn Hallinan,
Alan Ettinger
P5.070
Resource Utilization in
Patients with Suspected Psychogenic
Non-epileptic Seizures and Drug Resistant
Epilepsy in the Harris County Health
District Between 2009 and 2012 Brian
Wolf, Bonnie Hayashi, Ezekiel Sachs, Colin
Van Hook, Dona Murphey, Corey Goldsmith
P5.071
The Economic Burden of
Uncontrolled Epilepsy: A Retrospective
Study in a Commercially-Insured U.S.
Population Maria Malmenas, Thirupathi
Pattipaka, Vamsi Bollu, Fulton Velez
95
Wednesday
April 30
General Neurology IV
Wednesday, April 30
P5.072
Real-World Persistence
and Treatment Failure Associated with
First Line Use of Antiepileptic Drug
Treatment in a Large U.S. Managed Care
Population Victoria Divino, Allison Petrilla,
Shawn Hallinan, Vamsi Bollu, Fulton Velez,
Alan Ettinger, Charles Makin
ALS: Epidemiology and Registries
P5.073
Increased Prevalence of ALS
in Operation Enduring Freedom/Operation
Iraqi Freedom (OEF/OIF) Veterans Sasha
Zivkovic, Anne Van Cott, Huned Patwa,
Mary Jo Pugh
P5.074
Verification of Amyotrophic
Lateral Sclerosis (ALS) Cases Reported
to the State and Metropolitan Area ALS
Surveillance Projects Wendy Kaye, Laurie
Wagner, Vinicius Antao, Eric Sorenson
P5.075
State and Metropolitan Areabased Amyotrophic Lateral Sclerosis (ALS)
Surveillance Laurie Wagner, Wendy Kaye,
Heather Jordan, Lindsay Rechtman, Maggie
Ritsick, Marchelle Sanchez
P5.076
The Northeast ALS
Consortium (NEALS) Upper Motor Neuron
Disease (UMND) Registry Alyssa Murphy,
Lorena Loci, Hiroshi Mitsumoto, Catherine
Lomen-Hoerth, Yasushi Kisanuki, Jinsy
Andrews, Merit Cudkowicz, Nazem Atassi
P5.077
Using the National
Amyotrophic Lateral Sclerosis Registry as a
Subject Recruitment Tool for Research D.
Kevin Horton, Vinicius Antao, Paul Mehta
P5.078
National ALS Biorepository
Feasibility Study Wendy Kaye, Laurie
Wagner
P5.079
Enhancements to the U.S.
National Amyotrophic Lateral Sclerosis
(ALS) Registry Paul Mehta, Vinicius Antao,
D. Kevin Horton
P5.080
Findings from the New Jersey
State-wide Amyotrophic Lateral Sclerosis
(ALS) Surveillance Project Heather Jordan,
Jerald Fagliano, Daniel Lefkowitz, Lindsay
Rechtman, Wendy Kaye
P5.081
Cognitive Reserve in ALS
with Comorbid Frontotemporal Dementia
(FTD): A Population-Based Study Antonio
Canosa, Anna Montuschi, Barbara Iazzolino,
Andrea Calvo, Cristina Moglia, Davide
Bertuzzo, Leonardo Lopiano, Gabriella
Restagno, Maura Brunetti, Irene Ossola,
Anna Lo Presti, Stefania Cammarosano,
Adriano Chio
P5.084
Physical Activity Profile and
Barriers to Physical Activity in Individuals
with Myotonic Dystrophy Katy Eichinger,
Jeanne Dekdebrun, Nuran Dilek, Shree
Pandya, Ding-Geng Chen
P5.095
P5.085
P5.096
Brain Gray Matter and
White Matter Alterations in Patients
with Myotonic Dystrophy 1 Stojan Peric,
Federica Agosta, Francesca Caso, Vidosava
Rakocevic-Stojanovic, Giancarlo Comi,
Vladimir Kostic, Massimo Filippi
P5.086
Congenital Centronuclear
Myopathy Mimicking Congenital Myotonic
Dystrophy Watcharasarn Rattananan, Jill
Blandford, Gwendolyn Claussen, Shin Oh,
Mohammad Alsharabati
P5.087
Electrical Impedance
Myography Discriminates Congenital
Muscular Dystrophy from Controls Daniel
Schwartz, Anam Salman, Janannaz Dastgir,
Barbara Lear, Carsten Bonnemann, Tanya
Lehky
Hereditary Inclusion Body
Myositis (IBM2) with a GNE c.2228
T>C Mutation in 3 Saudi Arabian
Families. Ahmed Basndwah, Enass AlMowalad, Yousef Al-Said, Edward Cupler
P5.098
Immunotherapy for
Respiratory Complications of Sporadic Late
Onset Nemaline Myopathy (SLONM) with
Monoclonal Gammopathy Nancy Rosales,
Mihael Varosanec, Ramon Lugo, Richard
Prayson, Megan Rahmlow
P5.099Human α7 Integrin Gene
P5.108
Can Ultrasonography of
Median Nerve Differentiate Between
Mild, Moderate and Severe Carpal Tunnel
Syndrome? Vasudeva Iyer
P5.109
The Specificity of
Prolonged CMAP Durations and Severe
CMAP Reductions in Critical Illness
Neuromyopathy Christopher Kramer,
Andrea Boon, C. Harper, Brent Goodman
P5.110
Longitudinal Quantitative
EMG Findings During Reinnervation After
Complete Nerve Lesions Christian Krarup,
Michel Boeckstyns, Allan Ibsen, Simon
Archibald
Epidemiology
P5.100
Desmin C-terminus Tail
Mutation Is a New Cause of Autosomal
Dominant Limb-girdle Muscular
dystrophy Joshua Lovinger, Anna Szekely,
Huned Patwa, Zarife Sahenk
Stroke and Non Convulsive
Status Epilepticus. A Topographic and
Prognosis Description. Francisco Muñoz
Giacomelli, Analia Calle, Maria Gonzalez
Toledo, Fatima Pagani Cassara, Agustina
Tamargo, Alejandro Thomson, Diego Nadile,
Francisco Klein
P5.090
Neurophysiology/EMG
P5.113
Evaluation in 476 Turkish Dystrophinopathy
Patients Hacer Durmus, Nihan ErginelUnaltuna, Poda Mehves, Arman Çakar, Ayca
Altinkaya, Filiz Guclu-Geyik, Feza Deymeer,
Yesim Parman, Asli Tolun, Piraye Serdaroglu
Sociodemographic and Health
Related Profile of Adults with Duchenne/
Becker Muscular Dystrophy (DBMD): Data
from the Muscular Dystrophy Surveillance,
Tracking and Research Network (MD
STARnet) Shree Pandya, Anil Kumar, Kathy
James, Christine Westfield, Emma Ciafaloni,
Christopher Cunniff, Paul Romitti, Richard
Moxley
P5.091
Baseline Performance on
6MWT Correlates with Other Functional
Outcomes in a Phase IIb Study of ExonSkipping Antisense Oligonucleotide
Eteplirsen for Use in Duchenne Muscular
Dystrophy (DMD) Jihad Saoud, Jerry
Mendell, Louise Rodino-Klapac, Zarife
Sahenk, Kandice Roush, Loren Bird, Linda
Lowes, Lindsay Alfano, Ana Maria Gomez
Ramirez, Sarah Lewis, Vinod Malik, Kim
Shontz, Christopher Shilling, Peter Sazani,
Edward Kaye
P5.092
P5.093
96
P5.097
Ulnar Palm to Finger Sensory
Nerve Conduction Eduardo Davidovich,
Osvaldo Nascimento, Bruno Coutinho, Victor
Kosac
P5.089Genotype-Phenotype
Muscular Dystrophies
Correlation Between
Muscle Histopathology Impairment
and Spliceopathy in Myotonic
Dystrophies Giovanni Meola, Enrico
Bugiardini, Giuliana Rossi, Laura Valentina
Renna, Annalisa Botta, Rosanna Cardani
Analysis of Myostain and
Related Proteins in a Cardiotoxin Injury
Muscle Atrophy Model Kenya Murata,
Hidefumi Ito
P5.107
(ITGΑ7) Delivered by Adeno-Associated
Virus Reverses the Phenotype of the
Double Knock Out (DKO) Mouse Devoid
of Dystrophin and Utrophin Kristin Heller,
Chrystal Montgomery, Kim Shontz, Paul
Janssen, Reed Clark, Jerry Mendell, Louise
Rodino-Klapac
Telemedicine in the Home
for Veterans with Amyotrophic Lateral
Sclerosis Richard Bedlack
P5.083
A Novel Form of Nemaline
Myopathy Caused by an In-Frame Deletion
in TNNT1 Sarada Sakamuri, Carly Siskind,
Karolina Watson, Thomas Winder, Hannes
Vogel, John Day
To Report Clinical
Heterogeneity of Facio-scapulo-humeral
Muscular Dystrophy in Which Two
Patients Presented with Recurrent Facial
Palsy Uzma Usman, Bilal Hameed, Johnny
Salameh
P5.088
Elucidating the Mechanism of
Anoctamin 5 Deficiency with a Novel KO
Mouse Model Danielle Griffin, Eric Pozsgai,
William Grose, Kristin Heller, Jerry Mendell,
Zarife Sahenk, Louise Rodino-Klapac
P5.082
3:00 p.m.–6:30 p.m.
C. Elegans as a model System
to Study Nemaline Myopathy Ge Xiong,
Ken Choe, David Leung, Hiroshi Qadota, Guy
Benian, Desmond Zeng, Karen McFarland,
Tetsuo Ashizawa
P5.094
A Novel Heterozygous L1453P
Mutation in the MYH7 Gene Resulting
in Laing Distal Myopathy in an Irish
Family Stela Lefter, Orla Hardiman, Russell
McLaughlin, Sinead Murphy, Michael
Farrell, Aisling Ryan
P5.101Intraoperative
Neurophysiologic Monitoring with
Hoffman Reflex During Thoracic Spine
Surgery: A Lesson from a Series of 18
Patients Anteneh Feyissa, Robert Smith,
Sudhakar Tummala
P5.102
Motor Evoked Potentials From
Multiple Recording Sites of the Lower
Limbs as a Monitoring Tool of Central
Motor Function Walter Troni, Antonio
Bertolotto, Federica Melillo, Simona
Malucchi, Paola Berchialla, Francesca
Sperli, Alessia Di Sapio
P5.103
Electrophysiological Findings
in Acute Solanum Torvum Toxicity Robert
Glover, Daniel Patterson, Nichloas Connors,
Silas Smith, Mark Milstein, Michael
Swerdlow
P5.104
The Pain of Anticipation:
Differences Between Expected and
Experienced Pain in Electrodiagnostic
Testing John Barghols, Samiullah Kundi,
David Thompson, Eduardo De Sousa, Calin
Prodan
P5.105
Levodopa Responsiveness of
Blink Reflex Recovery Index: An Objective
Method of Differenting Parkinson Disease
from Parkinson Plus Syndromes Chandana
Gaddipati, Meenakshisundaram
Umaiorubahan
P5.106
Frequency of Radiculopathy in
Patients with Carpal Tunnel Syndrome and
Paracervical Pain Rocio Garcia Santibanez,
Nabil Altememi, Stephen Scelsa
P5.111
Cocaine and Ischemic
Stroke: Epidemiological and Clinical
Characteristics Anand Vaishnav, Kerri
Remmel, Kari Moore, Craig Ziegler
P5.112
Incidence and Mortality of
Ischemic Stroke Subtypes in Joinville,
Brazil: A Population-Based Study Marcos
Lange, Norberto Cabral, Carla Moro,
Alexandre Longo, Anderson Goncalves,
Viviane Zetola, Tatjana Rundek
P5.114
Incident Cancer in Stroke
Survivors: Analysis of the Vitamin
Intervention for Stroke Prevention (VISP)
Trial Muhammad Suri, Malik Adil, Gustavo
Rodriguez, Saqib Chaudhry, Adnan Qureshi
P5.115
Time Trends in Transient
Ischemic Attack Admission from the
Emergency Department Karen Albright,
John Donnelly, Michael Mullen, Brett
Cucchiara, Justin Blackburn, Alexander Lo
P5.116
Temporal Trends in
Hospitalization for Transient Ischemic
Attack in the United States, 20002010 May Kim-Tenser, Lucas Ramirez,
Natalie Valle, Steven Cen, William Mack,
Nerses Sanossian, Amy Towfighi
P5.117
Education Status and
Ischemic Stroke in Young: A Potential
Target Towards Future Population Based
Preventive Strategies. Anand Vaishnav,
Radhika Vaishnav
P5.118
Which Metabolic Syndrome
Criteria Is More Relevant for the Prediction
of Silent Brain Infarction? A Study in a
Korean Population Yong Bum Kim, PilWook Chung
P5.119
Neurology House Staff
Experience Doesn’t Affect Acute Stroke
Treatment Gonzalez Castellon Marco,
Joshua Stillman, Mitchell Elkind, Randolph
Marshall, Joshua Willey
Poster Session V
P5.120
“On-the-job” Fatal
Cardiovascular Events: Analysis of National
Institute for Occupational Safety and
Health Data Amna Zarar, Aveen Saed,
Nudrat Tasneem, Malik Adil, Adnan Qureshi
Intracranial Aneurysms and
Subarachnoid Hemorrhage
P5.121Thromboelastography
Determines a Transient Late
Hypercoagulable State After Aneurysmal
Subarachnoid Hemorrhage Preethi
Ramchand, S Frangos, F Quattrone, S
Doerfler, K Nawalinski, B Michel, C Ju, S
Nyirjesy, N Driscoll, E Maloney-Wilensky,
D Sandsmark, Michael Mullen, M Smith,
B Pukenas, E Zager, S Stein, Scott Kasner,
Joshua Levine, Monisha Kumar
P5.122
Inflammation, Nutritional
Status and Outcome after Aneurysmal
Subarachnoid Hemorrhage Neeraj
Badjatia, Aimee Monahan, Amanda
Carpenter, Laura Friedman, Jacqueline
Zimmerman, J. Michael Schmidt, Jan
Claassen, Kiwon Lee, E. Sander Connolly,
Stephan Mayer, Wahida Karmally, David
Seres
P5.123
THE VASOGRADE—A Simple,
Reliable Grading Scale for Aneurysmal
Subarachnoid Hemorrhage Airton
Leonardo de Oliveira Manoel, David
Turkel-Parrella, Ekaterina Kouzmina, Simon
Abrahamson, Thomas Marotta, Tom
Schweizer, Julian Spears, Loch MacDonald
P5.124
Clinical Outcomes After
High-Grade Aneurysmal Subarachnoid
Hemorrhage Airton Leonardo de Oliveira
Manoel, David Turkel-Parrella, Alberto
Goffi, Victoria McCredie, David Ben-Israel,
Ekaterina Kouzmina, Julian Spears, Thomas
Marotta, Simon Abrahamson
P5.125
Headaches Following
Endovascular Treatment of Cerebral
Aneurysms: Coil Embolization Versus Flow
Diversion Martin Ollenschleger, Michael
Mancini, Stephen Ohki, Gary Spiegel
P5.126
Rebleeding of a Cerebral
Aneurysm During Transcranial Doppler:
Hemodynamic Changes and Response to
Treatment Eric Marrotte, Tamer Abdelhak,
Leonard Melvin, Panayiotis Varelas
P5.127
Extensive Proximal Migration
of Posterior Communicating Artery
Aneurysm Coil Presenting with a Transient
Ischemic Attack Ahmed Itrat, Esteban
Cheng-Ching, Muhammad Hussain
P5.128
Utilization and Outcomes
of Ventriculostomy in Non-traumatic
Subarachnoid Hemorrhage During Last
Decade in United States Yogesh Moradiya,
Santosh Murthy, Shreyansh Shah, Sneha
Modi
P5.129
New Risk Score Improves
Vasospasm Prediction following
Subarachnoid Hemorrhage Using Markers
of Vascular Compliance Aashish Anand,
Haitham Hussein, Mustapha Ezzeddine,
Joseph Kass, Jose Suarez
P5.130
Long Term Survival and
Hospital Re-admission Rates in Elderly
Patients with Subarachnoid Hemorrhage
Treated with Surgical or Endovascular
Treatment Saqib Chaudry, Mohammad
Afzal, Alexanderos L. Georgiadis, Adnan
Qureshi
P5.142
Validation of ICH and
ICH-GS Scores in an Indian Cohort of
Patients with Intracerebral Hemorrhage
Treated Medically and with Surgical
Interventions Rohit Bhatia, V Sreenivas,
Shaily Singh, M. v Padma, Kameshwar
Prasad
P5.143
Spontaneous Spine Epidural
Hematoma Is Most Frequently Idiopathic in
Cause Michael Pizzi, Scott Silliman
Predictors of the CT
Angiography Spot Sign in Deep and
Lobar Intracerebral Hemorrhage Farid
Radmanesh, Guido Falcone, Christopher
Anderson, Thomas Battey, Alison Ayres,
Anastasia Vashkevich, Kristin Schwab,
Javier Romero, Anand Viswanathan, Steven
Greenberg, Joshua Goldstein, Jonathan
Rosand, H. Bart Brouwers
P5.132
P5.144
Intracerebral Hemorrhage
and Other Hemorrhages
P5.131
Spinal Epidural Hematoma
in a Patient with Repair of Aortic
Coarctation Imad Khan, Neha Mirchandani,
Laura Donarummo
P5.133
Cervico-Dorsal Intramedullary
Hematoma in a Patient with Pompe
Disease Diego Nadile, Maria Gonzalez
Toledo, Agustina Tamargo, Fatima Pagani
Cassara, Alejandro Thomson, Francisco
Muñoz, Francisco Klein
Development of PeriHematomal Edema Measurements in
Intracerebral Hemorrhage Sebastian
Urday, Lauren Beslow, David Asuzu,
Anastasia Vashkevich, Alison Ayres,
Thomas Battey, Magdy Selim, Jonathan
Rosand, William Kimberly, Kevin Sheth
P5.145
P5.134
Associated with Dietary Supplement
Containing DMAA Janet Elgallab, Robert
Glover, Deepa Bhupali, David Gordon,
Kathryn Kirchoff-Torres
The Impact on Radiology
Utilization of Disseminating an Analysis
on the Value of Neuroimaging Studies
in Intracerebral Hemorrhage: The
University Hospitals Case Medical
Center Comprehensive Stroke Center
Experience Tanzila Shams, LeighAnne
McCartney, Polly Westerberg, Cathy Sila
P5.135
P5.146
Lone Intraventricular
Hemorrhage and Intraventricular
Hemorrhage Associated with Small
Parenchymal Component: Two Different
Clinical Entities Ather Taqui, Lauren
Koffman, Muhammad Hussain, Ken Uchino
Etiologies of Intracerebral
Hemorrhages from 2009-2012 at Mayo
Clinic-Rochester James Klaas, Sherri
Braksick, Robert Brown, Alejandro
Rabinstein, Jennifer Fugate
P5.153
Clinical Profile of
Longitudinally Extensive Transverse
Myelitis in Indian Population: A Prospective
Study from a Tertiary Teaching Hospital
of South India Dhairyawan Pokalkar,
Veena Narisetty, Murali Chekuri, Sowjanya
Poosarla, Srilatha Sripuram, Sateesh Kumar
Kamera
P5.154
Common Comorbidities
Among Multiple Sclerosis Patients in the
United States: An Analysis of In-patient
Hospitalizations Anthony Asemota, Han
Wang, Shalini Selvarajah, Xuan Hui, Eric
Schneider, Arun Venkatesan
P5.155
Demographics and Clinical
Characteristics of Multiple Sclerosis in
Kuwait: An Analysis of the National MS
Registry Raed Alroughani, S Ahmed,
Jassem Al Hashel
P5.156
Familial Multiple Sclerosis
Recurrence Risk in Argentina Francisco
Varela, Mauricio Farez, María Balbuena
Aguirre, Vanesa Nagel, Alejandro Köhler,
Jorge Correale
P5.157
Excess Mortality in Multiple
Sclerosis: A Meta-Analysis of Incidence
and Standardized Mortality Rates Radu
Tanasescu, Cris Constantinescu, Christopher
Tench, Ali Manouchehrinia
P5.158
Sociocultural and
Demographic Risk Factors for the
Development of Multiple Sclerosis
in Kuwait Suhail Al-Shammri, Arpita
Chattopadhyay, Magdy Girgis, Reema
Mathew, Chetana Madala, Abayomi Akanji
P5.147
Fever and Transient
Neurologic Worsening in Intracerebral
Hemorrhage Matthew Maas, Michael
Berman, James Guth, Eric Liotta, Shyam
Prabhakaran, Andrew Naidech
P5.159
Role of Magnetic Resonance
Imaging in Non-Lobar Hypertensive
Intracerebral Hemorrhage Amir Adeli, Reza
Behrouz
P5.137
P5.148
CNS Diseases and
Differential Diagnosis
P5.136
Type of Substance
Use Predicts Hemorrhage Versus
Ischemia Emma Kaplan, Rebecca
Gottesman, Rafael Llinas, Elisabeth Marsh
P5.138
Associated with Oral Phenylephrine
Use Brian Tark, Steven Messe, Clotilde
Balucani, Steven Levine
P5.139
Reversible Cerebral
Vasoconstriction Syndrome Presenting
as Coital Headache and Intracerebral
Hemorrhage Alex Linn, Nancy Rosales,
Camilo Garcia-Gracia, Efrain Salgado
P5.140
Direct Thrombin Inhibitors
May Have a Decreased Risk of
Intracerebral Hemorrhage Compared with
Older Anticoagulants Sindhu Ravipati,
Daniel Woo, Padmini Sekar, Charles
Moomaw, Matthew Flaherty, Jennifer
Osborne
P5.141
Assessing the Safety and
Cost-Effectiveness of Admission of Patients
with Intracerebral Hemorrhage (ICH) to a
Neurovascular Step Down Unit. Shaheryar
Hafeez, Reza Behrouz
Transfer Rates from U.S. Emergency
Departments: Findings from the National
Hospital Ambulatory Medical Care
Survey John Donnelly, Michael Mullen,
Karen Albright, Justin Blackburn, Brett
Cucchiara, Alexander Lo
P5.149
Primary Intraventricular
Hemorrhage: A Review with Focus on
Diagnostic Testing and Etiologies Ather
Taqui, Lauren Koffman, Muhammad
Hussain, Ken Uchino
P5.150
Yield of Follow-Up Imaging in
Workup of Intracerebral Hemorrhage—a
Retrospective Chart Review Clifford
Meyers, Adam Kelly
Disease: Epidemiology
P5.151
Clinical and Demographic
Profile of Multiple Sclerosis Patients in
India: Registry database of MS patients
from All India Institute of Medical
Sciences(AIIMS), New Delhi Ankit Singhal,
Rohit Bhatia
P5.152
Unveiling Multiple
Sclerosis in Nigeria: The Conundrum
of Diagnosis and Access to Disease
Modifying Therapies Njideka Okubadejo,
Oluwadamilola Ojo, Temitope Lawal, Francis
Ojini, Mustapha Danesi
The Diagnosis of Multiple
Sclerosis in Hispanics Occurs Sooner in
the Young Than in Adults Megan Langille,
Lilyana Amezcua, Margaret Burnett, Jose
Aparicio, Wendy Mitchell
P5.160
Clinical and Immunological
Features of Hashimoto’s Encephalopathy
Presenting with Limbic Symptoms Akiko
Matsunaga, Toru Kishitani, Tomoko
Muramatsu, Tomomi Kame, Masamichi
Ikawa, Osamu Yamamura, Tadanori
Hamano, Yasunari Nakamoto, Makoto
Yoneda
P5.161
Susac’s Syndrome in a
25-year-old Pregnant Woman Yasemin
Tashman
P5.162
Postcontrast T2-FLAIR: a
Useful Tool for Diagnosing and Monitoring
Susac Syndrome Irene Cortese, Govind
Nair, Joan Ohayon, Luisa Vuolo, Martina
Absinta, Pascal Sati, Bibiana Bielekova,
Daniel Reich
P5.163
MRI in Susac’s Syndrome:
A Propos of the Barkhof-Tintore
Criteria Sreekanth Koneru, Neil Jouvenat,
Kathleen Healey, Rana Zabad
P5.164
Long Segment Spinal
Cord Involvement as the Initial Clinical
Manifestation of Sarcoidosis Jamie
Adams, Steven Galetta
97
Wednesday
April 30
Wednesday, April 30
P5.165
IgG4-Related Disease
Manifesting as Middle Cranial Fossa Mass:
A Case Report Prerna Malla, Joseph
Zachariah, Bashar Katirji
P5.166
Catatonia: a Duel of
Hashimoto’s Encephalopathy and Anti
NMDA Receptor Encephalitis Elena
Grebenciucova
P5.167
Clinical Manifestations,
Imaging Findings, and Immunomodulatory
Therapeutic Strategies for Three Patients
with Concurrent Stiff Person Syndrome
and Cerebellar Ataxia Due to Anti-GAD
Antibodies: A Case Series Lauren DeNiro,
Jerome Graber, Howard Geyer, Alexis Boro
P5.168
Association of Parenchymal
and Vascular Damage (Mixed Pattern)
in Neurobehçet: A Case Series
Study Youness Habtany, Fatima Dany,
Nada Benkirane, Bouchra El Moutawakil,
Mohamed Abdoh Rafai, Ilham Slassi
P5.169
A Rare Autoimmune
Encephalitis—Due to DipeptidylPeptidase-like Protein-6 (DPPX)
Autoantibody; A Case Report Shawna
Suchecki, Laura Risley, Earl Zimmerman, Eric
Molho, Era Hanspal, Josep Dalmau
P5.170
Cytokine Disarrangement
and Increased Soluble Amyloid A (SAA) in
Cerebrospinal Fluid (CSF) of Patients with
Neurosarcoidosis (NS) Maria ReyesMantilla, Anupama Kumar, Jorjetta Ilieva,
Carlos Pardo-Villamizar
P5.171
Common Variable
Immunodeficiency Mimicking
Neurosarcoidosis Konark Malhotra,
Santosh Ramanathan, Deeksha Agrawal,
Sandeep Rana, Thomas Scott
P5.172
Primary Central Nervous
System Lymphoma Mimicking Multiple
Sclerosis with Spontaneously Remitting
Lesions Erin Longbrake, Robert Schmidt,
Anne Cross, Enrique Alvarez
P5.173Leukoencephalopathy
Associated with Levamisole Toxicity from
Cocaine Use Nicky Sheldon, Bridget Bagert
P5.174
Hematopoietic Stem Cell
Transplantation for Adult Cerebral X-linked
Adrenoleukodystrophy Wolfgang Köhler,
Jörn-Sven Kühl
P5.175
Monoclonal B Cell Population
in a Patient with Neurosarcoidosis Justine
Brink
P5.176
TWEAK Stimulation
of Microglia and Implications for
Neuropsychiatric Lupus Ariel Stock, Chaim
Putterman
P5.177
Distinguishing ClinicoRadiological Features in Patients with
Central Nervous System Tumefactive
White Matter Lesions Xuling Lin, Kevin
Tan, Lishya Liauw, Aung Soe Tin, Weiling,
Eileen Soon, Zhu Yin Shih, Raphael, Boon
Ping Toe, Hwee Yee Lee, Wai-Yung Yu
P5.178
Memory Disturbance in
the Mice Treated with Intraventricular
Administration of CSF from NMDAREncephalitis Patients Keiko Tanaka,
Yongzhi Li, Nobuo Kato, Tsutomu Takegami
98
P5.179
Anti-NMDA Receptor
Antibodies in Neurologic Disease Jessica
Panzer, Bailey Baumann, Hiro Furukawa,
Noriko Simorowski, Amy Gleichman, David
Lynch
P5.180
Acute Transverse Myelitis:
CSF Determinants in the Differential
Diagnostics Laura Kupila, Nina
Jaakonmäki, Heini Huhtala, Laura Airas
P5.181
A Note of Caution About the
Diagnosis and Treatment of Suspected
Transverse Myelitis (TM) Jorge Jimenez
Arango, Maureen Mealy, Phillipe Gailloud,
Carlos Pardo-Villamizar
P5.182
Contribution of
Fluorodeoxyglucose Positron Emission
Tomography (FDG-PET) in Myelitis: A
Multicentre Cohort of 13 Cases Jessica
Orgeval, Denis Mariano Goulart, Laurent
Collombier, Giovanni Castelnovo, Mahmoud
Charif, Clarysse Carra, Xavier Ayrignac,
Nicolas Gaillard, Mohamed Chbicheb,
Dimitri Renard, Guillaume Taieb, Eric
Thouvenot, Astrid Corlobe, Nicolas
Champfleur, Pierre Labauge
P5.183
3:00 p.m.–6:30 p.m.
P5.191
Urinary Retention as
the Presenting Symptom of West
Nile Encephalitis: Report of Two
Cases. Rashedul Hasan, John DeToledo
P5.204
P5.192
Multiple Mothballs
or Multiple Sclerosis: A Diagnostic
Dilemma Divyanshu Dubey, Vibhash
Sharma, Olaf Stuve
P5.205
P5.193
P5.206
Magnetic Resonance
Imaging Changes After Plasma Exchange
Treatment in Steroid-Refractory Relapses
in Multiple Sclerosis and Other CNS
Idiopathic Inflammatory Demyelinating
Diseases. Jose Meca-Lallana, Rocio
Hernandez Clares, Ester Carreon Guarnizo,
Adelaida Leon Hernandez, Begoña Palazon
Cabanes, Gema Salgado Cecilia, Encarna
Andreu Reinon, Judith Jimenez Veiga,
Margarita Cacho Perez, Guadalupe Ruiz
Merino, Jose Javier Martin Fernandez
P5.194
Multiple Sclerosis Diagnosis:
A Survey of Neurology Residents’
Knowledge on Current Diagnostic
Criteria Salim Chahin, Nikitha Ashok,
Raymond Price, Clyde Markowitz
Cognitive Deficits,
Cerebrospinal Fluid Pleocytosis and White
Matter Lesions Following Parvovirus
B19 Infection in an Immunocompetent
Adult Ariel Antezana, Joseph Herbert, Ilya
Kister
P5.195
P5.184
P5.196
The Specificity of CSF B
Cell Reactivity in HTLV-1 Associated
Myelopathy Jerry Lin, Alexandra Berman,
Christopher Sears, Saud Sadiq
P5.185
Acute Disseminated
Encephalomyelitis Following an Acute
JC Virus Infection Sean Rogers, Ramsey
Falconer, Yasar Torres-Yaghi, Heather
Boynton, Chris Sonne, Carlos Mora, Carmelo
Tornatore
P5.186Paraneoplastic
Myelopathy with Positive Antigolgi
Autoantibody YuanKai Lee, Sonia Kumari,
Gordon Mazibrada
P5.187
N-methyl D-aspartate
Receptors (NMDAR) Antibodies Associated
with Distinct Clinico-Radiological White
Matter Syndromes: Clinical Evidence for an
Anti-NMDAR Leukoencephalopathy? Yael
Hacohen, Michael Absoud, Cheryl
Hemingway, Leslie Jacobson, Jean-Pierre
Lin, Mike Pike, Sunil Pullaperuma, Ata
Siddiqui, Evangeline Wassmer, Camila
Buckley, Sarosh Irani, Angela Vincent, Ming
Lim
P5.188
New Autoantibodies
Against Neutral Glycolipids in
Encephalomyeloradiculoneuropathy Tatsuro
Mutoh, Sayuri Shima, Tomomasa Ishikawa,
Akihiro Ueda, Kunihiko Asakura
P5.189
The Oxford Experience:
Clinical Features and Outcomes of 25
NMDAR-Ab Positive Patients Including
Those with Atypical Presentations Katrina
Morris, Camilla Buckley, Belinda Lennox,
Yael Hacohen, Ester Coutinho, Angela
Vincent
P5.190
Clinical Features, Diagnostic
Findings and Treatment of Susac
Syndrome: A Case Series Ivana Vodopivec,
Sashank Prasad, Nagagopal Venna
Bradycardia Leading to
Pacemaker Placement: A Characteristic
Prodromal Syndrome of VGKCC/LGI1
Antibody Associated Encephalitis Georges
Naasan, Sarosh Irani, Brianne Bettcher,
Michael Geschwind, Jeffrey Gelfand
MR Imaging Trailing Clinical
Expression of Natalizumab-Associated
PML in Multiple Sclerosis: A Rare But
Serious Diagnostic and Management
Problem Christopher Muth, Christian
Hernandez, Dusan Stefoski, Roumen
Balabanov, Michael Ko
P5.197
Predominantly Spinal
Phenotype of Relapsing-Remitting
Multiple Sclerosis Jacob Cogan, Nataliya
Ternopolska, Wendy Vargas, Susan
Gauthier, Nancy Nealon, Timothy Vartanian,
Jai Perumal
Headache: Epidemiology
P5.198
Headache in Service Members
Deployed to Afghanistan Richard Young,
Michael Myslenski, Peter Petrillo
P5.199
Distinctive Anatomical and
Physiological Features of Migraine Aura
Revealed by 18 Years of Recording. Jakob
Hansen, Serapio Baca, Andrew Charles
P5.200
Chiari Headache
Mechanisms: The Role of Neck Spasm and
Migraine Fredric Cantor, Jessica Mack,
John Heiss
P5.201WITHDRAWN
P5.202
Developing and Validating the
ID-Chronic Migraine (ID-CM) Screening
Tool Richard Lipton, Daniel Serrano,
Andrew Blumenfeld, David Dodick, Sheena
Aurora, Werner Becker, H. Diener, ShuuJiun Wang, Maurice Vincent, Dawn Buse,
Joanna Sanderson, Sepideh Varon, Michael
Reed
P5.203
No Laughing Matter: A Case
of Gelastic Migraine Paul Mathew, Carrie
Robertson
A Closer Look at the Patients
Who Present to the Emergency Department
with Headache Mia Minen, Benjamin
Friedman
The Case of Migraine with
Visual and Olfactory Hallucination Related
to Food Allergy Vladimir Klinov, Larisa
Syrow
Multifocal Multiform
Nummular Headache (NH): A Case
Report Stephanie Goldberg, Sarah
Vollbracht, Brian Grosberg
P5.207
Peripartum Pneumocephalus
Associated with Epidural Anesthesia for
Labor Sudama Reddi, Valentyna Honchar,
Matthew Robbins
Epidemiology
P5.208
Learning from our Mistakes:
APOE4 Influences Misdiagnosis of
Alzheimer’s Disease and Frontotemporal
Degeneration Jenna Haley, Corey
McMillan, David Irwin, Beth McCarty
Wood, Katya Rascovsky, David Wolk, John
Trojanowski, Leslie Shaw, Vivianna Van
P5.209
Epidemiology of Tandem
Gait Abnormalities in Aging Ilya Bragin,
Vijayaleskhmi Nair, Joe Verghese
P5.210
Risk Factors for Cognitive
Change in Patients with Dementia Due
to Alzheimer’s Disease Fabricio Oliveira,
Paulo Bertolucci, Marilia Smith, Elizabeth
Chen
P5.211
Prevalence, Incidence, and
Associations between APOE Genotype,
Cardiovascular Risk Factor, and Dementia
in Cuban Populations Jorge Jesús Llibre
Guerra, Milagros Guerra, Juan Carlos Llibre
Guerra, Juan Jesús Llibre Rodriguéz
P5.212
Cardiac Function and the Risk
of Dementia Renée de Bruijn, Maarten
Leening, Oscar Franco, Albert Hofman, Peter
Koudstaal, Mohammad Ikram
P5.213
Long-term Mortality in
Incident MCI Subtypes. Data from the
NEDICES Cohort Félix Bermejo-Pareja,
Alvaro Sánchez-Ferro, Israel Contador
Castillo, Elina Boycheva, Rocio Trincado,
Sara Llamas, Alejandro Herrero, Fernando
Sierra, Alberto Villarejo Galende, Julian
Benito-Leon
P5.214Plasma β-Amyloid and MRI
markers of Structural Brain Aging Sara
Kaffashian, Christophe Tzourio, Aicha
Soumare, Carole Dufouil, Bernard Mazoyer,
Susanna Schraen-Maschke, Luc Buee,
Stephanie Debette
P5.215
Comparing Cognitive
Screening Tools in a Rural Ecuadorian
Population: The Atahualpa Project Clinton
Wright, Hannah Gardener, Mauricio
Zambrano, Victor Del Brutto, Oscar Del
Brutto
Poster Session V
P5.216
Cognitive Impairment,
Asymptomatic Carotid Stenosis and
Arterial Hypertension in Adult Persons
Without a History of Stroke: A PopulationBased Epidemiological Study Petya
Mineva, Dimitar Talalaev, Valentin Proychev
Cerebrovascular Ischemia,
Metabolism, and Epidemiology
P5.217
Cognitive Enhancer
Based Treatment Outcome in Mild
to Moderate Alzheimer’s Disease Is
Modulated by Severity of White Matter
Hyperintensity Kok Pin Ng, Aloysius Ng,
Nagaendran Kandiah
P5.218
Clinical Predictors of a Higher
Cerebrovascular Burden in Dementia: A
Clinicopathological Study. Solene Moulin,
Julia Salleron, Gauthier Calais, Florence
Pasquier, Vincent Deramecourt
P5.219
Food Insecurity Is Associated
with Development of Faster Cognitive
Decline in the Boston Puerto Rican Health
Study Janice Wong, Tammy Scott, Yinge Li,
Katherine Tucker, Xiang Gao
P5.220
Silent Cerebral Ischemia Is
Highly Prevalent in AD and Is Independently
Associated with Medial Temporal
Atrophy Nagaendran Kandiah, Russell
Chander, Aloysius Ng, Pryseley Assam
P5.221
Effectiveness of Cognitive
Enhancers in Alzheimer’s Disease with
Concomitant Small Vessel Cerebrovascular
Disease. Kok Pin Ng, A Ng, E Heng, S
Huang, P Assam, Nagaendran Kandiah
P5.222
Burden of Silent
Cerebrovascular Disease and Not Acute
Infarct Characteristics Determine PostStroke Cognitive Impairment, Both in Small
Vessel and Large Vessel Strokes Yen
Yeong Poh, Yun Qi Josephine Poh, Aloysius
Ng, Maznah Marmin, Yee Lean Ho, Hani
Zainal, Nagaendran Kandiah
P5.223
Pharmacogenetics of Lipid
Metabolism Modulators in Patients
with Dementia Due to Alzheimer’s
Disease Fabricio De Oliveira, Paulo
Bertolucci, Marilia Smith, Elizabeth Chen
P5.224
Evidence on Diet Modification
for Alzheimer’s Disease and Mild Cognitive
Impairment Hilary Glazer, Christine Greer,
Dulce Barrios, Christopher Ochner, James
Galvin, Richard Isaacson
P5.225
Dementia: An Emerging Field
in Pakistan Quratulain Khan
P5.226
Forgetful But Not
Disabled: Predictors of Incident IADL
Limitations Pamela Rist, Jessica Marden,
Benjamin Capistrant, Qiong Wu, M. Maria
Glymour
Creutzfeldt-Jakob Disease and
Subacute Encephalopathies
P5.227
A Case of Refractory
Hashimoto’s Encephalopathy
Demonstrating Improvement with
Plasmapheresis Sarah Nelson, Yasir
Jassam, Lynne Taylor
P5.228
Voltage Gated Calcium
Channels Antibody-associated
Autoimmune Encephalitis Abdulrahman
Alwaki, Anibal Lugo, Christopher
Goshgarian, Omar Ahmad, Hebah Hefzy,
Panayiotis Mitsias
P5.229
Hashimoto Encephalopathy:
A Study of Clinical Profile, Radiological
and Electrophysiological Correlation
in a Tertiary Care Centre in South
India Rangasetty Srinivasa, Surya
Sharma, J.v. Mahendra, Rohan. Mahale,
Madhusudhan B.K
P5.230
Reversible Dementia with
Myoclonus due to Concurrent HSV-2 and
Syphilis Central Nervous System Infection
in an Immunocompetent Man. Liliana
Robles, Aashish Anand, Joseph Kass
P5.238
Paired Comparison
Study Distinguishing Parkinsonian
Dementia Syndromes from Parkinson’s
Disease Douglas Scharre, Shu-Ing Chang,
Haikady Nagaraja, Ariane Park, Punit
Agrawal, Anahita Adeli, Shannon Linder,
Anne Kloos, Deborah Kegelmeyer, Nora
Fritz, Maria Kataki
P5.239
Education Effects on Rate of
Cognitive Decline Compared in Autopsy
Confirmed Alzheimer’s, Lewy Body and
Vascular Dementia Lyla Mourany, Jagan
Pillai
P5.240
Changes in PSP: Comparison of PSPParkinsonism with PSP-Richardson
Syndrome Saria Refai, Linda Hershey,
David Thompson, Jennifer Lippoldt
P5.241
Direction of Finger
Displacement in Parkinson Disease (PD)
May Predict the Onset of Dementia Aman
Deep, Abraham Lieberman, Rohit Dhall,
An Tran, Ming-Jai Liu, Kamala Saha,
Naomi Salins, Arshia Sadreddin, Guillermo
Moguel-Cobos, John Karis, Narayanan
Krishnamurthi
P5.242
Presence of Voltage-gated
Potassium Channel (VGKC)-complex
Antibody in a Case of Genetic Prion
Disease Adham Jammoul, Richard
Lederman, Jinny Tavee, Yuebing Li
Transcranial Sonography(TCS)
in Lewy Body Disease (LBD) Versus
Other Dementia. Correlation with Clinical
Symptoms. Maria Fernandez, Nuria
Campora, Waleska Berrios, Juan Ignacio
Rojas, Jorge Norscini, Edgardo Cristiano,
Angel Golimstok
P5.232
P5.243
P5.231
Creutzfeldt-Jakob Disease
with Unusual Finding of Significant CSF
Pleocytosis Pawan Rawal, Drew Uhrig,
Leonardo Almeida, Hassan FathallahShaykh
P5.233
Hyperacusis as the Initial
Presentation of Creutzfeldt-Jakob
Disease Alexander Merkler, Joseph
Safdieh
P5.234
Increased Interleukin-17 in the
Cerebrospinal Fluid in Sporadic CreutzfeldtJakob Disease Koji Fujita, Naoko Matsui,
Yukitoshi Takahashi, Yasushi Iwasaki, Mari
Yoshida, Tatsuhiko Yuasa, Yuishin Izumi,
Ryuji Kaji
P5.235
Wernicke-Korsakoff Syndrome
Mimicking Sporadic Jakob-Creutzfeldt
Disease Serggio Lanata, Pierluigi Gambetti,
Michael Geschwind
P5.236
Novel Pomegranate Oil NanoEmulsions for the Prevention and Treatment
of Neurodegenerative Diseases: The Case
of Genetic CJD Ruth Gabizon, Michal
Mizrahi, Yael Friedman-Levy, Liraz Larush,
Kati Frid, Orli Binyamin, Nina Feinstein, Dvir
Dori, Haim Ovadia, Tamir Ben-Hur, Shlomo
Magdassi
Behavioral Neurology of
Movement Disorders
P5.237
Environmental Predictors
of Cognitive Impairment in Parkinson’s
Disease Anna Blanken, Mona Beyer, OleBjorn Tysnes, Guido Alves, Jan Larsen, Liana
Apostolova
Simple Motor Stereotypies
Are Not Specific Core Features of
Behavioral Frontotemporal Dementia Sara
Pompanin, Chiara Formentin, Zarantonello
Giulia, Nela Jelcic, Giacomo Rolma, Matteo
Tagliapietra, Giovanni Zorzi, Annachiara
Cagnin
P5.244
Modulation of FeedbackRelated Negativity During Trial-and-error
Task in Parkinson Disease: Assessing the
Role of Apathy and Depression in Cognitive
Deficits René Quilodran, Laura Viñales,
Alex Araneda, Irving Santos, Francisco
Castilla
P5.245
Focused Ultrasound
Thalamotomy Modulates Inhibitory Motor
Control in Essential Tremor Scott Sperling,
Carol Manning, W. Jeffrey Elias, Scott Wylie
P5.246
A Common Movement
Abnormality in Patients with LGI1 Limbic
Encephalitis Is a Manifestation of Tonic
Seizures. Danielle Andrade, Peter Tai,
Josep Dalmau, Richard Wennberg
Movement Disorders:
Atypical Parkinsonism
P5.247
Clinical Features of Patients
with Concomitant Parkinson’s Disease
and Progressive Supranuclear Palsy
Pathology Heather Rigby, Brittany Dugger,
Charles Adler, Thomas Beach, Holly Shill,
Erika Driver-Dunckley, Marwan Sabbagh,
Lucia Sue, John Caviness
P5.248
Three Sib-Pairs of AutopsyConfirmed Progressive Supranuclear
Palsy Shinsuke Fujioka, Monica Sanchez
Contreras, Audrey Strongosky, Kotaro Ogaki,
Nathaniel Whaley, Pawel Tacik, Jay Van
Gerpen, Ryan Uitti, Owen Ross, Zbigniew
Wszolek, Rosa Rademakers, Dennis Dickson
P5.249
Mutational Analysis of COQ2
in Italian Patients with MSA Dario Ronchi,
Sara Bonato, Ernesto Di Biase, Valentina
Melzi, Ilaria Trezzi, Stefania Corti, Nereo
Bresolin, Giacomo Comi, Alessio Di Fonzo
P5.250
Hypercapnic Respiratory
Failure Is Often Seen in Advanced
Progressive Supranuclear Palsy Nobu
Komai, Chiho Ishida, Kazuya Takahashi,
Atsuro Tagami
P5.251
FDG-PET in Pathologically
Confirmed 4R-Tauopathy Variants Nicholas
Zalewski, Hugo Botha, Jennifer Whitwell,
Val Lowe, Dennis Dickson, Keith Josephs
P5.252
Human Mirror Neuron System
Is the Anatomical Substrate for Imitation
Apraxia in Corticobasal Syndrome: (18F)FDG
PET and MRI studies HyukJun Yoon, Seok
Min Kim, Hyuk Jin Yun, Kyung A Kim, Doris
Doudet, Jong-Min Lee, Chong S Lee
P5.253
Do Autonomic Studies Help
Differentiate Multiple System Atrophy
from PD with Dysautonomia in Clinical
Practice? Aashoo Mentreddi, Svjetlana
Miocinovic, Pravin Khemani, Steven Vernino,
Srikanth Muppidi
P5.254
Atypical Parkinsonism
Following Occult Carbon Monoxide
Exposure Shruti Raja, Tara Dutta, Justin
Kwan
P5.255
A Case of Klinefelter
Syndrome Associated with
Parkinsonism Lourdes Lago, Henry Moore,
Carlos Singer
Movement Disorders: Cognition
and Parkinson’s Disease
P5.256
Which Cognitive Subdomain Is
Related with Motor Symptoms in the Early
Stage of Parkinson’s Disease? Minjik Kim
P5.257
Hallucinations and Dementia
in Parkinson’s Disease: Clinically Related
But Structurally Distinct Jennifer Goldman,
Glenn Stebbins, Doug Merkitch, Vy Dinh,
Bryan Bernard, Leyla DeToledo-Morrell,
Christopher Goetz
P5.258
What Level of Parkinson’s
Disease Severity Is Associated with
Significant Differences in Cognitive
Function? Christian Lachner, Melissa
Armstrong, Ann Gruber-Baldini, Erik Barr,
Paul Fishman, Stephen Reich, William
Weiner, Lisa Shulman
P5.259
Association of Cognitive
Screening Tests with Disability in
Parkinson’s Disease Melissa Armstrong,
Erik Barr, Ann Gruber-Baldini, Stephen
Reich, Christian Lachner, Paul Fishman, Lisa
Shulman
99
Wednesday
April 30
Wednesday, April 30
P5.260
Long-term Outcomes of
Parkinson’s Disease Patients with Normal
Cognition. Kara Pigott, Jacqueline Rick,
Howard Hurtig, Alice Chen-Plotkin, John
Duda, James Morley, Lama Chahine, Nabila
Dahodwala, Jori Fleisher, Rizwan Akhtar,
Andrew Siderowf, Rachel Goldmann Gross,
Sharon Xie, John Trojanowski, Daniel
Weintraub
P5.261
Parkinson’s Disease Patients
with Mild Cognitive Impairment do Not
Have Increased Brain Iron Concentrations
as Compared to Patients Without Cognitive
Impairment Jesper Hagemeier, Thomas
Guttuso, Niels Bergsland, Mari HeininenBrown, Ellen Carl, David Lichter, Robert
Zivadinov
P5.262
Cognitive Deficits in Veterans
with Parkinson’s Disease: A National
Database Analysis Brandon Barton,
Zhiping Huo, Sandra Kletzel, Kevin Stroupe,
Christopher Goetz, Frances Weaver
P5.263
Cholinesterase Inhibitors
for Cognitive Impairment in Patients
with Parkinson’s Disease: A MetaAnalysis Gennaro Pagano, Giuseppe
Rengo, Michele Tagliati
P5.264
Motor Phenotype Predicts Cognitive
Performance David Isaacs, Joshua Herb,
Nelleke Van Wouwe, Daniel Claassen
P5.265
Lower Education Status
Associates with Axial Motor Burden in
Parkinson Disease Vikas Kotagal, Roger
Albin, Martijn Muller, Robert Koeppe, Kirk
Frey, Nicolaas Bohnen
Movement Disorders: Sleep
and Movement Disorders and
Miscellaneous Diagnoses
P5.266
Restless Limbs Syndrome
(RLS) Presenting as Hemisyndrome: A Case
of Dejerine-Roussy Syndrome Responsive
to Dopamine Agonists David Dickoff
P5.267
Restless Limb Syndrome
(R.L.S.): The Real Patient Experience. David
Dickoff, Stephanie Dontje
P5.268
Effect of Rotigotine
Transdermal System on Nocturnal Blood
Pressure Changes Associated with Periodic
Limb Movements During Sleep in Patients
with Restless Legs Syndrome Wolfgang
Oertel, Axel Bauer, Werner Cassel, David
Rye, Arthur Walters, John Winkelman,
Lars Bauer, Lars Joeres, Frank Grieger,
Kimberly Moran, Erwin Schollmayer, John
Whitesides, Claudia Trenkwalder
P5.269
Extrapontine Myelinolysis
Presenting as L-DOPA-Unresponsive
Parkinsonism Nicolaas Anderson, Akshay
Shah
P5.270
Effect of IVIg on GAD Epitopes
in Patients with Stiff-Person Syndrome:
Implications for Other Antibody-Mediated
Neurological Disorders Responding to
IVIg Penelope Fouka, Harry Alexopoulos,
Panagiotis Politis, Marinos Dalakas
P5.271
Movement Disorders
in Chronic Regional Pain Syndrome
(CRPS) Mitesh Lotia, Kathrin LaFaver
100
P5.272
Hyperactivity and Obsessive
Compulsive Disorder: An Unusual
Presentation in Perry Syndrome. A
Clinicopathological Study. Guillaume
Lamotte, Françoise Chapon, Gilles Defer
P5.273
Factors Influencing Medical
Treatment of Parkinsonism with Conflicting
DaT Imaging: The Cleveland Clinic
Experience Dimitrios Nacopoulos, Srivadee
Oravivattanakul, Anwar Ahmed, Hubert
Fernandez
P5.274
Dopaminergic Neurons
Loss in Parkinson’s Disease: How Much
Sex Hormones Decline Contribute
to? Mahmoud Elhusseiny, Mohamed
Sarhan, Mohamed Salama, Mohamed
Elgamal, Sherif Shawer, Ahmed Attia,
Mohamed Sobh
P5.275
Investigating the Night to
Night Variability of REM Without Atonia
in Parkinson’s Disease Samuel Bolitho,
Sharon Naismith, Ron Grunstein, Zoe
Terpening, Moran Gilat, Simon Lewis
Sleep: Sleep Related Breathing
P5.276
Frequency and Causes of
Discontinuation of Continuous Positive
Airway Pressure Treatment in Multiple
System Atrophy Takayoshi Shimohata,
Hideaki Nakayama, Masatoyo Nishizawa
P5.277
REM Sleep Rebound on a First
CPAP Recovery Night in Severe Obstructive
Sleep Apnea Patients Raoul Biniaurishvili
P5.278
PAP Therapy Boosts REM
Dependent Memory Consolidation for
Perceptual Skill Learning in Patients with
Obstructive Sleep Apnea. Heidi Roth,
Chayla Hart, David Sanders, Young Truong,
Bradley Vaughn, Robert Stickgold
P5.279
Subjective Sleep Quality and
Insomnia: Correlation with Cardiovascular
Health Status in Community-Dwelling
Elders Living in Rural Coastal Ecuador—
The Atahualpa Project Pablo Castillo, Oscar
Del Brutto, Robertino Mera, Victor Del
Brutto
P5.280
OSA Is Under-reported in
Patients Admitted with Acute Stroke Scott
Shorten, Richard Dubinsky
P5.281
A Pilot Study Identifying a
Unique Pattern on the Repeatable Battery
for the Assessment of Neuropsychological
Status (RBANS) that Predicts Obstructive
Sleep Apnea (OSA) in a Dementia
Screening Setting Amber Gerber, Donn
Dexter
P5.282
A Novel Capability for
Monitoring Cerebral and Systemic
Hemodynamics, ECG and Actigraphy During
Sleep Vladimir Ivkovic, Gary Strangman,
Quan Zhang
P5.283
Diagnostic Thresholds for
Quantitative REM Sleep Muscle Densities,
Phasic Burst Duration, and REM Atonia
Index in REM Sleep Behavior Disorder with
Co-morbid Obstructive Sleep Apnea Erik
St. Louis, Stuart McCarter, Bradley Boeve,
Michael Silber
3:00 p.m.–6:30 p.m.
Sleep: Parasomnias and
Measurement Technologies
P5.284
Cortical Excitability Relation
to Periodic Leg Movements (PLMS)
and Sleep in Restless Legs Syndrome
(RLS) Rachel Marie Salas, Aadi Kalloo,
Tiana Krum, Richard Allen
P5.285
Sleep Quality, Duration,
Insomnia Symptoms, and Prevalence of
Sleep Disordered Breathing in Parkinson’s
Disease Shirin Shafazand, Douglas
Wallace, Silvia Vargas, Henry Moore,
Corneliu Luca, Heather Katzen, Bonnie Levin,
Carlos Singer
P5.286
Comparing Periodic Limb
Movements in Sleep in Subjects with
and Without Waking Paretic/Plegic
Limbs Mark Dyken, Miriam Zimmerman,
Kyoungbin Im, Deborah Lin-Dyken, Christine
Glenn, Mark Blumberg, Robert Rodnitzky,
Greta Sokoloff
P5.287
Use of a Non-invasive
Neurotechnology, HIRREM, Is Associated
with Improved Sleep and Mood in a
Heterogeneous Cohort. Jared Cook,
Catherine Tegeler, Sung Lee, Hossam
Shaltout, Meghan Franco, Charles Tegeler
P5.288
Treatment of Restless Legs
Syndrome (Willis-Ekbom Disease) with
Rotigotine and Pramipexole. Diego GarciaBorreguero, Melissa Sweeney
P5.289
The Effect of Prior Exposure
to Dopamine Agonists (DA) on Response
to Treatment with Gabapentin Enacarbil
(GEn) in Adult Patients with Moderate-toSevere Primary Restless Legs Syndrome
Trials William Ondo, Neal Hermanowicz,
Diego García-Borreguero, Mark Jaros,
Richard Kim, Gwendoline Shang
P5.290
The Efficacy of Gabapentin
Enacarbil (GEn) in Adult Patients with
Severe Primary Restless Legs Syndrome
Trials Daniel Lee, William Ondo, Alon
Avidan, Diego García-Borreguero, Mark
Jaros, Richard Kim, Gwendoline Shang
P5.294
Kleine-Levin Syndrome with
Rapid Cycling—Case Report and Review
of the Literature Claudio De Gusmao, Kiran
Maski, David Urion
P5.295
Sleep Dependent Memory
Consolidation in Children with Autism
Spectrum Disorders Kiran Maski, Hannah
Holbrook, Dara Manoach, Ellen Hanson,
Kush Kapur, Robert Stickgold
P5.296
Evaluation of the Effect
of Modafinil on Cognitive Functions in
Patients with Idiopathic Hypersomnia with
P300 Mehmet Yaman, Fatıma Karakaya,
Hasan Mayda, Ibrahim Guzel, Gokhan
Koyuncu, Serdar Oruc
P5.297
Sleep and Sleep Disruption
in Predator Odor Trauma Model of Posttraumatic Stress Disorder Omar Taranissi,
Rishi Sharma, Pradeep Sahota, Mahesh
Thakkar
P5.298
Sudden Onset of Sleep Due
to Bilateral Hypothalamic Lesions in
Neuromyelitis Optica Spectrum Disorder
Positive for Aquaporin 4 Antibody
(AQP4) Hidehiko Okuma, Yuki Hatanaka,
Kuwabara Midori, Kanbayashi Takamichi,
Masahiro Sonoo
Neuro Trauma, Critical Care, and
Sports Neurology: Concussion
P5.299
A Portable Non-invasive
Assess Sports Concussion and Mild
Traumatic Brain Injury Adam Simon, Janet
Van Gelder, Hashem Ashrafiuon, David
Devilbiss
P5.300
Effect of Concussion and
Blast Exposure on Clinical Symptoms
Following Deployment of U.S. Military
Personnel Mikias Wolde, Briana Perry,
Jay Haran, Justin Campbell, Alia Creason,
Catalina Sher, Lauren Stentz, Jack Tsao
P5.301
Hyperglycemia and
Leukocytosis as Predictors of Abnormal
Head CT Following Concussion Aakash
Bodhit, Yasamin Daneshvar, Pratik Patel,
Keith Peters, Latha Ganti
P5.291
P5.302
Sleep:
Intrinsic Disorders of Sleep
P5.303
Subjective Perception
of Sleepiness in a Driving Simulator
Is Different from Perception in the
Maintenance of Wakefulness Test David
Schreier, Corinne Roth, Johannes Mathis
P5.292
Energy Expenditure in
Narcolepsy Patients and Controls Claire
Donjacour, Paul Schoffelen, Sebastiaan
Overeem, Gert Jan Lammers, Hanno Pijl,
Klaas Westerterp
P5.293
Respiratory Safety of the
Orexin Receptor Antagonist Suvorexant
During Sleep in Patients with Compromised
Respiratory Function and in Healthy
Subjects Matthew Troyer, Naoto Uemura,
Jackie McCrea, John Palcza, Mardik
Donikyan, Gary Zammit, Rong Liu, Tara
Siringhaus, Janice Rowe, Deborah Card,
Sabrina Marsilio, Timothy Grant, Russell
Rosenberg, John Wagner, Hong Sun
Validation of a SelfAdministered iPad®- and iPod®-Based
Tool for Assessing Information
Processing Andrew Russman, Joshua
Hirsch, David Schindler, Daniel Burke, Susan
Linder, Jay Alberts
A Potential Biomarker
in Sports-Related Concussion: Brain
Functional Connectivity Alteration of the
Default-mode Network Measured with
Sequential Resting-state fMRI David
Zhu, Tracey Covassin, Sally Nogle, Scarlett
Doyle, Doozie Russell, Randolph Pearson,
Jeffrey Monroe, Christine Liszewski, J
DeMarco, David Kaufman
P5.304
Structural Imaging
Correlations with Memory Assessment and
Concussion in Retired NFL Athletes Kyle
Womack, Jeremy Strain, Nyaz Didehbani,
Heather Conover, Michael Kraut, Munro
Cullum, John Hart
Poster Session V
P5.305
Atlanto-axial Subluxation:
Treatable Cause of Post Concussion
Syndrome Kevin Crutchfield, Dennis
Rivenburgh, Laura Morris, Jenna Werner
P5.317
P5.306
Prevalence of Sleep and
Psychiatric Disorders in Patients Who
Present to the Emergency Department with
Concussion Pratik Patel, Aakash Bodhit,
Yasamin Daneshvar, Latha Ganti
P5.318
P5.307
P5.319
The King-Devick Test Is
Vastly Superior to the Symbol Digit
Modalities Test as a Sideline Determinant
of Concussion in Mixed Martial Arts
Fighters Daniel Kantor
P5.308
Barriers to Recovery after
Concussion Teena Shetty, Kelianne
Cummings, Christine Villegas, Erin Manning,
Niesha Voigt, Maxwell Singer, Joseph
Nguyen
P5.309
Post Concussion Delirium in
Children: Two Cases Gail Schuman
P5.310
fMRI Neuropsychological
Battery for Athletes with
Concussion David Hubbard, Adam
Hampshire, Adrian Owen
P5.311
The Utility of Pain Drawings
in the Diagnosis and Treatment of Military
Post-traumatic Headache Alan Finkel,
Juanita Yerry, Brian Ivins, Young Choi
P5.312
Clinical Course of Recovery
from Concussion in Children 6-12 Years
of Age Sarah Risen, Jennifer Reesman,
Gayane Yenokyan, Kelly Clark, Beth
Slomine, Stacy Suskauer
P5.313
Use of a Non-invasive
with Improved Sleep, Mood, and Baroreflex
Sensitivity in Athletes with Persisting PostConcussion Symptoms Charles Tegeler,
Catherine Tegeler, Jared Cook, Sung Lee,
Meghan Franco, Lee Gerdes, Hossam
Shaltout
Field Utilization of the
Cleveland Clinic Concussion iPad
Assessment Tool Jay Alberts, Joshua
Hirsch, Susan Linder, David Schindler
Quantification of the Balance
Error Scoring System with an iPad
Application David Schindler, Susan Linder,
Mandy Koop, Joshua Hirsch, Daniel Kana,
Jay Alberts
Consequences of Traumatic
Brain Injury in Male Ice Hockey
Players Ozan Toy, Mill Etienne, Ronald
Bogdasarian
P5.320
Comparison of Common
Football Helmets in Preventing Concussion,
Hemorrhage and Skull Fracture Using a
Modified Drop Test. John Lloyd, Francis
Conidi
Neuro Trauma, Critical Care,
and Sports Neurology:
Traumatic Brain Injury
P5.321
A Multiscale Biology
Approach in the Identification of Dementia
Risks in Subjects with TBI History Giulio
Pasinetti, Ke Hao, Drew Helmer
P5.322
MEG Findings Correlate to
Speech-Language Pathology Deficits in
Combat-Related mTBI and PTSD Maria
DeGraba, Warren Merrifield, Erin Mattingly,
Judy Mikola, Mihai Popescu, Anda Popescu,
Alexander Balbir, Thomas Balkin, Joseph
Bleiberg, Thomas DeGraba
P5.323
Etiology and Epidemiology of
Traumatic Brain injury in Relation to Gender
Differences Among African American
Patients Lien Diep, Robert Farney, Stacy
Cary-Thompson, Jean Belcourt, Robert
Farney, Janaki Kalyanam, Annapurni JayamTrouth
P5.324
P5.314
Onabotulinum Toxin A for
the Treatment of Chronic Post-Traumatic
Headache in Service Members with
a History of Mild Traumatic Brain
Injury Juanita Yerry, Alan Finkel, Devon
Kuehn, Steven Lewis
P5.315
P5.325
Alterations in Network
Dynamics Following Blast-induced Mild
Traumatic Brain Injury Andrei Vakhtin, Paul
Taylor, Corey Ford
Thalamic Volumes and
Exposure to Head Trauma in Retired
Professional Fighters Charles Bernick,
Sarah Banks, Nancy Obuchowski, Wanyong
Shin, Mark Lowe, Michael Phillips, Michael
Modic, Stephen Jones
P5.316
Post-traumatic Headache
in Soldiers: A Retrospective Record
Review of Active Duty Soldiers Presenting
to a Military Concussion Care Clinic
Center for Evaluation and Treatment of
Headache Alan Finkel, Juanita Yerry, Brian
Ivins, Young Choi
Is There Chronic Brain Damage
in Retired NFL Players? Neuroradiology,
Neuropsychology and Neurology of 45
Retired Players Ira Casson, David Viano,
E. Mark Haacke, Zhifeng Kou, Danielle
LeStrange
P5.326
Progressive Return to Activity
Following Acute mTBI: A Standardized
Approach Robert Labutta, Therese West,
Helen Coronel, Katherine Helmick
P5.327
Interdisciplinary Assessment
and Care in Service Members with Combat
Related TBI and PTSD Thomas DeGraba,
James Kelly, Joseph Bleiberg, Geoffrey
Grammer, Jesus Caban, Jennifer Bell,
Robert Koffman
P5.328
Thromboelastography Defines
Late Hypercoagulability After TBI Allie
Massaro, Sean Doerfler, Kelsey Nawalinski,
Nicolette Driscoll, Connie Ju, Hiren Patel,
Sarah Nyirjesy, Francis Quattrone, Suzanne
Frangos, Eileen Maloney-Wilensky, Robert
Siman, Sean Grady, Sherman Stein, Scott
Kasner, Monisha Kumar
P5.329
Mid-life Hypometabolism in
the Precuneus May Be Associated with
Prior History of Traumatic Brain Injury
(TBI) Salil Soman, Jauhtai Cheng, Steven
Chao, Jennifer Kong, Maheen Adamson, J.
Wesson Ashford, Ansgar Furst
P5.330
Antiplatelet Agent Use
Impacts Mortality But Not Progression
of Hemorrhagic Injury After Traumatic
Brain Injury Richard Choi, Rajanandini
Muralidharan, Connie Ju, Kelsey
Nawalinski, Francis Quattrone, Suzanne
Frangos, Eileen Maloney-Wilensky, Sue
Auerbach, Elsa Lin, Michael Miszczanczuk,
Bruce Sachais, Patrick Kim, Scott Kasner,
Soojin Park, Joshua Levine, W Kofke, Peter
Leroux, Monisha Kumar
P5.331
The Natural History of Acute
Recovery of Blast-induced Mild Traumatic
Brain Injury: A Case Series During
War Jason Hawley, David Larres, Elizandro
Gonzales, Walter Carr
P5.332
A Portable Non-invasive
Assess Cognitive Function and Mild
Traumatic Brain Injury Stephen Martino,
Adam Simon, David Devilbiss
P5.336
Subarachnoid Hemorrhage—
Which Grading Scale Best Predicts
Outcome? Kushak Suchdev, Hardik Doshi,
Mohammad Ibrahim, Navid SerajiBozorgzad
P5.337
How Much Does a Traumatic
Brain Injury Cost? Aakash Bodhit, Pratik
Patel, Yasamin Daneshvar, Keith Peters,
Latha Ganti
P5.338
Utility of Non-conventional
MRI in Assessing White Matter Damage
After Carbon Monoxide Poisoning Hiroshi
Kuroda, Kazuo Fujihara, Shigeki Kushimoto,
Masashi Aoki
P5.339
The Burden of Pediatric Spinal
Cord Injury in the United States Shalini
Selvarajah, Eric Schneider, Adil Haider,
Daniel Becker, Edward Hammond
P5.340
Utility of EEG During the Early
Hospital Course After Resuscitation from
Cardiac Arrest Elizabeth Cahill, David
Tirschwell, Glenn Schubert, Mark Holmes,
Shahin Hakimian, W. T. Longstreth, Michele
Olsufka, Kim Francis
P5.341
Study of Pseudobulbar Affect
Symptoms in Veterans with Mild Traumatic
Brain Injury Jennifer Fonda, Regina
McGlinchey, William Milberg, James
Rudolph, Phillip Hunt, Matthew Reynolds,
Charles Yonan
P5.342
Management of Intracranial
Hemorrhage and Return to Play in Sports:
Cases Without Neurologic Deficit Jose
Posas, Vernon Williams
P5.343
CNS Injuries Associated with
the Sport of Ice Hockey. Ozan Toy, Arielle
Berkowitz, Mill Etienne
Neuro Trauma, Critical Care, and
Sports Neurology: Outcomes
P5.333
The Value of Neurocognitive
Testing after Mild TBI in the Emergency
Department Latha Ganti, Pratik Patel,
Aakash Bodhit, Yasamin Daneshvar, Keith
Peters
P5.334
Ventilator Associated
Pneumonia in Neurology and Neurosurgery
Intensive Care Unit: Incidence, Risk Factors
and Pathogens Man Mohan Mehndiratta,
Rajeev Nayak, Sanjay Pandey, Ajay Sharma,
Archana Thakur
P5.335
Developing an Emergency
Department Based Protocol for Evaluating
Concussion—a Prospective Observational
Study Latha Ganti, Pratik Patel, Aakash
Bodhit, Yasamin Daneshvar, Keith Peters
Available March 2014!
Browse abstracts for the Annual Meeting Scientific Program with the Annual Meeting mobile app available for iPhone®, iPad®, and
Android® devices. Abstracts will also be searchable online. Learn more at AAN.com/view/AM14.
101
Wednesday
April 30
Wednesday, April 30
4:00 p.m.–5:45 p.m.
Utilizing a similar format to the popular Emerging Science Session, these dynamic sessions will feature five-minute author presentations
followed by five-minutes of questions and answers. The session will conclude with all authors participating in a panel discussion.
S34 MS and CNS
Inflammatory Disease: Risk
Factors for MS Disease and
Course
S35 Cerebrovascular
Neurology: Issues in Acute
Treatment
4:00 p.m.
S34.001
Integrating Genetic Burden and
Environmental Factors to Stratify
Risk for Multiple Sclerosis Zongqi
Xia, Alina von Korff, Daniel Reich,
Lori Chibnik, Philip De Jager
4:00 p.m.
S35.001
Minor Stroke and Rapidly Improving
Stroke Symptoms: To Treat or Not to
Treat?! Clotilde Balucani, Riccardo
Bianchi, Edward Feldmann, Jeremy
Weedon, Steven Levine
4:10 p.m.
S34.002
A Multivariate Risk Calculator for
Multiple Sclerosis and Study of
an Endophenotype in Siblings of
People with Multiple Sclerosis Ruth
Dobson, Joanne Topping, Declan
Chard, Klaus Schmierer, Paul Smith,
Sreeram Ramagopalan, Gavin
Giovannoni
4:10 p.m.
S35.002
Expedited Code Stroke Protocol: An
Updated Experience Ilana Spokoyny,
Rema Raman, Karin Ernstrom,
Dawn Meyer, Justin Sattin, Thomas
Hemmen, Brett Meyer
4:20 p.m.
S34.003
Hormonal Contraceptives and
Multiple Sclerosis Susceptibility Kerstin Hellwig, Lie Chen, Annette
Langer-Gould
4:30 p.m.
S34.004
Population Attributable Fractions
and Joint Effects Among Key Risk
Factors for Multiple Sclerosis: The
Ausimmune Study Ingrid van der
Mei, Robyn Lucas, Bruce Taylor,
Anne-Louise Ponsonby
4:40 p.m.
S34.005
Vaccines and the Risk of Multiple
Sclerosis and Other CNS
Demyelinating Diseases Annette
Langer-Gould, Lie Chen, Sara Tartof,
Chun Chao, Hung-Fu Tseng
4:50 p.m.
S34.006
Early Relapse-recovery Impacts
Progressive Disease Course in
Multiple Sclerosis Martina
Novotna, Melih Tutuncu, M. Paz
Soldan, Daniel Crusan, Elizabeth
Atkinson, Orhun Kantarci
5:00 p.m.
S34.007
Measuring Enduring Worsening of
Multiple Sclerosis in the Combirx
Study Fred Lublin, Stacey Cofield,
Flavia Nelson, Ponnada Narayana,
Tarah Gustafson, Jerry Wolinsky,
Gary Cutter
5:10 p.m.
S34.008
Are Recent Hispanic Immigrants at
Higher Risk of Disability with Multiple
Sclerosis? Lilyana Amezcua, Karina
Ladezma, Maziar Eslami, Jose
Aparicio, Annette Langer-Gould
5:20 p.m.
S34.009
CSF1R Gene Screening in a Cohort
of 218 Primary Progressive Multiple
Sclerosis (PPMS) Patients from the
Norwegian and Swedish National
PPMS Registries Christina
Sundal, Matthew Baker, Virginija
Karrenbauer, Kjell-Morten Myhr,
Kristoffer Haugarvoll, Shinsuke
Fujioka, Hanne Harbo, Jan Aasly,
Jan Hillert, Zbigniew Wszolek, Rosa
Rademakers, Oluf Andersen
5:30 p.m.
Panel Discussion
4:20 p.m.
S35.003
Effect of IV rtPA in Mild Strokes in
the Third International Stroke Trial
(IST3) Pooja Khatri, Darren Tayama,
Geoff Cohen, Richard Lindley, Joanna
Wardlaw, Sharon Yeatts, Joseph
Broderick, Peter Sandercock
4:30 p.m.
S35.004
Futile Revascularization After
Mechanical Thrombectomy for Acute
Ischemic Stroke: Pooled Analysis of
the Multi MERCI, TREVO and TREVO
2 Trials Zhong-Song Shi, David
Liebeskind, Bin Xiang, Sijian Grace
Ge, Lei Feng, Gregory Albers, Ronald
Budzik, Thomas Devlin, Rishi Gupta,
Olav Jansen, Tudor Jovin, Monika
Killer-Oberpfalzer, Helmi Lutsep, Juan
Macho, Raul Nogueira, Marilyn Rymer,
Wade Smith, Nils Wahlgren, Gary
Duckwiler
4:40 p.m.
S35.005
Testing the Presumption of Consent
to Emergency Thrombolysis for
Stroke Winston Chiong, Anthony
Kim, Ivy Huang, Nita Farahany, S.
Josephson
4:50 p.m.
S35.006
Prehospital Factors Associated
with Stroke Misdiagnosis by EMS
Providers Ethan Brandler, Mohit
Sharma, Elizabeth Helzner, Steven
Levine
5:00 p.m.
S35.007
CT Perfusion Variables Within 4.5
Hours of Stroke: Relating Physiology
to Time Since Onset Smriti Agarwal,
Tomasz Matys, S Tulasi Marrapu,
Jennifer Mitchell, P Simon Jones,
Jean-Claude Baron, Elizabeth
Warburton
5:10 p.m.
S35.008
Acute Stroke Reperfusion Trends
in the Expanded Time Window
Era Ganesh Asaithambi, Xin Tong,
Mary George, Albert Tsai, James
Peacock, Russell Luepker, Kamakshi
Lakshminarayan
5:20 p.m.
S35.009
National Trends in Utilization
and Outcomes of Intravenous
Thrombolytic Treatment Among
Pediatric Patients with Acute
Ischemic Stroke in United
States Mohammad Afzal, Saqib
Chaudry, Taqi Zafar, Mohammad
Owais, Malik Adil, Vishal Jani, Gautam
Sachdeva, Swaroop Pawar, Syed
Hussain, Adnan Qureshi
5:30 p.m.
102
S36 Neuromuscular
Disease: Clinical
4:00 p.m.
S36.001
ALS-Plus Syndrome: Nonmotor Features in a Large ALS
Cohort Shannon Vandriel, Leo
McCluskey, Lauren Elman, Ashley
Boller, Murray Grossman
4:10 p.m.
S36.002
Prevalence, Course and Associations
of Depression in ALS: Lack
of Worsening With Disease
Progression. Nimish Thakore, Erik
Pioro
4:20 p.m.
S36.003
Secondary Health Conditions
Among Males with Duchenne
or Becker Muscular Dystrophy
(DBMD) Rebecca Napoliello,
Natalie Street, Kristin Caspers,
Emma Ciafaloni, Christopher
Cunniff, Jennifer Donnelly, Deborah
Fox, Kathy James, Joyce Oleszek,
Christina Westfield
4:30 p.m.
S36.004
Thymectomy for Non-thymomatous
Myasthenia Gravis: A Propensity
Score Matched Study. Carolina
Barnett Tapia, Hans Katzberg, Shaf
Keshavjee, Vera Bril
4:40 p.m.
S36.005
A Distinctive, Delayed Form of
Exertional Rhabdomyolysis Lydia
Sharp, Ronald Haller
4:50 p.m.
S36.006
Neuropathy Associated with
Nondiabetic Obesity J. Singleton,
Eric Volckmann, Timothy Graham,
Albert Smith
5:00 p.m.
S36.007
Comparison of Baroreflex
Sensitivity to Fall and Rise in Blood
Pressure Induced by the Valsalva
maneuver Naoki Wada, Wolfgang
Singer, Tonette Gehrking, David
Sletten, James Schmelzer, Phillip
Low
5:10 p.m.
S36.008
Peripheral Nerve Amyloidosis:
Phenotype, Natural History, and
Autonomic Dysfunction in Inherited
Versus Acquired Subtypes Adam
Loavenbruck, Wolfgang Singer,
Paola Sandroni, Michelle
Mauermann, P. James B. Dyck,
Christopher Klein, Phillip Low
5:20 p.m.
S36.009
Is the Rituximab Response
in Acetylcholine Receptor
Autoantibody Myasthenia Gravis
Durable? Kimberly Robeson,
Benison Keung, Daniel DiCapua,
Jonathan Goldstein, Kevin O’Connor,
Richard Nowak
5:30 p.m.
Panel Discussion
Panel Discussion
S37 Clinical Aspects of
Parkinson's Disease
4:00 p.m.
S37.001
Low Diagnostic Accuracy of a Clinical
Diagnosis of Early Parkinson’s Disease:
Findings of the Arizona Parkinson’s
Disease Consortium Charles Adler,
Thomas Beach, Joseph Hentz, Holly
Shill, John Caviness, Erika DriverDunckley, Marwan Sabbagh, Lucia Sue,
Sandra Jacobson, Christine Belden,
Brittany Dugger
4:10 p.m.
S37.002
Mechanisms of Profound Myocardial
Norepinephrine Depletion in Parkinson
Disease David Goldstein, Patti
Sullivan, Courtney Holmes, Gary Miller,
Yehonatan Sharabi, Irwin Kopin
4:20 p.m.
S37.003
Determining Optimal Cutoff Scores
and Neuropsychological Tests for the
Diagnosis of Mild Cognitive Impairment
in Parkinson’s Disease Samantha
Holden, Bichun Ouyang, Glenn Stebbins,
Bryan Bernard, Christopher Goetz,
Jennifer Goldman
4:30 p.m.
S37.004
Heart Rate Variability in LRRK2
Parkinson’s Disease Samuel Goldman,
Birgitt Schuele, Grace Bhudhikanok,
Stephanie Cash, Monica Korell, Yamah
Amiri, Chen Meng, Kathleen Comyns,
Dolores Guest, Linda Rees, Sam Kim,
Farah Kausar, Sakunthala Sundarrajan,
Emily Drabant Conley, Nicholas Eriksson,
Grace Liang, Melanie Brandabur, James
Tetrud, J Langston, Caroline Tanner
4:40 p.m.
S37.005
What Are the Determinants of
Leaving the Workforce in Parkinson’s
Disease? Melissa Armstrong, Ann
Gruber-Baldini, Stephen Reich, Christian
Lachner, Karen Anderson, Paul Fishman,
Lisa Shulman
4:50 p.m.
S37.006
α-Synuclein in Red Blood Cells Is a
Potential Diagnostic Biomarker for
Parkinson’s Disease Rodolfo Savica,
Roy Dyer, Michelle Mielke, Bryan
Klassen, Bradley Boeve, George Klee, J.
Ahlskog, Walter Rocca, Marina RamirezAlvarado
5:00 p.m.
S37.007
Alpha-Synuclein within Cutaneous
Autonomic Nerves in Parkinson
Disease: A Biomarker of Disease
Severity and Autonomic
Dysfunction Christopher Gibbons,
Ningshan Wang, Roy Freeman
5:10 p.m.
S37.008
Elevated Blood Harmane
(1-methyl-9H-pyrido[3,4-b]indole)
Concentrations in Parkinson’s
Disease Elan Louis, Monika
Michalec, Wendy Jiang, Pam FactorLitvak, Wei Zheng
5:20 p.m.
S37.009
Oral Inosine Persistently Elevates
Plasma Antioxidant Capacity in
Early Parkinson’s Disease Shamik
Bhattacharyya, Rachit Bakshi, Robert
Logan, Alberto Ascherio, Eric Macklin,
Michael Schwarzschild
5:30 p.m.
Panel Discussion
Neurology: Plasma and
Other Biomarkers
4:00 p.m.
S38.001
A Plasma-based Biomarker Panel
Identifies Preclinical Alzheimer’s
Disease Mark Mapstone, Massimo
Fiandaca, Amrita Cheema, Xiaogang
Zhong, Ming Tan, Claudia Kawas,
Howard Federoff
4:10 p.m.
S38.002
High Accuracy of a MicroarrayBased Blood Test for Alzheimer’s
Disease Lucas Restrepo, Phillip
Stafford, Stephen Johnston
4:20 p.m.
S38.003
Presence of Phosphorylated Tau,
Alpha-Synuclein and Amyloid
Protein in the Skin of Patients with
Clinical Diagnosis of Alzheimer
Disease Ildefonso Rodriguez-Leyva,
Ana Calderon-Garciduenas, Martha
Santoyo, Erika Chi, Verónica MedinaMier, Maria Jimenez-Capdeville
4:30 p.m.
S38.004
Increased Plasma Pyroglutamate-3
Amyloid Beta Protein Levels in
Older Persons with Down Syndrome
(DS) Pankaj Mehta, Bruce Patrick,
Marc Barshatzky, David Miller
4:40 p.m.
S38.005
Association of Plasma Aβ Levels
with MRI Markers of Cerebral Small
Vessel Disease Sara Kaffashian,
Christophe Tzourio, Aicha Soumare,
Carole Dufouil, Fabrice Crivello,
Yicheng Zhu, Susanna SchraenMaschke, Bernard Mazoyer, Luc
Buee, Stephanie Debette
4:50 p.m.
S38.006
An Abeta Oligomer Receptor
Antagonist and Antibodies to Specific
Target Receptor Epitopes Displace
Abeta Oligomers in Alzheimer’s
Patient Brain Tissue Sections Susan
Catalano, Nicholas Izzo, Courtney
Rehak, Raymond Yurko, Kelsie
Mozzoni, Colleen Silky, Gary Look,
Gilbert Rishton, Hank Safferstein, Tara
Spires-Jones
5:00 p.m.
S38.007
Prevalence of Lewy-type
Synucleinopathy in the
Submandibular Gland of Subjects
with NeuropathologicallyConfirmed Dementia with Lewy
Bodies. Thomas Beach, Charles
Adler, Holly Shill, Lucia Sue, Geidy
Serrano, Brittany Dugger, Sandra
Jacobson, Marwan Sabbagh
5:10 p.m.
S38.008
Association of the MAPT with
Cerebrospinal Fluid Phosphorylated
Tau Levels in Frontotemporal
Degeneration Nam Eun Min, Corey
McMillan, David Irwin, Virginia Lee,
John Trojanowski, Vivianna Van Deerlin,
Murray Grossman
5:20 p.m.
S38.009
Complement Factor H Is a Biomarker
for Mild Cognitive Impairment Not Due
to Alzheimer’s Disease Trung Nguyen,
Kelly Watts, James Lah, Jonathan
Glass, Allan Levey, William Hu
5:30 p.m.
Panel Discussion
Platform Blitzes
4:00 p.m.
S39.001
Pediatric Primary Pseudotumor
Cerebri Syndrome (PTCS): New
Insights from Detailed Endocrine
Assessments Grace Lin, Claire
Sheldon, Evanette Burrows, Marianne
Chilutti, Shana McCormack, Grant Liu
4:10 p.m.
S39.002
White Matter Microstructure
Abnormalities in Patients with
Dominant Optic Atrophy and OPA1
Mutations Roberta Messina, Maria
Rocca, Stefania Bianchi Marzoli,
Iacopo Milesi, Maria Lucia Cascavilla,
Melissa Petrolini, Andrea Falini,
Giancarlo Comi, Massimo Filippi
4:20 p.m.
S39.003
Baseline Optical Coherence
Tomography (OCT) Measurements
in the Idiopathic Intracranial
Hypertension Treatment Trial:
Correlations and Relationship to
Clinical Features Mark Kupersmith
4:30 p.m.
S39.004
Opponent Mechanisms of Cone and
Melanopsin Pupil Control Geoffrey
Aguirre, Manuel Spitschan, Jain
Sandeep, David Brainard
4:40 p.m.
S39.005
Pre-Existing Afferent Visual System
Abnormalities Confound Vigabatrin
(VGB) Vision Analyses of Patients
with Epilepsy Robert Sergott, Rod
Foroozan, Chris Johnson, Deborah Lee,
Jouko Isojarvi
4:50 p.m.
S39.006
MRI Findings of Elevated Intracranial
Pressure in Pseudotumor Cerebri
Syndrome With and Without
Papilledema Robert Mallery, John
Woo, Madhura Tamhankar, Kenneth
Shindler, Yin Chen, Eric Medina,
Kathleen Digre, Deborah Friedman,
Grant Liu
5:00 p.m.
S39.007
Four-Year Results from the Sabril®
Registry Yield a Low Rate of
Discontinuation Secondary to Reports
of Visual Deficits Robert Sergott,
Rod Foroozan, John Pellock, R Faught,
W Shields, Greg Burkhart, Vijay
Prabhakaran, Sarah Torri, Deborah
Lee, Jouko Isojarvi
5:10 p.m.
S39.008
Visual Pathway Structure and
Function, Optic Neuritis and Fatigue
in Multiple Sclerosis. Salim Chahin,
Deborah Miller, Nikitha Ashok,
Reiko Sakai, James Wilson, Clyde
Markowitz, Dina Jacobs, Ari Green,
Peter Calabresi, Elliot Frohman, Steven
Galetta, Laura Balcer
5:20 p.m.
S39.009
Effects of Stimulating MelanopsinContaining Retinal Ganglion Cells in
Migraine Patients Using Multifocal
Objective Pupillometry Christian
Lueck, Eman Ali, Teddy Maddess,
Corinne Carle
5:30 p.m.
Panel Discussion
S40 General Neurology II
4:00 p.m.
S40.001
DPPX Autoantibody: Frequency,
Clinical Accompaniments and
Outcomes W. Oliver Tobin, Vanda
Lennon, Lars Komorowski, Christian
Probst, Stacey Clardy, Allen Aksamit,
Claudia Lucchinetti, Sean Pittock,
Maja Tippmann-Peikert, Elaine
Wirrell, Andrew McKeon
4:10 p.m.
S40.002
Plasma Lipids and Cerebral Small
Vessel Disease Sabrina Schilling,
Christophe Tzourio, Carole Dufouil,
Yicheng Zhu, Claudine Berr, Annick
Alpérovitch, Fabrice Crivello, Bernard
Mazoyer, Stéphanie Debette
4:20 p.m.
S40.003
Neurocognitive Changes
in High-Altitude U-2 Pilots:
Relationship to White Matter
Hyperintensities Adam Willis, John
Sladky, David Tate, Kent McDonald,
Joe Wood, Paul Sherman, Peter
Kochunov, Stephen McGuire
4:30 p.m.
S40.004
Detection of Increased Transcripts
of Human Endogenous Retrovirus
in Plasma of Patients with
Frontotemporal Dementia Associated
Amyotrophic Lateral Sclerosis Tariq
Alfahad, Allan Levey, Avindra Nath
4:40 p.m.
S40.005
Quantification of Sciatic Nerve
Pathology in Inherited Neuropathies
via Magnetization Transfer
MRI Richard Dortch, Lindsey
Dethrage, Audra Hamilton, John
Gore, Seth Smith, Jun Li
4:50 p.m.
S40.006
A Single Mode of Brain Alteration
in Blindness. A Multimodal MR
Imaging Study. Ritobrato Datta,
Noah Benson, Aleksandra Daina,
Efstathios Gennatas, Sashank
Prasad, Omar Butt, Geoffrey Aguirre
5:00 p.m.
S40.007
Subcortical White Matter
Hyperintensities on MRI in Two
Populations Exposed to Hypobaric
Non-Hypoxic Conditions Andrew
Robinson, Patrick Grogan, Peter
Kochunov, Paul Sherman, Stephen
McGuire
5:10 p.m.
S40.008
Ascending Paralysis from Rabies
17 Months Following Kidney
Transplant Sean Rogers, Mary
Denny, Rebecca O’Dwyer Vourganti,
Ramsey A. Falconer, Ping Zhai,
Friedhelm Sandbrink
5:20 p.m.
S40.009
The Effects of Combination Therapy
with Sodium Valproate, Peg-alpha
Interferon and Prednisolone on
Clinical Manifestations of Patients
With HTLV-1 Associated Spastic
Paraparesis (HAM/TSP) Ali
Shoeybi, Reza Boostani, Mohammad
Mehdi Etemadi, Seyed Abdolrahim
Rezaee, Mehdi Moshfegh
5:30 p.m.
Panel Discussion
S41 Headache: Clinical
4:00 p.m.
S41.001
Combined Concordant Peripheral
Neurostimulation for Chronic
Migraine Headaches: A
Retrospective Analysis of 188
Consecutive Patients Kenneth
Reed, Francis Conidi, Robert Bulger,
Kelly Will
4:10 p.m.
S41.002
Sociodemographic, Disability, and
Employment Differences Between
Persons with Chronic and Episodic
Migraine: Results of the CaMEO
(Chronic Migraine Epidemiology and
Outcomes) Study Richard Lipton,
Daniel Serrano, Dawn Buse, Kristina
Fanning, Aubrey Manack, Michael
Reed
4:20 p.m.
S41.003
Symptom Codes and Opioids:
Disconcerting Headache Practice
Patterns in Academic Primary
Care. K.C. Brennan, Colin Farrell,
Gregory Keough, Susan Baggaley,
Karly Pippitt, Susan Pohl, Kathleen
Digre, Lisa Gren
4:30 p.m.
S41.004
Long-term Efficacy of Outpatient
Interdisciplinary Treatment for
Patients Suffering from Chronic
Headaches Mark Stillman, Steven
Krause
4:40 p.m.
S41.005
Influence of Psychiatric Comorbidities
in Migraineurs in the Emergency
Department: A Cross Sectional
Analysis Mia Minen, Kaloyan Tanev
4:50 p.m.
S41.006
Headache Characteristics
at Baseline in the Idiopathic
Intracranial Hypertension Treatment
Trial Deborah Friedman
5:00 p.m.
S41.007
Association Between Stress
and Headache Frequency Sara
Schramm, Susanne Moebus,
Nils Lehmann, Ursula Galli, Mark
Obermann, Eva Bock, Min-Suk Yoon,
H. Diener, Zaza Katsarava
5:10 p.m.
S41.008
A Case Report of Acute Intracerebral
Vascular Ischemic Stroke After
Treatment with Dihydroergotamine
in a Patient with New Onset of
Migraine New Daily Persistent
Headache with Thunderclap
Onset Sana Ghafoor, William
Young
5:20 p.m.
S41.009
Adherence to Oral Migraine
Preventive Medications Among
Patients with Chronic Migraine:
Analysis of a Large US Health
Insurance Claims Database Zsolt
Hepp, David Dodick, Sepideh Varon,
Patrick Gillard, Ryan Hansen, Emily
Devine
5:30 p.m.
Panel Discussion
S42 Child Neurology I
4:00 p.m.
S42.001
A Novel Homozygous Mutation of
SLC52A3 Gene Associated with
Brown-Vialetto-Van Laere Syndrome
(BVVL) Sunil Naik, Eisha Chopra, Beth
Pletcher, Chirag Gordhan, Xue Ming
4:10 p.m.
S42.002
Abnormalities of the Attentional
Network Following Traumatic Brain
Injury in Pediatric Patients: A fMRI
Study Maria Rocca, Sandra Strazzer,
Paola Valsasina, Ermelinda De Meo,
Erika Molteni, Monica Recla, Susanna
Galbiati, Alessandra Bardoni, Giancarlo
4:20 p.m.
S42.003
Hypertension Is Associated with
Increased Mortality After Ischemic
Stroke in Children Alfredo Caceres,
Malik Adil, Adnan Qureshi, Lori Jordan
4:30 p.m.
S42.004
Neuronal Activity Promotes
Oligodendrogliogenesis and
Myelination in the Mammalian
Brain David Purger, Erin Gibson,
Christopher Mount, Andrea Goldstein,
Grant Lin, Ingrid Inema, Sarah Miller,
Gregor Bieri, J. Bradley Zuchero, Ben
Barres, Pamelyn Woo, Hannes Vogel,
Michelle Monje
4:40 p.m.
S42.005
Identification of New Genes
and Pathways for Undiagnosed
Infantile Spinal Muscular Atrophy
Disorders. Lisa Baumbach-Reardon,
Jesse Hunter, Mary Ellen Ahearn,
Judith Hall, John Carpten
4:50 p.m.
S42.006
Functional Outcome After Perinatal
Cerebral Sinovenous Thrombosis:
A Prospective Cohort Study Lori
Billinghurst, Michael Uohara, Daniel
Licht, Rebecca Ichord
5:00 p.m.
S42.007
Everolimus Long-Term Efficacy
and Safety for the Treatment
of Subependymal Giant Cell
Astrocytoma (SEGA) Associated
With Tuberous Sclerosis Complex
(TSC) David Franz, Elena Belousova,
Steven Sparagana, E Bebin, Michael
Frost, Rachel Kuperman, Olaf Witt,
Michael Kohrman, J. Robert Flamini,
Joyce Wu, Paolo Curatolo, Petrus de
Vries, Noah Berkowitz, Oezlem Anak,
Julie Niolat, Sergiusz Jozwiak
5:10 p.m.
S42.008
Cognitive and Developmental
Predictors of ASD in Infants with
Tuberous Sclerosis Complex. Shafali
Jeste, Joyce Wu, Damla Senturak,
Mustafa Sahin, Charles Nelson
5:20 p.m.
S42.009
Memantine for the Treatment of
Autism Spectrum Disorder: Overview
of the Phase II Clinical Development
Program Ephraim Katz, Jordan
Lateiner, Allan Spera, Robert Palmer,
Stephen Graham
5:30 p.m.
Panel Discussion
S43 Epilepsy and Clinical
Cognition
4:00 p.m.
S43.001
A Pilot Study of a Self-Management
Intervention for Cognitive Impairment
in Epilepsy Tracie Caller, Karen Secore,
Robert Ferguson, Robert Roth, Faith
Alexandre, Jessica Harrington, Barbara
Jobst
4:10 p.m.
S43.002
Cognitive Effects of Extended-release
Once-daily SPN-538 (Trokendi XR™)
Versus b.i.d. Immediate-Release
Topiramate (TPM-IR, Topamax®) in
Healthy Volunteers Janet Johnson,
Scott Brittain, Stefan Schwabe
4:20 p.m.
S43.003
Stereotactic Laser Ablation of
Hippocampus Leads to Better Cognitive
Outcome Than Open Temporal Lobe
Resections for the Treatment of
Epilepsy Daniel Drane, David Loring,
Voets Natalie, Price Michele, Jon Willie,
Sandra Helmers, Jeffrey Ojemann,
Vaishali Phatak, John Miller, Kimford
Meador, Robert Gross
4:30 p.m.
S43.004
Virtual Car Accident Rates of Epilepsy
Patients Are Significantly Increased
by Interictal Generalized Spike
Waves Heinz Krestel, Andreas von
Allmen, Christian Liechti, Maja Steinlin,
Johannes Mathis, Nirkko Arto
4:40 p.m.
S43.005
Mismatch of Structural and Functional
Reorganization in Language
Network in Left Temporal Lobe
Epilepsy Shigetoshi Takaya, Naoaki
Tanaka, Hesheng Liu, Douglas Greve,
Claus Reinsberger, Andrew Cole, Emad
Eskandar, Steven Stufflebeam
4:50 p.m.
S43.006
Efficacy of Transcranial Direct Current
Stimulation on Working Memory and
Mood in Patients with Temporal Lobe
Epilepsy Anli Liu, Orrin Devinsky,
Andrew Bryant, Ashlie Jefferson, Daniel
Friedman, Mouhsin Shafi, William Barr,
Daniel Press, Susan Herman, Margaret
O’Connor, Steven Schachter, Alvaro
Pascual-Leone
5:00 p.m.
S43.007
Seizures Lower the Pathologic
Threshold for the Development of
Mild Cognitive Impairment and Early
Dementia in Alzheimer’s Disease Ryan
Patrick, Erin Abner, Peter Nelson,
Gregory Jicha
5:10 p.m.
S43.008
Key Pathways for Visual Naming
and Object Recognition Revealed by
Diffusion Tensor Imaging Probabilistic
Tractography in Epilepsy Surgery
Patients Daniel Drane, Matthew
Glasser, Natalie Voets, Jeffrey Ojemann,
Amit Saindane, David Loring, Michele
Price, Mirjana Ivanisevic, Vaishali
Phatak, Jon Willie, Kimford Meador,
John Miller, Robert Gross
5:20 p.m.
S43.009
Facial Emotion Processing in Left
Temporal Lobe Epilepsy Jane
Allendorfer, Heidi Heyse, Lucy Mendoza,
Basia Szaflarski, Nancy Cohen, Jerzy
Szaflarski
5:30 p.m.
Panel Discussion
103
Wednesday
April 30
S39 Neuro-ophthalmology/
Neuro-otology II
Thursday, May 1
7:30 a.m.–11:00 a.m.
Poster Discussion Session: General Neurology V
P6.001
Analyses of Neural
Autoantibodies by a Clinical Laboratory for
the Evaluation of Paraneoplastic and NonParaneoplastic Neuronal Disorders Valerie
Brachet, Malgorzata Jaremko, Brian
Sansoucy, Sat Dev Batish, Keith Morneau,
Zhenyuan Wang, Michael Levy, Kaylan
Burnham, Joseph Higgins
P6.002
Cross-cultural Comparison of
Stigma Toward Mental and Neurological
Disorders Laila Gharzai, Jennifer Harney,
Suzanne Higgins, Robin High, Liyan Xu,
Ashley Reynolds, Douglas Inciarte, Diego
Torres-Russotto
P6.003
Efficacy of Dalfampridine
in Hereditary Spastic Paraplegia: a
Prospective Open Study Nicolas
Collongues, Matthieu Bereau, Jean Baptiste
Chanson, Gregory Tio, Yon Andoni Echaniz
Laguna, Christel Depienne, Mathieu
Anheim, Jerome De Seze
P6.004
Multidisciplinary Management
of Cerebral Edema Associated with
Fulminant Hepatic Encephalopathy
in a Neurosciences Intensive Care
Unit Panayiotis Varelas, Riad Ramadan,
Chandan Mehta, Marlissa Hawley, Tamer
Abdelhak, Mohammed Rehman
P6.005WITHDRAWN
P6.006
Discharge Delays on an
Inpatient Neurology Service Ayush Batra,
Joel Salinas, Adam Cohen
P6.007
Taking Neurology to the
Underserved—a Pilot Initiative in an Urban
Homebound Program Ritesh Ramdhani,
Michelle Fabian, Ania Wajnberg, Linda
DeCherrie, Stephen Krieger
P6.008
Demyelinating Polyneuropathy (CIDP)
Sera Alter Regulators of Schwann Cell
Differentiation Abhijeet Joshi, Ilja Bobylev,
Christian Ritter, Andre Heinen, Helmar
Lehmann
P6.009
Methotrexate Induced
Cerebellar Leukoencephalopathy Christopher Goshgarian, Abdulrahman
Alwaki, Anibal Lugo, Kavita Grover
P6.010
Subclinical Primary Sjögren’s
Syndrome and Associated Peripheral
Neuropathy: Optimizing Diagnostic
Approach. Etienne Laverse, Amal
Samaraweera, Wan Fai Ng, James Miller
NEW! e
Poster Session: Child Neurology V
P6.011
Recurrent Stroke-like Events
Preceding the X-linked Charcot-MarieTooth Disease Diagnosis Tara Kimbason,
Arayamparambil Anilkumar, Oleg Bronov
P6.012
Abnormal White Matter
Connectivity in Children with Autism or
Sensory Processing Disorder: Overlap
and Divergence. Elysa Marco, YiShin
Chang, Julia Owen, Shivani Desai, Julia
Harris, Susanna Hill, Anne Arnette, Pratik
Mukherjee
P6.013
An Abbreviated Exposure
to Chronic Hypoxia Is Sufficient to Induce
CNS Hypomyelination and Impair Motor
Development in Neonatal Mice Jens
Watzlawik, Meghan Painter, Louisa Papke,
Robert Kahoud, William Carey, Moses
Rodriguez
P6.014Infraslow
Electroencephalography Changes in
Infantile Spasms Ken Myers, Luis BelloEspinosa, Morris Scantlebury
P6.015
Anti NMDA Receptor
Encephalitis (ANMDARE): Outcome in a
Cohort of 13 Children Jay Selman
General Neurology VI
P6.021
Postural Orthostatic
Tachycardia Syndrome (POTS) and its
associated symptoms Anindita Deb, Karen
Morgenshtern, Anna Hohler
P6.022
Neurological Sequelae of
Varicella Zoster Virus Infection ( VZV): Case
Series of Varied Presentations Shamaehah
Javed, Maheep Singh, Stephen Marks,
Ramandeep Sahni, Brij Ahluwalia-Singh
P6.023
Hashimoto’s Encephalopathy
Complicated by Cerebellar Ataxia: A Case
Report Michael Hossack, Perry Richardson
P6.024
Unusual Presentation of Acute
Carbon Monoxide Poisoning Shivnaveen
Bains, Derrece Reid, Xuemei Huang
104
P6.025
Dabigatran—the Future of
Cortical Venous Thrombosis Therapy—a
Case Series Study Thomas Mathew, Lobo
Alexander, Gosala Sarma, Raghunandan
Nadig
P6.026
Intrathecal Baclofen
Toxicity Mimicking Nonconvulsive Status
Epilepticus Glynnis Zieman, Richard Burns
P6.027
Case Report: Uncommon
Presentation of Neurosarcoidosis Ikjae
Lee, Pooja Khatri, Ady Kendler, Jennifer
Molano
P6.028
Central Pontine and
Extrapontine Myelinolysis: Risk Factors and
Clinical Expression in Liver Transplanted
Patients Silvia Favaretto, Annachiara
Cagnin, Cristina Crivellin, Patrizia Boccagni,
Umberto Cillo, Patrizia Burra, Marco Senzolo
P6.016
Novel Mechanism for
Monitoring Cerebral Hemodynamics
in Pediatric ECMO David Busch, Ann
McCarthey, Jennifer Lynch, Erin Buckley,
James Connelly, Maryam Naim, Daniel Licht
P6.017
Stiff Person Syndrome
in Childhood: SPS-C Recognition and
Review Bennett Lavenstein, Sarah Evans,
Olga Morozova
P6.018
A Rare Case of
Microcephaly-Capillary Malformation
Syndrome Diagnosed via Whole Exome
Sequencing Nassim Zecavati, Reem
Saadeh-Haddad, Cesar Santos, Chahira
Kozma
P6.029
Unusual Case of Delayed
Postpartum Preeclampsia Associated
with Reversible Splenial Lesion
Syndrome Pedro Oliveira, Osama Zaidat
P6.030
Hypercholesterolemia and
Neurological Diseases Related Mortality
in the NEDICES Cohort Fernando SierraHidalgo, Alvaro Sanchez-Ferro, Rocio
Trincado, Jaime Díaz Guzmán, Jesús
Hernández Gallego, Julian Benito-Leon,
Saturio Vega, Felix Bermejo-Pareja
P6.031
Atypical Presentation of
Posterior Reversible Encephalopathy
Syndrome Annapoorna Bhat, Machteld
Hillen
P6.032
Neurological Disorders In
Rosai-Dorfman Disease Coralie Casulli,
Nathalie Caucheteux, Agnes Fromont,
Caroline Antoniol, Ayman Tourbah, Thibault
Moreau
P6.019
Does Duration of Steroid
Treatment Matter in Pdiatric Optic
Neuritis? Himali Jayakody, Daniel Bonthius,
Reid Longmuir, Charuta Joshi
P6.020
Functional Neurological
Disorder in the Pediatric Emergency Room:
Characteristics, Outcome and Diagnostic
Accuracy Claudio De Gusmao, Rejean
Guerriero, Miya Bernson-Leung, Danielle
Pier, Patricia Ibeziako, Simona Bujoreanu,
Kiran Maski, David Urion, Jeffrey Waugh
P6.033
Olfactory Function of the
Patients with Psoriasis Ercan Karabacak,
Hakan Tekeli, Aytuğ Altundağ, Ersin Aydin,
Mustafa Kendirli, Murat Salihoglu, Melih
Çayonu, Halit Yasar
P6.034
The Need for Repeat
Diagnostic Testing for the Identification of
Ovarian Pathology in a Patient with antiNMDA Receptor Limbic Encephalitis Mona
Bahouth, Carlos Pardo-Villamizar, Michael
Johnston
P6.035
Quality Improvement:
Maintaining an Accurate Medication List by
Standardizing the Outpatient Medication
Reconciliation Method Christina Nguyen,
Zhi-Jian Chen
Poster Session VI
Guillain-Barre in a Small
Illinois Community: An Epidemiology
Perspective Valerie Arias, Benjamin
Claytor, Anand Oroskar, Mujtaba Akhter,
Jorge Kattah
P6.037
The Epidemiology of
Neuromyelitis Optica at a City Hospital in
the Bronx, New York Sylvia Mohen, Lenore
Ocava
P6.038
Symptomatic Vitamin D
Deficiency in Dubai Stephanie Ybanez,
Tania Tayah
P6.039
Hyperkalemic Periodic
Paralysis Masquerading as Sleep
Paralysis Yelena Gorfinkel Pyatkevich
P6.040
POEMS Syndrome Associated
with Autoimmune Limbic Encephalitis, an
Unusual Occurrence Niraj Arora, Rohini
Bhole, Enrique Aradillas
P6.041
Neuroscience Education
in the Medical College: The Qatar
Experience Leopold Streletz, Naim Haddad,
Ziad Kronfol, Joseph Safdieh, Basim
Uthman
P6.042
Posterior Reversible
Encephalopathy Syndrome and GuillainBarre Syndrome in a Pregnant Lady: A Case
Report from a Tertiary Teaching Hospital of
South India Dhairyawan Pokalkar, Veena
Narisetty, Sateesh Kamera, Sowjanya
Poosarla, Srilatha Siripuram
Movement Disorders:
Spinocerebellar Ataxias
P6.043
Spinal Cord Damage in
Machado-Joseph Disease Camila Fahl,
Lucas Branco, Felipe Bergo, Iscia LopesCendes, Marcondes Franca, Jr.
P6.044
The Evaluation of Swallowing
in Patients with Spinocerebellar Ataxia and
Oropharyngeal Dysphagia: A Comparison
Study of Videofluoroscopic and Sonar
Doppler Edna Marcia Abdulmassih, Helio
Teive, Rosane Sampaio Santos, Bianca
Simone Zeigelboim
P6.045
Polysomnographic Findings
in Machado-Joseph Disease: Evaluation
of 47 Patients José Luiz Pedroso, Diogo
Santos, Gilmar Prado, Lucila Prado, Luciane
Carvalho, Pedro Braga-Neto, Orlando
Barsottini
P6.046
De Novo Deletion of AFG3L2
Causing Spinocerebellar Ataxia Type
28 in the Context of Multiple Genomic
Anomalies Ken Myers, Jodi Chardon, Kym
Boycott
P6.047
Coenzyme Q10, Statin, and
Spinocerebellar Ataxias Sheng-Han Kuo,
Raymond Lo, Karla Figueroa, Stefan Pulst,
Susan Perlman, George Wilmot, Christopher
Gomez, Jeremy Schmahmann, Henry
Paulson, Vikram Shakkottai, Sarah Ying,
Theresa Zesiewicz, Khalaf Bushara, Michael
Geschwind, Guangbin Xia, S Subramony,
Tetsuo Ashizawa
P6.048
Audiological Evaluation in
Spinocerebelar Ataxia Hélio Teive, Bianca
Zeigelboim, Walter Arruda, Ari Jurkiewicz,
Denise França, Jair Marques, Hugo
Carvalho, Edna Marcia Abdulmassih
P6.049
Wide Spectrum of Clinical
Presentation of Spinocerebellar Ataxia
Type 2 Shilpa Kolli, Anna Sorokin, Duarte
Machado
P6.050
Widespread Cerebral
Cortical Damage in Machado-Joseph
Disease Thiago Rezende, Anelyssa
D’Abreu, Rachel Guimarães, Iscia LopesCendes, Tátila Lopes, Gabriela Castellano,
Marcondes Franca, Jr.
P6.051
Dystonia in Machado-Joseph
Disease: Clinical Features and Levodopa
Response Marcelo Nunes, Alberto
Martinez, Iscia Lopes-Cendes, Anelyssa
D’Abreu, Marcondes Franca, Jr.
P6.052
Treatment of Spinocerebellar
Ataxia with Intravenous Immune Globulin
(IVIG) Theresa Zesiewicz, Tuan Vu, Kelly
Sullivan, Clifton Gooch, Israt Jahan,
Christopher Ward, Seok Kim
Movement Disorders:
Miscellaneous Ataxias
P6.053
Paroxysmal Dysarthria and
Ataxia After Treatment of Brainstem
Encephalitis James Klaas, Christopher
Boes, Allen Aksamit
P6.054
Sporadic Cerebellar GADAtaxia: A Retrospective Analysis Pezhman
Roohani, Adam Rizvi, Sara Mayer, Khalaf
Bushara
P6.055
Elevated Thyroid Antibody
Associated Sporadic Cerebellar Ataxia: A
Retrospective Analysis Pezhman Roohani,
Jamie Starks, Nik Haliza Nik Hassan, Khalaf
Bushara
P6.056
Autoimmune Cerebellar
Degeneration with Voltage Gated Calcium
Channel Antibodies: A Case Report and
Study of Antibody Reactivity Marilyn
McKasson, Stacey Clardy, Mark Bromberg,
Noel Carlson, John Greenlee
P6.057
Cerebellar Ataxia with
CoQ10 deficiency Due to a Novel Mutation
in ADCK3 Emanuele Barca, Olimpia
Musumeci, Lorenzo Peverelli, Anna Ciranni,
Salvatore DiMauro, Michio Hirano, Catarina
Maria Quinzii, Antonio Toscano
P6.058
A Novel Spinocerebellar
Ataxia with Hematologic Cytopenias:
Linkage Analysis and Exome Sequencing
Identifies a Candidate Gene Dong-Hui
Chen, Piper Below, Youngmee Sul, Mark
Matsushita, John Wolff, Emily Bonkowski,
Wendy Raskind, Thomas Bird
P6.059
iPatax: A New Method
for Quantitative Assessment for Motor
Coordination of Ataxia Masayoshi Tada,
Jun Tokunaga, Takahiro Nagai, Masatoyo
Nishizawa, Osamu Onodera
P6.060
Mutations in PNPLA6
Cause a Range of Neurodegenerative
Phenotypes Stephan Zuchner, Matthis
Synofzik, Marie Coutelier, Charles Marques
Lourenço, Tobias Haack, Rebecca Schüle,
Wilson Marques Junior, Ludger Schols,
Giovanni Stevanin
P6.061
Spinocerebellar Ataxias
with Hypogonadism: Unraveling a Novel
Group of Inherited Neurometabolic
Disorders Charles Lourenco, Claudia
Sobreira, Roberto Giugliani, Stephan
Zuchner, Wilson Marques, Jr.
P6.062
The Use of Adjustments
to Facilitate the Written in Patients
Diagnosed with Spinocerebellar
Ataxia Thais Canelossi Rosa, Renato
Nickel, Paulo Liberalesso, Helio Teive
Movement Disorders:
Parkinson’s Disease Imaging
P6.063
Cognitive Associations of
White Matter Hyperintensities in NonDemented Parkinson’s Disease Patients: A
Voxel-Wise Lesion Probability Study Elijah
Mak, Michael Dwyer, Deepa Ramasamy,
Wing Au, Louis Tan, Robert Zivadinov,
Nagaendran Kandiah
P6.064
A Longitudinal (11C)(±)
Dihydrotetrabenazine PET Study of
Gender Difference in the Progression
of Dopaminergic Dysfunction in the
Parkinsonian Caudate Nandhagopal
Ramachandiran, Michael Schulzer, Lisa
Kuramoto, Jacquelyn Cragg, Vesna Sossi,
Raúl de la Fuente-Fernández, A Stoessl
P6.065
Hyperechogenicity of
Substantia Nigra: A Potential Disease
Progression Marker in Early Onset
Parkinson’s Disease (EOPD) Balaji
Krishnaiah, Kala Venkiteswaran, Vikram
Shivkumar, Timothy Gilmour, Nitish Harid,
Robert Saadi, Thyagarajan Subramanian
P6.066
Mapping Track Density
Changes in Nigrostriatal and Extranigral
Pathways in Parkinson’s Disease Gaëtan
Garraux, Erik Ziegler, Maud Rouillard, Elodie
André, Tim Coolen, Johan Stender, Evelyne
Balteau, Christophe Phillips
P6.067
Subcortical Atrophy Is
Associated with Cognitive Impairment
in Mild Parkinson’s Disease: A Combined
Volumetric and Vertex-Based Shape
Analysis Study Elijah Mak, Niels
Bergsland, Robert Zivadinov, Kandiah
Nagaendran
P6.068
Cerebellar Atrophy in Patients
with Parkinson´s Disease Using the SUIT
Tool for Voxel-Based Morphometry Camila
Piccinin, Maria Cristina Santos, Luiza
Piovesana, Rachel Guimaraes, Brunno
Campos, Lidiane Campos, Paula Azevedo,
Fabio Torres, Marcondes Franca Jr, Augusto
Amato-Filho, Iscia Lopes-Cendes, Fernando
Cendes, Anelyssa D’Abreu
P6.069
Quantitative MRI Biomarker
Study in Parkinson’s Disease: High-field
1H-MR Spectroscopic and Multi-Modal
MRI Longitudinal Study of the Substantia
Nigra Navid Seraji-Bozorgzad, Fen Bao,
Natalya Shneyder, Edwin George, Carla
Santiago Martinez, Veronica Gorden, Shana
Krstevska, Christina Caon, Omar Khan
P6.070
Accuracy and Diagnosis Cutoff
Points of 123I-metaiodobenzylguanidine
Myocardial Scintigraphy for Lewy Body
Disease Diagnoses in Parkinsonian
Syndromes: A Study of 62 Consecutive
Patients in an Expert Center. Guillaume
Lamotte, Adrien Lebasnier, Denis Agostini,
Gilles Defer
P6.071
Multi-Modal High-Field
MRI Longitudinal Study of the Deep Gray
Matter, Frontal Lobe, and Corpus Callosum
in Parkinson’s Disease. Raeesa Khan, Fen
Bao, Natalya Shneyder, Navid SerajiBozorgzad, Krishna Thakore, Carla Santiago
Martinez, Veronica Gorden, Edwin George,
Shana Krstevska, Omar Khan
P6.072
Therapeutic Occupany of the
Dopamine Receptor Agonist Pramipexol
in Parkinson´s Disease (18F-Fallypride PET
study) Angela Deutschlaender, Christian
La Fougere, Guoming Xiong, Kai Bötzel, Paul
Cumming
Movement Disorders: Deep Brain
and Other Stimulation/Imaging
and Other Biomarkers
P6.073
Stimulating Frontostriatal
Circuitry to Treat Motor and Non-Motor
Symptoms of Parkinson’s Disease Nolan
Williams, Baron Short, Alexandra Jeffery,
Emily Williams, Colleen Hanlon, Gregory
Sahlem, Jeffery Korte, Gonzalo Revuelta,
Mark George
P6.074
Tinnitus After Deep Brain
Stimulation Surgery, a Case Series Umer
Akbar, Geoffrey Panjeton, Patrick Antonelli,
Pam Zeilman, Takashi Morishita, Michael
Okun
P6.075
Clinical Manifestations of
Tolerance to Deep Brain Stimulation Deepal Shah, Joohi Jimenez Shahed
P6.076
Use of Interleaving in Deep
Brain Stimulator Programming in Patients
with Movement Disorders Joohi Jimenez
Shahed, Olga Waln
P6.077
Clinical Significance of
Abnormal Electrode Impedance Readings
in Deep Brain Stimulation for Treatment
of Movement Disorders Olga Waln, Joohi
Jimenez Shahed
P6.078
A Case of Dystonic Head
Tremor Treated with Bilateral Globus
Pallidus Pars Interna Deep Brain
Stimulation Joanna O’Leary, M Brodsky
P6.079
Parkinson’s Disease Is
Associated with Enhanced Pain-Related
Disability and the Selective Loss of Gray
Matter in Subcortical Regions of the Brain
Related to Pain Processing Andrew Ahn,
Jared Tanner, Ann Horgas, Michael Okun,
Catherine Price
P6.080
Effect of Laterality in
Parkinson`s Disease: A Voxel-based
Morphometry Study Maria Cristina Arci
Santos, Lidiane Campos, Rachel Guimaraes,
Camila Piccinin, Paula Azevedo, Luiza
Piovesana, Brunno Campos, Augusto
Amato-Filho, Fernando Cendes, Anelyssa
D’Abreu
105
Thursday
May 1
P6.036
Thursday, May 1
P6.081(18F)FDG PET, (18F)FP-CIT
PET and MR Morphometry in Lewy Body
Dementia: Comparison with Alzheimer
Disease Hyunjin Kim, Seok Min Kim, Hyuk
Jin Yun, Sujeong Kim, Doris Doudet, JongMin Lee, Chong S. Lee
P6.082
Delivery of GDNF to the Brain
by Novel Nanovesicles for the Treatment
of Parkinson’s Disease Eliahu Heldman,
Sarina Grinberg, Charles Linder, Mary
Popov, Irwin Hollander
Neuropathy:
Imaging and Biomarkers
P6.083
High Resolution Ultrasound in
Combat-Related Peripheral Nerve Injuries:
A Case Series Jonathan Smith, Matthew
Miller, Craig Carroll, Walter Faillace, Leon
Nesti, Christina Cawley, Mark Landau
P6.084
Accuracy of Ultrasound
for Diagnosis of Carpal Tunnel
Syndrome in Patients with Bifid Median
Nerve Jonathan Beary, Seby John, Youran
Fan, Steven Shook
P6.085
Distinctive Patterns of
Sonographic Nerve Enlargement in
Charcot-Marie-Tooth type 1A and
Hereditary Neuropathy with Pressure
Palsies. Stephan Goedee, Geert
Brekelmans, Leonard Van den Berg,
Leendert Visser
P6.086
Peripheral Nerve Ultrasound
in Small Fiber Neuropathy Hamid Ebadi,
Hans Katzberg, Mylan Ngo, Vera Bril
P6.087
Neuromuscular Ultrasound
Findings in Eosinophilic Fasciitis Sarah
Stone, Lisa Hobson-Webb, Justin Mhoon,
Amanda Guidon, Carolina De Jesus-Acosta,
Michael Cartwright
P6.088
The Value of Including Sweat
Gland Nerve Fiber Density (SGNFD)
Analysis in the Neuropathy Workup Amiram Katz, Janet Berkley
P6.08999mTc-DPD
Cardiac Scintigraphy in Familiar
Amyloidosis Suzane Ferreira, Caroline
Amaral, Osvaldo Nascimento, Claudio
Tinoco, Ribeiro Sandra, Victor Kosac,
Frederico Prado
P6.090
Blood Pressure Dipping During
the Deep Breathing Maneuver (BPDB)
While Supine May be a Marker of Severe
Sympathetic Denervation Alexandru
Barboi, Vivialyn Cadell
P6.091
Increased Frequency
of Rhabdomyolysis in Familial
Dysautonomia Jose-Alberto Palma, Lucy
Norcliffe-Kaufmann, Felicia Axelrod, Horacio
Kaufmann
P6.092
Subacute Onset of Severe
CIDP Weakness Associated with Tumorlike Nerve Root Involvement: A Case
Report Sharon Stoll, Goran Rakocevic
Neuromuscular Disease
P6.093
Peripheral Neuropathy (PN)
in Individuals with Neurofibromatosis
Type 1 (NF1) and Plexiform Neurofibromas
(PNF) Tanya Lehky, Justin Kwan, Eva
Dombi, Andrea Baldwin, Srivandana
Akshintala, Andy Gillespie, Brigitte
Widemann
P6.094
Evaluation of Central
and Peripheral Neuropathy in Type 2
Diabetes: A Case-Control Study Prasanna
Venkatesan Eswaradass, Ramadoss
Kalidoss
P6.095
Idiopathic Peripheral
Neuropathy and Subsequent Development
of Diabetes Mellitus Ritika Mahajan, Molly
King
P6.096
Opioid Usage in Peripheral
Neuropathy: A Population-Based
Study E. Matthew Hoffman, Nathan Staff,
Christopher Klein
P6.097
Reference Attributes of Nerve
Conduction and Ethnicity: Comparison in
Northern Plain Indians, Mexican Americans
and Caucasians Rajat Lahoria, William
Litchy, P. James B. Dyck, Jenny Davies,
Rickey Carter, Peter Dyck
P6.098
A Population-Based
Epidemiologic Study of Adult
Neuromuscular Disease in the Republic of
Ireland Stela Lefter, Orla Hardiman, Aisling
Ryan
P6.099
Cost of Hospitalization of Elderly
Myasthenia Gravis Patients Treated with
Plasmapheresis from 1992 to 2009 Sedeek
Elmoursi, Mohammad El-Ghanem, Ankit
Pahwa, Wenzhuan He, Nizar Souayah
P6.100
Emerging Epidemiological
Trends of Autoimmune Myasthenia Gravis
in Connecticut Matthew Imperioli, Agnes
Acsadi
P6.101
Fainting in Teenagers Is not
Always Faking Sreenivas Avula, Manikum
Moodley
P6.102
CNS Toxoplasmosis: A Serious
Complication of Immunotherapy in the
Neuromuscular Patient Dan Bernardo,
Nizar Chahin
P6.103
Fingolimod (FTY720) Oral for
the Treatment of Chronic Inflammatory
Demyelinating Polyradiculoneuropathy
(CIDP): Study Design of the Phase 3
FORCIDP Trial Hans Hartung, Gen Sobue,
Marinos Dalakas, Norman Latov, Jean-Marc
Leger, Ingemar Merkies, Eduardo NobileOrazio, Katherine Agoropoulou, Dieter
Häring, Lixin Zhang-Auberson, Philipp Von
Rosenstiel, Richard Hughes
P6.104
Characteristics of
Muscle Cramps in Patients with
Polyneuropathy Hans Katzberg, Sarah
Maxwell, Seint Kokokyi, Hamid Ebadi, Ari
Breiner, Vera Bril
P6.105
Electrodiagnostic Profile of
Demyelination in Diabetic Neuropathy:
A novel approach Zubeda Sheikh, Ankit
Pahwa, Hongxin Chen, Nizar Souayah
106
7:30 a.m.–11:00 a.m.
P6.106
West Nile Virus
Encephalomyelityis Simulating Brain
Death Channaiah Srikanth-Mysore, John
Bertoni, Pariwat Thaisetthawatkul, Matthew
White, Jose Americo Fernandes-Filho
P6.107
Zoster Associated Limb
Paresis (ZALP) Is Associated with
Prolonged Weakness and Pain: A Natural
History Study Alex Nelson, James Watson,
Haatem Reda, Lyell Jones
P6.108
Branching Enzyme Deficiency:
Expanding the Clinical Spectrum Carmen
Paradas, Orhan H. Akman, Carolina Ionete,
Heather Lau, Peter Riskind, David Jones,
Thomas Smith, Michio Hirano, Salvatore
DiMauro
P6.109
Oxidative Metabolism
During Forearm Exercise in McArdle
Disease Ronald Haller, Lydia Sharp, Lauren
Phillips, Marta Newby, Phil Wyrick, Katja
Heinicke
P6.110
The Pattern of Pain in Carpal
Tunnel Syndrome Follows a Bell-shaped
Curve Benn Smith, Mark Ross, Brent
Goodman, Greg Thaera, Jonathan
McKinnon
P6.111
When Expected Turns
Unexpected: A Case of Subacute
Progressive Weakness and Paresthesias
of the Distal Lower Extremities Following
a Brief Diarrheal Episode. Divpreet Kaur,
Yadira Velazquez-Rodriguez, Aiesha Ahmed
Disease: Neuroimaging
P6.112
Clinical Impact of Brain Tissue
Damage Quantified by Fully Automated
Analysis of MR Images in Patients with
Multiple Sclerosis Alaleh Raji, Gerhard
Winkler, Lothar Spies, Anja Tewes, Roland
Opfer
P6.113
Sub-optimal Response to
Therapy in Disease-free MS Patients:
A Paradox? Fernando Figueira, Gustavo
Figueira, Paula Soares
P6.114
Longitudinal Effects of
Interferon-beta-1a Treatment on Cortical
Thickness in Relapsing-Remitting Multiple
Sclerosis Patients Anat Achiron, Chen
Hoffmann, Yael Nissan, Shmuel Miron
P6.115
Associations Between
Changes in Ferritin Levels and
Susceptibility-Weighted Imaging Filtered
Phase in Patients with Relapsing-Remitting
Multiple Sclerosis over Six Months Therapy
with Interferon Beta-1a Michael Dwyer,
Robert Zivadinov, Silva Markovic-Plese,
Niels Bergsland, Mari Heininen-Brown,
Ellen Carl, Cheryl Kennedy, Bianca
Weinstock-Guttman, Brooke Hayward,
Fernando Dangond
P6.116
Evolution of Corpus
Callosum Index in Patients with Relapsing
Remiting Multiple Sclerosis Treated with
Natalizumab Eva Costa Arpin, Tania Garcia
Sobrino, Clara Dominguez Vivero, M. C.
Amigo, Jose Prieto, Ana Rodriguez Regal,
Manuela Lema Bouzas
P6.117
Corpus Callosum Volume
Change in the First Year Is the Strongest
Predictor of 9-year Clinical Disability
in Multiple Sclerosis Dana Horakova,
Tomas Kalincik, Jan Krasensky, Manuela
Vaneckova, Zdenek Seidl, Eva Havrdova
P6.118
A New Composite Scale of
MRI-defined Disease Severity in Multiple
Sclerosis Mohit Neema, Antonia Ceccarelli,
Brian Healy, Bonnie Glanz, Shahamat
Tauhid, Gloria Kim, Jennifer Miller, Rohit
Bakshi
P6.119
Fully Automated Detection
and Quantification of T1 Hypointense
Lesions in Multiple Sclerosis Alaleh Raji,
Gerhard Winkler, Lothar Spies, Anja Tewes,
Roland Opfer
P6.120
Cerebellar and Brain
Gray-Matter Damage Predicts Fatigue in
Multiple Sclerosis Alfredo Damasceno,
Benito Damasceno, Fernando Cendes
P6.121
Abnormal White Matter
Fraction Predicts Cognitive Dysfunction in
Multiple Sclerosis Patients Manuela de
Stefano, Francesco Patti, Luigi Lavorgna,
Patrizia Montella, Silvia Messina, Chisari
Clara Grazia, Domenico Ippolito, Roberta
Lanzillo, Giuseppe Salemi, Paola Valentino,
Gabriella Coniglio, Maria Buccafusca,
Damiano Paolicelli, D’Ambrosio Alessandro,
Vincenzo Brescia Morra, Giovanni Savettieri,
Bruno Alfano, Antonio Gallo, Isabella
Simone, Mario Zappia, Panetta Valentina,
Simona Bonavita, Gioacchino Tedeschi
P6.122
Diffusional Kurtosis MRI
Correlates of Cognitive Functions in
Primary-Progressive MS Maria Petracca,
Heidi Bender, Colleen Farrell, Roxana
Teodorescu, Jonathan Howard, Claire Riley,
Johanna Cahall, Franchesca Arias, Michelle
Fabian, Fred Lublin, Matilde Inglese
P6.123
Functional Correlates of
Impaired Working Memory in MS Patients:
A Multicentre Study Alvino Bisecco, Maria
Rocca, Paola Valsasina, Khaled Abdel-Aziz,
Frederik Barkhof, Christian Enzinger, Franz
Fazekas, Antonio Gallo, Hanneke Hulst,
Xavier Montalban, Nils Muhlert, Gianna
Carla Riccitelli, Alex Rovira, Gioacchino
Tedeschi, Giancarlo Comi, Massimo Filippi
P6.124
Cognitive Reserve in Multiple
Sclerosis Modulates Hippocampal
Functional Connectivity and Protects from
Memory Deficits Maria Rocca, Alessandro
Meani, Paola Valsasina, Gianna Carla
Riccitelli, Mariaemma Rodegher, Bruno
Colombo, Andrea Falini, Giancarlo Comi,
Massimo Filippi
P6.125
Iron in the Deep Gray Matter:
Association with Cognitive Impairment in
Multiple Sclerosis Claire Modica, Robert
Zivadinov, Michael Dwyer, Niels Bergsland,
Andre Weeks, Ralph Benedict
P6.126
Brain White Matter Tract
Microstructural Alterations in Multiple
Sclerosis Patients with Depression
and Fatigue: A Diffusion Tensor MRI
Study Gianna Riccitelli, Maria Rocca,
Emanuele Pravatà, Elisabetta Pagani, Marta
Radaelli, Claudio Gobbi, Filippo Martinelli
Boneschi, Andrea Falini, Giancarlo Comi,
Massimo Filippi
Poster Session VI
P6.127
Contribution of Global and
Regional Damage of the Gray and White
Matter to Fatigue in MS Laura Parisi,
Maria Rocca, Elisabetta Pagani, Bruno
Colombo, Vittorio Martinelli, Andrea Falini,
P6.128
Network Efficiency as a Final
Common Pathway for Cognitive Deficits
in Multiple Sclerosis: A Single Network
Graph Theory Study Matteo Pardini, Varun
Sethi, Nils Muhlert, Oezguer Yaldizli, Fulvia
Palesi, Daniel Altmann, Maria Ron, Claudia
Wheeler-Kingshott, David Miller, Declan
Chard
P6.129
Microstructural Damage to
NAWM and GM But Not to Cortical Lesions
Contributes to Cognitive Impairment in
Multiple Sclerosis: A Diffusion Tensor
MRI Study Maria Elisa Morelli, Maria
Rocca, Elisabetta Pagani, Paolo Preziosa,
Massimiliano Copetti, Mariaemma
Rodegher, Federica Esposito, Andrea Falini,
P6.130
Patterns of Regional Gray
Matter and White Matter Atrophy in
“Cortical Multiple Sclerosis” Laura Parisi,
Maria Rocca, Flavia Mattioli, Ruggero
Capra, Massimo Filippi
P6.131
The Rate of New GM Lesion
Development Is Similar in all MS Disease
Subtypes Rasha Abdel-Fahim, Olivier
Mougin, Christopher Allen, Alain Pitiot,
Penny Gowland, Nikos Evangelou
P6.132
Global and Regional Brain
Concentration of Intra- and Extracellular Sodium in MS: A 7 Tesla MRI
Study Lazar Fleysher, Roxana Teodorescu,
Maria Petracca, Laura Jonkman, Niels
Oesingmann, Joseph Herbert, Matilde
Inglese
P6.133
Accrual and Evolution of
Cortical Gray Matter Lesions in People with
Relapse-onset Multiple Sclerosis Varun
Sethi, Tarek Yousry, Nils Muhlert, Daniel
Tozer, Daniel Altmann, Maria Ron, Claudia
Wheeler-Kingshott, David Miller, Declan
Chard
P6.134
MRI-Based Detection and
Characterization of Leptomeningeal
Contrast Enhancement in Multiple
Sclerosis Luisa Vuolo, Martina Absinta,
Elizabeth Sweeney, Daniel Reich
P6.135
The Use of BigBrain in MS: An
Ultrahigh-resolution 3D Template for Grey
Matter MRI Segmentation Shuang Liu,
Christina Azevedo, Daniel Pelletier
P6.136
A Robust and Fast Algorithm
for Quantifying Spinal Cord Cross-sectional
Area in Myelitis Govind Nair, Winston
Liu, Raya Massoud, Daniel Reich, Steven
Jacobson
P6.137
Relationship Between Spinal
Cord Atrophy and Brain Cortical Lesions
in Primary-Progressive MS Roxana
Teodorescu, Maria Petracca, Colleen Farrell,
Jonathan Howard, Claire Riley, Michelle
Fabian, Fred Lublin, Matilde Inglese
P6.138
The Neurofunctional Basis
of Sensorimotor Preservation in Multiple
Sclerosis Victoria Leavitt, James Sumowski
P6.139
Normal Appearing White
Matter Injury in MS Is Affected by
the Distance to the Nearest Cortical
Lesion Nikos Evangelou, Rasha AbdelFahim, Olivier Mougin, Justina Ruksenaite,
Abigail Lazenbury, Penny Gowland, Alain
Pitiot
Risk Factors for MS Disease
and Course
P6.140
Level of Homocysteine,
Homocysteine Thiolactone and Antibodies
Against N-homocysteinylated Proteins
in Patients with Multiple Sclerosis Anna
Jamroz-Wisniewska, Jerzy Beltowski,
Konrad Rejdak, Halina Bartosik-Psujek
P6.141
Smoking Cessation and
Disability Progression in Multiple Sclerosis:
An Observational Cohort Study Cris
Constantinescu, Ali Manouchehrinia, Radu
Tanasescu, John Britton
P6.142
Serum Lipid and
Antiphospholipid Antibodies Profiles
in Different Phases of Multiple
Sclerosis Tatiana Koudriavtseva, Chiara
Mandoj, Giovanni Cigliana, Giovanna
D’Agosto, Paola Cordiali-Fei, Laura Conti
P6.143
Multiple Sclerosis and
Premorbid Risk Behaviour: Association Is
Not Necessarily Causation Christopher
Hawkes, David Boniface
P6.144
Vitamin D and Multiple
Sclerosis: Are We Still in the
Dark? Michael Douglas, Lindsay Durant,
Ghaniah Hassan-Smith, James Hodson,
John Curnow, Atalanti Tsentemeidou
P6.145
Vitamin D Deficiency in
Multiple Sclerosis: Possible Influence
of Circulating Vitamin D Binding Protein
Levels. Suhail Al-Shammri, Abayomi
Akanji, Arpita Chattopadhyay, Chetana
Madala, Reema Mathew
P6.146
Modulating Effects of WT1
on the Relationship Between Interferon-β
and Vitamin D Levels in the Patients with
Multiple Sclerosis Rui Lin, Steve Simpson,
Jr., Jac Charlesworth, Ingrid van der Mei,
Leigh Blizzard, Niall Stewart
P6.147
The Role of Vitamin D in Optic
Neuritis—an Update Jodie Burton, Jessie
Trufyn, Chelsia Tung, Misha Eliasziw, Fiona
Costello
P6.151
Identification of Clostridium
Perfringens Epsilon Toxin as a Candidate
Trigger for New Lesion Formation in
Multiple Sclerosis Timothy Vartanian,
Kareem Rumah, Jennifer Linden
P6.152
Effects of a Low Fat Plant
Based Diet in Multiple Sclerosis (MS):
Results of a 1-year Long Randomized
Controlled (RC) Study Vijayshree Yadav,
Gail Marracci, Edward Kim, Rebecca Spain,
Michelle Cameron, Shannon Overs, John
McDougall, Jesus Lovera, Dennis Bourdette
P6.153
Expression of Multiple
Sclerosis Susceptible Loci Genes
May Assist in Diagnostic Decision
Making Michael Gurevich, Gadi Miron, Erez
Hanael, Anat Achiron
P6.154
A Multiple SclerosisAssociated Single Nucleotide
Polymorphism in the MERTK Receptor
Is Correlated with Altered MERTK
Expression Trevor Kilpatrick, Michele
Binder, Judith Field, Helmut Butzkueven,
Melissa Gresle
P6.155
Is it Worth it to Study Families
with Multiple Sclerosis (MS)? the Case of a
Novel Rare Variant in a Novel Unexpected
Interferon-stimulated Gene. Filippo
Martinelli Boneschi, Federica Esposito,
Ana-Maria Osiceanu, Melissa Sorosina,
Davide Cittaro, Dejan Lazarevic, Elia Stupka,
Giancarlo Comi
P6.156
CD58 and Multiple Sclerosis:
Genetic Association, Gene Expression and
Prognostic Value Michael Hecker, Jana
Blaschke, Paul Blaschke, Brit Fitzner, Dirk
Koczan, Hans-Juergen Thiesen, Uwe Zettl
P6.157
An Analysis of Novel
Antibody Repertoires in Patients with
Multiple Sclerosis: Do Particular Antibody
Genes Recognize Gray Matter Cellular
Targets? Ann Ligocki, William Rounds,
Min Li, Paul Henson, Donna Graves, Elliot
Frohman, Ann Stowe, Jacqueline Rivas,
Alyssa Guzman, Sally Ward, Benjamin
Greenberg, Nancy Monson
P6.158
Molecular Network of ChIPSeq-Based EBNA1-Target Cellular Genes
Supports Biological Implications of EBV
Persistence in Multiple Sclerosis Jun-ichi
Satoh, Yoshihiro Kino
MS Symptoms and Comorbidities
P6.148
Vitamin D, B-Cell
Immunoreactivity, and B-Cell Phenotypes
in Cerebrospinal Fluid of Patients with
Multiple Sclerosis Brigitte Wildemann,
Alexander Schwarz, Mirjam KorporalKuhnke, Sven Jarius, Juergen Haas
P6.159
P6.149
P6.160
Dietary Saturated Fatty
Acids Promote Differentiation of
Th1 and Th17 Cells and Aggravate
Neuroinflammation Ralf Linker, Markus
Kleinewietfeld, De-Hyung Lee, Dominik
Muller, Arndt Manzel
P6.150
Sodium Intake Is Associated
with Increased Disease Activity in Multiple
Sclerosis Mauricio Farez, Marcela Fiol,
Maria Gaitan, Francisco Quintana, Jorge
Correale
Gustatory Dysfunction in
Multiple Sclerosis Richard Doty, Isabelle
Tourbier, Fidias Leon-Sarmiento, Jayaram
Udupa, Bilge Karacali, Gul Moonis, Evan
Beals, Laura Fabius, Taehoon Kim, Bala
Palecanda, Andre Souza
Multiple Sclerosis Reported
Fatigue: Obstructive Sleep Apnea and
Abnormalities in Sleep Architecture in
a Community Cohort Mark Gudesblatt,
Myassar Zarif, Barbara Bumstead, Lori
Fafard, Marijean Buhse, Steven Brass,
Konstantina Bardhi, Steven Xian
P6.161
Visual Field Defects
in Multiple Sclerosis and Related
Disorders Dong Joo Yun, Jae-Gyu Kwak,
Byoung-Joon Kim
P6.162
Multiple Sclerosis
Exacerbation Presenting as Stress
Cardiomyopathy Tyler Webb, Tania Reyna,
Robert Blair, Robert Foreman
P6.163
Headache in Multiple
Sclerosis: Features and Implications for
Disease Management Jessica Wilcox,
David Tabby, Muhammad Hassan Majeed,
Branden Youngman
P6.164
Neuropathic Pain in Multiple
Sclerosis: A Contact Heat Evoked Potential
Stimulator (CHEPS) Evaluation Victor
Kosac, Osvaldo Nascimento, Frederico
Prado, Andre Matta, Eduardo Davidovich,
Bruno Coutinho, João Dib
P6.165
Longitudinal Changes of
Olfactory and Gustatory Function in
Patients with Multiple Sclerosis Felix
Schmidt, Christian Gertz, Florian Uecker,
Lutz Harms
P6.166
Multiple Sclerosis
Compromises Various Aspects of Female
Sexual Function Julia Koehn, Ralf Linker,
Tassanai Intravooth, Carl Crodel, Martina
Deutsch, De-Hyung Lee, Max Hilz
P6.167
Head-up Tilt Test, R-R Interval
Variation and Sympathetic Skin Response
in the Assessment of the Autonomic
Nervous System of Patients With Multiple
Sclerosis Hizir Ulvi
P6.168
Metabolic Syndrome
and Disability in Multiple Sclerosis: A
Retrospective Study Idanis Berrios
Morales, Chutima Saipetch, Anya Turetsky,
Kevin Kane, Neeta Garg, Peter Riskind
P6.169
Multiple Sclerosis and
Stroke Eleanor Sung, Lilyana Amezcua,
Steven Cen, Aaron Krug, Nerses Sanossian
P6.170
Prevalence of Thyroid Disease
in a Multiple Sclerosis Clinic Cohort Donald
Barone, Serge Khelemsky, Decosy Hercules,
Kathleen Barone
P6.171
A Study of Insulin Resistance
in Multiplesclerosis Subjects and Healthy
Controls Myla Goldman, Scott Koenig,
Rebecca Yeamans, Karen Johnston
P6.172
Multiple Sclerosis Patients
with Allergies Demonstrate Better Physical
Outcomes But Worse Psychological
Symptoms. Sahil Gupta, Katelyn Kavak,
Barbara Teter, Bianca Weinstock-Guttman
P6.173
Right Under Our Noses:
Olfactory Pathology in Central Nervous
System Demyelinating Diseases Gabriele
De Luca, Albert Joseph, Jithin George,
Richard Yates, Marie Hamard, Margaret
Esiri
P6.174
Deterioration or Improvement
of Depression in Women Is Associated
with Site and Size of Multiple Sclerosis
Lesions Klemens Winder, Tobias
Engelhorn, Ingrid Wagner, Carl Crodel,
Martina Deutsch, Julia Koehn, Ralf Linker,
De-Hyung Lee, Max Hilz
P6.175
Functional Limitations
Associated with Multiple Sclerosis:
Findings from the US Medical Expenditure
Panel Survey Joseph Menzin, Matthew
Sussman, Monica Fay, Terrie Livingston,
Glenn Phillips, Ravi Iyer
107
Thursday
May 1
Thursday, May 1
P6.176
Increased Incidence of Breast
Cancer in Multiple Sclerosis: The Influence
of Vitamin D and Estrogen in MS-Breast
Cancer Concordance Jacquelyn Laplant,
Robert Knobler
P6.177
Smoking in Multiple Sclerosis
Patients Is Negatively Associated
with Patient Perceived Psychosocial
Factors Katelyn Kavak, Barbara Teter,
P6.178
Risk of Mood Changes with
High Dose Corticosteroid Treatment
for Demyelinating Event in Multiple
Sclerosis Sarah Morrow, Jennifer Barr,
Heather Rosehart, Manera May, Sandra
Ulch
P6.188
The Outcome of Preconceptual
Counselling in Women with Epilepsy. Ellen
Campbell, Beth Irwin, Inez Cooke, Stephen
Hunt, John Craig, Jim Morrow
P6.189
The Effect of Valproate and
Lamotrigine Monotherapy on Bone Health
in Adult Epileptic Patients Mohammad
Alhalabi, Ola Albaghdadi, Zaynab Alourfi,
Lama Youssef
MEG and Imaging
P6.190
Quality of Life and Comorbidities
Response-driven Models
based on MRI and SPECT findings on
Hippocampus for Lateralization of
Temporal Lobe Epilepsy Mohammadreza
Nazemzadeh, Jason Schwalb, Kost
Elisevich, Hassan Bagher-Ebadian, Hamid
Soltanian-Zadeh
P6.179
P6.191
Patient and Caregiver
Quality of Life in Psychogenic NonEpileptic Seizures Compared to Epileptic
Seizures Ioannis Karakis, Georgia
Montouris, Charitomeni Piperidou, Marta
San Luciano, Kimford Meador, Andrew Cole
P6.180
Impact of Seizure Frequency
Reduction on Health-Related Quality of
Life Among Clinical Trial Subjects with
Refractory Partial-Onset Seizures: A
Pooled Analysis of Phase III Clinical Trials
of Eslicarbazepine Acetate Kathryn
Anastassopoulos, Fulton Velez, Rui Sousa,
T. Christopher Bond, Xuezhe Wang, David
Blum, Joyce Cramer
P6.181
Quality of Life and Sleep in
Young Male Patients with Epilepsy Hakan
Tekeli, Halit Yasar, Semih Alay, Mustafa
Kendirli, Mehmet Senol, Turker Turker,
Mehmet Saracoglu
P6.182
STOP-BANG Screening for
Obstructive Sleep Apnea in Epilepsy Joon
Kang, Maromi Nei
P6.183
Effects of Lacosamide on
Sleep Parameters in Healthy Subjects:
Results from an Open-label Study John
Hudson, Stephen Yates, Paulette Williams,
Jeff Guptill, William Byrnes, Neil D’Cruz
P6.184
Systematic Review of the
Impact of Rapid Eye Movement Sleep on
Seizure Frequency Marcus Ng, Milena
Pavlova
P6.185
Do Antidepressants Make
Seizures More or Less Likely in Focal
Epilepsy Patients Undergoing Elective
EEG Monitoring? Alyssa Brandt, Rachel
Godfred, Mihir Parikh, Alan Haltiner,
Nicole Fortier, Lisa Caylor, Jehuda Sepkuty,
Michael Doherty
P6.186
Does Vitamin D Use Alter
Seizure Collections During Elective Adult
Inpatient Video EEG Monitoring? Alyssa
Brandt, Rachel Godfred, Mihir Parikh, Nicole
Fortier, Alan Haltiner, Lisa Caylor, Jehuda
Sepkuty, Michael Doherty
P6.187
Prevalence of Metabolic
Syndrome in Valproate-treated Adult
Patients with Epilepsy Aleksei Rakitin, Triin
Eglit, Sulev Kõks, Margus Lember, Sulev
Haldre
108
Subtraction Imaging and MR
Co-registration to Increase Diagnostic Yield
of Ictal and Interictal SPECT in Localization
of Epileptogenic Foci in Patients with
Intractable Seizures Zachary Abramson,
Asim Choudhri, Hubert Magill, James
Wheless
P6.192
Magnetic Resonance
Grading of Hippocampal Sclerosis in
Temporal Lobe Epilepsy Patients Using an
Equilibrium Model Hassan Bagher-Ebadian,
Mohammadreza Nazem-Zadeh, Jason
Schwalb, Abdelrahman Hassane, Hamid
Soltanian-Zadeh
P6.193
Cerebral Hyperperfusion and
Vasodilatory Changes in Acute Seizure—
Report of Three Cases Balaji Krishnaiah,
Sarita Said Said, Krishnamoorthy Thamburaj
P6.194
Quantitative Analyses of
EEG with Special Electrodes in TGA
Patients Hye Ihn Kim, Jeong-Youn Kim,
Chang-Hwan Im, Won-Joo Kim
P6.195
WITHDRAWN
P6.196
Is Presurgical MEG Useful in
Intractable Temporal Lobe Epilepsy? Helen
Barkan, Shannon Sparrow, Ann Marie
Collier, Michael Funke
P6.197
Validation of
Magnetoencephalography (MEG) as
Presurgical Evaluaiton Tool in Pediatric
Patients with Localization-Related
Intractable Epilepsy. Helen Barkan, Marie
Collier, Shannon Sparrow, Michael Funke
P6.198
Comparison of
Diagnostic Methods for Optimizing
Epilepsy Surgery Outcome Including
Magnetoencephalography William Boles,
Jane Boggs, Valerie Woodard, Cormac
O’Donovan
7:30 a.m.–11:00 a.m.
P6.200
F MRI Analysis in Chronic
Migraine: Preliminary Report Licia Grazzi,
Frank Andrasik, Stefania Ferraro, Susanna
Usai, Luisa Chiapparini, Maria Grazia
Bruzzone, Gennaro Bussone
P6.201
White Matter Microstructure
Abnormalities in Paediatric Migraine
Patients: In-Vivo Measures of Brain
Hyperexcitability? Roberta Messina, Maria
Rocca, Bruno Colombo, Elisabetta Pagani,
Filippi
P6.202
A Case of Supratrochlear,
Supraorbital, and Trigeminal Neuralgia
Associated with Neurofibromas of Multiple
Cranial Nerves Kristina Lopez, David
Watson, Jeffery Hogg
P6.203
Mid-life Migraine and
Late-life Movement Disorder Symptoms:
AGES-Reykjavik Study Ann Scher, G. Ross,
Sigurdur Sigurdsson, Melissa Garcia, Larus
Gudmundsson, Sigurlaug Sveinbjornsdottir,
Vilmundur Gudnason, Lenore Launer
Retrospective Analysis of the
Predictors of Successful Posterior Fossa
Decompression in Patients with Headaches
Attributed to Chiari Malformation Naresh
Mullaguri, Rahul Khanna, Gulshan Uppal,
Prityi Rani, Natasha Kataria, Gauravjot
Sandhu, Niranjan Singh
P6.213
A Nutrition Intervention for
Migraines Anne Bunner, Joseph Gonzalez,
Francesca Valente, Ulka Agarwal, Neal
Barnard
P6.214Individualized
Pharmacogenetic Testing Improves
Mood and Anxiety Treatment Outcomes
in Chronic Migraine Patients Sandeep
Vaishnavi, Qian Liu, Liz Griffin, Tim Ramsey,
Mark Brennan
P6.215
A Live Patient Simulation
Model to Effectively Manage Difficult
Headache Patients Fermina Pirmohamed
P6.216
P6.204
Does the New International
Classification of Headache Disorders Affect
the Prevalence of Aura in Patients with
Migraine ? Hossein Ansari
Chronic Migraine with
Medication Overuse Is Associated with
Low Cognitive Reserve Marian Gomez
Beldarrain, Ane Anton Ladislao, Urko
Aguirre Larracoechea, Alberto Cabrera
Zubizarreta, Isabel Oroz, Carlos GarciaMonco Carra
P6.205
P6.217
Barriers to Chronic Migraine
Care: Results of the CaMEO (Chronic
Migraine Epidemiology and Outcomes)
Study Dawn Buse, Richard Lipton, Michael
Reed, Daniel Serrano, Kristina Fanning,
Aubrey Manack
P6.206
Association of the Long
Pentraxin PTX3 Gene Polymorphism
(rs3815627) With Migraine in Iranian
Population Alireza Zandifar, Niloufar
Iraji, Maryam Taheriun, Mohamadhasan
Tajaddini, Faraidoon Haghdoost, Ehsan
Zandifar, Samaneh Zandifar, Shaghayegh
Javanmard
P6.207
Sinking Bone Flap Causing
Paradoxical Orthostatic Headaches Mitra
Assadi Khansare, Aimee Walsh, Mandy
Binning
P6.208
Investigation of Chemokine
Receptor CCR2V64Il Gene Polymorphism
and Migraine in Iranian Population Alireza
Zandifar, Maryam Taheriun, Samira
Soleimani, Faraidoon Haghdoost,
Mohamadhasan Tajaddini, Samaneh
Zandifar, Ehsan Zandifar, Shaghayegh
Javanmard
Headache: Outcomes
P6.209
Idiopathic Intracerebral
Hypertension (IIH)/pseudotumor: Removing
Less CSF Is Best Franchesca Fiorito-Torres,
Melissa Rayhill, Michael Perloff
P6.210
Headache:
Imaging and Epidemiology
Peri Ictal Headache in
Epilepsy Natarajan Visvanathan,
Ramakrishnan Ramalingam, Radha
Mahadevan
P6.199
P6.211
Circle of Willis, Cerebral Blood
Flow, and White Matter Hyperintensities
in Migraine Brett Cucchiara, Ronald Wolf,
Lidia Nagae, Scott Kasner, John Detre
P6.212
Validating a Definition
of Alcohol Sensitivity in Women with
Migraine Qinyi Jiang, William Young,
Michael Oshinsky, Seokmin Kim, Evan Klein
Bilateral Pain Hypersensitivity
over the Trigeminal Region and Dental
Deafferentations in Patients with Classical
Trigeminal Neuralgia Nathalie Guy,
Béatrice Claise, Pierre Clavelou, Radhouane
Dallel
Structural Imaging
P6.218
in PSEN1-Related Spastic Paraparesis
Reveals Widespread White Matter
Abnormalities Steffan Soosman, Meredith
Braskie, Jeffry Alger, David Wharton, John
Ringman
P6.219
Shared Vulnerability of Two
Synaptically-Connected Medial Temporal
Areas to Age and Cognitive Decline: A
7T MRI Study Geoffrey Kerchner, Jeffrey
Bernstein, Michelle Fenesy, Gayle Deutsch,
Manojkumar Saranathan, Michael Zeineh,
Brian Rutt
P6.220
White Matter Disease
in Behavioral Variant Frontotemporal
Dementia Correlates with Risk-taking
Behavior John Powers, Corey McMillan,
Katya Rascovsky, Lisa Burkholder, Murray
Grossman
P6.221
The Symmetric and
Asymmetric Variant of Microvascular
White Matter Disease Bernard Galea,
Mushtaq Qureshi, Malik Adil, Muhammad
Suri, Adnan Qureshi
P6.222
Voxel-based Morphometry
Reveals Gray Matter Loss in Patients with
Paget’s Disease of the Bone Carrying
SQSTM1 Gene Mutations Innocenzo
Rainero, Elisa Rubino, Federico D’Agata,
Silvia Rossetti, Laura Gastaldi, Mauro
Bergui, Laura Orsi, Lorenzo Pinessi,
Giancarlo Isaia, Marco Di Stefano
Poster Session VI
P6.223
Regional Brain Differences in
Cortical Thickness Between Patients with
Amnesic Mild Cognitive Impairment and
Alzheimer`s Disease Dementia Ignacio
Demey, Fernando Ventrice, Galeno Rojas,
Veronica Somale, Ricardo Allegri, Fabian
Bevacqua, Sebastian Lescano
P6.224
Hippocampal Subfield
Analysis in MCI Patients: Comparing
FreeSurfer on 3T MRI with Hand
Segmentation on 7T Data Salil Soman,
Ansgar Furst, Geoffrey Kerchner
Language
P6.225
Functional Language
Lateralization of Primary Progressive
Aphasia Variants Zachary Miller, Leighton
Hinkley, Danielle Mizuiri, Susanne Honma,
Anne Findlay, Bruce Miller, Srikatan
Nagarajan, Maria Gorno Tempini
P6.226
A Cross-Culturally Valid
Assessment of Object Semantics Bonnie
Breining, Trisha Lala, Kyrana Tsapkini, Eleni
Peristeri, María Macarena Martínez Cuitiño,
Facundo Manes, Argye Hillis
P6.227
Neural Correlates of Sentence
Repetition in the Logopenic Variant of
Primary Progressive Aphasia Drew
Goldberg, Anna Isenberg, Murray Grossman
P6.228
Predictors of Recovery of
Chronic Aphasia Aarushi Suneja, Marlis
Gonzalez-Fernandez, Argye Hillis
P6.229
Syntactic Processing Skills
in the Three Variants of PPA Rajani
Sebastian, Cameron Davis, Yessenia Gomez,
Lydia Trupe, Argye Hillis
Memory
P6.235
Correlation between Cortical
Thickness Measurements from Magnetic
Resonance Imaging and Cognitive
Performance on Episodic and Semantic
Memory Tests Ignacio Demey, Galeno
Rojas, Veronica Somale, Fernando Ventrice
P6.236
Preservation of Spatial
Function: Role in Differential Diagnosis
of Behavioral Variant Frontotemporal
Dementia Anneliese Radke, Tracy Jerard,
Joel Kramer, Katherine Possin, Nikolas
Block, Alexander Beagle, Bruce Miller
P6.237
Validation of the Dynamic
Affect Recognition Test (DART): Behavior
and Anatomy in Neurodegenerative
Disease Anneliese Radke, Babu
Adhimoolam, Tal Shany-Ur, Katherine
Possin, David Marin, Diana Zackey, Pardis
Poorzand, Bruce Miller, Katherine Rankin
P6.233
Sensitivity of Consensus
Criteria in the Quantitative Classification
of Primary Progressive Aphasia Meredith
Wicklund, Joseph Duffy, Edythe Strand,
Mary Machulda, Jennifer Whitwell, Keith
Josephs
P6.234
Bilingualism and Language
Networks in the Semantic Variant of
Primary Progressive Aphasia. Ismael
Calandri, Alejandra Amengual, Hernán
Chaves, Cecilia Rollán, Mauricio Farez,
Liliana Sabe, Cristina Medina, Griselda
Russo, Silvia Vazquez, Ricardo Allegri
Anabolic Steroids Abuse
and Ischemic Stroke: A Case Report and
Literature Review Ge Xiong, Arnaldo Velez,
Anna Khanna
P6.262
P6.248
P6.263
A Case Series of Nonbacterial Thrombotic Endocarditis
Associated with Gynecological
Malignancies Alice Schabas, Philip Teal,
Samuel Yip, Sharanpal Mann
P6.249
Pituitary Apoplexy Presenting
as Anterior Choroidal Artery Territory
Infarct: A Case Report Sasikanth Gorantla,
Kasra Maasumi, Jason Felton, Nabeel Dar,
Jongyeol Kim
P6.250
Lacunar Infarct Presenting
Like Axillary Nerve Lesion: A case
report Oguzhan Oz, Serdar Tasdemir,
Hakan Akgun, Semih Alay, Ahmet Cetiz, Zeki
Odabasi, Seref Demirkaya
P6.239
White Matter Disease and
Cognitive Impairment in FMR1 Premutation
Carriers Christopher Filley, Mark Brown,
Karen Onderko, Megan Ray, Rachael
Bennett, Jim Grigsby
P6.252
P6.240
Age Effects on the Neural
Basis of Self-Generation in Verbal Paired
Associate Learning Jennifer Vannest,
Thomas Maloney, Benjamin Kay, Miriam
Siegel, Jane Allendorfer, Christi Banks,
Jerzy Szaflarski
P6.253
P6.241
P6.254
P6.242
18F-FDG-PET Metabolic
Patterns in the Semantic Variant of PPA:
Functional/Clinical Correlations. SingleSubject 18F-FDG-PET Beyond MRI Daniela
Perani, Leonardo Iaccarino, Lucia Guidi,
Pasquale Della Rosa, Giuseppe Magnani,
Stefano Cappa
P6.247
P6.251
P6.231
P6.232
P6.261
Cognitive Deficits of
Large-Vessel and Small-Vessel Vascular
Dementia Ju-Young Na, Bong-Goo Yoo
Language Networks Imaging
in Primary Progressive Aphasia in a Latin
Population Ismael Calandri, Alejandra
Amengual, Hernán Chaves, Cecilia Rollán,
Mauricio Farez, Liliana Sabe, Cristina
Medina, Zanuzo Patricia, Jorge Campos,
Gabriela Cohen, Jorge Calvar, Silvia
Vazquez, Ricardo Allegri
Impairment in Sentence
Comprehension in Patients with the
Behavioral Variant of Frontotemporal
Degeneration (bvFTD) Rebecca Williams,
Katya Rascovsky, Murray Grossman
A Case of
Akinetopsia Wolfgang Grisold, Sabine
Pollanz, Birgit Surböck, Barbara Horvath
P6.238
Accentuated Brain Responses
During Semantic Object Memory
Retrieval in Amnestic Mild Cognitive
Impairment as Measured by Event-Related
Potentials Hsueh-Sheng Chiang, Raksha
Mudar, Justin Eroh, Jeffrey Spence, Athula
Pudhiyidath, Jeremy Tanner, Erin Venza,
Audette Rackley, Kristin Martin-Cook, Kyle
Womack, Elizabeth Bartz, Michael Kraut,
John Hart
P6.230
P6.246
Dementia Severity Ratings and Memory
Accuracy Versus Certainty Matthew
Harris, Daniel Kaufer
P6.243
Changes of Face
Recognition After Medial Temporal Lobe
Resection Masoud Majed, Emad Ahmadi,
Seyed Mohammad Ghodsi, Sina Tafazoli,
Abdol Hossein Abbassian
Case Reports
P6.244
A Case of Perioperative Stroke
Caused by Tumor Embolus. Stella Hughes,
Annemarie Hunter, Jamie Campbell, Aidan
Brady, Brian Herron, Graham Smyth, Ian
Rennie, Stephen Hunt
P6.245
Thrombosis of the Vein
of Trolard Secondary to Renal Minimal
Change Disease: A Case Report and
Literature Review Marcelo Rocha, Steven
Feske, Allan Ropper
Case of Neurosyphilis
Presenting as MoyaMoya
Syndrome Saima Ali, Soundarya Gowda
Two Cases of Malignant
Cerebral Edema Related to Systemic Lupus
Erythematous Lauren Koffman, Khaled
Asi, Ashlee Russo, Dhimant Dani, Edward
Manno
Case Report: Multiple
Scattered Ischemic and Hemorrhagic
Strokes after Transarterial
Chemoembolization for Hepatocellular
Carcinoma Alhamza Al-Bayati, Douglas
Smith, Elia Haddad
The Clinical Features of
Cerebral Vein and Sinus Thrombosis in
Male Patients Hongyan Ding, Qiang Dong
P6.255
Intracranial Venous Sinus
Thrombosis: Report of Three Cases Hans
Reyes Garay, Carla Sueldo Feijoo, Jorge
Martin Gavidia Chucan
P6.256
Generalized Dilative
Arteriopathy Without Myopathy: A New
Phenotype of Pompe Disease Andoni
Echaniz-Laguna, Marc Bataillard, Véronique
Quenardelle
P6.257
Brain Herniation Due to
Mitochondrial Encephalomyopathy, Lactic
Acidosis, Stroke Like Events (MELAS)
with 3256 Mutation Responsive to
Decompressive Craniotomy Chunmei Cui,
Robert Schwendimann
P6.258
Cerebral Varicella Zoster
Vasculopathy Sine Herpete: Atypical
Ramsay-Hunt Syndrome presentation
in an Immunocompetent Patient Karina
Gonzalez Otarula, Verónica Bruno, Virginia
Pujol-Lereis, Sebastian Ameriso
Amusia: Unique Presentation
of Stroke Charu Ramchandani, Fawaz
Alsmaan, Heidi Schwarz, Ziad Alkhoury
Recurrent Intra-luminal Aortic
Thrombus and Ischemic Stroke in a Patient
with Essential Thrombocythemia Daniel
Vela-Duarte, Murray Flaster
Right Hemispheric Acute
Ischemic Stroke Secondary to Right
Common Carotid Artery Free Floating
Thrombus Due to Hypercoagulable State
in an Otherwise Healthy 48-year-old
Woman. Karen Orjuela, Rick Gill, Luka
Vlahovic, Sarkis Morales-Vidal
P6.264
Uncomon Cause Stroke:
Thalamic Stroke as Initial Presentation of
Dunnigan Familial Partial Lipodystrophy
(FPLD) Fatai Radji, Elena Leca Radu, Kahina
Dannepond, Marie-Laure Nunes
P6.265
Is Achondroplasia Linked
to Stroke? Harpreet Kaur, Shilpi Mittal,
Catherine Hosley
P6.266
“Pseudostroke”: Clinically
Diagnosed Ischemia Shown to Be
Multiple Sclerosis at Autopsy: A Case
Report Gulshan Uppal, Natasha Kataria,
Prityi Rani, Douglas Miller
P6.267
Delayed Cortical Blindness
After Cardiac Arrest Anibal Lugo,
Abdulrahman Alwaki, Christopher
Goshgarian, Justin Belsky, Panayiotis
Mitsias
P6.268
Case Report—Cerebral
Amyloid Angiopathy with Granulomatous
Angiitis Ali Saeed, Vibhav Bansal, Howard
Chang, Michael Flink, Anmar Razak, Syed
Hussain
P6.269
Paradoxical Cerebral
Embolism from Thrombolysis of a Clotted
Arteriovenous Graft Umang Shah, Ruchir
Shah
P6.270
A Rare Association Between
Ulcerative Colitis and Bilateral Thalamic
Stroke Sara Misthal, Dababneh Haitham,
Asif Bashir, Mohammed Hussain,
Mohammad Moussavi, Jawad Kirmani
P6.271
Monocular Diplopia After
Left Posterior Cerebral Artery Territory
Infarction Konstantinos Papadopoulos,
Brigitte Capron, Raphael Hourez
P6.272
Rapid High Volume CSF Loss:
A New Cause of Coma Minjee Kim, Rose
Du, Sherry Chou
P6.273
Thrombectomy with the
Penumbra 5 MAX ACE Achieves More
Efficient Recanalization Nazli Janjua,
Jeffrey Farkas, Karthikeyan Arcot,
Rajesh Kumar, Delbrune Jean, Nikolaos
Papamitsakis, Yevgeny Margulis, Subasini
Dash, Kenneth Levin, Salman Azhar
P6.259
Synthetic Cannabis and Acute
Ischemic Stroke Miya Bernson-Leung,
Lester Leung, Sandeep Kumar
P6.260
A Novel Heterozygous
c.164G>C Mutation in the Exon 2 of the
NOTCH3 Gene Causing Cadasil Raphael
Hourez, Konstantinos Papadopoulos, Guy
Bruninx, Yves Sznajer
109
Thursday
May 1
Thursday, May 1
Risk Factors
P6.285
P6.274
P6.286
Visit-to-visit Systolic Blood
Pressure Variability Predicts All-cause and
Cardiovascular Mortality After Lacunar
Infarct Gary Lau, Yuen Kwun Wong,
Richard Chang, KC Teo, Sonny Hon, Koon
Chan, KL Wat, Raymond Cheung, Leonard Li,
David Siu, Shu Leong Ho, Hung Fat Tse
P6.275
Medicare’s New Two
Midnight Rule for In-patient Status
Admission Applied to Transient Ischemic
Attack Patients Predicted by Hypertension
History and Age Maria Chavez-Keatts,
Ramy El Khoury, Sheryl Martin-Schild
P6.276
High Burden of Brain
Microvascular Disease in Difficult-tocontrol Hypertension Maria Zurru, Claudia
Alonzo, Laura Brescacin, Ariel Luzzi, Luis
Camera, Gabriel Waisman, Edgardo
Cristiano
P6.277
Comparison of Classical Risk
Factors, Lypids, Stress and Depression
Among Patients with First Ischemic Stroke
and Acute Myocardial Infarction in a Center
from Buenos Aires. Dario Lisei, Martin
Lopez Vicchi, Gabriel Persi, Matías Failo,
Ricardo Iglesias, Maria Ballarino, Sebastian
Camerlingo, Virginia Laura Parisi, Emilia
Gatto
P6.278
Analysis of Comorbidities in
Ischemic Stroke Patients Thomas Cochran,
Jose Chaves, Eric Fulmer, Dawn Blackhurst,
Shannon Sternberg, R. Leacock, Thomas
Nathaniel
P6.279
Low Density Lipoprotein
Receptor Related Protein-1 and 6 Gene
Variants and Ischemic Stroke Risk Andrea
Harriott, Michael Heckman, Sruti Rayaprolu,
Alexandra Soto-Ortolaza, Rainer Malik
for METASTROKE Consortium, John Cole,
James Meschia, Owen Ross
P6.280
Stroke in Very Old
Patients Drini Dobi, Mira Kapisyzi, Jera
Kruja
P6.281
Analysis of the Relation
Between Chronic Kidney Disease and
Acute Ischemic Stroke. Patricio Blaya,
Mariano Borrelli, Mariela Cabrera, Claudia
Gonzalez, Walter Gramajo, Javier Rolle,
Nestor Estevez, Jorge Gimenez, Cristina
Trujillo, Marcelo Mattiazzi
P6.282
The Relationship
Between Leukocytosis and Time to
Neurodeterioration Amelia Boehme,
James Siegler, Karen Albright, Alexander
George, Dominique Monlezun, Jr, Adam
Friedant, Brittany Gouse, T. Beasley, Sheryl
Martin-Schild
Neuro-ophthalmology/
Neuro-otology II
P6.283
Incidence, Seasonality, and
Comorbidity in Vestibular Neuritis Ivan
Adamec, Magdalena Krbot, Mario Habek
P6.284
Retinal Ganglion Cell Injury
Precedes RNFL loss in Acute Optic
Neuritis John Guy, Vittorio Porciatti,
William Feuer, Angela Herro, Byron Lam
110
Gordon Holmes 100 Years
Later: Cortical Folding Predicts Retinotopic
Organization Noah Benson, Omar Butt,
David Brainard, Geoffrey Aguirre
Retinal Structure and Function
in Adults with Refractory Complex Partial
Seizures (rCPS) Treated with Vigabatrin:
Initial Results of the Sabril Vision
Study Robert Wechsler, Chris Johnson,
Robert Sergott, Kenneth Laxer, Yekaterina
Dribinsky, Colleen Canavan, Jouko Isojarvi,
Deborah Lee
P6.287
Vision-Based Concussion
Testing in a Youth Ice Hockey
Cohort: Effects of Age and Visual
Crowding Jennifer Morganroth, Steven
Galetta, Laura Balcer
P6.288
Saccade Properties
and Fixation Instability Differentiate
Ataxias Pamela Federighi, Francesca
Rosini, Elena Pretegiani, Claudia
Vinciguerra, Gabriele Lucii, David Zee, R.
John Leigh, Lance Optican, M.T. Dotti,
Antonio Federico, Alessandra Rufa
P6.289
Quantitative Videooculography to Differentiate Stroke
from Vestibular Neuritis in Acute
Vertigo—Vestibulo-ocular Reflex Gain
Distributions and Optimal Test Thresholds
for Diagnosis Ali Saber Tehrani, Georgios
Mantokoudis, Amy Wozniak, Karin
Eibenberger, Jorge Kattah, Cynthia Guede,
David Zee, David Newman-Toker
P6.290
Susac’s Syndrome: Five Cases
with Predominant Branch Retinal Artery
Occlusion Thomas Seifert-Held, Alexander
Barounig, Maria Storch, Hans Offenbacher,
Martin Weger, Beate Langner-Wegscheider,
Franz Fazekas
P6.291
Correlation of Acute Phase
Reactants and Temporal Artery Biopsy
(TAB) in Patients with Giant Cell Arteritis
(GCA) Padmaja Sudhakar, Sachin Kedar
P6.292
Clinical and
Electrophysiological Photostress Recovery
Times in Distinguishing Demiyelinating
Optic Neuritis And Maculopathy Fethi
Idiman, Ahmet Onur Keskin, Mahmut Kaya,
Egemen Idiman, Onur Bulut
P6.293
A Retrospective Study of
Chronic Relapsing Inflammatory Optic
Neuropathy (CRION) Padmaja Sudhakar,
Sachin Kedar, Joseph Berger
P6.294
Eye Movement Features
in Rare Hereditary Parkinsonian
Syndromes Elena Pretegiani, Gabriele Lucii,
Pamela Federighi, Francesca Rosini, Antonio
Federico, Alessandra Rufa
P6.295
Ocular Motility Disturbances
in Orbitofacial Neurofibromatosis Type 1 Thomas Bosley, Ibrahim Alorainy, Jose
Morales, Imtiaz Chaudhry, Darren Oystreck
P6.296
Neurosurgical Cases
with Cortical Vision Loss Followed by
Improvement Bonnie Keung, Julian Lin,
Jeffrey Klopfenstein, Jorge Kattah
P6.297
Optical Coherence
Tomography Quadrant Analysis of Retinal
Nerve Fiber Layer in Relapsing and
Remitting Multiple Sclerosis John Rose,
Anette Fjeldstad
7:30 a.m.–11:00 a.m.
P6.298
Demyelinating Optic
Chiasmopathy Due to Mycobacterium
Haemophilum in a Patient with
AIDS Alexander Merkler, George Parlitsis,
Alison May, Dara Bier, Sara Simpson, Sarju
Patel, Ehud Lavi, Audrey Shuetz, Marc Dinkin
P6.299
Visual Evoked Potential and
Magnetic Resonance Imagine Are More
Effective Markers of Multiple Sclerosis
Progression Than Laser Polarimetry with
Variable Corneal Compensation Ema
Kantorova, Peter Žiak, Koyšová Mária,
Kamil Zeleňák, Egon Kurča, Mária Hladká,
Alexandra Sedláková
P6.300
Presence of AQP4 Antibodies
Correlates with Negative Outcome of Optic
Neuritis Jana Lizrova Preiningerova, Petra
Nytrova, Pavel Kuthan, Pavel Diblik, Eva
Havrdova
P6.301
Evidence of Multi-Domain
Mild Cognitive Impairment in Idiopathic
Intracranial Hypertension Anat Kesler
P6.302
‘Ping-Pong’ Gaze in
Hypoglycemic Encephalopathy Saima Ali,
Scott Haines
P6.303
Do Not Forget Susac
Syndrome in Patients with Unexplained
Acute Confusion Michael Star, Maria
Bruzzone, Felipe De Alba, Rick Gill, Michael
Schneck, Jose Biller
P6.304
Clinical Utility of Cervical
Vestibular Evoked Myogenic Potential
(VEMPc) in Ménière’s disease Guillermo
Videla, Ana Bisonni, Jorge Norscini,
Edgardo Cristiano
P6.305
An Unusual Case Of Idiopathic
Intracranial Hypertension Presenting with
Simultaneous IIIrd, VIth and V11th Nerve
Palsies Akshat Katyayan, Venu Parachuri,
Delphin Sallowm, Ryan Walsh
P6.306
Restricted Diffusion Imaging
in Active Seizure: A Case Report Adnan
Subei, Eric Eggenberger
P6.307
Presence of AQP4 Antibodies
Correlates with Negative Outcome of Optic
Neuritis Jana Lizrova Preiningerova, Petra
Nytrova, Pavel Kuthan, Pavel Diblik, Eva
Havrdova
P6.308
Diplopia and Esophoria
Induced by Medial Thalamic Deep Brain
Stimulation Barbara Kelly Changizi,
Catherine Cho, Brian Kopell, Janet Rucker
Imaging
P6.309
Decline in Perceptual
Motor Speed and Cognitive Flexibility
Associated with Regional Patterns of FDG
PET Hypometabolism Alan Lerner, Alok
Sachdeva, Curtis Tatsuoka
P6.310
A fMRI Graph Theory Study of
the Effect of Gender and Aging on Topology
of Functional Brain Networks Gianna
Riccitelli, Maria Rocca, Paola Valsasina,
Alessandro Meani, Federica Agosta,
Massimo Filippi
P6.311
Early Striatal Perfusion
Deficits in Autosomal Dominant Alzheimer
Disease Detected with Arterial Spin
Labeled MRI. Eric McDade, Albert Kim,
Jeffrey James, Davneet Minhas, Snezana
Ikonomovic, Oscar Lopez, Beth Snitz, Julie
Price, James Becker, Chester Mathis,
William Klunk
P6.312
The Effect of Age of Onset
on the Brain Functional Connectivity in
Alzheimer’s Disease: A Graph Analysis
Study Elisa Canu, Federica Agosta,
Sebastiano Galantucci, Alessandro Meani,
Filippi
P6.313
Microstructural White
Matter Alterations Correlate with Cerebral
Amyloid Angiopathy Burden and Cognitive
Measures: A DTI/PET Study Yael Reijmer,
Panagiotis Fotiadis, Sergi Martinez-Ramirez,
Aaron Schultz, Anne Reed, Alison Ayres,
Kristin Schwab, Jonathan Rosand, Anand
Viswanathan, Keith Johnson, Steven
Greenberg, Edip Gurol
P6.314
Strategic Choice in
Frontotemporal Dementia: A Pilot
Study Alessandra Dodich, Chiara Cerami,
Nicola Canessa, Chiara Crespi, Alessandra
Marcone, Andrea Falini, Stefano Cappa
P6.315
Decreased White Matter
NAA in Alzheimer’s Disease Navid SerajiBozorgzad, Fen Bao, Krishna Thakore, Omar
Khan
P6.316
Medial Parietal Cortex GABA
Measurements in Alzheimer’s Disease
Are Inversely Associated with Functional
Response Novraj Dhanjal, Mark McPhail,
Marzena Wylezinska, Richard Wise
P6.317
Dorsolateral Prefrontal Cortex
Modulation by Caudate Dopamine During
a Working Memory Task in Parkinson
Disease Joseph Masdeu, Daniel Eisenberg,
Catherine Hegarty, Brett Cropp, Daniel
Rubinstein, Philip Kohn, Karen Berman
P6.318
Region Specific Alpha-band
Resting-state Functional Connectivity
Predicts Focal Cognitive Deficits in
Alzheimer’s Disease Spectrum Kamalini
Ranasinghe, Leighton Hinkley, Alexander
Beagle, Danielle Mizuiri, Anne Dowling,
Susanne Honma, Mariel Finucane, Carole
Scherling, Bruce Miller, Srikatan Nagarajan,
Keith Vossel
P6.319
Florbetapir F18 Positron
Emission Tomography Identification
of Beta-Amyloid in the Living Brain: A
Consecutive Clinical Case Series Effie
Mitsis, Heidi Bender, Lale Kostakoglu, Josef
Machac, Jane Martin, Jennifer Woehr,
Martin Goldstein, Mary Sano, Samuel
Gandy
P6.320
Differences in 11C-PIBPET Imaging Patterns in Patients with
Alzheimer’s Disease Without Microbleeds
and Those with Cerebral Amyloid
Angiopathy Yuichi Hayashi, Jun Shinoda,
Nobuaki Yoshikura, Masahiro Waza,
Yoshitaka Asano, Akio Kimura, Takashi
Inuzuka
Poster Session VI
P6.321
Association Between
Longitudinal Increases in Serum Glucose
and Metabolic Decline in Azheimer’s
Disease-Related Brain Regions Christine
Burns, Alfred Kaszniak, Kewei Chen, Wendy
Lee, Daniel Bandy, Richard Caselli, Eric
Reiman
Effects of β-Amyloid Load on
White Matter Integrity in Dementia with
Lewy Bodies Zuzana Nedelska, Christopher
Schwarz, Bradley Boeve, Robert Reid, Scott
Przybelski, Jeffrey Gunter, Matthew Senjem,
Glenn Smith, Tanis Ferman, Yonas Geda,
David Knopman, Ronald Petersen, Clifford
Jack, Kejal Kantarci
P6.322
P6.323
Florbetapir Scanning Excludes
Alzheimer’s Disease in a Retired NFL Player
with Delayed Cognitive Impairment Effie
Mitsis, Silvana Riggio, Emily D’Antonio,
Martin Goldstein, Steven DeKosky, Thomas
Naidich, Bradley Delman, Josef Machac,
Lale Kostakoglu, Gregory Elder, Mary Sano,
Samuel Gandy, Wayne Gordon
P6.324
Alzheimer as a Default
Mode Network Disease: A Grey Matter,
Functional and Structural Connectivity
Study Marcio Balthazar, Marina Weiler,
Brunno Campos, Thiago Rezende, Benito
Damasceno, Fernando Cendes
P6.325(18F)FDG PET Evidence of
PIB-Positive PET in
Individuals with Early- But Not Late-onset
Frontotemporal Dementia Eric Brown,
Ariel Graff-Guerrero, Sylvain Houle, Alan
Wilson, Zahinoor Ismail, Bruce Pollock,
Benoit Mulsant, David Tang-Wai, Nicolaas
Verhoeff, Morris Freedman, Romina Mizrahi,
Tiffany Chow
P6.332
P6.327
P6.333
Cavum Septum Pellucidum
in Symptomatic Retired Pro-football
Players Raquel Gardner, Christopher Hess,
Katherine Possin, Brendan Cohn-Sheehy,
Joel Kramer, Mitchel Berger, Bruce Miller,
Kristine Yaffe, Gil Rabinovici
P6.328
Reliable Detection of Striatal
Amyloid with (18F) Flutemetamol: Validation
with Postmortem Histopathology Thomas
Beach, Dietmar Thal, Adrian Smith, Chris
Buckley
P6.329
Progressive Hippocampus
Atrophy in Persons with Mild Cognitive
Impairment: A Longitudinal MRI
Study Iryna Lobanova, Amna Sohail, Malik
Adil, Adnan Qureshi
P6.330WITHDRAWN
P6.331
Pathologic validation of the
EADC-ADNI Harmonized Hippocampal
Protocol Liana Apostolova, Chris Zarow,
Kristina Biado, Sona Babakchanian,
Marina Boccardi, Johanne Somme, Hedieh
Honarpisheh, Anna Blanken, Jenny Brook,
Spencer Tung, Denise Ng, Jeffrey Alger,
Harry Vinters, Martina Bocchetta, Martina
Bocchetta, Henri Duvernoy, Clifford Jack,
Giovanni Frisoni
Dementia with Lewy bodies:
Pathological Basis of the Cingulate Island
Sign Jonathan Graff-Radford, Melissa
Murray, Val Lowe, Bradley Boeve, Tanis
Ferman, Scott Przybelski, Timothy Lesnick,
Matthew Senjem, Jeffery Gunter, Glenn
Smith, David Knopman, Clifford Jack, Dennis
Dickson, Ronald Petersen, Kejal Kantarci
Progressive Hippocampus
Atrophy in Persons with Alzheimer’s
Disease: A Longitudinal MRI study Iryna
Lobanova, Amna Sohail, Malik Adil, Aveen
Saed, Adnan Qureshi
P6.334
Genetic Variation
Within the Oxidative Phosphorylation
Pathway in Stroke and Alzheimer’s
Disease Alessandro Biffi, Mert Sabuncu,
Rahul Desikan, Schmansky Nick, David
Salat, Jonathan Rosand, Christopher
Anderson
Neurophysiology: Autoimmune
Epilepsy, Intraoperative
Monitoring, and Corticography
P6.335
Stereo-electroencephalography
Versus Subdural Grids and Depth Electrode
Placements: When to Use Which? Adetoun
Abisogun, Zianka Fallil, Ashesh Mehta,
Cynthia Harden
P6.336
Critical Intraoperative
Neurophysiologic Monitoring (IONM)
Changes Associated with Patient
Positioning Maneuvers Leslie Lee, Sungho
Cho, Viet Nguyen, John Ratliff, Jongsoo
Park, Jaime Lopez
P6.337
Does Intraoperative
Neurophysiologic Monitoring (IONM)
Cause Delays in Surgical Cases? Forough
Ghavami, Viet Nguyen, Scheherazade Le,
Leslie Lee, Charles Cho, Richard Jaffe,
Jaime Lopez
P6.338
Fingerprinting Method for
Identifying Spatiotemporal-Frequency
Motifs in Electrocorticographic Data. Dan
Bernardo, Tim Pluta, Hae Won Shin
P6.339
Post Resection Electrocorticography Predicts Seizure
Outcome—a Multivariate Logistic
Analysis Sonia Krish, Omotola Hope,
Giridhar Kalamangalam, Jeremy Slater,
Nitin Tandon
P6.340
The Predictive Value
of Electrocorticography in Patients
with Mesial Temporal Lobe
Epilepsy Undergoing Selective
Amygdalohippocampectomy Aline
Herlopian, L Greenfield, Bashir Shihabuddin
P6.341
Refractory Status Epilepticus:
a Report of Two Cases to Illustrate the
Significance of GAD Antibody Ayaz
Khawaja, Amy Amara
P6.342
NMDA Receptor Encephalitis
Presenting as Partial Status Epilepticus.
Case Report and Discussion Simona
Proteasa, Josiane LaJoie, Joseph Maytal
P6.343
Is Rasmussen’s Encephalitis
a NMDA Encephalitis? A Case Report and
Review of Literature Simona Proteasa,
Lines Vargas Collado, Shefali Karkare
P6.344
Intravenous Immunoglobulin
Therapy for Late-Stage Rasmussen’s
Encephalitis: Long-Term Seizure
Freedom Rahul Dave, Enrique Serrano
Thursday
May 1
Atypical Medial Temporal Lobe Dysfunction
in Prodromal Alzheimer’s Disease Chiara
Cerami, Pasquale Della Rosa, Alessandra
Dodich, Giuseppe Magnani, Alessandra
Marcone, Andrea Falini, Stefano Cappa,
Daniela Perani
P6.326
2015 Education Course Proposal Process
2015 Annual Meeting: Washington, DC
The AAN invites you to submit an Education Program suggestion for May 16, 2014. To submit your proposal, please visit
the 67th Annual Meeting. Proposals for new programs are due by
AAN.com/view/SearchAM.
Thursday, May 30
Frontiers in Neuroscience Plenary Session
9:00 a.m.–12:00 p.m.
F ocuses on translational research related to clinical issues of importance. Six physician scientists outline their recent research findings, along
with the clinical implications.
Moderator: Massimo Pandolfo MD
Member, Science Committee; Chair, International Subcommittee
Tissue Environments
for Brain Repair
Using Fixed Circuits
to Generate Flexible
Behaviors
S. Thomas Carmichael, MD, PhD
David Geffen School of Medicine
at UCLA, Los Angeles, CA
Cori Bargmann, PhD
Rockefeller University, New York, NY
Opportunities and
Challenges of Robot
Assisted and Facilitated
Neurorecovery
Advances in
Mapping Human Brain
Connectivity: The Human
Connectome Project
Albert Lo, MD, PhD
Brown University, Providence VA
Medical Center, Providence, RI
Bruce R. Rosen, MD, PhD
Harvard Medical School, Boston, MA
The Nightlife of Astrocytes
Network-based
Neurodegeneration
Maiken Nedergaard, MD, DMSc
University of Rochester Medical
Center, Rochester, NY
William Seeley, MD
112
American Academy of Neurology and American Brain Foundation
2O14 Awards Luncheon
Join AAN leaders for lunch honoring top accomplishments in the
field from enterprising high school students to world-renowned
researchers. Seating is limited.
Wednesday, April 30
12:00 p.m.-1:30 p.m.
Public Leadership in Neurology
Award Winner Ben Utecht
NFL star-turned-singer Ben Utecht will receive the American
Brain Foundation’s 2014 Public Leadership in Neurology
Award for his commitment to spreading the word about how
concussions and traumatic brain injury have affected his life.
After winning a Super Bowl ring in 2007, his career ended
unexpectedly after a traumatic brain injury in 2009. Many saw
this as an ending, but Ben saw an opportunity to pursue
another lifelong passion—singing.
April 26 – May 3, 2014
Philadelphia, PA
Thursday, May 1
S44 MS and CNS
Neuroimaging I
S45 Cerebrovascular
Neurology: Rehabilitation,
Recovery, and Complications
1:00 p.m.
S44.001
Leptomeningeal Contrast
Enhancement in Multiple Sclerosis:
a Possible Marker of Inflammation
in the Subarachnoid Space Daniel
Reich, Anuradha Rao, Luisa Vuolo,
Martina Absinta, Govind Nair, John
Butman, Irene Cortese
1:00 p.m.
S45.001
Stroke Survivors with Aphasia
May Overestimate Communication
Skills: Survivor Versus Caregiver
Report Vahid Behravan, James
Maniscalco, Darlene Williamson,
A. Barrett
1:15 p.m.
S44.002
Direct MRI Detection of Impending
Plaque Development in MS Martina
Absinta, Pascal Sati, Govind Nair,
Massimo Filippi, Irene Cortese,
Daniel Reich
1:15 p.m.
S45.002
The Association Between Meeting
Life’s Simple 7 Goals and Mortality
After Stroke in the US Michelle Lin,
Daniela Markovic, Bruce Ovbiagele,
Amy Towfighi
1:30 p.m.
S44.003
In Vivo PET Imaging of Activated
Microglial Cells Can Be Used to
Differentiate Between Inactive and
Active Chronic Lesions in Progressive
Multiple Sclerosis Laura Airas,
Eero Rissanen, Jouni Tuisku, Alex
Dickens, Daniel Anthony, Juha Rinne
1:30 p.m.
S45.003
The Amphetamine-Enhanced Stroke
Recovery (AESR) Trial: Primary Part
1 Results Larry Goldstein, Meheroz
Rabadi, Michael Reding, Laura
Lennihan, David Good, Alexander
Dromerick, John Pura, Gregory
Samsa
1:45 p.m.
S44.004
Myelin-Related Advanced MRI
Demonstrates Different Degrees
of Change Between Various White
Matter Tracts in MS Shannon
Kolind, Irene Vavasour, Alexander
Rauscher, Andrew Riddehough,
David Leppert, Nicolas Seneca,
Yinshan Zhao, Roger Tam, A.
MacKay, David Li, Anthony
Traboulsee
1:45 p.m.
S45.004
Hospital Factors Associated with
Feeding Tube Placement for US
Stroke Inpatients Benjamin George,
Adam Kelly, Eric Schneider, Robert
Holloway
2:00 p.m.
S44.005
Longitudinal Changes in Myelin
Water Fraction in New Multiple
Sclerosis Lesions Wendy Vargas,
Elizabeth Monohan, Sneha Pandya,
Michael Dayan, Thanh Nguyen,
Ashish Raj, Susan Gauthier
2:15 p.m.
S44.006
Ultra-high-resolution Imaging of
Brain-free Water for Rapid Atrophy
Assessment in MS Katherine Gao,
Govind Nair, Irene Cortese, Alan
Koretsky, Daniel Reich
2:30 p.m.
S44.007
Intracortical Laminar Pathology in
the Motor Cortex Is Associated with
Tractographically Connected White
Matter Injury in Multiple Sclerosis:
a Multimodal 7T and 3T MRI
Study. Céline Louapre, Sindhuja
Govindarajan, Costanza Giannì,
Julien Cohen-Adad, Sean Tobyne,
Revere Kinkel, Caterina Mainero
114
2:00 p.m.
S45.005
Utilization of In-hospital Palliative
Care for Ischemic Stroke Deaths in
United States Shah Shreyansh,
Yogesh Moradiya, Santosh Murthy
2:15 p.m.
S45.006
Subjective Judgments of Physicians
and Nurses Are More Accurate
Than Formal Clinical Scales in
Predicting Functional Outcome After
Intracerebral Hemorrhage David
Hwang, Cameron Dell, Mary Sparks,
Tiffany Watson, Carl Langefeld,
Mary Comeau, Jonathan Rosand,
Thomas Battey, Sebastian Koch,
Mario Perez, Michael James,
Jessica McFarlin, Jennifer Osborne,
Daniel Woo, Steven Kittner, Kevin
Sheth
2:30 p.m.
S45.007
Efficacy of Single and Multiple
Injections of Human Umbilical
Tissue-Derived Cells Following
Experimental Stroke in Rats Amjad
Shehadah, Jieli Chen, Brian Kramer,
Alex Zacharek, Yisheng Cui, Cynthia
Roberts, Mei Lu, Michael Chopp
1:00 p.m.–2:45 p.m.
S46 Neuromuscular
Disease: Genetics,
Pathogenesis,
and Measures
1:00 p.m.
S46.001
Exome Sequencing Identifies PINCH2
Mutations in Early Onset Autosomal
Recessive LGMD with Severe
Cardiomyopathy and Triangular
Tongues Jodi Warman Chardon,
Amanda Smith, John Woulfe, Kawan
Rakhra, Elena Pena Fernandez,
Chandree Beaulieu, Jeremy
Schwartzentruber, Cynthia Hawkins,
Matthew Harms, Mei Zhang, Jacek
Majewski, Dennis Bulman, Kym
Boycott, David Dyment
1:15 p.m.
S46.002
Founder Mutation in the
γ-Sarcoglycan Gene Causes Milder
Phenotype of Limb-Girdle Muscular
Dystrophy Type 2C (LGMD2C) in
the Hispanic Population of Puerto
Rico Samiah Al-Zaidy, Vinod Malik,
Kelley Kneile, Xiomara Rosales, Julie
Gastier-Foster, Peter Kang, Basil
Darras, Louis Kunkel, Steven Moore,
Robert Pyatt, Jerry Mendell
1:30 p.m.
S46.003
Novel Mutation in VCP Causes
Charcot-Marie-Tooth Type 2 (CMT2)
Phenotype Shawna Feely, Michael
Gonzalez, Chris Weihl, Michael Shy,
Stephan Zuchner
1:45 p.m.
S46.004
Ethoxyquin Prevents Development
of Neuropathy in Rodent Models of
Diabetic Peripheral Neuropathy and
HIV-Associated Neuropathy Ahmet
Hoke, Nicole Reed, Jing Zhu
2:00 p.m.
S46.005
Monocarboxylate Transporter 1
(MCT1) Is Critical for Regeneration
in Peripheral Nerves Brett
Morrison, Akivaga Tsingalia, Sylvain
Lengacher, Luc Pellerin, Pierre
Magistretti, Jeffrey Rothstein
2:15 p.m.
S46.006
Amyotrophic Lateral Sclerosis
Quality Measures Robert Miller,
Benjamin Brooks, Rebecca SwainEng, Robert Basner, Gregory Carter,
Patricia Casey, Adam Cohen, Richard
Dubinsky, Dallas Forshew, Carlayne
Jackson, Edward Kasarskis,
Nicholas Procaccini, Mohammed
Sanjak, Fredrik Tolin
2:30 p.m.
S46.007
NeuroBANK™ and Global Unique
Patient Identifier Allow for Secure
Collaboration, Data Aggregation
and Sharing Alexander Sherman,
Igor Katsovskiy, Roger Selsov, Ervin
Sinani, Jason Walker, James Berry,
Jonathan Katz, Merit Cudkowicz
S47 Movement Disorders:
Huntington's Disease,
Ataxia, and Wilson's
Disease
1:00 p.m. Presentation of Jon
Stolk Award in Movement Disorders
for Young Investigators
Recipient:
Alice Chen-Plotkin, MD
Philadelphia, PA
1:15 p.m.
S47.002
The Huntington’s Disease-Behavioral
Questionnaire (HD-BQ): a New
Screening Tool for Behavioral
Disturbances in HD Jody CoreyBloom, Andrew Herndon, Elizabeth
Breen, Sean Huynh, Paul Gilbert
1:30 p.m.
S47.003
Selected Health and Life Style
Factors and Time to Phenoconversion
in Huntington’s Disease Caroline
Tanner, Karen Marder, Shirley
Eberly, Kevin Biglan, David Oakes,
Ira Shoulson
1:45 p.m.
S47.004
Safety and Tolerability of Selisistat
for the Treatment of Huntington’s
Disease: Results from a Randomized,
Double-Blind, Placebo-Controlled
Phase II Trial Ralf Reilmann,
Ferdinando Squitieri, Josef Priller,
Carsten Saft, Caterina Mariotti,
Sigurd Suessmuth, Andrea Nemeth,
Sarah Tabrizi, Oliver Quarrell,
David Craufurd, Hugh Rickards,
Anne Rosser, Darpo Borje, Tessari
Michaela, Szynol Angieszka, David
Fischer, Douglas Macdonald, Ignacio
Munoz-Sanjuan, Robert Pacifici,
Chris Frost, Ruth Farmer, Bernhard
Landwehrmeyer, Goran Westerberg
2:00 p.m.
S47.005
A Novel Familial Mutation in
the CACNA1A Gene Associated
with an Episodic Ataxia Type 2
Phenotype Jessica Tate, Mustafa
Siddiqui, Ihtsham Haq
2:15 p.m.
S47.006
Treatment of Spinocerebellar Ataxia
Type 2 (SCA2) with MOE Antisense
Oligonucleotides Daniel Scoles,
Gene Hung, Lance Pflieger, Khanh
Thai, Frank Bennett, Stefan Pulst
2:30 p.m.
S47.007
Complete Neurological Recovery in
Wilson Disease: Experience with
100 Consecutive Patients Seen from
2005-2013 Annu Aggarwal, Mohit
Bhatt
Neurology: MRI Imaging
1:00 p.m.
S48.001
Focal Cortical Patterns in
Hippocampal Sparing AD
Reveal Significant Clinical
Differences Melissa Murray,
Ranjan Duara, Ashley Cannon,
Amanda Liesinger, Owen Ross,
Ronald Petersen, Bradley Boeve,
Neill Graff-Radford, Dennis Dickson
1:15 p.m.
S48.002
Subcortical Rather Than Cortical
Microinfarcts Are More Strongly
Associated with Cerebral Cortical
Atrophy on MRI Ling Zheng, Harry
Vinters, Wendy Mack, Michael
Weiner, Helena Chui
1:30 p.m.
S48.003
Microinfarcts Are as Strongly
Related to Dementia as Tangles in
the Oldest-Old: the 90+ Study Maria
Corrada, Claudia Kawas, Szofia
Bullain, Joshua Sonnen
1:45 p.m.
S48.004
Pattern of Brain Atrophy Rates on
Serial MRI in Autopsy-confirmed
Dementia with Lewy Bodies Zuzana
Nedelska, Tanis Ferman, Bradley
Boeve, Scott Przybelski, Timothy
Lesnick, Melissa Murray, Jeffrey
Gunter, Matthew Senjem, Glenn
Smith, Yonas Geda, Jonathan
Graff-Radford, David Knopman,
Ronald Petersen, Clifford Jack,
Joseph Parisi, Dennis Dickson, Kejal
Kantarci
2:00 p.m.
S48.005
ApoE4 Worsens Hippocampal CA1
Apical Neuropil Atrophy and Episodic
Memory Geoffrey Kerchner,
Daniela Berdnik, Jadon Shen,
Jeffrey Bernstein, Michelle Fenesy,
Gayle Deutsch, Tony Wyss-Coray,
Brian Rutt
2:15 p.m.
S48.006
The EADC-ADNI Harmonized
Protocol for Hippocampal
Segmentation on Magnetic
Resonance: Evidence of
Validity Marina Boccardi, Martina
Bocchetta, Clarissa Ferrari, Simon
Duchesne, Clifford Jack, Giovanni
Frisoni
2:30 p.m.
S48.007
Genetic and Neuroanatomic
Associations in Sporadic
Frontotemporal Lobar
Degeneration Corey McMillan, Jon
Toledo, Brian Avants, Philip Cook,
Elisabeth Wood, Eunran Suh, David
Irwin, John Powers, Christopher
Olm, Lauren Elman, Leo McCluskey,
Gerard Schellenberg, Virginia Lee,
John Trojanowski, Vivianna Van
Scientific Sessions
1:00 p.m.
S49.001
Prospective Study of Cost of Care at
Multidisciplinary Centers Adhering to
AAN Amyotrophic Lateral Sclerosis
(ALS) Practice Parameters Rup
Tandan, Kevin Boylan, Todd Levine,
Catherine Lomen-Hoerth, Peter
Callas, Kimberly Maginnis, Mary
Lyon
1:15 p.m.
S49.002
Redesigned Stroke Care for a Value
Based World: Better Outcomes,
Lower Spending Waimei Tai, Lucy
Kalanithi, Jared Conley, Arnold
Milstein
1:30 p.m.
S49.003
Readmission Rates to the UAMS
Inpatient Neurology Services Jay
Hinkle, Archana Hinduja
1:45 p.m.
S49.004
Social Media and Multiple Sclerosis:
An Italian Experience Luigi
Lavorgna, Manuela De Stefano,
Daniela Buonanno, Eboli Simone,
Gallo Antonio, Simona Bonavita,
Gioacchino Tedeschi
2:00 p.m.
S49.005
Appropriateness of Dopamine
Antagonist Prescribing in
Hospitalized Patients with
Dopamine Requiring Diseases After
Implementation of an Automated
Prescribing Alert System Marie
Morris, Allison Willis, Franklin
McCann, Angela Birke, Brad Racette
2:15 p.m.
S49.006
High Accordance Rate of Neurologist
Referrals for Psychogenic Patients
with Expert Opinion at the Movement
Disorders Screening Clinic at the
Human Motor Control Section of
the National Institute of Neurologic
Disorders and Stroke Vesper
Ramos, Monica Anne Faye Villegas,
Alina Esquenazi, Mark Hallett
2:30 p.m.
S49.007
Limitations of Quantative EEG
Analysis in the Adult ICU. Mirhan
Ozbalik, Victor Gonzalez-Montoya,
Soundarya Gowda, Lawrence
Morton
Electrophysiology, Imaging
and Functional Connectivity
S51 Cerebrovascular
Neurology: Large Vessel
Atherosclerotic Disease
Founders Award
1:00 p.m. Presentation
of Michael S. Pessin Stroke
Leadership Prize
Recipient:
Shennan Weiss, MD, PhD
New York, NY
1:15 p.m.
S50.002
Extra-hippocampal Gray Matter
Atrophy in Seizure-free Patients
with Temporal Lobe Epilepsy
With and Without Hippocampal
Sclerosis Marina Alvim, Ana Coan,
Clarissa Yasuda, Brunno Campos,
Fernando Cendes
1:30 p.m.
S50.003
Resection of Ictal Phase Locked HFOs
Is Correlated with Outcome Following
Epilepsy Surgery Shennan Weiss,
Robert Connors, Garrett Banks,
Guy McKhann Jr, Binsheng Zhao,
Christopher Filippi, Ronald Emerson,
Andrew Trevelyan, Catherine
Schevon
1:45 p.m.
S50.004
Human Mesial Temporal Lobe
Single Neuron Dynamics During
Recruitment into a Generalizing
Seizure Amrit Misra, Xianda Long,
Ashwini Sharan, Michael Sperling,
Karen Moxon
2:00 p.m.
S50.005
Functional Connectivity Between
Insula, Hippocampus, and Amygdala
Investigated Using Cortico-Cortical
Evoked Potentials (CCEPs) Bilal
Zonjy, Ayham Alkhachroum, Emine
Kahriman, Nuria Lacuey, Jonathan
Miller, Hans Luders
2:15 p.m.
S50.006
Graph Theory Based Functional
Connectivity in Lateralized Temporal
Lobe Epilepsy Sharon Chiang, John
Stern, Jerome Engel, Harvey Levin,
Zulfi Haneef
2:30 p.m.
S50.007
Physiologic and Cortical Response
to Acute Psychosocial Stress in
Left Temporal Lobe Epilepsy Jane
Allendorfer, Heidi Heyse, Lucy
Mendoza, Jerzy Szaflarski
Recipient:
Hooman Kamel, MD
New York, NY
1:15 p.m.
S51.002
Vascular Inflammation Imaging
with 18F-FDG PET/CT for In-Stent
Restenosis After Intracranial
Stent Deployment in a Swine
Model Zhong-Song Shi, Zhong Liu,
Jin-Shan Wang, Dong-Hong Liu,
Xin-Chong Shi, Xiang-Song Zhang,
De-Ji Chen, Ying Liu, Yan-Qiu Liu,
Qing-Yuan Wang, Lei Feng
1:30 p.m.
S51.003
Safe Triage to Acute Versus Delayed
Carotid Imaging Is Achievable Using
ABCD3 Scores Johansson Elias,
Jakob Bjellerup, Per Wester
1:45 p.m.
S51.004
Frequency of Occurrence Acute
Asymptomatic Ischemic Lesions of
Brain After CAS. I. Sinitsyn
2:00 p.m.
S51.005
Effect of Carotid Revascularization
Endarterectomy Versus Stenting
Trial Results on Performance of
Carotid Artery Stent Placement and
Carotid Endarterectomy in United
States Farhan Siddiq, Malik Adil,
Ahmed Malik, Saqib Chaudhry,
Adnan Qureshi
2:15 p.m.
S51.006
The Cost Per Stroke Prevented (CPSP)
from Symptomatic Carotid Artery
Stenosis in Ontario, Canada David
Turkel-Parrella, Airton de Oliveira
Manoel, Thomas Marotta, Julian
Spears
2:30 p.m.
S51.007
Delay in the Diagnosis of Basilar
Artery Ischemic Stroke Joseph
Burns, Rima Sestokas, Christopher
Carr, Helena Lau, Deborah Green,
Anna Marisa Cervantes-Arslanian,
Rony Salem, Carlos Kase
S52 General Neurology III
1:00 p.m.
S52.001
Intra-spinal Transplantation of
Mesenchymal Stem Cell-Neural
Progenitor (MSC-NP) in Patients
with Amyotrophic Lateral Sclerosis
(ALS) Saeed Shahbeigi, Ehsaun
Hamediseresht, Nasser Aghadmi,
Reza Bakhshandepour, Abbas
Najjari, Forough Nejatollahi, Ghazal
Jalilzadeh, Sara Samavati, Maliheh
Heydari, Toraj Orang, Somaye
Noroozi
1:15 p.m.
S52.002
Connecting Invasive and Noninvasive
Brain Stimulation Michael Fox,
Randy Buckner, Andres Lozano,
Alvaro Pascual-Leone
1:30 p.m.
S52.003
Autoimmunity to Inhibitory Synaptic
Proteins in Stiff-Person Spectrum
of Symptoms Eugenia MartinezHernandez, Nuria Gresa-Arribas,
Mar Petit-Pedrol, Helena Ariño,
Albert Saiz, Francesc Graus, Josep
Dalmau
1:45 p.m.
S52.004
GCH1 Heterozygous Mutation
Identified by Whole-ExomeSequencing as a Treatable
Condition in a Patient Presenting
with Progressive Spastic
Paraplegia Zheng Fan, Robert
Greenwood, Ana Felix, Yael ShilohMalawsky, Myra Roche, Kristy
Crooks, Jonathan Berg, James Evans
2:00 p.m.
S52.005
Confirmed: The Antigen of
Paraneoplastic Antibodies Previously
Named “anti-Tr” Is Delta/Notch-like
Epidermal Growth Factor-related
Receptor (DNER) Maxwell Greene,
Yongjie Lai, Josep Dalmau, Eric
Lancaster
2:15 p.m.
S52.006
Aphasia as a Complication of CD19Targeted Chimeric Antigen Receptor
Immunotherapy Sarah Kranick, Giao
Phan, James Kochenderfer, Steven
Rosenberg, Avindra Nath
2:30 p.m.
S52.007
Does Therapeutic Hypothermia
Affect the Prognostic Accuracy of a
Clinical Neurological Examination
and SSEP? Dragancea Irina
S53 MS and CNS
Biomarkers and
1:00 p.m.
S53.001
Following Anti-CD20 Treatment
Immune-Competent B Cells Reoccur
in Bone Marrow and Spleen Before
They Can Be Detected in Peripheral
Blood Martin Weber
1:15 p.m.
S53.002
B Lymphocytes Induce CNS
Pathology Involving Reactive
Astrogliosis and Oligodendrocyte
Loss in a Murine System and in
Human Multiple Sclerosis Leila
Jackson, Danielle Harlow, Sean
Selva, Tracy Niedzielko, Wendy
Macklin, Timothy Vollmer
1:30 p.m.
S53.003
Increased CSF Level of Monocyte/
Microgrial Activation Maker in
Progressive-Multiple Sclerosis Mika
Komori, Andrew Blake, Elena Romm,
Yen-Chih Lin, Bibiana Bielekova
1:45 p.m.
S53.004
S1P Receptor Modulation by
Fingolimod Promotes Human
Oligodendrocyte Progenitor
Cell Differentiation Through
Cell-Autonomous and Non-Cell
Autonomous Mechanisms via ERK1/2
and p38MAPK Activation Qiaoling
Cui, Timothy Kennedy, Guillermina
Almazan, Jack Antel
2:00 p.m.
S53.005
Chitinase 3-like 1 and Chitinase
3-like 2 as Diagnostic and
Prognostic Biomarkers of Multiple
Sclerosis Eric Thouvenot, Geoffrey
Hinsinger, Nathalie Galeotti, Nicolas
Nabholz, Serge Urbach, Valerie
Rigau, Christophe Demattei, Sylvain
Lehmann, William Camu, Pierre
Labauge, Giovanni Castelnovo,
David Brassat, Laplaud DavidAxel, Olivier Casez, Joël Bockaert,
Philippe Marin
2:15 p.m.
S53.006
Dimethyl Fumarate Utilizes
Nrf2-independent and Nrf2dependent Pathways for Immune
Modulation Ulf Schulze-Topphoff,
Michel Varrin-Doyer, Kara Pekarek,
Robert Scannevin, Scott Zamvil
2:30 p.m.
S53.007
Antibodies Against the Inward
Rectifying Potassium Channel KIR4.1
Precede the Onset of Multiple
Sclerosis Viola Biberacher,
Rajneesh Srivastava, Sudhakar
Reddy Kalluri, Lucas Schirmer,
Dorothea Buck, Rebecca Selter,
Bernhard Hemmer
Thursday
May 1
S49 Practice, Policy,
and Ethics
Thursday, May 1
I9 Emerging Concepts in Headache Therapy
1:00 p.m.–5:00 p.m.
Coordinators: Andrew H. Ahn, MD, PhD and Morris Levin, MD, FAAN
1:00 p.m.–1:30 p.m.
Pathophysiology of Migraine: New Therapeutic Targets Andrew Charles, MD
1:30 p.m.–2:00 p.m.
Critical Challenges in the Diagnosis of Headache Peter Goadsby, MD, PhD
2:00 p.m.–2:30 p.m.
Opportunities and Controversies in Headache Medicine Richard B. Lipton, MD, FAAN
2:30 p.m.–3:00 p.m.
How Comorbidities Set the Agenda for Headache Therapy Deborah I. Friedman, MD, FAAN
3:00 p.m.–3:30 p.m.
Neuromodulation: Increasing the Gain on Headache Therapy Morris Levin, MD, FAAN
I9-1.001
Patient Satisfaction with
MAP0004: Results of an Optional Survey
During a Long-term Open-label Safety
Study Sheena Aurora, Dawn Buse, Biao
Lu, Donald Kellerman, Wade Cooper,
Shashidhar Kori
I9-1.004 Barriers to Chronic Migraine
I9-1.002 Optical Imaging of Facial
I9-1.005 Bilateral Pain
Perfusion in Migraine Jonas Peterson,
Lindsay Hunter, Melissa Cortez, Jeremy
Theriot, KC Brennan
I9-1.003 Therapeutic Efficacy of
Transcranial Direct Current Stimulation
in Trigeminal Neuralgia Mark Obermann,
Vera Bude, Dagny Holle, Tim Hagenacker, H.
Diener, Zaza Katsarava
Care: Results of the CaMEO (Chronic
Migraine Epidemiology and Outcomes)
Study Dawn Buse, Richard Lipton, Michael
Reed, Daniel Serrano, Kristina Fanning,
Aubrey Manack
Hypersensitivity over the Trigeminal
Region and Dental Deafferentations
in Patients with Classical Trigeminal
Neuralgia Nathalie Guy, Béatrice Claise,
Pierre Clavelou, Radhouane Dallel
I9-1.006 Idiopathic Intracerebral
Hypertension (IIH)/pseudotumor: Removing
Less CSF Is Best Franchesca Fiorito-Torres,
Melissa Rayhill, Michael Perloff
I9-1.007 Long Term Therapeutic
Response of Sphenopalatine Ganglion
(SPG) Stimulation for Cluster Headache—
Pathway CH-1 Study Miguel Lainez,
Rigmor Jensen, Arne May, Charly Gaul,
Anthony Caparso, Amy Goodman, Jean
Schoenen
I9-1.008 White Matter
Microstructure Abnormalities in Paediatric
Migraine Patients: In-Vivo Measures of
Brain Hyperexcitability? Roberta Messina,
Maria Rocca, Bruno Colombo, Elisabetta
Pagani, Andrea Falini, Giancarlo Comi,
Massimo Filippi
I9-1.009 Interictal Reduced
Cranial Parasympathetic Tone in Cluster
Headache Hilde Karen Ofte, Therese von
Hanno, Karl Alstadhaug
I9-1.010
Treatment of Withdrawal
Headache in Patients with Medication
Overuse Headache (MOH): A Randomized,
Single-blinded, Placebo Controlled
Study Sabina Cevoli, Giulia Giannini,
Valentina Favoni, Elisa Sancisi, Marianna
Nicodemo, Stefano Zanigni, Daniela
Grimaldi, Giulia Pierangeli, Pietro Cortelli
4:30 p.m.
I9-2.001
Mid-life Migraine and Late-life Movement
Disorder Symptoms: AGES-Reykjavik
Study Ann Scher, G. Ross, Sigurdur
Sigurdsson, Melissa Garcia, Larus
Gudmundsson, Sigurlaug Sveinbjornsdottir,
Vilmundur Gudnason, Lenore Launer
4:35 p.m.
I9-2.002
Efficacy and Safety of AVP-825, a Novel
Breath-Powered™ Powder Sumatriptan
Intranasal Treatment, for Acute
Migraine Roger Cady, John Messina,
Jennifer Carothers, Ramy Mahmoud
4:40 p.m.
I9-2.003
Characterization of Photosensitivity and
Pupil Oscillation Rate in Migraine Lindsay
Hunter, Jonas Peterson, Melissa Cortez,
Jeremy Theriot, K.C. Brennan
4:45 p.m.
I9-2.004
4:50 p.m.
I9-2.005
Chronic Migraine with Medication
Overuse Is Associated with Low Cognitive
Reserve Marian Gomez Beldarrain, Ane
Anton Ladislao, Urko Aguirre Larracoechea,
Alberto Cabrera Zubizarreta, Isabel Oroz,
Carlos Garcia-Monco Carra
Gammacore Device for Treatment of
Migraine Attack: Preliminary Data Licia
Grazzi, Susanna Usai, Gennaro Bussone
116
I10 The Global Burden of Neurological Diseases
1:00 p.m.–5:00 p.m.
Coordinators: Jerome H. Chin, MD, PhD, MPH and Massimo Pandolfo, MD
1:00 p.m.–1:15 p.m.
Global Health and Neurology Jerome H. Chin, MD, PhD, MPH; Massimo Pandolfo, MD
1:15 p.m.–1:45 p.m.
Global Epidemiology of Parkinson’s Disease Walter A. Rocca, MD, MPH
1:45 p.m.–2:15 p.m.
Neurocysticercosis and Epilepsy Oscar H. Del Brutto MD, FAAN
2:15 p.m.–2:45 p.m.
Cerebrovascular Disease in China Yi-Cheng Zhu, MD, PhD
2:45 p.m.–3:15 p.m.
Traumatic Brain Injury: The Neglected Global Epidemic Jerome H. Chin, MD, PhD, MPH
3:15 p.m.–3:30 p.m.
I10-1.001 Risk Factors for Epilepsy in
Children with HIV/AIDS in Botswana David
Bearden, Greg Bisson, Dennis Kolson,
Andrew Steenhoff, Sudha Kessler, Dennis
Dlugos
I10-1.002 Comparing Cognitive
Screening Tools in a Rural Ecuadorian
Population: The Atahualpa Project Clinton
Wright, Hannah Gardener, Mauricio
Zambrano, Victor Del Brutto, Oscar Del
Brutto
I10-1.003 The Risk of Large-artery
I10-1.004 Incidence and Mortality
I10-1.006Neuro-Developmental
I10-1.005 Prevalence, Incidence and
I10-1.007 Clinical and Bacteriological
of Ischemic Stroke Subtypes in Joinville,
Brazil: A Population-based Study Marcos
Lange, Norberto Cabral, Carla Moro,
Alexandre Longo, Anderson Goncalves,
Viviane Zetola, Tatjana Rundek
Associations Between APOE Genotype,
Cardiovascular Risk Factor and Dementia
in Cuban Populations Jorge Jesús Llibre
Guerra, Milagros Guerra, Juan Carlos Llibre
Guerra, Juan Jesús Llibre Rodriguéz
Atherosclerotic Stroke Is Proportionally
Greater than Cardioembolic Stroke in
HIV-infected Individuals Compared to HIVuninfected Controls Felicia Chow, Richard
Price, Priscilla Hsue, Anthony Kim
Disorders in India—From Epidemiology to
Public Policy Donald Silberberg, Narendra
Arora, Vinod Bhutani, Maureen Durkin,
Shefalli Gulati, Mkc Nair, Jennifer PintoMartin
Features of Central Nervous System
Tuberculosis in Patients with HIV-Infection
in Siberian Region of Russia Yury Bykov,
Tatiana Filippova, Olga Novitskaya
I10-1.009 A Phone App to Diagnose
Epileptic Seizures: A Useful Tool to Reduce
the Epilepsy Treatment Gap in Poorer
Countries Victor Patterson, Mamta Singh,
Hemav Rajbhandari
I10-1.010 Hypertension in Rural
Uganda: Findings from a Community-Based
Screening Project Jerome Chin
I10-1.008 Stroke Mortality and Its
Predictors in Nigeria: Results of a HospitalBased Study Kolawole Wahab, Emmanuel
Sanya, Babatunde Ademiluyi, Bello
Abiodun, Wemimo Alaofin
I10-2.001
The Association Between Meeting Life’s
Simple 7 Goals and Mortality After Stroke
in the US Michelle Lin, Daniela Markovic,
Bruce Ovbiagele, Amy Towfighi
4:35 p.m.
I10-2.002
4:40 p.m.
I10-2.003
Variations in Brain Death Declaration: A
Worldwide Survey Sarah Wahlster, Eelco
Wijdicks, Pratik Patel, David Greer, Claude
Hemphill, Farrah Mateen
Indonesia Stroke Registry Fenny Yudiarto,
Mochammad Machfoed, Amir Darwin,
Anam Ong, Muhammad Karyana, Siswanto
4:45 p.m.
I10-2.004
Helping Haiti: Addressing the Burden of
Neurologic Disease Veronica Santini,
Anthony Alessi, Elaine Jones, Mill Etienne,
Anna Hohler
4:50 p.m.
I10-2.005
Performance of Cerebrospinal Fluid (CSF)
Plasmodium falciparum Histidine-Rich
Protein-2 (pfHRP-2) in Prediction of Death
in Cerebral Malaria Kiran Thakur, Jimmy
Vareta, Kathryn Carson, Terrie Taylor, David
Sullivan, Karl Seydel
117
Thursday
May 1
4:30 p.m.
Thursday, May 1
First Authors stand by Posters from 5:00 p.m.–6:30 p.m
3:00 p.m.–6:30 p.m.
oster Discussion Session:
P
Neuromuscular and Clinical Neurophysiology (EMG) II
P7.001
Deletion of Sarm1 Gene
Protects Against Paclitaxel-induced
Peripheral Neuropathy Ahmet Hoke, Elliot
Turkiew, Nicole Reed
P7.002
Frequency and Time
to Relapse after Discontinuing
6-month Therapy with Intravenous
Immunoglobulin or Methylprednisolone
in Chronic Inflammatory Demyelinating
Polyradiculoneuropathy Eduardo
Nobile-Orazio, Dario Cocito, Stefano Jann,
Antonino Uncini, Paolo Messina, Ettore
Beghi, Giovanni Antonini, Raffaella Fazio,
Francesca Gallia, Angelo Schenone, Ada
Francia, Davide Pareyson, Lucio Santoro,
Stefano Tamburin, Guido Cavaletti, Fabio
Giannini, Mario Sabatelli
P7.003
Sudoscan as a Diagnostic
Tool for Diabetic and Idiopathic Peripheral
Neuropathy A. Smith, Margaret Lessard, J.
Singleton
P7.004
Defective Muscle
Mitochondrial Biogenesis in Spinal
Muscular Atrophy. Dario Ronchi, Michela
Ripolone, Emanuele Barca, Angela
Berardinelli, Lucia Morandi, Marina Mora,
Andreina Bordoni, Francesco Fortunato,
Gigliola Fagiolari, Raffaella Violano, Dionis
Vallejo, Stefania Corti, Antonio Toscano,
Monica Sciacco, Salvatore DiMauro,
Giacomo Comi, Maurizio Moggio
P7.005
Genetic Epidemiology of
C9ORF72 in ALS: a National Study in
Italy Adriano Chio, Stefania Battistini,
Andrea Calvo, Claudia Caponnetto,
Francesca Conforti, Massimo Corbo, Fabio
Giannini, Jessica Mandrioli, Fabrizio Salvi,
Gabriele Mora, Mario Sabatelli, Vincenzo
La Bella, Giancarlo Logroscino, Isabella
Simone, Maria Monsurrò, Letizia Mazzini,
Giuseppe Borghero, Francesco Logullo,
Christian Lunetta, Paolo Volanti, Maura
Pugliatti, Paola Mandich, Sandra D’Alfonso,
Silvana Penco, Marcella Zollino, Maria
Murru, Gabriella Restagno
P7.006
Increased Cerebral Oxidative
Stress in Amyotrophic Lateral Sclerosis: A
62
Cu-ATSM PET Study Masamichi Ikawa,
Hidehiko Okazawa, Tetsuya Tsujikawa,
Tomoko Muramatsu, Toru Kishitani, Tomoko
Kamisawa, Akiko Matsunaga, Osamu
Yamamura, Tetsuya Mori, Tadanori Hamano,
Yasushi Kiyono, Yasunari Nakamoto,
Makoto Yoneda
P7.008
P7.007
P7.009
The Diagnostic Value
of Diffusion Tensor MRI Metrics in
Relation to the MND Phenotype
Heterogeneity Edoardo Spinelli, Federica
Agosta, Nilo Riva, Massimiliano Copetti,
Sebastiano Galantucci, Adriano Chiò,
Stefano Messina, Sandro Iannaccone,
Andrea Calvo, Vincenzo Silani, Andrea
Falini, Giancarlo Comi, Massimo Filippi
Muscular Dystrophy
Association U.S. Neuromuscular Disease
Registry—Preliminary Findings Jodi Wolff,
Joline Dalton, Valerie Cwik, Annie Kennedy,
Michelle Morgan, Jane Larkindale, Alan
Beggs, Joshua Benditt, James Berry,
Thomas Crawford, Emily Munson, Rachel
Richesson, Jeffrey Rosenfeld, Carly Siskind,
Kevin Flanigan
The Course and Outcome of
Pregnancy in Women with Nondystrophic
Myotonias Yuliya Snyder, Colleen DonlinSmith, Eva Pressman, Emma Ciafaloni
P7.010
Myasthenia and Risk of
Cancer: A Population-based Case-control
Study Emil Pedersen, Anton Pottegaard,
Jesper Hallas, Soren Friis, Klaus Hansen,
Poul Erik Jensen, David Gaist
NEW! e
Poster Session: Neuro-oncology
P7.011
Differential Sensitivity of
Oligodendrocyte Precursor Cells and
Microglia to Methotrexate in Grey Versus
White Matter Lauren Wood, Sarah Miller,
Hannes Vogel, Michelle Monje
P7.013
P7.012
Functional Expression of K2P
Potassium Channels in Tumor Infiltrating
Lymphocytes of Malignant Glioma Ole
Simon, Thomas Muentefering, Stefan
Bittner, Nico Melzer, Heinz Wiendl, Oliver
Grauer, Sven Meuth
P7.014
General Neurology VII
P7.024
Polyneuropathy in Multiple
Myeloma Patients Correlate with the
Presence of Autoantibodies Adam
Niezgoda, Slawomir Michalak, Lidia Gil,
Mieczyslaw Komarnicki, Wojciech Kozubski
Development of a
Mouse Model of Leptomeningeal
Metastasis Adrienne Boire, Lisa DeAngelis,
Joan Massagué
P7.021
Babinski or Withdrawal?
A New Way to Decide Sayyed Sohrab,
Douglas Gelb
P7.022
P7.025
P7.023
Rare Presentation of Eagle’s
Syndrome as Bell’s Palsy Nancy Rosales,
Rachana Gandhi, Ramon Lugo
118
Paraneoplastic Neurological
Syndromes: A Single Institution 10-Year
Case Series Amy Chan, Joachim Baehring
P7.017
Delayed Diagnosis of
Brachial Plexus Neurolymphomatosis in
Post-transplant Patient with Diffuse Large
B-cell Lymphoma Milena Stosic, Sudhakar
Tummala
P7.015WITHDRAWN
When the Typical Becomes
Atypical: Anti-Ri Antibody Associated
Paraneoplastic Syndrome WITHOUT
Opsoclonus-Myoclonus Yadira VelazquezRodriguez, Divpreet Kaur, Aiesha Ahmed
Absent Inferior Vena Cava
with Resulting Venous Congestion
Causing Intermittent Cauda Equina
Dysfunction Carrie Grouse, Steven Lewis
P7.016
Diagnostic Confusion About
a Confused Patient: A Case of Delayed
Post-Anoxic Leukoencephalopathy
Syndrome Tammam Dayyoub, Ahmad Riad
Ramadan, Panayiotis Mitsias
P7.026
Nutritional Intake and Iron
Bioavailability in Adolescents with Postural
Tachycardia Syndrome Imad Jarjour, Keli
Hawthorne, Steven Abrams
P7.027
Restoration of Altered
Epigenetic Signature by a Quinoline
Compound, S4, (2-(2-methylquinolin-4ylamino)-N-phenyl acetamide), Resulting
in Inhibition of Alcohol Drinking Tuhin
Banerjee
P7.028
Mitochondrial Variants in
ALS Kevin Kenna, Russell McLaughlin,
Susan Byrne, Marwa Elamin, Colette
Donaghy, Daniel Bradley, Orla Hardiman
P7.029
Refractory IgG4Related Intracranial Hypertrophic
Pachymeningitis Bing Liao, Carlos Kamiya
Matsuoka, Xiang Fang, Robert Smith
P7.018
Non-Richter’s Transformation
CLL in the CNS: A Case Series Varoon
Thavapalan, Lawrence Kenyon, Moshe
Mizrahi
P7.019
Photodynamic Therapy (PDT)
of Brain Tumors Venu Parachuri, Akshat
Katyayan, Harry Whelan
P7.020
Primary Central Nervous
System Lymphoma in Rheumatoid Arthritis
Treated with Leflunomide Andrew Bayat,
Jeremy Jones, Harris Naina
P7.030
Detecting Malingering: The
Honest Palm Sign David Black
P7.031
Case Report of Weston Hurst
Syndrome Rick Magun, John Provias
P7.032
A Case of PML After Initiation
of Brentuximab Vedotin for CD30 Positive
Cutaneous T Cell Lymphoma Judy Jia,
Ethan Goldberg, Joseph Berger, Amy Pruitt
Poster Session VII
Electroencephalographic and
Positron Emission Tomography Correlates
in Anti-N-methyl-D-aspartate Receptor
Encephalitis David Benavides, John
Probasco, Beatriz Wills, Angela Wabulya,
Gregory Bergey, Peter Kaplan
P7.046
P7.034
P7.047
Extra-motor Symptoms in
Amyotrophic Lateral Sclerosis. Analysis
of 112 Patients Hector Martinez, Jorge
Moreno-Cuevas, María-Teresa GonzalezGarza, Arturo Robles Tenorio, César
Escamilla Ocañas, Sergio Salazar Marioni,
Ubaldo Martínez
P7.035Hyperammonemic
Encephalopathy in Late-Onset Ornithine
Transcarbamylase (OTC) Deficiency
Unmasked by Acetaminophen
Overuse Heeral Mehta, Danyel Tacker,
Anne Josiah, Paola Pergami
P7.036
Picture This! A Meta-Analysis
Comparing Affective Salience of Words
Versus Images Eithan Kotkowski, Peter Fox
P7.037
The Belgian Neuromuscular
Disease Registry, Results of the 2012
Data Anna Roy, Philip Van Damme, Peter
Van den Bergh, Viviane Van Casteren
P7.038
Abnormal Near Field
Potentials of Brainstem Origin in
Parkinson’s Disease (PD) Fidias LeonSarmiento, Rosanna Sobota, Richard Doty
P7.039
CXCL10, CCL5 and IL-6 in
Cerebrospinal Fluid of Neuropsychologically
Unaffected Patients Correlate with
Neurofilament H Simon Faissner, Björn
Ambrosius, Norbert Brockmeyer, Gabriele
Arendt, Ralf Gold, Thomas Grunwald,
Andrew Chan
P7.040
Prevalence and Predictors of
Suicidal Ideation in Epilepsy and Multiple
Sclerosis Leah Dickstein, Amy Nowacki,
Adele Viguera
Movement Disorders:
Deep Brain Stimulation for
P7.041
How Thin Can a Deep Brain
Stimulation Lead Be? Zhe Li, Khong Siong
Ng, Yan Ye, Xiaoping Li
P7.042
Wearable Sensors for
Quantifying Deep Brain Stimulation
Washout Effects on Gait in Parkinson’s
Disease Elizabeth Brokaw, Thomas Mera,
David Riley, Benjamin Walter, Alberto Espay,
Fredy Revilla, Joseph Giuffrida, Dustin
Heldman
P7.043
How Optogenetics Can
Help Improve Deep Brain Stimulation
for the Motor Symptoms of Parkinson’s
Disease John Eraifej, Hardev Pall
P7.044
Neuronal Oscillation Patterns
in the Subthalamic Nucleus in Parkinsonia
Patients with Off Dystonia Ping Zhuang,
Mark Hallett, Li Xiaoyu, Yuqing Zhang,
Jianyu Li, Yongjie Li
P7.045
Deep Brain Stimulation
(DBS) and Oropharyngeal Dysfunction
in Parkinson’s Disease (PD): A Case
Report Pichet Termsarasab, Winona Tse
Impedance Changes Occur
During Threshold Measurements in Deep
Brain Stimulation Patients Stephen
Carcieri, Martin Reich, Frank Steigerwald,
Michael Barbe, Ljubomir Manola, Lars
Timmermann, Jens Volkmann
Atrophy and the Emergence
of Induced Side Effects in Deep Brain
Stimulation Daniel Martinez-Ramirez,
Takashi Morishita, Pam Zeilman, Michael
Okun
P7.048
Comorbidities and the
Outcome of Deep Brain Stimulation
Surgery in Parkinson’s Disease Faisal
Alsallom, Hesham Abboud, Gencer Genc,
Srivadee Oravivattanakul, Anwar Ahmed,
Scott Cooper, Michal Gostkowski, Andre
Machado, Hubert Fernandez
P7.049
A Multiple-Target DBS
Strategy for Parkinson’s Disease. MasaAki Higuchi, Takashi Morishita, Kelly Foote,
Kelsey Nestor, Justin Hillard, Michael Okun
P7.050
Deep Brain Stimulation of the
Nucleus Accumbens Has Positive Effects on
Parkinson’s Disease-related Apathy Nolan
Williams, Baron Short, Emily Williams,
Alexandra Jeffery, Suzanne Kerns, Gregory
Sahlem, Colleen Hanlon, Gonzalo Revuelta,
Istvan Takacs, Mark George
Movement Disorders:
Surgical Approaches to
P7.051
Acute Lower Urinary Tract
Dysfunction After Bilateral STN Deep Brain
Stimulation Surgery for PD: Case Reports
and Literature Review Richard Salazar,
Toby Chai, Paul Fishman, Howard Eisenberg,
Stephen Reich
P7.052
Determinants of the
Frequency of Post-Operative DBS Office
Visits Justin Martello, Melissa Armstrong,
Ann Gruber-Baldini, Erik Barr, Stephen
Reich, Paul Fishman, Lisa Shulman
P7.053
Contextual Regulation of
Simple Decisions in Parkinson’s Disease:
Effects of STN-DBS and L-Dopa Miguel
Ulla, Philippe Domenech, Valentin Wyart,
Laetitia Silvert, Jean Claude Dreher, Franck
Durif
P7.054
Interleaving Could be a Better
Programming Technique for Parkinson’s
Disease and Dystonia Patients Denny
Reyes, Michelle Ferreira, Nestor GalvezJimenez, Tarannum Khan
P7.058
Impact of Socioeconomic
Status on Outcome of Deep Brain
Stimulation Surgery for Parkinson’s
Disease Gencer Genc, Hesham Abboud,
Srivadee Oravivattanakul, Faisal Alsallom,
Nicholas Thompson, Scott Cooper, Michal
Gostkowski, Andre Machado, Hubert
Fernandez
P7.059
Effect of Dorsal and Ventral
Subthalamic Nucleus Deep Brain
Stimulation on Actual and Perceived Sense
of Postural Balance Travis Larsh, Jonathan
Eskenazi, Enrique Urrea Mendoza, Ashutosh
Mani, Amit Bhattacharya, Andrew Duker,
Cyndy Cox, Maureen Gartner, Fredy Revilla
P7.060
Dorsal and Ventral
Stimulation Induced Cerebral Blood Flow
and Motor Responses Mwiza Ushe,
Meghan Campbell, Samer Tabbal, Morvarid
Karimi, Johanna Hartlein, Tamara Hershey,
Joel Perlmutter
Movement Disorders:
Dystonia Treatment
Movement Disorders:
Treatment of Parkinson’s
Disease and Other Disorders
P7.070
Mayo Clinic Florida
Collection of Human Skin Fibroblast
Cultures from Patients with Hereditary
Neurodegenerative Disorders Zbigniew
Wszolek, Pawel Tacik, Shinsuke Fujioka,
Audrey Strongosky, Jing Zhao, Takahisa
Kanekiyo, Guojun Bu
P7.071
P7.072
Cervical Dystonia
Patient Registry for Observation of
OnabotulinumtoxinA Efficacy (CD
PROBE): Treatment Patterns and Subject
Disposition P. Charles, Joseph Jankovic,
Cynthia Comella, Mark Stacy, Marc
Schwartz, Aubrey Manack, Mitchell Brin
P7.063ANCHOR-CD
(AbobotulinumtoxinA Neurotoxin: Clinical
and Health Economics Outcomes Registry
in Cervical Dystonia): A Multicenter,
Observational Study of Dysport in Cervical
Dystonia: Baseline Data and Cycle One
Efficacy Data Daniel Truong, Richard
Trosch, Cynthia Comella, Jack Chen,
Dominic Marchese, Chandra Abbott, Wes
Cetnarowski, Alberto Espay
P7.064
Clinical Audit of the Efficacy of
Xeomin Against Dysport for the Treatment
of Dystonia Daveena Meeks, Christopher
Clough
P7.065
P7.066
Globus Pallidus Versus
Stimulation For Parkinson’s Disease: A
Meta-Analysis Michele Tagliati, Valentina
Pecoraro, Giuseppe Rengo, Cristina Motto,
Lorenzo Moja, Gennaro Pagano
Treatment Outcomes in
Cervical Dystonia Patient Registry for
Observation of OnabotulinumtoxinA
Efficacy (CD PROBE) Joseph Jankovic,
Charles Adler, P. Charles, Cynthia Comella,
Mark Stacy, Marc Schwartz, Aubrey
Manack, Mitchell Brin
P7.062
P7.056
P7.057
P7.069
Response to
IncobotulinumtoxinA After Resistance
to OnabotulinumtoxinA and
RimabotulinumtoxinB Vesper Ramos,
Barbara Karp, Codrin Lungu, Katharine Alter,
Mark Hallett
P7.061
Concurrent Bilateral Vim
and STN DBS in a Patient with ET/
PD Subhashie Wijemanne, Olga Waln,
Joohi Jimenez Shahed
Comparison of Screening
Tools for Assessing Deep Brain Stimulation
Candidacy in Parkinson Disease Kelvin
Chou, Robert Coleman, Parag Patil, Vikas
Kotagal
Stability of Botulinum Toxin
A Dosage Over Time in Patients with
Hemifacial Spasm, Blepharospasm and
Cervical Dystonia/Torticollis. Shira
McMahan, Denny Reyes, Tarannum Khan
Changes in Troublesome
Dyskinesia and its Relationship with
Dose in Advanced Parkinson’s Disease
Patients Treated with Levodopa-Carbidopa
Intestinal Gel Infusion Angelo Antonini,
Victor Fung, James Boyd, John Slevin,
Coleen Hall, Jordan Dubow, Krai Chatamra,
Janet Benesh
The Retrospective Evaluation
of the Dose of IncobotulinumtoxinA and
OnabotulinumtoxinA for the Clinical
Management of Cervical Dystonia
and Blepharospasm: TRUDOSE Pilot
Study Charalampos Tzoulis, Ruth Kent,
Adrian Robertson, John Maltman, Chris
Purdy, Raf Magar
P7.055
P7.068
Deep Brain Stimulation In
Patients with Primary Dystonia with GNAL
Mutation: A Case Series Harini Sarva,
Richard Trosch, Amanda Glickman, Deborah
Raymond, Laurie Ozelius, Susan Bressman,
Rachel Saunders-Pullman
P7.067
Patient experience of
Botulinum toxin injections for dystonia and
hemifacial spasm: knowledge of diagnosis
and treatment David Grosset, Elaine Tyrrell,
Katherine Grosset, Donald Grosset
Apomorphine Improves
Morning Akinesia in Parkinson’s Disease:
Interim Analysis of the AM-IMPAKT
Trial Stuart Isaacson, William Ondo,
Fernando Pagan
P7.073
Approach to Treatment
of Depression in Parkinson’s Disease:
Results from NPF-QII Peter Schmidt, Mark
Guttman, Laura Marsh, John Nutt, Tanya
Simuni, Eugene Nelson, Jorge Zamudio,
Michael Okun
P7.074
Pathophysiological Decrease
in the Regional Cerebral Blood Flow
in Pure Autonomic Failure with Lewy
Body Tomoko Kamisawa, Masamichi
Ikawa, Yuki Saito, Tomoko Muramatsu,
Akiko Matsunaga, Osamu Yamamura,
Tadanori Hamano, Shigeo Murayama,
Yasunari Nakamoto, Hidehiko Okazawa,
Makoto Yoneda
P7.075
Complicated Hereditary
Paraplegia with Novel B4GALNT1
Mutations Expanding, the Phenotype and
Genotype Saeed Bohlega, Salma Wakil,
Dorota Monies, Edward Cupler, Layla
Bastaki, Brian Meyer
P7.076
Spinal Cord Atrophy in
Hereditary Spastic Paraplegia Caused by
SPG4 Mutations Lucas Branco, Lamas
Gustavo, Felipe Bergo, Iscia Lopes-Cendes,
Marcondes Franca, Jr.
P7.077
Cerebral Damage in SPG4Hereditary Spastic Paraplegia (HSP):
a VBM Study Gustavo Lamas, Cynthia
Bonilha Da Silva, Thiago Rezende, Iscia
Lopes-Cendes, Marcondes Franca, Jr.
P7.078
A Novel Objective Brain MRI
Assessment Scale for Wilson disease
(MAS for WD) Annu Aggarwal, Mihir
Munshi, Darshana Sanghvi, Amruta Ravan,
Saloni Parekh, Pooja Rane, Mohit Bhatt
119
Thursday
May 1
P7.033
Thursday, May 1
P7.079
Dystonia in Machado-Joseph
Disease (MJD/SCA3) Is Associated with
Thalamic and Brainstem Atrophy Alberto
Martinez, Marcelo Nunes, Thiago Rezende,
Rachel Guimarães, Anelyssa D’Abreu, Iscia
Lopes-Cendes, Marcondes Franca, Jr.
Movement Disorders:
Parkinson’s Disease Therapy
P7.080
IPX066 Dose Conversion from
Immediate-Release Carbidopa-Levodopa,
Carbidopa-Levodopa+Entacapone, and
Controlled-Release Carbidopa-Levodopa
in Patients with Advanced Parkinson’s
Disease (PD) Ann Hsu, Sarita Khanna,
Sherron Kell, Robert Rubens, Suneel Gupta
P7.081
Long-term Safety and
Maintenance of Efficacy from an Openlabel Extension of the Double-blind Pivotal
Study of Levodopa-carbidopa Intestinal
Gel (LCIG) in Advanced Parkinson’s Disease
Patients Hubert Fernandez, Rejko Krueger,
John Slevin, Coleen Hall, Susan Eaton,
Jordan Dubow, Krai Chatamra, Janet
Benesh
P7.082
Improved Motor Performance
Associated with Smoother Levodopa
Time-Concentration Profiles with
DM-1992, a Gastroretentive, Extendedrelease Carbidopa/Levodopa Tablet,
in Patients with Advanced Parkinson’s
Disease Leonard Verhagen Metman,
Natividad Stover, Cuiping Chen, Verne
Cowles, Michael Sweeney
P7.083
Safety Analyses from Openlabel Clinical Trials of Levodopa-Carbidopa
Intestinal Gel in Patients with Advanced
Parkinson’s Disease: Events Not Related
to Device or Procedure Anthony Lang,
Sylvain Chouinard, Cindy Zadikoff, Weining
Robieson, Jordan Dubow, Krai Chatamra,
Janet Benesh
P7.084
OPTIPUMP: Different
Treatment Strategies Using Continuous
Apomorphine Pump Therapy in
Parkinsonian Patients and Their Influence
on Patient Quality of Life. A French
6 Month, 145 Patients, Propective,
Multicentre, Observational Study Sophie
Drapier, Marc Verin, David Devos, Alexandre
Eusebio, Emmanuel Roze, Bertrand Degos,
Caroline Moreau, Jean Azulay, Francois
Viallet, Luc Defebvre, Christine BrefelCourbon, Christine Tranchant, Valérie Fraix,
Sébastien Woynar, David Andrieu, Adrien
Borsik, Laetitia Mauger, Franck Durif
P7.085
Gastrointestinal Safety of the
Levodopa-Carbidopa Intestinal Gel Delivery
System in Treating Advanced Parkinson’s
Patients Michael Epstein, David Johnson,
Robert Hawes, Nathan Schmulewitz,
Arvydas Vanagunas, Susan Eaton, Krai
Chatamra, Weining Robieson, Janet Benesh
P7.086
A Novel Approach to
Treating Impulse Control Disorders (ICDs)
in Parkinson’s Disease (PD)—a Case
Series John Liang, Mark Groves, Vicki
Shanker
120
P7.087
Phase-3 Clinical Trials of
Adjunctive Therapy with Preladenant,
an Adenosine 2a Antagonist, in Patients
with Parkinson’s Disease Robert Hauser,
Fabrizio Stocchi, Olivier Rascol, Susan
Huyck, Xianwei Ha, Rachel Capece, Kenneth
Wolski, Tony Ho, Peter Sklar, Christopher
Lines, David Michelson, David Hewitt
P7.088
Post-hoc Analyses of Phase-3
Data with Preladenant, an Adenosine 2a
Antagonist, in Patients with Parkinson’s
Disease Olivier Rascol, Robert Hauser,
Fabrizio Stocchi, Xianwei Ha, Rachel
Capece, Kenneth Wolski, Tony Ho, Peter
Sklar, Christopher Lines, David Michelson,
David Hewitt, Susan Huyck
Neuromuscular Disease: Therapy
P7.089WITHDRAWN
P7.090
The Effect of Intravenous
Immunoglobulin on Regulatory T Cells
and Disability Progression in Patients
with Chronic Inflammatory Demyelinating
Polyradiculoneuropathy Jason Thonhoff,
Luis Lay, Sharon Halton, David Beers, Ericka
Simpson
P7.091
Anti-TNF Alpha-induced
Neuropathies Pinelopi Tsouni, Olivier Bill,
David Benninger, Francois Ochsner, Thierry
Kuntzer
P7.092
Multicentre, Randomised,
Open-label Trial to Compare Efficacy
and Tolerance of Prednisone and IVIG in
Patients with CIDP on a One-year FollowUp Jean-Philippe Camdessanche, Karine
Ferraud, Emmeline Lagrange, Karine Viala,
Victor Chan, Nathalie Guy Renouil, Sarah
Louis Leonard, Andoni Echaniz-Laguna,
Gerard Besson, Francoise Bouhour, Emilien
Delmont, Agnes Fromont, Julien Gallard,
Armelle Magot, Guillaume Nicolas, David
Uzenot, Blanc-Lassere Karine, Tanya
Stojkovic, Sandrine Wiertlevski, Boutte
Celia, Jean-Christophe Antoine
P7.093
Small Fiber Neuropathy
in Sarcoidosis: The Cleveland Clinic
Experience Zubair Ahmed, Jinny Tavee,
Daniel Culver, Joseph Parambil
P7.094
Effect of Agmatine Sulfate on
Neuropathic Pain Vahid Tohidi, Bahareh
Hassanzadeh, Karna Sherwood, Wei Ma,
Michael Rosenberg, Varda Gilad, Gad Gilad
P7.095
Assessment of 2 Patients with
Myotonia Congenita Following Intravenous
Lidocaine Treatment Saugat Dey, David
Roshal, Luisa Rojas, Robert Schwartzman,
Anahita Deboo, Terry Heiman-Patterson
P7.096
Angiotensin Receptor
Blockade Can Ameliorate Peripheral Nerve
Inflammation in Experimental Autoimmune
Neuritis Toshiki Fujioka, Hisao Kitazono,
Wataru Hagiwara, Masashi Inoue, Shingo
Konno
P7.097
Agomelatine Increases
Muscle Strength and Reduces the
Expression of Inflammatory Cytokines
in mdx Dystrophic Mice Alzira Carvalho,
Vinicius Tondato, Larissa Iamnhuk, Fernanda
Gomiero, Giuliana Petri, Pamela Delgado,
Beatriz Alves, Fernando Fonseca, David
Feder
3:00 p.m.–6:30 p.m.
P7.098
Assessment of Bulbar
Function in ALS Clinical Trials Richard
Smith, Gary Pattee, Erik Pioro, David
Schoenfeld
Neuromuscular Health Services/
Outcomes Research
P7.099
Ig Treatment Outcomes
Assessment and Clinical Guidelines Study
(the “INSIGHTS Study”): Preliminary
Findings on Scope of Practice from
the INSIGHTS Database Todd Levine,
Jonathan Katz, Richard Barohn, Tahseen
Mozaffar, Gil Wolfe, David Saperstein, Lara
Katzin, Mazen Dimachkie, Elissa Ritt, Leslie
Vaughan, Michelle Greer
P7.100
Trends in Outcome and Cost
of Hospitalization of Elderly Myasthenia
Gravis Patients from 1992 to 2009
Data from Nationwide Inpatient Survey
(NIS)1997-2009 Andrew Ji, Ankit Pahwa,
Nizar Souayah
P7.101
Racial and Ethnic Differences
Across Amyotrophic Lateral Sclerosis
(ALS) Cases from Three State and
Eight Metropolitan Area Surveillance
Projects Lindsay Rechtman, Heather
Jordan, Laurie Wagner, D. Kevin Horton,
Wendy Kaye
P7.102
Profile of Medical Care Costs
in Patients with Amyotrophic Lateral
Sclerosis in Medicare Program and Under
Commercial Insurance Lisa Meng, Scott
Jordan, Amy Bian, Jinsy Andrews, Jeremy
Shefner, Andrew Wolff, Helen Blumen,
Kosuke Iwasaki, Bruce Pyenson
P7.103
Is Intravenous Immunoglobulin
More Cost Effective Than Plasmapheresis
in Treatment of Pediatric Myasthenia
Gravis Patients? Data from Kids’ Inpatient
Database (KID) and Nationwide Inpatient
Sample (NIS) Ankit Pahwa, Rania Elenein,
Nizar Souayah
P7.104
The Safety Profile of Home
Infusion of Intravenous Immunoglobulin
in Neuroimmunological Disorders Ankit
Pahwa, Melissa Allan, Shari O’Connor, Kelly
Corl, Nizar Souayah
P7.105
Trends in Outcome and Cost of
Hospitalization of Adult Myasthenia Gravis.
Data Analysis from Nationwide Inpatient
Survey (NIS) from 1992 to 2009 Wenzhuan
He, Weizhen Wang, Anshul Saxena, Hafiz
Khan, Ankit Pahwa, Nizar Souayah
P7.106
ALD Connect, an Allinclusive Consortium to Improve
Care and Drug Discovery for X-Linked
Adrenoleukodystrophy Florian Eichler, Ben
Lenail, Keith van Haren, Ali Fatemi, Anthony
Gonzalez, Gerald Raymond, Leila Jamal,
Joshua Bonkowsky, Sanjay Magavi, John
Fink, Tara O’Meara, Robert Brown, Amber
Salzman, Alexander Sherman
P7.107
Con-focal Microscopy
Documents Significant Epidermal Nerve
Demyelization in Patients with Clinical
Neuropathy But Normal Neurophysiologic
Studies Amiram Katz
P7.108
Validation of Diseasespecific Patient Reported Outcomes in the
Home Environment Gretchen Ayer, Lisa
Christopher-Stine, Shafeeq Ladha, Tahseen
Mozaffar, Yuen So, Michael Hehir, Nicholas
Silvestri
Neuromuscular Outcome
Measures
P7.109
Axonal GBS in a Midwest
Medical Center; Clinical Characteristics
and Outcome Muna Irfan, Pezhman
Roohani, Ezgi Tiryaki
P7.110
Recommended Cut-off Values
for Diagnosis of Carpal Tunnel Syndrome
Using Ultrasonography in Females Ha
Ra Jeon, Jung Bin Shin, Seong Woo Kim,
Hyoung Seop Kim, Ji Sung Hong, Da Wa
Jung, Da Sol Ha, Hyo In Kim, Jin Hyoung Lee
P7.111
Efficacy and Safety of Home
Infusion of Intravenous Immunoglobulin
in Multifocal Motor Neuropathy: A
Longitudinal Study. Gretchen Ayer, Nizar
Souayah
P7.112
Video Assisted Thoracoscopic Surgery
Thymectomy for Myasthenia Gravis With
and Without Thymoma: A Comparative
Study Deepa Dash, V. Goyal, A. Kumar, G.
Shukla, M. Behari
P7.113
A Retrospective Analysis of
Patient-reported Outcomes for 34 Patients
with Stiff Person Syndrome Receiving
Home IVIG Infusions. Shafeeq Ladha,
Gretchen Ayer, Nizar Souayah
P7.114
Electrophysiological Motor
Unit Function in SMNΔ7 Mice Following
SMN Restoration William Arnold, Vicki
McGovern, Xiaohui Li, Arthur Burghes
P7.115
Neuropathy Signs and Tests
in Therapeutic Trials of Transthyretin
Amyloidosis Polyneuropathy Narupat
Suanprasert
P7.116
Retrospective Review of
Patients with Sciatic Nerve Palsy After
Total Joint Arthoplasty Teena Shetty, Erin
Manning, Kelianne Cummings, Christine
Villegas, Niesha Voigt, Maxwell Singer,
Joseph Nguyen
P7.117
Perceived Fatigue and
Physiological Fatigue in Spinal Muscular
Atrophy (SMA): Are They Related? Sally
Dunaway, Jacqueline Montes, Samantha
Kramer, Bernadette Podwika, Ashwini Rao,
Darryl De Vivo
Issues in Acute Stroke Treatment
P7.118
The Discharge Modified
Rankin Scale Score Correlates with
Established Hemorrhagic Transformation
Scores in Ischemic Stroke Patients Treated
with Thrombolysis David Asuzu, Karin
Nystrom, Janet Halliday, Charles Wira,
David Greer, David Pritchard, Joseph
Schindler, Kevin Sheth
Poster Session VII
P7.119
Predictors of Hemorrhagic
Transformation of Acute Ischemic Stroke:
Prospective Validation of a Hemorrhage
Risk Model Elisabeth Marsh, Rafael Llinas,
Argye Hillis, Rebecca Gottesman
P7.120
The Western States Stroke
Consortium Telestroke Project Gene Sung,
Bart Demaerschalk, Christopher Fanale,
Jennifer Majersik, Matthew Grantz, Nobl
Barazangi, Dan Capampangan
P7.132
Perception of Stroke
Symptoms and Utilization of Emergency
Medical Systems in Argentina Maximiliano
Hawkes, Ismael Calandri, Mauricio
Farez, Julieta Arena, Virginia Pujol Lereis,
Sebastian Ameriso
P7.133
Awareness of Stroke and
Knowledge of its Warning Signs and Risk
Factors in a Developing Country Omer
Sokrab, Ahmed Sokrab, El Fadil Hassan
P7.121
“Tele” Phone Medicine—Is
Hearing Enough? Rebecca Sugg, Milner
Jessica, Alexander Auchus
P7.134
P7.122
P7.135
Why Ischemic Stroke
Patients Do Not Receive Thrombolytic
Treatment? Sourabh Lahoti, Jessica Lee
P7.123
Resulting in Acute Ischemic Stroke
Recanalization Can Lead to Cerebral
Hyperperfusion Syndrome Jonathan Ong,
Leonard Yeo, Eric Ting, Arvind Sinha, Hock
Luen Teoh, Bernard Chan, Chee Seong Seet,
Vijay Sharma
P7.124
Cerebral Ischemic Events
Associated with Intravenous Thrombolytic
Administration in International Joint
Efficacy Comparison of Thrombolytics
(INJECT) Trial Nudrat Tasneem, Malik Adil,
P7.125
A Smartphone Application
to Aid in the Evaluation, Treatment, and
Clinical Trial Enrollment of the Acute Stroke
Patient Claude Nguyen, Tzu-Ching Wu,
Andrew Barreto, James Grotta, Sean Savitz
Barriers and Opportunities
in Acute Stroke Treatment
Stroke Awareness in Aseer
Region, Community Based Cross Sectional
Study Adel Alhazzani
Stroke Awareness Among
Community Residents in Chicago Subin
Mathew, Kathleen O’Neill, Heather
Beckstrom, Fredrick Giles, Neelum
Aggarwal, Shyam Prabhakaran
Outcome and Mortality
P7.136
Hyperacute Neurologic
Changes and Outcome after Intracerebral
Hemorrhage Matthew Maas, Michael
Berman, James Guth, Eric Liotta, Shyam
Prabhakaran, Andrew Naidech
P7.137
Body Mass Index and
Intracerebral Hemorrhage Stephanie
Holmes, Rajeev Garg, James Conners,
Vivien Lee
P7.138
Predictors of Inpatient
Mortality After Intracerebral Hemorrhage.
Analysis of US Nationwide Inpatient
Sample Database. Vijayakumar Javalkar,
Robert Schwendimann, Anil Nanda
P7.139
Where Are Opportunities
to Increase Intravenous Thrombolysis in
Current Practice? George Koch, Nancy
Kung, Dushyant Damania, Minal Jain,
Anunaya Jain, Curtis Benesch, Babak
Jahromi
Being Overweight or Obese
Is Associated with Lesser Disability
After Intracerebral Hemorrhage Neha
Dangayach, Gian Marco De Marchis,
Harpreet Grewal, Rachel Bruce, Aarti
Chhatlani, Christina Falo, E. Sander
Connolly, Sachin Agarwal, Jan Claassen,
Michael Schmidt, Stephan Mayer
P7.127
P7.140
P7.126
Onset to Treatment Time Has a Small
Effect on In-hospital Outcomes in Acute
Ischemic Stroke Konark Malhotra, Santosh
Ramanathan, Chris Hackett, Matt Quigley,
Melissa Tian, Jack Protetch, Crystal Wong,
David Wright, Ashis Tayal
P7.128
Modified Helsinki Model
Reduced Stroke Thrombolysis Delays in
a Resource Limited, Non-Metropolitan
Australian Hospital (RLNMAH) Nirosen
Vijiaratnam, Elizabeth Mackey, Hans Tu,
Zelko Matkovic, Tissa Wijeratne
Risk Factors and Outcomes
of Prolonged Hospitalization After
Intracerebral Hemorrhage in United
States Yogesh Moradiya, Santosh Murthy,
Shreyansh Shah, Sneha Modi
P7.141
Antiplatelet Drugs Resumption
After Antiplatelet-Related Intracerebral
Hemorrhage In Chinese Kay Cheong Teo,
Gary Lau, Raymand Lee, Richard SK Chang,
David CW Siu, Gilberto KK Leung, Raymond
Cheung, Shu Leong Ho, Koon Ho Chan
P7.142
An Initiative to Improve Door
to Needle Time for Stroke Thrombolysis
in Chicago Shyam Prabhakaran, Kathleen
O’Neill
Warfarin Associated
Intracerebral Hemorrhage in Hong Kong
Chinese Kay Cheong Teo, Neeraj R
Mahboobani, Raymand Lee, David CW Siu,
Raymond Cheung, Shu Leong Ho, Gary KK
Lau, Koon Ho Chan
P7.130
P7.143
P7.129
Quality Improvement Project:
Improving the Time To Treatment in
Inpatient Acute Ischemic Stroke John
Liang, Rocio Garcia Santibanez, Amy
Walker, Irene Boniece
P7.131
The Presence of Neurology
Impacting Door to Needle Time in Acute
Stroke Donna Kurowski, Oscar Soto
Blood Transfusion Does
Not Improve Outcomes in Patients
with Spontaneous Intracerebral
Hemorrhage Wazim Mohamed, Sanath
Reddy, Sanjeev Sivakumar, Gregory Norris,
Mohammad Ibrahim
P7.144
Seasonal Variation in the
Incidence and Mortality of Intracerebral
Hemorrhage. Anand Patel, Archana
Hinduja, Jamil Dibu, Eugene Achi, Rajan
Patel
P7.145
Intracerebral Hematoma
Volume Measurement Using ITK-SNAP
Software: Initial Experience Monika
Mishra, Priyank Shukla, Aakash Bodhit,
Ganesh Asaithambi, Arnaldo Velez,
Christian Rosado, Mohit Mishra, Pradeepan
Saravanapavan, S Khan, V Reddy,
Vishunmurthy Hedna
Predictors of Outcome
After Ischemic Stroke
P7.146
Natural Autoantibodies in
the Serum of Post-stroke patients with
Different Clinical Outcomes Alla Guekht,
Eugene Gusev, Vera Alferova, Natalia
Gulyaeva, Alexander Poletaev, Alexander
Yakovlev
P7.147
Impact of Stroke Location
on Stroke Outcome Archana Hinduja,
Kaustubh Limaye, Anand Patel, Zabeend
Mahuwala
P7.148WITHDRWN
P7.149
Predictors of Outcome in
Patients with Acute M2 Occlusion Muhib
Khan, Jiaying Zhang, Majaz Moonis, Richard
Goddeau, Nils Henninger
P7.150
Elderly Non-Demented
Patients Have Better Outcome with
Reperfusion Therapy Than Demented
Patients Following Ischemic Stroke Neeta
Duggal, Trenton Myers, James Kim, Iftekhar
Ahmed
P7.151
Diastolic Function of Heart
and Outcomes After Ischemic Stroke Ahn
Hee Seung, Ryu Wi-Sun
P7.152
Combined Elevation of FVIII
and von Willebrand Factor Predicts Risk for
Worse Outcomes in Patients with Acute
Ischemic Stroke (AIS) Alyana Samai,
Lauren Dowell, Laurie Schluter, Ramy El
P7.153
Leukoaraiosis Is Associated
with Impaired Functional Recovery
and Outcome After Mild Ischemic
Stroke. Sanjeeva Onteddu, Artin Minaeian,
Richard Goddeau, Nils Henninger
P7.154
Does the Magnitude of the
Electrocardiogram QT Interval Dispersion
Predict Stroke Outcome? Yitzchok
Lederman, Leah Steinberg, Clotilde
Balucani, Charles Philip, Jason Lazar,
Jeremy Weedon, Gautam Mirchandani,
Giovanna Viticchi, Lorenzo Falsetti, Mauro
Silvestrini, James Gugger, David Aharonoff,
Pirouz Piran, Zachary Adler, Steven Levine
P7.155
Areas of Cerebral Ischemia
Have Increased Propensity to Convert to
Infarct Among Diabetics Wazim Mohamed,
Sanath Reddy, Pratik Bhattacharya
Post-Stroke Function
P7.156
Return to Driving Following
Stroke Shelly Ozark, Andrea Boan, Tanya
Turan, Charles Ellis, Daniel Lackland, David
Bachman
P7.157
Evaluation of Sexual Functions
of Women with Stroke Haluk Gumus,
Halim Yilmaz, Sema Yilmaz
P7.158
NIHSS Score May Help
Predict Health Literacy Levels After Acute
Ischemic Stroke Kalina Sanders, Carmen
Smotherman, Scott Silliman
P7.159
Dysphagia in Patients with
Acute Ischemic Stroke Mohamed AlKhaled, Christine Matthis, Georg Royl
P7.160
Relative Importance of
Stroke Sequelae According to Patients and
Caregivers. Victor Urrutia, Brenda Johnson,
Argye Hillis
P7.161
BMI Impact in Neurological
Diseases Jora Xhaxho, Sokrat Xhaxho,
Drini Dobi, Jera Kruja
P7.162
The Association of Clinical
Factors and Highly-Sensitive C-Reactive
Protein (hsCRP) with Depression in Stroke
Patients Ahmed Itrat, Sandra Griffith,
Nicolas Thompson, George Tesar, Irene
Katzan
P7.163
Proteomics Reveals the
Dysregulation of Lipid Metabolism in
the Plasma of Post Stroke Depression
Patients Jun Mu
P7.164
Correlation of NIH Stroke
Scale Change and Vascular Risk Factors
in Acute Stroke Patients Prashanth
Krishnamohan, Michael Dobbs
Carotid Disease
P7.165
Rates and Predictors of
Five Year Survival in Asymptomatic
Medicare Beneficiaries Undergoing Carotid
Revascularization Muhammad Suri, Saqib
Chaudhry, Adnan Qureshi
P7.166
Influence of CREST on CEA
and CAS Trends in Women—do the
Results Matter? Shahram Khalid, Sanath
Reddy, Seemant Chaturvedi, Kumar
Rajamani, Pratik Bhattacharya, Navid SerajiBozorgzad
P7.167
Carotid Artery Stent
Placement and Carotid Endarterectomy in
Patients with Dialysis Dependent Renal
Failure Malik Adil, Fahad Saeed, Adnan
Qureshi
P7.168
Basilar TIAs of Symptomatic
Carotid Artery Stenosis Felix Veloso
P7.169
Symptomatic Carotid NearOcclusion with String Sign Incurs a Very
High Risk of Stroke Elias Johansson, Per
Wester
P7.170
Carotid Artery Stenosis and
Randomized Controlled Trials—Should We
Abandon the Gold Standard Akshal Patel,
Gary Gronseth, Michael Glantz
Thursday
May 1
Thursday, May 1
P7.171
Early and Long-term
Outcome After Carotid Endarterectomy Is
Determined Not by Coexisting Traditional
High Risk But by Risk of Coronary Heart
Disease Only Sung Hyuk Heo, Hyojung
Nam, Jinsan Lee, Dae-Il Chang, Seon Hee
Bu
P7.172
Are Carotid Artery StenosisIsolated and Carotid Artery-Plus Two
Distinct Entities? Vishal Jani, Adil Malik,
Syed Hussain, Adnan Qureshi
P7.173
Pituitary Apoplexy: An
Unusual Complication of Carotid
Endarterectomy Sandrine Jeangette,
Denis Bataille, Guy Bruninx, Christo Chaskis,
Raphael Hourez
P7.174
Association of Resting Heart
Rate with Cerebrovascular Risk Factors and
Carotid Artery Stenosis. Syed Hussain,
Vishal Jani, Adnan Safdar, Anmar Razak,
Mounzer Kassab, Malathi Rao, Asif Khan,
Adil Malik, Adnan Qureshi
Headache: Treatment
P7.175
Assessment of Cardiovascular
Safety in Cynomolgus Monkeys Following
IV Administration of LBR-101 Sarah Walter,
Michele Bronson, Marcelo Bigal
P7.176
Spinning Out of Control:
The Black Box of Basilar and Hemiplegic
Migraine Regina Krel, Paul Mathew,
Warren Spinner, Shivang Joshi
P7.184
Incidence of Adverse Events
with MAP0004 Does Not Increase with
Increased Frequency of Dosing: Results
from a Long-Term Phase 3 Study Paul
Winner, Sylvia Lucas, Biao Lu, Emilee
Connors, Frederick Freitag, Shashidhar Kori
P7.185
SUNCT Syndrome Responding
to OnabotulinumtoxinA Injections: A Case
Report Jina Youn, Kerry Knievel
P7.186
The Durability of
OnabotulinumtoxinA for the Treatment
of Chronic Migraine: CLARITY Pilot
Study Andrew Blumenfeld, Andrew
Inocelda, Cedric Cunanan, Chris Purdy, Laura
Dalfonso, Raf Magar
P7.187
Headache and Treatment of
Unruptured Intracranial Aneurysms Julieta
Arena, Maximiliano Hawkes, Mauricio
Farez, Lucia Pertierra, Alejandro Kohler,
Dario Benito, Maria Goicochea, Virginia
Pujol Lereis, Juan Miranda, Sebastian
Ameriso
P7.188
Incobotulinumtoxin A for the
Preventive Treatment of Chronic Migraine
Headaches Patrick Grogan, Andrew
Robinson, Wendy Chao, Aven Ford
P7.189
The IV Pharmaokinetics of
Single and Multiple Doses of LBR-101 in
Healthy Volunteers Sarah Walter, Rafael
Escandon, Marcelo Bigal
P7.190
P7.177
Safety and Tolerability
of LBR-101, a Humanized Monoclonal
Antibody That Blocks the Binding of CGRP
to Its Receptor—Results of the Phase
1 Program Rafael Escandon, Michele
Bronson, Sarah Walter, Marcelo Bigal
P7.178
P7.191
Randomized Controlled Trial:
Targeted Neck Cooling in the Treatment of
the Migraine Patient Alexandra Gabriel,
Jon Brown, Melvin Yee
Successful Treatment of
Spontaneous Low-Pressure Headache
Due to Prominent Cervical CSF Leak with
Cervical Epidural Blood Patch Eugene
Wang, Dajie Wang
P7.179
Intranasal Capsaicin (IC)
Rapidly Relieves the Pain of Migraine and
Other Severe Headaches Maria Alexianu,
Anjan Chatterjee
P7.180
An Inpatient Course of
Intravenous Dihydroergotamine Use for
New Daily Persistent Headache Michael
Eller, Amy Gelfand, Nina Riggins, Peter
Goadsby
P7.181
Cerebral Blood Flow Velocity
in Migraine and Tension-type Headache
Patients Sebnem Karacay Ozkalayci, Ceyla
Irkec, Bijen Nazliel
P7.182
A Randomized, Open-label,
Parallel Two-arm Study Evaluating the
Efficacy of H.P. Acthar Injection Gel in
the Treatment of Adults with Intractable
Chronic Migraine Laszlo Mechtler, John
Rothrock, Roger Cady, Peter McAllister
P7.183
Trigeminal Trophic Syndrome
with Intractable Pain, Successfully Treated
with Spinal Cord Stimulation Erin Golden,
Carrie Robertson, John Moossy, Paola
Sandroni, Ivan Garza
122
High Asymmetric
Dimethylarginine Levels in Migraine During
the Interictal Period Aylin Reyhani, Yahya
Celik, Talip Asil, Hakan Karadag, Ozgur
Gunduz, Necdet Sut
P7.192
Effects of Antiepileptic
Drugs on Spreading Depression in the
Chick Retina: Implications for Migraine
Prophylaxis Joao De Moraes
P7.193
Lamotrigine as a Prophylactic
Treatment for Migraine-Associated Vertigo:
A Case Series Lixin Zhang, Merika Wilson,
Lisa Yamagishi
3:00 p.m.–6:30 p.m.
P7.198
Cardiovascular and
Hemodynamic Parameters in Women
Following IV Administration of LBR101, a Monoclonal Antibody Against
CGRP Marcelo Bigal, Abbas Alibhoy,
Michele Bronson, Sarah Walter, Rafael
Escandon
P7.199
Efficacy and Safety of High
Dose of Intravenous Methylprednisolone in
Cluster Headache Patients Not Responders
to Oral Therapy Elisa Rubino, Paola De
Martino, Giovanna Vaula, Salvatore Gentile,
Lorenzo Pinessi, Innocenzo Rainero
P7.200
Safety of Dihydroergotamine
Use in Patients with Symptoms of
Hemiplegic or Basilar Type Migraine Brad
Klein, Wael Hanna, Bhuvin Buddhdev, Mary
Naglak
P7.201
Long Term Therapeutic
Response of Sphenopalatine Ganglion
(SPG) Stimulation for Cluster Headache—
Pathway CH-1 Study Miguel Lainez,
Rigmor Jensen, Arne May, Charly Gaul,
Anthony Caparso, Amy Goodman, Jean
Schoenen
P7.202
Peripheral Nerve Blocks for
Pregnant Patients with Headache Shravya
Govindappagari, Tracy Grossman, Ashlesha
Dayal, Brian Grosberg, Sarah Vollbracht,
Matthew Robbins
P7.203
AVP-825, a Novel Breath-Powered™
Powder Sumatriptan Intranasal Treatment,
for Acute Migraine Roger Cady, John
Messina, Jennifer Carothers, Ramy
Mahmoud
P7.204
Initial Management of
Migraine Headaches with Oral Medications
in a Pediatric Emergency Unit Bhooma
Aravamuthan, Kristine Williams, Soe Mar
Diseases: Treatment
P7.205
An Observational Comparison
of Natalizumab and Fingolimod Using JCV
Serology to Randomize Therapy Robert
Carruthers, Dalia Rotstein, Brian Healy,
Tanuja Chitnis, Howard Weiner, Guy Buckle
P7.206
Cardiac Side Effects of
Dihydroergotamine Erin Bange, Robert
Rennie, Betts Patti-Ann, Christina Szperka
Fingolimod Is Not Able
to Inhibit Multiple Sclerosis Disease
Reactivation After Natalizumab
Discontinuation Marco Capobianco,
Alessia Di Sapio, Simona Malucchi, Maria
Malentacchi, Manuela Matta, Francesca
Sperli, Alessandra Oggero, Antonio
Bertolotto
P7.196
Gammacore Device for
Treatment of Migraine Attack: Preliminary
Data Licia Grazzi, Susanna Usai, Gennaro
Bussone
P7.207
P7.197
P7.208
P7.194
A Critical Evaluation of
Migraine Trigger Site Deactivation
Surgery Paul Mathew
P7.195
Transient Exacerbation
Of Headache In Patients Receiving
Intravenous Dihydroergotamine For
Inpatient Management Of Chronic Migraine
Does Not Alter Outcomes Michael Eller,
Amy Gelfand, Nina Riggins, Christoph
Schankin, Peter Goadsby
Stopping Disease Modifying
Therapy in Progressive Multiple
Sclerosis—a Prospective Study Gary
Birnbaum
Comparison of Switching
to Natalizumab Versus Remaining on
Interferon-Beta or Glatiramer Acetate
After On-Treatment MS Relapse
Using Propensity-Matched Registry
Data Timothy Spelman, Tomas Kalincik,
Fabio Pellegrini, Annie Zhang, Maria
Trojano, Heinz Wiendl, Ludwig Kappos,
Robert Hyde, Shibeshih Belachew, Freek
Verheul, Francois Grand-Maison, Helmut
Butzkueven
P7.209
Natalizumab in Multiple
Sclerosis with Spinal Involvement Chiara
Zecca, Christian Kamm, Gianna Carla
Riccitelli, Mirjam Heldner, Matteo Caporro,
Claudio Staedler, Claudio Gobbi
P7.210
Impact of Natalizumab
Treatment for Multiple Sclerosis on Patientreported Physical Functioning Over 3 Years
in US Clinical Practices Timothy Vollmer,
John Foley, Kavita Nair, Judith Stephenson,
Timothy Niecko, Sonalee Agarwal, Crystal
Watson
P7.211
Relapse Rates Among
Patients with Multiple Sclerosis Who
Switch from Interferon Therapy to
Fingolimod or Glatiramer Acetate: A
Retrospective US Claims Database
Analysis Raquel Lahoz, Niklas Bergvall,
Neetu Agashivala, Ashish Pradhan, Gorana
Capkun, Jonathan Korn, Allison Petrilla,
Swapna Karkare, Catherine Balderston
McGuiness, Charles Makin
P7.212
Reactivation During Switch
from Natalizumab to Fingolimod: Is it
Predictible? Adil Maarouf, Anne Laure
Pernelet, Adrien Maitrot, Nathalie
Caucheteux, Laure Daelman, Marie-Pierre
Chaunu, Laurent Pierot, Ayman Tourbah
P7.213
Multiple Sclerosis Symptom
Recrudescence Is Common at the End
of the Natalizumab Dosing Cycle John
Ratchford, Regina Brock-Simmons, Amanda
Augsburger, Sonya Steele, Kristie Mohn,
Mandi Rhone, Jinyan Bo, Kathleen Costello
P7.214
Estimating the Onset of
Efficacy with Teriflunomide in Patients
with Relapsing Forms of Multiple
Sclerosis Jerry Wolinsky, Deborah Dukovic,
Philippe Truffinet, Ludwig Kappos
P7.215
A Five-year Clinical Follow-up
Study of Patients with Multiple Sclerosis
Who Started Natalizumab Luca Prosperini,
Valeria Barletta, Laura De Giglio, Fulvia
Fanelli, Giovanna Borriello, Carlo Pozzilli
P7.216
Natalizumab Therapy, How
to Treat How to Stop: The TY-STOP
Study Marinella Clerico, Stefania De
Mercanti, Federico Piazza, Eleonora Virgilio,
Dario Gned, Vincenzo Brescia Morra,
Roberta Lanzillo, Luca Amato, Mario
Quarantelli, Angelo Ghezzi, Anna Bianchi,
Damiano Baroncini, Giuseppe Salemi,
Sabrina Realmuto, Maria Teresa Ferrò,
Francesca Vitetta, Giulia Superti, Paola
Cavalla, Mariangela D’Onghia, Damiano
Paolicelli, Irene Schiavetti, Maria Pia
Sormani, Lorenzo Pinessi, Maria Trojano,
Luca Durelli
P7.217
Recommendations for
Fingolimod Treated Patients Vacinated
for Varicella Zoster Virus. Sergio Stecchi,
Cinzia Scandellari, Liliana Gabrielli, Tiziana
Lazzarotto
P7.218
Treatment Satisfaction After
Switching to Fingolimod Directly from
an Injectable Therapy Edward Fox, Keith
Edwards, John Burch, Kevin McCague, Luigi
Barbato
Poster Session VII
P7.219
Adherence to, and
Effectiveness of, Treatment with
Subcutaneous Interferon Beta-1a in
Relapsing Multiple Sclerosis Patients
Using RebiSmart™ for Self-Injection: Final
Results of the One-Year International,
Observational SMART Study Antonios
Bayas, Jean-Christophe Ouallet, Boris
Kallmann, Raymond Hupperts, Ulrich Fulda,
Kurt Marhardt
P7.220
Improved Estimation of
Treatment Effects: Analysis of Time
to Recurrent Relapse with Fingolimod
or Intramuscular Interferon Beta-1a
Treatment Using the Proportional Means
Model Xiangyi Meng, M. Zahur Islam, Peter
Chin, Nadia Tenenbaum, Gary Cutter
P7.221
Switching from Injectable
Therapy Leads to High Continuation Rate
on Fingolimod Yves Lapierre, Daniel
Selchen, Virginia Devonshire, Robyn
Schecter
P7.222
Relapse Rates Among
Patients with a History of Relapses Treated
with Fingolimod Compared with Interferons
or Glatiramer Acetate for the Treatment
of Multiple Sclerosis: A Retrospective
US Claims Database Analysis Jonathan
Korn, Niklas Bergvall, Raquel Lahoz, Neetu
Agashivala, Ashish Pradhan, Gorana
Capkun, Allison Petrilla, Swapna Karkare,
Catherine Balderston McGuiness, Charles
Makin
P7.223
Efficacy of Fingolimod Therapy
Does Not Depend on the Individual Body
Mass Index in Patients with MS Thomas
Dehmel, Clemens Warnke, Anne Mausberg,
Kathleen Wolffram, Maria Diaz-Lorente,
Hans Hartung, Bernd Kieseier
P7.229
Marburg Variant Multiple
Sclerosis, Responsive to Natalizumab
Acutely and Chronically Sara Mayer, Adam
Carpenter, Pezhman Roohani
P7.230
Fingolimod Treatment
In Relapsing-Remitting Multiple
Sclerosis Patients: A Clinical Practice
Experience Rocco Totaro, Gianfranco
Costantino, Roberta Fantozzi, Paolo
Bellantonio, Caterina Di Carmine, Aurora
Fuiani, Ciro Mundi, Stefano Ruggieri,
Antonio Carolei
P7.231
Prospective Evaluation of
Persistence, Treatment Adherence, Quality
of Life, and Treatment Satisfaction in
Patients Treated with an Intramuscular
Interferon Beta-1a Autoinjector in a RealWorld Clinical Setting Antonio Salgado,
Veit Becker, Raymond Hupperts, Claes
Martin, Sergio Slawka, Xiaojun You, Bjorn
Sperling
P7.232
Comparison of Efficacy
and Treatment Satisfaction of Patients
on Baseline Therapy or Fingolimod:
Results of the Interim Analysis of Two
German Registry Studies PANGAEA
and PEARL Tjalf Ziemssen, Sylia Moser,
Alexandra Fuchs, Christian Cornelissen
P7.233
Fingolimod First-dose Effects
in Patients with Relapsing-Remitting
Multiple Sclerosis Concomitantly Treated
with Serotonin-Specific Reuptake
Inhibitors Robert Bermel, Ron Hashmonay,
Xiangyi Meng, Philipp Von Rosenstiel,
Nicolaos Sfikas, Simrat Randhawa, Daniel
Kantor
P7.234
Positive Response to
Alemtuzumab (ALE) Rescue Immunotherapy
in a High Disability, Treatment-Refractory
Multiple Sclerosis (MS) Cohort Samuel
Hunter, Heli Hunter, Daniel Kantor
Systematic Literature Review
and Network Meta-Analysis of Pegylated
Interferon Beta-1a and Disease Modifying
Therapies for Relapsing/Remitting Multiple
Sclerosis Keith Tolley, Michael Hutchinson,
Andrew Pachner, Elizabeth Kinter, Bjorn
Sperling, Xiaojun You, Ping Wang, Ankush
Taneja, Mohd. Kashif Siddiqui
P7.225
P7.235
P7.224
Persistence and Adherence of
Fingolimod Compared with Other DiseaseModifying Therapies for the Treatment
of Multiple Sclerosis: A Retrospective
US Claims Database Analysis Jonathan
Korn, Niklas Bergvall, Raquel Lahoz, Neetu
Agashivala, Ashish Pradhan, Gorana
Capkun, Allison Petrilla, Swapna Karkare,
Catherine Balderston McGuiness, Charles
Makin
P7.226
Clinical Predictors for
Fingolimod (Gilenya) Treatment Response in
Multiple Sclerosis Patients Dalia Rotstein,
Muhammad Taimur Malik, Brian Healy,
Howard Weiner, Tanuja Chitnis
P7.227
Changes in Natalizumab
Treatment Patterns and Association
with Relapse Outcomes: A Retrospective
Study Robert McQueen, Brieana Buckley,
Terrie Livingstone, Timothy Vollmer, John
Corboy, Kavita Nair, Jonathan Campbell
P7.228
A Two-Year Retrospective
Analysis of Rituximab Therapy in
Secondary-Progressive Multiple
Sclerosis Christopher Perrone, Biljana
Beretich, Peter Riskind, Carolina Ionete
Treatment Satisfaction,
Adherence and Behavioral Assessment in
Patients De-Escalating from Natalizumab
to Interferon Beta Claudio Gobbi, Gianna
Riccitelli, Pasquale Calabrese, Emanuele
Pravatà, Ursula Candrian, Charles Guttmann,
Chiara Zecca
P7.236
The Providence MS Center’s
Dimethyl Fumarate (DMF) Registry Kyle
Smoot, Bobbie Lee Roth, Chiayi Chen, Kiren
Kresa-Reahl, Leah Gaedeke, Stanley Cohan
P7.237
Pharmacokinetics of
Laquinimod, an Oral Immunomodulatory
Agent in Development for The Treatment
of Relapsing-Remitting Multiple
Sclerosis Hayrettin Tumani, Tjalf Ziemssen,
Friedemann Paul, Martin Marziniak, Nils
Richter, Christoph Heesen, Yossi GilgunSherki, Tali Gorfine, Ofer Spiegelstein, Emil
Samara, Yulia Sidi, Dorit Mimrod
P7.238
Clinical And Radiological
Activity During The Fingolimod Treatment
Prescribed After Natalizumab. A Multiple
Sclerosis Unit Experience Rocio Hernandez
Clares, Ester Carreon, Begoña Palazon,
Encarnación Andreu, Jose Javier Martin,
Jose Meca La Llana
P7.239
Safety and Efficacy in
Patients Receiving Natalizumab Therapy
in Hungary Tunde Csepany, Lovas Gabor,
Bencsik Krisztina, Csilla Rozsa, Magdolna
Simo, Krisztina Kovacs, Samuel Komoly,
Peter Barsi, Zoltan Mor
P7.240
Subcutaneous Interferon Beta1a Decreases the Evolution of GadoliniumEnhancing Lesions Into Chronic Black Holes
in Relapsing Multiple Sclerosis Anthony
Traboulsee, David Li, Yinshan Zhao, Roger
Tam, Guojun Zhao, Yan Cheng, Andrew
Riddehough, Fernando Dangond, Juanzhi
Fang, Ludwig Kappos
P7.241
Risk Factors for Relapses
After Switching from Natalizumab to
Fingolimod Joachim Havla, Robert
Hoepner, Christian Eienbröker, Bjorn
Tackenberg, Kerstin Hellwig, Ingrid Meinl,
Ralf Gold, Reinhard Hohlfeld, Tania
Kuempfel, Ingo Kleiter
P7.242
Short-term Follow-up of
Central Motor Conduction Failure in
Relapsing Multiple Sclerosis Patients
Undergoing High-dose Steroid
Treatment Alessia Di Sapio, Antonio
Bertolotto, Federica Melillo, Simona
Malucchi, Paola Berchialla, Francesca
Sperli, Walter Troni
P7.243
Epidemiological Study to
Identify Factors That Influence Clinical
Decision Making in Patients with
Relapsing Remitting Multiple Sclerosis
(RRMS) After at Least 2 Years of
Treatment with Immunomodulators in
Germany (EPIDEM) Stephan Schmidt,
Petra Schicklmaier, Christine Winterstein,
Wettmarshausen Christine, Matthias
Meergans, Colin Wernsdoerfer
Treatment of Specific
Multiple Sclerosis Symptoms
P7.244
Dalfampridine Real World
Utilization and Efficacy Assessment Sylvia
Klineova, Joshua Friedman, Colleen Farrell,
Christine Hannigan, Fred Lublin, Stephen
Krieger
P7.245
Aspirin Is Unlikely to Have a
Clinically Meaningful Effect on Multiple
Sclerosis-Related Fatigue: Data from
a Randomized Controlled Trial Dean
Wingerchuk, Mark Keegan, Elizabeth
Shuster, Jonathan Carter, Joe Hentz, Greg
Thaera, Melissa Cortez, Moses Rodriguez
P7.246
Effects of Prolonged-Released
Fampridine on Walking Parameters, Upper
Limb Function, Fatigue and Quality of
Life Etienne Allart, Anne Benoit, Anne
Blanchard, Helene Zephir, Olivier Outteryck,
Arnaud Lacour, Patrick Vermersch
P7.247
Prolonged-release Fampridine
(Fampyra®) Post-marketing Experience in
the Alsace Region Jean-Claude Ongagna,
Carole Berthe, Nicolas Collongues, Frederic
Blanc, Jerome De Seze
P7.248
Long-Term Course and
Clinical Assessment Parameters of
Patients with Multiple Sclerosis Under
Dalfampridine Tobias Ruck, Stefan Bittner,
Nico Melzer, Heinz Wiendl, Matthias
Schilling, Sven Meuth
P7.249
Monotherapy with THC/
CBD Spray in Multiple Sclerosis Induced
Spasticity Juergen Koehler, Walter
Poellmann, Wolfgang Walter Feneberg,
Martin Meier
P7.250
Use of Medical Marijuana
for Symptoms of Multiple Sclerosis
(MS) Among Participants of the
Pacific Northwest MS Registry
(PNWMSR) Tamela Stuchiner, Elizabeth
Baraban, Chiayi Chen, Stanley Cohan
P7.251
Attenuation of Dimethyl
Fumarate-related Gastrointestinal
Symptoms with Montelukast Carmelo
Tornatore, Faria Amjad
P7.252
25G Sprotte Needle Strongly
Reduces the Risk of Post-Lumbar Puncture
Headache in Clinical Practice. Antonio
Bertolotto, Francesca Sperli, Marco
Capobianco, Maria Malentacchi, Annalisa
Pulizzi, Simona Malucchi
P7.253
A Double-blind Placebo
Controlled Study of the Effect of BetaAlanine, a Nonessential Amino-Acid, on
Neurologic, Motor Function, Quality of Life,
and Fatigue in Patients Diagnosed With
Multiple Sclerosis John Kanter, Elizabeth
Keiner, Arielle Biwer, Elizabeth Coughlin,
Brittany DiFabio, Donya Salmasinia,
Michael Ormsbee, John Giannini, Charles
Maitland
Neuro-oncology:
CNS Metastases and
Complications of Treatment
P7.254
Brain Metastases In
Ovarian Cancer—a Comprehensive
Review. Shabnam Pakneshan, Damoun
Safarpour, Fattaneh Tavassoli, Bahman
Jabbari
P7.255
A Case of Primary Meningeal
Melanoma Bhaskar Roy, Fatmah Al Zahmi,
Richard Danialan, Srinivas Mandavilli
P7.256
Isolated Primary CNS
Infiltrative Parenchymal Histiocytosis
with Intraventricular Hemorrhage Eric
Mittelmann, Patrick LaSala, Karen
Weidenheim, Jerome Graber
P7.257
Brainstem Glioma 8 Years
After External Beam Radiotherapy for
Pituitary Macroadenoma: Correlation
with Radiation Treatment Dose and
Volume Salim Abboud, Leo Wolansky,
Sunil Manjila, Simon Lo, Bahaudden Arafah,
Warren Selman, Lisa Rogers
P7.258
Effects of Ionizing Radiation
on Human Microglial Cells Hongxin Chen,
Sonia De Toledo, Edward Azzam, Nizar
Souayah
Neuro-oncology: Primary
CNS Lymphoma and Other
Hematologic Malignancies
P7.259
Salvage Therapy with
Bendamustine for Methotrexate Refractory
Recurrent Primary CNS Lymphoma:
A Retrospective Case Series Marc
Chamberlain
123
Thursday
May 1
Thursday, May 1
P7.260
Primary Natural Killer/T-cell
Lymphoma Presenting as Leptomeningeal
Disease Carlos Kamiya-Matsuoka,
Bing Liao, Yun Gong, Merry Chen, Karin
Woodman, Nathan Fowler, Charles Conrad
P7.261
Rituximab and Bendamustine
for CNS Involvement by Chronic
Lymphocytic Leukemia Geraldine Faivre,
Samuel Singer, Lisa DeAngelis, Ariela Noy,
Antonio Omuro
P7.262Neurolymphomatosis:
Heterogenous Presentations Daniel
Winkel
P7.263
VEGF and Pentraxin-3 Levels
in POEMS Syndrome: A 2-Year Longitudinal
Study. Chiara Dalla Torre, Marina Scarlato,
Federica Lessi, Marta Campagnolo, Marta
Lucchetta, Susanna Ruggero, Elisabetta
Toffanin, Angelo Manfredi, Mario Ermani,
Fausto Adami, Chiara Briani
P7.264
Bing-Neel Syndrome:
Presentation of Three Unusual
Patients Louis Royer-Perron, François
Moreau, Sylvie Gosselin
P7.265
Central Neuropathy
in a Patient with Waldenstrom’s
Macroglobulinemia: Should You Suspect
Bing-Neel Syndrome Even in the Absence
of Abnormal Brain Imaging? Neha Gupta
Neuro-oncology:
Primary CNS Tumors: Gliomas
P7.266
Hormone Replacement
Therapy and Risk of Glioma: A Nationwide
Nested Case-Control Study Lene
Andersen, Soren Friis, Jesper Hallas,
Pernille Ravn, David Gaist
P7.267
Surgery and Neurostimulation
Attention/Neglect
P7.275
P7.286
Outcome of Intracranial EEG
Monitoring and Surgery in MRI-negative
Temporal Lobe Epilepsy Ricky Lee,
Marietta Hoogs, David Burkholder, Max
Trenerry, Joseph Drazkowski, Jerry Shih,
William Tatum, Gregory Cascino, Elaine
Wirrell, Gregory Worrell, Elson So
P7.276
Comparison of
Seizure Outcome After Selective
Amygdalohippocampectomy in Adult
Versus Pediatric Onset Temporal Lobe
Seizures Aradia Fu, Steve Chung
P7.277
Reasons for Delayed Temporal
Lobe Epilepsy Surgery Aditi Narechania,
Paz Abergel, Irena Garic, Michael Macken,
Elizabeth Gerard, Stephan Schuele
P7.278
Surgical Outcome of Parietal
Lobe Epilepsy Anna-Marieta Moise, Janice
Jordan, Lola Morgan, Linda Leary, Kameel
Karkar, Octavian Lie, Jose Cavazos, JeanLouis Caron, Alexander Papanastassiou,
Charles Szabo
P7.279
Electrical Stimulation of the
Anterior and Centromedian Nucleus of
Thalamus for Treatment of Refractory
Epilepsy—Report of Four Cases Wei Hu,
Bryan Klassen, Kendall Lee, Daniel Clayton,
Squire Stead
P7.280
Deep Brain Stimulation for
the Management of Seizures in MECP2
Duplication Syndrome. Fabio Nascimento,
Hanna Faghfoury, Timo Krings, Anfal Ali,
Jonathan Fridhandler, Andres Lozano,
Richard Wennberg, Danielle Andrade
CD44v6 and E-cadherin Expression in
Human Primary Brain Tumors Leslaw Zub,
Boguslaw Paradowski, Julia Bar, Anna LisNawara, Leszek Noga, Michal Jelen
P7.281
P7.268
A Novel Therapeutic
Target for Treatment of Malignant Brain
Tumors Nazanin Majd, Kazutaka Sumita,
Hirofumi Yoshino, Dillon Chen, Atsuo Sasaki
P7.282
P7.269
P7.283
Posterior Fossa Recurrences
of Supratentorial WHO Grade II and III
Gliomas Robert Terziev, Gregorio Petrirena,
Jean-Yves Delattre
P7.270
Posterior Fossa Tumours in
Children as Seen in a Tertiary and Referral
Hospital in Sub-Saharan Africa Victor
Kwasi
P7.271
Oligodendroglial Gliomatosis
Cerebri Exhibiting Leptomeningeal and
Nerve Root Involvement Grace Mcmacken,
Brian Herron, Ailsa Fulton
P7.272
A Case Report: Primary
Glioblastoma of the Pineal Regina Krel,
Yana Krutoshinskaya, Arthur Rosiello,
Roberta Seidman, Agnes Kowalska
P7.273
Aggressive Medical Care at
the End of Life (EOL) in Glioblastoma (GBM):
The 5-year Memorial Sloan-Kettering
Cancer Center (MSKCC) Experience Alexis
Dallara, Alan Carver, Eli Diamond
3:00 p.m.–6:30 p.m.
The Efficacy of VNS in
Patients with Pharmacoresistant Epilepsy
of Temporal Versus Extra-temporal
Locations Abuhuzeifa Abubakr, Ilse
Wambacq
Prospective Memory After
Mesial Temporal Resection Carla Adda,
Luiz Henrique Castro, Carmen Jorge, Rosa
Valerio, Hung Wen
Database Systems and
Online Tools for Early Referral to Epilepsy
Surgery Evaluation in Mesial Temporal
Lobe Epilepsy Rodolfo Callejas, Ildefonso
Rodriguez-Leyva
P7.284
Association Between
Chronobiology of Seizures and Hemispheric
Laterality in Patients Who Underwent
Surgery for Refractory Epilepsy Anca
Popescu, Amrit Misra, Maromi Nei
P7.285
Vagal Nerve Stimulation
and Cortical Source Localization in
Pre- and Post-operation EEG Data: A
Case Study Hakan Ekmekci, Mastaneh
Torkamani Azar, Ali Okatan, Serefnur Ozturk
Memantine Effects on
Attention in FXTAS: A Double-blind ERP
Study Jinchen Yang, Annette Rodriguez,
Merve Avar, Ryan Brill, Christa Simon,
Yu-Qiong Niu, Ashley Royston, Randi
Hagerman, John Olichney
P7.287
The Mind’s Eye: Effects of
Aging, Hemispace and Movement Direction
on Estimates of Distance Tigran Kesayan,
Adam Falchook, John Williamson, Kenneth
Heilman
Emergence of New
Responders to Treatment and New Adverse
Events in Clinical Trials of Pregabalin
in Diabetic Peripheral Neuropathy and
Postherpetic Neuralgia Parsons, Birol
Emir
P7.300
Contact Heat Evoked
Potentials Stimulator (CHEPS) in
the Assessement of Painful Leprosy
Neuropathy Camila Pupe, Osvaldo
Nascimento, Marcos Freitas, Eduardo
Davidovich, Caroline Bittar, Ricardo Dornas,
Bruno Coutinho
P7.301Pharmacological,
Predictors of Recovery of
Allocentric and Egocentric Neglect: The
Role of Education Joseph Posner, Lydia
Trupe, Cameron Davis, Yessenia Gomez,
Donna Tippett, Argye Hillis
Pharmacokinetics and Safety Profiles of
DS-5565, a Novel α2δ Ligand Tomihisa
Yokoyama, Naohisa Arakawa, Yuki Domon,
Fumihiko Matsuda, Tatsuya Inoue, Yutaka
Kitano, Makoto Takahashi, Naotoshi
Yamamura, Kiyonori Kai
P7.289
P7.302
P7.288
Spatial Neglect Commonly
Occurs After Traumatic Brain Injury Peii
Chen, Irene Ward, Kimberly Hreha, Yan Liu,
Ummais Khan
P7.290
Changes of Vertical
and Horizontal Pseudoneglect with
Aging Nicholas Milano, Anouchka Douyon,
Adam Falchook, Kenneth Heilman
P7.291
Effects of Gaze, Head and
Hand Location on Motor Function: Evidence
from TMS in Normal Subjects H. Coslett,
Olu Faseyitan, Jared Medina, Michael
Iannacone
P7.292
Things Look Up With
Aging Anouchka Douyon, Adam Falchook,
Kenneth Heilman, Nicholas Milano
P7.293
Leftward Where Bias and
Rightward Distraction in Chronic Neglect. A. Barrett, Kelly Goedert, Mooyeon Oh-Park
P7.294
Spatial Neglect and Parkinson
Disease Adam Falchook, Liliana Salazar,
Dan Neal, Tigran Kesayan, John Williamson,
Irene Malaty, Nikolaus McFarland, Michael
Okun, Ramon Rodriguez, Aparna WagleShukla, Kenneth Heilman
P7.295
Apparent Body Size Alters
Motor Function H. Coslett, Jared Medina,
Olu Faseyitan
P7.296
Central Nervous System
Safety and Tolerability of DS-5565: A
Randomized, Double-Blind, Placebo- and
Active Comparator-controlled Phase II
Study in Diabetic Peripheral Neuropathic
Pain Aaron Vinik, Uma Sharma, Karen
Feins, Ching Hsu, Domenico Merante
P7.297
Pharmacologic and
Non-Pharmacologic Treatments of
Adolescents with Chronic Tension-type
Headache. Peter Przekop, Allison Przekop
P7.298
Efficacy of Pregabalin in the
Treatment of Prediabetic Neuropathic
Pain Maria Alejandra Gonzalez Duarte,
Karla Cardenas-Soto, Monica Lem, Cinthia
Castillo, Christopher Gibbons, Roy Freeman
P7.274
Neuro-oncology Telemedicine
Follow-up Visits Richard Green, Emily
Woyshner, Amanda Hauser Dehaven
124
P7.299
An Assessment of Pain
Reports in Amyotrophic Lateral Sclerosis
Using Three Large Data Sets Helen
Stephens, Stephanie Felgoise, Susan
Walsh, Zachary Simmons
P7.303
Parkinson’s Disease Patients’
Preferences for Communication About
Advanced Care Planning Keiran Tuck, Lissa
Brod, John Nutt, Erik Fromme
P7.304
Quality of Care in the
Recognition and Management of Pain
Syndromes at the Emergency Room
of a Tertiary Hospital from January
2010-December 2010 (A Needs
Assessment) Ma. Alma Carandang, Amado
San Luis
P7.305
Mindfulness-Based Therapies
in the Treatment of Somatization Disorders:
A Meta-Analysis Lakhan Shaheen
P7.306
False Localizing Exam in a
Lumbar Spinal Epidural Abscess (SEA):
Right Paraspinal Pain and Contralateral
Leg Weakness Pavis Laengvejkal, Inhyup
Kim, Kunut Kijsirichareanchai, Sahawat
Tantikittichaikul, John DeToledo
P7.307
The PRIZM (Patient Registry
of Intrathecal Ziconotide Management)
Study for Patients with Severe Chronic
Pain Michael Saulino, David Caraway, Eric
Grigsby, Michael Leong, Richard Rauck,
Timothy Deer, Philip Kim, Mark Wallace,
Gladstone MCDowell, Sonja Hokett, Sarah
Alvarez-Horine, Geertrui Vanhove
P7.308
Pharmacokinetics and Urine Drug Screen
for Opioids: A Method to Determine
Efficacy, Safety and Abuse Fadi Delly,
Gulshan Oberoi, Rudram Muppuri,
Shushovan Chakrabortty
P7.309
Persistent Na+ and K+ Channel
Dysfunctions After Chronic Exposure
to Insecticides and Pyridostigmine
Bromide Nan Jiang, Thomas Nutter, Brian
Cooper
P7.310
Pain Profiles in Small Fiber
Neuropathy Maria Alejandra Gonzalez
Duarte, Karla Cárdenas-Soto, Mónica Lem,
Cinthia Castillo, Enoe Cruz-Martinez
Poster Session VII
P7.311
Contact Heat Evoked
Potentials Stimulator (CHEPS) and Thermal
Quantitative Sensory Testing (QST) in the
Assement of Atypical Orofacial Pain Bruno
Coutinho, Osvaldo Nascimento
P7.312
Shifts in Pain Severity
Categories Among Patients with Painful
Diabetic Peripheral Neuropathy or
Postherpetic Neuralgia Treated with
Pregabalin Parsons Bruce, Birol Emir
P7.313
Pharmacokinetics of DS-5565,
a Novel α2δ Ligand, in Rats and Monkeys,
and Assessment of DDI Risk Naotoshi
Yamamura, Makiko Yamada, Makoto
Takahashi, Minoru Uchiyama, Hiroko Koda,
Tsuyoshi Mikkaichi, Yumi Nishiya, Tomoyo
Honda, Naohisa Arakawa, Yuki Domon,
Thomas Fischer, Juergen Mueller
P7.314
Suicide in a Woman
Diagnosed with Bulbar Predominant
Amyotrophic Lateral Sclerosis: A Case
Report and Literature Review Maggie
McNulty, John-Michael Li, Madhu Soni
P7.315
Approaching the Mechanisms
Underlying Analgesia Induced by
High Voltage Electrical Stimulation of
Lumbosacral Nerve Roots Walter Troni,
Federica Melillo, Alessia Di Sapio, Antonio
Bertolotto
P7.316
The Palliative Care Needs
of Patients Living with Life-Limiting
Neurological Illness Marvin Chum, Valerie
Schulz, Christopher Watling, Teneille Gofton
P7.317
Combined Supraorbital
(SONS) and Occipital Nerve Stimulation
(ONS) for Intractable Post-Herpetic
Neuralgia Robert Bulger, Francis Conidi,
Kenneth Reed
P7.318
The Need for Early
Recognition of Complex Regional Pain
Syndrome to Facilitate Early Effective
Treatment Jacquelyn Laplant, Robert
Knobler
Child Neurology and
Developmental Neurology VI
P7.319
Abnormal Measures of White
Matter Integrity in Newborns with Hypoxic
Ischemic Encephalopathy (HIE) Paola
Pergami, Tania Nanavati, Bob Hou, Panitan
Yossuck, Ashley Smith, Jeffrey Carpenter,
Mark Haut
P7.320
A Noninvasive
with Symptom Reduction and Improved
Cardiovascular Autonomic Measures in
Adolescents with POTS Catherine Tegeler,
John Fortunato, Jared Cook, Sung Lee,
Meghan Franco, Charles Tegeler
P7.321
A Novel SUCLA2 Mutation
Associated with a Complex Childhood
Movements Disorder Caterina Garone,
Juliana Gurgel-Giannetti, Simone SannaCherchi, Sindu Krishna, Ali Naini, Catarina
M Quinzii, Michio Hirano
P7.322
An Unusual Presentation
of Neuropathy Secondary to Leprosy
(Hansen’s disease) Derrece Reid, Debra
Byler, Kimberly Harbaugh, Jennifer Baccon
P7.323
Increased Coherence Between
the Basal Ganglia and Motor Cortex in a
Rat Model of Pediatric Asphyxial Cardiac
Arrest. Bhooma Aravamuthan, Michael
Shoykhet
P7.324Neuro-Developmental
Disorders in India—From Epidemiology to
Public Policy Donald Silberberg, Narendra
Arora, Vinod Bhutani, Maureen Durkin,
Shefalli Gulati, Mkc Nair, Jennifer PintoMartin
P7.325
Rituximab Therapy as a
First-line Immunosuppressive Treatment
in Children with Neuromyelitis Optica
Spectrum Disorder: A Single-center
Experience. Giulia Longoni, Brenda
Banwell, Massimo Filippi, E. Ann Yeh
P7.326Periventricularlaminar
Heterotopia (PLH): Characterization in a
Series of 18 Patients Dina Amrom, Firas
Fahoum, Francois Dubeau, Gary Clark,
Eugen Boltshauser, Paolo Curatolo, Renzo
Guerrini, Ruben Kuzniecky, Anne Tsai,
Parul Jayakar, Mitsuhiro Kato, A Barkovich,
Donatella Tampieri, Denis Melancon,
Frederick Andermann, Eva Andermann,
William Dobyns
P7.327
A Case Report of 4H
Syndrome Probably Caused by a
Heterozygous Abnormality of the
POLR3A Gene with Preserved Intellectual
Function Kuwabara Midori, Yuki Hatanaka,
Takamichi Kanbayashi, Hidehiko Okuma,
Masahiro Sonoo, Hirotomo Saitsu,
Naomichi Matsumoto
P7.328
Sideroflexin-4 Defects Cause
a New Infantile Mitochondrial Disorder
Affecting Hematopoietic and Central
Nervous Systems. Caterina Garone,
Gordon J Hildick-Smith, Jeffrey D Cooney,
Laura S Kremer, Tobias B Haack, Jonathan
N Thon, Non Miyata, Daniel Lieber,
Sarah Calvo, Orhan H. Akman, Yvette Y
Yen, Nicholas C Huston, Diana S Branco,
Dhvanit I Shah, Matthew L Freedman, Carla
M Koehler, Joseph E Italiano, Andreas
Merkenschlager, Skadi Beblo, Tim Strom,
Thomas Meitinger, Peter Freisinger, Alice
Donati, Holger Prokisch, Vamsi Mootha,
Barry Paw, Salvatore DiMauro
P7.329
Intrinsic Excitability Defects
in Specific Subtypes of Medial Prefrontal
Cortex Pyramidal Neurons in a Mouse
Model of Autism Audrey Brumback, Vikaas
Sohal
P7.330
A Comparison of Colocated and Traditional Outpatient
Consultation for the Treatment of ADHD
in Two Urban Medical Homes: Costs and
Outcomes David Urion
P7.331
Ehlers-Danlos Type
IV Presenting with a Peroneal
Neuropathy Amitha Ananth, Yaping Yang,
Seema Lalani, Lotze Timothy
P7.332
Patients with Electrical Status
Epilepticus in Sleep and Normal Magnetic
Resonance Imaging Have Smaller Thalamic
Volume than Controls Ivan Sanchez
Fernandez, Alireza Akhondi-Asl, Jacquelyn
Klehm, Simon Warfield, Jurriaan Peters,
Tobias Loddenkemper
P7.333
Brainstem Disconnection
Syndrome in a Patient with Fetal Alcohol
Syndrome Chandan Mehta, Rajkumar
Agarwal, Ajay Kumar, Mohsin Maqbool
P7.334
Cerebrospinal Fluid Opening
Pressure in a Pediatric Demyelinating
Disease Cohort Sona Narula, Grant
Liu, Robert Avery, Brenda Banwell, Amy
Waldman
P7.335
Soto-like Syndrome and
Cortical Malformation Associated with
Chromosome 19p13.2 Microdeletion
Including Nuclear Factor-1X (NFIX) Swati
Karmarkar, Ina Amarillo, Douglas Larsen
P7.337
Neurocognitive and
Psychological Profiles of Children with
Idiopathic Epilepsy Adel Eladl, Hoda Atwa
P7.338Multi-domain
Neurodevelopmental Delays in Multiple
Gestation and Singleton Preterm
Infants Imad Jarjour, Laila Jarjour,
Alexandra Sibley
P7.339
Retrospective Review
of Inpatient Headache Admissions:
Looking AT Determinants of a Successful
Admission Arnold Sansevere
P7.340
Resting State EEG Serves as
a Promising Biomarker of Cognitive and
Language Function in Young Children with
ASD. Kevin McEvoy, Shafali Jeste
P7.341
Pathology of the
Neurovascular Unit in Cerebral X-linked
Adrenoleukodystrophy Sandra Jimenez,
Patricia Musolino, Tracey Suter, Florian
Eichler
P7.342
Cortical Involvement in
Early and Late Stages of Metachromatic
Leukodystrophy Jan-Mendelt Tillema,
Marloes Derks, Petra Pouwels, Pim de
Graaf, Frederik Barkhof, Marjo Van Der
Knaap, Nicole Wolf
P7.343
Stroke due to Extracranial
Internal Carotid Artery Dissection After
Roller Coaster Rides in a 4-year-old
Boy Amre Nouh, Daniel Vela-Duarte,
Thomas Grobelny, George Hoganson, David
Pasquale, Jose Biller
P7.344
Video EEG Monitoring in
Infants: Predictors of Subclinical Seizures
in the ICU Setting Eileen Broomall, Anna
Mrelashvili, Elaine Wirrell
Movement Disorders:
Other Parkinsonian Disorders
P7.345
Case Study with Video
Clips: Midbrain Dysfunction and
Restoration in a 30-year-old Woman
with Hydrocephalus Sarah Dolgonos,
Emmanuelle Schindler, Joshua Lovinger,
Duarte Machado
P7.336
Efficacy of EPA Enriched
Phosphatidylserine-Omega-3 (Vayarin) on
Children with ADHD Stephanie Nguyen,
Cindy Nguyen, Robert Chudnow, Van Miller,
Anthony Riela, Gerald So, Patricia Mireles,
Lina Shah
Obtaining Your CME and Evaluations
To receive CME for education programs or scientific sessions, evaluations must be completed online or via the Annual Meeting mobile app.
Wireless internet hotspots will be available at the convention center. Details will be provided prior to the meeting.
Thursday
May 1
Thursday, May 1
S54 MS and CNS
Neuroimaging II
S55 Pediatric Stroke and
Stroke in the Young
3:15 p.m.
S54.001
The Origin of Chronic T2* and Phase
Rims in MS Lesions: A Longitudinal
7T MRI Study Martina Absinta,
Pascal Sati, Massimo Filippi, Daniel
Reich
3:15 p.m.
S55.001
Moyamoya Disease in Children:
Results of the International Pediatric
Stroke Study Sarah Lee, Michael
Rivkin, Adam Kirton, Gabrielle
DeVeber, Jorina Elbers
3:30 p.m.
S54.002
Is Primary Progressive Multiple
Sclerosis a Disease Entity of its
Own? Preliminary Results of a 7T
MRI Study Joseph Kuchling, Ivan
Bozin, Jan-Markus Dörr, Lutz Harms,
Berit Rosche, Thoralf Niendorf,
Friedemann Paul, Tim Sinnecker,
Jens Wuerfel
3:30 p.m.
S55.002
Intraoperative Neurophysiologic
Monitoring of Surgical and
Endovascular Treatment of Pediatric
Arteriovenous Malformations Viet
Nguyen, Santiago Avila, Leslie Lee,
Sungho Cho, Scheherazade Le,
Jaime Lopez
3:45 p.m.
S54.003
Early Neuronal Damage in the
Cervical Cord of Patients with
Primary Progressive Multiple
Sclerosis Demonstrated by
MR Spectroscopy and Q-space
Imaging Khaled Abdel-Aziz, Torben
Schneider, Bhavana Solanky,
Claudia Wheeler-Kingshott, Day
Brian, Marios Yiannakas, Daniel
Altmann, Amy Peters, Alan
Thompson, Olga Ciccarelli
4:00 p.m.
S54.004
Relationships Between Quantitative
Spinal Cord MRI and Retinal Layers
in Multiple Sclerosis Jiwon Oh,
Elias Sotirchos, Shiv Saidha, Anna
Whetstone, Min Chen, Scott
Newsome, Kathleen Zackowski,
Jerry Prince, Marie Diener-West,
Daniel Reich, Peter Calabresi
4:15 p.m.
S54.005
Cortical Lesions in Multiple Sclerosis
Correlate with Retinal Pathology
as Measured by Optical Coherence
Tomography Daniel Harrison, Anna
Whetstone, Omar Al-Louzi, Peter
Calabresi
4:30 p.m.
S54.006
The Effect of Cardiovascular
Risk Factors on Lesion Burden
and Brain Atrophy in Multiple
Sclerosis Natalie Kappus, Bianca
Weinstock-Guttman, Jesper
Hagemeier, Cheryl Kennedy,
Rebecca Melia, Ellen Carl, Deepa
Ramasamy, Maryia Cherneva,
Jackie Durfee, Niels Bergsland,
Michael Dwyer, Channa Kolb, Murali
Ramanathan, Robert Zivadinov
4:45 p.m.
S54.007
Early Clinical and MRI Predictors
of Time to Second Attack and
Disability in Children with Acute
Demyelinating Syndromes: Findings
from a Prospective National Cohort
Study Leonard Verhey, Ruth-Ann
Marrie, Amit Bar-Or, Dessa
Sadovnick, Manohar Shroff, Douglas
Arnold, Brenda Banwell
126
3:45 p.m.
S55.003
Marijuana Use and the Risk of
Ischemic Stroke: The Stroke
Prevention in Young Adults
Study Tara Dutta, Kathleen Ryan,
Yuching Cheng, Steven Kittner,
John Cole
4:00 p.m.
S55.004
Trends in Substance Abuse
Preceding Stroke in Young Adults: An
Update Felipe De Los Rios La Rosa,
Dawn Kleindorfer, Jane Khoury,
Joseph Broderick, Kathleen Alwell,
Charles Moomaw, Pooja Khatri,
Opeolu Adeoye, Matthew Flaherty,
Daniel Woo, Jane Eilerman, Simona
Ferioli, Brett Kissela
4:15 p.m.
S55.005
Thrombophilia in Young Patients with
Cerebrovascular Disease. AISYF
Study Luciana Leon Cejas, Ricardo
Reisin
4:30 p.m.
S55.006
Long Distance Travel Potentiates
Other Novel Risk Factors in PFO
Related Strokes—“Economy Class
Strokes” MingMing Ning, D Sena,
K Feeney, T Wickham, M Elia, W
Deng, I Chou, J Hung, L Chen, I
Inglessis-Azuaje, S Silverman, R
Schainfeld, D McMullin, G Dec, E Lo,
I Palacios, F Buonanno
4:45 p.m.
S55.007
Oral Contraceptive Use and Incident
Stroke in Women with Sickle Cell
Disease Taqi Zafar, Malik Adil,
Muhammad Umair, Saqib Chaudhry,
Amna Zarar, Muhammad Suri,
Adnan Qureshi
3:15 p.m.–5:00 p.m.
3:15 p.m. Presentation of Sheila
Essey Award: An Award for ALS
Research
Recipient:
Jeremy Shefner, MD, PhD
Syracuse, NY
3:45 p.m.
S56.003
HuR Is Essential for TDP43 Expression Through
Posttranscriptional Mechanisms:
Implications for Motor Neuron
Toxicity and ALS Liang Lu, Lei
Zheng, Ying Si, Shin Oh, Peter King
4:00 p.m.
S56.004
GGGGCC Repeat Expansion of
C9ORF72 Is Toxic via Sequestration
of RNA Binding Proteins and
Consequent Disruption of RNA
Splicing Johnathan CooperKnock, Matthew Walsh, Adrian
Higginbottom, J Robin Highley,
Joanna Bury, Mark Dickman,
Magnus Rattray, Paul Heath,
Matthew Wyles, Paul Ince, Stephen
Wharton, Stuart Wilson, Janine
Kirby, Guillaume Hautbergue,
Pamela Shaw
4:15 p.m.
S56.005
The TREM2 Variant p.R47H Is a Risk
Factor for Sporadic Amyotrophic
Lateral Sclerosis Matthew Harms,
Janet Cady, Erica Koval, Bruno
Benitez, Craig Zaidman, Jennifer
Jockel-Balsarotti, Peggy Allred,
Robert Baloh, John Ravits, Ericka
Simpson, Stanley Appel, Alan
Pestronk, Alison Goate, Timothy
Miller, Carlos Cruchaga
4:30 p.m.
S56.006
Spinal Muscular Atrophy Phenotype
Is Ameliorated Either by SMN
Increase or Modulation of Secondary
Cell Death Events with RNA
Therapy Giulietta Riboldi, Monica
Nizzardo, Chiara Simone, Federica
Rizzo, Margherita Ruggieri, Serena
Pagliarani, Gianna Ulzi, Sabrina
Salani, Andrea DalMas, Monica
Bucchia, Emanuele Frattini, Giulia
Stuppia, Francesca Magri, Nereo
Bresolin, Franco Pagani, Giacomo
Comi, Stefania Corti
4:45 p.m.
S56.007
iPSC-derived Neural Stem Cells
Ameliorate the Phenotype of Spinal
Muscular Atrophy with Respiratory
Distress Type 1 (SMARD1) Stefania
Corti, Chiara Simone, Monica
Nizzardo, Federica Rizzo, Margherita
Ruggieri, Sabrina Salani, Monica
Bucchia, Paola Rinchetti, Chiara
Zanetta, Irene Faravelli, Erika
Monguzzi, Francesca Magri, Nereo
Bresolin, Giacomo Comi
S57 Movement Disorders:
Imaging
3:15 p.m.
S57.001
Abnormal Transcallosal Motor
Projections In Cervical Dystonia:
An fMRI and Tractographic
Analysis Jeff Waugh, Jake Kuster,
Jacob Levenstein, Woodman
Sandra, Trisha Multhaupt-Buell,
Makris Nikos, Lewis Sudarsky, Hans
Breiter, Nutan Sharma, Anne Blood
3:30 p.m.
S57.002
Dopamine Transporter Imaging in
Essential Tremor With and Without
Parkinsonian Features Olga Waln,
Ying Wu, Reid Perlman, Anh Kim
Van, Juliet Wendt, Joseph Jankovic
3:45 p.m.
S57.003
Diffusion Tensor Imaging as
a Biomarker for REM Sleep
Behavior Disorder and Parkinson’s
Disease Matthew Brodsky, John
Grinstead, David Lahna, Jeffrey
Pollock
4:00 p.m.
S57.004
Midbrain Microstructural Atrophy
Associated with Parkinson’s Disease
Motor and Cognitive Symptoms
Using 7-Tesla MRI Kathleen Poston,
Laura Santoso, Jeffrey Bernstein,
Matthew Cruadhlaoich, David
Everling, Sophie YorkWilliams,
Michelle Fenesy, Michael Zeineh,
Geoffrey Kerchner
4:15 p.m.
S57.005
Exploring the Neural Circuitry of
REM Sleep Behavior Disorder in
Parkinson’s Disease Using Functional
MRI Samuel Bolitho, James Shine,
Sharon Naismith, Ron Grunstein,
Peter Bell, Simon Lewis
4:30 p.m.
S57.006
The ‘Swallow Tail’ Appearance of
the Healthy Nigrosome—a New
Accurate Test of Parkinson’s Disease:
a Case-Control and Retrospective
Cross-Sectional MRI Study at
3T Stefan Schwarz, Mohammed
Afzal, Paul Morgan, Nin Bajaj, Penny
Gowland, Dorothee Auer
4:45 p.m.
S57.007
Mapping Regional Grey and White
Matter Damage in Patients with
Progressive Supranuclear Palsy
Syndrome Francesca Caso,
Federica Agosta, Maria Antonietta
Volontè, Daniele Martinelli, Lidia
Sarro, Francesca Spagnolo, Andrea
Falini, Giancarlo Comi, Massimo
Filippi
Neurology: Clinical Aspects
3:15 p.m.
S58.001
Alzheimer Patients Show Significant
Disturbance in Water Influx Into CSF
Space Strongly Supporting β-amyloid
Clearance Hypothesis Tsutomu
Nakada, Hironaka Igarashi, Yuji
Suzuki, Ingrid Kwee
3:30 p.m.
S58.002
Medical Risk Factors For
Frontotemporal Degeneration:
Analysis of the NACC Uniform
Dataset Mariel Deutsch, Mario
Mendez, Edmond Teng
3:45 p.m.
S58.003
Cholesterol, Statins and the Risk of
Dementia in the Oldest-Old: The 90+
Study Marcella Evans, Claudia
Kawas, Maria Corrada
4:00 p.m.
S58.004
The Effect of Triglycerides on
Cognitive Function in Aging Adults:
A Cross-Sectional Study Vishnu
Parthasarathy, Darvis Frazier, Laura
Jastrzab, Linda Chao, Helena Chui,
Brianne Bettcher, Joel Kramer
4:15 p.m.
S58.005
Association of Type 2 Diabetes
Cognitive Impairment Is Mediated
by Brain Atrophy Rosebud Roberts,
David Knopman, Scott Przybelski,
Michelle Mielke, Kejal Kantarci,
Vernon Pankratz, Yonas Geda,
Bradley Boeve, Walter Rocca,
Ronald Petersen, Clifford Jack
4:30 p.m.
S58.006
Factor Scores for Brain Reserve,
Alzheimer and Vascular Pathology
Are Independent Risk Factors
for Dementia in a Populationbased Cohort Study: The Kame
Project Amy Borenstein, James
Mortimer, Eric Larson
4:45 p.m.
S58.007
Impaired Cerebral Autoregualtion
Is Associated with a Greater 7-year
Decline in Gait Speed in an Elderly
Population: The MOBILIZE Boston
Study Farzaneh Sorond, Sushmita
Purkayastha, Lewis Lipsitz, Suzanne
Leveille
Scientific Sessions
3:15 p.m.
S59.001
Malformation Risks of Antiepileptic
Drug Monotherapies in Pregnancy:
An Update from the UK and
Ireland Epilepsy and Pregnancy
Registers Ellen Campbell, Fiona
Kennedy, Aline Russell, W Smithson,
Linda Parsons, Beth Irwin, Brenda
Liggan, Norman Delanty, Patrick
Morrison, Stephen Hunt, John Craig,
Jim Morrow
3:30 p.m.
S59.002
Congenital Malformations in Infants
Born to Women with Epilepsy at
Boston Medical Center Gina Deck,
Alexandra Lovett, Neil Nadkarni,
Georgia Montouris
3:45 p.m.
S59.003
Drivers for Epilepsy Readmissions: A
Retrospective Cohort Study Tracie
Caller, Jasper Chen, Jessica
Harrington, Barbara Jobst
4:00 p.m.
S59.004
Antiepileptic Drug Prescribing for
OEF/OIFVeterans with New-onset
Epilepsy: 2008-2010 Mary Jo Pugh,
Anne Van Cott, Christine Baca,
Megan Amuan
4:15 p.m.
S59.005
Factors Independently Associated
with Anxiety and Depression in
Epilepsy Heidi Munger Clary, Marla
Hamberger
4:30 p.m.
S59.006
Comparison of Heart Rate
Variability Parameters Between
Partial and Idiopathic Generalized
Epilepsy Patients in the Interictal
Period Kadriye Agan, Aslihan
Ergun, Altug Cincin, Damla Ozbek
Cetinkaya, Hatice Omercikoglu
Ozden, Alper Kepez, Osman
Yesildag, Ipek Midi
4:45 p.m.
S59.007
Influences of Temporal Lobe Epilepsy
and Temporal Lobe Resection on
Olfactory Function Richard Doty,
Isabelle Tourbier, Taehoon Kim,
Jonathan Silas, Paul Moberg,
Ashwini Sharan, Michael Sperling,
Bruce Turetsky
S60 Child Neurology II
3:15 p.m.
S60.001
Evidence of Impaired Age-expected
Growth and Atrophy of the
Cerebellum in Pediatric Patients with
Monophasic Acquired Demyelinating
Syndrome and Multiple
Sclerosis Katrin Weier, Vladimir
Fonov, Bérengère Aubert-Broche,
Douglas Arnold, Brenda Banwell,
D. Collins
S61 Muscle Disease: Gene
Therapy and Models
3:15 p.m.
S61.001
Restoration of Dystrophin Expression
in a Novel Duchenne Mouse
Model, the Dup2 Mouse, by IresMediated Translation of a Highly
Functional N-truncated Dystrophin
Protein Kevin Flanigan, Adeline
Vulin-Chaffiol, Nicolas Wein, Paul
Janssen
3:30 p.m.
S60.002
Incidence of Early Seizures with
Levetiracetam Prophylaxis in Children
After Traumatic Brain Injury Melissa
Chung, Nicole O’Brien
3:30 p.m.
S61.002
β-Sarcoglycan Gene Transfer Leads
to Functional Improvement in a
Model of LGMD2E Eric Pozsgai,
Danielle Griffin, Kristin Heller, Jerry
Mendell, Louise Rodino-Klapac
3:45 p.m.
S60.003
Incidence of Epilepsy Following
Perinatal Stroke: A Prospective
Cohort Study Rebecca Ichord,
Niharika Gupta, Michael Uohara,
Lori Billinghurst, Daniel Licht, Lauren
Beslow
3:45 p.m.
S61.003
MicroRNA-29 Overexpression
Delivered by Adeno-Associated Virus
Suppresses Fibrosis in mdx:utrn +/Mice Eric Meadows, Janaiah Kota,
Vinod Malik, Reed Clark, Zarife
Sahenk, Scott Harper, Jerry Mendell
4:00 p.m.
S60.004
Viral Infections during Pregnancy:
a Risk Factor for the Development
of Concurrent Autism and
Epilepsy in the Offspring Raman
Sankar, Andrey Mazarati, James
Washington III, Eduardo Pineda,
Don Shin
4:00 p.m.
S61.004
AAV Gene Transfer Utilizing
Homologous Overlap Vectors
Mediates Functional Recovery
of Dysferlin Deficiency Patricia
Sondergaard, Eric Pozsgai, Danielle
Griffin, Jerry Mendell, Louise
Rodino-Klapac
4:15 p.m.
S60.005
Predictors of Outcome in a Large
Cohort of Infantile Spasms of
Unknown Cause Christopher
Yuskaitis, Maura Madou, Katherine
Howell, Annapurna Poduri, Elliott
Sherr
4:15 p.m.
S61.005
Fhl1 W122S Knock-in Mice
Manifest Late-onset Mild
Myopathy Valentina Emmanuele,
Akatzuki Kubota, Beatriz Garcia-Diaz,
Caterina Garone, Orhan H. Akman,
Kurenai Tanji, Catarina Quinzii,
Michio Hirano
4:30 p.m.
S60.006
Pellagra-like Syndrome Proves to be a
Variant of Xeroderma PigmentosumCockayne Syndrome and Niacin
Confers Clinical Benefit Mustafa
Salih, Hadia Hijazi, Muddathir
Hamad, Hamdy Hassan, Shinu
Ansari, Fowzan Alkuraya
4:45 p.m.
S60.007
Presurgical Evaluations in Children
with Pathology Confirmed
Focal Cortical Dysplasia Anna
Mrelashvili, Katherine Nickels,
Elaine Wirrell, Lily Wong-Kisiel
4:30 p.m.
S61.006
Impaired Muscle Regeneration
in CAPN3-KO Mice Related to
MicroRNA Dysregulation Zarife
Sahenk, Cilwyn Braganza, Lei Chen,
Syed-Rehan Hussain, Eric Meadows,
Sarah Lewis, Kevin Flanigan, K. Reed
Clark, Jerry Mendell
4:45 p.m.
S61.007
Mutations in Zaspopathy Cause
Disruption of Actinin-Crosslinked
Actin Filaments, the Core Structure
of Skeletal Muscle Z-discs Xiaoyan
Lin, Janelle Ruiz, Ilda Bajraktari,
Rachel Ohman, Robert Griggs,
Kenneth Fischbeck, Ami Mankodi
S62 Cerebrovascular
Neurology: Cognitive and
Behavioral
3:15 p.m.
S62.001
Post-Surgical Cognitive
Outcomes Tania Giovannetti, Molly
Fanning, Sarah Ratcliffe, Catherine
Price, Steven Messe, Ola Selnes,
Michael Acker, Thomas Floyd,
Wilson Szeto, Joseph Bavaria
3:30 p.m.
S62.002
Antiphospholipid Antibodies, Brain
Infarcts, and Cognitive and Motor
Decline in Aging (ABICMA): Final
Cerebral Infarct Results from a
Community-Based, Longitudinal,
Clinical-Pathological Study Steven
Levine, Zoe Arvanitakis, Robin Brey,
Jacob Rand, Julie Schneider, Lei Yu,
Sue Leurgans, David Bennett
3:45 p.m.
S62.003
Elevated Blood Pressure and
Risk of Incident Amnestic Mild
Cognitive Impairment/Alzheimer’s
Disease Steven Edland, Guerry
Peavy, David Salmon, Douglas
Galasko
4:00 p.m.
S62.004
Influence of Pre-Existing Cognitive
Impairment on the Outcome of Stroke
Patients Treated by Thrombolytic
Therapy. Results of the OPHELIECOG Study Kei Murao, Didier Leys,
Solene Moulin, Yasushi Okada
4:15 p.m.
S62.005
Early Depression Screening Is
Feasible in Hospitalized Stroke
Patients Rahul Karamchandani,
Farhaan Vahidy, Suhas Bajgur, Kim
Yen Thi Vu, H. Alex Choi, Adeolu
Oladunjoye, Robert Hamilton, Sean
Savitz
4:30 p.m.
S62.006
Pre-Existing and Incident Cerebral
Microbleeds Are Associated with
Progression of Ischemic Vascular
Lesions Saloua Akoudad,
Mohammad Ikram, Peter Koudstaal,
Albert Hofman, Wiro Niessen,
Steven Greenberg, Aad Van Der
Lugt, Meike Vernooij
4:45 p.m.
S62.007
Comparing Semi-quantitative and
Volumetric Measurements of MRI
White Matter Hyperintensities: The
Northern Manhattan Study Carly
Oboudiyat, Hannah Gardener,
Chensy Marquez, Mitchell Elkind,
Ralph Sacco, Charles DeCarli,
Clinton Wright
S63 Neuromyelitis
Optica and Autoimmune
Encephalitis
3:15 p.m.
S63.001
Revised Diagnostic Criteria for
Neuromyelitis Optica Spectrum
Disorders Dean Wingerchuk,
Brenda Banwell, Jeffrey Bennett,
Philippe Cabre, William Carroll,
Tanuja Chitnis, Jerome De Seze,
Kazuo Fujihara, Benjamin Greenberg,
Anu Jacob, Sven Jarius, Marco
Lana-Peixoto, Michael Levy, Jack
Simon, Silvia Tenembaum, Anthony
Traboulsee, Patrick Waters, Kay
Wellik, Brian Weinshenker
3:30 p.m.
S63.002
Differentiating NMO and MSassociated Optic Neuritis by
MRI Maureen Mealy, Anna
Whetstone, Peter Calabresi, Michael
Levy
3:45 p.m.
S63.003
Clinical and Demographic Features
of Children with NMO: Report from
the U.S. Network of Pediatric MS
Centers of Excellence Tanuja
Chitnis, Jayne Ness, Lauren Krupp,
Emmanuelle Waubant, Tyler Hunt,
Moses Rodriguez, Timothy Lotze,
Mark Gorman, Anita Belman,
Bianca Weinstock-Guttman, Marc
Patterson, John Rose, Charlie
Casper
4:00 p.m.
S63.004
AQP4-IgG Assays Comparison in
Laboratory Clinical Serivce James
Fryer, Vanda Lennon, Sean Pittock,
Sarah Jenkins, Stacey Clardy,
Erika Horta, Eric Jedynak, Claudia
Lucchinetti, Elizabeth Shuster, Brian
Weinshenker, Dean Wingerchuk,
Andrew McKeon
4:15 p.m.
S63.005
Therapeutic Effect of Plasma
Exchange (PLEX) in Neuromyelitis
Optica (NMO): Immediate and
Long Term Response Moogeh
Baharnoori, Marika Hohol, Katerina
Pavenski, Paul O’Connor
4:30 p.m.
S63.006
Neuromyelitis Optica Spectrum
with Autoantibodies Against
Myelin-Oligodendrocyte Glycoprotein
have Distinct Clinical Features
and Prognosis from Seronegative
Patients Douglas Sato, Dagoberto
Callegaro, Marco Lana-Peixoto,
Patrick Waters, Satoru Tanaka,
Frederico Jorge, Toshiyuki
Takahashi, Tatsuro Misu, Samira
Apostolos-Pereira, Natalia Talim,
Renata Simm, Angelina Lino, Ichiro
Nakashima, Kyoichi Nomura,
Masashi Aoki, Kazuo Fujihara
4:45 p.m.
S63.007
From Behavior to Synapse: A
Murine Model of Passive Transfer
of Antibodies from Patients with
Anti-NMDAR Encephalitis Mannara
Francesco, Javier Gutierrez Cuesta,
Frank Leypoldt, Jesús Planagumà,
Elena Martín García, Ankit Jain,
Francesc Graus, Rita Balice-Gordon,
Rafael Maldonado Lopez, Josep
Dalmau
127
Thursday
May 1
Reproduction, Health Care
Delivery, and Co-morbidities
Thursday, May 1
1
Controversies in Neurology Plenary Session
5:30 p.m.–7:00 p.m.
The program features experts discussing the most current and controversial issues in neurology. It is set up as a series of debates in which two
speakers argue opposing sides of a single topic, followed by a rebuttal. Each round concludes with a 10-minute question and answer period.
Moderators:
Joseph Jankovic, MD, FAAN
Member, Science Committee
Walter A. Rocca, MD, MPH
Member, Science Committee;
Chair, Clinical Research
Subcommittee
Does Preventing Relapses Protect Against Progressive MS?
Pro: Maria Trojano, MD
University of Bari, Bari, Italy
Con: Helen Tremlett, PhD, BPharm
University of British Columbia,
Vancouver, BC, Canada
Is Intervention for Asymptomatic AVM Useful?
Pro: Robert M. Friedlander, MD
UPMC Presbyterian, Pittsburgh, PA
Con: J. P. Mohr, MD, FAAN
Should Neurologists Prescribe Marijuana for Neurological Disorders?
Pro: Barbara S. Koppel, MD, FAAN
Metropolitan Hospital, Rye, NY
Con: John C. M. Brust, MD, FAAN
New York Neurological Institute,
New York, NY
128
Friday, May 2
Integrated Neuroscience Session
Proteinopathy in Neurodegenerative Disease
I11 8:00 a.m.–12:00 p.m.
Coordinators: Carol F. Lippa, MD, and David G. Munoz, MD
8:00 a.m.–8:15 a.m.
Neurodegenerative Disease: Past, Present, and Future David G. Munoz, MD
8:15 a.m.–8:45 a.m.
Bioenergetic Consequences of Protein Misfolding in Neurodegenerative Diseases M. Flint Beal, MD, FAAN
8:45 a.m.–9:15 a.m.
Molecular Correlates of Alzheimer Progression Bradley T. Hyman, MD, PhD
9:15 a.m.–9:45 a.m.
Alpha-Synuclein Associated Mechanisms of Neuronal Injury: The Mitochondrial Link J. Timothy Greenamyre, MD, PhD
9:45 a.m.–10:15 a.m. Prion-like Diseases: The Future is Unfolding Neil R. Cashman, MD
10:15 a.m.–10:30 a.m. Panel Discussion
I11-1.001 An Abeta Oligomer Receptor
Antagonist and Antibodies to Specific
Target Receptor Epitopes Displace Abeta
Oligomers in Alzheimer’s Patient Brain
Tissue Sections Susan Catalano, Nicholas
Izzo, Courtney Rehak, Raymond Yurko, Kelsie
Mozzoni, Colleen Silky, Gary Look, Gilbert
Rishton, Hank Safferstein, Tara Spires-Jones
I11-1.002 Imaging Tau Pathology in
Vivo in FTLD: Initial Experience with (18F)
T807 PET Bradford Dickerson, Kimiko
Domoto-Reilly, Daisy Hochberg, Michael
Brickhouse, Michael Stepanovic, Keith
Johnson
I11-1.003 A CSF Signature of
Frontotemporal Lobar Degeneration with
C9orf72 Repeat Expansions William Hu,
Jonathan Glass, Vivianna Van Deerlin,
Murray Grossman, Kelly Watts, James Lah,
John Trojanowski, Allan Levey
I11-1.004 Progressive Supranuclear
Palsy (PSP): Diagnosis Through Skin
Biopsy Ildefonso Rodriguez-Leyva, Ana
Calderon-Garcidueñas, Martha Santoyo,
Erika Chi, Verónica Medina-Mier, Maria
Jimenez-Capdeville
I11-1.006 Complement Factor H Is a
Biomarker for Mild Cognitive Impairment
Not Due to Alzheimer’s Disease Trung
Nguyen, Kelly Watts, James Lah, Jonathan
Glass, Allan Levey, William Hu
I11-1.007 Cytoplasmic Redistribution
of Mutant TDP-43 in a BAC Based
Mouse Model of Amyotrophic Lateral
Sclerosis Kevin Talbot, David Gordon,
Ruxandra Mutihac, Javier AlegreAbarrategui, Lucy Farrimond, Ben Davies,
Richard Wade-Martins
I11-1.005 Spinocerebellar Ataxias
I11-1.008 Coenzyme Q10, Statin, and
Spinocerebellar Ataxias Sheng-Han Kuo,
Raymond Lo, Karla Figueroa, Stefan Pulst,
Susan Perlman, George Wilmot, Christopher
Gomez, Jeremy Schmahmann, Henry
Paulson, Vikram Shakkottai, Sarah Ying,
Theresa Zesiewicz, Khalaf Bushara, Michael
Geschwind, Guangbin Xia, S Subramony,
Tetsuo Ashizawa
I11-1.009 Epigenetic Mechanisms
Linking Diabetes and Synaptic
Plasticity Giulio Pasinetti
I11-1.010 PACAP Deficit in Alzheimer’s
with Hypogonadism: Unraveling a Novel
Group of Inherited Neurometabolic
Disorders Charles Lourenco, Claudia
Sobreira, Roberto Giugliani, Stephan
Zuchner, Wilson Marques, Jr.
Disease and Protection Against BetaAmyloid Toxicity PengCheng Han, Zhiwei
Tang, Jun-Xiang Yin, Thomas Beach, Eric
Reiman, Jiong Shi
Data Blitz: 11:30 a.m.–12:00 p.m.
11:30 a.m.
1II-2.001
11:35 a.m.
1II-2.002
RER1: A Novel Regulator of AlphaSynuclein Nikolaus McFarland, Hyo-Jin
Park, Lauren Ricchiuti
HuR Is Essential for TDP-43 Expression
Through Posttranscriptional Mechanisms:
Implications for Motor Neuron Toxicity and
ALS Liang Lu, Lei Zheng, Ying Si, Shin Oh,
Peter King
11:40 a.m.
1II-2.003
α-Synuclein in Red Blood Cells Is a
potential Diagnostic Biomarker for
Parkinson’s Disease Rodolfo Savica, Roy
Dyer, Michelle Mielke, Bryan Klassen,
Bradley Boeve, George Klee, J. Ahlskog,
Walter Rocca, Marina Ramirez-Alvarado
11:45 a.m.
1II-2.004
Isradipine Rescues Alpha-synuclein Toxicity
in a Zebrafish Model of Parkinson’s Disease
by Upregulating Autophagy Mark Stahl,
Shubhangi Prabhudesai, Aaron Lulla, Jeff
Bronstein
11:50 a.m.
Education Program Syllabi
Full text syllabi and program slides will be available electronically only—online or via the Annual Meeting mobile app. All registered
attendees will receive an email notification once syllabi are available.
130
1II-2.005
GGGGCC Repeat Expansion of C9ORF72
Is Toxic Via Sequestration of RNA Binding
Proteins and Consequent Disruption of
RNA Splicing Johnathan Cooper-Knock,
Matthew Walsh, Adrian Higginbottom,
J Robin Highley, Joanna Bury, Mark
Dickman, Magnus Rattray, Paul Heath,
Matthew Wyles, Paul Ince, Stephen
Wharton, Stuart Wilson, Janine Kirby,
Guillaume Hautbergue, Pamela Shaw
Plenary Session
Current as of 2/13/2014 Clinical Trials Plenary Session
12:00 p.m.–1:30 p.m.
This mid-day session covers important clinical topics that affect patient care identified from other society meetings. The latest updates within
several clinical trials conducted over the course of the last year will be presented with an open panel discussion at the conclusion.
Moderators:
Natalia Sana Rost, MD, FAAN
Vice-Chair, Science Committee
The Idiopathic Intracranial
Hypertension Treatment
Trial: A Multicenter, DoubleBlind, Randomized Clinical
Trial Comparing
Acetazolamide and
Placebo on Visual Outcome
Michael Wall, MD, FAAN
University of Iowa, Iowa City, IA
Anti-angiogenic Therapy for
Glioblastoma: A
Randomized, DoubleBlinded Phase III Trial of
Bevacizumab in Newly
Diagnosed Patients
Mark R. Gilbert, MD
The University of Texas MD Anderson Cancer Center,
Houston, TX
TOPIC: Efficacy and Safety
of Once-daily Oral
Teriflunomide in
Patients with First Clinical
Episode Consistent With
Multiple Sclerosis
Petra Kaufmann, MD
Member/Federal Liaison,
Clinical Research Subcommittee
FAST-MAG Trial in Acute
Ischemic Stroke
Jeffrey L. Saver, MD, FAAN
UCLA School of Medicine, Los
Angeles, CA
CGRP Monoclonal Antibody
LY2951742 for the Prevention
of Migraine: A Phase 2,
Randomized, Double-Blind,
Placebo-Controlled Study
avid Dodick, MD
D
Mayo Clinic, Phoenix, AZ
Randomized, Double-blind,
Placebo-controlled Trial of
ALD403: An Anti-CGRP
Peptide Antibody in the
Prevention of Frequent
Episodic Migraine
University of California, San Francisco, CA
Aaron E. Miller, MD, FAAN
Mt. Sinai School of Medicine, New York, NY
131
Section Topic Controversies/
Integrated Neuroscience
Friday, May 2
Pain: Methods of Treatment
1:00 p.m.–2:30 p.m.
Guy Burrows, MD
1:50 p.m.–2:05 p.m.
Headache: Classification Morris Levin, MD
1:05 p.m.–1:20 p.m.
Interventional Pain Procedures for
Headache and Facial Pain Syndromes
Charles Brock, MD
2:05 p.m.–2:25 p.m.
Panel Discussion
2:25 p.m.–2:30 p.m.Conclusion Guy Burrows, MD
1:20 p.m.–1:35 p.m.
Pain Connection with Sleep Disorders
lon Avidan, MD, MPH
A
1:35 p.m.–1:50 p.m.
Opioids in Neurology Practice
C hristopher Gibbons, MD
Concussion in Sports and the Military
I12 1:00 p.m.–5:00 p.m.
Coordinators: Anthony G. Alessi, MD, FAAN, and Jack W. Tsao, MD, DPhil, FAAN
1:10 p.m.–1:40 p.m.
Headaches Following Concussion Tad Seifert, MD
1:40 p.m.–2:10 p.m.
Imaging Following Concussion Gary Small, MD, PhD
2:10 p.m.–2:40 p.m.
Sleep Disturbances Following Concussion Joseph Krainin, MD
2:40 p.m.–3:10 p.m.
Blast Effects Causing TBI and Role of Blast Sensors Geoffrey Ling, MD, PhD, FAAN
3:10 p.m.–3:30 p.m.
I12-1.001 fMRI Neuropsychological
I12-1.004 Alterations in Network
I12-1.002 Etiology and Epidemiology of
I12-1.005 Structural Imaging
Battery for Athletes with
Concussion David Hubbard, Adam
Hampshire, Adrian Owen
Traumatic Brain Injury in Relation to Gender
Differences Among African American
Patients Lien Diep, Robert Farney, Stacy
Cary-Thompson, Jean Belcourt, Robert
Farney, Janaki Kalyanam, Annapurni JayamTrouth
I12-1.003 Is There Chronic Brain
Damage in Retired NFL Players?
Neuroradiology, Neuropsychology and
Neurology of 45 Retired Players Ira Casson, David Viano, E. Mark Haacke,
Zhifeng Kou, Danielle LeStrange
Dynamics Following Blast-Induced Mild
Traumatic Brain Injury Andrei Vakhtin, Paul
Taylor, Corey Ford
Correlations with Memory Assessment and
Concussion in Retired NFL Athletes Kyle
Womack, Jeremy Strain, Nyaz Didehbani,
Heather Conover, Michael Kraut, Munro
Cullum, John Hart
I12-1.006 Progressive Return
to Activity Following Acute mTBI: A
Standardized Approach Robert Labutta,
Therese West, Helen Coronel, Katherine
Helmick
I12-1.007 Axonal Injury,
Neuroinflammation and Amyloid Pathology
After Traumatic Brain Injury: Making
Connections to Neurodegeneration David
Sharp, Gregory Scott, Ramlackasingh
Anil, Hellyer Peter, Leech Robert, Federico
Turkheimer, Paul Matthews, David Brooks
I12-1.008 Neural Correlates of
Cognitive Anosognosia in Veterans
with Mild Traumatic Brain Injury
(mTBI) Mohammed Ahmed, Ihtsham
Haq, Robin Hurley, Katherine Taber, Jared
Rowland, Ruth Yoash-Gantz, Stephen
Kramer
I12-1.009 Comparison of Headache
in OEF/OIF Veterans with Traumatic Brain
Injury (TBI) Against Controls Matched
for Age, Sex, Race, and Deployment
Time James Couch, Kenneth Stewart
I12-1.010 The King-Devick Test
Is Vastly Superior to the Symbol Digit
Modalities Test as a Sideline Determinant
of Concussion in Mixed Martial Arts
Fighters Daniel Kantor
Data Blitz Session: 4:30 p.m.–5:00 p.m.
4:30 p.m.
I12-2.001
Effect of Concussion and Blast Exposure on
Clinical Symptoms Following Deployment
of U.S. Military Personnel Mikias Wolde,
Briana Perry, Jay Haran, Justin Campbell,
Alia Creason, Catalina Sher, Lauren Stentz,
Jack Tsao
132
4:35 p.m.
I12-2.002
The Natural History of Acute Recovery
of Blast-induced Mild Traumatic Brain
Injury: A Case Series During War Jason
Hawley, David Larres, Elizandro Gonzales,
Walter Carr
4:40 p.m.
I12-2.003
4:45 p.m.
I12-2.004
Field Utilization of the Cleveland Clinic
Concussion iPad Assessment Tool Jay
Alberts, Joshua Hirsch, Susan Linder, David
Schindler
Development of a Medical Device for the
Rapid Assessment of Concussion Donald
Weaver, Ying Tam, Christopher Barden,
Ryan D’Arcy, Love Kalra, Lauren Petley,
Chen Wei
4:50 p.m.
I12-2.005
Vision Testing Is Additive to the
Sideline Assessment of Sports-Related
Concussion Rachel Ventura, Zoe
Marinides, Steven Galetta, James
Clugston, Laura Balcer
Plenary Session
Current as of 2/13/2014 Neurology Year in Review Plenary Session
5:30 p.m.–7:00 p.m.
This plenary session will feature six speakers, each focusing on the latest research that has happened in the last year
within a specific subspecialty topic.
Moderator: Lisa M. DeAngelis, MD, FAAN
Multiple Sclerosis
Movement Disorders
Anne H. Cross, MD
Washington University School of
Medicine, St. Louis, MO
Rush University Medical Center,
Chicago, IL
Headache/Pain
Neurocritical Care
David M. Greer, MD
Yale University School of
Medicine, New Haven, CT
Neuromuscular
Alzheimer’s Disease
Robert C. Griggs, MD, FAAN
University of Rochester,
Rochester, NY
Todd E. Golde, MD, PhD
University of Florida,
Gainesville, FL
133
AANonDemand.com/premeeting
2O14 Annual Meeting On Demand
AAN is pleased to offer three educational products to
enhance your experience at this year’s Annual Meeting.
1. Best Value: AAN Annual Meeting On Demand— is the comprehensive digital library of content with more
than 500 hours* of presentations from the 2014 AAN Annual Meeting educational programs (including the Syllabi on CD and
Neurology Update On Demand library). Watch presenters’ slides while listening to fully synchronized audio as if you were
actually attending each session.
Features of AAN Annual Meeting On Demand include:
¡¡ Online access to content within 24 hours of live presentations
¡¡ Streaming content for viewing on iPad® and most mobile devices
¡¡ Companion portable hard drive for offline access
(shipped after the meeting)
¡¡ Downloadable MP3 files for convenient on-the-go audio
(listen in the car, or on your MP3 player)
¡¡ Advanced Search: Search any word on the slides and
immediately jump to that part of the presentation
2. Neurology Update On Demand— offers a paired-down library of approximately 70 hours* of presentations focused on the
latest updates in the field of neurology. Sessions in this online only catalog will be available within 24 hours of the live presentation. Save $100
or more off the list price (savings depend on membership status and registration category).
3. Syllabi on CD— serves as a quick reference tool with syllabi summaries of more than 160 programs presented during the
2014 Annual Meeting for only $299.
* T otal hours of presentations available subject to speaker permissions.
Pre-order now to save with deep discounts.
AAN Annual Meeting On Demand + Syllabi
Online, Portable Hard Drive, Mobile Streaming
$1,599 (List Price)
$599 (save $1,000)
$699 (save $900)
$399 (save $1,200)
$899 (save $700)
Member Attendee before May 3, 2014
Nonmember Attendee before May 3, 2014
Junior Attendee before May 3, 2014
Non Attendee before May 3, 2014
Syllabi CD
CD
Neurology Update
Online, Mobile Streaming
$299 (List Price)
$249 (save $50)
$299
$99 (save $200)
$299
$599 (List Price)
$399 (save $200)
$499 (save $100)
$249 (save $250)
$499 (save $100)
To lock in the best prices, purchase the AAN Annual Meeting on Demand when you register
for the 2014 Annual Meeting at AAN.com/view/register
Order one of three ways:
1.
When you register for the Annual
Meeting online you are able to conveniently
add the on demand products you wish to
purchase. Register for the Annual Meeting
and purchase these on demand products
at AAN.com/view/register.
2.
If you are not attending this
year’s Annual Meeting, you are still
able to purchase on demand products
to see what you missed! Visit
AANonDemand.com/PreMeeting
to learn more and purchase.
3.
Or call us at (800) 501-2303 or
(818) 844-3299. Monday–Friday,
6:00 a.m.–5:00 p.m. PST.
135
Connect at Social Events
There’s no better way to combine an evening of great fun and entertainment with unparalleled networking than to attend the
Opening Party, Closing Party—or both. Whether you attend the Annual Meeting at the beginning of the week, or the end, the
events are not-to-be-missed.
Comedy Show: The Water Coolers
8:30 p.m.–10:00 p.m.
Opening Party
Sunday, April 27
6:00 p.m.–10:00 p.m.
Join your friends and colleagues for an exciting evening filled with
delicious food, beverages, and entertainment. Each registered
meeting attendee will receive one free ticket to these events. Guest
tickets are available through registration for $50.
Neurobowl®
6:00 p.m.–8:00 p.m.
This popular event hosted by AAN former president Thomas R.
Swift, MD, FAAN, is one of the Annual Meeting’s premier
happenings. Neurobowl showcases the best and brightest in
neurology competing for the
coveted Neurobowl trophy in an
entertaining game-show format.
Ever start your day with 300 meetings scheduled, 700 emails in
your inbox, and a soccer game at 3:00? Join the Water Coolers,
the music and comedy act
E Entertainment calls “the
hottest ticket in town,” for a
hilarious evening of laughout-loud song and sketch
comedy that answers the
question “does this stuff
happen to anyone else?”
Closing Party
Friday, May 2
7:30 p.m.–9:00 p.m.
Celebrate the end of a great meeting with the Closing Party! Each
registered meeting attendee will receive one free ticket to this event.
Guest tickets are available through registration for $50.
Musical Entertainment
7:30 p.m.–9:00 p.m.
NFL star-turned-singer—and Public Leadership in Neurology Awardwinner—Ben Utecht will enchant you with his inimitable vocal
stylings. After winning a Super Bowl ring in 2007, his career ended
unexpectedly after a traumatic brain injury in 2009. Many saw this
as an ending, but Ben saw an opportunity to pursue another lifelong
passion—singing.
Main Stage: JellyRoll
8:30 p.m.–10:00 p.m.
Don’t miss this high-energy, 11-piece band that will get your feet
moving with a repertoire including material from the classics to the
newest top 40 hits. Fronted by the JellyRoll vocalists, driven by The
JellyRoll Horns and Philadelphia’s tightest rhythm section, the awardwinning JellyRoll has won over audiences from Madison Square
Garden in New York City to the White House in Washington, DC,
with their unique blend of dance music.
136
Monday, April 28
4:30 p.m.–6:30 p.m.
Attend the opening reception to mingle with fellow attendees and
preview the latest products and services available in the neurologic
industry. Light hors d’oeuvres and beverages will be served. The
exhibits will be open at this time.
American Academy of Neurology
and American Brain Foundation
Awards Luncheon
Wednesday, April 30
12:00 p.m.–1:30 p.m.
Public Leadership in Neurology
Award Winner Ben Utecht
Run/Walk For Brain Research
Tuesday, April 29
6:30 a.m.–8:30 a.m.
Support research in neurology and join us for a 5k run or onemile walk along the Philadelphia waterfront. Both occasional and
seasoned runners—and walkers—will enjoy this beautiful trek for a
good cause. All proceeds will go to the American Brain Foundation to
help support research. The race is open to all meeting attendees and
their families. Water and refreshments will be available following the
race. The registration fee is $25.
More information about this event will be posted as it becomes
available on AAN.com/view/AMEvents.
Bus service to and from the race site will be provided. For registration
and details, visit AAN.com/view/RunWalk or contact Andrew
Halverson at ahalverson@aan.com or (612) 928-6117.
Reunion/Alumni Meetings
Reconnect with your peers and program directors, and network with
your fellow alumni at various department reunion meetings occurring
throughout the Annual Meeting.
If your department is interested in hosting its alumni meeting
during the 2014 Annual Meeting, reserve your meeting today
at AAN.com/view/alumni or by contacting Tammi Sand at
tsand@aan.com or (612) 928-6136.
NFL star-turned-singer Ben Utecht will
receive the American Brain Foundation’s 2014
Public Leadership in Neurology Award for his
commitment to spreading the word about
how concussions and traumatic brain injury
have affected his life. After winning a Super
Bowl ring in 2007, his career ended
unexpectedly after a traumatic brain injury in
2009. Many saw this as an ending, but Ben saw an opportunity to
pursue another lifelong passion—singing.
Join AAN leaders as they honor the recipients of the 2014 AAN and
American Brain Foundation Awards. From enterprising high school
students to world-renowned researchers, this program recognizes
some of the top accomplishments in neuroscience research. Past
keynote speakers on the importance of neurologic diseases include
Billy McLaughlin, Tedy Bruschi, Dame Julie Andrews, Cuba Gooding
Jr., Leeza Gibbons, and Michael J. Fox.
Tickets are available for $60 through registration. Students and
Junior members of the AAN may attend this event at no cost
by requesting a ticket. Buy a ticket and show your support for
award recipients.
Reserve a Department Table and Be Recognized
Bring your department together and gain exposure for your team
at the Awards Luncheon by reserving a department table. Give
your residents and fellows the chance to sit together with
department faculty and chairs in a place of honor among the
top minds in the neurology/neuroscience academic community.
For questions, contact Laurie Dixon at ldixon@aan.com or
(612) 928-6154.
Yoga Sessions
Need to relax before a day filled with the latestbreaking science and the best in education? Yoga
sessions will be offered Sunday and Monday from 6:30
a.m.-7:30 a.m. If you need to unwind after the day we
will be offering a Wednesday evening Yoga session
from 5:00 p.m.-6:00 p.m. The registration fee is
$10 per session. For registration and details
please visit AAN.com/view/AMEvents.
137
Highlights for Students, Residents, and Fellows
The AAN Annual Meeting is an ideal setting for students, residents, and fellows to gain exposure to a variety of
interests and career disciplines, as well as network with leading neurologists and neurology professionals from around the world.
Registration
FREE for Medical Students
Annual Meeting registration is FREE to medical students, graduate
students, and PhD candidates who present a student ID card or are
AAN members.
Only $100 for Junior Residents and Junior Fellows
2014 Medical
Students, Residents, and
Fellows Guide
Annual Meeting registration is only $100 (a $740 savings from
nonmember neurologist registration!) before the April 3, 2014, early
registration deadline.
Opportunities to Save Money
Rush Line Tickets
Check in at the Registration Booth located in the Convention Center
each morning for FREE tickets to Education Programs for that day. A
minimum of two tickets will be held for each program available on a
first-come, first-served basis.
nts,
ical Stude
2014 Med llows Guide
, and Fe
Residents
Co nn ec tin
uro log
g All of Ne
y
3, 2014
26 – Ma y
• Ap ril
hia , PA
Phi lad elp
Get 50% Off Education Program Registration
Junior members who register for two Education Programs at full price
will receive 50% off the cost of a third Education Program of equal or
lesser value.
Volunteer Opportunities
Serve as a program monitor or a workshop volunteer to gain free
access to the specific program (see page 142).
A detailed guide highlighting all
events and opportunities of
interest to Students, Residents,
and Fellows is available at
AAN.com/view/resident.
“[The Annual Meeting Science Programs give me] a lot of exposure
to different researchers and to different work that people do in the
field of neurology. When you come to this place, you are exposed
to everything: the cutting-edge science, the new techniques, the
basically new science, the new indications, the new guidelines.”
Mohamed El Hag, MD (Resident)
Cleveland, OH
138
There’s no better way to combine an evening of great fun and entertainment with
unparalleled networking than to attend the Opening Party, Closing Party—or both!
Whether you attend the Annual Meeting at the beginning of the week, or the end, these
parties are not-to-be-missed.
Opening
Party
Sunday, April 27
6:OO p.m.–1O:OO p.m.
Join your friends and colleagues for an exciting
evening filled with entertainment, including:
Neurobowl® 6:OO p.m.–8:OO p.m.
This popular event is one of the Annual Meeting’s premier happenings. Neurobowl® showcases
the best and brightest in neurology competing for the coveted Neurobowl® trophy in an
entertaining game-show format.
Main Stage Music: JellyRoll 8:3O p.m.–1O:OO p.m.
Don’t miss this high-energy, 11-piece band that will get your feet moving with a repertoire
including material from the classics to the newest top 40 hits. Fronted by the JellyRoll
vocalists, driven by The JellyRoll Horns and Philadelphia’s tightest rhythm section, the
award-winning JellyRoll has won over audiences from Madison Square Garden in New
York City to the White House in Washington, DC, with their unique blend of dance music.
Comedy Show: The Water Coolers 8:3O p.m.–1O:OO p.m.
Ever start your day with 300 meetings scheduled, 700 emails in your inbox, and a soccer
game at 3:00? Join The Water Coolers, the music and comedy act E Entertainment calls
“the hottest ticket in town,” for a hilarious evening of laugh-out-loud song and sketch
comedy that answers the question “does this stuff happen to anyone else?”
Closing
Party
Friday, May 2
7:3O p.m.–9:OO p.m.
Musical Entertainment
Former NFL star-turned-singer and Public Leadership in
Neurology Award-winner Ben Utecht will enchant you
with his inimitable vocal stylings.
General Information
CME/Accreditation/Core Competencies
Accreditation
The American Academy of Neurology
Institute (AANI), the education subsidiary
of the American Academy of Neurology, is
accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to
provide continuing medical education (CME) for physicians.
AMA Credit Designation
The AANI designates this live activity for a maximum of (*) AMA
PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
*See individual program descriptions in this booklet for the maximum
number of credits per program.
CME/Participation Records
knowledge, skills, and professional performance and relationships
that a physician uses to provide services for patients, the public or
the profession. The content of CME is the body of knowledge and
skills generally recognized and accepted by the profession as within
the basic medical sciences, the discipline of clinical medicine, and the
provision of health care to the public. (HOD policy #300.988)
Certified CME is defined as:
1.Nonpromotional learning activities certified for credit prior to
the activity by an organization authorized by the credit system
owner, or
2.Nonpromotional learning activities for which the credit system
owner directly awards credit
Accredited CME providers may certify nonclinical subjects (e.g.,
office management, patient-physician communications, faculty
development) for AMA PRA Category 1 Credit™ as long as these
are appropriate to a physician audience and benefit the profession,
patient care, or public health.
AANI has mechanisms in place to record, and when authorized by
the participating physician, verify participation in the CME activity. To
receive CME for the Annual Meeting live program, participants must:
(1) register for the program(s); (2) attend the program(s); (3) submit
the evaluation form for the program(s). CME is given only when all
three steps are completed. AAN member CME and participation
transcripts are available approximately four to six weeks following
the close of the meeting via the AAN’s NeuroTracker AAN.com/cmeand-moc/track-and-view-transcript/ . Nonmembers’ CME credits and
participation transcripts will be sent via email.
CME activities may describe or explain complementary and
alternative health care practices. As with any CME activity, these
need to include discussion of the existing level of scientific evidence
that supports the practices. However, education that advocates
specific alternative therapies or teaches how to perform associated
procedures, without scientific evidence or general acceptance among
the profession that supports their efficacy and safety, cannot be
certified for AMA PRA Category 1 Credit™.
Core Competencies
The AANI, as an ACCME accredited provider, is responsible for
validating the clinical content of CME activities that it provides.
Specifically, 1. All the recommendations involving clinical medicine in
a CME activity must be based on evidence that is accepted within the
profession of medicine as adequate justification for their indications
and contraindications in the care of patients. 2. All scientific research
referred to, reported or used in CME in support or justification of a
patient care recommendation must conform to the generally accepted
standards of experimental design, data collection and analysis.
The AANI develops its activities/educational interventions in
the context of the desirable physician attributes. Specifically, the
AANI develops its educational interventions in the contents of the
Accreditation Council for Graduate Medical Education (ACGME) Core
Competencies which include:
¡¡ Patient Care
¡¡ Practice-Based Learning
and Improvement
¡¡ Medical Knowledge
¡¡ Professionalism
¡¡ Interpersonal and
Communication Skills
¡¡ Systems-Based Practice
For more information on the definitions of the ACGME core
competencies, please consult the following webpage:
www.acgme.org
Once again, this year’s Annual Meeting CME offerings, at the program
and lecture level, are identified according to these competencies.
Through identifying individual programs by competencies, attendees
can easily identify and attend programs that meet each core
competency.
AMA CME Definition/ Educational Content of
Certified CME
The AMA HOD and the Council on Medical Education have defined
continuing medical education as follows: CME consists of educational
activities which serve to maintain, develop, or increase the
140
Content Validation
Disclaimers/Disclosures
AAN/AANI Education/Scientific Disclaimer
The primary purpose of the Annual Meeting is to meet the
educational needs of its members and address practice gaps by
providing practice-oriented and scientifically based educational
activities that will maintain and advance competence and
performance in the field of neurology.
A diversity of opinions exists in the medical field and the views of the
Annual Meeting faculty do not represent those of the AAN/AANI or
constitute endorsement by the AAN/AANI. The AAN/AANI disclaims
any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed
at the Annual Meeting.
Relationship Disclosure and
Conflict of Interest Resolution
Internet Kiosks
According to AANI and ACCME policies, everyone who is in a
position to control the content of an education activity must disclose
financial relationships with any commercial interest to the provider.
An individual who refuses to disclose relevant financial relationships
is disqualified from being a planning committee member, a teacher,
or an author of CME, and cannot have control of, or responsibility for,
the development, management, presentation or evaluation of the
CME activity. In addition, the AANI must implement a mechanism
to identify and resolve all conflicts of interest prior to the education
activity being delivered to learners. The resolution of conflict is
handled by the Education and Science Committees. Disclosures for
everyone in the position to control Annual Meeting content can be
found on the AAN Annual Meeting website. In addition, education
and science faculty disclosures can also be found in the syllabi, slides,
handouts, and/or is done verbally from the podium.
Unlabeled Use Disclosure
The AANI requires all Annual Meeting presenters to disclose if a
therapy/product is not labeled for the use being discussed or if the
therapy/product is still investigational. Unlabeled use disclosures can
be found in the program materials.
Education Grants
Some Annual Meeting education and scientific programs
are supported in part by educational grants from commercial
entities. Disclosure of the educational grant is done through
acknowledgement statements on the program materials, signs
outside of the room, and verbally from the podium. Although
educational grants are received, all programs are developed and
implemented solely by the Education Committee and Science
Committee. The terms, conditions, and purposes of the commercial
support are documented in a written agreement between the AANI
and commercial supporter. The AAN uses grant funds to support and
enhance existing, as well as new, education programs.
The internet kiosks provide attendees with computer workstations
and Internet access. Check email, search the AAN website, or
complete online evaluations to obtain CME Credit.
Wireless Connection
Wireless Internet hotspots will be available at the Pennsylvania
Convention Center.
Business Center
The Pennsylvania Convention Center has a business center that
offers administrative and office services, including copy machines,
faxes, and shipping services. The business center is located on the
lobby level of the Pennsylvania Convention Center.
First Aid Station
A First Aid station is located on the lobby level of the Pennsylvania
Convention Center. The station is staffed by licensed medical
professionals and fully equipped with supplies, including automatic
external defibrillators (AED). The station is operational throughout the
duration of the Annual Meeting.
Brain Food
During the 2014 Annual Meeting, attendees will be provided with
light, brain healthy, meals throughout each day. Small break carts
will be placed in an accessible area to allow attendees registered for
paid Education Programs will be served a great tasting, healthy snack
during the break time to keep all energized and ready to learn.
Prayer Room
A prayer room will be available in the Convention Center for
attendees looking for a quiet space for thought, reflection, and prayer.
Mother’s Room
A private room will be available in the Convention Center for nursing
mothers and others with sensitive personal health needs. Please
note that this room will not be staffed.
Services
Guidelines
Child Care Information
Photography and Recording of Programs
A variety of child care options are available in Philadelphia. Check
with the concierge at your hotel on or before your arrival to make your
arrangements.
The AAN strictly prohibits all unauthorized photography (flash,
digital, or otherwise), audio and/or video recording during the Annual
Meeting. Equipment will be confiscated. Photography is allowed only
in the Poster Sessions.
Luggage Check
No luggage check is available at the Pennsylvania Convention Center.
Check with your concierge at your hotel to make your arrangements.
Shuttle Service
Complimentary shuttle bus service will be provided between
designated official AAN hotels and the convention center. Schedules
will be available at the Pennsylvania Convention Center and will also
be posted in each hotel lobby.
Consent to Use of Photographic Images
Registration and attendance at, or participation in, AAN/AANI
meetings and other related activities constitutes attendee’s
authorization to AAN’s use and distribution (both now and in the
future) of the attendee’s image or voice in photographs, video
recordings, electronic reproductions, audio recordings and other
media throughout the world and royalty free.
General Information
Cell Phones
The AAN requests that attendees turn cellular phones and pagers
to vibrate mode upon entering all Annual Meeting programs.
Language
The official language of the Annual Meeting is English.
No simultaneous translation is available.
No Smoking
The Pennsylvania Convention Center is a nonsmoking facility.
For the health and comfort of everyone, smoking is prohibited at
Annual Meeting functions, which include all education and
scientific activities and social functions.
Press Room
Only authorized media may use the Press Room at the Annual
Meeting. Journalists must check in at the Press Room and provide
proper credentials. For more information, contact Rachel Seroka at
rseroka@aan.com or (612) 807-6968.
Volunteer Opportunities
Education and Scientific Program Monitors
RED: 14AM RunWalk Ad
MonitorsNeurology
are needed
for alloreducation
programPractice,
offerings
and scientific
Placed in AANnews,
Journal,
Neurology Clinical
AMRAP
8.25"x5.4375",
Full Bleed
+0.125",
(BWdirectors,
if in NJ) faculty, session co-chairs, and
platform
sessions
to 4C
assist
staff as required. The AAN will waive all monitors' Annual Meeting
registration, registration fee for monitored program, as well as grant
CME credit for the monitored program. Space is available on a firstcome, first-served basis. For an application form or more information,
contact Laurie Dixon at ldixon@aan.com or (612) 928-6154.
Skills Workshop Volunteers
Volunteers are needed to participate in the Neurophysiologic
Intraoperative Monitoring Skills Workshop on Sunday, April 27.
Volunteers are also needed to participate in the EMG Clinical Skills
Workshop Monday, April 28, and the Neuromuscular Ultrasound
Skills Pavilion on Friday, May 2. Skills workshop subjects will receive
a waived meeting registration and workshop fee as well as payment
of $40 per noninvasive session and $60 per invasive session. Space
is available on a first-come, first-served basis. For more information,
contact Elizabeth Busch at ebusch@aan.com or (612) 928-6115.
Weather/Attire
The climate in Philadelphia in April is generally warm and pleasant.
In April, temperatures usually range from 66 degrees to 73 degrees
Fahrenheit. The AAN promotes business casual attire for the duration
of the Annual Meeting. Consider bringing a light jacket or sweater
to Annual Meeting activities since meeting room temperatures and
personal comfort levels vary.
Run/Walk for Brain Research
On your mark, get set…help cure BRAIN DISEASE!
Join your colleagues on Tuesday, April 29, 2014, at 6:30 a.m., for a friendly run/walk.
All proceeds will go to the American Brain Foundation to help support research.
Sign up for the Run/Walk at AAN.com/view/RunWalk
Annual Meeting App
Coming Soon!
The Mobile App puts all the information you
need conveniently on your phone or tablet:
¡
View your itinerary
¡
Find room locations
¡
Access program slides and syllabi
¡
More
A LITE version is available now, which allows
you to browse programs, speakers, and
convention details. Full version to be available
prior to the meeting.
Available for iPhone®, iPad®, or Android ®
Sponsored by:
Registration
The field of neurology is rapidly changing, and there’s nowhere like the AAN Annual Meeting to make sure you’re up
to date. The 66th AAN Annual Meeting in Philadelphia offers breakthrough research, exceptional education programs, and
boundless networking opportunities. Log in to the registration site where you can:
¡¡ Register quickly and easily
¡¡ Make your hotel selection and reservation
¡¡ Create your itinerary incorporating your education programs,
scientific sessions and other Annual Meeting events
¡¡ Print your schedule and not miss a thing at the meeting!
Ways to Save
The Annual Meeting offers a great value for the quality and quantity of programming. Try some of these savings tips:
¡¡ Renew your AAN membership or join the AAN now for maximum savings on registration and course fees at AAN.com/view/membership .
¡¡ Register now to avoid increased rates after the April 3, 2014, early registration deadline.
¡¡ Purchase education programs individually or select the new BUY ALL registration option and register for any course of interest for one flat rate.*
Member Type
General
Registration1
Before April 3, 2014
General
Registration
After April 3, 2014
Students
$0
$0
Senior
$0
$0
Honorary Member
$0
$0
Junior and
Non-Neurologist Member
(Junior Intern, Resident or Junior Fellow,
Business Administrator, Non-Neurologist Clinician,
Research Scientist, Research Coordinator)
$100
$130
Member Neurologist
(Active, Associate, Fellow)
$305
$420
Nonmember
$610
$840
* Skills Workshops and Skills Pavilions excluded from BUY ALL
pricing. Attendee must identify courses to be included as part of
“BUY ALL” purchase. Courses are subject to closure due to
reaching maximum capacity. BUY ALL registration option is only
available prior to early registration deadline of April 3, 2014.
144
Course Fees
Early:$45-$350
On-Site: $45-$350
Early:$85-$460
On-Site: $105-$480
Early:$85-$460
On-Site: $105-$480
Early:$45-$350
On-Site: $45-$350
Early:$85-$460
On-Site: $105-$480
Early:$115-$615
On-Site: $135-$635
BUY ALL*
Registration Option2
Before April 3, 2014
$400
$400
$400
$400
$1,000
$2,000
(includes meeting access only, education courses must be
paid for individually)
2 (includes access to meeting and ability to register for courses
at no additional cost)
1 2O14 Scientific Abstract Listing and Annual Meeting Information
Three Easy Ways to Register
Online
Fast, easy online registration available at AAN.com/view/AM14
Online registration walks you step-by-step through completing your registration, reserving a hotel, and personalizing your itinerary with top-tier
education courses, scientific sessions, special Annual Meeting events, and more!
Fax/Mail
A printable registration form is available at AAN.com/view/register
Download and print a registration form to complete and mail or fax to:
Deadline: April 3
Mail: AAN Registration/CMR
33 New Montgomery, Suite 1100
Registrations received after April 3, 2014,
San Francisco, CA 94105
will be processed at a higher rate.
Questions
Online:
Email:
AAN.com/view/register
aanreg@cmrus.com
Fax: (415) 293-4071
Telephone
US/Canada: (800) 676-4226
International: (415) 979-2283
Fees
General Registration Fee
Cancellations/Refunds of Registration
The general registration fee is mandatory for all registrants and is
determined by AAN member type. Attendees selecting the new BUY
ALL option will have the general registration fee included in the price.
Until April 3, 2014 April 4–April 18, 2014 After April 18, 2014
Education Programs
Purchase programs individually or select the new BUY ALL option
to register for any course of interest for one flat rate (Note: Skills
Workshops and Skills Pavilions are excluded from the BUY ALL
registration package.)
In addition, Junior Members who register for two Education
Programs at full price will receive 50% off the cost of a third
education program of equal or lesser value.
Changes in Education Programs
Select education programs carefully. An administrative fee of $20
($30 after April 3, 2014) will be charged for program cancellations
without a replacement program.
Many programs and events are included with your registration.
See page 6 for details.
Cancelled or Closed Programs
Education programs may be closed due to reaching maximum
capacity or cancelled due to insufficient enrollment. In the event
of cancellation, registration for the cancelled course will be fully
refunded. The AAN is not responsible for airfare, hotel, or
other costs incurred by participants in the event of program
or registration closure or cancellation.
Refund less $50 administrative fee
Refund less $100 administrative fee
No refund
¡¡ All cancellations must be submitted in writing to
aanreg@cmrus.com or faxed to (415) 293-4071.
¡¡ No-shows will not receive a refund.
¡¡ Name substitutions are not permitted.
¡¡ No refunds will be processed for amounts of $20 or less.
Special Accommodations Deadline: April 3
The Pennsylvania Convention Center and the AAN are in compliance
with the Americans with Disabilities Act or Human Rights Code and
strive to accommodate all visitors. Information booths, designated
parking, and assisted listening devices are available. If you require
special accommodation to attend the Annual Meeting, submit your
request while registering online or contact Laurie Dixon no later than
April 3, 2014, at ldixon@aan.com or (612) 928-6154.
Kosher meals may be provided at any breakfast or lunch, and must be
arranged on or before April 3, 2014, through the registration website
or by contacting AAN Registration/CMR at aanreg@cmrus.com,
(800) 676-4226, or (415) 979-2283. There is a $50 surcharge per meal.
On-site requests cannot be accommodated.
Group Registration Deadline: March 26
Group registrations are those in which 10 or more individuals’ fees are
paid for with one check or credit card. Special registration instructions
are available online AAN.com/view/register or by contacting CMR’s
Group Registration at (800) 676-4226 (US/Canada) or (415) 979-2283
(International). See page 114 for housing information.
Hotel Reservations
Why Book a Hotel Room Through the AAN?
Booking your room through the official AAN housing company assures you are getting a room at the hotel that best fits your
needs. You are also helping the AAN maintain consistent and competitive registration fees. The reason is simple. When a city is
selected as the site for the AAN Annual Meeting, contracts are signed with several hotels reserving a specific number of rooms
to be available for meeting attendees. If these rooms are not sold, the AAN is liable financially. Penalties incurred affect the
overall costs of the Annual Meeting and what the AAN charges for registration, exhibit space, and other services.
Save on Hotel Reservations
Take advantage of the AAN’s special hotel rates to make your trip
more affordable. Annual Meeting hotel reservations are processed
by Convention Management Resources (CMR).
AAN Online Hotel Reservations
AAN.com/view/BookHotel
The AAN makes it easy and convenient to book your hotel rooms for
the 66th Annual Meeting. Booking online allows you to:
¡¡ Take advantage of the AAN’s special hotel rates
¡¡ View room descriptions, photos, and availability
¡¡ Access maps of hotel proximity to Annual Meeting locations
Telephone Reservations
All correspondence, questions, and inquiries should be directed to
CMR at:
Phone:Hours:
Credit card reservations only
Monday–Friday
US/Canada (800) 676-4226
6:00 a.m.–6:00 p.m.(PST)
International (415) 979-2283
Deposits
¡¡ All hotels require a credit
card guarantee or a check
deposit of $300 (US dollars)
per room and $500 (US
dollars) per suite. Deposits
will be credited towards your
first night’s room and tax.
¡¡ No hotel reservation will be
processed without a credit
card guarantee or a deposit.
¡¡ Deposits are refundable up
to seven days prior to arrival,
after which there will be
no refunds.
¡¡ Credit cards will be charged for one night’s room and tax if you
fail to arrive on the confirmed date of arrival or if you fail to
cancel your reservation at least seven days prior to arrival.
Confirmations, Changes, and Cancellations
¡¡ You will receive your hotel confirmation from CMR. This is the
only confirmation you will receive.
¡¡ Please check your arrival and departure dates on the
confirmation carefully.
¡¡ After March 26, 2014, contact CMR to book a room. After this
date, however, rooms are subject to availability.
Note: Some hotels may charge a penalty for changes made to your
departure date after you have checked in.
Group Accommodations
Blocks of 10 or more sleeping rooms are considered a group. Fax
your written request to (415) 293-4071 or email to
aanhousing@cmrus.com and you will be contacted by an
AAN Housing Consultant.
Additional Tax/Assessments
¡¡ Rates do not include the 15.5% hotel tax.
¡¡ An $8 per night assessment fee is included to offset
the expense of the meeting.
146
Corporate Therapeutic Updates
Tuesday, April 29, 2O14 and Wednesday, April 3O, 2O14
Starting at 7:00 p.m.
Registration is free and open to registered Annual Meeting attendees.
Representatives from the following companies invite you to an informational session on therapeutic updates. This program provides you
the opportunity to learn about current therapies and projects in the corporate pipeline.
Tuesday, April 29
Wednesday, April 3O
Baxter Healthcare
Multifocal Motor Neuropathy (MMN)
Location: Loews Philadelphia Hotel
Common Wealth
Biogen Idec
Tecfidera® (dimethyl fumarate): An Interactive,
Case-Based Presentation
Location: Philadelphia Marriott Downtown
Grand Ballroom Salon EF
Biogen Idec
TYSABRI® (natalizumab) Label Update
Grand Ballroom Salon EF
Eisai Inc
Now Available: FYCOMPA™ (perampanel) as an
Adjunctive Therapy for the Treatment of Partial-Onset
Seizures in Patients 12 Years and Older
Congress ABC
Genzyme, A Sanofi Company
The Evolving Treatment Paradigm: Individualizing MS Care
Location: Sheraton Philadelphia Downtown Hotel
Liberty CD
Time: 7:00 p.m.–8:30 p.m.
Genzyme, A Sanofi Company
Challenging Cases in Neuromuscular Disorders:
Shortening the Diagnostic Odyssey
Location: Sheraton Philadelphia Downtown Hotel
Liberty AB
Time: 8:45 p.m.–10:00 p.m.
Medtronic, Inc.
DBS Therapy Innovation Reception
Liberty ABC
Mylan
Mylan Neurology: Patient-Focused, High Quality Medicines
Grand Ballroom Salon GH
Teva CNS
The Evolution of COPAXONE ®
Regency Ballroom B
*Commitments as of February 3, 2014
Novartis Pharma AG Basel, Switzerland
Time for Change: Evolution of Outcome Measures in MS
Grand Ballroom Salon GH
RSVP is recommended for these events.
Please visit www.AAN.com/view/CTU for more information.
No CME will be given by any accredited organization for the
Corporate Therapeutic Updates, and the AAN cannot affirm
claims pertaining to FDA off-label medication, research use
of pre-FDA drugs, or other research information that might be
discussed. Corporate Therapeutic Updates are corporate events.
Hotel Map and Amenities
Rate
Smoke
Free
Hotel
Distance to
Convention
Center
$251–$271
Y
2.0 Blocks
Y
No Charge
1
No Charge
$159
N
1.0 Blocks
Y
No Charge
0
N/A
$229
N
6.0 Blocks
Y
$9.95
1
No Charge
$242
N
4.0 Blocks
Y
$9.95
1
No Charge
$189
Y
Adjacent
Y
No Charge
1
No Charge
$289
Y
4.5 Blocks
Y
$18.00
1
No Charge
$159–$169
Y
1.0 Block
Y
No Charge
0
No Charge
$239
Y
1.0 Block
Y
No Charge
1
No Charge
$184
Y
4.0 Blocks
Y
No Charge
0
N/A
$239
Y
1.0 Block
Y
No Charge
0
No Charge
$219
N
2.7 Miles
Y
No Charge
0
No Charge
$259
Y
8.0 Blocks
Y
$10.00
1
No Charge
$259
Y
9.0 Blocks
Y
$11.99
1
No Charge
$275
Y
6.0 Blocks
Y
$9.99
2
No Charge
$239–$264
Y
1.6 Miles
Y
$9.95
1
No Charge
$269
Y
2.3 Miles
Y
No Charge
1
No Charge
Hotel Name
& Address
1100 Arch Street
Holiday Inn Express Midtown
1305 Walnut Street
Home2 Suites
1200 Arch Street
Homewood Suites University City
4109 Walnut Street
Hotel Monaco
433 Chestnut Street
Hotel Palomar
117 South 17th Street
Hyatt at the Bellevue
200 South Broad Street
Hyatt Regency at Penn’s Landing
201 South Columbus Blvd
Inn at Penn
Filber t
3600 Sansom
St. Street
S
St
N 21st
N 22nd
St.
St.
St.
N 23rd
K
A MT R A
Chestnu
t St.
St.
t.
S 21st S
S 20 th
Spruce
St.
St.
St
t.
Blvd.
erce St.
Market
S 22nd
Walnut
S
St.
St.
St.
Kennedy
Comm
S 23rd
16
Ludlow
St.
Sansom
t St.
John F
S 24th
Chestnu
Blvd.
ress
way
t.
26
St.
Kennedy
St.
Exp
St.
Ludlow
John F
Market
Sch
uyl
kill
Spruce
St.
t St.
St.
Locust
St.
St.
S 30 th
.
S 41st St
St.
Walnut
S
S 42nd
S 43rd
St.
Sansom
Winter
76
Filber t
.
11
Chestnu
32
St.
S 31st St
Ludlow
St.
Market
S 32nd
16
Hilton Garden Inn Center City
St.
15
1301 Race Street
S 33 th
14
Hampton Inn City Center
St.
13
1 Logan Square
S 34th
12
Four Seasons
St.
11
1201 Race Street
S 36 th
10
Four Points City Center
St.
9
1776 Benjamin Franklin Pkwy
S 37th
8
Embassy Suites Center City
.
7
237 Broad Street
rsit y Ave
6
Doubletree Center City
S Unive
5
1227 Race Street
St.
4
Days Inn Philadelphia
Convention Center Hotel
S 39 th
3
21 North Juniper Street
St.
2
Courtyard Downtown
S 40 th
1
High Speed
Business
Number of
On-Site
Internet Cost
Center
Restaurants Fitness Center
per Day
Current as of 1/31/2014 –Subject to change
Rate
Smoke
Free
Hotel
Distance to
Convention
Center
$259
N
9.0 Blocks
Y
No Charge
0
No Charge
$299
Y
3.0 Blocks
Y
No Charge
4
No Charge
$249–$279
Y
1.0 Block
Y
$12.95
1
No Charge
Hotel Name
& Address
Latham Hotel
17
Le Meridien
18
1421 Arch Street
Loews
19
1200 Market Street
20
Omni Hotel at Independence
Park
$259–$279
Y
1.0 Mile
Y
No Charge
1
No Charge
21
Philadelphia Marriott Downtown
Headquarter Hotel
$279–$299
Y
1.0 Block
Y
No Charge
1
No Charge
$218
Y
10.0 Blocks
Y
No Charge
3
No Charge
$251
Y
2.0 Blocks
Y
No Charge
0
No Charge
$279
Y
4.5 Blocks
Y
$9.95
1
No Charge
$219
Y
10.0 Blocks
Y
$12.95
1
No Charge
$209
Y
2.2 Miles
Y
No Charge
1
No Charge
$199
Y
9.0 Blocks
Y
$9.95
1
No Charge
$259
Y
8.0 Blocks
Y
$5.95
1
No Charge
$209
Y
5.0 Blocks
Y
No Charge
2
No Charge
$299
Y
5.0 Blocks
Y
$12.95
1
No Charge
$199
Y
1.0 Mile
Y
No Charge
1
No Charge
arlton S
99 South 17thWCStreet
t.
t.
N 8th S
t.
t.
N 9th S
t.
N 6th S
N Colu
Market
Chestnu
St.
12
t St.
Chestnu
95
20
t St.
t.
S 6th S
t.
31
t.
St.
t.
r St.
3
N 7th S
19
Walnut
S
St.
Broad
St.
S 15th
S 16 th
St.
22
Pine St.
Junipe
14
Market
Arch S
St.
S 7th S
St
9
Filber t
t.
17
t.
23
Square
24
8
t.
10 21
S 13 th
St.
Walnut
S
Locust
13
S 17th
St.
S 18 th
St.
S 19 th
28
Arch S
S 8th S
1
30
S Penn
St.
Pennsylv
Conventi ania
on Cente
r
t.
29
t.
676
St.
ay
Race S
18
St.
N 16 th
w
5
S 10 th
rk
2
St.
Pa
Rt. 676
Vine St.
S 11th
St.
in
St.
Cherr y
kl
N 17th
N 18 th
N 19 th
an
St.
Fr
St.
in
7
t.
St.
am
S 12 th
Race S
nj
St.
St.
St.
Be
N 20 th
25
4
N 15th
6
N 13 th
e St.
St.
Carlton
St.
Wood S
t.
Pearl S
t.
400 Arch
Street
Vin
N 10 th
Wyndham
Historic District
Vine St.
31
S 9th S
ood St.
Blvd.
hillSt.
Westin Philadelphia
30
mb u s
Callow
t.
1800 Market Street
N 2nd S
Sonesta
29
t.
Walnut
S
t.
t.
Sofitel
28
N 3rd S
1 Dock Street
S 2nd S
Sheraton Society Hill
27
t.
3549 Chestnut Street
N 4th S
Sheraton University City
26
t.
201 North 17th Street
S 3rd S
Sheraton Downtown
25
t.
10 Avenue of the Arts
N 5th S
Ritz Carlton
24
t.
1 East Penn Square
S 4th S
Residence Inn Center City
23
t.
1701 South Locust Street
S 5th S
Radisson Blu Warwick
St.
1201 Market Street
N 11th
401 Chestnut Street
22
St
High Speed
Business
Number of
On-Site
Internet Cost
Center
Restaurants Fitness Center
per Day
27
15
Travel Information
Reservations and Discounts
The official travel agency for the Annual Meeting is Association
Travel Pros. For 2%–10% discounted airline tickets to the Annual
Meeting, contact them at:
Phone: (877) 309-4330
Email: mytravelagent@innovativetvl.com
Hours: Monday–Friday, 8:30 a.m.–5:30 p.m. CST
Closed weekends and holidays
A $25 service fee will be assessed per ticket for reservations made
via phone. You may also book online with all airline meeting discounts
applied at www.aantvlmeetings.com . A $10 service fee will apply to
online bookings.
Direct Through Airlines
You may also contact your preferred airline directly. You must
reference the AAN Annual Meeting and provide the appropriate
airline discount codes listed below.
Airline Discount Codes Phone Number Website
American A7544AG*
Delta
NMGW2
United
ZQVV245289
(800) 433-1790
(800) 328-1111
(800) 521-4041
www.aa.com
www.delta.com
www.united.com
Discounts are subject to availability, so book well in advance. Normal
mileage and status upgrades apply for all airline programs. A service
fee will be charged for reservations made via phone.
Travel Website
For travel forms and information updates, visit the AAN Annual
Meeting website at AAN.com/view/AM14.
* Please use discount code 7544AG for travel
direct through www.aa.com.
Travel Tips
Travel Documents/Passports and
Entry Requirements
Non-US visitors must have valid travel documents/passports to
enter Philadelphia to provide proof of their citizenship. Document
requirements vary depending on your country of origin, citizenship,
the reason for your visit, and the length of your stay, and may include
passport or a birth certificate, photo ID, and/or a visa.
For more information, or to request a Letter of Announcement for the
2014 Annual Meeting, visit AAN.com/view/AMinfo.
Currency
Philadelphia’s currency is the US dollar; currency exchange is
available at banks and kiosks throughout the city and at the airport.
Cash machines/ATMs are available in most banks, hotels, and
shopping centers. For denominations under one dollar, the
currency is coins.
Customs and Immigration
From an international point of arrival, upon arriving in Philadelphia,
you will be required to go through a US Customs and Border
Protection (CBP) inspection. Before you land, your flight crew will
distribute an Immigration and Customs Declaration Form for you to
complete; forms are also available at the airport upon your arrival.
You will need to present this form, along with your passport, visa (if
any), and return tickets to the CBP officer.
150
Measurements
Philadelphia uses the United States customary system for weights
and measurements. If you choose to drive in Philadelphia, be aware
the speed limits are posted in miles per hour.
Medication
If you are entering Philadelphia with prescription drugs and syringes:
keep the medication in its original, labeled container; include medical
certificate with syringes showing they are for medical use and have
them declared to US Customs officials; bring an extra prescription
in case your medication is lost and/or to attest to your need to
take such prescriptions; and carry the generic name of
prescription medicines.
Time Zone
Philadelphia is in the Eastern Standard Time Zone. In April it will be
the same time as New York, one hour ahead of Chicago, three hours
ahead of Los Angeles, five hours behind London, and 13 hours
behind Tokyo.
For more information, visit AAN.com/view/AMinfo.
2O14 Annual Meeting Supporters
The American Academy of Neurology and the American Brain Foundation thank the following companies, foundations, and organizations for their
demonstrated vision, commitment, and strong support of programs which find answers and improve lives through neurologic education and research.
ACTRIMS
¡ Exhibit Guide
The Allergan Foundation
¡ Minority Scholars Program &
Visiting Professor Program
Allergan, Inc.
¡
¡
¡
¡
¡
¡
¡
C18 Therapy of Headache
C81 Chronic Migraine Education Program
AANextra
Brain Health Fair – Gold Event Sponsor
Exhibit Guide
Presentation Stage
Athena Diagnostics
¡ Exhibit Hall Passport
Baxter
¡ Corporate Therapeutic Update (4/29)
Biogen Idec
¡
¡
¡
¡
¡
¡
¡
¡
¡
5K Run/1K Walk for Brain Research
Annual Meeting Mobile App
Corporate Therapeutic Update (4/29 and 4/30)
Emerging Leaders Forum
Exhibit Hall Coffee Break (5/1)
Footprints
Eisai Inc.
¡ Corporate Therapeutic Update (4/29)
ElectroCore
Eli Lilly and Company
¡ Emerging Leaders Forum
EMD Serono, Inc.
¡ Resident Scholarship Fund
Geisinger Health System
Genzyme, a Sanofi Company
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
AANextra
Brain Health Fair – Silver Event Sponsor
Buy A Brain® campaign
Carpet Marketing
Corporate Therapeutic Update (2) (4/29)
Door Drop Insert (4/28)
Exhibit Guide
Fellow Scholarship Fund
Pillar Wrap
Posters Online
Presentation Stage
Resident Scholarship Fund
The HCA Earn While You Learn
Stipend Program
¡ Resident and Fellow Scholarship Fund
Ipsen Biopharmaceuticals, Inc.
¡ C28 Botulinum Toxins: Practical Issues
and Clinical Uses for Neurologists
¡ C53 Clinical Usefulness of Botulinum Toxin
and Treatment of Dystonia Skills Pavilion
Kronus, Inc.
¡ Exhibit Guide
Lundbeck LLC
¡
¡
¡
¡
AANextra
Exhibit Hall Cell Phone Charging Station
Exhibit Hall Passport
Medtronic, Inc.
¡
¡
¡
¡
C95 Deep Brain Stimulation Management
Corporate Therapeutic Update (4/29)
Presentation Stage
Merck & Co., Inc.
Brain Food Station (4/30)
Door Drop Insert (4/28 and 4/29)
Exhibit Guide
Exhibit Hall Cell Phone Charging Stations (2)
Exhibit Hall Coffee Breaks (4/29 and 4/30)
Exhibit Hall Internet Center (2)
Exhibit Hall Footprints
Exhibit Hall Pillar Wrap
Presentation Stage
Supernus Pharmaceuticals, Inc.
¡ Door Drop Insert (4/28)
¡ Exhibit Guide
Teva CNS
¡
¡
¡
¡
¡
¡
¡
¡
¡
Merz Pharmaceuticals LLC
¡ Women in Leadership Program
Emerging Leaders Forum
Hotel Key Cards
C99 Epilepsy Skills Pavilion
C157 Therapy of Epilepsy
Brain Health Fair – Silver Event Sponsor
Walgreens Infusion Services
Mylan
Exhibit Guide
Presentation Stage
The Resident Experience
Novartis Pharmaceuticals Corporation
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
¡
Upsher-Smith Laboratories, Inc.
¡ C10 Approach to Sleep Symptoms:
Sleepy or Sleepless
¡ C147 Dementia Update
¡
¡
¡
¡
¡
Sunovion Pharmaceuticals Inc.
Airport Dioramas
Exhibit Guide
Taxi Tops
Wayfinding Kiosk
Wi-Fi Access
PSAV - Presentation Services
¡ Neuro Film Festival®
Questcor Pharmaceuticals, Inc.
Wolters Kluwer Health/Lippincott
Williams & Wilkins, publisher of the
AAN publications Neurology ®,
Neurology ®Clinical Practice,
Neurology ®Neuroimmunology & Neuroinflammation,
Continuum: Lifelong Learning in Neurology ®,
Neurology Today ®, and Neurology Now ®
¡
¡
¡
¡
¡
¡
¡
Book Bags
Brain Health Fair—Silver Event Sponsor
Exhibit Hall Cell Phone Charging Station
Exhibit Hall Internet Center
Resident Scholarship Fund
Shuttle Buses
Transit Shelters
XenoPort, Inc.
Regency Therapeutics, a Division of
Luitpold Pharmaceuticals
* Commitments received as of January 31, 2014
Exhibitor Listing
AbbVie
ABCN/ABRET
Acorda Therapeutics, Inc.
ACRM/American Congress of
Rehabilitation Medicine
ACTRIMS
Akorn Pharmaceuticals
Allergan, Inc.
Alzheimer’s Association
American Association
of Neuromuscular and
Electrodiagnostic Medicine
American Board of Psychiatry &
Neurology
American Headache Society
American Neurological Association
American Physician Institute
American Society for Apheresis
(ASFA)
Athena Diagnostics, Inc.
Aurora Health Care
Avanir Medical Affairs
Avanir Pharmaceuticals, Inc.
AxelaCare Health Solutions
Balanceback
Banner Health
Baxter Healthcare
Bayer HealthCare
Benign Essential Blepharospasm
Research Foundation, Inc.
Biogen Idec
Biomed Pharmaceuticals
Blackrock NeuroMed
Cadwell
Cambridge University Press
Captureproof, Inc.
Carle Physician Group
Catalyst Pharmaceutical
Partners, Inc.
Charleston Area Medical Center
Child Neurology Foundation
Cleveland Clinic
CNS Vital Signs
Community Health Systems
Compumedics USA
CRC Press / Taylor & Francis Group
Critical Care Assessment
Cytokinetics
Dementia Society of America
152
Demos Medical Publishing
DENT Neurologic Institute
Depomed, Inc.
DigiTrace EEG Services
DynaMed/EBSCO
Dysautonomia International
Dystonia Medical Research
Foundation
EFNS-ENS
Eisai Inc.
Electrical Geodesics, Inc. (EGI)
Electro-Cap International, Inc.
ElectroCore
Elsevier, Inc.
EMD Serono, Inc.
Forest Pharmaceuticals, Inc.
FR Carrick Research Institute
GBS/CIDP Foundation International
GE Healthcare
Geisinger Health System
GeneDx
Genentech,INC
Genzyme
Genzyme Corporation
Global Neuro-Diagnostics
Great Lakes NeuroTechnologies
Grifols USA
Hayes Locums
Hospital Corporation of America
(HCA)
IcoMetrix
Impeto Medical
Interacoustics
International Essential Tremor
Foundation (IETF)
International Parkinson and
Movement Disorder Society (MD)
Intrafusion
IPSEN Biopharmaceuticals, Inc.
Jackson & Coker
Jari Electrode Supply
Jari Electrode Supply
KabaFusion
Kadlec Health System
Karger Publishers
KEGO FMI
Kennedy Krieger Institute
Kronus, Inc.
La Lettre Du Neurologue
LocumTenens. com
Lundbeck
Magstim
Mallinckrodt Pharmaceuticals
Max Neuro Supply Inc.
Mayo Medical Laboratories
McGraw-Hill
Medical Neurogenetics
MedLink Corporation
Medtronic, Inc.
Merz Neurosciences
Ministry Health Care
MotherToBabystudies Conducted
By the Organization of Teratology
Information Spec
MS Coalition
Multigon Industries, Inc.
Multiple Sclerosis Association of
America
Multiple Sclerosis Foundation
Mylan Inc.
National Ataxia Foundation
National Institute of Neurological
Disorders and Stroke (NINDS)
National Multiple Sclerosis Society
Natus Neurology Incorporated
Nervline-NeurologicDx
Neurology Reviews
Neurovirtual USA, Inc.
Nihon Kohden America, Inc.
Norton Healthcare Physician
Services
Novartis Pharma AG
Novartis Pharmaceuticals
Corporation
Ochsner Health System
Opexa Therapeutics
Otometrics
Oxford University Press
Parkinson’s Action Network
Pfizer Inc.
Physicians Committee for
Responsible Medicine
Pikeville Medical Center, Inc.
Piramal Imaging
Polar Products Inc.
Practical Neurology
PracticeLink. com
PracticeMatch Services LLC
PRC Clinical
ProtoKinetics, LLC
Providence Health & Services
Regency Therapeutics, a Division
of Luitpold Pharmaceuticals
Rochester Electro-Medical, Inc.
RosmanSearch, Inc.
RRS
Salem Health
Sensonics Int’l
Soothe Personalized Medicine Rx
Southeast Health
Spastic Paraplegia Foundation
SpecialtyCare
Spectrum Health Medical Group
Springer
St. Luke’s University Health
Network
Synapse Biomedical, Inc
Tenet South Florida—Advanced
Neuroscience Network
TEVA Neuroscience, Inc.
The Electrode Store
The Guthy-Jackson Charitable
Foundation
The JAMA Network
Tourette Syndrome Association
Transgenomic, Inc
UCB, Inc.
United Council for Neurologic
Subspecialties (UCNS)
US WorldMeds
Vanda Pharmaceuticals Inc.
VISTA Staffing Solutions
Walgreens Infusion Services
Wiley
Wolters Kluwer Health
World Association of Sleep
Medicine (WASM)
WR Medical Electronics
XenoPort, Inc.
2O14 Corporate Roundtable Members*
Corporate Roundtable support enables the American Academy of Neurology and the American Brain Foundation to improve patient care
through their support of neuroscience research, education, and patient outreach.
$40,000
$30,000
$20,000
Acorda Therapeutics, Inc.
Medtronic, Inc.
Amgen, Inc.
Piramal Imaging
Baxter Healthcare Corporation
Eisai Inc.
EMD Serono, Inc.
*Commitments as of January 31, 2014
July 11–13 • Chicago, IL
Shining the Spotlight on
Concussion Research
Chicago, IL • July 11–13, 2014
Register Now!
AAN.com/view/ConcussionConference
66th Annual Meeting Committee Members
Meeting Management
Committee
Stefan M. Pulst, MD, FAAN, Chair
Timothy A. Pedley, MD, FAAN, AAN
President
Terrence L. Cascino, MD, FAAN, AAN
President Elect
Brenda Banwell, MD
Neil A. Busis, MD, FAAN
Cynthia L. Comella, MD, FAAN
John Corboy, MD, FAAN
Lisa M. DeAngelis, MD, FAAN
Mill Etienne, MD, MPH, CPH
Jonathan P. Hosey, MD, FAAN
Carlayne E. Jackson, MD, FAAN
Ralph F. Józefowicz, MD, FAAN
Jennifer R. Molano, MD
John C. Morris, MD, FAAN
Ronald C. Petersen, PhD, MD
Michael Pursel, Bpharm, MBA, FASCP
Maisha T. Robinson, MD
Stephen M. Sergay, MB BCh, FAAN
Bruce Sigsbee, MD, FAAN
Thomas R. Swift, MD, FAAN
Education Committee
Cynthia L. Comella, MD, FAAN, Chair
Steven L. Lewis, MD, FAAN, Vice Chair
Allen J. Aksamit Jr., MD, FAAN
Imran I. Ali, MD, FAAN
Allison Brashear, MD, FAAN
Bruce A. C. Cree, MD, PhD, MCR
Barry M. Czeisler, MD
John W. Engstrom, MD, FAAN
Charles C. Flippen II, MD, FAAN
Blair Ford, MD, FAAN
J. Clay Goodman, MD, FAAN
Laurie Gutmann, MD, FAAN
Jaffar Khan, MD, FAAN
Rebecca K. Lehman, MD
Janis Miyasaki, MD, FAAN
Mark L. Moster, MD, FAAN
Bruce I. Ovbiagele, MD, MSc, FAAN
Lori Ann Schuh, MD, FAAN
Joseph I. Sirven, MD, FAAN
A. Gordon Smith, MD, FAAN
Science Committee
Practice Committee
Lisa M. DeAngelis, MD, FAAN, Chair
Natalia Sana Rost, MD, Vice Chair
Gregory K. Bergey, MD, FAAN
Edward H. Bertram, MD
David Q. Beversdorf, MD
Paul M. George, MD, PhD, MSE
Neill R. Graff-Radford, MD, FAAN
Joseph Jankovic, MD, FAAN
Eric Klawiter, MD
Walter J. Koroshetz, MD, FAAN
Catherine Lomen-Hoerth, MD, PhD
Randolph S. Marshall, MD, FAAN
Mark F. Mehler, MD, FAAN
Jose G. Merino, MD, M.Phil
Massimo Pandolfo, MD
Rosebud Roberts, MD
Walter A. Rocca, MD, MPH
Nina F. Schor, MD, PhD
Ericka P. Simpson, MD
Mark H. Tuszynski, MD, PhD
Barbara G. Vickrey, MD, MPH, FAAN
Aleksandar Videnovic, MD, MSc
Ryan Walsh, MD, PhD
Jonathan P. Hosey, MD, FAAN, Chair
Heidi B. Schwarz, MD, FAAN, Vice-Chair
Wayne E. Anderson, MD
Carmel Armon, MD, FAAN
Sarah M. Benish, MD
Bruce H. Cohen, MD, FAAN
Richard M. Dubinsky, MD, MPH, FAAN
Miriam L. Freimer, MD
Joseph V. Fritz, PhD
Larry B. Goldstein, MD, FAAN, FAHA
Raghav Govindarajan, MD
Cynthia L. Harden, MD
Anna D. Hohler, MD, FAAN
Donald J. Iverson, MD, FAAN
Michael J. Kaminski, MD, FAAN
David J. Likosky, MD, SFHM
Pushpa Narayanaswami, MBBS, MD, FAAN
Marilyn M. Rymer, MD
Don B. Smith, MD, FAAN
James C. Stevens, MD, FAAN
Jack W. Tsao, MD, DPhil, FAAN
Raissa Villanueva, MD
David Z. Wang, DO, FAHA, FAAN
Medical Economics and
Management Committee
Abstract Reviewers
Orly Avitzur, MD, MBA, FAAN, Chair
Gregory J. Esper, MD, MBA, Vice-Chair
Neil A. Busis, MD, FAAN
Allison Brashear, MD, FAAN
Bruce H. Cohen, MD, FAAN
Peter D. Donofrio, MD, FAAN
David A. Evans, MBA
Terry D. Fife, MD, FAAN
William S. Henderson, FACMPE
Lyell K. Jones, MD
Joel M. Kaufman, MD, FAAN
Constantine Moschonas, MD
John Ney, MD
Marianna V. Spanaki, MD, PhD
Alex Abou-Chebl, MD
Andrew H. Ahn, MD, PhD
Yama Akbari, MD,PhD
Roger L. Albin, MD
Phillip J. Albrecht, PhD
Roy Alcalay, MD
Jason Lamar Aldred, MD
Beau M. Ances, MD, PhD, MS
Liana Apostolova, MD
Charles E. Argoff, MD
Misha-Miroslav Backonja, MD
Alison Baird, FRACP, PhD, MBBS,MPH
Laura J. Balcer, MD, MSCE, FAAN
Brenda Banwell, MD
Sergio Baranzini, PhD
Amit Bar-Or, MD, FRCPC
Kevin M. Barrett, MD
A. M. Barrett, MD
Tracy T. Batchelor, MD, MPH
E Martina Bebin, MD
66th Annual Meeting Committee Members
Joseph R. Berger, MD, FAAN
Bibiana Bielekova, MD
Kevin M. Biglan, MD
Arnaud Biraben, MD
Gretchen L. Birbeck, MD, MPH,
DTMH, FAAN
Karen Ann Blindauer, MD
Christopher J. Boes, MD
James H. Bower, MD, MSc
K.C. Brennan, MD
Jeffrey W. Britton, MD
Matthew A. Brodsky, MD
Amy Brodtmann, MD, PhD, FRACP
Krzysztof Bujarski, MD
Rami Burstein, PhD
Cheryl Bushnell, MD, MHS
Peter A. Calabresi, MD, FAAN
Patrizia Casaccia, MD, PhD
Sydney Cash, MD
John N. Caviness, MD, FAAN
Antonia Ceccarelli, MD
Marc Chamberlain, MD, FAAN
Seemant Chaturvedi, MD, FAAN, FAHA
Tanuja Chitnis, MD
Tracey Cho, MD
Emma Ciafaloni, MD, FAAN
Adam B. Cohen, MD
Amy Colcher, MD
Greg Cole, PhD
Giacomo Pietro Comi, MD
Francis X. Conidi, MD, DO
Wayne T. Cornblath, MD, FAAN
Fiona Evann Costello, MD
Patricia K. Coyle, MD, FAAN
Claire Creutzfeldt, MD
Ricardo Cruciani, MD
Kevin E. Crutchfield, MD
Nabila Dahodwala, MD
Debra G. Davis, MD
Philip De Jager, MD, PhD
Stephanie Debette, MD, PhD
Suhayl S. Dhib-Jalbut, MD, FAAN
Alan Lee Diamond, DO
Bradford Dickerson, MD
Mazen M. Dimachkie, MD, FAAN
Barbara A. Dworetzky, MD
156
P. James B. Dyck, MD, FAAN
Eric R. Eggenberger, DO, FAAN
Deniz Erten-Lyons, MD
Amelia Evoli, MD
Stewart A. Factor, DO, FAAN
Samuel A. Frank, MD
Johanna Therese Fifi, MD
Elizabeth Fisher, PhD
Kevin M. Flanigan, MD, FAAN
Roy L. Freeman, MD
Deborah I. Friedman, MD, FAAN
Jennifer A. Frontera, MD
Jessica Gautreaux, MD
Frank G. Gilliam, MD, MPH
Darren R. Gitelman, MD
Christopher Glisson, DO
Alica M. Goldman, MD
Jennifer G. Goldman, MD
Myla Goldman, MD
Pedro Gonzalez-Alegre, MD
Ari Green, MD
Robert S. Greenwood, MD, FAAN
David M. Greer, MD
Rishi Gupta, MD
Roop Gursahani, MD
Amy K. Guzik, MD
Katrina A. Gwinn, MD
Karen Gylys, PhD, RN
Atticus Hainsworth, MD
E. Clarke Haley, Jr., MD, FAAN
Rashmi B. Halker, MD
Roy H. Hamilton, MD, MS
John Hart, MD
Anhar Hassan, MBBCH
Michael K. Hehir, II, MD
Victor W. Henderson, MD, FAAN
David N. Herrmann, MD, FAAN
Michio Hirano, MD, FAAN
Timea M. Hodics, MD
Yolanda Holler, MD
Julia Holtmann, MD
Muhammad Shazam Hussain, MD
Matilde Inglese, MD, PhD
Kurt A. Jaeckle, MD, FAAN
Alan C. Jackson, MD, FAAN
Carlayne E. Jackson, MD, FAAN
Michael S. Jaffee, MD, FAAN
Nathalie Jette, MD, MSc, FRCPC
Glen Jickling, MD
Barbara C. Jobst, MD, FAAN
Nicholas Elwood Johnson, MD
S. Andrew Josephson, MD
Tudor G. Jovin, MD
Vern C. Juel, MD, FAAN
Larry Junck, MD
Andres M. Kanner, MD
Orhun H. Kantarci, MD
Jonathan S. Katz, MD
Daniel Kaufer, MD, FAAN
Claudia Kawas, MD
Mark Keegan, MD
Omar A. Khan, MD, PhD
Babar Khokhar, MD
Eric Klawiter, MD
Peter J. Koehler, MD, PhD, FAAN
Matthew A. Koenig, MD
Martin Kohrmann, MD
Mohamad Koubeissi, MD, FAAN
Jeff Kraakevik, MD
Fred A. Lado, MD
Annette M. Langer-Gould, MD
Maarten G. Lansberg, MD
Douglas J. Lanska, MD, FAAN
Suzette M. LaRoche, MD, FAAN
Alan D. Legatt, MD, PhD, FAAN
Richard A. Lewis, MD, FAAN
David S. Liebeskind, MD, FAAN
Arne Lindgren, MD
Italo Linfante, MD
Carol F. Lippa, MD
Eric L. Logigian, MD, FAAN
Zachary N. London, MD
Jau-Shin Lou, MD, PhD, FAAN
Fred D. Lublin, MD, FAAN
Jennifer Lyons, MD
Jennifer J. Majersik, MD
Andrew Mammen, MD, PhD
Ruth-Ann Marrie, MD
Randolph S. Marshall, MD, FAAN
Warren P. Mason, MD
Katherine D. Mathews, MD
Farrah J. Mateen, MD
Kimford J. Meador, MD, FAAN
Matthew N. Meriggioli, MD, FAAN
Tom Mikkelsen, MD
Martha Morrell, MD, FAAN
Ellen M. Mowry, MD
Tahseen Mozaffar, MD, FAAN
Susanne Muehlschlegel, MD
Nils Hendrik Mueller, MD
Louis Burt Nabors, III, MD
Abraham J. Nagy, MD
Sandra Narayanan, MD
Avindra Nath, MBBS, FAAN
Mohit Neema, MD
Lawrence C. Newman, MD, FAAN
David E. Newman-Toker, MD, PhD, FAAN
Thanh Ngoc Nguyen, MD
Paul Alan Nyquist, MD, MPH
Darin T. Okuda, MD
Adriana Elena Palade, MD
Mamatha Pasnoor, MD
Neepa J. Patel, MD
Steven G. Pavlakis, MD, FAAN
Aimee Lucinda Pierce, MD
Istvan Pirko, MD, FAAN
Sean J. Pittock, MD
Ela B. Plow, PhD
Ann N. Poncelet, MD
Shyam Prabhakaran, MD
J. Javier Provencio, MD, FAAN
Vinaykumar Puduvalli, MD
John Pula, MD
Svetlana Pundik, MD
Mark S. Quigg, MD
Goran Rakocevic, MD
Anthony Reder, MD
Daniel Reich, MD,PhD
Awais Riaz, MD, PhD, FAAN
John Ringman, MD
Ramon L. Rodriguez, MD
Michael R. Rose, MD
Yelena Roshchina, MD
Natalia Sana Rost, MD, FAAN
Janet C. Rucker, MD
Robert L. Ruff, MD, PhD, FAAN
Seward B. Rutkove, MD
Ned C. Sacktor, MD
Joseph E. Safdieh, MD
Juan R. Sanchez-Ramos, MD, PhD
Valeria Sansone, MD
Sean I. Savitz, MD
Michael Joel Schneck, MD, FAAN
Todd J. Schwedt, MD
Lauren Seeberger, MD
Benjamin M. Segal, MD
Duygu Selcen, MD, FAAN
Linda M. Selwa, MD, FAAN
William R. Shapiro, MD, FAAN
Kazim Ali Sheikh, MD
Kevin N. Sheth, MD
Holly A. Shill, MD
Joshua M. Shulman, MD
Nancy L. Sicotte, MD, FAAN
Lisa C. Silbert, MD, FAAN
David K. Simon, MD, PhD
Joseph I. Sirven, MD, FAAN
Jeffrey Statland, MD
Israel Steiner, MD
Victor W. Sung, MD
Firas A. Taha, MD
Nilufer Taner, MD, PhD
Alrabi Tawil, MD, FAAN
Edmond Teng, MD, PhD
Claudia M. Testa, MD, PhD
William H. Theodore, MD, FAAN
Parthasarathy Thirumala, MD
Matthew J. Thurtell, MD
Michel T. Torbey, MD, MPH
Helen Tremlett, PhD, BPharm
Jay A. Van Gerpen, MD
Panayiotis N. Varelas, MD, PhD
Kathryn Rae Wagner, MD, PhD
David Walk, MD
Michael Mei-Hwa Wang, MD
Michael F. Waters, MD, PhD
Nathaniel F. Watson, MD
Emmanuelle Waubant, MD, FAAN
Thomas W. Weber, MD
Bianca Weinstock-Guttman, MD
Patrick Y. Wen, MD, FAAN
Norman S. Werdiger, MD, FAAN
Dean M. Wingerchuk, MD, FAAN
Elaine C. Wirrell, MD
George F. Wittenberg, MD, PhD
Bradford B. Worrall, MD, MSc, FAAN
James P. Wymer, MD, PhD, FAAN
Dileep R. Yavagal, MD
Manuel S. Yepes, MD
Scott S. Zamvil, MD, PhD, FAAN
Wendy C. Ziai, MD
Charles Zollinger, MD
157
Meeting Information and Contacts
Hotel Reservation Deadline:
March 26, 2014
Meeting Registration
Deadline:
April 3, 2014
Registration, Hotel,
and Travel Reservations:
Meeting Registration
and Housing
Phone:
Credit card reservations only
US/Canada (800) 676-4226
Travel Reservation Services
Airline Reservations:
Association Travel Pros
Phone: (877) 309-4330
www.aantvlmeetings.com
Hours: Monday–Friday
6:00 a.m.–6:00 p.m. PST
Hours: Monday–Friday,
8:30 a.m.–5:30 p.m. CST
Closed weekends and holidays
Email:
Email: mytravelagent@innovativetvl.com
AAN.com/view/AM14
Registration: aanreg@cmrus.com
Housing: aanhousing@cmrus.com
Annual Meeting Oversight
Science Program
Corporate Relations
Catherine M. Rydell, CAE
Chief Executive Officer/Executive Director,
AAN, AAN Institute, and
American Brain Foundation
science@aan.com
Alberta Zais
Director, Corporate Relations
Christine E. Phelps
Deputy Executive Director, AANI and
American Brain Foundation
Erin Jackson
Senior Manager, Scientific Programs
Nate Kosher
Senior Administrator, Scientific Programs
Registration
Kris Fridgen
Senior Director, Research, Education, and
Development
AANReg@cmrus.com
Kevin Heinz
Associate Director, Education and Science
Housing
Deb Stender
Senior Manager, Meetings and
Conference Management
Education Program
education@aan.com
Amy Nostdahl
Senior Manager, Education Programs
Heather Lundgren
Administrator, Education Programs
158
Laurie Dixon
Administrator, Registration and Logistics
Bridget Farley
Senior Manager, Corporate Relations
Compliance Issues
Susan Rodmyre
Senior Director, Education
Resident and Student Activities
Lucy Persaud Samaroo
Manager, Education
Julie Ratzloff
Manager, Conference Management
Cheryl Alementi
Senior Administrator, Education Programs
Affiliate Events
Practice and Advocacy
Related Issues
Tammi Sand
Senior Manager, Meetings and
Conference Management
Exhibits
Franziska Schwarz
Manager, Exhibits and Services
advocacy@aan.com
Rod Larson
Chief Health Policy Officer
For direct email and phone contacts,
please contact Member Services at:
memberservices@aan.com
(800) 879-1960 or
Take Your Commitment
to Your Profession
to the Next Level
2O14 AAN Physician Leadership Programs
Whether you want to be a mentor or an advocate, to guide or inspire others,
you need to cultivate the skills to be an effective leader.
NEW for 2O14!
Monday, April 28, 9:OO a.m.-5:OO p.m.
Women in Leadership
The AAN is seeking talented, highly motivated AAN member women with a commitment to neurology who are interested in
learning from successful female members in the field of neurology, including members of the AAN Board of Directors, about how
to lead at senior levels. If this is you, apply today for the new Women in Leadership course during the 2014 AAN Annual Meeting
in Philadelphia! Selected recipients will receive complimentary registration for this course.
Directors:
Allison Brashear, MD, MBA, FAAN, Winston Salem, NC
Barbara Hoese, Principal President, The Inventure Group, Minneapolis, MN
Space is limited and the application deadline is April 4, 2014.
Apply now at AAN.com/view/WomenLead.
Sunday, April 27, 8:OO a.m.-12:OO p.m.
Life Reimagined
Are you at a point in your life where you are asking “What’s next?” You’ve finished one chapter and have not written the next.
Many of us face these transitions at midlife, but they can happen at any point. It’s a time of enormous potential and it defines a
whole new phase of life. It’s called a Life Reimagined.
Director:
Richard Leider, Founder, The Inventure Group, Minneapolis, MN
Other Leadership Development Opportunity
Monday, April 28, 1:OO p.m.-5:OO p.m.
Improving Your Leadership Skills: A Practical Approach
Leadership has been defined as “having a sound vision and convincing others to follow you.” This course will assist you in
implementing the vision and offer practical tips and case examples on how to persuade others to follow.
Directors:
Terrence L. Cascino, MD, FAAN, Rochester, MN
Ralph L. Sacco, MD, MS, FAHA, FAAN, Miami, FL
PAID
201 Chicago Avenue
Minneapolis, MN 55415
Permit No. 3840
Twin Cities, MN
Non-Profit Org.
US Postage
Register Today for the
66th AAN Annual Meeting
April 26–May 3, 2O14
Philadelphia, PA
¡¡ Hotel Reservation Deadline: March 26, 2014
¡¡ Early Registration Deadline: April 3, 2014
¡ AAN Member Services: (800) 879-1960
Use #AANAM and follow the AAN
AMERICAN ACADEMY OF NEUROLOGY
AAN.com/view/AM14

Scientific Abstract Listing and Annual Meeting Information

Transcription

Similar documents

Brochure

W-12 view

The use of immune modulating drugs for the

poster packs - Oxford SA Blog

Scientific Abstract Listing and Meeting Information

A Concert by the Foothill High School`s Dickens` Carolers

Seafood and Sandals

Mechanical vs. Hydraulic vs. Servo Presses

Multiple Sclerosis, An Autoimmune Inflammatory Disease - Direct-MS

September edition - American Academy of Neurology